PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9784414-2	1998	Combined treatment of HGF and a specific inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethylornithine (DFMO), reduced the levels of hyper-phosphorylated and hypo-phosphorylated forms of RB and increased the levels of the non-phosphorylated form, compared to HGF alone, but did not affect the total level of RB.	Eflornithine	85-114	hepatocyte growth factor	Rattus norvegicus	22-25
9784414-2	1998	Combined treatment of HGF and a specific inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethylornithine (DFMO), reduced the levels of hyper-phosphorylated and hypo-phosphorylated forms of RB and increased the levels of the non-phosphorylated form, compared to HGF alone, but did not affect the total level of RB.	Eflornithine	85-114	ornithine decarboxylase 1	Rattus norvegicus	54-77
9784414-2	1998	Combined treatment of HGF and a specific inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethylornithine (DFMO), reduced the levels of hyper-phosphorylated and hypo-phosphorylated forms of RB and increased the levels of the non-phosphorylated form, compared to HGF alone, but did not affect the total level of RB.	Eflornithine	85-114	hepatocyte growth factor	Rattus norvegicus	271-274
9784414-2	1998	Combined treatment of HGF and a specific inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethylornithine (DFMO), reduced the levels of hyper-phosphorylated and hypo-phosphorylated forms of RB and increased the levels of the non-phosphorylated form, compared to HGF alone, but did not affect the total level of RB.	Eflornithine	116-120	hepatocyte growth factor	Rattus norvegicus	22-25
9784414-2	1998	Combined treatment of HGF and a specific inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethylornithine (DFMO), reduced the levels of hyper-phosphorylated and hypo-phosphorylated forms of RB and increased the levels of the non-phosphorylated form, compared to HGF alone, but did not affect the total level of RB.	Eflornithine	116-120	ornithine decarboxylase 1	Rattus norvegicus	54-77
9784414-2	1998	Combined treatment of HGF and a specific inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethylornithine (DFMO), reduced the levels of hyper-phosphorylated and hypo-phosphorylated forms of RB and increased the levels of the non-phosphorylated form, compared to HGF alone, but did not affect the total level of RB.	Eflornithine	116-120	ornithine decarboxylase 1	Rattus norvegicus	79-82
9784414-2	1998	Combined treatment of HGF and a specific inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethylornithine (DFMO), reduced the levels of hyper-phosphorylated and hypo-phosphorylated forms of RB and increased the levels of the non-phosphorylated form, compared to HGF alone, but did not affect the total level of RB.	Eflornithine	116-120	hepatocyte growth factor	Rattus norvegicus	271-274
9756034-8	1998	Injection of the ODC inhibitor, alpha-difluoromethylornithine (500 mg/kg) at the onset of withdrawal resulted in a significant reduction in the severity of withdrawal behaviors.	Eflornithine	32-61	ornithine decarboxylase 1	Rattus norvegicus	17-20
9719082-3	1998	In a short-term phase IIa trial, we determined that low doses of alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (an enzyme involved in polyamine synthesis), reduced the polyamine content of normal-appearing rectal mucosa of subjects with a prior history of resected colon polyps.	Eflornithine	65-94	ornithine decarboxylase 1	Homo sapiens	119-142
9719082-3	1998	In a short-term phase IIa trial, we determined that low doses of alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (an enzyme involved in polyamine synthesis), reduced the polyamine content of normal-appearing rectal mucosa of subjects with a prior history of resected colon polyps.	Eflornithine	96-100	ornithine decarboxylase 1	Homo sapiens	119-142
9688614-5	1998	Administration of DFMO not only depleted intracellular polyamines but also significantly increased the mRNA levels of TGF-beta.	Eflornithine	18-22	transforming growth factor, beta 1	Rattus norvegicus	118-126
9688614-6	1998	Increased TGF-beta mRNA in DFMO-treated cells was paralleled by an increase in TGF-beta content.	Eflornithine	27-31	transforming growth factor, beta 1	Rattus norvegicus	10-18
9688614-6	1998	Increased TGF-beta mRNA in DFMO-treated cells was paralleled by an increase in TGF-beta content.	Eflornithine	27-31	transforming growth factor, beta 1	Rattus norvegicus	79-87
9688614-8	1998	The half-life of mRNA for TGF-beta in normal cells was approximately 65 min and increased to >16 h in cells treated with DFMO for 6 or 12 days.	Eflornithine	124-128	transforming growth factor, beta 1	Rattus norvegicus	26-34
9688614-9	1998	Exogenous polyamine, when given together with DFMO, prevented the increased half-life of TGF-beta mRNA in IEC-6 cells.	Eflornithine	46-50	transforming growth factor, beta 1	Rattus norvegicus	89-97
9688665-5	1998	This proliferative response correlated with an increase in ODC activity that was partially inhibited (20%) by difluoromethylornithine (DFMO), an inhibitor of ODC (IC50, 30 pM).	Eflornithine	110-133	ornithine decarboxylase 1	Homo sapiens	59-62
9688665-5	1998	This proliferative response correlated with an increase in ODC activity that was partially inhibited (20%) by difluoromethylornithine (DFMO), an inhibitor of ODC (IC50, 30 pM).	Eflornithine	110-133	ornithine decarboxylase 1	Homo sapiens	158-161
9688665-5	1998	This proliferative response correlated with an increase in ODC activity that was partially inhibited (20%) by difluoromethylornithine (DFMO), an inhibitor of ODC (IC50, 30 pM).	Eflornithine	135-139	ornithine decarboxylase 1	Homo sapiens	59-62
9688665-5	1998	This proliferative response correlated with an increase in ODC activity that was partially inhibited (20%) by difluoromethylornithine (DFMO), an inhibitor of ODC (IC50, 30 pM).	Eflornithine	135-139	ornithine decarboxylase 1	Homo sapiens	158-161
9688665-7	1998	DFMO completely inhibited the proliferative response of TGF-alpha (IC50, 3 pM).	Eflornithine	0-4	transforming growth factor alpha	Homo sapiens	56-65
9744537-8	1998	The development and the maintenance of these ODC/ras tumors was ODC-dependent since alpha-difluoromethylornithine (DFMO), a specific ODC inhibitor, prevented the formation and caused the regression of these tumors.	Eflornithine	84-113	ornithine decarboxylase, structural 1	Mus musculus	45-48
9744537-8	1998	The development and the maintenance of these ODC/ras tumors was ODC-dependent since alpha-difluoromethylornithine (DFMO), a specific ODC inhibitor, prevented the formation and caused the regression of these tumors.	Eflornithine	84-113	ornithine decarboxylase, structural 1	Mus musculus	64-67
9744537-8	1998	The development and the maintenance of these ODC/ras tumors was ODC-dependent since alpha-difluoromethylornithine (DFMO), a specific ODC inhibitor, prevented the formation and caused the regression of these tumors.	Eflornithine	84-113	ornithine decarboxylase, structural 1	Mus musculus	64-67
9744537-8	1998	The development and the maintenance of these ODC/ras tumors was ODC-dependent since alpha-difluoromethylornithine (DFMO), a specific ODC inhibitor, prevented the formation and caused the regression of these tumors.	Eflornithine	115-119	ornithine decarboxylase, structural 1	Mus musculus	45-48
9744537-8	1998	The development and the maintenance of these ODC/ras tumors was ODC-dependent since alpha-difluoromethylornithine (DFMO), a specific ODC inhibitor, prevented the formation and caused the regression of these tumors.	Eflornithine	115-119	ornithine decarboxylase, structural 1	Mus musculus	64-67
9744537-8	1998	The development and the maintenance of these ODC/ras tumors was ODC-dependent since alpha-difluoromethylornithine (DFMO), a specific ODC inhibitor, prevented the formation and caused the regression of these tumors.	Eflornithine	115-119	ornithine decarboxylase, structural 1	Mus musculus	64-67
9686762-9	1998	The thrombin-mediated increase in putrescine production was reversed by N(G)-methyl-L-arginine, a competitive inhibitor of cationic amino acid transport, or by alpha-difluoromethylornithine (DFMO), an ODC inhibitor.	Eflornithine	160-189	coagulation factor II, thrombin	Homo sapiens	4-12
9686762-9	1998	The thrombin-mediated increase in putrescine production was reversed by N(G)-methyl-L-arginine, a competitive inhibitor of cationic amino acid transport, or by alpha-difluoromethylornithine (DFMO), an ODC inhibitor.	Eflornithine	191-195	coagulation factor II, thrombin	Homo sapiens	4-12
9686762-10	1998	DFMO also inhibited thrombin-induced SMC proliferation.	Eflornithine	0-4	coagulation factor II, thrombin	Homo sapiens	20-28
10987683-0	1998	Inhibited expression of insulin-like growth factor I mRNA and attenuated cardiac hypertrophy in volume overloaded hearts treated with difluoromethylornithine.	Eflornithine	134-157	insulin-like growth factor 1	Rattus norvegicus	24-52
9638584-6	1998	Treatment for 24 h with difluoromethylornithine (DFMO), a selective blocker of the enzyme ornithine decarboxylase and an inducer of the polyamine transport system, significantly increased the cellular uptake of 14C-FL-SPD and 14C-FL-SPM compared to that of control cells.	Eflornithine	24-47	ornithine decarboxylase 1	Homo sapiens	90-113
9638584-6	1998	Treatment for 24 h with difluoromethylornithine (DFMO), a selective blocker of the enzyme ornithine decarboxylase and an inducer of the polyamine transport system, significantly increased the cellular uptake of 14C-FL-SPD and 14C-FL-SPM compared to that of control cells.	Eflornithine	49-53	ornithine decarboxylase 1	Homo sapiens	90-113
9695073-7	1998	In addition, ursodeoxycholic acid and alpha-difluoromethylornithine, a selective inhibitor of ornithine decarboxylase, have been employed in human intervention trials.	Eflornithine	38-67	ornithine decarboxylase 1	Homo sapiens	94-117
9712166-2	1998	In this study, rats with intact or suppressed ODC activity by alpha-difluoromethylornithine (DFMO, 400 mg/kg i.p.)	Eflornithine	62-91	ornithine decarboxylase 1	Rattus norvegicus	46-49
9712166-2	1998	In this study, rats with intact or suppressed ODC activity by alpha-difluoromethylornithine (DFMO, 400 mg/kg i.p.)	Eflornithine	93-97	ornithine decarboxylase 1	Rattus norvegicus	46-49
9841492-2	1998	Ornithine decarboxylase (ODC) was localized along the mouse and rat nephron by incubating viable nephron segments isolated by microdissection from collagenase-treated kidneys with or without D,L-2-(difluoromethyl)ornithine (DFMO), a selective inactivator of ODC.	Eflornithine	224-228	ornithine decarboxylase, structural 1	Mus musculus	0-23
9841492-2	1998	Ornithine decarboxylase (ODC) was localized along the mouse and rat nephron by incubating viable nephron segments isolated by microdissection from collagenase-treated kidneys with or without D,L-2-(difluoromethyl)ornithine (DFMO), a selective inactivator of ODC.	Eflornithine	224-228	ornithine decarboxylase, structural 1	Mus musculus	25-28
9841492-10	1998	This ODC activity was strongly inhibited in DFMO-treated mice.	Eflornithine	44-48	ornithine decarboxylase, structural 1	Mus musculus	5-8
9626454-0	1998	Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial.	Eflornithine	111-140	epidermal growth factor receptor	Homo sapiens	0-32
9626454-2	1998	The purpose of this study was to examine expression of epidermal growth factor receptor (EGFR) as a marker for progression of cervical intraepithelial neoplasia (CIN) and as a surrogate end point biomarker in a chemoprevention trial with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase.	Eflornithine	238-267	epidermal growth factor receptor	Homo sapiens	55-87
9626454-2	1998	The purpose of this study was to examine expression of epidermal growth factor receptor (EGFR) as a marker for progression of cervical intraepithelial neoplasia (CIN) and as a surrogate end point biomarker in a chemoprevention trial with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase.	Eflornithine	238-267	epidermal growth factor receptor	Homo sapiens	89-93
9626454-2	1998	The purpose of this study was to examine expression of epidermal growth factor receptor (EGFR) as a marker for progression of cervical intraepithelial neoplasia (CIN) and as a surrogate end point biomarker in a chemoprevention trial with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase.	Eflornithine	269-273	epidermal growth factor receptor	Homo sapiens	55-87
9626454-2	1998	The purpose of this study was to examine expression of epidermal growth factor receptor (EGFR) as a marker for progression of cervical intraepithelial neoplasia (CIN) and as a surrogate end point biomarker in a chemoprevention trial with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase.	Eflornithine	269-273	epidermal growth factor receptor	Homo sapiens	89-93
9626454-8	1998	Although the overall levels of EGFR expression were not modulated in either histological responders or nonresponders, responders showed a prominent down-regulation of EGFR expression away from the basal layer after DFMO treatment.	Eflornithine	215-219	epidermal growth factor receptor	Homo sapiens	167-171
9626454-9	1998	Interestingly, pretreatment EGFR expression levels predicted for DFMO response [i.e., eight responses (72.7%) for 11 cases with RSI levels below 0.35 versus one response (9.1%) for 11 cases with RSI levels above 0.35 (P < 0.01)].	Eflornithine	65-69	epidermal growth factor receptor	Homo sapiens	28-32
9626454-10	1998	These results suggest that CIN progression is associated with a spatial dysregulation of EGFR expression that can be reversed by DFMO treatment, especially in patients whose pretreatment CIN 3 lesions exhibit relatively low EGFR expression.	Eflornithine	129-133	epidermal growth factor receptor	Homo sapiens	89-93
9626454-10	1998	These results suggest that CIN progression is associated with a spatial dysregulation of EGFR expression that can be reversed by DFMO treatment, especially in patients whose pretreatment CIN 3 lesions exhibit relatively low EGFR expression.	Eflornithine	129-133	epidermal growth factor receptor	Homo sapiens	224-228
9855067-1	1998	OBJECTIVE: The effect of blockade of the enzyme ornithine decarboxylase by difluoromethylornithine (DFMO) on hepatocellular necrosis and survival in rats treated with thioacetamide (TAA) was investigated.	Eflornithine	75-98	ornithine decarboxylase 1	Rattus norvegicus	48-71
9855067-1	1998	OBJECTIVE: The effect of blockade of the enzyme ornithine decarboxylase by difluoromethylornithine (DFMO) on hepatocellular necrosis and survival in rats treated with thioacetamide (TAA) was investigated.	Eflornithine	100-104	ornithine decarboxylase 1	Rattus norvegicus	48-71
9702002-8	1998	Difluoromethylornithine, a specific inhibitor of ODC, decreased the level of PUT in the liver, and inhibited [3H] thymidine incorporation.	Eflornithine	0-23	ornithine decarboxylase 1	Rattus norvegicus	49-52
9719479-1	1998	Alpha-difluoromethylornithine (DFMO) is commonly used as a specific ornithine decarboxylase (ODC, EC4.1.1.17) irreversible inhibitor.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	68-91
9719479-1	1998	Alpha-difluoromethylornithine (DFMO) is commonly used as a specific ornithine decarboxylase (ODC, EC4.1.1.17) irreversible inhibitor.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	93-96
9719479-1	1998	Alpha-difluoromethylornithine (DFMO) is commonly used as a specific ornithine decarboxylase (ODC, EC4.1.1.17) irreversible inhibitor.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	68-91
9719479-1	1998	Alpha-difluoromethylornithine (DFMO) is commonly used as a specific ornithine decarboxylase (ODC, EC4.1.1.17) irreversible inhibitor.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	93-96
9719479-11	1998	The inhibitory effect of DFMO upon arginase, one step upstream of the ODC reaction in the metabolic conversion of L-arginine to polyamines, is of potential physiological importance, since it could alter the production of ornithine and thus its metabolism in pathways other than the ODC pathway.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	70-73
9719479-11	1998	The inhibitory effect of DFMO upon arginase, one step upstream of the ODC reaction in the metabolic conversion of L-arginine to polyamines, is of potential physiological importance, since it could alter the production of ornithine and thus its metabolism in pathways other than the ODC pathway.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	282-285
10987683-3	1998	Difluoromethylornithine (DFMO) 2%, which is a specific, irreversible blocker of ornithine decarboxylase, was administered in the drinking water to intervention groups and one sham group, respectively, 24 h prior to surgery and for up to 26 days.	Eflornithine	0-23	ornithine decarboxylase 1	Rattus norvegicus	80-103
10987683-3	1998	Difluoromethylornithine (DFMO) 2%, which is a specific, irreversible blocker of ornithine decarboxylase, was administered in the drinking water to intervention groups and one sham group, respectively, 24 h prior to surgery and for up to 26 days.	Eflornithine	25-29	ornithine decarboxylase 1	Rattus norvegicus	80-103
10987683-4	1998	DFMO blocked transiently the early over-expression of right ventricular IGF-I mRNA and attenuated the rapid development of both right and left ventricular hypertrophy during volume overload.	Eflornithine	0-4	insulin-like growth factor 1	Rattus norvegicus	72-77
9615732-9	1998	It may be concluded that suramin affects polyamine metabolism, and that its effects in some respects are opposite to those of alpha-difluoromethylomithine (DFMO), a specific inhibitor of ODC.	Eflornithine	156-160	ornithine decarboxylase, structural 1	Mus musculus	187-190
9615733-3	1998	We have earlier shown that suramin affects cellular polyamine metabolism and transport, and that these effects were, in some respects, opposite to those of alpha-difluoromethylomithine (DFMO), a specific inhibitor to ornithine decarboxylase, a key metabolic enzyme for polyamines.	Eflornithine	186-190	ornithine decarboxylase, structural 1	Mus musculus	217-240
9506849-7	1998	Cell exposure to difluoromethylornithine, an irreversible inhibitor of ODC enzyme, dramatically antagonised both serum- and phorbol 12-myristate 13-acetate (PMA)-stimulated DNA synthesis.	Eflornithine	17-40	ornithine decarboxylase 1	Homo sapiens	71-74
9486143-6	1998	In both cell lines, ornithine decarboxylase mRNA levels increased and protooncogene c-myc mRNA decreased in the presence of DFMO.	Eflornithine	124-128	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	84-89
9486179-9	1998	DFMO completely abolished elevation of ODC activity 6 h after reperfusion but did not change the percentage of fragmented DNA.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	39-42
9486183-4	1998	In contrast, both MDL-72527 and DFMO inhibited the increase in putrescine level and DNA synthesis at 16.5 h. These findings suggest that putrescine produced from preexistent spermidine by SSAT is responsible for the initial DNA synthesis after mucosal injury induced by NaCl and that both SSAT and ODC are involved in formation of putrescine, which is required for subsequent DNA synthesis.	Eflornithine	32-36	spermidine/spermine N1-acetyl transferase 1	Rattus norvegicus	188-192
9486183-4	1998	In contrast, both MDL-72527 and DFMO inhibited the increase in putrescine level and DNA synthesis at 16.5 h. These findings suggest that putrescine produced from preexistent spermidine by SSAT is responsible for the initial DNA synthesis after mucosal injury induced by NaCl and that both SSAT and ODC are involved in formation of putrescine, which is required for subsequent DNA synthesis.	Eflornithine	32-36	spermidine/spermine N1-acetyl transferase 1	Rattus norvegicus	289-293
9486183-4	1998	In contrast, both MDL-72527 and DFMO inhibited the increase in putrescine level and DNA synthesis at 16.5 h. These findings suggest that putrescine produced from preexistent spermidine by SSAT is responsible for the initial DNA synthesis after mucosal injury induced by NaCl and that both SSAT and ODC are involved in formation of putrescine, which is required for subsequent DNA synthesis.	Eflornithine	32-36	ornithine decarboxylase 1	Rattus norvegicus	298-301
9549231-7	1998	Administration of DFMO, an irreversible inhibitor of the proliferation-associated enzyme ornithine decarboxylase (ODC), prevented diabetes-I induced jejunal hyperplasia and decreased all of the above enzymic parameters in both diabetic and control rats.	Eflornithine	18-22	ornithine decarboxylase 1	Rattus norvegicus	89-112
9549231-7	1998	Administration of DFMO, an irreversible inhibitor of the proliferation-associated enzyme ornithine decarboxylase (ODC), prevented diabetes-I induced jejunal hyperplasia and decreased all of the above enzymic parameters in both diabetic and control rats.	Eflornithine	18-22	ornithine decarboxylase 1	Rattus norvegicus	114-117
9549231-8	1998	In our previous in vivo study, DFMO administration also blocked diabetic jejunal hyperplasia and in addition decreased ornithine decarboxylase and tyrosine kinase activities jejunal and tyrosine phosphorylation of proteins.	Eflornithine	31-35	ornithine decarboxylase 1	Rattus norvegicus	119-142
9548411-2	1998	It was found that ifenprodil inhibited ornithine decarboxylase activity with the same potency as alpha-difluoromethylornithine, a major inhibitor of ornithine decarboxylase.	Eflornithine	97-126	ornithine decarboxylase 1	Homo sapiens	149-172
9020157-1	1997	When ornithine decarboxylase, the initial and highly regulated enzyme in polyamine biosynthesis, is irreversibly inactivated by alpha-difluoromethylornithine, F9 teratocarcinoma stem cells are depleted of putrescine and spermidine and as a result differentiate into a cell type which phenotypically resembles the parietal endoderm cells of the early mouse embryo.	Eflornithine	128-157	ornithine decarboxylase, structural 1	Mus musculus	5-28
9368191-3	1998	Treatment with alpha-difluoromethylornithine (DFMO), a selective inhibitor of the rate-limiting biosynthetic enzyme ornithine decarboxylase, produced dose-dependent inhibition of the respiratory burst in PMNs that were primed by these agents and subsequently activated by formyl-Met-Leu-Phe (fMLP).	Eflornithine	15-44	ornithine decarboxylase 1	Homo sapiens	116-139
9368191-3	1998	Treatment with alpha-difluoromethylornithine (DFMO), a selective inhibitor of the rate-limiting biosynthetic enzyme ornithine decarboxylase, produced dose-dependent inhibition of the respiratory burst in PMNs that were primed by these agents and subsequently activated by formyl-Met-Leu-Phe (fMLP).	Eflornithine	15-44	formyl peptide receptor 1	Homo sapiens	272-290
9368191-3	1998	Treatment with alpha-difluoromethylornithine (DFMO), a selective inhibitor of the rate-limiting biosynthetic enzyme ornithine decarboxylase, produced dose-dependent inhibition of the respiratory burst in PMNs that were primed by these agents and subsequently activated by formyl-Met-Leu-Phe (fMLP).	Eflornithine	15-44	formyl peptide receptor 1	Homo sapiens	292-296
9368191-3	1998	Treatment with alpha-difluoromethylornithine (DFMO), a selective inhibitor of the rate-limiting biosynthetic enzyme ornithine decarboxylase, produced dose-dependent inhibition of the respiratory burst in PMNs that were primed by these agents and subsequently activated by formyl-Met-Leu-Phe (fMLP).	Eflornithine	46-50	ornithine decarboxylase 1	Homo sapiens	116-139
9368191-3	1998	Treatment with alpha-difluoromethylornithine (DFMO), a selective inhibitor of the rate-limiting biosynthetic enzyme ornithine decarboxylase, produced dose-dependent inhibition of the respiratory burst in PMNs that were primed by these agents and subsequently activated by formyl-Met-Leu-Phe (fMLP).	Eflornithine	46-50	formyl peptide receptor 1	Homo sapiens	272-290
9368191-3	1998	Treatment with alpha-difluoromethylornithine (DFMO), a selective inhibitor of the rate-limiting biosynthetic enzyme ornithine decarboxylase, produced dose-dependent inhibition of the respiratory burst in PMNs that were primed by these agents and subsequently activated by formyl-Met-Leu-Phe (fMLP).	Eflornithine	46-50	formyl peptide receptor 1	Homo sapiens	292-296
9368191-5	1998	Antagonism of priming by DFMO correlated with a dose-dependent attenuation of fMLP-induced intracellular Ca2+ mobilization (r > or = 0.96).	Eflornithine	25-29	formyl peptide receptor 1	Homo sapiens	78-82
9525811-1	1998	The polyamine inhibitor DL-alpha-difluoromethylornithine (DFMO) is a specific irreversible inhibitor of ornithine decarboxylase which is a rate-limiting enzyme in the polyamine bio-synthesis pathway.	Eflornithine	24-56	ornithine decarboxylase 1	Homo sapiens	104-127
9525811-1	1998	The polyamine inhibitor DL-alpha-difluoromethylornithine (DFMO) is a specific irreversible inhibitor of ornithine decarboxylase which is a rate-limiting enzyme in the polyamine bio-synthesis pathway.	Eflornithine	58-62	ornithine decarboxylase 1	Homo sapiens	104-127
9525827-2	1998	Eflornithine, an irreversible inhibitor of ornithine decarboxylase, reduces cellular polyamine levels and has also been reported to cause tumor regression in patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.	Eflornithine	0-12	ornithine decarboxylase 1	Homo sapiens	43-66
9580224-5	1998	Clenbuterol-linked cardiac hypertrophy could be prevented by co-administration of either the non-specific beta-adrenergic antagonist, propranolol, or the irreversible inhibitor of ornithine decarboxylase, alpha-difluoromethylornithine.	Eflornithine	205-234	ornithine decarboxylase, structural 1	Mus musculus	180-203
9476255-5	1998	The DL-difluoromethylornithine (DFMO) and MDL 72527DA, two well known inhibitors of ornithine decarboxylase (ODC) and Polyamine Oxidase (PAO) respectively, had no toxicity on the P388D1 cells compared to our compounds.	Eflornithine	32-36	polyamine oxidase (exo-N4-amino)	Mus musculus	118-135
9396730-1	1997	DH23A cells, an alpha-difluoromethylornithine-resistant variant of the parental hepatoma tissue culture cells, express high levels of stable ornithine decarboxylase.	Eflornithine	16-45	ornithine decarboxylase 1	Rattus norvegicus	141-164
9396730-2	1997	Aberrantly high expression of ornithine decarboxylase results in a large accumulation of endogenous putrescine and increased apoptosis in DH23A cells when alpha-difluoromethylornithine is removed from the culture.	Eflornithine	155-184	ornithine decarboxylase 1	Rattus norvegicus	30-53
9361192-1	1997	alpha-Difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase, and all-trans-retinoic acid (RA) are known to induce F9 teratocarcinoma stem cell differentiation.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	84-107
9361192-1	1997	alpha-Difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase, and all-trans-retinoic acid (RA) are known to induce F9 teratocarcinoma stem cell differentiation.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	84-107
9361192-4	1997	Thus, retinoic acid receptor (RAR) alpha mRNA is weakly expressed during DFMO treatment, but strongly induced during an early phase of RA treatment.	Eflornithine	73-77	retinoic acid receptor alpha	Homo sapiens	6-40
9361192-5	1997	RAR beta mRNA is not detectable in DFMO-treated cells, but very strongly induced by RA and maintained at a high level throughout the differentiative process.	Eflornithine	35-39	retinoic acid receptor beta	Homo sapiens	0-8
9361192-6	1997	RAR gamma mRNA is relatively strongly expressed in untreated control cells and remains at approximately the same level during DFMO-induced differentiation.	Eflornithine	126-130	retinoic acid receptor gamma	Homo sapiens	0-9
9374496-10	1997	The lyso-PC-mediated increase in the production of putrescine was reversed by NG-methyl-L-arginine, a competitive inhibitor of cationic amino acid transport, or by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor.	Eflornithine	164-193	ornithine decarboxylase 1	Homo sapiens	198-221
9417887-4	1997	Inhibitors of ODC such as difluoromethylornithine (DFMO) completely blocked ODC activity, resulting in growth inhibition but not apoptosis.	Eflornithine	26-49	ornithine decarboxylase 1	Homo sapiens	14-17
9417887-4	1997	Inhibitors of ODC such as difluoromethylornithine (DFMO) completely blocked ODC activity, resulting in growth inhibition but not apoptosis.	Eflornithine	26-49	ornithine decarboxylase 1	Homo sapiens	76-79
9417887-4	1997	Inhibitors of ODC such as difluoromethylornithine (DFMO) completely blocked ODC activity, resulting in growth inhibition but not apoptosis.	Eflornithine	51-55	ornithine decarboxylase 1	Homo sapiens	14-17
9417887-4	1997	Inhibitors of ODC such as difluoromethylornithine (DFMO) completely blocked ODC activity, resulting in growth inhibition but not apoptosis.	Eflornithine	51-55	ornithine decarboxylase 1	Homo sapiens	76-79
9417887-5	1997	Addition of putrescine, the product of ODC enzymatic action, to Ramos cells had only a minor effect on growth, did not cause apoptosis, did not augment or block anti-IgM-mediated growth inhibition and apoptosis, but did reverse DFMO-mediated growth inhibition.	Eflornithine	228-232	ornithine decarboxylase 1	Homo sapiens	39-42
9371082-14	1997	Nonetheless, the activity in the screen of the known ODC inhibitor difluoromethylornithine (DFMO) validates the concept that specific recombinant microorganisms can serve as the basis for extremely selective and facile screens.	Eflornithine	67-90	ornithine decarboxylase 1	Homo sapiens	53-56
9371082-14	1997	Nonetheless, the activity in the screen of the known ODC inhibitor difluoromethylornithine (DFMO) validates the concept that specific recombinant microorganisms can serve as the basis for extremely selective and facile screens.	Eflornithine	92-96	ornithine decarboxylase 1	Homo sapiens	53-56
9367837-2	1997	In difluoromethylornithine-resistant L1210 cells stimulated to growth from quiescence, treatment with LY294002 inhibited cell growth and provoked a complete block of the induction of ODC activity (IC50 approximately 2 microM) and ODC protein.	Eflornithine	3-26	ornithine decarboxylase, structural 1	Mus musculus	183-186
9367837-2	1997	In difluoromethylornithine-resistant L1210 cells stimulated to growth from quiescence, treatment with LY294002 inhibited cell growth and provoked a complete block of the induction of ODC activity (IC50 approximately 2 microM) and ODC protein.	Eflornithine	3-26	ornithine decarboxylase, structural 1	Mus musculus	230-233
9331102-9	1997	Next, a specific inhibitor of ODC, difluoromethylornithine, at a dose of 10 mM, completely blocked the ER response in cultured normal skin fibroblasts, suggesting that the ODC enzyme is in fact essential for the ER response.	Eflornithine	35-58	ornithine decarboxylase 1	Homo sapiens	30-33
9331102-9	1997	Next, a specific inhibitor of ODC, difluoromethylornithine, at a dose of 10 mM, completely blocked the ER response in cultured normal skin fibroblasts, suggesting that the ODC enzyme is in fact essential for the ER response.	Eflornithine	35-58	ornithine decarboxylase 1	Homo sapiens	172-175
9252524-1	1997	The inhibition of ornithine decarboxylase, a rate-limiting enzyme of polyamine biosynthesis, with alpha-difluoromethylornithine in IEC-6 cells (small intestinal crypt cell line) reduces cell migration by 70%, inhibits protein cross-linking, and affects the cytoskeletal assembly.	Eflornithine	98-127	ornithine decarboxylase 1	Rattus norvegicus	18-41
9210401-0	1997	Inhibition of the expression of ornithine decarboxylase and c-Myc by cell-permeant ceramide in difluoromethylornithine-resistant leukaemia cells.	Eflornithine	95-118	ornithine decarboxylase, structural 1	Mus musculus	32-55
9210401-0	1997	Inhibition of the expression of ornithine decarboxylase and c-Myc by cell-permeant ceramide in difluoromethylornithine-resistant leukaemia cells.	Eflornithine	95-118	myelocytomatosis oncogene	Mus musculus	62-65
9210401-2	1997	In difluoromethylornithine-resistant L1210 cells stimulated to growth from quiescence, the cell-permeant analogues of ceramide N-acetylsphingosine (C2-ceramide) and N-hexanoylsphingosine (C6-ceramide) inhibited the induction of ornithine decarboxylase (ODC) activity with IC50 of 8.3 and 1.5 microM respectively.	Eflornithine	3-26	ornithine decarboxylase, structural 1	Mus musculus	228-251
9210401-2	1997	In difluoromethylornithine-resistant L1210 cells stimulated to growth from quiescence, the cell-permeant analogues of ceramide N-acetylsphingosine (C2-ceramide) and N-hexanoylsphingosine (C6-ceramide) inhibited the induction of ornithine decarboxylase (ODC) activity with IC50 of 8.3 and 1.5 microM respectively.	Eflornithine	3-26	ornithine decarboxylase, structural 1	Mus musculus	253-256
9223132-3	1997	Female CD-1 mice infected with an eflornithine-resistant trypanosome stabilate and treated with the trypanocidal compound diminazene aceturate on or after day 21 post-infection develop a reactive encephalopathy and relapsing parasitaemia.	Eflornithine	34-46	CD1 antigen complex	Mus musculus	7-11
9160048-0	1997	alpha-difluoromethylornithine modifies gonadotropin-releasing hormone release and follicle-stimulating hormone secretion in the immature female rat.	Eflornithine	0-29	gonadotropin releasing hormone 1	Rattus norvegicus	39-69
9160048-2	1997	In a previous study, inhibition of their synthesis by alpha-difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase, during development in female rats, was followed by prolonged high follicle-stimulating hormone (FSH) serum level and a delayed puberty onset.	Eflornithine	54-83	ornithine decarboxylase 1	Rattus norvegicus	133-156
9160048-2	1997	In a previous study, inhibition of their synthesis by alpha-difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase, during development in female rats, was followed by prolonged high follicle-stimulating hormone (FSH) serum level and a delayed puberty onset.	Eflornithine	85-89	ornithine decarboxylase 1	Rattus norvegicus	133-156
9160048-13	1997	In summary, DFMO treatment in a critical developmental period in the female rat impacts the immature GnRH neuronal network and immature gonadotropes.	Eflornithine	12-16	gonadotropin releasing hormone 1	Rattus norvegicus	101-105
9194572-7	1997	This was in contrast to DFMO, which inhibited ODC activity, but significantly increased its mRNA content.	Eflornithine	24-28	ornithine decarboxylase, structural 1	Mus musculus	46-49
9139705-8	1997	However, the addition of difluoromethylornithine, a specific ODC inhibitor, to the transgenic keratinocytes reduced both intracellular polyamine levels and CK2 enzyme activity.	Eflornithine	25-48	ornithine decarboxylase, structural 1	Mus musculus	61-64
9139705-8	1997	However, the addition of difluoromethylornithine, a specific ODC inhibitor, to the transgenic keratinocytes reduced both intracellular polyamine levels and CK2 enzyme activity.	Eflornithine	25-48	casein kinase 2, alpha prime polypeptide	Mus musculus	156-159
9142900-9	1997	In the presence of DFMO, exogenous TGF-beta restored cell migration to normal.	Eflornithine	19-23	transforming growth factor, beta 1	Rattus norvegicus	35-43
9142900-4	1997	Gene expression of TGF-beta was dramatically stimulated after wounding of a monolayer of cells not treated with DFMO.	Eflornithine	112-116	transforming growth factor, beta 1	Rattus norvegicus	19-27
9142900-7	1997	Depletion of intracellular polyamines in DFMO-treated cells significantly inhibited increased expression of the TGF-beta gene in response to wounding.	Eflornithine	41-45	transforming growth factor, beta 1	Rattus norvegicus	112-120
9142900-10	1997	These results indicate that 1) polyamine depletion induced by DFMO is associated with decreases in the expression of the TGF-beta gene and cell migration in IEC-6 cells and 2) exogenous TGF-beta reverses the inhibitory effect of polyamine depletion on cell migration.	Eflornithine	62-66	transforming growth factor, beta 1	Rattus norvegicus	121-129
9142900-10	1997	These results indicate that 1) polyamine depletion induced by DFMO is associated with decreases in the expression of the TGF-beta gene and cell migration in IEC-6 cells and 2) exogenous TGF-beta reverses the inhibitory effect of polyamine depletion on cell migration.	Eflornithine	62-66	transforming growth factor, beta 1	Rattus norvegicus	186-194
9073131-3	1997	Male Wistar rats were either treated with the synthetic trypsin inhibitor camostate (200 mg/kg body wt orally twice daily), camostate plus the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) (2% in drinking water plus 3 x 300 mg/kg body wt intraperitoneally during daytime) or saline as controls.	Eflornithine	177-206	ornithine decarboxylase 1	Rattus norvegicus	143-166
21533396-8	1997	These results indicate that the administration of piroxicam, a non-steroidal anti-inflammatory drug, and DFMO, a irreversible inhibitor of ornithine decarboxylase, may inhibit selective proliferation of initiated cells containing activated las and/or mutant p53.	Eflornithine	105-109	ornithine decarboxylase 1	Rattus norvegicus	139-162
21533396-8	1997	These results indicate that the administration of piroxicam, a non-steroidal anti-inflammatory drug, and DFMO, a irreversible inhibitor of ornithine decarboxylase, may inhibit selective proliferation of initiated cells containing activated las and/or mutant p53.	Eflornithine	105-109	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	258-261
21533396-9	1997	Dietary DFMO exerted more pronounced inhibition of selective amplification of initiated cells containing mutated ras and/or p53.	Eflornithine	8-12	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	124-127
9458728-4	1998	Polyamine biosynthesis in IEC-6 cells was interrupted by treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase, the primary rate-limiting enzyme of polyamine biosynthesis.	Eflornithine	72-101	ornithine decarboxylase 1	Rattus norvegicus	134-157
9458728-4	1998	Polyamine biosynthesis in IEC-6 cells was interrupted by treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase, the primary rate-limiting enzyme of polyamine biosynthesis.	Eflornithine	103-107	ornithine decarboxylase 1	Rattus norvegicus	134-157
9397163-6	1998	alpha-Difluoromethylornithine (DFMO) pretreatment, by lowering putrescine and spermidine in HGF- or IL-1 beta-treated cells, prevented the induction of cSAT.	Eflornithine	0-29	hepatocyte growth factor	Homo sapiens	92-95
9397163-6	1998	alpha-Difluoromethylornithine (DFMO) pretreatment, by lowering putrescine and spermidine in HGF- or IL-1 beta-treated cells, prevented the induction of cSAT.	Eflornithine	0-29	interleukin 1 beta	Homo sapiens	100-109
9397163-6	1998	alpha-Difluoromethylornithine (DFMO) pretreatment, by lowering putrescine and spermidine in HGF- or IL-1 beta-treated cells, prevented the induction of cSAT.	Eflornithine	31-35	hepatocyte growth factor	Homo sapiens	92-95
9397163-6	1998	alpha-Difluoromethylornithine (DFMO) pretreatment, by lowering putrescine and spermidine in HGF- or IL-1 beta-treated cells, prevented the induction of cSAT.	Eflornithine	31-35	interleukin 1 beta	Homo sapiens	100-109
9397163-9	1998	DFMO prevented almost completely the enhancement of c-jun mRNA expression by IL-1 beta, and this effect was reversed by exogenous putrescine or spermidine.	Eflornithine	0-4	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	52-57
9397163-9	1998	DFMO prevented almost completely the enhancement of c-jun mRNA expression by IL-1 beta, and this effect was reversed by exogenous putrescine or spermidine.	Eflornithine	0-4	interleukin 1 beta	Homo sapiens	77-86
9872505-3	1998	In this study, rats with intact or suppressed ODC activity by alpha-difluoromethy-ornithine (DFMO, 400 mg/kg i.p.)	Eflornithine	93-97	ornithine decarboxylase 1	Rattus norvegicus	46-49
9343440-11	1997	Inhibiting ODC activity with alpha-difluoromethylornithine delayed DCVC-induced cell death.	Eflornithine	29-58	ornithine decarboxylase 1	Sus scrofa	11-14
9316423-3	1997	Administration of alpha-difluoromethylornithine (DFMO), a specific inhibitor of polyamine synthesis, for 4 or 6 days not only almost completely depleted total (whole) cellular and nuclear polyamines but also significantly decreased expression of the protooncogenes c-myc and c-jun in IEC-6 cells.	Eflornithine	18-47	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	265-270
9316423-3	1997	Administration of alpha-difluoromethylornithine (DFMO), a specific inhibitor of polyamine synthesis, for 4 or 6 days not only almost completely depleted total (whole) cellular and nuclear polyamines but also significantly decreased expression of the protooncogenes c-myc and c-jun in IEC-6 cells.	Eflornithine	49-53	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	265-270
9316423-4	1997	Using nuclear run-on transcription assay, we demonstrated that the basal rate of transcription of c-myc was decreased by 55% at 4 days and by 60% at 6 days in the DFMO-treated cells.	Eflornithine	163-167	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	98-103
9316423-8	1997	Furthermore, direct administration of spermidine to isolated nuclei from polyamine-deficient (caused by DFMO) cells resulted in a 2- to 2.5-fold increase in c-myc and c-jun transcription.	Eflornithine	104-108	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	157-162
9224728-5	1997	Difluoromethylornithine (DFMO), an inhibitor of ODC, inhibited MEL cell proliferation, which was reversed by the simultaneous addition of putrescine, a product of ODC, but did not affect differentiation.	Eflornithine	0-23	ornithine decarboxylase, structural 1	Mus musculus	48-51
9224728-5	1997	Difluoromethylornithine (DFMO), an inhibitor of ODC, inhibited MEL cell proliferation, which was reversed by the simultaneous addition of putrescine, a product of ODC, but did not affect differentiation.	Eflornithine	0-23	ornithine decarboxylase, structural 1	Mus musculus	163-166
9224728-5	1997	Difluoromethylornithine (DFMO), an inhibitor of ODC, inhibited MEL cell proliferation, which was reversed by the simultaneous addition of putrescine, a product of ODC, but did not affect differentiation.	Eflornithine	25-29	ornithine decarboxylase, structural 1	Mus musculus	48-51
9224728-5	1997	Difluoromethylornithine (DFMO), an inhibitor of ODC, inhibited MEL cell proliferation, which was reversed by the simultaneous addition of putrescine, a product of ODC, but did not affect differentiation.	Eflornithine	25-29	ornithine decarboxylase, structural 1	Mus musculus	163-166
9186364-6	1997	The ODC-activity in the prostate was significantly increased by IGF-I after 3 days of treatment, and administration of IGF-I concomitantly with DFMO significantly inhibited ODC activity and the weight increase of the prostate.	Eflornithine	144-148	insulin-like growth factor 1	Rattus norvegicus	119-124
9186364-6	1997	The ODC-activity in the prostate was significantly increased by IGF-I after 3 days of treatment, and administration of IGF-I concomitantly with DFMO significantly inhibited ODC activity and the weight increase of the prostate.	Eflornithine	144-148	ornithine decarboxylase 1	Rattus norvegicus	173-176
9009157-3	1997	Upon chronic selective pressure with alpha-difluoromethyl-ornithine (DFMO) (an irreversible inhibitor of ODC), infected MCF-10A cells exhibited an approximately 250-fold increase in ODC activity, which persisted despite discontinuation of DFMO.	Eflornithine	69-73	ornithine decarboxylase 1	Homo sapiens	105-108
9142900-2	1997	Administration of alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (the first rate-limiting enzyme for polyamine synthesis), depleted cellular polyamines putrescine, spermidine, and spermine in IEC-6 cells.	Eflornithine	18-47	ornithine decarboxylase 1	Rattus norvegicus	80-103
9142900-2	1997	Administration of alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (the first rate-limiting enzyme for polyamine synthesis), depleted cellular polyamines putrescine, spermidine, and spermine in IEC-6 cells.	Eflornithine	49-53	ornithine decarboxylase 1	Rattus norvegicus	80-103
9142900-3	1997	DFMO also significantly reduced basal levels of TGF-beta mRNA in unwounded cells.	Eflornithine	0-4	transforming growth factor, beta 1	Rattus norvegicus	48-56
9416763-7	1997	Our results suggest that, in rat uterus, forskolin: a) produced cAMP-dependent relaxation, as this is antagonized by Rp-cAMP and TPCK, and b) increased the activity of ornithine decarboxylase, as this is inhibited by DFMO.	Eflornithine	217-221	ornithine decarboxylase 1	Rattus norvegicus	168-191
9022291-9	1996	The presence of DFMO, an irreversible inhibitor of ODC, led to apoptotic fragmentation of DNA, similar to that observed in TGF-beta 1-treated cultures.	Eflornithine	16-20	ornithine decarboxylase, structural 1	Mus musculus	51-54
9017896-5	1996	Additionally, seven animals were simultaneously treated with the ODC inhibitor alpha-difluoromethylornithine (DFMO) and sacrificed seven days after a single DMH injection.	Eflornithine	79-108	ornithine decarboxylase 1	Rattus norvegicus	65-68
8937449-0	1996	Inhibition of the expression of ornithine decarboxylase by haloperidol in difluoromethylornithine-resistant leukemia cells.	Eflornithine	74-97	ornithine decarboxylase, structural 1	Mus musculus	32-55
8937449-1	1996	In difluoromethylornithine-resistant L1210 cells stimulated to grow from quiescence, haloperidol caused an early and dose-dependent inhibition of the induction of ornithine decarboxylase (ODC) activity, with an IC50 of 3.5 microM.	Eflornithine	3-26	ornithine decarboxylase, structural 1	Mus musculus	163-186
8937449-1	1996	In difluoromethylornithine-resistant L1210 cells stimulated to grow from quiescence, haloperidol caused an early and dose-dependent inhibition of the induction of ornithine decarboxylase (ODC) activity, with an IC50 of 3.5 microM.	Eflornithine	3-26	ornithine decarboxylase, structural 1	Mus musculus	188-191
9009157-3	1997	Upon chronic selective pressure with alpha-difluoromethyl-ornithine (DFMO) (an irreversible inhibitor of ODC), infected MCF-10A cells exhibited an approximately 250-fold increase in ODC activity, which persisted despite discontinuation of DFMO.	Eflornithine	37-67	ornithine decarboxylase 1	Homo sapiens	105-108
9009157-3	1997	Upon chronic selective pressure with alpha-difluoromethyl-ornithine (DFMO) (an irreversible inhibitor of ODC), infected MCF-10A cells exhibited an approximately 250-fold increase in ODC activity, which persisted despite discontinuation of DFMO.	Eflornithine	37-67	ornithine decarboxylase 1	Homo sapiens	182-185
9083339-1	1997	Inhibitors of ornithine decarboxylase (ODC), such as alpha-difluoromethylornithine (DFMO), may influence the cytotoxicity of anti-tumour agents that interact with DNA.	Eflornithine	53-82	ornithine decarboxylase 1	Homo sapiens	14-37
9083339-1	1997	Inhibitors of ornithine decarboxylase (ODC), such as alpha-difluoromethylornithine (DFMO), may influence the cytotoxicity of anti-tumour agents that interact with DNA.	Eflornithine	53-82	ornithine decarboxylase 1	Homo sapiens	39-42
9083339-1	1997	Inhibitors of ornithine decarboxylase (ODC), such as alpha-difluoromethylornithine (DFMO), may influence the cytotoxicity of anti-tumour agents that interact with DNA.	Eflornithine	84-88	ornithine decarboxylase 1	Homo sapiens	14-37
9083339-1	1997	Inhibitors of ornithine decarboxylase (ODC), such as alpha-difluoromethylornithine (DFMO), may influence the cytotoxicity of anti-tumour agents that interact with DNA.	Eflornithine	84-88	ornithine decarboxylase 1	Homo sapiens	39-42
9589357-4	1997	Our group plans phase I and II trials using alpha-difluoromethylornithine, a suicide inhibitor of ornithine decarboxylase and potent antiproliferative chemopreventive agent.	Eflornithine	44-73	ornithine decarboxylase 1	Homo sapiens	98-121
9563003-2	1997	We studied the combined effects of taxol with 0.1 mM of the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) in the MCF-7 human breast adenocarcinoma cell line.	Eflornithine	94-123	ornithine decarboxylase 1	Homo sapiens	60-83
9009157-3	1997	Upon chronic selective pressure with alpha-difluoromethyl-ornithine (DFMO) (an irreversible inhibitor of ODC), infected MCF-10A cells exhibited an approximately 250-fold increase in ODC activity, which persisted despite discontinuation of DFMO.	Eflornithine	69-73	ornithine decarboxylase 1	Homo sapiens	182-185
9009157-3	1997	Upon chronic selective pressure with alpha-difluoromethyl-ornithine (DFMO) (an irreversible inhibitor of ODC), infected MCF-10A cells exhibited an approximately 250-fold increase in ODC activity, which persisted despite discontinuation of DFMO.	Eflornithine	239-243	ornithine decarboxylase 1	Homo sapiens	182-185
9009157-6	1997	Lesser degrees of increased ODC activity were obtained reproducibly by re-exposing the cells to incremental small doses of DFMO.	Eflornithine	123-127	ornithine decarboxylase 1	Homo sapiens	28-31
8695842-9	1996	The use of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC enzyme activity, indicates that ODC is not necessary for the c-myc-mediated differentiation block.	Eflornithine	11-40	ornithine decarboxylase 1	Homo sapiens	78-81
8695842-9	1996	The use of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC enzyme activity, indicates that ODC is not necessary for the c-myc-mediated differentiation block.	Eflornithine	42-46	ornithine decarboxylase 1	Homo sapiens	78-81
8760367-0	1996	Overproduction of stable ornithine decarboxylase and antizyme in the difluoromethylornithine-resistant cell line DH23b.	Eflornithine	69-92	ornithine decarboxylase 1	Homo sapiens	25-48
8842565-6	1996	DFMO attenuated both the rise in bp (p < 0.05) and vascular spermidine (p < 0.05) in the angII infused rats but vascular structure was apparently unaffected on day 12.	Eflornithine	0-4	angiotensinogen	Rattus norvegicus	95-100
8864401-6	1996	alpha-Difluoromethylornithine showed an ornithine decarboxylase inhibition of 97.1%.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	40-63
9306606-3	1997	The putrescine level and ornithine decarboxylase (ODC) activity were significantly higher in the ischemia + hepatectomy group than in the control group, but were markedly decreased in the DFMO + ischemia + hepatectomy group.	Eflornithine	188-192	ornithine decarboxylase 1	Rattus norvegicus	50-53
8726018-5	1996	In addition, CGP 40215A also cured a model central nervous system infection in combination with the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine (DFMO; Ornidyl, eflornithine).	Eflornithine	134-166	ornithine decarboxylase 1	Homo sapiens	100-123
8726018-5	1996	In addition, CGP 40215A also cured a model central nervous system infection in combination with the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine (DFMO; Ornidyl, eflornithine).	Eflornithine	168-172	ornithine decarboxylase 1	Homo sapiens	100-123
8664348-0	1996	Inhibition of the expression of ornithine decarboxylase by some kappa-opioidergic receptor ligands in difluoromethylornithine-resistant L1210 cells.	Eflornithine	102-125	ornithine decarboxylase, structural 1	Mus musculus	32-55
8967490-4	1996	The role of ODC was assessed by treating experimental rats with the irreversible ODC inhibitor alpha-difluoromethylornithine (DFMO) for 24 h. Animals receiving DFMO demonstrated a decreased CO2 production from [2-(14)C]pyruvate along the entire crypt-villus axis coupled with an increase in lactate production in the upper cell populations.	Eflornithine	95-124	ornithine decarboxylase 1	Rattus norvegicus	12-15
8967490-4	1996	The role of ODC was assessed by treating experimental rats with the irreversible ODC inhibitor alpha-difluoromethylornithine (DFMO) for 24 h. Animals receiving DFMO demonstrated a decreased CO2 production from [2-(14)C]pyruvate along the entire crypt-villus axis coupled with an increase in lactate production in the upper cell populations.	Eflornithine	95-124	ornithine decarboxylase 1	Rattus norvegicus	81-84
8967490-4	1996	The role of ODC was assessed by treating experimental rats with the irreversible ODC inhibitor alpha-difluoromethylornithine (DFMO) for 24 h. Animals receiving DFMO demonstrated a decreased CO2 production from [2-(14)C]pyruvate along the entire crypt-villus axis coupled with an increase in lactate production in the upper cell populations.	Eflornithine	126-130	ornithine decarboxylase 1	Rattus norvegicus	81-84
8967490-4	1996	The role of ODC was assessed by treating experimental rats with the irreversible ODC inhibitor alpha-difluoromethylornithine (DFMO) for 24 h. Animals receiving DFMO demonstrated a decreased CO2 production from [2-(14)C]pyruvate along the entire crypt-villus axis coupled with an increase in lactate production in the upper cell populations.	Eflornithine	160-164	ornithine decarboxylase 1	Rattus norvegicus	12-15
8967490-4	1996	The role of ODC was assessed by treating experimental rats with the irreversible ODC inhibitor alpha-difluoromethylornithine (DFMO) for 24 h. Animals receiving DFMO demonstrated a decreased CO2 production from [2-(14)C]pyruvate along the entire crypt-villus axis coupled with an increase in lactate production in the upper cell populations.	Eflornithine	160-164	ornithine decarboxylase 1	Rattus norvegicus	81-84
8618048-5	1996	The ODC inhibitor 2-difluoromethylornithine could prevent hair loss and partially normalize skin histology if administered before the onset of ODC overexpression.	Eflornithine	18-43	ornithine decarboxylase, structural 1	Mus musculus	4-7
8618048-5	1996	The ODC inhibitor 2-difluoromethylornithine could prevent hair loss and partially normalize skin histology if administered before the onset of ODC overexpression.	Eflornithine	18-43	ornithine decarboxylase, structural 1	Mus musculus	143-146
8849262-1	1996	Difluoromethylornithine (DFMO; eflornithine hydrochloride [Ornidyl]), a suicide inhibitor of the key polyamine biosynthesis enzyme ornithine decarboxylase (ODC), is effective in treating Pneumocystis carinii pneumonia, a common opportunistic infection associated with AIDS.	Eflornithine	0-23	ornithine decarboxylase 1	Rattus norvegicus	156-159
8849262-1	1996	Difluoromethylornithine (DFMO; eflornithine hydrochloride [Ornidyl]), a suicide inhibitor of the key polyamine biosynthesis enzyme ornithine decarboxylase (ODC), is effective in treating Pneumocystis carinii pneumonia, a common opportunistic infection associated with AIDS.	Eflornithine	25-29	ornithine decarboxylase 1	Rattus norvegicus	156-159
8849262-1	1996	Difluoromethylornithine (DFMO; eflornithine hydrochloride [Ornidyl]), a suicide inhibitor of the key polyamine biosynthesis enzyme ornithine decarboxylase (ODC), is effective in treating Pneumocystis carinii pneumonia, a common opportunistic infection associated with AIDS.	Eflornithine	31-57	ornithine decarboxylase 1	Rattus norvegicus	156-159
8849262-2	1996	Despite DFMO"s specificity for ODC, the reason for its selective toxicity against P. carinii is unknown since both host and parasite are dependent on the same enzyme for polyamine biosynthesis.	Eflornithine	8-12	ornithine decarboxylase 1	Rattus norvegicus	31-34
8674387-3	1996	To distinguish these possibilities, rats were treated with difluoromethylornithine, blocking ornithine decarboxylase activity and thereby adaptive bowel growth.	Eflornithine	59-82	ornithine decarboxylase 1	Rattus norvegicus	93-116
8801123-0	1996	Effects of gestational or neonatal treatment with alpha-difluoromethylornithine on ornithine decarboxylase and polyamines in developing rat brain and on adult rat neurochemistry.	Eflornithine	50-79	ornithine decarboxylase 1	Rattus norvegicus	83-106
8814137-3	1996	DNA synthesis was determined by [3H]thymidine incorporation into the acid-insoluble fraction after the addition of an inhibitor of ODC (alpha-difluoromethylornithine [DFMO]) or SAMDC (methylglyoxal bis[guanylhydrazone] [MGBG]).	Eflornithine	136-165	ornithine decarboxylase	Bos taurus	131-134
8801123-1	1996	Pregnant rats were treated for five consecutive days during gestation with s.c. injections of the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	138-167	ornithine decarboxylase 1	Rattus norvegicus	98-121
8801123-1	1996	Pregnant rats were treated for five consecutive days during gestation with s.c. injections of the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	138-167	ornithine decarboxylase 1	Rattus norvegicus	123-126
8801123-1	1996	Pregnant rats were treated for five consecutive days during gestation with s.c. injections of the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	169-173	ornithine decarboxylase 1	Rattus norvegicus	98-121
8801123-1	1996	Pregnant rats were treated for five consecutive days during gestation with s.c. injections of the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	169-173	ornithine decarboxylase 1	Rattus norvegicus	123-126
8779979-2	1996	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), for 4 days totally inhibited ODC activity and depleted intracellular polyamines in the IEC-6 cells.	Eflornithine	15-44	ornithine decarboxylase 1	Rattus norvegicus	77-100
8779979-2	1996	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), for 4 days totally inhibited ODC activity and depleted intracellular polyamines in the IEC-6 cells.	Eflornithine	15-44	ornithine decarboxylase 1	Rattus norvegicus	102-105
8779979-2	1996	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), for 4 days totally inhibited ODC activity and depleted intracellular polyamines in the IEC-6 cells.	Eflornithine	15-44	ornithine decarboxylase 1	Rattus norvegicus	137-140
8779979-2	1996	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), for 4 days totally inhibited ODC activity and depleted intracellular polyamines in the IEC-6 cells.	Eflornithine	46-50	ornithine decarboxylase 1	Rattus norvegicus	77-100
8779979-2	1996	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), for 4 days totally inhibited ODC activity and depleted intracellular polyamines in the IEC-6 cells.	Eflornithine	46-50	ornithine decarboxylase 1	Rattus norvegicus	102-105
8779979-2	1996	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), for 4 days totally inhibited ODC activity and depleted intracellular polyamines in the IEC-6 cells.	Eflornithine	46-50	ornithine decarboxylase 1	Rattus norvegicus	137-140
8779979-7	1996	The administration of wortmannin, an inhibitor of myosin light chain kinase, significantly inhibited cell migration over the denuded area in control cells and in those treated with DFMO + polyamines.	Eflornithine	181-185	myosin light chain kinase	Rattus norvegicus	50-75
9094379-1	1996	This study examined the effect of difluoromethylornithine (DFMO) on regional activities of ornithine decarboxylase (ODC) and edema formation in bilateral cerebral cortex and hippocampus after a unilateral controlled cortical-impact (CCI) injury in rats.	Eflornithine	59-63	ornithine decarboxylase 1	Rattus norvegicus	91-114
9094379-0	1996	Effect of difluoromethylornithine treatment on regional ornithine decarboxylase activity and edema formation after experimental brain injury.	Eflornithine	10-33	ornithine decarboxylase 1	Rattus norvegicus	56-79
9094379-1	1996	This study examined the effect of difluoromethylornithine (DFMO) on regional activities of ornithine decarboxylase (ODC) and edema formation in bilateral cerebral cortex and hippocampus after a unilateral controlled cortical-impact (CCI) injury in rats.	Eflornithine	34-57	ornithine decarboxylase 1	Rattus norvegicus	91-114
9094379-1	1996	This study examined the effect of difluoromethylornithine (DFMO) on regional activities of ornithine decarboxylase (ODC) and edema formation in bilateral cerebral cortex and hippocampus after a unilateral controlled cortical-impact (CCI) injury in rats.	Eflornithine	34-57	ornithine decarboxylase 1	Rattus norvegicus	116-119
8550737-3	1996	Spermidine depletion induced by the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine (DFMO), resulted in complete cytostasis and loss of mitogenic response to either E2 or insulin (or IGF-I).	Eflornithine	71-100	insulin	Homo sapiens	188-195
8550737-3	1996	Spermidine depletion induced by the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine (DFMO), resulted in complete cytostasis and loss of mitogenic response to either E2 or insulin (or IGF-I).	Eflornithine	71-100	insulin like growth factor 1	Homo sapiens	200-205
8550737-3	1996	Spermidine depletion induced by the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine (DFMO), resulted in complete cytostasis and loss of mitogenic response to either E2 or insulin (or IGF-I).	Eflornithine	102-106	insulin	Homo sapiens	188-195
8550737-3	1996	Spermidine depletion induced by the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine (DFMO), resulted in complete cytostasis and loss of mitogenic response to either E2 or insulin (or IGF-I).	Eflornithine	102-106	insulin like growth factor 1	Homo sapiens	200-205
8550737-5	1996	Whereas antiestrogen-resistant growth in insulin-treated cells was halted by DFMO, the antiestrogen did not further inhibit growth upon prior polyamine depletion.	Eflornithine	77-81	insulin	Homo sapiens	41-48
8550737-7	1996	Moreover, spermidine depletion and decarboxylated S-adenosylmethionine accumulation induced by DFMO required prior mitogenic stimulation by E2 and/or IGF-I.	Eflornithine	95-99	insulin like growth factor 1	Homo sapiens	150-155
8550737-10	1996	On the other hand, DFMO depressed the cycling fraction of E2/IGF-I-stimulated MCF-7 cell population far more dramatically than the antiestrogen and to less than that noted in mitogen-deprived cells.	Eflornithine	19-23	insulin like growth factor 1	Homo sapiens	61-66
9156788-3	1996	We examined the effect of sepsis in rats on polyamine biosynthesis in isolated jejunal enterocytes and measured mucosal protein synthesis following inhibition of ornithine decarboxylase (ODC) activity with difluoromethylornithine.	Eflornithine	206-229	ornithine decarboxylase 1	Rattus norvegicus	187-190
9156788-7	1996	Treatment of rats with difluoromethylornithine prevented the sepsis-induced increase in mucosal ODC activity, putrescine concentration, and protein synthesis rate.	Eflornithine	23-46	ornithine decarboxylase 1	Rattus norvegicus	96-99
8768305-1	1996	The effect of difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the rate limiting enzyme of polyamine biosynthesis, and its combined action with GM1 ganglioside, was studied on the GFAP content in a model of remote astrogliosis evoked in the hippocampus by lateral fimbria transection.	Eflornithine	14-37	ornithine decarboxylase 1	Rattus norvegicus	100-103
8768305-1	1996	The effect of difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the rate limiting enzyme of polyamine biosynthesis, and its combined action with GM1 ganglioside, was studied on the GFAP content in a model of remote astrogliosis evoked in the hippocampus by lateral fimbria transection.	Eflornithine	39-43	ornithine decarboxylase 1	Rattus norvegicus	75-98
8768305-2	1996	DFMO markedly suppressed hippocampal gliosis as measured by GFAP immunoblotting seven days postsurgery.	Eflornithine	0-4	glial fibrillary acidic protein	Rattus norvegicus	60-64
8772501-5	1996	The treatment of the sucklings with RU-38486 or with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC, dramatically reduced the amount of SI mRNA.	Eflornithine	53-82	ornithine decarboxylase 1	Rattus norvegicus	115-118
8772501-5	1996	The treatment of the sucklings with RU-38486 or with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC, dramatically reduced the amount of SI mRNA.	Eflornithine	53-82	sucrase-isomaltase	Rattus norvegicus	155-157
8772501-5	1996	The treatment of the sucklings with RU-38486 or with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC, dramatically reduced the amount of SI mRNA.	Eflornithine	84-88	ornithine decarboxylase 1	Rattus norvegicus	115-118
8772501-5	1996	The treatment of the sucklings with RU-38486 or with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC, dramatically reduced the amount of SI mRNA.	Eflornithine	84-88	sucrase-isomaltase	Rattus norvegicus	155-157
8772501-7	1996	Sucklings receiving HC and treated concomitantly with either RU-38486 or DFMO exhibited a reduced amount of ODC mRNA and a dramatic decline in both SI mRNA and activity.	Eflornithine	73-77	ornithine decarboxylase 1	Rattus norvegicus	108-111
8772501-7	1996	Sucklings receiving HC and treated concomitantly with either RU-38486 or DFMO exhibited a reduced amount of ODC mRNA and a dramatic decline in both SI mRNA and activity.	Eflornithine	73-77	sucrase-isomaltase	Rattus norvegicus	148-150
9094379-1	1996	This study examined the effect of difluoromethylornithine (DFMO) on regional activities of ornithine decarboxylase (ODC) and edema formation in bilateral cerebral cortex and hippocampus after a unilateral controlled cortical-impact (CCI) injury in rats.	Eflornithine	59-63	ornithine decarboxylase 1	Rattus norvegicus	116-119
9094379-9	1996	DFMO, an irreversible inhibitor of ODC, abolished the increase in ODC in all regions.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	35-38
9094379-9	1996	DFMO, an irreversible inhibitor of ODC, abolished the increase in ODC in all regions.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	66-69
8554515-7	1995	Moreover, the pHi-dependence of the rate of Na(+)-dependent H+ extrusion after an acid stress was altered by DFMO and BE-3-4-3, resulting in a set-point which was lower by 0.25-0.30 pH unit in polyamine-depleted cells.	Eflornithine	109-113	glucose-6-phosphate isomerase 1	Mus musculus	14-17
8594622-5	1996	Inhibition of their synthesis during this period by alpha- difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase, impairs normal brain development.	Eflornithine	52-82	ornithine decarboxylase 1	Rattus norvegicus	132-155
8594622-5	1996	Inhibition of their synthesis during this period by alpha- difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase, impairs normal brain development.	Eflornithine	84-88	ornithine decarboxylase 1	Rattus norvegicus	132-155
8594622-15	1996	It is concluded that DFMO, an inhibitor of ornithine decarboxylase, administered during the first week of life in female rats is followed by prolonged high FSH serum levels and delayed puberty, but once puberty occurs, fertility is normal.	Eflornithine	21-25	ornithine decarboxylase 1	Rattus norvegicus	43-66
7493642-0	1995	Relationship between ornithine decarboxylase and cytoskeletal organization in cultured human keratinocytes: cellular responses to phorbol esters, cytochalasins, and alpha-difluoromethylornithine.	Eflornithine	165-194	ornithine decarboxylase 1	Homo sapiens	21-44
8572176-8	1995	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC, not only completely depleted intracellular polyamines but also significantly prevented the increased expression of c-myc in cells exposed to gastrin.	Eflornithine	15-44	ornithine decarboxylase 1	Rattus norvegicus	77-80
8572176-8	1995	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC, not only completely depleted intracellular polyamines but also significantly prevented the increased expression of c-myc in cells exposed to gastrin.	Eflornithine	15-44	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	197-202
8572176-8	1995	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC, not only completely depleted intracellular polyamines but also significantly prevented the increased expression of c-myc in cells exposed to gastrin.	Eflornithine	15-44	gastrin	Rattus norvegicus	223-230
8572176-8	1995	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC, not only completely depleted intracellular polyamines but also significantly prevented the increased expression of c-myc in cells exposed to gastrin.	Eflornithine	46-50	ornithine decarboxylase 1	Rattus norvegicus	77-80
8572176-8	1995	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC, not only completely depleted intracellular polyamines but also significantly prevented the increased expression of c-myc in cells exposed to gastrin.	Eflornithine	46-50	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	197-202
8572176-8	1995	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC, not only completely depleted intracellular polyamines but also significantly prevented the increased expression of c-myc in cells exposed to gastrin.	Eflornithine	46-50	gastrin	Rattus norvegicus	223-230
8572176-9	1995	These results show that 1) gastrin stimulates both polyamine biosynthesis and the expression of the c-myc protooncogene, and 2) depletion of intracellular polyamines by DFMO significantly prevented the increased expression of c-myc by gastrin.	Eflornithine	169-173	gastrin	Rattus norvegicus	27-34
8572176-9	1995	These results show that 1) gastrin stimulates both polyamine biosynthesis and the expression of the c-myc protooncogene, and 2) depletion of intracellular polyamines by DFMO significantly prevented the increased expression of c-myc by gastrin.	Eflornithine	169-173	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	100-105
8572176-9	1995	These results show that 1) gastrin stimulates both polyamine biosynthesis and the expression of the c-myc protooncogene, and 2) depletion of intracellular polyamines by DFMO significantly prevented the increased expression of c-myc by gastrin.	Eflornithine	169-173	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	226-231
8572176-9	1995	These results show that 1) gastrin stimulates both polyamine biosynthesis and the expression of the c-myc protooncogene, and 2) depletion of intracellular polyamines by DFMO significantly prevented the increased expression of c-myc by gastrin.	Eflornithine	169-173	gastrin	Rattus norvegicus	235-242
7595561-4	1995	Pretreatment with alpha-difluoromethylornithine (DFMO) significantly blocked the ODC activity at 2, 4, and 6 h. Significant edema formation was found at 2, 4, and 6 h. At 2 h, edema formation was unaffected by administration of DFMO.	Eflornithine	18-47	ornithine decarboxylase 1	Homo sapiens	81-84
7595561-4	1995	Pretreatment with alpha-difluoromethylornithine (DFMO) significantly blocked the ODC activity at 2, 4, and 6 h. Significant edema formation was found at 2, 4, and 6 h. At 2 h, edema formation was unaffected by administration of DFMO.	Eflornithine	49-53	ornithine decarboxylase 1	Homo sapiens	81-84
7595561-5	1995	However, DFMO treatment reduced later edema formation at 4 and 6 h. These results demonstrate that ODC activity and edema formation are delayed in gerbils after the induction of transient ischemia even with the removal of anesthetic agents and their potentially protective effects.	Eflornithine	9-13	ornithine decarboxylase 1	Homo sapiens	99-102
7595561-7	1995	DFMO treatment reduced both the ODC activity and edema formation, indicating a role for polyamines in postischemic edema formation.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	32-35
7646459-4	1995	(2) The results revealed that ODC gene copy number started to decrease after 4 weeks growth without DFMO, to a final level of less than 30% of the original gene dosage.	Eflornithine	100-104	ornithine decarboxylase 1	Homo sapiens	30-33
7493642-9	1995	NHEK treated with cytochalasin B or D to inhibit actin polymerization exhibited a diffuse ODC localization that could be reversed by removal of the cytochalasin; inhibition of ODC by alpha-difluoromethylornithine caused a diffuse ODC localization.	Eflornithine	183-212	ornithine decarboxylase 1	Homo sapiens	176-179
7493642-9	1995	NHEK treated with cytochalasin B or D to inhibit actin polymerization exhibited a diffuse ODC localization that could be reversed by removal of the cytochalasin; inhibition of ODC by alpha-difluoromethylornithine caused a diffuse ODC localization.	Eflornithine	183-212	ornithine decarboxylase 1	Homo sapiens	176-179
7575451-1	1995	We previously reported that difluoromethylornithine (DFMO), an inhibitor of polyamine biosynthesis, exerted significant beneficial effects on the lifespan and disease expression of MRL-lpr/lpr mice, which spontaneously develop a lupus-like syndrome.	Eflornithine	28-51	Fas (TNF receptor superfamily member 6)	Mus musculus	185-188
7575451-1	1995	We previously reported that difluoromethylornithine (DFMO), an inhibitor of polyamine biosynthesis, exerted significant beneficial effects on the lifespan and disease expression of MRL-lpr/lpr mice, which spontaneously develop a lupus-like syndrome.	Eflornithine	28-51	Fas (TNF receptor superfamily member 6)	Mus musculus	189-192
7575451-1	1995	We previously reported that difluoromethylornithine (DFMO), an inhibitor of polyamine biosynthesis, exerted significant beneficial effects on the lifespan and disease expression of MRL-lpr/lpr mice, which spontaneously develop a lupus-like syndrome.	Eflornithine	53-57	Fas (TNF receptor superfamily member 6)	Mus musculus	185-188
7575451-1	1995	We previously reported that difluoromethylornithine (DFMO), an inhibitor of polyamine biosynthesis, exerted significant beneficial effects on the lifespan and disease expression of MRL-lpr/lpr mice, which spontaneously develop a lupus-like syndrome.	Eflornithine	53-57	Fas (TNF receptor superfamily member 6)	Mus musculus	189-192
7575451-5	1995	Treatment of MRL-lpr/lpr mice with DFMO increased [Ca2+]i to 360 +/- 30 nM (P < 0.05).	Eflornithine	35-39	Fas (TNF receptor superfamily member 6)	Mus musculus	17-20
7575451-5	1995	Treatment of MRL-lpr/lpr mice with DFMO increased [Ca2+]i to 360 +/- 30 nM (P < 0.05).	Eflornithine	35-39	Fas (TNF receptor superfamily member 6)	Mus musculus	21-24
7575451-7	1995	DFMO treatment increased InsP3 levels in concanavalin A-treated MRL-lpr/lpr T-cells to 67%.	Eflornithine	0-4	Fas (TNF receptor superfamily member 6)	Mus musculus	68-71
7575451-7	1995	DFMO treatment increased InsP3 levels in concanavalin A-treated MRL-lpr/lpr T-cells to 67%.	Eflornithine	0-4	Fas (TNF receptor superfamily member 6)	Mus musculus	72-75
7575451-9	1995	DFMO treatment reduced tyrosine phosphorylation of p56lck of MRL-lpr/lpr mice significantly (P < 0.001).	Eflornithine	0-4	lymphocyte protein tyrosine kinase	Mus musculus	51-57
7575451-9	1995	DFMO treatment reduced tyrosine phosphorylation of p56lck of MRL-lpr/lpr mice significantly (P < 0.001).	Eflornithine	0-4	Fas (TNF receptor superfamily member 6)	Mus musculus	65-68
7575451-9	1995	DFMO treatment reduced tyrosine phosphorylation of p56lck of MRL-lpr/lpr mice significantly (P < 0.001).	Eflornithine	0-4	Fas (TNF receptor superfamily member 6)	Mus musculus	69-72
7575451-12	1995	These data show that DFMO treatment could alter signal-transduction pathways of splenic T-cells of MRL-lpr/lpr mice.	Eflornithine	21-25	Fas (TNF receptor superfamily member 6)	Mus musculus	103-106
7575451-12	1995	These data show that DFMO treatment could alter signal-transduction pathways of splenic T-cells of MRL-lpr/lpr mice.	Eflornithine	21-25	Fas (TNF receptor superfamily member 6)	Mus musculus	107-110
7646459-1	1995	(1) Human myeloma cell line Sultan, resistant to 20 mM difluoro-methylornithine (DFMO) owing to ornithine decarboxylase (ODC) gene amplification, was grown in the absence of DFMO for a period of 10 months.	Eflornithine	81-85	ornithine decarboxylase 1	Homo sapiens	96-119
7646459-2	1995	The gene copy number and methylation status of the ODC gene were monitored after withdrawal of DFMO.	Eflornithine	95-99	ornithine decarboxylase 1	Homo sapiens	51-54
7559809-5	1995	Additionally, DMSpm supports cell growth in cells which have been depleted of their natural polyamines by the ornithine decarboxylase inhibitor, 2-difluoromethylornithine.	Eflornithine	145-170	ornithine decarboxylase 1	Homo sapiens	110-133
7474658-4	1995	However, the concomitant treatment with difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, as a 2% solution in the drinking water completely abolished the increase of renal ODC, but the kidney weights increased and other androgenic effects, such as the induction of renal beta-glucuronidase, were not affected.	Eflornithine	40-63	ornithine decarboxylase, structural 1	Mus musculus	101-104
7474658-4	1995	However, the concomitant treatment with difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, as a 2% solution in the drinking water completely abolished the increase of renal ODC, but the kidney weights increased and other androgenic effects, such as the induction of renal beta-glucuronidase, were not affected.	Eflornithine	40-63	ornithine decarboxylase, structural 1	Mus musculus	188-191
7474658-4	1995	However, the concomitant treatment with difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, as a 2% solution in the drinking water completely abolished the increase of renal ODC, but the kidney weights increased and other androgenic effects, such as the induction of renal beta-glucuronidase, were not affected.	Eflornithine	65-69	ornithine decarboxylase, structural 1	Mus musculus	101-104
7474658-4	1995	However, the concomitant treatment with difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, as a 2% solution in the drinking water completely abolished the increase of renal ODC, but the kidney weights increased and other androgenic effects, such as the induction of renal beta-glucuronidase, were not affected.	Eflornithine	65-69	ornithine decarboxylase, structural 1	Mus musculus	188-191
7646459-5	1995	The methylation status of the ODC gene, however, remained almost unaltered, displaying only a modest increase in methylation after 10 months without DFMO.	Eflornithine	149-153	ornithine decarboxylase 1	Homo sapiens	30-33
7646459-9	1995	(3) Due to the grossly elevated ODC enzyme activity, levels of putrescine and spermidine first peaked and then stabilized at 6 weeks after DFMO withdrawal.	Eflornithine	139-143	ornithine decarboxylase 1	Homo sapiens	32-35
7628376-7	1995	Difluoromethylornithine, a specific inhibitor of ODC activity, induced a similar inhibition of UMR 106-01 cell proliferation, indicating the importance of the polyamine pathway in this osteoblastic cell line.	Eflornithine	0-23	ornithine decarboxylase 1	Rattus norvegicus	49-52
7634128-11	1995	In vitro, treatment with DL-alpha-difluoromethylornithine (DFMO) or methylglyoxal bis-(guanylhydrazone) (MGBG) led to an increase in AdoMetDC.	Eflornithine	25-57	S-adenosylmethionine decarboxylase 1	Mus musculus	133-141
7570589-6	1995	Administration of alpha-difluoromethylornithine, a suicide inhibitor of ODC, prevented both an increase in putrescine level and DNA synthesis in the crypt cells.	Eflornithine	18-47	ornithine decarboxylase 1	Rattus norvegicus	72-75
7790255-6	1995	Ornithine decarboxylase (ODC) activity was rapidly inhibited (1-2 h) following 10 microM BE-4-4-4-4 exposure in all SCC cell lines (approximately 90%), whereas identical exposure to 10 microM difluoromethylornithine (DFMO) induced animal ODC inhibition (approximately 10%).	Eflornithine	192-215	ornithine decarboxylase 1	Homo sapiens	0-23
7790255-6	1995	Ornithine decarboxylase (ODC) activity was rapidly inhibited (1-2 h) following 10 microM BE-4-4-4-4 exposure in all SCC cell lines (approximately 90%), whereas identical exposure to 10 microM difluoromethylornithine (DFMO) induced animal ODC inhibition (approximately 10%).	Eflornithine	192-215	ornithine decarboxylase 1	Homo sapiens	25-28
7790255-6	1995	Ornithine decarboxylase (ODC) activity was rapidly inhibited (1-2 h) following 10 microM BE-4-4-4-4 exposure in all SCC cell lines (approximately 90%), whereas identical exposure to 10 microM difluoromethylornithine (DFMO) induced animal ODC inhibition (approximately 10%).	Eflornithine	217-221	ornithine decarboxylase 1	Homo sapiens	0-23
7790255-6	1995	Ornithine decarboxylase (ODC) activity was rapidly inhibited (1-2 h) following 10 microM BE-4-4-4-4 exposure in all SCC cell lines (approximately 90%), whereas identical exposure to 10 microM difluoromethylornithine (DFMO) induced animal ODC inhibition (approximately 10%).	Eflornithine	217-221	ornithine decarboxylase 1	Homo sapiens	25-28
21153204-4	1995	DDT(1)-MF-2 cell growth was inhibited by TA and difluoromethyl ornithine (DFMO), an irreversible inhibitor of ODC.	Eflornithine	48-72	ornithine decarboxylase 1	Homo sapiens	110-113
21153204-4	1995	DDT(1)-MF-2 cell growth was inhibited by TA and difluoromethyl ornithine (DFMO), an irreversible inhibitor of ODC.	Eflornithine	74-78	ornithine decarboxylase 1	Homo sapiens	110-113
21153204-6	1995	Ten muM: DFMO inhibited ODC activity to a maximum of 50% of control.	Eflornithine	9-13	ornithine decarboxylase 1	Homo sapiens	24-27
21153204-7	1995	The concentration of ODC mRNA was maximally decreased at 15 h after TA administration.Though TA and DFMO inhibited cell growth and ODC activity in DDT(1)-MF2 cells, growth inhibition by DFMO, but not by TA, was overcome by the addition of putrescine, the product of ODC reaction.	Eflornithine	100-104	ornithine decarboxylase 1	Homo sapiens	21-24
21153204-7	1995	The concentration of ODC mRNA was maximally decreased at 15 h after TA administration.Though TA and DFMO inhibited cell growth and ODC activity in DDT(1)-MF2 cells, growth inhibition by DFMO, but not by TA, was overcome by the addition of putrescine, the product of ODC reaction.	Eflornithine	100-104	ornithine decarboxylase 1	Homo sapiens	131-134
21153204-7	1995	The concentration of ODC mRNA was maximally decreased at 15 h after TA administration.Though TA and DFMO inhibited cell growth and ODC activity in DDT(1)-MF2 cells, growth inhibition by DFMO, but not by TA, was overcome by the addition of putrescine, the product of ODC reaction.	Eflornithine	100-104	ornithine decarboxylase 1	Homo sapiens	131-134
21153204-7	1995	The concentration of ODC mRNA was maximally decreased at 15 h after TA administration.Though TA and DFMO inhibited cell growth and ODC activity in DDT(1)-MF2 cells, growth inhibition by DFMO, but not by TA, was overcome by the addition of putrescine, the product of ODC reaction.	Eflornithine	186-190	ornithine decarboxylase 1	Homo sapiens	21-24
7634128-11	1995	In vitro, treatment with DL-alpha-difluoromethylornithine (DFMO) or methylglyoxal bis-(guanylhydrazone) (MGBG) led to an increase in AdoMetDC.	Eflornithine	59-63	S-adenosylmethionine decarboxylase 1	Mus musculus	133-141
7896889-5	1995	ODC-overexpressing MCF-7 cells were resistant to the antiproliferative effects of low but not high concentrations of the enzyme inhibitor, alpha-difluoromethylornithine.	Eflornithine	139-168	ornithine decarboxylase 1	Homo sapiens	0-3
7664813-7	1995	Postnatal treatment with alpha-difluoromethylornithine reduced the total polyamine content of area CA1 in 10- to 15-day-old rats almost to the adult level (although spermine content was unaffected).	Eflornithine	25-54	carbonic anhydrase 1	Rattus norvegicus	99-102
7650539-4	1995	alpha-Difluoromethylornithine is a specific inhibitor of ornithine decarboxylase, Ifenprodil is an inhibitor of the polyamine binding site on the n-methyl-d-aspartate receptor, and MK-801 is an antagonist to n-methyl-d-aspartate binding to the n-methyl-d-aspartate receptor.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	57-80
7650539-5	1995	Addition of putrescine, the product of ornithine decarboxylase activity, reversed the effect of alpha-difluoromethylornithine and restored the pericapillary swelling.	Eflornithine	96-125	ornithine decarboxylase 1	Rattus norvegicus	39-62
7599326-4	1995	The participation of ODC in early events evoked by OA in leukemic cells was confirmed by the decrease of the stimulatory effect of OA on cell proliferation in the presence of alpha-difluoromethylornithine (DFMO)--an irreversible inhibitor of ODC.	Eflornithine	175-204	ornithine decarboxylase 1	Homo sapiens	21-24
7599326-4	1995	The participation of ODC in early events evoked by OA in leukemic cells was confirmed by the decrease of the stimulatory effect of OA on cell proliferation in the presence of alpha-difluoromethylornithine (DFMO)--an irreversible inhibitor of ODC.	Eflornithine	175-204	ornithine decarboxylase 1	Homo sapiens	242-245
7599326-4	1995	The participation of ODC in early events evoked by OA in leukemic cells was confirmed by the decrease of the stimulatory effect of OA on cell proliferation in the presence of alpha-difluoromethylornithine (DFMO)--an irreversible inhibitor of ODC.	Eflornithine	206-210	ornithine decarboxylase 1	Homo sapiens	21-24
7599326-4	1995	The participation of ODC in early events evoked by OA in leukemic cells was confirmed by the decrease of the stimulatory effect of OA on cell proliferation in the presence of alpha-difluoromethylornithine (DFMO)--an irreversible inhibitor of ODC.	Eflornithine	206-210	ornithine decarboxylase 1	Homo sapiens	242-245
7598514-3	1995	Mechanisms of antitrypanosomal action of these drugs are mostly unknown, except for eflornithine, which is a suicide inhibitor of ornithine decarboxylase.	Eflornithine	84-96	ornithine decarboxylase 1	Homo sapiens	130-153
7780833-10	1995	DFMO, which completely inhibited the activity of renal ODC, did not influence significantly the testosterone-induced arginase and the testosterone-decreased OAT.	Eflornithine	0-4	ornithine decarboxylase, structural 1	Mus musculus	55-58
7584666-5	1995	Combination of IFN-alpha with either DFMO or dietary beta-carotene supplementation improved the effect of an otherwise suboptimal IFN-alpha therapy regimen.	Eflornithine	37-41	interferon alpha	Mus musculus	130-139
7742812-3	1995	Studies on the cell culture system of cultured rat hepatoma (HTC) cells treated with alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, clearly showed the presence of Is and Ip when I was administered, and IIs and IIp when II was administered, with no detection of putrescine or spermidine.	Eflornithine	85-114	ornithine decarboxylase 1	Rattus norvegicus	119-142
7852843-4	1995	Difluoromethylornithine (DFMO), a selective inhibitor of ODC, inhibited these increases and blunted the enhancement of superoxide generation and secondary granule release associated with priming by TNF.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	57-60
7852843-4	1995	Difluoromethylornithine (DFMO), a selective inhibitor of ODC, inhibited these increases and blunted the enhancement of superoxide generation and secondary granule release associated with priming by TNF.	Eflornithine	0-23	tumor necrosis factor	Homo sapiens	198-201
7852843-4	1995	Difluoromethylornithine (DFMO), a selective inhibitor of ODC, inhibited these increases and blunted the enhancement of superoxide generation and secondary granule release associated with priming by TNF.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	57-60
7852843-4	1995	Difluoromethylornithine (DFMO), a selective inhibitor of ODC, inhibited these increases and blunted the enhancement of superoxide generation and secondary granule release associated with priming by TNF.	Eflornithine	25-29	tumor necrosis factor	Homo sapiens	198-201
7773346-7	1995	When the increase of ornithine decarboxylase activity was suppressed by alpha-difluoromethylornithine, epidermal growth factor failed to facilitate the repair of intestinal mucosa.	Eflornithine	72-101	ornithine decarboxylase 1	Rattus norvegicus	21-44
8747382-4	1995	alpha-Difluoromethylornithine (DFMO), a specific suicide inhibitor of ODC, exhibits antitumor and antimetastasis activities, and displays effectiveness in many carcinogen-induced animal chemoprevention models.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	70-73
8538189-4	1995	In animal models of colon carcinogenesis, inhibition of ODC by difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor, reduces the number and size of colon adenomas and carcinomas.	Eflornithine	63-86	ornithine decarboxylase 1	Homo sapiens	56-59
8538189-4	1995	In animal models of colon carcinogenesis, inhibition of ODC by difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor, reduces the number and size of colon adenomas and carcinomas.	Eflornithine	88-92	ornithine decarboxylase 1	Homo sapiens	56-59
8538190-2	1995	Many highly specific and potent inhibitors of ODC are based on the lead compound alpha-difluoromethylornithine (DFMO), which is an enzyme-activated irreversible inhibitor.	Eflornithine	81-110	ornithine decarboxylase 1	Homo sapiens	46-49
8538190-2	1995	Many highly specific and potent inhibitors of ODC are based on the lead compound alpha-difluoromethylornithine (DFMO), which is an enzyme-activated irreversible inhibitor.	Eflornithine	112-116	ornithine decarboxylase 1	Homo sapiens	46-49
8538190-3	1995	DFMO is accepted as a substrate by ODC and is decarboxylated, leading to the formation of a highly reactive species that forms a covalent adduct with either cysteine-360 (90%) or lysine-69 (10%).	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	35-38
8747382-4	1995	alpha-Difluoromethylornithine (DFMO), a specific suicide inhibitor of ODC, exhibits antitumor and antimetastasis activities, and displays effectiveness in many carcinogen-induced animal chemoprevention models.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	70-73
7899459-9	1995	In contrast, the azaserine-induced significant increase in hepatic putrescine was lower and transient, was accompanied by an increase in ODC and SAM-DC, and was completely inhibited by simultaneous DFMO treatment but not by MDL 72527.	Eflornithine	198-202	ornithine decarboxylase 1	Rattus norvegicus	137-140
7796931-5	1995	Treatment of diabetic rats with the selective ODC inhibitor di-fluoro-methyl-ornithine (DFMO) was maintained for two periods (days 7-14 and days 50-71).	Eflornithine	60-86	ornithine decarboxylase 1	Rattus norvegicus	46-49
7796931-5	1995	Treatment of diabetic rats with the selective ODC inhibitor di-fluoro-methyl-ornithine (DFMO) was maintained for two periods (days 7-14 and days 50-71).	Eflornithine	88-92	ornithine decarboxylase 1	Rattus norvegicus	46-49
7899459-6	1995	Furthermore, animals were simultaneously treated with the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO) or the polyamine oxidase inhibitor MDL 72527 and killed 6 and 12 h after azaserine injection.	Eflornithine	98-127	ornithine decarboxylase 1	Rattus norvegicus	83-86
7945802-2	1994	We investigated the effect of alpha-difluoromethylornithine (DFMO) on matrilysin expression in this cell line because others have shown that DFMO can inhibit invasion and carcinogenesis in epithelial tissues, including the colon, in experimental models.	Eflornithine	30-59	matrix metallopeptidase 7	Homo sapiens	70-80
7945802-2	1994	We investigated the effect of alpha-difluoromethylornithine (DFMO) on matrilysin expression in this cell line because others have shown that DFMO can inhibit invasion and carcinogenesis in epithelial tissues, including the colon, in experimental models.	Eflornithine	61-65	matrix metallopeptidase 7	Homo sapiens	70-80
7945802-3	1994	DFMO reduced extracellular levels of matrilysin protein after 4 d of treatment.	Eflornithine	0-4	matrix metallopeptidase 7	Homo sapiens	37-47
7945802-4	1994	Intracellular levels of matrilysin protein were minimally affected by DFMO treatment.	Eflornithine	70-74	matrix metallopeptidase 7	Homo sapiens	24-34
7945802-5	1994	The decrease in extracellular matrilysin protein levels caused by DFMO was not a consequence of lowered steady-state levels of matrilysin mRNA.	Eflornithine	66-70	matrix metallopeptidase 7	Homo sapiens	30-40
7945802-7	1994	These data show that polyamine depletion by DFMO can suppress the expression of matrilysin, a gene product thought to be involved in tumor invasion.	Eflornithine	44-48	matrix metallopeptidase 7	Homo sapiens	80-90
7945802-8	1994	The decrease in extracellular matrilysin protein caused by DFMO treatment appears to be due to a posttranscriptional mechanism, although transcription of this gene also seems to be affected by polyamines in SW1116 cells.	Eflornithine	59-63	matrix metallopeptidase 7	Homo sapiens	30-40
7918572-0	1994	Post-transcriptional inhibition of ornithine decarboxylase induction by zinc in a difluoromethylornithine resistant cell line.	Eflornithine	82-105	ornithine decarboxylase 1	Homo sapiens	35-58
7943199-10	1994	DFMO is a specific and irreversible inhibitor of ornithine decarboxylase, a rate-limiting enzyme of polyamine biosynthesis.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	49-72
7943199-11	1994	In IEC-6 cells, tissue TGA activity decreased significantly with DFMO treatment concurrent with a rise in inactive TGA protein as measured by Western blot analysis.	Eflornithine	65-69	T-box transcription factor 1	Homo sapiens	23-26
7943199-12	1994	On the other hand, in Caco-2 cells, tissue TGA activity and protein increased significantly with DFMO treatment.	Eflornithine	97-101	T-box transcription factor 1	Homo sapiens	43-46
7943199-13	1994	In both cell lines, addition of polyamines to the DFMO treatment restored cell migration, tissue TGA activity, and protein to control levels.	Eflornithine	50-54	T-box transcription factor 1	Homo sapiens	97-100
7951165-0	1994	Eflornithine treatment in SHR: potential role of vascular polyamines and ornithine decarboxylase in hypertension.	Eflornithine	0-12	ornithine decarboxylase 1	Rattus norvegicus	73-96
7951165-2	1994	The effects of chronic administration of eflornithine (alpha-difluoromethylornithine; DFMO), a highly specific inhibitor of ornithine decarboxylase (the rate limiting enzyme in polyamine biosynthesis), on vascular polyamine contents, vascular structure and function, and blood pressure was studied.	Eflornithine	41-53	ornithine decarboxylase 1	Rattus norvegicus	124-147
7951165-2	1994	The effects of chronic administration of eflornithine (alpha-difluoromethylornithine; DFMO), a highly specific inhibitor of ornithine decarboxylase (the rate limiting enzyme in polyamine biosynthesis), on vascular polyamine contents, vascular structure and function, and blood pressure was studied.	Eflornithine	55-84	ornithine decarboxylase 1	Rattus norvegicus	124-147
7951165-2	1994	The effects of chronic administration of eflornithine (alpha-difluoromethylornithine; DFMO), a highly specific inhibitor of ornithine decarboxylase (the rate limiting enzyme in polyamine biosynthesis), on vascular polyamine contents, vascular structure and function, and blood pressure was studied.	Eflornithine	86-90	ornithine decarboxylase 1	Rattus norvegicus	124-147
7565449-5	1995	Preincubation of the cells with 10(-8)M 1,25-(OH)2D3 for 48 h attenuated the serum-induced rise in ODC activity by 12 h. alpha-Difluoromethylornithine (DFMO), a specific inhibitor of ODC, inhibited the serum-stimulated [3H]thymidine incorporation.	Eflornithine	121-150	ornithine decarboxylase	Bos taurus	99-102
7565449-5	1995	Preincubation of the cells with 10(-8)M 1,25-(OH)2D3 for 48 h attenuated the serum-induced rise in ODC activity by 12 h. alpha-Difluoromethylornithine (DFMO), a specific inhibitor of ODC, inhibited the serum-stimulated [3H]thymidine incorporation.	Eflornithine	121-150	ornithine decarboxylase	Bos taurus	183-186
7565449-5	1995	Preincubation of the cells with 10(-8)M 1,25-(OH)2D3 for 48 h attenuated the serum-induced rise in ODC activity by 12 h. alpha-Difluoromethylornithine (DFMO), a specific inhibitor of ODC, inhibited the serum-stimulated [3H]thymidine incorporation.	Eflornithine	152-156	ornithine decarboxylase	Bos taurus	183-186
7810648-7	1994	DL-alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, prevents the transient increases in both ODC activity and the three polyamines in the smooth muscle.	Eflornithine	0-32	ornithine decarboxylase 1	Rattus norvegicus	70-73
7810648-7	1994	DL-alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, prevents the transient increases in both ODC activity and the three polyamines in the smooth muscle.	Eflornithine	0-32	ornithine decarboxylase 1	Rattus norvegicus	116-119
7810648-7	1994	DL-alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, prevents the transient increases in both ODC activity and the three polyamines in the smooth muscle.	Eflornithine	34-38	ornithine decarboxylase 1	Rattus norvegicus	70-73
7810648-7	1994	DL-alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, prevents the transient increases in both ODC activity and the three polyamines in the smooth muscle.	Eflornithine	34-38	ornithine decarboxylase 1	Rattus norvegicus	116-119
7810663-5	1994	After a 6-day treatment with the ornithine decarboxylase inhibitor alpha-difluoromethylornithine, the duration of postprandial disruption of MMCs, but not the stimulation of colonic motility, induced by a 3-g meal was significantly reduced.	Eflornithine	67-96	ornithine decarboxylase 1	Rattus norvegicus	33-56
7929646-6	1994	Pretreatment of animals with DFMO resulted in attenuation of the ODC activity following 5 min of ischemia and 4 h of reperfusion.	Eflornithine	29-33	ornithine decarboxylase 1	Homo sapiens	65-68
7898610-3	1994	ODC inhibitor, alpha-difluoromethylornithine (DFMO), and NMDA antagonist, 2-amino-5-phosphonovaleric acid (D-AP5), both blocked increases in ODC activity and PA levels.	Eflornithine	15-44	ornithine decarboxylase 1	Rattus norvegicus	141-144
7898610-3	1994	ODC inhibitor, alpha-difluoromethylornithine (DFMO), and NMDA antagonist, 2-amino-5-phosphonovaleric acid (D-AP5), both blocked increases in ODC activity and PA levels.	Eflornithine	46-50	ornithine decarboxylase 1	Rattus norvegicus	0-3
7898610-3	1994	ODC inhibitor, alpha-difluoromethylornithine (DFMO), and NMDA antagonist, 2-amino-5-phosphonovaleric acid (D-AP5), both blocked increases in ODC activity and PA levels.	Eflornithine	46-50	ornithine decarboxylase 1	Rattus norvegicus	141-144
7899459-9	1995	In contrast, the azaserine-induced significant increase in hepatic putrescine was lower and transient, was accompanied by an increase in ODC and SAM-DC, and was completely inhibited by simultaneous DFMO treatment but not by MDL 72527.	Eflornithine	198-202	adenosylmethionine decarboxylase 1	Rattus norvegicus	145-151
8074711-2	1994	Treatments of the transfected cells with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC), and dexamethasone, an inducer of antizyme, both caused a decrease in ODC activity and polyamine contents and inhibition of cell growth.	Eflornithine	41-70	ornithine decarboxylase, structural 1	Mus musculus	95-118
8074711-2	1994	Treatments of the transfected cells with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC), and dexamethasone, an inducer of antizyme, both caused a decrease in ODC activity and polyamine contents and inhibition of cell growth.	Eflornithine	41-70	ornithine decarboxylase, structural 1	Mus musculus	120-123
8074711-2	1994	Treatments of the transfected cells with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC), and dexamethasone, an inducer of antizyme, both caused a decrease in ODC activity and polyamine contents and inhibition of cell growth.	Eflornithine	41-70	ornithine decarboxylase, structural 1	Mus musculus	195-198
8074711-2	1994	Treatments of the transfected cells with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC), and dexamethasone, an inducer of antizyme, both caused a decrease in ODC activity and polyamine contents and inhibition of cell growth.	Eflornithine	72-76	ornithine decarboxylase, structural 1	Mus musculus	95-118
8074711-2	1994	Treatments of the transfected cells with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC), and dexamethasone, an inducer of antizyme, both caused a decrease in ODC activity and polyamine contents and inhibition of cell growth.	Eflornithine	72-76	ornithine decarboxylase, structural 1	Mus musculus	120-123
8048943-3	1994	alpha-Difluoromethylornithine, a specific inhibitor of ODC, prevented the transcription of c-myc in cells grown at 37 degrees C. Putrescine, at physiological concentrations, triggered the transcription of c-myc and c-fos in cells grown at 42 degrees C, when Ki-ras was not expressed.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	55-58
8048943-3	1994	alpha-Difluoromethylornithine, a specific inhibitor of ODC, prevented the transcription of c-myc in cells grown at 37 degrees C. Putrescine, at physiological concentrations, triggered the transcription of c-myc and c-fos in cells grown at 42 degrees C, when Ki-ras was not expressed.	Eflornithine	0-29	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	91-96
8048943-3	1994	alpha-Difluoromethylornithine, a specific inhibitor of ODC, prevented the transcription of c-myc in cells grown at 37 degrees C. Putrescine, at physiological concentrations, triggered the transcription of c-myc and c-fos in cells grown at 42 degrees C, when Ki-ras was not expressed.	Eflornithine	0-29	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	205-210
8048943-3	1994	alpha-Difluoromethylornithine, a specific inhibitor of ODC, prevented the transcription of c-myc in cells grown at 37 degrees C. Putrescine, at physiological concentrations, triggered the transcription of c-myc and c-fos in cells grown at 42 degrees C, when Ki-ras was not expressed.	Eflornithine	0-29	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	215-220
8048943-3	1994	alpha-Difluoromethylornithine, a specific inhibitor of ODC, prevented the transcription of c-myc in cells grown at 37 degrees C. Putrescine, at physiological concentrations, triggered the transcription of c-myc and c-fos in cells grown at 42 degrees C, when Ki-ras was not expressed.	Eflornithine	0-29	KRAS proto-oncogene, GTPase	Rattus norvegicus	258-264
7972938-4	1994	The functional role of polyamines in regulation of ANP was assessed by exposing the cardiocytes to difluoromethylornithine (DFMO) which is an inhibitor of ornithine decarboxylase, an initial rate-limiting enzyme in the biosynthesis of polyamines.	Eflornithine	99-122	natriuretic peptide A	Rattus norvegicus	51-54
7972938-4	1994	The functional role of polyamines in regulation of ANP was assessed by exposing the cardiocytes to difluoromethylornithine (DFMO) which is an inhibitor of ornithine decarboxylase, an initial rate-limiting enzyme in the biosynthesis of polyamines.	Eflornithine	99-122	ornithine decarboxylase 1	Rattus norvegicus	155-178
7972938-4	1994	The functional role of polyamines in regulation of ANP was assessed by exposing the cardiocytes to difluoromethylornithine (DFMO) which is an inhibitor of ornithine decarboxylase, an initial rate-limiting enzyme in the biosynthesis of polyamines.	Eflornithine	124-128	natriuretic peptide A	Rattus norvegicus	51-54
7972938-4	1994	The functional role of polyamines in regulation of ANP was assessed by exposing the cardiocytes to difluoromethylornithine (DFMO) which is an inhibitor of ornithine decarboxylase, an initial rate-limiting enzyme in the biosynthesis of polyamines.	Eflornithine	124-128	ornithine decarboxylase 1	Rattus norvegicus	155-178
7972938-5	1994	The results showed that DFMO reduced the levels of putrescine (diamine) and spermidine (triamine) in cultured cardiocytes, and it decreased the levels of ANP in media and cellular extracts of cardiocytes as a function of its dose.	Eflornithine	24-28	natriuretic peptide A	Rattus norvegicus	154-157
8063013-2	1994	alpha-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase significantly abolished stimulation of protein synthesis evoked by EGF, TGF-alpha or -beta 1 in L6 and fetal bovine myoblasts.	Eflornithine	0-29	ornithine decarboxylase	Bos taurus	60-83
8063013-2	1994	alpha-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase significantly abolished stimulation of protein synthesis evoked by EGF, TGF-alpha or -beta 1 in L6 and fetal bovine myoblasts.	Eflornithine	0-29	LOC521832	Bos taurus	151-154
8063013-2	1994	alpha-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase significantly abolished stimulation of protein synthesis evoked by EGF, TGF-alpha or -beta 1 in L6 and fetal bovine myoblasts.	Eflornithine	0-29	transforming growth factor alpha	Bos taurus	156-165
7958401-3	1994	Treatment of the cells with 1 mM of the specific L-ornithine decarboxylase (ODC) inhibitor DL-alpha-difluoromethylornithine (DFMO) resulted in a 97% decrease in ODC activity, lowered contents of putrescine (96%) and spermidine (85%) and cell proliferation rates (90%) along with a compensatory 15-fold increase in S-adenosyl-L-methionine decarboxylase (SAMDC) activity.	Eflornithine	91-123	ornithine decarboxylase 1	Homo sapiens	49-74
7958401-3	1994	Treatment of the cells with 1 mM of the specific L-ornithine decarboxylase (ODC) inhibitor DL-alpha-difluoromethylornithine (DFMO) resulted in a 97% decrease in ODC activity, lowered contents of putrescine (96%) and spermidine (85%) and cell proliferation rates (90%) along with a compensatory 15-fold increase in S-adenosyl-L-methionine decarboxylase (SAMDC) activity.	Eflornithine	91-123	ornithine decarboxylase 1	Homo sapiens	76-79
7958401-3	1994	Treatment of the cells with 1 mM of the specific L-ornithine decarboxylase (ODC) inhibitor DL-alpha-difluoromethylornithine (DFMO) resulted in a 97% decrease in ODC activity, lowered contents of putrescine (96%) and spermidine (85%) and cell proliferation rates (90%) along with a compensatory 15-fold increase in S-adenosyl-L-methionine decarboxylase (SAMDC) activity.	Eflornithine	91-123	ornithine decarboxylase 1	Homo sapiens	161-164
7958401-3	1994	Treatment of the cells with 1 mM of the specific L-ornithine decarboxylase (ODC) inhibitor DL-alpha-difluoromethylornithine (DFMO) resulted in a 97% decrease in ODC activity, lowered contents of putrescine (96%) and spermidine (85%) and cell proliferation rates (90%) along with a compensatory 15-fold increase in S-adenosyl-L-methionine decarboxylase (SAMDC) activity.	Eflornithine	91-123	adenosylmethionine decarboxylase 1	Homo sapiens	314-351
7958401-3	1994	Treatment of the cells with 1 mM of the specific L-ornithine decarboxylase (ODC) inhibitor DL-alpha-difluoromethylornithine (DFMO) resulted in a 97% decrease in ODC activity, lowered contents of putrescine (96%) and spermidine (85%) and cell proliferation rates (90%) along with a compensatory 15-fold increase in S-adenosyl-L-methionine decarboxylase (SAMDC) activity.	Eflornithine	91-123	adenosylmethionine decarboxylase 1	Homo sapiens	353-358
7958401-3	1994	Treatment of the cells with 1 mM of the specific L-ornithine decarboxylase (ODC) inhibitor DL-alpha-difluoromethylornithine (DFMO) resulted in a 97% decrease in ODC activity, lowered contents of putrescine (96%) and spermidine (85%) and cell proliferation rates (90%) along with a compensatory 15-fold increase in S-adenosyl-L-methionine decarboxylase (SAMDC) activity.	Eflornithine	125-129	ornithine decarboxylase 1	Homo sapiens	49-74
7958401-3	1994	Treatment of the cells with 1 mM of the specific L-ornithine decarboxylase (ODC) inhibitor DL-alpha-difluoromethylornithine (DFMO) resulted in a 97% decrease in ODC activity, lowered contents of putrescine (96%) and spermidine (85%) and cell proliferation rates (90%) along with a compensatory 15-fold increase in S-adenosyl-L-methionine decarboxylase (SAMDC) activity.	Eflornithine	125-129	ornithine decarboxylase 1	Homo sapiens	76-79
7958401-3	1994	Treatment of the cells with 1 mM of the specific L-ornithine decarboxylase (ODC) inhibitor DL-alpha-difluoromethylornithine (DFMO) resulted in a 97% decrease in ODC activity, lowered contents of putrescine (96%) and spermidine (85%) and cell proliferation rates (90%) along with a compensatory 15-fold increase in S-adenosyl-L-methionine decarboxylase (SAMDC) activity.	Eflornithine	125-129	ornithine decarboxylase 1	Homo sapiens	161-164
7958401-3	1994	Treatment of the cells with 1 mM of the specific L-ornithine decarboxylase (ODC) inhibitor DL-alpha-difluoromethylornithine (DFMO) resulted in a 97% decrease in ODC activity, lowered contents of putrescine (96%) and spermidine (85%) and cell proliferation rates (90%) along with a compensatory 15-fold increase in S-adenosyl-L-methionine decarboxylase (SAMDC) activity.	Eflornithine	125-129	adenosylmethionine decarboxylase 1	Homo sapiens	314-351
7958401-3	1994	Treatment of the cells with 1 mM of the specific L-ornithine decarboxylase (ODC) inhibitor DL-alpha-difluoromethylornithine (DFMO) resulted in a 97% decrease in ODC activity, lowered contents of putrescine (96%) and spermidine (85%) and cell proliferation rates (90%) along with a compensatory 15-fold increase in S-adenosyl-L-methionine decarboxylase (SAMDC) activity.	Eflornithine	125-129	adenosylmethionine decarboxylase 1	Homo sapiens	353-358
7958401-4	1994	DFMO treatment also led to a decrease in cellular content of CT (33%) and CGRP (26%), while the drug enhanced secretion of CT (31%) but depressed that of CGRP (26%), and elevated the ratio of CT to CGRP secreted into the medium by 74%.	Eflornithine	0-4	calcitonin related polypeptide alpha	Homo sapiens	61-63
7958401-4	1994	DFMO treatment also led to a decrease in cellular content of CT (33%) and CGRP (26%), while the drug enhanced secretion of CT (31%) but depressed that of CGRP (26%), and elevated the ratio of CT to CGRP secreted into the medium by 74%.	Eflornithine	0-4	calcitonin related polypeptide alpha	Homo sapiens	74-78
7958401-4	1994	DFMO treatment also led to a decrease in cellular content of CT (33%) and CGRP (26%), while the drug enhanced secretion of CT (31%) but depressed that of CGRP (26%), and elevated the ratio of CT to CGRP secreted into the medium by 74%.	Eflornithine	0-4	calcitonin related polypeptide alpha	Homo sapiens	154-158
7958401-4	1994	DFMO treatment also led to a decrease in cellular content of CT (33%) and CGRP (26%), while the drug enhanced secretion of CT (31%) but depressed that of CGRP (26%), and elevated the ratio of CT to CGRP secreted into the medium by 74%.	Eflornithine	0-4	calcitonin related polypeptide alpha	Homo sapiens	154-158
8002964-5	1994	The irreversible inhibitor of ODC, alpha-difluoromethylornithine (DFMO), inhibited approx.	Eflornithine	35-64	ornithine decarboxylase 1	Rattus norvegicus	30-33
7980394-5	1994	1,12-Dimethylspermine had no effect on the AbeAdo-induced cytostasis of chronically treated cells, although it was active in permitting growth of cells treated with the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine.	Eflornithine	204-233	ornithine decarboxylase, structural 1	Mus musculus	169-192
8002964-5	1994	The irreversible inhibitor of ODC, alpha-difluoromethylornithine (DFMO), inhibited approx.	Eflornithine	66-70	ornithine decarboxylase 1	Rattus norvegicus	30-33
8002964-6	1994	60% of the ODC activity of all brain regions, whereas kidney ODC was inhibited totally by DFMO.	Eflornithine	90-94	ornithine decarboxylase 1	Rattus norvegicus	61-64
8203532-5	1994	Administration of alpha-difluoromethylornithine (DFMO, 500 mg/kg ip) totally prevented the marked increases in ODC activity and polyamine levels.	Eflornithine	18-47	ornithine decarboxylase 1	Rattus norvegicus	111-114
8203532-5	1994	Administration of alpha-difluoromethylornithine (DFMO, 500 mg/kg ip) totally prevented the marked increases in ODC activity and polyamine levels.	Eflornithine	49-53	ornithine decarboxylase 1	Rattus norvegicus	111-114
8203532-6	1994	DFMO also completely inhibited the expression of c-fos and significantly decreased c-myc mRNA and oncoprotein in the gastric mucosa of stressed rats.	Eflornithine	0-4	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	49-54
8203532-6	1994	DFMO also completely inhibited the expression of c-fos and significantly decreased c-myc mRNA and oncoprotein in the gastric mucosa of stressed rats.	Eflornithine	0-4	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	83-88
8162572-7	1994	The high level of expression of ODC may be a critical factor in the transformed phenotype of the P2 cells since the ability of these cells to grow in soft agar was blocked by levels of the ODC inhibitor, alpha-difluoromethylornithine, that reduced the ODC activity to values comparable to those of the parent 3T3 cells.	Eflornithine	204-233	ornithine decarboxylase, structural 1	Mus musculus	32-35
8162572-7	1994	The high level of expression of ODC may be a critical factor in the transformed phenotype of the P2 cells since the ability of these cells to grow in soft agar was blocked by levels of the ODC inhibitor, alpha-difluoromethylornithine, that reduced the ODC activity to values comparable to those of the parent 3T3 cells.	Eflornithine	204-233	ornithine decarboxylase, structural 1	Mus musculus	189-192
8162572-7	1994	The high level of expression of ODC may be a critical factor in the transformed phenotype of the P2 cells since the ability of these cells to grow in soft agar was blocked by levels of the ODC inhibitor, alpha-difluoromethylornithine, that reduced the ODC activity to values comparable to those of the parent 3T3 cells.	Eflornithine	204-233	ornithine decarboxylase, structural 1	Mus musculus	189-192
8172613-1	1994	Dilution of quiescent L1210-DFMOr (difluoromethylornithine-resistant) cells in fresh medium containing serum led to the induction of ornithine decarboxylase (ODC) and to the expression of its mRNA, as determined by a sensitive solution-hybridization-RNase-protection assay.	Eflornithine	35-58	ornithine decarboxylase 1	Homo sapiens	133-156
8172613-0	1994	Zinc is required for the expression of ornithine decarboxylase in a difluoromethylornithine-resistant cell line.	Eflornithine	68-91	ornithine decarboxylase 1	Homo sapiens	39-62
8172613-1	1994	Dilution of quiescent L1210-DFMOr (difluoromethylornithine-resistant) cells in fresh medium containing serum led to the induction of ornithine decarboxylase (ODC) and to the expression of its mRNA, as determined by a sensitive solution-hybridization-RNase-protection assay.	Eflornithine	35-58	ornithine decarboxylase 1	Homo sapiens	158-161
8143969-7	1994	RESULTS: alpha-Difluoromethylornithine inhibited hepatocyte growth factor-induced DNA synthesis by only 21%.	Eflornithine	9-38	hepatocyte growth factor	Homo sapiens	49-73
7935984-1	1994	alpha-Difluoromethyl ornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC), depletes cellular polyamine levels which is significantly correlated to neoplastic transformation.	Eflornithine	0-30	ornithine decarboxylase, structural 1	Mus musculus	55-78
8050630-1	1994	The synthetic compound 2-(difluoromethyl)-dl-ornithine irreversibly inhibits ornithine decarboxylase and reduces the intracellular levels of the polyamine cell cycle factors putrescine and spermidine.	Eflornithine	23-54	ornithine decarboxylase 1	Rattus norvegicus	77-100
8141779-2	1994	In addition, inhibition of ODC by alpha-difluoromethylornithine (DFMO) results in growth arrest of MCs.	Eflornithine	34-63	ornithine decarboxylase 1	Rattus norvegicus	27-30
8141779-2	1994	In addition, inhibition of ODC by alpha-difluoromethylornithine (DFMO) results in growth arrest of MCs.	Eflornithine	65-69	ornithine decarboxylase 1	Rattus norvegicus	27-30
8141779-7	1994	Expression of these genes reached a peak at 60 min and disappeared at 3 h. Treatment of MCs with a growth-suppressing dose of DFMO (5 mM) inhibited mRNAs of all three IEGs by 52-87% at 1 h. Total expression of Egr-1 over 20-120 min was diminished by 41%, and the time point of maximal expression was delayed by 40 min.	Eflornithine	126-130	early growth response 1	Rattus norvegicus	210-215
8138442-2	1994	The cytostatic agent alpha-difluoromethylornithine (DFMO) was investigated for its capacity to slow proliferation kinetics in human squamous cell carcinomas (SCC) of the head and neck (H&N), with the ultimate objective of improving locoregional control in rapidly dividing tumors treated with radiation therapy.	Eflornithine	21-50	serpin family B member 3	Homo sapiens	158-161
8138442-2	1994	The cytostatic agent alpha-difluoromethylornithine (DFMO) was investigated for its capacity to slow proliferation kinetics in human squamous cell carcinomas (SCC) of the head and neck (H&N), with the ultimate objective of improving locoregional control in rapidly dividing tumors treated with radiation therapy.	Eflornithine	52-56	serpin family B member 3	Homo sapiens	158-161
8027512-7	1994	The effects of DFMO on ricin toxicity were markedly influenced by altering various pharmacokinetic parameters.	Eflornithine	15-19	ricin	Ricinus communis	23-28
8027512-8	1994	The antioxidants butylated hydroxyanisole and vitamin E succinate also extended survival time in response to a lethal dose of ricin, but to a lesser extent than did dexamethasone and DFMO.	Eflornithine	183-187	ricin	Ricinus communis	126-131
8012036-6	1994	Treatment of MCF-7 cells with 1 mM difluoromethylornithine (DFMO), an inhibitor of ODC, suppressed putrescine, spermidine, and spermine levels by 74, 78, and 10%, respectively, within 48 h. Cells treated with DFMO for 48 h were supplemented with either putrescine or its homologs or spermidine or its homologs.	Eflornithine	35-58	ornithine decarboxylase 1	Homo sapiens	83-86
8012036-6	1994	Treatment of MCF-7 cells with 1 mM difluoromethylornithine (DFMO), an inhibitor of ODC, suppressed putrescine, spermidine, and spermine levels by 74, 78, and 10%, respectively, within 48 h. Cells treated with DFMO for 48 h were supplemented with either putrescine or its homologs or spermidine or its homologs.	Eflornithine	60-64	ornithine decarboxylase 1	Homo sapiens	83-86
8065308-6	1994	ODC induced cell death in a dose-dependent fashion, and alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC enzyme activity, effectively blocked ODC-induced cell death.	Eflornithine	56-85	ornithine decarboxylase, structural 1	Mus musculus	123-126
8065308-6	1994	ODC induced cell death in a dose-dependent fashion, and alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC enzyme activity, effectively blocked ODC-induced cell death.	Eflornithine	56-85	ornithine decarboxylase, structural 1	Mus musculus	123-126
8065308-6	1994	ODC induced cell death in a dose-dependent fashion, and alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC enzyme activity, effectively blocked ODC-induced cell death.	Eflornithine	87-91	ornithine decarboxylase, structural 1	Mus musculus	123-126
8065308-6	1994	ODC induced cell death in a dose-dependent fashion, and alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC enzyme activity, effectively blocked ODC-induced cell death.	Eflornithine	87-91	ornithine decarboxylase, structural 1	Mus musculus	123-126
8125959-9	1994	alpha-Difluoromethylornithine, a selective inhibitor of ornithine decarboxylase, inhibited both cadaverine and putrescine export.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	56-79
8017845-3	1994	Highly efficient in vitro selective inhibitors of ornithine decarboxylase such as DFMO do not produce important antitumoral effects in vivo, due to the ability of tumor cells to uptake extracellular polyamines.	Eflornithine	82-86	ornithine decarboxylase 1	Homo sapiens	50-73
8074989-2	1994	Ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, and thus in tissue growth and development, has been localized in mouse dental tissues, in vivo as well as in vitro by light and electron microscopic autoradiography with radiolabeled alpha-difluoromethylornithine ([3H]DFMO).	Eflornithine	254-283	ornithine decarboxylase, structural 1	Mus musculus	0-23
8074989-2	1994	Ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, and thus in tissue growth and development, has been localized in mouse dental tissues, in vivo as well as in vitro by light and electron microscopic autoradiography with radiolabeled alpha-difluoromethylornithine ([3H]DFMO).	Eflornithine	254-283	ornithine decarboxylase, structural 1	Mus musculus	25-28
8074989-2	1994	Ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, and thus in tissue growth and development, has been localized in mouse dental tissues, in vivo as well as in vitro by light and electron microscopic autoradiography with radiolabeled alpha-difluoromethylornithine ([3H]DFMO).	Eflornithine	289-293	ornithine decarboxylase, structural 1	Mus musculus	0-23
8074989-2	1994	Ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, and thus in tissue growth and development, has been localized in mouse dental tissues, in vivo as well as in vitro by light and electron microscopic autoradiography with radiolabeled alpha-difluoromethylornithine ([3H]DFMO).	Eflornithine	289-293	ornithine decarboxylase, structural 1	Mus musculus	25-28
8138442-5	1994	DFMO effects on in vitro SCC radiosensitivity using clonogenic survival were also studied.	Eflornithine	0-4	serpin family B member 3	Homo sapiens	25-28
8138442-6	1994	RESULTS: A noncytotoxic exposure to DFMO (5mM x 72 hours) induced pronounced growth inhibition in all three SCC cell lines (70-90% at 7 days), and induced a 2-3 fold delay in volume doubling time for SCC tumor xenografts when administered orally in the drinking water (1.5%) to athymic mice.	Eflornithine	36-40	serpin family B member 3	Homo sapiens	108-111
8138442-7	1994	Kinetic analysis via flow cytometry confirmed that DFMO produced a lengthening of SCC cell cycle times, but did not alter in vitro radiosensitivity.	Eflornithine	51-55	serpin family B member 3	Homo sapiens	82-85
8138442-9	1994	CONCLUSION: These data indicate that antiproliferative agents, such as DFMO, are capable of altering human SCC growth kinetics without altering intrinsic radiosensitivity.	Eflornithine	71-75	serpin family B member 3	Homo sapiens	107-110
8313364-11	1994	Treatment of synchronized cells with the polyamine biosynthetic inhibitor, difluoromethylornithine attenuated cyclin B1 mRNA degradation in the presence of estradiol.	Eflornithine	75-98	cyclin B1	Homo sapiens	110-119
8012036-8	1994	Among a series of triamines, H2N(CH2)nNH(CH2)3NH2 (where n = 2 to 8; abbreviated as APn n = 4 for spermidine, or AP4), spermidine was most effective in reversing the effects of DFMO, whereas compounds with shorter or longer methylene bridging regions were less effective.	Eflornithine	177-181	alanyl aminopeptidase, membrane	Homo sapiens	84-87
8106560-1	1994	DH23A cells, an alpha-difluoromethylornithine (DFMO)-resistant variant of rat hepatoma tissue culture cells (HTC), contain high levels of very stable ornithine decarboxylase (ODC).	Eflornithine	47-51	ornithine decarboxylase 1	Rattus norvegicus	150-173
8106560-7	1994	It is possible to mimic the effects of high levels of stable ODC by treatment of cells with exogenous putrescine in the presence of DFMO.	Eflornithine	132-136	ornithine decarboxylase 1	Rattus norvegicus	61-64
7578852-3	1994	Inhibition of ODC with 0.5-1.5% (w/v) difluoromethylornithine (DFMO) in drinking water prolonged life-span and ameliorated renal disease.	Eflornithine	38-61	ornithine decarboxylase, structural 1	Mus musculus	14-17
7578852-3	1994	Inhibition of ODC with 0.5-1.5% (w/v) difluoromethylornithine (DFMO) in drinking water prolonged life-span and ameliorated renal disease.	Eflornithine	63-67	ornithine decarboxylase, structural 1	Mus musculus	14-17
7578852-9	1994	Putrescine levels were 2- to 4-fold higher in kidney of lpr strains than that of BALB/c and DFMO-treated MRL-lpr/lpr mice.	Eflornithine	92-96	Fas (TNF receptor superfamily member 6)	Mus musculus	109-112
7578852-9	1994	Putrescine levels were 2- to 4-fold higher in kidney of lpr strains than that of BALB/c and DFMO-treated MRL-lpr/lpr mice.	Eflornithine	92-96	Fas (TNF receptor superfamily member 6)	Mus musculus	109-112
7578852-10	1994	DFMO treatment significantly reduced ODC activity and polyamine levels.	Eflornithine	0-4	ornithine decarboxylase, structural 1	Mus musculus	37-40
8174830-6	1994	Treatment with alpha-difluoromethyl-ornithine, a selective inactivator of ornithine decarboxylase prevented the accumulation of active enzyme, but did not prevent morphological healing.	Eflornithine	15-45	ornithine decarboxylase 1	Rattus norvegicus	74-97
8150743-9	1994	The period of increased polyamine synthesis coincides with the critical period for ototoxicity induced by alpha-difluoromethylornithine, a specific ODC inhibitor, and the period of rapid cochlear development.	Eflornithine	106-135	ornithine decarboxylase 1	Rattus norvegicus	148-151
7616752-14	1994	Particularly, the ODC inhibitor DFMO was active in the colon, mammary glands, and bladder models, while the dithiolthione, oltipraz, was efficacious in all the models listed above (i.e., lung, colon, mammary glands, skin, and bladder).	Eflornithine	32-36	ornithine decarboxylase, structural 1	Mus musculus	18-21
8290291-8	1994	ODC activity is elevated in the developing rat cochlea, aminoglycosides inhibit cochlear ODC in developing rats, and alpha-difluoromethylornithine (a specific ODC inhibitor) impairs development of cochlear function.	Eflornithine	117-146	ornithine decarboxylase 1	Rattus norvegicus	0-3
7935984-1	1994	alpha-Difluoromethyl ornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC), depletes cellular polyamine levels which is significantly correlated to neoplastic transformation.	Eflornithine	0-30	ornithine decarboxylase, structural 1	Mus musculus	80-83
7935984-1	1994	alpha-Difluoromethyl ornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC), depletes cellular polyamine levels which is significantly correlated to neoplastic transformation.	Eflornithine	32-36	ornithine decarboxylase, structural 1	Mus musculus	55-78
7935984-1	1994	alpha-Difluoromethyl ornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC), depletes cellular polyamine levels which is significantly correlated to neoplastic transformation.	Eflornithine	32-36	ornithine decarboxylase, structural 1	Mus musculus	80-83
8242864-12	1993	In control animals, ODC activity was decreased by DFMO treatment and selenium supplementation in the distal colon and liver, but not the proximal colon.	Eflornithine	50-54	ornithine decarboxylase 1	Rattus norvegicus	20-23
7906881-6	1994	Treatment with alpha-difluoromethylornithine (DFMO) decreased both basal ODC activity and putrescine levels in the duodenal mucosa.	Eflornithine	15-44	ornithine decarboxylase 1	Rattus norvegicus	73-76
7906881-6	1994	Treatment with alpha-difluoromethylornithine (DFMO) decreased both basal ODC activity and putrescine levels in the duodenal mucosa.	Eflornithine	46-50	ornithine decarboxylase 1	Rattus norvegicus	73-76
8227016-11	1993	These results indicate that inactivation of ODC by DFMO can occur via interaction with either of two separate residues that form essential parts of the active site.	Eflornithine	51-55	ornithine decarboxylase, structural 1	Mus musculus	44-47
8227016-13	1993	In contrast to the results with DFMO, the C360A mutant ODC was completely resistant to inactivation by (R,R)-delta-methyl-alpha-acetylenicputrescine and was much less sensitive than the wild type enzyme to alpha-monofluoromethyldehydromethylornithine, showing that the reactive species formed from these inhibitors either cannot be formed by this mutant or are unable to react with lysine 69.	Eflornithine	32-36	ornithine decarboxylase, structural 1	Mus musculus	55-58
7509180-8	1993	Difluoromethylornithine (DFMO), an inhibitor of spermidine synthesis that blocks ornithine decarboxylase, caused a slight dose-dependent decrease in 65Zn uptake over the range 10(-6)-5 x 10(-3)M (p < 0.002) and tended to decrease 65Zn-uptake in lactogenic hormone-stimulated cells with 8 h of incubation, but not at other times.	Eflornithine	0-23	ornithine decarboxylase, structural 1	Mus musculus	81-104
7509180-8	1993	Difluoromethylornithine (DFMO), an inhibitor of spermidine synthesis that blocks ornithine decarboxylase, caused a slight dose-dependent decrease in 65Zn uptake over the range 10(-6)-5 x 10(-3)M (p < 0.002) and tended to decrease 65Zn-uptake in lactogenic hormone-stimulated cells with 8 h of incubation, but not at other times.	Eflornithine	25-29	ornithine decarboxylase, structural 1	Mus musculus	81-104
8221660-0	1993	Development of resistance to hydroxyurea during treatment of human myelogenous leukemia K562 cells with alpha-difluoromethylornithine as a result of coamplification of genes for ornithine decarboxylase and ribonucleotide reductase R2 subunit.	Eflornithine	104-133	ornithine decarboxylase 1	Homo sapiens	178-201
8221660-1	1993	alpha-Difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase (ODC), was used to select two very highly drug-resistant cell lines, designated K562-DFMOr and V79-DFMOr.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	84-107
8221660-1	1993	alpha-Difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase (ODC), was used to select two very highly drug-resistant cell lines, designated K562-DFMOr and V79-DFMOr.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	109-112
8221660-1	1993	alpha-Difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase (ODC), was used to select two very highly drug-resistant cell lines, designated K562-DFMOr and V79-DFMOr.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	84-107
8221660-1	1993	alpha-Difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase (ODC), was used to select two very highly drug-resistant cell lines, designated K562-DFMOr and V79-DFMOr.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	109-112
8221660-2	1993	Both DFMO-resistant cell lines exhibited elevated ODC expression due to gene amplification.	Eflornithine	5-9	ornithine decarboxylase 1	Homo sapiens	50-53
8221660-5	1993	This is the first description of a DFMO-induced mutant cell line exhibiting coamplification of the genes for ODC and R2, and overexpression of their products.	Eflornithine	35-39	ornithine decarboxylase 1	Homo sapiens	109-112
8396915-4	1993	Exogenous spermidine can restore stress inducibility of N1-SSAT to DFMO-treated cells, and induce this enzyme activity in non-heat-shocked but polyamine-depleted cells.	Eflornithine	67-71	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	56-63
8415771-3	1993	Groups of diabetic and control rats were given difluoromethylornithine in drinking water to suppress intestinal mucosal ornithine decarboxylase activity.	Eflornithine	47-70	ornithine decarboxylase 1	Rattus norvegicus	120-143
8415771-5	1993	Treating diabetic and control rats with difluoromethylornithine suppressed jejunal mucosal growth by over 30%, ornithine decarboxylase activity by over 80%, and brush border membrane vesicle 22Na+ uptake by over 60%.	Eflornithine	40-63	ornithine decarboxylase 1	Rattus norvegicus	111-134
8357843-6	1993	DFMO also significantly affected the other biochemical markers of hyperplasia, namely lowered CB 3717-induced cell proliferation rate and increased S-adenosylmethionine decarboxylase (AdoMetDC) activity.	Eflornithine	0-4	S-adenosylmethionine decarboxylase 1	Mus musculus	148-182
8357843-6	1993	DFMO also significantly affected the other biochemical markers of hyperplasia, namely lowered CB 3717-induced cell proliferation rate and increased S-adenosylmethionine decarboxylase (AdoMetDC) activity.	Eflornithine	0-4	S-adenosylmethionine decarboxylase 1	Mus musculus	184-192
8408313-2	1993	We determined the effects of alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC, on infarct size and ODC activity in a rat model of transient focal ischemia.	Eflornithine	29-58	ornithine decarboxylase 1	Rattus norvegicus	91-94
8408313-2	1993	We determined the effects of alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC, on infarct size and ODC activity in a rat model of transient focal ischemia.	Eflornithine	29-58	ornithine decarboxylase 1	Rattus norvegicus	116-119
8408313-2	1993	We determined the effects of alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC, on infarct size and ODC activity in a rat model of transient focal ischemia.	Eflornithine	60-64	ornithine decarboxylase 1	Rattus norvegicus	91-94
8408313-2	1993	We determined the effects of alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC, on infarct size and ODC activity in a rat model of transient focal ischemia.	Eflornithine	60-64	ornithine decarboxylase 1	Rattus norvegicus	116-119
8408313-3	1993	DFMO blocked the ischemia-induced increase in ODC and significantly reduced infarct volumes by 57-45%, depending upon the treatment regimen.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	46-49
8396915-3	1993	Depletion of intracellular spermidine pools by alpha-difluoromethylornithine (DFMO) inhibits stress induction of N1-SSAT activity.	Eflornithine	47-76	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	116-120
8396915-3	1993	Depletion of intracellular spermidine pools by alpha-difluoromethylornithine (DFMO) inhibits stress induction of N1-SSAT activity.	Eflornithine	78-82	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	116-120
7688751-3	1993	Addition of the ODC inhibitor alpha-difluoromethyl ornithine (DFMO) to the cells (in polyamine-free medium) before shift to permissive temperature prevented the depolymerization of filamentous actin and morphological transformation.	Eflornithine	30-60	ornithine decarboxylase 1	Homo sapiens	16-19
8368314-10	1993	Treatment with DFMO not only prevented increased expression of c-myc and c-jun protooncogenes at 4 days, but also significantly reduced steady-state levels of c-myc and c-jun mRNA between 6 and 12 days.	Eflornithine	15-19	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	63-68
8368314-10	1993	Treatment with DFMO not only prevented increased expression of c-myc and c-jun protooncogenes at 4 days, but also significantly reduced steady-state levels of c-myc and c-jun mRNA between 6 and 12 days.	Eflornithine	15-19	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	159-164
7688751-3	1993	Addition of the ODC inhibitor alpha-difluoromethyl ornithine (DFMO) to the cells (in polyamine-free medium) before shift to permissive temperature prevented the depolymerization of filamentous actin and morphological transformation.	Eflornithine	62-66	ornithine decarboxylase 1	Homo sapiens	16-19
8355506-5	1993	Simultaneous addition of an irreversible inhibitor of ODC, difluoromethyl ornithine (DFMO), also abolished the inductions of ODC and DNA synthesis by hPRL.	Eflornithine	59-83	ornithine decarboxylase 1	Homo sapiens	54-57
8355506-5	1993	Simultaneous addition of an irreversible inhibitor of ODC, difluoromethyl ornithine (DFMO), also abolished the inductions of ODC and DNA synthesis by hPRL.	Eflornithine	59-83	ornithine decarboxylase 1	Homo sapiens	125-128
8355506-5	1993	Simultaneous addition of an irreversible inhibitor of ODC, difluoromethyl ornithine (DFMO), also abolished the inductions of ODC and DNA synthesis by hPRL.	Eflornithine	59-83	prolactin	Homo sapiens	150-154
8355506-5	1993	Simultaneous addition of an irreversible inhibitor of ODC, difluoromethyl ornithine (DFMO), also abolished the inductions of ODC and DNA synthesis by hPRL.	Eflornithine	85-89	ornithine decarboxylase 1	Homo sapiens	54-57
8355506-5	1993	Simultaneous addition of an irreversible inhibitor of ODC, difluoromethyl ornithine (DFMO), also abolished the inductions of ODC and DNA synthesis by hPRL.	Eflornithine	85-89	ornithine decarboxylase 1	Homo sapiens	125-128
8355506-5	1993	Simultaneous addition of an irreversible inhibitor of ODC, difluoromethyl ornithine (DFMO), also abolished the inductions of ODC and DNA synthesis by hPRL.	Eflornithine	85-89	prolactin	Homo sapiens	150-154
8355506-6	1993	The inhibitory effect of DFMO on hPRL-induced DNA synthesis was reversed by the addition of putrescine to the culture medium.	Eflornithine	25-29	prolactin	Homo sapiens	33-37
8318203-6	1993	Similarly, DFMO administered continuously via the drinking water to athymic mice harboring human SCC xenografts induced a prolongation of in vivo tumor volume doubling.	Eflornithine	11-15	serpin family B member 3	Homo sapiens	97-100
8318203-7	1993	CONCLUSIONS: These data indicate that biologic agents, such as DFMO, can alter SCC growth kinetics and may prove useful in designing new therapeutic strategies for rapidly proliferating tumors such as those that occur in the head and neck.	Eflornithine	63-67	serpin family B member 3	Homo sapiens	79-82
8504104-3	1993	Two distinct mutants were obtained using oligonucleotide-directed mutagenesis: In one, cysteine-360, the major alpha-(difluoromethyl)ornithine (alpha-DFMO, a suicide inhibitor of ODC) binding site was converted to alanine.	Eflornithine	144-154	ornithine decarboxylase 1	Homo sapiens	179-182
8352568-3	1993	It was found that treatment of ACHN cells with the specific ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) resulted in profound decreases of ODC activity, polyamine content and cell proliferation rates along with a compensatory increase in S-adenosylmethionine decarboxylase (SAMDC) activity.	Eflornithine	100-123	ornithine decarboxylase 1	Homo sapiens	60-83
8352568-3	1993	It was found that treatment of ACHN cells with the specific ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) resulted in profound decreases of ODC activity, polyamine content and cell proliferation rates along with a compensatory increase in S-adenosylmethionine decarboxylase (SAMDC) activity.	Eflornithine	100-123	ornithine decarboxylase 1	Homo sapiens	85-88
8352568-3	1993	It was found that treatment of ACHN cells with the specific ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) resulted in profound decreases of ODC activity, polyamine content and cell proliferation rates along with a compensatory increase in S-adenosylmethionine decarboxylase (SAMDC) activity.	Eflornithine	100-123	ornithine decarboxylase 1	Homo sapiens	165-168
8352568-3	1993	It was found that treatment of ACHN cells with the specific ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) resulted in profound decreases of ODC activity, polyamine content and cell proliferation rates along with a compensatory increase in S-adenosylmethionine decarboxylase (SAMDC) activity.	Eflornithine	100-123	adenosylmethionine decarboxylase 1	Homo sapiens	264-298
8352568-3	1993	It was found that treatment of ACHN cells with the specific ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) resulted in profound decreases of ODC activity, polyamine content and cell proliferation rates along with a compensatory increase in S-adenosylmethionine decarboxylase (SAMDC) activity.	Eflornithine	100-123	adenosylmethionine decarboxylase 1	Homo sapiens	300-305
8352568-3	1993	It was found that treatment of ACHN cells with the specific ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) resulted in profound decreases of ODC activity, polyamine content and cell proliferation rates along with a compensatory increase in S-adenosylmethionine decarboxylase (SAMDC) activity.	Eflornithine	125-129	ornithine decarboxylase 1	Homo sapiens	60-83
8352568-3	1993	It was found that treatment of ACHN cells with the specific ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) resulted in profound decreases of ODC activity, polyamine content and cell proliferation rates along with a compensatory increase in S-adenosylmethionine decarboxylase (SAMDC) activity.	Eflornithine	125-129	ornithine decarboxylase 1	Homo sapiens	85-88
8352568-3	1993	It was found that treatment of ACHN cells with the specific ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) resulted in profound decreases of ODC activity, polyamine content and cell proliferation rates along with a compensatory increase in S-adenosylmethionine decarboxylase (SAMDC) activity.	Eflornithine	125-129	ornithine decarboxylase 1	Homo sapiens	165-168
8352568-3	1993	It was found that treatment of ACHN cells with the specific ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) resulted in profound decreases of ODC activity, polyamine content and cell proliferation rates along with a compensatory increase in S-adenosylmethionine decarboxylase (SAMDC) activity.	Eflornithine	125-129	adenosylmethionine decarboxylase 1	Homo sapiens	264-298
8352568-3	1993	It was found that treatment of ACHN cells with the specific ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) resulted in profound decreases of ODC activity, polyamine content and cell proliferation rates along with a compensatory increase in S-adenosylmethionine decarboxylase (SAMDC) activity.	Eflornithine	125-129	adenosylmethionine decarboxylase 1	Homo sapiens	300-305
8358715-0	1993	Chemopreventive effects of dietary D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, on initiation and postinitiation stages of diethylnitrosamine-induced rat hepatocarcinogenesis.	Eflornithine	35-68	ornithine decarboxylase 1	Rattus norvegicus	73-96
8333497-4	1993	EGF significantly stimulated ornithine decarboxylase (ODC) activity, an effect that was blocked by the specific ODC inhibitor, difluoromethylornithine (DFMO).	Eflornithine	152-156	ornithine decarboxylase 1	Rattus norvegicus	29-52
8333497-4	1993	EGF significantly stimulated ornithine decarboxylase (ODC) activity, an effect that was blocked by the specific ODC inhibitor, difluoromethylornithine (DFMO).	Eflornithine	152-156	ornithine decarboxylase 1	Rattus norvegicus	54-57
8333497-4	1993	EGF significantly stimulated ornithine decarboxylase (ODC) activity, an effect that was blocked by the specific ODC inhibitor, difluoromethylornithine (DFMO).	Eflornithine	127-150	epidermal growth factor like 1	Rattus norvegicus	0-3
8333497-4	1993	EGF significantly stimulated ornithine decarboxylase (ODC) activity, an effect that was blocked by the specific ODC inhibitor, difluoromethylornithine (DFMO).	Eflornithine	127-150	ornithine decarboxylase 1	Rattus norvegicus	29-52
8333497-4	1993	EGF significantly stimulated ornithine decarboxylase (ODC) activity, an effect that was blocked by the specific ODC inhibitor, difluoromethylornithine (DFMO).	Eflornithine	152-156	ornithine decarboxylase 1	Rattus norvegicus	112-115
8333497-4	1993	EGF significantly stimulated ornithine decarboxylase (ODC) activity, an effect that was blocked by the specific ODC inhibitor, difluoromethylornithine (DFMO).	Eflornithine	127-150	ornithine decarboxylase 1	Rattus norvegicus	54-57
8333497-8	1993	Thus the DFMO effect was specific to EGF.	Eflornithine	9-13	epidermal growth factor like 1	Rattus norvegicus	37-40
8333497-4	1993	EGF significantly stimulated ornithine decarboxylase (ODC) activity, an effect that was blocked by the specific ODC inhibitor, difluoromethylornithine (DFMO).	Eflornithine	127-150	ornithine decarboxylase 1	Rattus norvegicus	112-115
8333497-4	1993	EGF significantly stimulated ornithine decarboxylase (ODC) activity, an effect that was blocked by the specific ODC inhibitor, difluoromethylornithine (DFMO).	Eflornithine	152-156	epidermal growth factor like 1	Rattus norvegicus	0-3
8478959-1	1993	BACKGROUND: alpha-Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC), the key enzyme in mammalian polyamine biosynthesis.	Eflornithine	12-41	ornithine decarboxylase 1	Homo sapiens	81-104
8508705-7	1993	Consistent with a direct effect of spermine on the intestinal cell, the cytosolic activity of ornithine decarboxylase was depressed by 27-fold (P < 0.005 vs controls) in the jejunum, while inhibition of ornithine decarboxylase by alpha-difluoromethylornithine did markedly decrease but did not suppress the cell response to spermine.	Eflornithine	233-262	ornithine decarboxylase 1	Rattus norvegicus	94-117
8478959-1	1993	BACKGROUND: alpha-Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC), the key enzyme in mammalian polyamine biosynthesis.	Eflornithine	12-41	ornithine decarboxylase 1	Homo sapiens	106-109
8486633-2	1993	The cells accumulated ODC protein in the presence of alpha-difluoromethylornithine.	Eflornithine	53-82	ornithine decarboxylase 1	Homo sapiens	22-25
8478959-1	1993	BACKGROUND: alpha-Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC), the key enzyme in mammalian polyamine biosynthesis.	Eflornithine	43-47	ornithine decarboxylase 1	Homo sapiens	81-104
8478959-1	1993	BACKGROUND: alpha-Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC), the key enzyme in mammalian polyamine biosynthesis.	Eflornithine	43-47	ornithine decarboxylase 1	Homo sapiens	106-109
8478959-4	1993	PURPOSE: A randomized phase I study of DFMO was conducted to determine the lowest daily oral dose that can achieve at least 50% inhibition of ODC activity induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in human skin, with minimal clinical toxicity (grade 1 or lower; Eastern Cooperative Oncology Group [ECOG]).	Eflornithine	39-43	ornithine decarboxylase 1	Homo sapiens	142-145
8478959-10	1993	To evaluate the effectiveness of DFMO in reducing TPA-induced ODC activity, we calculated the percent change from pretreatment ODC levels in skin biopsy specimens and the percentage of subjects with at least a 50% reduction in ODC levels.	Eflornithine	33-37	ornithine decarboxylase 1	Homo sapiens	62-65
8481891-4	1993	In combination with alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, only 5,8-dimethylspermine had a favorable effect.	Eflornithine	51-55	ornithine decarboxylase, structural 1	Mus musculus	61-84
8354641-4	1993	The specific inhibitor of ODC, alpha-difluoromethylornithine (DFMO), resulted in a complete inhibition of ODC activity and depletion of putrescine, spermidine and spermine levels.	Eflornithine	31-60	ornithine decarboxylase 1	Homo sapiens	26-29
8354641-4	1993	The specific inhibitor of ODC, alpha-difluoromethylornithine (DFMO), resulted in a complete inhibition of ODC activity and depletion of putrescine, spermidine and spermine levels.	Eflornithine	31-60	ornithine decarboxylase 1	Homo sapiens	106-109
8354641-4	1993	The specific inhibitor of ODC, alpha-difluoromethylornithine (DFMO), resulted in a complete inhibition of ODC activity and depletion of putrescine, spermidine and spermine levels.	Eflornithine	62-66	ornithine decarboxylase 1	Homo sapiens	26-29
8354641-4	1993	The specific inhibitor of ODC, alpha-difluoromethylornithine (DFMO), resulted in a complete inhibition of ODC activity and depletion of putrescine, spermidine and spermine levels.	Eflornithine	62-66	ornithine decarboxylase 1	Homo sapiens	106-109
8386981-6	1993	Inhibition of carcinogenesis by piroxicam and difluoromethyl ornithine inhibited alpha 1AT expression.	Eflornithine	46-70	serpin family A member 1	Homo sapiens	81-90
8472334-8	1993	The AOM-induced expression of biochemically active p21ras was significantly suppressed by dietary DFMO and piroxicam.	Eflornithine	98-102	HRas proto-oncogene, GTPase	Rattus norvegicus	51-57
8472334-9	1993	DFMO exerted a more pronounced inhibitory effect on AOM-induced colon tumor development as well as the expression of biochemically active p21ras.	Eflornithine	0-4	HRas proto-oncogene, GTPase	Rattus norvegicus	138-144
8328299-3	1993	In the present paper the effects of treatments with alpha-difluoromethylornithine, a suicide inhibitor of ornithine decarboxylase, have been investigated in a model of transient forebrain ischemia.	Eflornithine	52-81	ornithine decarboxylase 1	Rattus norvegicus	106-129
8328299-10	1993	In addition, other alterations of lesioned tissue were observed in alpha-difluoromethylornithine-treated animals, including increases of non-neuronal cells at 7 and especially 40 days post-lesion in striatum and CA3 hippocampal field.	Eflornithine	67-96	carbonic anhydrase 3	Rattus norvegicus	212-215
8441821-0	1993	Effect of difluoromethylornithine on atrial natriuretic peptide in rat atria.	Eflornithine	10-33	natriuretic peptide A	Rattus norvegicus	37-63
8492070-4	1993	The effect of DFMO was associated with reduced levels of putrescine in the anterior pituitary gland, suggesting that ODC activity in the lactotroph might be involved in the prolactin surge.	Eflornithine	14-18	ornithine decarboxylase 1	Rattus norvegicus	117-120
8444085-1	1993	The effect of difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase activity, was evaluated in vivo and in vitro on the growth of a gastrin-sensitive human colon carcinoma (WiDr).	Eflornithine	14-37	gastrin	Homo sapiens	158-165
8444085-1	1993	The effect of difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase activity, was evaluated in vivo and in vitro on the growth of a gastrin-sensitive human colon carcinoma (WiDr).	Eflornithine	39-43	gastrin	Homo sapiens	158-165
8444085-6	1993	DFMO, on the other hand, decreased both ODC activity and growth.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	40-43
8095973-5	1993	Glutamate-induced ODC activation but not neurotoxicity was blocked by the ODC inhibitor difluoromethylornithine.	Eflornithine	88-111	ornithine decarboxylase 1	Rattus norvegicus	18-21
8095973-5	1993	Glutamate-induced ODC activation but not neurotoxicity was blocked by the ODC inhibitor difluoromethylornithine.	Eflornithine	88-111	ornithine decarboxylase 1	Rattus norvegicus	74-77
8499611-10	1993	This ODC activity was inhibited by alpha-difluoromethylornithine and anti-mouse ODC antisera in a manner consistent with that reported for the mouse ODC.	Eflornithine	35-64	ornithine decarboxylase, structural 1	Mus musculus	5-8
8441821-2	1993	In this study, difluoromethylornithine (DFMO), an inhibitor of polyamine synthesis, was used to investigate its effect on atrial natriuretic peptide (ANP) in atria of rat.	Eflornithine	15-38	natriuretic peptide A	Rattus norvegicus	122-148
8441821-2	1993	In this study, difluoromethylornithine (DFMO), an inhibitor of polyamine synthesis, was used to investigate its effect on atrial natriuretic peptide (ANP) in atria of rat.	Eflornithine	15-38	natriuretic peptide A	Rattus norvegicus	150-153
8441821-2	1993	In this study, difluoromethylornithine (DFMO), an inhibitor of polyamine synthesis, was used to investigate its effect on atrial natriuretic peptide (ANP) in atria of rat.	Eflornithine	40-44	natriuretic peptide A	Rattus norvegicus	122-148
8441821-2	1993	In this study, difluoromethylornithine (DFMO), an inhibitor of polyamine synthesis, was used to investigate its effect on atrial natriuretic peptide (ANP) in atria of rat.	Eflornithine	40-44	natriuretic peptide A	Rattus norvegicus	150-153
8441821-4	1993	Radioimmunoassay of ANP in atrial extracts indicated that DFMO treatment increased ANP contents of atria.	Eflornithine	58-62	natriuretic peptide A	Rattus norvegicus	20-23
8441821-4	1993	Radioimmunoassay of ANP in atrial extracts indicated that DFMO treatment increased ANP contents of atria.	Eflornithine	58-62	natriuretic peptide A	Rattus norvegicus	83-86
8441821-6	1993	The predominant ANP peptide in both control and DFMO group migrated at 17 kDa.	Eflornithine	48-52	natriuretic peptide A	Rattus norvegicus	16-19
8441821-9	1993	The incorporation of ANP into control and DFMO group peaked at 30 min and returned to a basal level by 60 min.	Eflornithine	42-46	natriuretic peptide A	Rattus norvegicus	21-24
8441821-10	1993	DFMO decreased the incorporation of [35S]methionine into ANP.	Eflornithine	0-4	natriuretic peptide A	Rattus norvegicus	57-60
8441821-12	1993	At 60 min following, the amount of labeled ANP in DFMO + putrescine-treated group was significantly lower than that in DFMO group.	Eflornithine	50-54	natriuretic peptide A	Rattus norvegicus	43-46
8441821-12	1993	At 60 min following, the amount of labeled ANP in DFMO + putrescine-treated group was significantly lower than that in DFMO group.	Eflornithine	119-123	natriuretic peptide A	Rattus norvegicus	43-46
8447376-1	1993	The selective ornithine decarboxylase (ODC) inhibitor difluoromethyl ornithine (DFMO) was used to investigate the role of polyamines in initial diabetic renal enlargement.	Eflornithine	54-78	ornithine decarboxylase 1	Rattus norvegicus	14-37
8428357-0	1993	Chemoprevention of oral carcinogenesis by DL-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor: dose-dependent reduction in 4-nitroquinoline 1-oxide-induced tongue neoplasms in rats.	Eflornithine	42-74	ornithine decarboxylase 1	Rattus norvegicus	79-102
8447376-1	1993	The selective ornithine decarboxylase (ODC) inhibitor difluoromethyl ornithine (DFMO) was used to investigate the role of polyamines in initial diabetic renal enlargement.	Eflornithine	54-78	ornithine decarboxylase 1	Rattus norvegicus	39-42
8447376-3	1993	Insulin treatment normalized renal ODC activity, whereas DFMO treatment totally inhibited the kidney ODC activity.	Eflornithine	57-61	ornithine decarboxylase 1	Rattus norvegicus	101-104
8447376-9	1993	Finally, selective inhibition of ODC activity by DFMO resulted in kidneys of normal size, despite unaltered diabetic metabolic aberrations.	Eflornithine	49-53	ornithine decarboxylase 1	Rattus norvegicus	33-36
8425439-6	1993	Administration of EGF, spermine, aminoguanidine (an inhibitor of degradation of PA), or 16,16-dmPGE2 after stress promoted significantly the healing and DNA synthesis, but pretreatment with DFMO abolished the effect of EGF but not that of spermine.	Eflornithine	190-194	epidermal growth factor like 1	Rattus norvegicus	18-21
8425439-6	1993	Administration of EGF, spermine, aminoguanidine (an inhibitor of degradation of PA), or 16,16-dmPGE2 after stress promoted significantly the healing and DNA synthesis, but pretreatment with DFMO abolished the effect of EGF but not that of spermine.	Eflornithine	190-194	epidermal growth factor like 1	Rattus norvegicus	219-222
8424111-3	1993	As in previous studies, suppression of ODC activity by DFMO prevented not only the jejunal epithelial hyperplasia in the diabetic rats, but also retarded jejunal epithelial growth in the control rats.	Eflornithine	55-59	ornithine decarboxylase 1	Rattus norvegicus	39-42
8439287-5	1993	A decrease in the proliferation rate of TNF-sensitive cells induced by either alpha-difluoromethylornithine treatment (resulting in polyamine depletion) or serum starvation rendered the cells insensitive to TNF-induced cytotoxicity, further suggesting a role for mitogenic signals and cell division in TNF-mediated cytotoxicity.	Eflornithine	78-107	tumor necrosis factor	Homo sapiens	40-43
8424111-4	1993	DFMO administration lowered ODC activity by over 80% in both diabetic and control rat enterocytes and prevented the rise in enterocyte contents of putrescine and spermidine in the diabetic rat.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	28-31
8094315-1	1993	We tested the effect of DL-alpha-(difluoromethyl)ornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), on recordings in area CA1 of rat hippocampal slices.	Eflornithine	24-58	ornithine decarboxylase 1	Rattus norvegicus	91-114
8465553-1	1993	The polyamine dependence of enterocyte growth and differentiation was studied in the human intestinal cell line CaCo-2 using a specific inhibitor of the key enzyme ornithine decarboxylase (ODC), difluoromethylornithine (DFMO).	Eflornithine	195-218	ornithine decarboxylase 1	Homo sapiens	164-187
8465553-2	1993	ODC was highest during the initial phase of rapid growth and was inhibited in a dose dependent fashion by DFMO at 0.06-2 mM.	Eflornithine	106-110	ornithine decarboxylase 1	Homo sapiens	0-3
8465553-6	1993	The DFMO mediated suppression of cell replication, enzymatic and morphologic differentiation was reversible in the presence of the ODC product putrescine.	Eflornithine	4-8	ornithine decarboxylase 1	Homo sapiens	131-134
8097305-3	1993	The primary efflux peak is attenuated by the continual infusion via the dialysis probe of either the ornithine decarboxylase inhibitor difluoromethylornithine or by the NMDA antagonist 2-APV.	Eflornithine	135-158	ornithine decarboxylase 1	Rattus norvegicus	101-124
8273569-4	1993	Treatment of lpr mouse with difluoromethylornithine (DFMO) reduced ODC activity in lpr kidney to the level of normal strains.	Eflornithine	28-51	Fas (TNF receptor superfamily member 6)	Mus musculus	13-16
8273569-4	1993	Treatment of lpr mouse with difluoromethylornithine (DFMO) reduced ODC activity in lpr kidney to the level of normal strains.	Eflornithine	28-51	ornithine decarboxylase, structural 1	Mus musculus	67-70
8273569-4	1993	Treatment of lpr mouse with difluoromethylornithine (DFMO) reduced ODC activity in lpr kidney to the level of normal strains.	Eflornithine	28-51	Fas (TNF receptor superfamily member 6)	Mus musculus	83-86
8273569-4	1993	Treatment of lpr mouse with difluoromethylornithine (DFMO) reduced ODC activity in lpr kidney to the level of normal strains.	Eflornithine	53-57	Fas (TNF receptor superfamily member 6)	Mus musculus	13-16
8273569-4	1993	Treatment of lpr mouse with difluoromethylornithine (DFMO) reduced ODC activity in lpr kidney to the level of normal strains.	Eflornithine	53-57	ornithine decarboxylase, structural 1	Mus musculus	67-70
8273569-4	1993	Treatment of lpr mouse with difluoromethylornithine (DFMO) reduced ODC activity in lpr kidney to the level of normal strains.	Eflornithine	53-57	Fas (TNF receptor superfamily member 6)	Mus musculus	83-86
8273569-5	1993	In contrast, ODC mRNA level increased 12-fold by DFMO treatment.	Eflornithine	49-53	ornithine decarboxylase, structural 1	Mus musculus	13-16
8273569-7	1993	The beneficial effect of DFMO on murine lupus suggests a pathogenic role for altered ODC regulation in lpr mouse.	Eflornithine	25-29	ornithine decarboxylase, structural 1	Mus musculus	85-88
8273569-7	1993	The beneficial effect of DFMO on murine lupus suggests a pathogenic role for altered ODC regulation in lpr mouse.	Eflornithine	25-29	Fas (TNF receptor superfamily member 6)	Mus musculus	103-106
8418689-2	1993	ODC catalyzes the rate-limiting step in the biosynthesis of polyamines that are necessary for normal cell growth; alpha-difluoromethylornithine (DFMO) specifically inhibits ODC activity.	Eflornithine	114-143	ornithine decarboxylase 1	Rattus norvegicus	0-3
8418689-2	1993	ODC catalyzes the rate-limiting step in the biosynthesis of polyamines that are necessary for normal cell growth; alpha-difluoromethylornithine (DFMO) specifically inhibits ODC activity.	Eflornithine	114-143	ornithine decarboxylase 1	Rattus norvegicus	173-176
8418689-2	1993	ODC catalyzes the rate-limiting step in the biosynthesis of polyamines that are necessary for normal cell growth; alpha-difluoromethylornithine (DFMO) specifically inhibits ODC activity.	Eflornithine	145-149	ornithine decarboxylase 1	Rattus norvegicus	0-3
8418689-2	1993	ODC catalyzes the rate-limiting step in the biosynthesis of polyamines that are necessary for normal cell growth; alpha-difluoromethylornithine (DFMO) specifically inhibits ODC activity.	Eflornithine	145-149	ornithine decarboxylase 1	Rattus norvegicus	173-176
8418689-8	1993	Increased ODC activity and polyamine content in both the proximal and distal gut mucosa of burned rats preceded restoration of mucosal weight and DNA content that occurred at 48 hours postburn; these responses were prevented by DFMO treatment.	Eflornithine	228-232	ornithine decarboxylase 1	Rattus norvegicus	10-13
8447420-2	1993	In that model, the inhibition of ornithine decarboxylase, a rate-limiting enzyme of polyamine biosynthesis, with alpha-difluoromethylornithine (DFMO) almost entirely prevented healing.	Eflornithine	113-142	ornithine decarboxylase 1	Rattus norvegicus	33-56
8447420-2	1993	In that model, the inhibition of ornithine decarboxylase, a rate-limiting enzyme of polyamine biosynthesis, with alpha-difluoromethylornithine (DFMO) almost entirely prevented healing.	Eflornithine	144-148	ornithine decarboxylase 1	Rattus norvegicus	33-56
8243835-2	1993	Furthermore it was investigated whether the simultaneous inhibition of the polyamine interconversion pathway by the potent polyamine oxidase inhibitor MDL-72527 together with the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO) is able to enhance and prolong the only initial and transient inhibitory effects of DFMO on camostate-induced pancreatic growth.	Eflornithine	219-248	ornithine decarboxylase 1	Rattus norvegicus	179-202
8243835-2	1993	Furthermore it was investigated whether the simultaneous inhibition of the polyamine interconversion pathway by the potent polyamine oxidase inhibitor MDL-72527 together with the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO) is able to enhance and prolong the only initial and transient inhibitory effects of DFMO on camostate-induced pancreatic growth.	Eflornithine	219-248	ornithine decarboxylase 1	Rattus norvegicus	204-207
8243835-3	1993	Simultaneous administration of DFMO and MDL-72527 resulted in a significant inhibition of the camostate-induced increases in pancreatic putrescine, ODC and DNA over 5 days, while the initial significant inhibition of pancreatic weight, protein content, DNA-polymerase and especially spermidine was absent after 5 days and spermine as well as N1-acetylspermidine were even increased.	Eflornithine	31-35	ornithine decarboxylase 1	Rattus norvegicus	148-151
8417156-3	1993	This response was attenuated by the ornithine decarboxylase inhibitor alpha-difluoromethylornithine and the N-methyl-D-aspartate receptor antagonist 5-aminophosphonovaleric acid.	Eflornithine	70-99	ornithine decarboxylase	Gallus gallus	36-59
8417156-6	1993	Postreceptor inhibition of the ornithine decarboxylase/polyamine cascade by alpha-difluoromethylornithine may provide neuroprotection against N-methyl-D-aspartate-induced excitotoxicity.	Eflornithine	76-105	ornithine decarboxylase	Gallus gallus	31-54
1458466-1	1992	alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme ornithine decarboxylase, inhibits the growth of brain tumor cell lines and is undergoing clinical trials as a treatment for brain tumors.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	101-124
1458466-1	1992	alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme ornithine decarboxylase, inhibits the growth of brain tumor cell lines and is undergoing clinical trials as a treatment for brain tumors.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	101-124
1300481-1	1992	Mechanical injury to the brain results in enhanced immunostaining for glial fibrillary acidic protein (GFAP) that is markedly inhibited by difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	139-162	glial fibrillary acidic protein	Mus musculus	70-101
1300481-1	1992	Mechanical injury to the brain results in enhanced immunostaining for glial fibrillary acidic protein (GFAP) that is markedly inhibited by difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	139-162	glial fibrillary acidic protein	Mus musculus	103-107
1300481-1	1992	Mechanical injury to the brain results in enhanced immunostaining for glial fibrillary acidic protein (GFAP) that is markedly inhibited by difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	139-162	ornithine decarboxylase, structural 1	Mus musculus	200-223
1300481-1	1992	Mechanical injury to the brain results in enhanced immunostaining for glial fibrillary acidic protein (GFAP) that is markedly inhibited by difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	164-168	glial fibrillary acidic protein	Mus musculus	70-101
1300481-1	1992	Mechanical injury to the brain results in enhanced immunostaining for glial fibrillary acidic protein (GFAP) that is markedly inhibited by difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	164-168	glial fibrillary acidic protein	Mus musculus	103-107
1300481-1	1992	Mechanical injury to the brain results in enhanced immunostaining for glial fibrillary acidic protein (GFAP) that is markedly inhibited by difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	164-168	ornithine decarboxylase, structural 1	Mus musculus	200-223
1300481-2	1992	In the current study, systemic exposure of mice to the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), also increased GFAP but, unlike mechanical injury, this increase was not prevented by DFMO pretreatment.	Eflornithine	222-226	glial fibrillary acidic protein	Mus musculus	151-155
1482141-2	1992	In combination with the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine (DFMO; Ornidyl), MDL73811 acted synergistically to cure seven of eight infections.	Eflornithine	58-90	ornithine decarboxylase, structural 1	Mus musculus	24-47
1482141-2	1992	In combination with the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine (DFMO; Ornidyl), MDL73811 acted synergistically to cure seven of eight infections.	Eflornithine	92-96	ornithine decarboxylase, structural 1	Mus musculus	24-47
1463454-7	1992	The expression of AdoMetDC from pSAMh1 in COS-7 cells was greatly inhibited by DFMO treatment, although endogenous AdoMetDC activity was increased.	Eflornithine	79-83	adenosylmethionine decarboxylase 1	Homo sapiens	18-26
1330658-14	1992	Finally, the depletion of polyamines, particularly spermidine, by DL-alpha-difluoromethylornithine treatment also prevents c-jun induction by insulin but DL-alpha-difluoromethylornithine treatment has no effect on c-jun induction by vanadate.	Eflornithine	66-98	jun proto-oncogene	Mus musculus	123-128
8094315-1	1993	We tested the effect of DL-alpha-(difluoromethyl)ornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), on recordings in area CA1 of rat hippocampal slices.	Eflornithine	24-58	ornithine decarboxylase 1	Rattus norvegicus	116-119
8094315-1	1993	We tested the effect of DL-alpha-(difluoromethyl)ornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), on recordings in area CA1 of rat hippocampal slices.	Eflornithine	24-58	carbonic anhydrase 1	Rattus norvegicus	144-147
8094315-1	1993	We tested the effect of DL-alpha-(difluoromethyl)ornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), on recordings in area CA1 of rat hippocampal slices.	Eflornithine	60-64	ornithine decarboxylase 1	Rattus norvegicus	91-114
8094315-1	1993	We tested the effect of DL-alpha-(difluoromethyl)ornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), on recordings in area CA1 of rat hippocampal slices.	Eflornithine	60-64	ornithine decarboxylase 1	Rattus norvegicus	116-119
8094315-1	1993	We tested the effect of DL-alpha-(difluoromethyl)ornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), on recordings in area CA1 of rat hippocampal slices.	Eflornithine	60-64	carbonic anhydrase 1	Rattus norvegicus	144-147
8094315-2	1993	In the concentration range in which it is used as an ODC inhibitor, DFMO increased neuronal excitability and blocked paired-pulse inhibition.	Eflornithine	68-72	ornithine decarboxylase 1	Rattus norvegicus	53-56
8094315-7	1993	DFMO has frequently been used as a tool to study the role of the ODC-polyamine system in neural preparations.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	65-68
1415709-12	1992	Treatment with DL-alpha-difluoromethylornithine (DFMO), a specific ODC inhibitor, prevented the increases in both cellular putrescine levels and SAMDC activity in asparagine- and serum-treated cells.	Eflornithine	15-47	ornithine decarboxylase 1	Rattus norvegicus	67-70
1415709-12	1992	Treatment with DL-alpha-difluoromethylornithine (DFMO), a specific ODC inhibitor, prevented the increases in both cellular putrescine levels and SAMDC activity in asparagine- and serum-treated cells.	Eflornithine	15-47	adenosylmethionine decarboxylase 1	Rattus norvegicus	145-150
1415709-12	1992	Treatment with DL-alpha-difluoromethylornithine (DFMO), a specific ODC inhibitor, prevented the increases in both cellular putrescine levels and SAMDC activity in asparagine- and serum-treated cells.	Eflornithine	49-53	ornithine decarboxylase 1	Rattus norvegicus	67-70
1415709-12	1992	Treatment with DL-alpha-difluoromethylornithine (DFMO), a specific ODC inhibitor, prevented the increases in both cellular putrescine levels and SAMDC activity in asparagine- and serum-treated cells.	Eflornithine	49-53	adenosylmethionine decarboxylase 1	Rattus norvegicus	145-150
1415709-13	1992	In the presence of DFMO, exogenous putrescine returned SAMDC activity toward control levels but had no effect on ODC.	Eflornithine	19-23	adenosylmethionine decarboxylase 1	Rattus norvegicus	55-60
1397089-3	1992	Here we report that treatment of LSTRA cells for 2-18 h with alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, decreased the amount of phosphotyrosine in several cellular substrates including the T cell protein tyrosine kinase p56lck.	Eflornithine	61-90	ornithine decarboxylase, structural 1	Mus musculus	128-131
1397089-3	1992	Here we report that treatment of LSTRA cells for 2-18 h with alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, decreased the amount of phosphotyrosine in several cellular substrates including the T cell protein tyrosine kinase p56lck.	Eflornithine	61-90	lymphocyte protein tyrosine kinase	Mus musculus	249-255
1394136-2	1992	Pretreatment of LC-AH cells with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, before seeding them onto a CPAE cell monolayer and culturing them for 24 h in the absence of DFMO decreased the number of penetrating tumor cells time and dose dependently (about 35% of the maximal inhibition) without affecting their viability or proliferative activity.	Eflornithine	33-62	ornithine decarboxylase	Bos taurus	87-110
1397089-3	1992	Here we report that treatment of LSTRA cells for 2-18 h with alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, decreased the amount of phosphotyrosine in several cellular substrates including the T cell protein tyrosine kinase p56lck.	Eflornithine	92-96	ornithine decarboxylase, structural 1	Mus musculus	128-131
1397089-3	1992	Here we report that treatment of LSTRA cells for 2-18 h with alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, decreased the amount of phosphotyrosine in several cellular substrates including the T cell protein tyrosine kinase p56lck.	Eflornithine	92-96	lymphocyte protein tyrosine kinase	Mus musculus	249-255
1394136-2	1992	Pretreatment of LC-AH cells with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, before seeding them onto a CPAE cell monolayer and culturing them for 24 h in the absence of DFMO decreased the number of penetrating tumor cells time and dose dependently (about 35% of the maximal inhibition) without affecting their viability or proliferative activity.	Eflornithine	64-68	ornithine decarboxylase	Bos taurus	87-110
1397089-5	1992	DFMO did not affect the catalytic activity of p56lck in vitro and the activity of p56lck immunoprecipitated from DFMO-treated cells was unaltered.	Eflornithine	113-117	lymphocyte protein tyrosine kinase	Mus musculus	82-88
1397089-6	1992	Addition of putrescine, the reaction product of ODC, completely reversed the effect of DFMO on tyrosine phosphorylation.	Eflornithine	87-91	ornithine decarboxylase, structural 1	Mus musculus	48-51
1436709-2	1992	In the absence of gross morphological changes, retinoic acid reduced the growth rate without major change of IGF-II mRNA expression, while alpha-difluoromethylornithine produced a complete growth arrest and a sharp decrease of IGF-II mRNA expression.	Eflornithine	139-168	insulin like growth factor 2	Homo sapiens	227-233
1415554-8	1992	Significantly, alpha-difluoromethylornithine (DFMO), which inhibits ornithine decarboxylase and polyamine synthesis, almost totally prevented cell migration.	Eflornithine	15-44	ornithine decarboxylase 1	Rattus norvegicus	68-91
1415554-8	1992	Significantly, alpha-difluoromethylornithine (DFMO), which inhibits ornithine decarboxylase and polyamine synthesis, almost totally prevented cell migration.	Eflornithine	46-50	ornithine decarboxylase 1	Rattus norvegicus	68-91
1444206-1	1992	We reported previously that polyamine deprivation by feeding a polyamine deficient diet combined with gastrointestinal tract decontamination and polyamine oxidase inhibition considerably enhanced the antitumoral effect of DFMO, a selective inhibitor of ornithine decarboxylase.	Eflornithine	222-226	ornithine decarboxylase, structural 1	Mus musculus	253-276
1426528-2	1992	The effect of dichlororibofuranosylbenzimidazole (DiCl-RB), an inhibitor of hnRNA synthesis and casein kinase-2 activity, on ornithine decarboxylase (ODC) was investigated in a difluoromethylornithine (DFMO) resistant, ODC overproducing cell line.	Eflornithine	177-200	Ornithine decarboxylase 1	Drosophila melanogaster	125-148
1520491-11	1992	Inhibition of ODC with alpha-difluoromethylornithine (DFMO) also induced SPD transport, as evidenced by an increase in the Vmax to 65 pmol/min/10(6) cells.	Eflornithine	23-52	ornithine decarboxylase 1	Rattus norvegicus	14-17
1520491-11	1992	Inhibition of ODC with alpha-difluoromethylornithine (DFMO) also induced SPD transport, as evidenced by an increase in the Vmax to 65 pmol/min/10(6) cells.	Eflornithine	54-58	ornithine decarboxylase 1	Rattus norvegicus	14-17
1360694-3	1992	The preliminary exposure of cultured monocytes to alpha-difluoromethylornithine (DFMO) significantly reduced TGc induction caused by RA.	Eflornithine	50-79	transglutaminase 2	Homo sapiens	109-112
1360694-3	1992	The preliminary exposure of cultured monocytes to alpha-difluoromethylornithine (DFMO) significantly reduced TGc induction caused by RA.	Eflornithine	81-85	transglutaminase 2	Homo sapiens	109-112
1360694-6	1992	The supplementation of putrescine (1 mM) or spermidine (0.5 mM) to culture medium reversed the inhibiting effect of DFMO on RA-mediated induction of TGc.	Eflornithine	116-120	transglutaminase 2	Homo sapiens	149-152
1520332-0	1992	Recovery of ornithine decarboxylase activity after inhibition with alpha-difluoromethylornithine.	Eflornithine	67-96	ornithine decarboxylase 1	Homo sapiens	12-35
1340062-8	1992	As expected, the ODC inhibitor difluoromethylornithine (DFMO) inhibited AR42J cell DNA synthesis, and the addition of exogenous putrescine reversed this effect.	Eflornithine	31-54	ornithine decarboxylase 1	Rattus norvegicus	17-20
1340062-8	1992	As expected, the ODC inhibitor difluoromethylornithine (DFMO) inhibited AR42J cell DNA synthesis, and the addition of exogenous putrescine reversed this effect.	Eflornithine	56-60	ornithine decarboxylase 1	Rattus norvegicus	17-20
1520332-1	1992	alpha-Difluoromethylornithine is an effective inhibitor of polyamine biosynthesis because of its specificity for ornithine decarboxylase and the fact that its attachment to this enzyme is considered to be irreversible.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	113-136
1499692-8	1992	In order to study the role of putrescine in edema formation in this model we treated the traumatized rats with alpha-difluoromethyl-ornithine (DFMO), an inhibitor of ornithine-decarboxylase, the rate limiting enzyme in putrescine biosynthesis.	Eflornithine	111-141	ornithine decarboxylase 1	Rattus norvegicus	166-189
1514608-4	1992	In whole animal experiments, bolus intraileal injection of 10 nM hrIGF-I in anesthetized rats induced a 300% increase in ileal mucosal ODC activity, which was sensitive to inhibition with difluoromethylornithine (DFMO).	Eflornithine	188-211	ornithine decarboxylase 1	Rattus norvegicus	135-138
1514608-4	1992	In whole animal experiments, bolus intraileal injection of 10 nM hrIGF-I in anesthetized rats induced a 300% increase in ileal mucosal ODC activity, which was sensitive to inhibition with difluoromethylornithine (DFMO).	Eflornithine	213-217	ornithine decarboxylase 1	Rattus norvegicus	135-138
1514608-7	1992	Intraperitoneal treatment with 200 mg/kg DFMO three times per day had little effect on ileal mucosal mass, but completely inhibited the trophic response to IGF-I infusion.	Eflornithine	41-45	insulin-like growth factor 1	Rattus norvegicus	156-161
1324153-6	1992	Exposure of cells to 5 mM alpha-difluoromethylornithine blocked both the VIP-induced increase in cell number and the VIP-induced increase in ODC activity.	Eflornithine	26-55	vasoactive intestinal peptide	Homo sapiens	73-76
1324153-6	1992	Exposure of cells to 5 mM alpha-difluoromethylornithine blocked both the VIP-induced increase in cell number and the VIP-induced increase in ODC activity.	Eflornithine	26-55	vasoactive intestinal peptide	Homo sapiens	117-120
1324153-6	1992	Exposure of cells to 5 mM alpha-difluoromethylornithine blocked both the VIP-induced increase in cell number and the VIP-induced increase in ODC activity.	Eflornithine	26-55	ornithine decarboxylase 1	Homo sapiens	141-144
1499692-8	1992	In order to study the role of putrescine in edema formation in this model we treated the traumatized rats with alpha-difluoromethyl-ornithine (DFMO), an inhibitor of ornithine-decarboxylase, the rate limiting enzyme in putrescine biosynthesis.	Eflornithine	143-147	ornithine decarboxylase 1	Rattus norvegicus	166-189
1323950-3	1992	The addition of H-7 to both the 3T3 and 3T3/SV40 cells, inhibited the cell proliferation, though the level of inhibition was always lower than in those treated with the DFMO alone.	Eflornithine	169-173	histocompatibility 7	Mus musculus	16-19
1341266-12	1992	Our finding of significant stimulation of polyamine uptake by NaB after inhibition of endogenous synthesis (by an ODC-dependent pathway) in DFMO-treated cells suggests that cellular requirements are increased for polyamines in NaB-treated cells.	Eflornithine	140-144	ornithine decarboxylase, structural 1	Mus musculus	114-117
1378845-2	1992	Our previous studies have determined that depletion of intracellular polyamines by alpha-difluoromethylornithine results in a marked decrease in the transcription of the human c-myc gene.	Eflornithine	83-112	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	176-181
1359466-4	1992	Treatment with the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine, prevented the ischaemia-induced increase in tissue PU without affecting infarct volume.	Eflornithine	59-88	ornithine decarboxylase 1	Rattus norvegicus	19-42
1359466-4	1992	Treatment with the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine, prevented the ischaemia-induced increase in tissue PU without affecting infarct volume.	Eflornithine	59-88	ornithine decarboxylase 1	Rattus norvegicus	44-47
1618050-3	1992	A total of 26 dogs were studied, eight of which received 2% difluoromethylornithine (DFMO, a specific inhibitor of ODC) in drinking water.	Eflornithine	60-83	ornithine decarboxylase 1	Canis lupus familiaris	115-118
1618050-3	1992	A total of 26 dogs were studied, eight of which received 2% difluoromethylornithine (DFMO, a specific inhibitor of ODC) in drinking water.	Eflornithine	85-89	ornithine decarboxylase 1	Canis lupus familiaris	115-118
1618323-3	1992	In the studies reported here, it was found that inhibitors of polyamine biosynthesis, methylglyoxal-bis[quanylhydrazone] (MGBG) and difluoromethylornithine (DFMO), prevent mitogen-induced accumulation of mRNAs encoding major cytoskeletal components, beta-actin and alpha-tubulin, in mouse splenocytes.	Eflornithine	132-155	actin, beta	Mus musculus	250-260
1600622-1	1992	Our previous studies have shown that dietary piroxicam, a non-steroidal anti-inflammatory drug (NSAID), and D,L-alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, act as potential chemopreventive agents in inhibiting azoxymethane (AOM)-induced colon carcinogenesis in male F344 rats.	Eflornithine	108-141	ornithine decarboxylase 1	Rattus norvegicus	153-176
1587335-3	1992	We measured the effects of an acute treatment of adult rats with difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, on biochemical alterations following kainate-induced seizure activity.	Eflornithine	65-88	ornithine decarboxylase 1	Rattus norvegicus	126-129
1587335-3	1992	We measured the effects of an acute treatment of adult rats with difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, on biochemical alterations following kainate-induced seizure activity.	Eflornithine	90-94	ornithine decarboxylase 1	Rattus norvegicus	126-129
1600622-1	1992	Our previous studies have shown that dietary piroxicam, a non-steroidal anti-inflammatory drug (NSAID), and D,L-alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, act as potential chemopreventive agents in inhibiting azoxymethane (AOM)-induced colon carcinogenesis in male F344 rats.	Eflornithine	108-141	ornithine decarboxylase 1	Rattus norvegicus	178-181
1600622-1	1992	Our previous studies have shown that dietary piroxicam, a non-steroidal anti-inflammatory drug (NSAID), and D,L-alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, act as potential chemopreventive agents in inhibiting azoxymethane (AOM)-induced colon carcinogenesis in male F344 rats.	Eflornithine	143-147	ornithine decarboxylase 1	Rattus norvegicus	153-176
1600622-1	1992	Our previous studies have shown that dietary piroxicam, a non-steroidal anti-inflammatory drug (NSAID), and D,L-alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, act as potential chemopreventive agents in inhibiting azoxymethane (AOM)-induced colon carcinogenesis in male F344 rats.	Eflornithine	143-147	ornithine decarboxylase 1	Rattus norvegicus	178-181
1600622-14	1992	The results demonstrate that DFMO, an inhibitor of ODC, suppresses cell proliferation, whereas piroxicam, a NSAID, inhibits prostaglandins, and emphasize the need to develop agent-dependent intermediate biomarker(s) to validate the efficacy of chemopreventive agent(s) in colon carcinogenesis.	Eflornithine	29-33	ornithine decarboxylase 1	Rattus norvegicus	51-54
1566849-3	1992	We examined the effect of inhibition of polyamine synthesis with alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of the ODC enzyme, on regenerating liver weight and total DNA, RNA, and protein, [3H]thymidine and [14C]leucine incorporation, number of mitotic figures, and putrescine, spermidine, and spermine contents.	Eflornithine	96-100	ornithine decarboxylase 1	Rattus norvegicus	136-139
1568161-1	1992	The author has studied the effects of alpha-difluoromethylornithine (alpha DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase; human fibroblast interferon (IFN beta); and their combination on human gastric cancer cell growth in vitro.	Eflornithine	69-79	interferon beta 1	Homo sapiens	182-190
1568161-4	1992	When alpha DFMO (0.1 mmol/l) was administered in combination with IFN beta (100 and 1000 IU/ml), synergistic antiproliferative activity was observed 7 days after continuous exposure.	Eflornithine	5-15	interferon beta 1	Homo sapiens	66-74
1601800-1	1992	On the basis of the previous findings that alpha-difluoromethylornithine (DFMO, an inhibitor of ornithine decarboxylase, which is the rate-limiting enzyme in polyamine biosynthesis) treatment prevents monocrotaline-(MCT) induced pulmonary hypertension and that ventilatory dysfunction precedes pulmonary hypertension in MCT-treated rats, we hypothesize that MCT-induced changes in airway/lung function are polyamine dependent.	Eflornithine	43-72	ornithine decarboxylase 1	Rattus norvegicus	96-119
1601800-1	1992	On the basis of the previous findings that alpha-difluoromethylornithine (DFMO, an inhibitor of ornithine decarboxylase, which is the rate-limiting enzyme in polyamine biosynthesis) treatment prevents monocrotaline-(MCT) induced pulmonary hypertension and that ventilatory dysfunction precedes pulmonary hypertension in MCT-treated rats, we hypothesize that MCT-induced changes in airway/lung function are polyamine dependent.	Eflornithine	74-78	ornithine decarboxylase 1	Rattus norvegicus	96-119
1566849-6	1992	In rats receiving DFMO, ODC and putrescine changed minimally but spermidine increased as usual.	Eflornithine	18-22	ornithine decarboxylase 1	Rattus norvegicus	24-27
1312903-4	1992	The respiratory burst response was inhibited in a dose-dependent manner with difluoromethylornithine, an inhibitor of ornithine decarboxylase, and methylglyoxal-bis(guanylhydrazone), an inhibitor of the formation of spermidine and spermine.	Eflornithine	77-100	ornithine decarboxylase 1	Homo sapiens	118-141
1551114-3	1992	Polyamine depletion using DL-alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, has been shown to suppress cell growth in a variety of settings, including those of tumor and lymphocyte proliferation.	Eflornithine	26-58	ornithine decarboxylase, structural 1	Mus musculus	83-106
1551114-3	1992	Polyamine depletion using DL-alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, has been shown to suppress cell growth in a variety of settings, including those of tumor and lymphocyte proliferation.	Eflornithine	60-64	ornithine decarboxylase, structural 1	Mus musculus	83-106
1551114-7	1992	Putrescine also reversed the growth-inhibitory effects of DFMO on 4 tumor cell lines that we tested: 28-13-3S, YAC-1, P-815, and K562.	Eflornithine	58-62	ADP-ribosyltransferase 1	Mus musculus	111-116
1569411-5	1992	When difluoromethylornithine (DFMO), an irreversible inhibitor of ODC activity, was administered to pregnant mice throughout the period of palate development (days 11-14), palatal tissue ODC activity was reduced by 85%.	Eflornithine	5-28	ornithine decarboxylase, structural 1	Mus musculus	66-69
1569411-5	1992	When difluoromethylornithine (DFMO), an irreversible inhibitor of ODC activity, was administered to pregnant mice throughout the period of palate development (days 11-14), palatal tissue ODC activity was reduced by 85%.	Eflornithine	5-28	ornithine decarboxylase, structural 1	Mus musculus	187-190
1569411-5	1992	When difluoromethylornithine (DFMO), an irreversible inhibitor of ODC activity, was administered to pregnant mice throughout the period of palate development (days 11-14), palatal tissue ODC activity was reduced by 85%.	Eflornithine	30-34	ornithine decarboxylase, structural 1	Mus musculus	66-69
1569411-5	1992	When difluoromethylornithine (DFMO), an irreversible inhibitor of ODC activity, was administered to pregnant mice throughout the period of palate development (days 11-14), palatal tissue ODC activity was reduced by 85%.	Eflornithine	30-34	ornithine decarboxylase, structural 1	Mus musculus	187-190
1532891-1	1992	alpha-Difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, reduced intestinal lesions in tumor-bearing mice caused by treatment with N3-(3-methylbenzoyl)-3",5"-diacetyl [corrected]-FUDR (FF-705), a derivative of 5-fluoro-2"-deoxyuridine (FUDR).	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	54-77
1551519-6	1992	DFMO also inhibited ornithine decarboxylase activity and prevented increases in duodenal mucosal polyamine content.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	20-43
1532891-1	1992	alpha-Difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, reduced intestinal lesions in tumor-bearing mice caused by treatment with N3-(3-methylbenzoyl)-3",5"-diacetyl [corrected]-FUDR (FF-705), a derivative of 5-fluoro-2"-deoxyuridine (FUDR).	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	54-77
1563337-0	1992	Ornithine decarboxylase induction and polyamine synthesis in the kindling of seizures: the effect of alpha-difluoromethylornithine.	Eflornithine	101-130	ornithine decarboxylase 1	Homo sapiens	0-23
1580563-4	1992	Ornithine decarboxylase was shown to be incompletely inhibited by administration of DFMO with the diet.	Eflornithine	84-88	ornithine decarboxylase, structural 1	Mus musculus	0-23
1563337-5	1992	In the present study we examined the progress of kindling during treatment with alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC.	Eflornithine	80-109	ornithine decarboxylase 1	Homo sapiens	147-150
1563337-5	1992	In the present study we examined the progress of kindling during treatment with alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC.	Eflornithine	111-115	ornithine decarboxylase 1	Homo sapiens	147-150
1730582-2	1992	Mouse ornithine decarboxylase (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5"-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	287-316	ornithine decarboxylase, structural 1	Mus musculus	6-29
1532663-5	1992	Quantitation of ANP in plasma by radioimmunoassay indicated that both basal and stimulated levels of ANP in DFMO-treated animals were 21.5% and 50% of those in control rats.	Eflornithine	108-112	natriuretic peptide A	Rattus norvegicus	16-19
1532663-5	1992	Quantitation of ANP in plasma by radioimmunoassay indicated that both basal and stimulated levels of ANP in DFMO-treated animals were 21.5% and 50% of those in control rats.	Eflornithine	108-112	natriuretic peptide A	Rattus norvegicus	101-104
1532663-6	1992	The administration of putrescine restored the levels of basal and AVP-stimulated levels of ANP in plasma which confirmed that DFMO effect on ANP secretion occurred specifically through the polyamine pathway.	Eflornithine	126-130	natriuretic peptide A	Rattus norvegicus	91-94
1532663-6	1992	The administration of putrescine restored the levels of basal and AVP-stimulated levels of ANP in plasma which confirmed that DFMO effect on ANP secretion occurred specifically through the polyamine pathway.	Eflornithine	126-130	natriuretic peptide A	Rattus norvegicus	141-144
1569411-7	1992	The lack of a teratogenic effect by DFMO treatment could be due to sufficient remaining ODC activity in craniofacial tissue and/or maintenance of intracellular polyamine levels by the activity of a polyamine transport system.	Eflornithine	36-40	ornithine decarboxylase, structural 1	Mus musculus	88-91
1371646-3	1992	Treatment of AR42J cells with the ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) inhibited DNA synthesis.	Eflornithine	74-97	ornithine decarboxylase 1	Rattus norvegicus	34-57
1371646-3	1992	Treatment of AR42J cells with the ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) inhibited DNA synthesis.	Eflornithine	74-97	ornithine decarboxylase 1	Rattus norvegicus	59-62
1371646-3	1992	Treatment of AR42J cells with the ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) inhibited DNA synthesis.	Eflornithine	99-103	ornithine decarboxylase 1	Rattus norvegicus	34-57
1371646-3	1992	Treatment of AR42J cells with the ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) inhibited DNA synthesis.	Eflornithine	99-103	ornithine decarboxylase 1	Rattus norvegicus	59-62
1730582-0	1992	Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alpha-difluoromethylornithine.	Eflornithine	79-108	ornithine decarboxylase, structural 1	Mus musculus	52-75
1472637-4	1992	Recent studies demonstrated that down-regulation of polyamine biosynthesis by irreversible inhibition of ODC with difluoromethylornithine (DFMO0 is a novel therapeutic approach for the treatment of murine lupus in autoimmune MRL-lpr/lpr mice.	Eflornithine	114-137	ornithine decarboxylase, structural 1	Mus musculus	105-108
1306095-1	1992	Difluoromethylornithine (DFMO) is an investigational chemopreventive agent that inhibits ornithine decarboxylase (ODC) activity, lowers cellular polyamine concentrations, and decreases cell proliferation in vivo and in vitro.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	89-112
1306095-1	1992	Difluoromethylornithine (DFMO) is an investigational chemopreventive agent that inhibits ornithine decarboxylase (ODC) activity, lowers cellular polyamine concentrations, and decreases cell proliferation in vivo and in vitro.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	114-117
1306095-1	1992	Difluoromethylornithine (DFMO) is an investigational chemopreventive agent that inhibits ornithine decarboxylase (ODC) activity, lowers cellular polyamine concentrations, and decreases cell proliferation in vivo and in vitro.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	89-112
1306095-1	1992	Difluoromethylornithine (DFMO) is an investigational chemopreventive agent that inhibits ornithine decarboxylase (ODC) activity, lowers cellular polyamine concentrations, and decreases cell proliferation in vivo and in vitro.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	114-117
1306095-4	1992	ODC activity in EBM was high (approximately 1 mumol/min/mg protein), resistant to DFMO inhibition (Ki = 4200 microM), dependent on GTP concentration (maximal at 0.1 mM), and was reduced concomitantly with bacterial concentration by antiseptic mouthwashing.	Eflornithine	82-86	ornithine decarboxylase 1	Homo sapiens	0-3
1730582-2	1992	Mouse ornithine decarboxylase (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5"-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	287-316	ornithine decarboxylase, structural 1	Mus musculus	31-34
1730582-2	1992	Mouse ornithine decarboxylase (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5"-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	318-322	ornithine decarboxylase, structural 1	Mus musculus	6-29
1730582-2	1992	Mouse ornithine decarboxylase (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5"-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	318-322	ornithine decarboxylase, structural 1	Mus musculus	31-34
1406501-2	1992	Since atrophic changes of the intestinal mucosa have been observed in uremia the present study investigated whether intestinal atrophy induced by difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase, could affect the absorption of Al.	Eflornithine	146-169	ornithine decarboxylase 1	Rattus norvegicus	202-225
1289667-2	1992	DFMO is an irreversible, enzyme-activated, suicide inhibitor of ornithine decarboxylase (ODC), the enzyme responsible for the first and rate-limiting step in mammalian polyamine synthesis.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	64-87
1289667-2	1992	DFMO is an irreversible, enzyme-activated, suicide inhibitor of ornithine decarboxylase (ODC), the enzyme responsible for the first and rate-limiting step in mammalian polyamine synthesis.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	89-92
1289667-5	1992	ODC activity in the prostate was shown to be more susceptible to DFMO inhibition than in other organs.	Eflornithine	65-69	ornithine decarboxylase 1	Homo sapiens	0-3
1289667-6	1992	We have found the ODC activity of the Dunning R3327 rat prostatic carcinomas to be as sensitive to inhibition by DFMO as the normal rat prostate.	Eflornithine	113-117	ornithine decarboxylase 1	Rattus norvegicus	18-21
1389696-12	1992	A subsequent clinical trial with a biologic endpoint used alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, to test whether a low dose could produce changes in polyamine content in gastrointestinal mucosa.	Eflornithine	89-93	ornithine decarboxylase 1	Homo sapiens	125-128
1406501-2	1992	Since atrophic changes of the intestinal mucosa have been observed in uremia the present study investigated whether intestinal atrophy induced by difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase, could affect the absorption of Al.	Eflornithine	171-175	ornithine decarboxylase 1	Rattus norvegicus	202-225
1290060-5	1992	The effects of ornithine decarboxylase (ODC) blockade with difluoromethyl ornithine (DFMO) and of diamine oxidase (DAO) blockade with aminoguanidine, are described.	Eflornithine	59-83	ornithine decarboxylase, structural 1	Mus musculus	40-43
1290060-5	1992	The effects of ornithine decarboxylase (ODC) blockade with difluoromethyl ornithine (DFMO) and of diamine oxidase (DAO) blockade with aminoguanidine, are described.	Eflornithine	85-89	ornithine decarboxylase, structural 1	Mus musculus	40-43
1661161-2	1991	We have previously shown that alpha-difluoromethyl ornithine, a suicide inhibitor of ornithine decarboxylase (ODC, EC 4.1.1.17) and suboptimal concentrations of dibutyryl cAMP (0.1 to 0.2 mM) are effective in inducing the differentiation of mouse Neuro-2a (N2a) neuroblastoma cells.	Eflornithine	30-60	ornithine decarboxylase, structural 1	Mus musculus	85-108
1661161-2	1991	We have previously shown that alpha-difluoromethyl ornithine, a suicide inhibitor of ornithine decarboxylase (ODC, EC 4.1.1.17) and suboptimal concentrations of dibutyryl cAMP (0.1 to 0.2 mM) are effective in inducing the differentiation of mouse Neuro-2a (N2a) neuroblastoma cells.	Eflornithine	30-60	ornithine decarboxylase, structural 1	Mus musculus	110-113
1790596-1	1991	Impairment of polyamine synthesis by treatment with difluoromehtylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, has been shown to alter normal brain development.	Eflornithine	77-81	ornithine decarboxylase 1	Rattus norvegicus	113-136
1719956-1	1991	The ornithine decarboxylase (ODC; EC 4.1.1.17) gene in parental, dexamethasone-resistant and 2-difluoromethylornithine (DFMO)-resistant human IgG-myeloma-cell lines was studied with the aid of methylation-sensitive restriction endonucleases and probes recognizing different parts of the gene.	Eflornithine	93-118	ornithine decarboxylase 1	Homo sapiens	4-27
1663805-6	1991	We also measured ODC activity and polyamine concentration in these cell lines, and determined their sensitivity to an ODC inhibitor, difluoromethylornithine (DFMO).	Eflornithine	133-156	ornithine decarboxylase 1	Homo sapiens	118-121
1663805-6	1991	We also measured ODC activity and polyamine concentration in these cell lines, and determined their sensitivity to an ODC inhibitor, difluoromethylornithine (DFMO).	Eflornithine	158-162	ornithine decarboxylase 1	Homo sapiens	118-121
1787820-7	1991	Alpha-difluoromethylornithine (DFMO) inhibits ornithine decarboxylase and so lowers the levels of spermine and spermidine.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	46-69
1787820-7	1991	Alpha-difluoromethylornithine (DFMO) inhibits ornithine decarboxylase and so lowers the levels of spermine and spermidine.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	46-69
1953732-3	1991	It is shown that (i) CKII accumulates in nuclei of adrenocortical cells exposed to their trophic hormone ACTH; (ii) this CKII nuclear translocation is concomitant with an increase in nuclear polyamine content resulting from ACTH-induced polyamine synthesis; (iii) selective inhibition of polyamine biosynthesis by DFMO results in the inhibition of both ACTH-induced cellular polyamine increase and CKII nuclear accumulation.	Eflornithine	314-318	casein kinase 2 alpha 1	Homo sapiens	21-25
1953732-3	1991	It is shown that (i) CKII accumulates in nuclei of adrenocortical cells exposed to their trophic hormone ACTH; (ii) this CKII nuclear translocation is concomitant with an increase in nuclear polyamine content resulting from ACTH-induced polyamine synthesis; (iii) selective inhibition of polyamine biosynthesis by DFMO results in the inhibition of both ACTH-induced cellular polyamine increase and CKII nuclear accumulation.	Eflornithine	314-318	casein kinase 2 alpha 1	Homo sapiens	121-125
1953732-3	1991	It is shown that (i) CKII accumulates in nuclei of adrenocortical cells exposed to their trophic hormone ACTH; (ii) this CKII nuclear translocation is concomitant with an increase in nuclear polyamine content resulting from ACTH-induced polyamine synthesis; (iii) selective inhibition of polyamine biosynthesis by DFMO results in the inhibition of both ACTH-induced cellular polyamine increase and CKII nuclear accumulation.	Eflornithine	314-318	casein kinase 2 alpha 1	Homo sapiens	121-125
1719956-1	1991	The ornithine decarboxylase (ODC; EC 4.1.1.17) gene in parental, dexamethasone-resistant and 2-difluoromethylornithine (DFMO)-resistant human IgG-myeloma-cell lines was studied with the aid of methylation-sensitive restriction endonucleases and probes recognizing different parts of the gene.	Eflornithine	120-124	ornithine decarboxylase 1	Homo sapiens	29-32
1719956-4	1991	Two of the parental clones represented a hypomethylated type very close to that exclusively found among the DFMO-resistant clones with ODC gene amplification.	Eflornithine	108-112	ornithine decarboxylase 1	Homo sapiens	135-138
1932110-4	1991	This cell line was isolated by selection for resistance to the antiproliferative effect of the ODC inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	109-138	ornithine decarboxylase 1	Homo sapiens	95-98
1932110-4	1991	This cell line was isolated by selection for resistance to the antiproliferative effect of the ODC inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	140-144	ornithine decarboxylase 1	Homo sapiens	95-98
1932110-6	1991	When L1210-DFMOr cells were grown in the presence of 20 mM DFMO (i.e., when their polyamine content was reduced to an extent that still permitted a normal growth rate) ODC represented 4-5% of the soluble protein synthesized.	Eflornithine	11-15	ornithine decarboxylase 1	Homo sapiens	168-171
1932110-7	1991	After transfer of the cells to a medium lacking DFMO (i.e., when their polyamine pools were repleted), the rate of incorporation of [35S]methionine into ODC was one order of magnitude lower.	Eflornithine	48-52	ornithine decarboxylase 1	Homo sapiens	153-156
1898085-0	1991	Stable ornithine decarboxylase in a rat hepatoma cell line selected for resistance to alpha-difluoromethylornithine.	Eflornithine	86-115	ornithine decarboxylase 1	Rattus norvegicus	7-30
1898085-5	1991	This cell variant was induced by selection for growth in stepwise increasing concentrations (up to 10 mM) of the irreversible ODC inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	141-170	ornithine decarboxylase 1	Rattus norvegicus	126-129
1898085-5	1991	This cell variant was induced by selection for growth in stepwise increasing concentrations (up to 10 mM) of the irreversible ODC inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	172-176	ornithine decarboxylase 1	Rattus norvegicus	126-129
1898085-9	1991	ODC purified from the variant cells was found to be identical to the control cell enzyme in size, isoelectric point, substrate binding kinetics, and sensitivity to the inhibitor DFMO.	Eflornithine	178-182	ornithine decarboxylase 1	Rattus norvegicus	0-3
1745018-8	1991	In the presence of alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ODC, the growth rate of MCs, assessed by cell counts and by 3H-TdR uptake, was markedly reduced by 62 to 100%.	Eflornithine	19-48	ornithine decarboxylase 1	Rattus norvegicus	103-106
1745018-8	1991	In the presence of alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ODC, the growth rate of MCs, assessed by cell counts and by 3H-TdR uptake, was markedly reduced by 62 to 100%.	Eflornithine	50-54	ornithine decarboxylase 1	Rattus norvegicus	103-106
1745018-9	1991	This antiproliferative effect of DFMO could be reversed by addition of putrescine, the reaction product of ODC.	Eflornithine	33-37	ornithine decarboxylase 1	Rattus norvegicus	107-110
16668466-12	1991	DFMO increased the activity of diamine oxidase by about 25%.	Eflornithine	0-4	copper amino oxidase	Glycine max	31-46
16668466-14	1991	Ornithine decarboxylase activity was also suppressed by DFMO, but putrescine and spermidine contents were not affected, except in the meristematic tissues.	Eflornithine	56-60	ornithine decarboxylase	Glycine max	0-23
1898373-0	1991	Levels of ornithine decarboxylase genomic sequences, heterogeneous nuclear RNA and mRNA in human myeloma cells resistant to alpha-difluoromethylornithine.	Eflornithine	124-153	ornithine decarboxylase 1	Homo sapiens	10-33
1716059-12	1991	DFMO (5 mM) totally inhibited the increase in ODC activity but had no effect on the cellular uptake of polyamines in the presence of putrescine.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	46-49
1887898-4	1991	DFMO treatment completely abolished the I/R-induced increase in ODC activity.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	64-67
1768053-7	1991	DFMO inhibited the ODC activity totally and depleted the cellular polyamine levels.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	19-22
1859381-2	1991	For this purpose RINm5F cells were exposed for 4 days to the specific ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO).	Eflornithine	110-133	ornithine decarboxylase 1	Rattus norvegicus	70-93
1859381-2	1991	For this purpose RINm5F cells were exposed for 4 days to the specific ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO).	Eflornithine	110-133	ornithine decarboxylase 1	Rattus norvegicus	95-98
1859381-2	1991	For this purpose RINm5F cells were exposed for 4 days to the specific ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO).	Eflornithine	135-139	ornithine decarboxylase 1	Rattus norvegicus	70-93
1859381-2	1991	For this purpose RINm5F cells were exposed for 4 days to the specific ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO).	Eflornithine	135-139	ornithine decarboxylase 1	Rattus norvegicus	95-98
1719956-1	1991	The ornithine decarboxylase (ODC; EC 4.1.1.17) gene in parental, dexamethasone-resistant and 2-difluoromethylornithine (DFMO)-resistant human IgG-myeloma-cell lines was studied with the aid of methylation-sensitive restriction endonucleases and probes recognizing different parts of the gene.	Eflornithine	93-118	ornithine decarboxylase 1	Homo sapiens	29-32
1719956-1	1991	The ornithine decarboxylase (ODC; EC 4.1.1.17) gene in parental, dexamethasone-resistant and 2-difluoromethylornithine (DFMO)-resistant human IgG-myeloma-cell lines was studied with the aid of methylation-sensitive restriction endonucleases and probes recognizing different parts of the gene.	Eflornithine	120-124	ornithine decarboxylase 1	Homo sapiens	4-27
1860716-2	1991	The effects of chronic administration of alpha-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase and thus polyamine biosynthesis, on vascular polyamine contents, structure, and function as well as the development of hypertension was studied.	Eflornithine	41-70	ornithine decarboxylase 1	Rattus norvegicus	109-132
2051159-2	1991	on rat behavior, brain damage, and polyamine levels and the action of the specific ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) on these effects.	Eflornithine	117-146	ornithine decarboxylase 1	Rattus norvegicus	83-106
1710934-9	1991	Difluoromethyl ornithine (DFMO), a specific ODC inhibitor, given orally (8% in drinking water) to nursing dams at postnatal day 5 for 5 days caused an 83% inhibition of pancreatic ODC activity in thyroxine-treated pups when compared to thyroxine-treated pups not exposed to DFMO.	Eflornithine	0-24	ornithine decarboxylase 1	Rattus norvegicus	44-47
1710934-9	1991	Difluoromethyl ornithine (DFMO), a specific ODC inhibitor, given orally (8% in drinking water) to nursing dams at postnatal day 5 for 5 days caused an 83% inhibition of pancreatic ODC activity in thyroxine-treated pups when compared to thyroxine-treated pups not exposed to DFMO.	Eflornithine	0-24	ornithine decarboxylase 1	Rattus norvegicus	180-183
1710934-9	1991	Difluoromethyl ornithine (DFMO), a specific ODC inhibitor, given orally (8% in drinking water) to nursing dams at postnatal day 5 for 5 days caused an 83% inhibition of pancreatic ODC activity in thyroxine-treated pups when compared to thyroxine-treated pups not exposed to DFMO.	Eflornithine	26-30	ornithine decarboxylase 1	Rattus norvegicus	44-47
1710934-9	1991	Difluoromethyl ornithine (DFMO), a specific ODC inhibitor, given orally (8% in drinking water) to nursing dams at postnatal day 5 for 5 days caused an 83% inhibition of pancreatic ODC activity in thyroxine-treated pups when compared to thyroxine-treated pups not exposed to DFMO.	Eflornithine	26-30	ornithine decarboxylase 1	Rattus norvegicus	180-183
1718794-5	1991	Addition of alpha-difluoromethylornithine (DFMO, 4 mM), an inhibitor of PA biosynthesis, consistently lowered IGFBP-2 mRNA in the MCF-7 and BT-20 cell lines and IGFBP-1 mRNA in MDA-MB-231 cells.	Eflornithine	12-41	insulin like growth factor binding protein 2	Homo sapiens	110-117
1927551-8	1991	DFMO administration for 4 days completely inhibited mucosal ornithine decarboxylase and abolished the rise of ileal sucrase activity.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	60-83
1957703-0	1991	In vivo inhibition of parasympathetic nerve induced increases in ornithine decarboxylase activity of the rat sublingual gland by alpha-difluoromethylornithine.	Eflornithine	129-158	ornithine decarboxylase 1	Rattus norvegicus	65-88
1718794-5	1991	Addition of alpha-difluoromethylornithine (DFMO, 4 mM), an inhibitor of PA biosynthesis, consistently lowered IGFBP-2 mRNA in the MCF-7 and BT-20 cell lines and IGFBP-1 mRNA in MDA-MB-231 cells.	Eflornithine	12-41	insulin like growth factor binding protein 1	Homo sapiens	161-168
1718794-5	1991	Addition of alpha-difluoromethylornithine (DFMO, 4 mM), an inhibitor of PA biosynthesis, consistently lowered IGFBP-2 mRNA in the MCF-7 and BT-20 cell lines and IGFBP-1 mRNA in MDA-MB-231 cells.	Eflornithine	43-47	insulin like growth factor binding protein 2	Homo sapiens	110-117
1718794-5	1991	Addition of alpha-difluoromethylornithine (DFMO, 4 mM), an inhibitor of PA biosynthesis, consistently lowered IGFBP-2 mRNA in the MCF-7 and BT-20 cell lines and IGFBP-1 mRNA in MDA-MB-231 cells.	Eflornithine	43-47	insulin like growth factor binding protein 1	Homo sapiens	161-168
2040654-8	1991	DFMO decreased the cellular levels of putrescine and spermidine and suppressed IL-1 beta release and IL-1 beta mRNA expression by 65%.	Eflornithine	0-4	interleukin 1 beta	Homo sapiens	101-110
1782416-6	1991	Pretreatment with difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), a key enzyme in the biosynthesis of polyamines, did not affect ethanol lesions, but reversed the protective effect EGF but not spermine against ethanol.	Eflornithine	18-41	ornithine decarboxylase 1	Rattus norvegicus	79-102
1782416-6	1991	Pretreatment with difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), a key enzyme in the biosynthesis of polyamines, did not affect ethanol lesions, but reversed the protective effect EGF but not spermine against ethanol.	Eflornithine	18-41	ornithine decarboxylase 1	Rattus norvegicus	104-107
1782416-6	1991	Pretreatment with difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), a key enzyme in the biosynthesis of polyamines, did not affect ethanol lesions, but reversed the protective effect EGF but not spermine against ethanol.	Eflornithine	18-41	epidermal growth factor like 1	Rattus norvegicus	225-228
1782416-6	1991	Pretreatment with difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), a key enzyme in the biosynthesis of polyamines, did not affect ethanol lesions, but reversed the protective effect EGF but not spermine against ethanol.	Eflornithine	43-47	ornithine decarboxylase 1	Rattus norvegicus	79-102
1782416-6	1991	Pretreatment with difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), a key enzyme in the biosynthesis of polyamines, did not affect ethanol lesions, but reversed the protective effect EGF but not spermine against ethanol.	Eflornithine	43-47	ornithine decarboxylase 1	Rattus norvegicus	104-107
1912611-4	1991	In the same experiments, on the other hand, addition of DFMO completely blocked the growth stimulatory effect of exogenous TGF-alpha.	Eflornithine	56-60	transforming growth factor alpha	Homo sapiens	123-132
1912611-5	1991	However, when the culture conditions were changed to serum-free medium, TGF-alpha and E2-induced cell proliferation was affected modestly or not at all by DFMO administration, despite similar suppression of cellular ornithine decarboxylase (ODC) activity and PA levels.	Eflornithine	155-159	transforming growth factor alpha	Homo sapiens	72-81
2067204-2	1991	Difluoromethylornithine (DFMO) is an irreversible inhibitor of ODC and thereby depletes putrescine and spermidine levels in vivo and in vitro.	Eflornithine	0-23	ornithine decarboxylase, structural 1	Mus musculus	63-66
2040654-7	1991	To find whether these peaks were related to IL-1 beta production, DL-alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ODC, was added together with TPA and 1,25(OH)2D3.	Eflornithine	66-98	interleukin 1 beta	Homo sapiens	44-53
2040654-7	1991	To find whether these peaks were related to IL-1 beta production, DL-alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ODC, was added together with TPA and 1,25(OH)2D3.	Eflornithine	66-98	ornithine decarboxylase 1	Homo sapiens	144-147
2040654-7	1991	To find whether these peaks were related to IL-1 beta production, DL-alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ODC, was added together with TPA and 1,25(OH)2D3.	Eflornithine	100-104	ornithine decarboxylase 1	Homo sapiens	144-147
2040654-8	1991	DFMO decreased the cellular levels of putrescine and spermidine and suppressed IL-1 beta release and IL-1 beta mRNA expression by 65%.	Eflornithine	0-4	interleukin 1 beta	Homo sapiens	79-88
2067204-2	1991	Difluoromethylornithine (DFMO) is an irreversible inhibitor of ODC and thereby depletes putrescine and spermidine levels in vivo and in vitro.	Eflornithine	25-29	ornithine decarboxylase, structural 1	Mus musculus	63-66
2067204-3	1991	Previous studies in lupus-prone MRL-lpr/lpr mice treated with 1% DFMO in drinking water have been associated with improved lifespan, and reduced anti-DNA antibody production, lymphadenopathy, and splenic polyamine levels.	Eflornithine	65-69	Fas (TNF receptor superfamily member 6)	Mus musculus	36-39
2067204-3	1991	Previous studies in lupus-prone MRL-lpr/lpr mice treated with 1% DFMO in drinking water have been associated with improved lifespan, and reduced anti-DNA antibody production, lymphadenopathy, and splenic polyamine levels.	Eflornithine	65-69	Fas (TNF receptor superfamily member 6)	Mus musculus	40-43
1679009-4	1991	On the contrary, DFMO determined a dramatic reduction of tTG expression and of the apoptotic index.	Eflornithine	17-21	transglutaminase 2	Homo sapiens	57-60
1651771-1	1991	DFMO and IFN have both been shown to suppress the intracellular activity of ornithine decarboxylase in rapidly proliferating tissues.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	76-99
1651771-8	1991	In contrast, the activity of the 68-kDa interferon induced protein kinase (PK) in IFN/DFMO-treated cells was 1.6-fold greater at 48 and 72 h than that found for IFN alone.	Eflornithine	86-90	interferon alpha 1	Homo sapiens	82-85
1651771-8	1991	In contrast, the activity of the 68-kDa interferon induced protein kinase (PK) in IFN/DFMO-treated cells was 1.6-fold greater at 48 and 72 h than that found for IFN alone.	Eflornithine	86-90	interferon alpha 1	Homo sapiens	161-164
1651771-9	1991	These studies demonstrate that the synergistic antiproliferative activity of IFN/DFMO combination may be due, in part, to modification of the activity of IFN-inducible enzymes.	Eflornithine	81-85	interferon alpha 1	Homo sapiens	77-80
1651771-9	1991	These studies demonstrate that the synergistic antiproliferative activity of IFN/DFMO combination may be due, in part, to modification of the activity of IFN-inducible enzymes.	Eflornithine	81-85	interferon alpha 1	Homo sapiens	154-157
2017155-1	1991	Our previous studies suggested that the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) inhibits bone resorption by mechanisms that are independent of polyamine depletion.	Eflornithine	74-103	ornithine decarboxylase, structural 1	Mus musculus	40-63
1852267-0	1991	Differential effects of difluoromethylornithine on basal and induced activity of cerebral ornithine decarboxylase and mRNA.	Eflornithine	24-47	ornithine decarboxylase 1	Homo sapiens	90-113
1852267-5	1991	Susceptibility to difluoromethylornithine may be directly correlated with a slower turnover rate for ornithine decarboxylase.	Eflornithine	18-41	ornithine decarboxylase 1	Homo sapiens	101-124
2017155-1	1991	Our previous studies suggested that the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) inhibits bone resorption by mechanisms that are independent of polyamine depletion.	Eflornithine	105-109	ornithine decarboxylase, structural 1	Mus musculus	40-63
1905904-1	1991	The oral administration of alpha-difluoromethylornithine (DFMO), an enzyme-activated inhibitor of ornithine decarboxylase (ODC), produced a marked decrease in the rate of growth of amelanotic Harding-Passey melanoma transplanted in mice.	Eflornithine	27-56	ornithine decarboxylase, structural 1	Mus musculus	98-121
1905904-1	1991	The oral administration of alpha-difluoromethylornithine (DFMO), an enzyme-activated inhibitor of ornithine decarboxylase (ODC), produced a marked decrease in the rate of growth of amelanotic Harding-Passey melanoma transplanted in mice.	Eflornithine	27-56	ornithine decarboxylase, structural 1	Mus musculus	123-126
1905904-1	1991	The oral administration of alpha-difluoromethylornithine (DFMO), an enzyme-activated inhibitor of ornithine decarboxylase (ODC), produced a marked decrease in the rate of growth of amelanotic Harding-Passey melanoma transplanted in mice.	Eflornithine	58-62	ornithine decarboxylase, structural 1	Mus musculus	98-121
1905904-1	1991	The oral administration of alpha-difluoromethylornithine (DFMO), an enzyme-activated inhibitor of ornithine decarboxylase (ODC), produced a marked decrease in the rate of growth of amelanotic Harding-Passey melanoma transplanted in mice.	Eflornithine	58-62	ornithine decarboxylase, structural 1	Mus musculus	123-126
1672500-6	1991	Trypanosomes taken from rats treated for 36 h with eflornithine, an inhibitor of ODC, were depleted of putrescine and had markedly decreased spermidine levels.	Eflornithine	51-63	ornithine decarboxylase 1	Rattus norvegicus	81-84
1905904-6	1991	However, the activity of SAMDC increased up to 30-fold in DFMO-treated melanoma, while only a moderate increase was observed in the renal enzyme.	Eflornithine	58-62	S-adenosylmethionine decarboxylase 1	Mus musculus	25-30
1831810-1	1991	DL-alpha-Difluoromethylornithine (DFMO) is a specific inhibitor of the rate-limiting enzyme in polyamine biosynthesis, ornithine decarboxylase (ODC).	Eflornithine	0-32	ornithine decarboxylase, structural 1	Mus musculus	119-142
1831810-1	1991	DL-alpha-Difluoromethylornithine (DFMO) is a specific inhibitor of the rate-limiting enzyme in polyamine biosynthesis, ornithine decarboxylase (ODC).	Eflornithine	0-32	ornithine decarboxylase, structural 1	Mus musculus	144-147
1831810-1	1991	DL-alpha-Difluoromethylornithine (DFMO) is a specific inhibitor of the rate-limiting enzyme in polyamine biosynthesis, ornithine decarboxylase (ODC).	Eflornithine	34-38	ornithine decarboxylase, structural 1	Mus musculus	119-142
1831810-1	1991	DL-alpha-Difluoromethylornithine (DFMO) is a specific inhibitor of the rate-limiting enzyme in polyamine biosynthesis, ornithine decarboxylase (ODC).	Eflornithine	34-38	ornithine decarboxylase, structural 1	Mus musculus	144-147
1831810-3	1991	Putrescine (PUT; 1 mM) and spermidine (SPD; 0.01 mM) reversed DFMO inhibition, indicating that DFMO inhibition was caused by ODC antagonism.	Eflornithine	95-99	ornithine decarboxylase, structural 1	Mus musculus	125-128
1932775-8	1991	This effect was abolished by the pretreatment with difluoromethylornithine, an inhibitor of ornithine decarboxylase, the key enzyme in the biosynthesis of polyamines.	Eflornithine	51-74	ornithine decarboxylase	Bos taurus	92-115
2023214-3	1991	There was a reduction of IgG and IgA levels in older DFMO treated mice, whereas IgM level was not affected.	Eflornithine	53-57	immunoglobulin heavy constant alpha	Mus musculus	33-36
1847359-3	1991	Activation of the polyamine-producing system appears to be a necessary step in the proliferative response of HT29 cells since cell growth is arrested by addition of difluoromethylornithine (DFMO, an inhibitor of ODC), then restored by further addition of putrescine into the culture medium.	Eflornithine	165-188	ornithine decarboxylase 1	Homo sapiens	212-215
1847359-3	1991	Activation of the polyamine-producing system appears to be a necessary step in the proliferative response of HT29 cells since cell growth is arrested by addition of difluoromethylornithine (DFMO, an inhibitor of ODC), then restored by further addition of putrescine into the culture medium.	Eflornithine	190-194	ornithine decarboxylase 1	Homo sapiens	212-215
1702074-12	1991	In animals given the specific inhibitor of ornithine decarboxylase, alpha-difluoromethylornithine, increases in duodenal mucosal ornithine decarboxylase activity and polyamine levels were inhibited and mucosal repair was almost completely prevented following stress.	Eflornithine	68-97	ornithine decarboxylase 1	Rattus norvegicus	43-66
1985877-3	1991	alpha-Difluoromethylornithine (DFMO) is an enzyme-activated irreversible inhibitor of ODC, and a known anti-neoplastic agent.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	86-89
1985877-3	1991	alpha-Difluoromethylornithine (DFMO) is an enzyme-activated irreversible inhibitor of ODC, and a known anti-neoplastic agent.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	86-89
1984779-6	1991	Treatment with 1% DFMO was associated with an increase in uterine estrogen receptor DNA binding (1,100 +/- 218 fmoles/mg of DNA) in MRL-lpr/lpr mice (P less than 0.001).	Eflornithine	18-22	Fas (TNF receptor superfamily member 6)	Mus musculus	136-139
2067204-10	1991	DFMO treatment reduced ODC activity and polyamine concentrations in treated mice.	Eflornithine	0-4	ornithine decarboxylase, structural 1	Mus musculus	23-26
2018351-1	1991	An almost complete prevention of tumor growth was achieved in U-251 human glioblastoma xenografted nude mice, by partial decontamination of the gastrointestinal tract and feeding of a polyamine-free diet containing inhibitors of ornithine decarboxylase (DFMO) and of polyamine oxidase (MDL 72527).	Eflornithine	254-258	ornithine decarboxylase, structural 1	Mus musculus	229-252
1984779-6	1991	Treatment with 1% DFMO was associated with an increase in uterine estrogen receptor DNA binding (1,100 +/- 218 fmoles/mg of DNA) in MRL-lpr/lpr mice (P less than 0.001).	Eflornithine	18-22	Fas (TNF receptor superfamily member 6)	Mus musculus	140-143
2039841-3	1991	Such hormonal activation of breast cancer growth was completely abolished by treatment with alpha-difluoromethyl-ornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase, which lowered tumor content of polyamines.	Eflornithine	92-122	ornithine decarboxylase 1	Rattus norvegicus	168-191
1984779-7	1991	Polyamine levels were 2-6-fold higher in the uterine tissues of untreated MRL-lpr/lpr mice compared with the BALB/c mice and were significantly reduced by DFMO treatment.	Eflornithine	155-159	Fas (TNF receptor superfamily member 6)	Mus musculus	78-81
1984779-7	1991	Polyamine levels were 2-6-fold higher in the uterine tissues of untreated MRL-lpr/lpr mice compared with the BALB/c mice and were significantly reduced by DFMO treatment.	Eflornithine	155-159	Fas (TNF receptor superfamily member 6)	Mus musculus	82-85
2039841-3	1991	Such hormonal activation of breast cancer growth was completely abolished by treatment with alpha-difluoromethyl-ornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase, which lowered tumor content of polyamines.	Eflornithine	124-128	ornithine decarboxylase 1	Rattus norvegicus	168-191
1884248-1	1991	Polyamines are essential for cell growth of normal and neoplastic tissue, alpha-Difluoromethylornithine (DFMO) is a known irreversible inhibitor or ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	74-103	ornithine decarboxylase, structural 1	Mus musculus	148-171
1959325-6	1991	The purified frog ODC showed three bands on SDS-polyacrylamide gel electrophoretic analysis, as confirmed by [3H]alpha-difluoromethylornithine binding.	Eflornithine	113-142	ornithine decarboxylase, structural 1	Mus musculus	18-21
1884248-1	1991	Polyamines are essential for cell growth of normal and neoplastic tissue, alpha-Difluoromethylornithine (DFMO) is a known irreversible inhibitor or ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	74-103	ornithine decarboxylase, structural 1	Mus musculus	173-176
1884248-1	1991	Polyamines are essential for cell growth of normal and neoplastic tissue, alpha-Difluoromethylornithine (DFMO) is a known irreversible inhibitor or ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	105-109	ornithine decarboxylase, structural 1	Mus musculus	148-171
1884248-1	1991	Polyamines are essential for cell growth of normal and neoplastic tissue, alpha-Difluoromethylornithine (DFMO) is a known irreversible inhibitor or ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	105-109	ornithine decarboxylase, structural 1	Mus musculus	173-176
1884248-9	1991	DFMO caused a significant reduction (compared with controls that did not receive DFMO) in the ODC activity of tumors; however, ODC activity of the kidney, pancreas, and liver of tumor-bearing mice was not affected.	Eflornithine	0-4	ornithine decarboxylase, structural 1	Mus musculus	94-97
1884248-11	1991	DFMO lowered ODC activity in the kidney, pancreas, and liver of tumor-free mice.	Eflornithine	0-4	ornithine decarboxylase, structural 1	Mus musculus	13-16
1997467-0	1991	Influence of gastrin, gastrin receptor blockers, epidermal growth factor, and difluoromethylornithine on the growth and the activity of ornithine decarboxylase of colonic carcinoma cells.	Eflornithine	78-101	ornithine decarboxylase 1	Homo sapiens	136-159
1900801-1	1991	Interferon (IFN)-alpha, -gamma, and two inhibitors of polyamine biosynthesis (alpha-difluoromethyl ornithine; DFMO and methyl glyoxal bis-guanyl hydrazone; MGBG) inhibited the clonal growth of Raji cells.	Eflornithine	78-108	interferon alpha 1	Homo sapiens	0-22
1997467-6	1991	Growth and ODC activity of all cell lines were inhibited by DFMO.	Eflornithine	60-64	ornithine decarboxylase 1	Homo sapiens	11-14
2005184-1	1991	DL-alpha-Difluoromethylornithine (DFMO), a suicide inhibitor of eukaryotic ornithine decarboxylase (ODC), has therapeutic activities against African trypanosomiasis.	Eflornithine	0-32	ornithine decarboxylase, structural 1	Mus musculus	75-98
2005184-1	1991	DL-alpha-Difluoromethylornithine (DFMO), a suicide inhibitor of eukaryotic ornithine decarboxylase (ODC), has therapeutic activities against African trypanosomiasis.	Eflornithine	0-32	ornithine decarboxylase, structural 1	Mus musculus	100-103
2005184-1	1991	DL-alpha-Difluoromethylornithine (DFMO), a suicide inhibitor of eukaryotic ornithine decarboxylase (ODC), has therapeutic activities against African trypanosomiasis.	Eflornithine	34-38	ornithine decarboxylase, structural 1	Mus musculus	75-98
2005184-1	1991	DL-alpha-Difluoromethylornithine (DFMO), a suicide inhibitor of eukaryotic ornithine decarboxylase (ODC), has therapeutic activities against African trypanosomiasis.	Eflornithine	34-38	ornithine decarboxylase, structural 1	Mus musculus	100-103
2005184-2	1991	The Ki value of DFMO for ODC of Trypanosoma brucei is somewhat higher than that for mouse ODC.	Eflornithine	16-20	ornithine decarboxylase, structural 1	Mus musculus	25-28
2052154-9	1991	Acute inhibition of ornithine decarboxylase activity by alpha-difluoromethylornithine did not alter DNA synthesis, indicating that the decreases in DNA synthesis induced by beta-endorphin are unrelated to the ornithine decarboxylase/polyamine system.	Eflornithine	56-85	ornithine decarboxylase 1	Rattus norvegicus	20-43
2068137-2	1991	The expression of POMC mRNA decreases when the cell lines are differentiated with retinoic acid or alpha-difluoromethylornithine.	Eflornithine	99-128	proopiomelanocortin	Homo sapiens	18-22
2006469-1	1991	The physiological consequences of early neonatal growth retardation in the kidney were investigated using alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase (ODC), a key enzyme in the biosynthesis of polyamines.	Eflornithine	106-135	ornithine decarboxylase 1	Rattus norvegicus	181-204
2006469-1	1991	The physiological consequences of early neonatal growth retardation in the kidney were investigated using alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase (ODC), a key enzyme in the biosynthesis of polyamines.	Eflornithine	106-135	ornithine decarboxylase 1	Rattus norvegicus	206-209
2006469-1	1991	The physiological consequences of early neonatal growth retardation in the kidney were investigated using alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase (ODC), a key enzyme in the biosynthesis of polyamines.	Eflornithine	137-141	ornithine decarboxylase 1	Rattus norvegicus	181-204
2006469-1	1991	The physiological consequences of early neonatal growth retardation in the kidney were investigated using alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase (ODC), a key enzyme in the biosynthesis of polyamines.	Eflornithine	137-141	ornithine decarboxylase 1	Rattus norvegicus	206-209
2088816-7	1990	With administration of the specific inhibitor of ODC (difluoromethylornithine, DFMO) the increase in ODC and polyamines is inhibited and intestinal growth is suppressed.	Eflornithine	54-77	ornithine decarboxylase 1	Rattus norvegicus	49-52
2088816-7	1990	With administration of the specific inhibitor of ODC (difluoromethylornithine, DFMO) the increase in ODC and polyamines is inhibited and intestinal growth is suppressed.	Eflornithine	54-77	ornithine decarboxylase 1	Rattus norvegicus	101-104
2088816-7	1990	With administration of the specific inhibitor of ODC (difluoromethylornithine, DFMO) the increase in ODC and polyamines is inhibited and intestinal growth is suppressed.	Eflornithine	79-83	ornithine decarboxylase 1	Rattus norvegicus	49-52
2088816-7	1990	With administration of the specific inhibitor of ODC (difluoromethylornithine, DFMO) the increase in ODC and polyamines is inhibited and intestinal growth is suppressed.	Eflornithine	79-83	ornithine decarboxylase 1	Rattus norvegicus	101-104
2227276-7	1990	An inhibition of ornithine decarboxylase activity by difluoromethyl ornithine also augmented stress-induced ulcerogenesis and abolished the protective action of epidermal growth factor while the administration of spermine almost completely prevented stress ulcerations in rats both without and with pretreatment with difluoromethylornithine.	Eflornithine	53-77	ornithine decarboxylase 1	Rattus norvegicus	17-40
2227276-7	1990	An inhibition of ornithine decarboxylase activity by difluoromethyl ornithine also augmented stress-induced ulcerogenesis and abolished the protective action of epidermal growth factor while the administration of spermine almost completely prevented stress ulcerations in rats both without and with pretreatment with difluoromethylornithine.	Eflornithine	53-77	epidermal growth factor like 1	Rattus norvegicus	161-184
2227276-7	1990	An inhibition of ornithine decarboxylase activity by difluoromethyl ornithine also augmented stress-induced ulcerogenesis and abolished the protective action of epidermal growth factor while the administration of spermine almost completely prevented stress ulcerations in rats both without and with pretreatment with difluoromethylornithine.	Eflornithine	317-340	ornithine decarboxylase 1	Rattus norvegicus	17-40
1846274-10	1991	Treatment of rats with alpha-difluoromethylornithine (DFMO) prevented the infection-induced elevations in mucosal ODC activity, polyamine levels, DNA synthesis, and DNA, RNA, and protein content without influencing the development of inflammation or the parasite"s life cycle.	Eflornithine	23-52	ornithine decarboxylase 1	Rattus norvegicus	114-117
1846274-10	1991	Treatment of rats with alpha-difluoromethylornithine (DFMO) prevented the infection-induced elevations in mucosal ODC activity, polyamine levels, DNA synthesis, and DNA, RNA, and protein content without influencing the development of inflammation or the parasite"s life cycle.	Eflornithine	54-58	ornithine decarboxylase 1	Rattus norvegicus	114-117
1997467-2	1991	Modulation of the cellular polyamine content by 2-difluoromethylornithine (DFMO) inhibiting ornithine decarboxylase (ODC), or by hormones inducing ODC, influences cell growth.	Eflornithine	48-73	ornithine decarboxylase 1	Homo sapiens	92-115
1997467-2	1991	Modulation of the cellular polyamine content by 2-difluoromethylornithine (DFMO) inhibiting ornithine decarboxylase (ODC), or by hormones inducing ODC, influences cell growth.	Eflornithine	48-73	ornithine decarboxylase 1	Homo sapiens	117-120
1997467-2	1991	Modulation of the cellular polyamine content by 2-difluoromethylornithine (DFMO) inhibiting ornithine decarboxylase (ODC), or by hormones inducing ODC, influences cell growth.	Eflornithine	75-79	ornithine decarboxylase 1	Homo sapiens	92-115
1997467-2	1991	Modulation of the cellular polyamine content by 2-difluoromethylornithine (DFMO) inhibiting ornithine decarboxylase (ODC), or by hormones inducing ODC, influences cell growth.	Eflornithine	75-79	ornithine decarboxylase 1	Homo sapiens	117-120
2221073-4	1990	Difluoromethylornithine (DFMO; 2 mM), an irreversible inhibitor of ODC, completely abolished the gastrin-mediated stimulation of ODC but not Tyr-k activity.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	67-70
1699428-4	1990	Mucosal polyamine levels peaked 4 h after stress and remained significantly elevated for 12 h. The healing process, which was significant by 12 h, was inhibited by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC.	Eflornithine	164-196	ornithine decarboxylase 1	Rattus norvegicus	229-232
1699428-4	1990	Mucosal polyamine levels peaked 4 h after stress and remained significantly elevated for 12 h. The healing process, which was significant by 12 h, was inhibited by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC.	Eflornithine	198-202	ornithine decarboxylase 1	Rattus norvegicus	229-232
1699428-5	1990	DFMO totally prevented the marked increases in ODC and polyamine levels that usually followed stress.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	47-50
2221073-4	1990	Difluoromethylornithine (DFMO; 2 mM), an irreversible inhibitor of ODC, completely abolished the gastrin-mediated stimulation of ODC but not Tyr-k activity.	Eflornithine	0-23	gastrin	Homo sapiens	97-104
2221073-4	1990	Difluoromethylornithine (DFMO; 2 mM), an irreversible inhibitor of ODC, completely abolished the gastrin-mediated stimulation of ODC but not Tyr-k activity.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	129-132
2221073-4	1990	Difluoromethylornithine (DFMO; 2 mM), an irreversible inhibitor of ODC, completely abolished the gastrin-mediated stimulation of ODC but not Tyr-k activity.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	67-70
2221073-4	1990	Difluoromethylornithine (DFMO; 2 mM), an irreversible inhibitor of ODC, completely abolished the gastrin-mediated stimulation of ODC but not Tyr-k activity.	Eflornithine	25-29	gastrin	Homo sapiens	97-104
2221073-4	1990	Difluoromethylornithine (DFMO; 2 mM), an irreversible inhibitor of ODC, completely abolished the gastrin-mediated stimulation of ODC but not Tyr-k activity.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	129-132
2242341-3	1990	Administration of the polyamine biosynthetic inhibitor, alpha-difluoromethylornithine (DFMO) induced a marked suppression of cellular ornithine decarboxylase (ODC) activity and polyamine levels which was associated with significant, although partial, inhibition of E2-stimulated growth.	Eflornithine	56-85	ornithine decarboxylase 1	Homo sapiens	134-157
1974604-6	1990	Thereafter, ODC activity declined but remained significantly greater than control levels for 32 h. Pretreatment of animals with the irreversible ODC inhibitor difluoromethylornithine prevented the induction of ODC by kainate.	Eflornithine	159-182	ornithine decarboxylase 1	Rattus norvegicus	12-15
1974604-6	1990	Thereafter, ODC activity declined but remained significantly greater than control levels for 32 h. Pretreatment of animals with the irreversible ODC inhibitor difluoromethylornithine prevented the induction of ODC by kainate.	Eflornithine	159-182	ornithine decarboxylase 1	Rattus norvegicus	145-148
1974604-6	1990	Thereafter, ODC activity declined but remained significantly greater than control levels for 32 h. Pretreatment of animals with the irreversible ODC inhibitor difluoromethylornithine prevented the induction of ODC by kainate.	Eflornithine	159-182	ornithine decarboxylase 1	Rattus norvegicus	145-148
2242341-3	1990	Administration of the polyamine biosynthetic inhibitor, alpha-difluoromethylornithine (DFMO) induced a marked suppression of cellular ornithine decarboxylase (ODC) activity and polyamine levels which was associated with significant, although partial, inhibition of E2-stimulated growth.	Eflornithine	56-85	ornithine decarboxylase 1	Homo sapiens	159-162
2242341-3	1990	Administration of the polyamine biosynthetic inhibitor, alpha-difluoromethylornithine (DFMO) induced a marked suppression of cellular ornithine decarboxylase (ODC) activity and polyamine levels which was associated with significant, although partial, inhibition of E2-stimulated growth.	Eflornithine	87-91	ornithine decarboxylase 1	Homo sapiens	134-157
2242341-3	1990	Administration of the polyamine biosynthetic inhibitor, alpha-difluoromethylornithine (DFMO) induced a marked suppression of cellular ornithine decarboxylase (ODC) activity and polyamine levels which was associated with significant, although partial, inhibition of E2-stimulated growth.	Eflornithine	87-91	ornithine decarboxylase 1	Homo sapiens	159-162
2228567-1	1990	Difluoromethylornithine (DFMO) irreversibly inhibits ornithine decarboxylase (ODC), a crucial enzyme in polyamine synthesis, and impairs mitogen-induced lymphocyte proliferation.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	53-76
2148071-5	1990	In a small number of hearts, ornithine decarboxylase (ODC) activity was assayed in order to verify that dfmo, which is a suicide inhibitor of ODC, had effectively interrupted the polyamines pathway.	Eflornithine	104-108	ornithine decarboxylase 1	Rattus norvegicus	29-52
2148071-5	1990	In a small number of hearts, ornithine decarboxylase (ODC) activity was assayed in order to verify that dfmo, which is a suicide inhibitor of ODC, had effectively interrupted the polyamines pathway.	Eflornithine	104-108	ornithine decarboxylase 1	Rattus norvegicus	54-57
2148071-5	1990	In a small number of hearts, ornithine decarboxylase (ODC) activity was assayed in order to verify that dfmo, which is a suicide inhibitor of ODC, had effectively interrupted the polyamines pathway.	Eflornithine	104-108	ornithine decarboxylase 1	Rattus norvegicus	142-145
1693880-0	1990	Tumor angiogenesis and polyamines: alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro.	Eflornithine	35-64	ornithine decarboxylase	Bos taurus	95-118
1693880-1	1990	alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, inhibited B16 melanoma-induced angiogenesis in chick embryo chorioallantoic membrane and subsequently the growth of the tumor on the chorioallantoic membrane.	Eflornithine	0-29	ornithine decarboxylase	Gallus gallus	67-90
1693880-1	1990	alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, inhibited B16 melanoma-induced angiogenesis in chick embryo chorioallantoic membrane and subsequently the growth of the tumor on the chorioallantoic membrane.	Eflornithine	31-35	ornithine decarboxylase	Gallus gallus	67-90
1693880-4	1990	DFMO strongly inhibited DNA synthesis and proliferation of bovine pulmonary artery endothelial (BPAE) cells in culture and decreased their ornithine decarboxylase activity and intracellular polyamine concentrations.	Eflornithine	0-4	ornithine decarboxylase	Gallus gallus	139-162
2228567-1	1990	Difluoromethylornithine (DFMO) irreversibly inhibits ornithine decarboxylase (ODC), a crucial enzyme in polyamine synthesis, and impairs mitogen-induced lymphocyte proliferation.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	78-81
2228567-1	1990	Difluoromethylornithine (DFMO) irreversibly inhibits ornithine decarboxylase (ODC), a crucial enzyme in polyamine synthesis, and impairs mitogen-induced lymphocyte proliferation.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	53-76
2228567-1	1990	Difluoromethylornithine (DFMO) irreversibly inhibits ornithine decarboxylase (ODC), a crucial enzyme in polyamine synthesis, and impairs mitogen-induced lymphocyte proliferation.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	78-81
2228567-5	1990	Concentrations of IL 2 increased 7-fold in DFMO-treated, PHA-stimulated PBMC cultures, compared with untreated cells; whereas IL 2 receptor expression as measured by the anti-Tac monoclonal antibody was not affected by the inhibition of ODC.	Eflornithine	43-47	interleukin 2	Homo sapiens	18-22
2114097-1	1990	S-Adenosylmethionine decarboxylase (AdoMetDC) activity was elevated 18.8-fold in Swiss 3T3 fibroblasts which were depleted of cellular polyamines by using the inhibitor difluoromethylornithine (DFMO).	Eflornithine	169-192	adenosylmethionine decarboxylase 1	Rattus norvegicus	0-34
2114097-1	1990	S-Adenosylmethionine decarboxylase (AdoMetDC) activity was elevated 18.8-fold in Swiss 3T3 fibroblasts which were depleted of cellular polyamines by using the inhibitor difluoromethylornithine (DFMO).	Eflornithine	169-192	adenosylmethionine decarboxylase 1	Rattus norvegicus	36-44
2114097-1	1990	S-Adenosylmethionine decarboxylase (AdoMetDC) activity was elevated 18.8-fold in Swiss 3T3 fibroblasts which were depleted of cellular polyamines by using the inhibitor difluoromethylornithine (DFMO).	Eflornithine	194-198	adenosylmethionine decarboxylase 1	Rattus norvegicus	0-34
2114097-1	1990	S-Adenosylmethionine decarboxylase (AdoMetDC) activity was elevated 18.8-fold in Swiss 3T3 fibroblasts which were depleted of cellular polyamines by using the inhibitor difluoromethylornithine (DFMO).	Eflornithine	194-198	adenosylmethionine decarboxylase 1	Rattus norvegicus	36-44
2114097-6	1990	The shift of the AdoMetDC message into large polysomes occurred within 18 h after addition of DFMO to the cultures and could be reversed by adding exogenous putrescine.	Eflornithine	94-98	adenosylmethionine decarboxylase 1	Rattus norvegicus	17-25
2109653-0	1990	Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet.	Eflornithine	125-158	ornithine decarboxylase 1	Rattus norvegicus	163-186
2293084-1	1990	The effect of alpha-difluoromethylornithine (alpha-DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC) the rate limiting enzyme of polyamine biosynthesis, was studied on the astroglial reaction in a model of mechanical brain injury.	Eflornithine	14-43	ornithine decarboxylase 1	Rattus norvegicus	87-110
2293084-1	1990	The effect of alpha-difluoromethylornithine (alpha-DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC) the rate limiting enzyme of polyamine biosynthesis, was studied on the astroglial reaction in a model of mechanical brain injury.	Eflornithine	14-43	ornithine decarboxylase 1	Rattus norvegicus	112-115
2293084-1	1990	The effect of alpha-difluoromethylornithine (alpha-DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC) the rate limiting enzyme of polyamine biosynthesis, was studied on the astroglial reaction in a model of mechanical brain injury.	Eflornithine	45-55	ornithine decarboxylase 1	Rattus norvegicus	87-110
2293084-1	1990	The effect of alpha-difluoromethylornithine (alpha-DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC) the rate limiting enzyme of polyamine biosynthesis, was studied on the astroglial reaction in a model of mechanical brain injury.	Eflornithine	45-55	ornithine decarboxylase 1	Rattus norvegicus	112-115
2293084-2	1990	alpha-DFMO markedly decreased the astroglial activation induced by the microdialysis probe implantation in the striatum of the male rat, as studied by glial fibrillary acidic protein (GFAP) immunocytochemistry.	Eflornithine	0-10	glial fibrillary acidic protein	Rattus norvegicus	184-188
2109637-10	1990	Treatment of rats with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, reduced tissue polyamine content, although it had slight effects only on basolateral polyamine transport.	Eflornithine	23-52	ornithine decarboxylase 1	Rattus norvegicus	77-100
2109637-10	1990	Treatment of rats with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, reduced tissue polyamine content, although it had slight effects only on basolateral polyamine transport.	Eflornithine	54-58	ornithine decarboxylase 1	Rattus norvegicus	77-100
1697882-3	1990	EGF infused subcutaneously (50 micrograms/kg-h) in conscious rats with intact or removed salivary glands stimulated pancreatic protein secretion after 4 h of peptide infusion; this effect was completely prevented by the pretreatment with DL-difluoromethyl-ornithine (DFMO) (200 mg/kg), an irreversible inhibitor of activity of ornithine decarboxylase (ODC), a key enzyme in polyamine synthesis.	Eflornithine	267-271	epidermal growth factor like 1	Rattus norvegicus	0-3
1697882-5	1990	DFMO injected in a single dose (200 mg/kg), before the infusion of EGF to the rats, completely abolished the stimulatory effect of EGF on amylase release, but failed to affect that of spermine.	Eflornithine	0-4	epidermal growth factor like 1	Rattus norvegicus	131-134
2180965-11	1990	Inhibition of ODC activity by difluoromethylornithine (DFMO) did not suppress oncogenic ras-induced neurite outgrowth, suggesting that these two ras-triggered events are mechanistically independent.	Eflornithine	30-53	ornithine decarboxylase 1	Homo sapiens	14-17
2180965-11	1990	Inhibition of ODC activity by difluoromethylornithine (DFMO) did not suppress oncogenic ras-induced neurite outgrowth, suggesting that these two ras-triggered events are mechanistically independent.	Eflornithine	55-59	ornithine decarboxylase 1	Homo sapiens	14-17
2124561-0	1990	Effects of starvation and difluoromethylornithine (DFMO) on diamine oxidase activity in rat ileum.	Eflornithine	26-49	amine oxidase, copper containing 1	Rattus norvegicus	60-75
2105957-0	1990	Regulation of ornithine decarboxylase expression by anisosmotic shock in alpha-difluoromethylornithine-resistant L1210 cells.	Eflornithine	73-102	ornithine decarboxylase, structural 1	Mus musculus	14-37
2312502-11	1990	This, in association with the inhibitory effect on OKG action of difluoromethylornithine, a specific inhibitor of ornithine decarboxylase, suggests a link between the polyamine biosynthesis pathway and the anabolic effect of OKG.	Eflornithine	65-88	ornithine decarboxylase 1	Homo sapiens	114-137
2104755-5	1990	Further, covalent modification of ODC near its active site by difluoromethylornithine or phosphate also increases its sensitivity to antizyme.	Eflornithine	62-85	ornithine decarboxylase 1	Homo sapiens	34-37
1689120-9	1990	alpha-Difluoromethylornithine (DFMO), a specific inhibitor of ODC, not only inhibited the ODC activity but significantly delayed the recovery from injury as well.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	62-65
1689120-9	1990	alpha-Difluoromethylornithine (DFMO), a specific inhibitor of ODC, not only inhibited the ODC activity but significantly delayed the recovery from injury as well.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	90-93
1689120-9	1990	alpha-Difluoromethylornithine (DFMO), a specific inhibitor of ODC, not only inhibited the ODC activity but significantly delayed the recovery from injury as well.	Eflornithine	31-35	ornithine decarboxylase 1	Rattus norvegicus	62-65
1689120-9	1990	alpha-Difluoromethylornithine (DFMO), a specific inhibitor of ODC, not only inhibited the ODC activity but significantly delayed the recovery from injury as well.	Eflornithine	31-35	ornithine decarboxylase 1	Rattus norvegicus	90-93
2109593-0	1990	Inhibition of tumor promotion by DL-alpha-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase.	Eflornithine	33-65	ornithine decarboxylase 1	Homo sapiens	104-127
2124561-0	1990	Effects of starvation and difluoromethylornithine (DFMO) on diamine oxidase activity in rat ileum.	Eflornithine	51-55	amine oxidase, copper containing 1	Rattus norvegicus	60-75
2124561-1	1990	Starvation and difluoromethylornithine (DFMO) administration have profound affects on intestinal proliferation, ornithine decarboxylase activity, and tissue polyamine levels.	Eflornithine	15-38	ornithine decarboxylase 1	Rattus norvegicus	112-135
2124561-1	1990	Starvation and difluoromethylornithine (DFMO) administration have profound affects on intestinal proliferation, ornithine decarboxylase activity, and tissue polyamine levels.	Eflornithine	40-44	ornithine decarboxylase 1	Rattus norvegicus	112-135
2124561-5	1990	The homogenates from the DFMO group also were found to have decreased ODC activity however, mucosal diamine oxidase activity was also decreased.	Eflornithine	25-29	amine oxidase, copper containing 1	Rattus norvegicus	100-115
2124562-5	1990	In order to investigate a possible regulation of DAO expression by ODC, we studied the effect of difluoromethylornithine (DFMO), a selective, irreversible inhibitor of ODC, on DAO activity in isolated rat small bowel enterocytes.	Eflornithine	97-120	ornithine decarboxylase 1	Rattus norvegicus	168-171
2124562-5	1990	In order to investigate a possible regulation of DAO expression by ODC, we studied the effect of difluoromethylornithine (DFMO), a selective, irreversible inhibitor of ODC, on DAO activity in isolated rat small bowel enterocytes.	Eflornithine	97-120	amine oxidase, copper containing 1	Rattus norvegicus	176-179
2124562-5	1990	In order to investigate a possible regulation of DAO expression by ODC, we studied the effect of difluoromethylornithine (DFMO), a selective, irreversible inhibitor of ODC, on DAO activity in isolated rat small bowel enterocytes.	Eflornithine	122-126	amine oxidase, copper containing 1	Rattus norvegicus	176-179
2124562-6	1990	Our data demonstrate that in isolated small bowel enterocytes ODC inhibition by 10 mM DFMO reduced DAO activity by 53%, suggesting that, in our experimental conditions, ODC plays a regulatory role on DAO expression.	Eflornithine	86-90	ornithine decarboxylase 1	Rattus norvegicus	62-65
2124562-6	1990	Our data demonstrate that in isolated small bowel enterocytes ODC inhibition by 10 mM DFMO reduced DAO activity by 53%, suggesting that, in our experimental conditions, ODC plays a regulatory role on DAO expression.	Eflornithine	86-90	amine oxidase, copper containing 1	Rattus norvegicus	99-102
2124562-6	1990	Our data demonstrate that in isolated small bowel enterocytes ODC inhibition by 10 mM DFMO reduced DAO activity by 53%, suggesting that, in our experimental conditions, ODC plays a regulatory role on DAO expression.	Eflornithine	86-90	ornithine decarboxylase 1	Rattus norvegicus	169-172
2124562-6	1990	Our data demonstrate that in isolated small bowel enterocytes ODC inhibition by 10 mM DFMO reduced DAO activity by 53%, suggesting that, in our experimental conditions, ODC plays a regulatory role on DAO expression.	Eflornithine	86-90	amine oxidase, copper containing 1	Rattus norvegicus	200-203
2124563-3	1990	After jejunectomy, there were up to 93% increases in mean enterocyte ODC activity when compared with the corresponding cell fractions from the TRCs, but in both the control and jejunectomised rats, DFMO treatment markedly inhibited ODC activity (p less than 0.05-0.01) and reduced spermidine and particularly putrescine concentrations (p less than 0.005-0.001) in all four cell fractions.	Eflornithine	198-202	ornithine decarboxylase 1	Rattus norvegicus	232-235
2144749-9	1990	The antiproliferative effects of 4-hydroxytamoxifen and DFMO cannot be accounted for by either suppression of IGF-1 secretion (a growth stimulatory factor) or stimulation of TGF-beta production (a growth inhibitory polypeptide).	Eflornithine	56-60	insulin like growth factor 1	Homo sapiens	110-115
2262070-2	1990	In addition, supplementation of medium with putrescine alone reverses the inhibition of proliferation produced by inhibition of ODC with difluoromethylornithine (DFMO).	Eflornithine	137-160	ornithine decarboxylase 1	Rattus norvegicus	128-131
2262070-2	1990	In addition, supplementation of medium with putrescine alone reverses the inhibition of proliferation produced by inhibition of ODC with difluoromethylornithine (DFMO).	Eflornithine	162-166	ornithine decarboxylase 1	Rattus norvegicus	128-131
2262070-6	1990	This was verified by measuring [3H]DFMO binding; serum-stimulated induction of activity was accompanied by a corresponding 20-fold increase in the specific binding of DFMO to ODC.	Eflornithine	35-39	ornithine decarboxylase 1	Rattus norvegicus	175-178
2262070-6	1990	This was verified by measuring [3H]DFMO binding; serum-stimulated induction of activity was accompanied by a corresponding 20-fold increase in the specific binding of DFMO to ODC.	Eflornithine	167-171	ornithine decarboxylase 1	Rattus norvegicus	175-178
2104805-1	1990	The current study examined both in vivo and in vitro the effects of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), on regeneration of sensory axons from a local crush of the adult frog sciatic nerve.	Eflornithine	68-97	ornithine decarboxylase 1	Homo sapiens	135-158
2104805-1	1990	The current study examined both in vivo and in vitro the effects of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), on regeneration of sensory axons from a local crush of the adult frog sciatic nerve.	Eflornithine	68-97	ornithine decarboxylase 1	Homo sapiens	160-163
2104805-1	1990	The current study examined both in vivo and in vitro the effects of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), on regeneration of sensory axons from a local crush of the adult frog sciatic nerve.	Eflornithine	99-103	ornithine decarboxylase 1	Homo sapiens	135-158
2104805-1	1990	The current study examined both in vivo and in vitro the effects of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), on regeneration of sensory axons from a local crush of the adult frog sciatic nerve.	Eflornithine	99-103	ornithine decarboxylase 1	Homo sapiens	160-163
1696247-5	1990	The AGS-6 clone exhibited little or no increased sensitivity as a result of pretreatment with DFMO, even though the DFMO-induced reductions in ODC and polyamine values in these cells were similar to those produced in the more sensitive parental line.	Eflornithine	116-120	ornithine decarboxylase 1	Homo sapiens	143-146
2104632-5	1990	The activity was inhibited by the specific ornithine decarboxylase inhibitor alpha-difluoromethyl ornithine.	Eflornithine	77-107	ornithine decarboxylase, structural 1	Mus musculus	43-66
2107554-2	1990	Polyamine synthesis was inhibited by alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	37-66	ornithine decarboxylase 1	Homo sapiens	104-127
2107554-2	1990	Polyamine synthesis was inhibited by alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	68-72	ornithine decarboxylase 1	Homo sapiens	104-127
1694401-10	1990	Inhibition of ODC with DL-alpha-difluoromethylornithine additionally decreased DNA, RNA, and protein content, exacerbating the damage.	Eflornithine	23-55	ornithine decarboxylase 1	Rattus norvegicus	14-17
3125182-3	1988	A mutant L1210 cell line, in which ODCase represents 4-5% of all soluble protein synthesized, was isolated by stepwise selection for resistance to the ODCase inhibitor 2-difluoromethylornithine (DFMO).	Eflornithine	168-193	ornithine decarboxylase, structural 1	Mus musculus	35-41
3125182-3	1988	A mutant L1210 cell line, in which ODCase represents 4-5% of all soluble protein synthesized, was isolated by stepwise selection for resistance to the ODCase inhibitor 2-difluoromethylornithine (DFMO).	Eflornithine	168-193	ornithine decarboxylase, structural 1	Mus musculus	151-157
33818897-5	2021	Moreover, the proposed work offers an adequate sensitive and selective determination for alpha-difluoromethylornithine where the detection limits were 0.90 mug mL-1 and 0.071 mug mL-1 for the spectrophotometric method and the spectrofluorimetric method, respectively.	Eflornithine	89-118	L1 cell adhesion molecule	Mus musculus	160-164
33818897-5	2021	Moreover, the proposed work offers an adequate sensitive and selective determination for alpha-difluoromethylornithine where the detection limits were 0.90 mug mL-1 and 0.071 mug mL-1 for the spectrophotometric method and the spectrofluorimetric method, respectively.	Eflornithine	89-118	L1 cell adhesion molecule	Mus musculus	179-183
2144749-9	1990	The antiproliferative effects of 4-hydroxytamoxifen and DFMO cannot be accounted for by either suppression of IGF-1 secretion (a growth stimulatory factor) or stimulation of TGF-beta production (a growth inhibitory polypeptide).	Eflornithine	56-60	transforming growth factor beta 1	Homo sapiens	174-182
15015763-0	2003	Alpha-difluoromethylornithine, ornithine decarboxylase inhibitor, antagonizes H2O2-induced cytotoxicity in HL-60 leukemia cells: regulation of iron-dependent lysosomal damage.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	31-54
31765147-4	2019	The tested analogues overcame growth arrest induced by a 72 h treatment with alpha-difluoromethylornithine, an ornithine decarboxylase (ODC) inhibitor, and entered into DU145 cells via the polyamine transporter.	Eflornithine	77-106	ornithine decarboxylase 1	Homo sapiens	111-134
31765147-4	2019	The tested analogues overcame growth arrest induced by a 72 h treatment with alpha-difluoromethylornithine, an ornithine decarboxylase (ODC) inhibitor, and entered into DU145 cells via the polyamine transporter.	Eflornithine	77-106	ornithine decarboxylase 1	Homo sapiens	136-139
34133404-5	2021	Our data demonstrates that treatment with DFMO significantly enhances both the viability and activation status of intratumoral CD8+ T cells, most likely through an indirect mechanism.	Eflornithine	42-46	CD8a molecule	Homo sapiens	127-130
15015763-3	2003	Alpha-difluoromethylornithine treatment (DFMO, 3 mmol/L, 48 h), which depletes intracellular putrescine by inhibiting ornithine decarboxylase, reduced H2O2-induced cell death in the HL-60 leukemia cells.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	118-141
15015763-3	2003	Alpha-difluoromethylornithine treatment (DFMO, 3 mmol/L, 48 h), which depletes intracellular putrescine by inhibiting ornithine decarboxylase, reduced H2O2-induced cell death in the HL-60 leukemia cells.	Eflornithine	41-45	ornithine decarboxylase 1	Homo sapiens	118-141
34947972-0	2021	DFMO Improves Survival and Increases Immune Cell Infiltration in Association with MYC Downregulation in the Pancreatic Tumor Microenvironment.	Eflornithine	0-4	myelocytomatosis oncogene	Mus musculus	82-85
34947972-5	2021	Here, we targeted KRAS, through inhibition of downstream c-RAF with GW5074, and MYC expression via difluoromethylornithine (DFMO).	Eflornithine	99-122	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	18-22
34947972-5	2021	Here, we targeted KRAS, through inhibition of downstream c-RAF with GW5074, and MYC expression via difluoromethylornithine (DFMO).	Eflornithine	99-122	myelocytomatosis oncogene	Mus musculus	80-83
34947972-5	2021	Here, we targeted KRAS, through inhibition of downstream c-RAF with GW5074, and MYC expression via difluoromethylornithine (DFMO).	Eflornithine	124-128	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	18-22
34947972-5	2021	Here, we targeted KRAS, through inhibition of downstream c-RAF with GW5074, and MYC expression via difluoromethylornithine (DFMO).	Eflornithine	124-128	myelocytomatosis oncogene	Mus musculus	80-83
34947972-9	2021	To further investigate, immunohistochemical staining showed DFMO diminished MYC expression and increased tumor infiltration of macrophages, CD86+ cells, CD4+ and CD8+ T lymphocytes.	Eflornithine	60-64	myelocytomatosis oncogene	Mus musculus	76-79
34947972-9	2021	To further investigate, immunohistochemical staining showed DFMO diminished MYC expression and increased tumor infiltration of macrophages, CD86+ cells, CD4+ and CD8+ T lymphocytes.	Eflornithine	60-64	CD86 antigen	Mus musculus	140-144
34947972-9	2021	To further investigate, immunohistochemical staining showed DFMO diminished MYC expression and increased tumor infiltration of macrophages, CD86+ cells, CD4+ and CD8+ T lymphocytes.	Eflornithine	60-64	CD4 antigen	Mus musculus	153-156
34947972-11	2021	Collectively, this study highlights that in contrast to GW5074, the inhibition of MYC through DFMO may be an effective treatment modality to modulate PDAC immunosuppression.	Eflornithine	94-98	myelocytomatosis oncogene	Mus musculus	82-85
34129075-3	2021	The ODC inhibitor alpha-difluoromethylornithine (DFMO, or Eflornithine) has been FDA-approved for the treatment of trypanosomiasis and hirsutism and has advanced to clinical cancer trials including NB as well as cancer-unrelated human diseases.	Eflornithine	18-47	ornithine decarboxylase 1	Homo sapiens	4-7
34129075-3	2021	The ODC inhibitor alpha-difluoromethylornithine (DFMO, or Eflornithine) has been FDA-approved for the treatment of trypanosomiasis and hirsutism and has advanced to clinical cancer trials including NB as well as cancer-unrelated human diseases.	Eflornithine	49-53	ornithine decarboxylase 1	Homo sapiens	4-7
34129075-3	2021	The ODC inhibitor alpha-difluoromethylornithine (DFMO, or Eflornithine) has been FDA-approved for the treatment of trypanosomiasis and hirsutism and has advanced to clinical cancer trials including NB as well as cancer-unrelated human diseases.	Eflornithine	58-70	ornithine decarboxylase 1	Homo sapiens	4-7
34129075-7	2021	RESULTS: The organic anion transport 1/3 (OAT 1/3) inhibitor probenecid reduces the renal clearance of DFMO and significantly increases the antitumor activity of DFMO in PDX of NB (P < 0.02).	Eflornithine	103-107	solute carrier family 22 member 6	Homo sapiens	42-49
34129075-7	2021	RESULTS: The organic anion transport 1/3 (OAT 1/3) inhibitor probenecid reduces the renal clearance of DFMO and significantly increases the antitumor activity of DFMO in PDX of NB (P < 0.02).	Eflornithine	162-166	solute carrier family 22 member 6	Homo sapiens	42-49
34129075-8	2021	Excised tumors revealed that DFMO/probenecid treatment decreases polyamines putrescine and spermidine, reduces MYCN protein levels and dephosphorylates retinoblastoma (Rb) protein (p-RbSer795), suggesting DFMO/probenecid-induced cell cycle arrest.	Eflornithine	29-33	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	111-115
34129075-8	2021	Excised tumors revealed that DFMO/probenecid treatment decreases polyamines putrescine and spermidine, reduces MYCN protein levels and dephosphorylates retinoblastoma (Rb) protein (p-RbSer795), suggesting DFMO/probenecid-induced cell cycle arrest.	Eflornithine	29-33	RB transcriptional corepressor 1	Homo sapiens	152-171
34129075-8	2021	Excised tumors revealed that DFMO/probenecid treatment decreases polyamines putrescine and spermidine, reduces MYCN protein levels and dephosphorylates retinoblastoma (Rb) protein (p-RbSer795), suggesting DFMO/probenecid-induced cell cycle arrest.	Eflornithine	205-209	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	111-115
34129075-8	2021	Excised tumors revealed that DFMO/probenecid treatment decreases polyamines putrescine and spermidine, reduces MYCN protein levels and dephosphorylates retinoblastoma (Rb) protein (p-RbSer795), suggesting DFMO/probenecid-induced cell cycle arrest.	Eflornithine	205-209	RB transcriptional corepressor 1	Homo sapiens	152-171
34529197-8	2021	Inhibitor of polyamine synthesis (difluoromethylornithine, DFMO, 5 mM) was quite effective in suppressing HG-mediated cell proliferation and ODC activity in MDA-MB-231 and MCF-10A cells.	Eflornithine	34-57	ornithine decarboxylase 1	Homo sapiens	141-144
34529197-8	2021	Inhibitor of polyamine synthesis (difluoromethylornithine, DFMO, 5 mM) was quite effective in suppressing HG-mediated cell proliferation and ODC activity in MDA-MB-231 and MCF-10A cells.	Eflornithine	59-63	ornithine decarboxylase 1	Homo sapiens	141-144
34133404-7	2021	Taken together, these data suggest that DFMO might represent a potential immunomodulatory agent that can enhance current PD-1-based checkpoint therapies.	Eflornithine	40-44	programmed cell death 1	Homo sapiens	121-125
34376808-2	2021	We studied 94 variants in 54 genes for association with gastric cancer, including rs2302615 in ornithine decarboxylase (ODC1), which may affect response to chemoprevention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO).	Eflornithine	196-208	ornithine decarboxylase 1	Homo sapiens	95-118
34744477-7	2021	PGE3 exposure enhanced the level of c-Myc, RhoA and Cdk2 proteins, and reversed the inhibition of these proteins expression induced by DFMO.	Eflornithine	135-139	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	36-41
34744477-7	2021	PGE3 exposure enhanced the level of c-Myc, RhoA and Cdk2 proteins, and reversed the inhibition of these proteins expression induced by DFMO.	Eflornithine	135-139	ras homolog family member A	Rattus norvegicus	43-47
34744477-7	2021	PGE3 exposure enhanced the level of c-Myc, RhoA and Cdk2 proteins, and reversed the inhibition of these proteins expression induced by DFMO.	Eflornithine	135-139	cyclin dependent kinase 2	Rattus norvegicus	52-56
34376808-2	2021	We studied 94 variants in 54 genes for association with gastric cancer, including rs2302615 in ornithine decarboxylase (ODC1), which may affect response to chemoprevention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO).	Eflornithine	196-208	ornithine decarboxylase 1	Homo sapiens	120-124
34376808-2	2021	We studied 94 variants in 54 genes for association with gastric cancer, including rs2302615 in ornithine decarboxylase (ODC1), which may affect response to chemoprevention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO).	Eflornithine	196-208	ornithine decarboxylase 1	Homo sapiens	181-184
34376808-2	2021	We studied 94 variants in 54 genes for association with gastric cancer, including rs2302615 in ornithine decarboxylase (ODC1), which may affect response to chemoprevention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO).	Eflornithine	210-233	ornithine decarboxylase 1	Homo sapiens	95-118
34376808-2	2021	We studied 94 variants in 54 genes for association with gastric cancer, including rs2302615 in ornithine decarboxylase (ODC1), which may affect response to chemoprevention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO).	Eflornithine	210-233	ornithine decarboxylase 1	Homo sapiens	120-124
34376808-2	2021	We studied 94 variants in 54 genes for association with gastric cancer, including rs2302615 in ornithine decarboxylase (ODC1), which may affect response to chemoprevention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO).	Eflornithine	210-233	ornithine decarboxylase 1	Homo sapiens	181-184
34376808-2	2021	We studied 94 variants in 54 genes for association with gastric cancer, including rs2302615 in ornithine decarboxylase (ODC1), which may affect response to chemoprevention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO).	Eflornithine	235-239	ornithine decarboxylase 1	Homo sapiens	95-118
34376808-2	2021	We studied 94 variants in 54 genes for association with gastric cancer, including rs2302615 in ornithine decarboxylase (ODC1), which may affect response to chemoprevention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO).	Eflornithine	235-239	ornithine decarboxylase 1	Homo sapiens	120-124
34376808-2	2021	We studied 94 variants in 54 genes for association with gastric cancer, including rs2302615 in ornithine decarboxylase (ODC1), which may affect response to chemoprevention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO).	Eflornithine	235-239	ornithine decarboxylase 1	Homo sapiens	181-184
34376808-8	2021	In conclusion, the ODC1 variant, rs2302615, is associated with gastric cancer and supports chemoprevention trials with DFMO, particularly in individuals homozygous for the T allele at rs1927914.	Eflornithine	119-123	ornithine decarboxylase 1	Homo sapiens	19-23
34638596-7	2021	Additionally, significant changes in Bcl-2, Bcl-xL, Bax protein levels, activation of caspase-3, and cleavage of poly (ADP-ribose) polymerase were observed, indicating the apoptotic effects of DFMO.	Eflornithine	193-197	BCL2 associated X, apoptosis regulator	Homo sapiens	52-55
34638596-7	2021	Additionally, significant changes in Bcl-2, Bcl-xL, Bax protein levels, activation of caspase-3, and cleavage of poly (ADP-ribose) polymerase were observed, indicating the apoptotic effects of DFMO.	Eflornithine	193-197	caspase 3	Homo sapiens	86-95
34638596-7	2021	Additionally, significant changes in Bcl-2, Bcl-xL, Bax protein levels, activation of caspase-3, and cleavage of poly (ADP-ribose) polymerase were observed, indicating the apoptotic effects of DFMO.	Eflornithine	193-197	poly(ADP-ribose) polymerase 1	Homo sapiens	113-141
34638596-8	2021	We also found that the effect of DFMO was mediated by AP-1 through the activation of upstream JNK via phosphorylation.	Eflornithine	33-37	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	54-58
34638596-8	2021	We also found that the effect of DFMO was mediated by AP-1 through the activation of upstream JNK via phosphorylation.	Eflornithine	33-37	mitogen-activated protein kinase 8	Homo sapiens	94-97
35100927-3	2022	ODC is a MYC target gene and rate-limiting enzyme of polyamine biosynthesis and the FDA-approved anti-protozoan drug alpha-difluoromethylornithine (DFMO) inhibits ODC activity and induces polyamine depletion that leads to tumor growth arrest.	Eflornithine	117-146	ornithine decarboxylase 1	Homo sapiens	0-3
34638596-0	2021	Difluoromethylornithine Induces Apoptosis through Regulation of AP-1 Signaling via JNK Phosphorylation in Epithelial Ovarian Cancer.	Eflornithine	0-23	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	64-68
34638596-0	2021	Difluoromethylornithine Induces Apoptosis through Regulation of AP-1 Signaling via JNK Phosphorylation in Epithelial Ovarian Cancer.	Eflornithine	0-23	mitogen-activated protein kinase 8	Homo sapiens	83-86
34638596-1	2021	Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), has promising activity against various cancers and a tolerable safety profile for long-term use as a chemopreventive agent.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	61-84
34638596-1	2021	Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), has promising activity against various cancers and a tolerable safety profile for long-term use as a chemopreventive agent.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	86-89
34638596-1	2021	Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), has promising activity against various cancers and a tolerable safety profile for long-term use as a chemopreventive agent.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	61-84
34638596-1	2021	Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), has promising activity against various cancers and a tolerable safety profile for long-term use as a chemopreventive agent.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	86-89
34638596-5	2021	DFMO treatment inhibited the activity and downregulated the expression of ODC in ovarian cancer cells.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	74-77
34638596-7	2021	Additionally, significant changes in Bcl-2, Bcl-xL, Bax protein levels, activation of caspase-3, and cleavage of poly (ADP-ribose) polymerase were observed, indicating the apoptotic effects of DFMO.	Eflornithine	193-197	BCL2 apoptosis regulator	Homo sapiens	37-42
34638596-7	2021	Additionally, significant changes in Bcl-2, Bcl-xL, Bax protein levels, activation of caspase-3, and cleavage of poly (ADP-ribose) polymerase were observed, indicating the apoptotic effects of DFMO.	Eflornithine	193-197	BCL2 like 1	Homo sapiens	44-50
34067619-8	2021	Analysis of intracellular DFMO after withdrawal from growth medium showed residual DFMO in the cells with concomitant decreases in polyamine content, ODC protein level, and cell growth.	Eflornithine	26-30	ornithine decarboxylase 1	Homo sapiens	150-153
34067619-8	2021	Analysis of intracellular DFMO after withdrawal from growth medium showed residual DFMO in the cells with concomitant decreases in polyamine content, ODC protein level, and cell growth.	Eflornithine	83-87	ornithine decarboxylase 1	Homo sapiens	150-153
34252566-3	2021	Cancer cell growth can be inhibited by the polyamine biosynthesis inhibitor difluoromethylornithine (DFMO) which inhibits ornithine decarboxylase (ODC), the rate-limiting enzyme in the polyamine biosynthesis pathway.	Eflornithine	76-99	ornithine decarboxylase 1	Homo sapiens	122-145
34252566-3	2021	Cancer cell growth can be inhibited by the polyamine biosynthesis inhibitor difluoromethylornithine (DFMO) which inhibits ornithine decarboxylase (ODC), the rate-limiting enzyme in the polyamine biosynthesis pathway.	Eflornithine	76-99	ornithine decarboxylase 1	Homo sapiens	147-150
34252566-3	2021	Cancer cell growth can be inhibited by the polyamine biosynthesis inhibitor difluoromethylornithine (DFMO) which inhibits ornithine decarboxylase (ODC), the rate-limiting enzyme in the polyamine biosynthesis pathway.	Eflornithine	101-105	ornithine decarboxylase 1	Homo sapiens	122-145
34252566-3	2021	Cancer cell growth can be inhibited by the polyamine biosynthesis inhibitor difluoromethylornithine (DFMO) which inhibits ornithine decarboxylase (ODC), the rate-limiting enzyme in the polyamine biosynthesis pathway.	Eflornithine	101-105	ornithine decarboxylase 1	Homo sapiens	147-150
34282722-0	2021	Repurposing eflornithine to treat a patient with a rare ODC1 gain-of-function variant disease.	Eflornithine	12-24	ornithine decarboxylase 1	Homo sapiens	56-60
34206987-7	2021	A pronounced stimulation of cell proliferation and interferon-gamma (IFN-gamma) secretion in response to concanavalin A was shown for antioxidant N-acetylcysteine (NAC), polyamine biosynthesis inhibitor 2-difluoromethylornithine (DFMO), and TLR9 agonist CpG ODN 1826 (CpG).	Eflornithine	203-228	interferon gamma	Homo sapiens	51-67
34206987-7	2021	A pronounced stimulation of cell proliferation and interferon-gamma (IFN-gamma) secretion in response to concanavalin A was shown for antioxidant N-acetylcysteine (NAC), polyamine biosynthesis inhibitor 2-difluoromethylornithine (DFMO), and TLR9 agonist CpG ODN 1826 (CpG).	Eflornithine	203-228	interferon gamma	Homo sapiens	69-78
34206987-7	2021	A pronounced stimulation of cell proliferation and interferon-gamma (IFN-gamma) secretion in response to concanavalin A was shown for antioxidant N-acetylcysteine (NAC), polyamine biosynthesis inhibitor 2-difluoromethylornithine (DFMO), and TLR9 agonist CpG ODN 1826 (CpG).	Eflornithine	230-234	interferon gamma	Homo sapiens	51-67
34206987-7	2021	A pronounced stimulation of cell proliferation and interferon-gamma (IFN-gamma) secretion in response to concanavalin A was shown for antioxidant N-acetylcysteine (NAC), polyamine biosynthesis inhibitor 2-difluoromethylornithine (DFMO), and TLR9 agonist CpG ODN 1826 (CpG).	Eflornithine	230-234	interferon gamma	Homo sapiens	69-78
34206987-10	2021	NAC and DFMO suppressed NO and interleukin 10 (IL-10) production by splenocytes, while DFMO increased the levels of IL-12.	Eflornithine	8-12	interleukin 10	Homo sapiens	31-45
34206987-10	2021	NAC and DFMO suppressed NO and interleukin 10 (IL-10) production by splenocytes, while DFMO increased the levels of IL-12.	Eflornithine	8-12	interleukin 10	Homo sapiens	47-52
35100927-3	2022	ODC is a MYC target gene and rate-limiting enzyme of polyamine biosynthesis and the FDA-approved anti-protozoan drug alpha-difluoromethylornithine (DFMO) inhibits ODC activity and induces polyamine depletion that leads to tumor growth arrest.	Eflornithine	117-146	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	9-12
35100927-3	2022	ODC is a MYC target gene and rate-limiting enzyme of polyamine biosynthesis and the FDA-approved anti-protozoan drug alpha-difluoromethylornithine (DFMO) inhibits ODC activity and induces polyamine depletion that leads to tumor growth arrest.	Eflornithine	117-146	ornithine decarboxylase 1	Homo sapiens	163-166
35100927-3	2022	ODC is a MYC target gene and rate-limiting enzyme of polyamine biosynthesis and the FDA-approved anti-protozoan drug alpha-difluoromethylornithine (DFMO) inhibits ODC activity and induces polyamine depletion that leads to tumor growth arrest.	Eflornithine	148-152	ornithine decarboxylase 1	Homo sapiens	0-3
35100927-3	2022	ODC is a MYC target gene and rate-limiting enzyme of polyamine biosynthesis and the FDA-approved anti-protozoan drug alpha-difluoromethylornithine (DFMO) inhibits ODC activity and induces polyamine depletion that leads to tumor growth arrest.	Eflornithine	148-152	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	9-12
35100927-3	2022	ODC is a MYC target gene and rate-limiting enzyme of polyamine biosynthesis and the FDA-approved anti-protozoan drug alpha-difluoromethylornithine (DFMO) inhibits ODC activity and induces polyamine depletion that leads to tumor growth arrest.	Eflornithine	148-152	ornithine decarboxylase 1	Homo sapiens	163-166
35100927-5	2022	We show that the eIF5A1 is significantly upregulated in EC cells compared to control cells (p = 0.000038) and that combined pharmacological targeting of ODC and eIF5A hypusination with cytostatic drugs DFMO and N1-guanyl-1,7-diaminoheptane (GC7), respectively, reduces eIF5A1 activation and synergistically induces apoptosis in EC cells.	Eflornithine	202-206	eukaryotic translation initiation factor 5A	Homo sapiens	17-23
35100927-5	2022	We show that the eIF5A1 is significantly upregulated in EC cells compared to control cells (p = 0.000038) and that combined pharmacological targeting of ODC and eIF5A hypusination with cytostatic drugs DFMO and N1-guanyl-1,7-diaminoheptane (GC7), respectively, reduces eIF5A1 activation and synergistically induces apoptosis in EC cells.	Eflornithine	202-206	ornithine decarboxylase 1	Homo sapiens	153-156
35100927-5	2022	We show that the eIF5A1 is significantly upregulated in EC cells compared to control cells (p = 0.000038) and that combined pharmacological targeting of ODC and eIF5A hypusination with cytostatic drugs DFMO and N1-guanyl-1,7-diaminoheptane (GC7), respectively, reduces eIF5A1 activation and synergistically induces apoptosis in EC cells.	Eflornithine	202-206	eukaryotic translation initiation factor 5A	Homo sapiens	161-166
35100927-5	2022	We show that the eIF5A1 is significantly upregulated in EC cells compared to control cells (p = 0.000038) and that combined pharmacological targeting of ODC and eIF5A hypusination with cytostatic drugs DFMO and N1-guanyl-1,7-diaminoheptane (GC7), respectively, reduces eIF5A1 activation and synergistically induces apoptosis in EC cells.	Eflornithine	202-206	eukaryotic translation initiation factor 5A	Homo sapiens	269-275
2505959-3	1989	DFMO is an irreversible inhibitor of ornithine decarboxylase, a rate-limiting step in polyamine biosynthesis.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	37-60
35541910-8	2022	By treating the MTAP-repressing BC cells with specific ODC inhibitor Difluoromethylornithine (DFMO) or treating the MTAP-overexpressing BC cells with additional putrescine, metastasis-promoting or -suppressing phenotype of these MTAP-manipulated cells was significantly reversed, respectively.	Eflornithine	69-92	ornithine decarboxylase 1	Homo sapiens	55-58
35541910-8	2022	By treating the MTAP-repressing BC cells with specific ODC inhibitor Difluoromethylornithine (DFMO) or treating the MTAP-overexpressing BC cells with additional putrescine, metastasis-promoting or -suppressing phenotype of these MTAP-manipulated cells was significantly reversed, respectively.	Eflornithine	94-98	ornithine decarboxylase 1	Homo sapiens	55-58
2511847-2	1989	Our previous studies have shown that generalized polyamine depletion of the human colon cancer cell line COLO 320 by 2-difluoromethylornithine is associated with decreased transcription of the c-myc, c-fos, and ornithine decarboxylase (ODC) genes.	Eflornithine	117-142	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	193-198
2511847-2	1989	Our previous studies have shown that generalized polyamine depletion of the human colon cancer cell line COLO 320 by 2-difluoromethylornithine is associated with decreased transcription of the c-myc, c-fos, and ornithine decarboxylase (ODC) genes.	Eflornithine	117-142	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	200-205
2511847-6	1989	Furthermore, ODC mRNA levels are increased when all polyamines are decreased by DFMO, but are unaffected by a selective reduction in intracellular spermidine levels by AdoDATO.	Eflornithine	80-84	ornithine decarboxylase 1	Homo sapiens	13-16
2790802-14	1989	Addition of either CaCl2 (2 mumol/ml) or difluoromethylornithine (2 nmol/ml) the irreversible inhibitor of ODC, significantly suppressed the methylazoxymethanol-induced activity of both ODC and Tyr-k. We conclude that calcium may have a chemoprotective role and tyrosine kinases may have a regulatory role in the early stages of AOM induction of colon cancer.	Eflornithine	41-64	ornithine decarboxylase 1	Rattus norvegicus	107-110
2790802-14	1989	Addition of either CaCl2 (2 mumol/ml) or difluoromethylornithine (2 nmol/ml) the irreversible inhibitor of ODC, significantly suppressed the methylazoxymethanol-induced activity of both ODC and Tyr-k. We conclude that calcium may have a chemoprotective role and tyrosine kinases may have a regulatory role in the early stages of AOM induction of colon cancer.	Eflornithine	41-64	ornithine decarboxylase 1	Rattus norvegicus	186-189
35209071-6	2022	The obtained results showed that UA significantly inhibited the adhesion and migration of MCF-7/ADR cells, and had higher affinities with key active cavity residues of ODC compared to the known inhibitor di-fluoro-methyl-ornithine (DFMO).	Eflornithine	232-236	ornithine decarboxylase 1	Homo sapiens	168-171
12412756-1	1989	Difluoromethylornithine (DFMO), an experimental drug that inactivates ornithine decarboxylase and thus reduces the production of polyamines has a beneficial effect on the mean survival time and the clinical and laboratory manifestations of murine lupus in female MRL-lpr/lpr mice.	Eflornithine	0-23	ornithine decarboxylase, structural 1	Mus musculus	70-93
12412756-1	1989	Difluoromethylornithine (DFMO), an experimental drug that inactivates ornithine decarboxylase and thus reduces the production of polyamines has a beneficial effect on the mean survival time and the clinical and laboratory manifestations of murine lupus in female MRL-lpr/lpr mice.	Eflornithine	0-23	Fas (TNF receptor superfamily member 6)	Mus musculus	267-270
12412756-1	1989	Difluoromethylornithine (DFMO), an experimental drug that inactivates ornithine decarboxylase and thus reduces the production of polyamines has a beneficial effect on the mean survival time and the clinical and laboratory manifestations of murine lupus in female MRL-lpr/lpr mice.	Eflornithine	0-23	Fas (TNF receptor superfamily member 6)	Mus musculus	271-274
12412756-1	1989	Difluoromethylornithine (DFMO), an experimental drug that inactivates ornithine decarboxylase and thus reduces the production of polyamines has a beneficial effect on the mean survival time and the clinical and laboratory manifestations of murine lupus in female MRL-lpr/lpr mice.	Eflornithine	25-29	ornithine decarboxylase, structural 1	Mus musculus	70-93
12412756-1	1989	Difluoromethylornithine (DFMO), an experimental drug that inactivates ornithine decarboxylase and thus reduces the production of polyamines has a beneficial effect on the mean survival time and the clinical and laboratory manifestations of murine lupus in female MRL-lpr/lpr mice.	Eflornithine	25-29	Fas (TNF receptor superfamily member 6)	Mus musculus	267-270
12412756-1	1989	Difluoromethylornithine (DFMO), an experimental drug that inactivates ornithine decarboxylase and thus reduces the production of polyamines has a beneficial effect on the mean survival time and the clinical and laboratory manifestations of murine lupus in female MRL-lpr/lpr mice.	Eflornithine	25-29	Fas (TNF receptor superfamily member 6)	Mus musculus	271-274
2600452-1	1989	The effect of cyclosporine A (CsA) and alpha-difluoromethylornithine (DFMO) on the camostate-induced increase in pancreatic ornithine decarboxylase (ODC) activity and polyamine biosynthesis has been studied in vivo.	Eflornithine	39-68	ornithine decarboxylase 1	Rattus norvegicus	124-147
2479558-2	1989	alpha-difluoromethylornithine, an irreversible and specific inhibitor of ornithine decarboxylase, was applied simultaneously to elucidate the essential role of polyamines in pancreatic growth.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	73-96
2479558-5	1989	alpha-difluoromethylornithine significantly delayed the increase in ornithine decarboxylase, putrescine and spermidine as well as all trophic parameters.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	68-91
2558942-5	1989	ODC activity in control and treated mucosal extracts was inhibited by the specific ODC inhibitor difluoromethylornithine.	Eflornithine	97-120	ornithine decarboxylase 1	Sus scrofa	0-3
2558942-5	1989	ODC activity in control and treated mucosal extracts was inhibited by the specific ODC inhibitor difluoromethylornithine.	Eflornithine	97-120	ornithine decarboxylase 1	Sus scrofa	83-86
2504484-8	1989	To determine the role of polyamine synthesis in affecting the severity of radiation damage in the large intestine, difluoromethylornithine, an ornithine decarboxylase inhibitor, was administered in the drinking water of the animals 24 h prior to and following radiation treatment.	Eflornithine	115-138	ornithine decarboxylase, structural 1	Mus musculus	143-166
2600452-5	1989	DFMO (2% in drinking water and additionally 300 mg/kg b wt intraperitoneally at 8 AM, 12 noon, and 4 PM) inhibited the increase in both, ODC activity, and putrescine, significantly in an equipotent degree as 2.5 mg CsA/kg b wt, whereas higher doses of CsA proved to be more effective than DFMO in the chosen subtoxic dose.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	137-140
2560478-5	1989	Ileal Na+/H+ activity was therefore examined in control, fasted, refed fasted, and in rats given the specific inhibitor of ornithine decarboxylase alpha-difluoromethylornithine.	Eflornithine	147-176	ornithine decarboxylase 1	Rattus norvegicus	123-146
2515533-0	1989	The enzyme-activated irreversible inhibitor of ornithine decarboxylase, DL-alpha-difluoromethylornithine: a chemopreventive agent.	Eflornithine	72-104	ornithine decarboxylase 1	Homo sapiens	47-70
2515533-1	1989	DL-alpha-Difluoromethylornithine (DFMO) is an enzyme-activated irreversible inhibitor of mammalian ornithine decarboxylase.	Eflornithine	0-32	ornithine decarboxylase 1	Homo sapiens	99-122
2515533-1	1989	DL-alpha-Difluoromethylornithine (DFMO) is an enzyme-activated irreversible inhibitor of mammalian ornithine decarboxylase.	Eflornithine	34-38	ornithine decarboxylase 1	Homo sapiens	99-122
2600452-1	1989	The effect of cyclosporine A (CsA) and alpha-difluoromethylornithine (DFMO) on the camostate-induced increase in pancreatic ornithine decarboxylase (ODC) activity and polyamine biosynthesis has been studied in vivo.	Eflornithine	70-74	ornithine decarboxylase 1	Rattus norvegicus	124-147
2483473-10	1989	Difluoromethylornithine, a specific inhibitor of ornithine decarboxylase, inhibited growth induced by both TPA and TSH in putrescine-free medium.	Eflornithine	0-23	ornithine decarboxylase 1	Rattus norvegicus	49-72
2479085-2	1989	The effect of an inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethylornithine (DFMO), on rat pancreatic protein secretion and synthesis and on growth in response to hormonal stimulation was therefore studied.	Eflornithine	92-96	ornithine decarboxylase 1	Rattus norvegicus	55-58
2616547-14	1989	The ornithine decarboxylase inhibitor, alpha-difluoromethylornithine, significantly inhibited growth even at low concentrations.	Eflornithine	39-68	ornithine decarboxylase 1	Homo sapiens	4-27
2501317-9	1989	The addition of exogenous putrescine concomitantly with EGF blocked the induction of ODC, while in the presence of difluoromethylornithine (DFMO) (irreversible inhibitor of ODC) the initial rate of putrescine transport remained elevated throughout the time course studied.	Eflornithine	115-138	ornithine decarboxylase, structural 1	Mus musculus	173-176
2501317-9	1989	The addition of exogenous putrescine concomitantly with EGF blocked the induction of ODC, while in the presence of difluoromethylornithine (DFMO) (irreversible inhibitor of ODC) the initial rate of putrescine transport remained elevated throughout the time course studied.	Eflornithine	140-144	ornithine decarboxylase, structural 1	Mus musculus	173-176
2501317-11	1989	EGF"s ability to stimulate cellular DNA synthesis was inhibited by DFMO.	Eflornithine	67-71	epidermal growth factor	Mus musculus	0-3
2501317-12	1989	If DFMO-treated cells were stimulated with EGF in the presence of exogenous putrescine, this stimulatory effect was preserved.	Eflornithine	3-7	epidermal growth factor	Mus musculus	43-46
2479085-5	1989	The ODC activity in the pancreas was markedly reduced by DFMO, but DFMO did not affect pancreatic juice volume or protein output.	Eflornithine	57-61	ornithine decarboxylase 1	Rattus norvegicus	4-7
2479085-7	1989	The ODC activity and putrescine concentration in the pancreas were significantly reduced by DFMO at 8 and 24 h but not at 48 h. DFMO also significantly reduced the activities of RNA polymerase, DNA polymerase, and thymidine kinase at 24 h, but not at 48 h. The present study thus indicates that polyamines play a role in the initiation of the growth response to hormonal stimulation but does not support a similar dependence for early pancreatic protein synthetic and secretory responses.	Eflornithine	92-96	ornithine decarboxylase 1	Rattus norvegicus	4-7
2479085-7	1989	The ODC activity and putrescine concentration in the pancreas were significantly reduced by DFMO at 8 and 24 h but not at 48 h. DFMO also significantly reduced the activities of RNA polymerase, DNA polymerase, and thymidine kinase at 24 h, but not at 48 h. The present study thus indicates that polyamines play a role in the initiation of the growth response to hormonal stimulation but does not support a similar dependence for early pancreatic protein synthetic and secretory responses.	Eflornithine	128-132	ornithine decarboxylase 1	Rattus norvegicus	4-7
2507897-0	1989	[Antitumor effect of alpha-difluoromethylornithine (DFMO) changes in ornithine decarboxylase (ODC) activity and polyamine (PA) levels in human tumor transplanted into nude mice].	Eflornithine	21-50	ornithine decarboxylase 1	Homo sapiens	69-92
2505399-1	1989	DFMO (alpha-difluoromethylornithine) is a specific irreversible inhibitor of ornithine decarboxylase (ODC), a key enzyme in the biosynthesis of polyamines, which in turn control macromolecule synthesis during cell proliferation.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	77-100
2505399-1	1989	DFMO (alpha-difluoromethylornithine) is a specific irreversible inhibitor of ornithine decarboxylase (ODC), a key enzyme in the biosynthesis of polyamines, which in turn control macromolecule synthesis during cell proliferation.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	102-105
2505399-1	1989	DFMO (alpha-difluoromethylornithine) is a specific irreversible inhibitor of ornithine decarboxylase (ODC), a key enzyme in the biosynthesis of polyamines, which in turn control macromolecule synthesis during cell proliferation.	Eflornithine	6-35	ornithine decarboxylase 1	Rattus norvegicus	77-100
2505399-1	1989	DFMO (alpha-difluoromethylornithine) is a specific irreversible inhibitor of ornithine decarboxylase (ODC), a key enzyme in the biosynthesis of polyamines, which in turn control macromolecule synthesis during cell proliferation.	Eflornithine	6-35	ornithine decarboxylase 1	Rattus norvegicus	102-105
2504519-1	1989	The objective of the present investigation was to examine the effect of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, in combination with the immunosuppressant cyclosporin A (CsA) on cytolytic T lymphocytes (CTL) induction in vitro and in vivo.	Eflornithine	72-101	ornithine decarboxylase 1	Homo sapiens	139-162
2504519-1	1989	The objective of the present investigation was to examine the effect of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, in combination with the immunosuppressant cyclosporin A (CsA) on cytolytic T lymphocytes (CTL) induction in vitro and in vivo.	Eflornithine	103-107	ornithine decarboxylase 1	Homo sapiens	139-162
2504519-9	1989	CsA treatment with or without DFMO did reduce detectable levels of interleukin 2 (IL-2) activity.	Eflornithine	30-34	interleukin 2	Homo sapiens	67-80
2504519-9	1989	CsA treatment with or without DFMO did reduce detectable levels of interleukin 2 (IL-2) activity.	Eflornithine	30-34	interleukin 2	Homo sapiens	82-86
2504519-11	1989	These results indicate that CsA and DFMO may inhibit different processes required for CTL induction, IL-2 production and polyamine biosynthesis.	Eflornithine	36-40	interleukin 2	Homo sapiens	101-105
2493096-4	1989	Continuous oral administration of DFMO at 1% (approximately 8 mg/g body wt/wk) and 0.25% (approximately 2 mg/g body wt/wk) produced 93% inhibition of ODC induction by AOM in the right and left colons throughout the study.	Eflornithine	34-38	ornithine decarboxylase 1	Rattus norvegicus	150-153
2493979-4	1989	When tested at comparable cell density, the two cell lines had similar levels of ODC activity and PA. Administration of DFMO (0.01, 0.1, 1, 4 mM) for 6 days caused a similar dose-dependent inhibition of proliferation (up to approximately 15% of control) associated with suppression of ODC activity to undetectable levels at the highest dose.	Eflornithine	120-124	ornithine decarboxylase 1	Homo sapiens	81-84
2493979-4	1989	When tested at comparable cell density, the two cell lines had similar levels of ODC activity and PA. Administration of DFMO (0.01, 0.1, 1, 4 mM) for 6 days caused a similar dose-dependent inhibition of proliferation (up to approximately 15% of control) associated with suppression of ODC activity to undetectable levels at the highest dose.	Eflornithine	120-124	ornithine decarboxylase 1	Homo sapiens	285-288
2493979-7	1989	In detailed time-course studies, DFMO administration (0.1 mM) similarly suppressed by 80% the rise in ODC observed in both cell lines following a medium change.	Eflornithine	33-37	ornithine decarboxylase 1	Homo sapiens	102-105
2499305-2	1989	In all but one of these cell lines the resistance to DFMO was based on an overproduction of ODC.	Eflornithine	53-57	ornithine decarboxylase 1	Homo sapiens	92-95
2538226-7	1989	Prostaglandin E and leukotriene (LTB4) syntheses, ODC activity and mammary tumorigenesis were significantly inhibited by feeding the diet containing menhaden oil or by adding 0.5% DFMO to any of the high fat diets.	Eflornithine	180-184	ornithine decarboxylase 1	Rattus norvegicus	50-53
2646950-5	1989	Nevertheless, inhibition of ODC with difluoromethylornithine blocks the growth response.	Eflornithine	37-60	ornithine decarboxylase 1	Rattus norvegicus	28-31
2496768-1	1989	It was established that difluoromethylornithine (DFMO) and methylglyoxal-bis(guanylhydrazone) blocked the mitogenic response of hepatocytes to epidermal growth factor.	Eflornithine	24-47	epidermal growth factor	Homo sapiens	143-166
2496768-1	1989	It was established that difluoromethylornithine (DFMO) and methylglyoxal-bis(guanylhydrazone) blocked the mitogenic response of hepatocytes to epidermal growth factor.	Eflornithine	49-53	epidermal growth factor	Homo sapiens	143-166
2537154-7	1989	The specific, irreversible ODC inhibitor alpha-difluoromethylornithine (DFMO, 5-10 mM) blocked the testosterone-evoked increase in ODC activity and polyamine levels and the stimulation of Ca2+ fluxes, endocytosis, hexose transport, and amino acid transport.	Eflornithine	41-70	ornithine decarboxylase 1	Rattus norvegicus	27-30
2537154-7	1989	The specific, irreversible ODC inhibitor alpha-difluoromethylornithine (DFMO, 5-10 mM) blocked the testosterone-evoked increase in ODC activity and polyamine levels and the stimulation of Ca2+ fluxes, endocytosis, hexose transport, and amino acid transport.	Eflornithine	41-70	ornithine decarboxylase 1	Rattus norvegicus	131-134
2537154-7	1989	The specific, irreversible ODC inhibitor alpha-difluoromethylornithine (DFMO, 5-10 mM) blocked the testosterone-evoked increase in ODC activity and polyamine levels and the stimulation of Ca2+ fluxes, endocytosis, hexose transport, and amino acid transport.	Eflornithine	72-76	ornithine decarboxylase 1	Rattus norvegicus	27-30
2537154-7	1989	The specific, irreversible ODC inhibitor alpha-difluoromethylornithine (DFMO, 5-10 mM) blocked the testosterone-evoked increase in ODC activity and polyamine levels and the stimulation of Ca2+ fluxes, endocytosis, hexose transport, and amino acid transport.	Eflornithine	72-76	ornithine decarboxylase 1	Rattus norvegicus	131-134
2537154-8	1989	Putrescine (0.5-1 mM), the ODC product, reversed DFMO inhibition and restored the increase in polyamines, 45Ca fluxes, and Ca2+-dependent membrane transport processes.	Eflornithine	49-53	ornithine decarboxylase 1	Rattus norvegicus	27-30
2495941-1	1989	Contrary to previous findings, ornithine decarboxylase (ODC) was stabilized by treatment of cells with DL-alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ODC.	Eflornithine	103-135	ornithine decarboxylase 1	Homo sapiens	31-54
2495941-1	1989	Contrary to previous findings, ornithine decarboxylase (ODC) was stabilized by treatment of cells with DL-alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ODC.	Eflornithine	103-135	ornithine decarboxylase 1	Homo sapiens	56-59
2495941-1	1989	Contrary to previous findings, ornithine decarboxylase (ODC) was stabilized by treatment of cells with DL-alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ODC.	Eflornithine	103-135	ornithine decarboxylase 1	Homo sapiens	183-186
2924752-3	1989	alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), inhibits squamous metaplasia caused by asbestos or vitamin A deficiency, whereas addition of methylglyoxal bis(guanylhydrazone) (MGBG), a structural analog of spermidine and inhibitor of S-adenosylmethionine decarboxylase, causes an enhancement of metaplasia under both circumstances.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	92-95
2924752-3	1989	alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), inhibits squamous metaplasia caused by asbestos or vitamin A deficiency, whereas addition of methylglyoxal bis(guanylhydrazone) (MGBG), a structural analog of spermidine and inhibitor of S-adenosylmethionine decarboxylase, causes an enhancement of metaplasia under both circumstances.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	92-95
2493197-3	1989	Polyamines appeared to be necessary for the proliferation of these cells, as growth was completely inhibited by the addition of 5 mM difluoromethylornithine, a specific inhibitor of ODC, to the media.	Eflornithine	133-156	ornithine decarboxylase 1	Homo sapiens	182-185
2475032-6	1989	DL-alpha-Difluoromethylornithine (DFMO, a specific ODC inhibitor) prevented the increase in ODC in both tissues and increased the loss of DNA and RNA from duodenal mucosa.	Eflornithine	0-32	ornithine decarboxylase 1	Rattus norvegicus	51-54
2475032-6	1989	DL-alpha-Difluoromethylornithine (DFMO, a specific ODC inhibitor) prevented the increase in ODC in both tissues and increased the loss of DNA and RNA from duodenal mucosa.	Eflornithine	0-32	ornithine decarboxylase 1	Rattus norvegicus	92-95
2475032-6	1989	DL-alpha-Difluoromethylornithine (DFMO, a specific ODC inhibitor) prevented the increase in ODC in both tissues and increased the loss of DNA and RNA from duodenal mucosa.	Eflornithine	34-38	ornithine decarboxylase 1	Rattus norvegicus	51-54
2475032-6	1989	DL-alpha-Difluoromethylornithine (DFMO, a specific ODC inhibitor) prevented the increase in ODC in both tissues and increased the loss of DNA and RNA from duodenal mucosa.	Eflornithine	34-38	ornithine decarboxylase 1	Rattus norvegicus	92-95
2500977-1	1989	LLC-PK1 cells were brought to a quiescent state by treatment with DL-2-difluoromethylornithine (DFMO), a specific inhibitor of L-ornithine decarboxylase (ODC).	Eflornithine	96-100	ornithine decarboxylase 1	Sus scrofa	127-152
2500977-1	1989	LLC-PK1 cells were brought to a quiescent state by treatment with DL-2-difluoromethylornithine (DFMO), a specific inhibitor of L-ornithine decarboxylase (ODC).	Eflornithine	96-100	ornithine decarboxylase 1	Sus scrofa	154-157
2499419-2	1989	In these experiments, we evaluated the individual and combined effects of the polyamine biosynthesis inhibitor alpha-difluoromethylornithine (DFMO) and ovariectomy on the growth and cellular levels of ornithine decarboxylase (ODC) and polyamines of N-nitrosomethylurea-induced rat mammary tumors.	Eflornithine	111-140	ornithine decarboxylase 1	Rattus norvegicus	201-224
2499419-2	1989	In these experiments, we evaluated the individual and combined effects of the polyamine biosynthesis inhibitor alpha-difluoromethylornithine (DFMO) and ovariectomy on the growth and cellular levels of ornithine decarboxylase (ODC) and polyamines of N-nitrosomethylurea-induced rat mammary tumors.	Eflornithine	111-140	ornithine decarboxylase 1	Rattus norvegicus	226-229
2499419-2	1989	In these experiments, we evaluated the individual and combined effects of the polyamine biosynthesis inhibitor alpha-difluoromethylornithine (DFMO) and ovariectomy on the growth and cellular levels of ornithine decarboxylase (ODC) and polyamines of N-nitrosomethylurea-induced rat mammary tumors.	Eflornithine	142-146	ornithine decarboxylase 1	Rattus norvegicus	201-224
2507471-2	1989	alpha-Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	69-92
2507471-2	1989	alpha-Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	94-97
2507471-2	1989	alpha-Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	69-92
2507471-2	1989	alpha-Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	94-97
2499956-5	1989	Mitogenic responses of cultures containing the potent ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO) were also inhibited in a time and dose dependent fashion.	Eflornithine	94-123	ornithine decarboxylase 1	Homo sapiens	54-77
2499956-5	1989	Mitogenic responses of cultures containing the potent ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO) were also inhibited in a time and dose dependent fashion.	Eflornithine	94-123	ornithine decarboxylase 1	Homo sapiens	79-82
2499956-5	1989	Mitogenic responses of cultures containing the potent ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO) were also inhibited in a time and dose dependent fashion.	Eflornithine	125-129	ornithine decarboxylase 1	Homo sapiens	54-77
2499956-5	1989	Mitogenic responses of cultures containing the potent ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO) were also inhibited in a time and dose dependent fashion.	Eflornithine	125-129	ornithine decarboxylase 1	Homo sapiens	79-82
2499956-6	1989	ODC activity, which was much greater in cultures stimulated with Con A than LPS, was markedly decreased by inclusion of diamine or DFMO in the culture medium.	Eflornithine	131-135	ornithine decarboxylase 1	Homo sapiens	0-3
2525116-1	1989	Although treatment with the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) leads to depletion of intracellular polyamines and to related growth inhibition in vitro, its cytostatic effects in vivo are disappointing.	Eflornithine	62-91	ornithine decarboxylase, structural 1	Mus musculus	28-51
2525116-1	1989	Although treatment with the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) leads to depletion of intracellular polyamines and to related growth inhibition in vitro, its cytostatic effects in vivo are disappointing.	Eflornithine	93-97	ornithine decarboxylase, structural 1	Mus musculus	28-51
2498524-2	1989	It is reasoned that perturbation of a second regulatory element in polyamine biosynthesis, i.e., the generation of propylamine groups from S-adenosylmethionine (AdoMet), would potentiate the effectiveness of DFMO.	Eflornithine	208-212	methionine adenosyltransferase 1A	Rattus norvegicus	161-167
2548479-4	1989	The increase in SAT activity, after exposure to DDC or another stress (heat shock), was inhibited in cells depleted of putrescine and spermidine by alpha-difluoromethylornithine (DFMO), the enzyme-activated suicide inhibitor of ODC.	Eflornithine	148-177	diamine acetyltransferase 1	Cricetulus griseus	16-19
2548479-4	1989	The increase in SAT activity, after exposure to DDC or another stress (heat shock), was inhibited in cells depleted of putrescine and spermidine by alpha-difluoromethylornithine (DFMO), the enzyme-activated suicide inhibitor of ODC.	Eflornithine	179-183	diamine acetyltransferase 1	Cricetulus griseus	16-19
2502598-3	1989	injection of difluoromethylornithine (DFMO; 40-400 mg/kg), a specific inhibitor of the activity of ornithine decarboxylase, at 15.00 h on pro-oestrus had a differential effect on the rise in plasma concentrations of the various hormones thereafter.	Eflornithine	13-36	ornithine decarboxylase 1	Rattus norvegicus	99-122
2502598-3	1989	injection of difluoromethylornithine (DFMO; 40-400 mg/kg), a specific inhibitor of the activity of ornithine decarboxylase, at 15.00 h on pro-oestrus had a differential effect on the rise in plasma concentrations of the various hormones thereafter.	Eflornithine	38-42	ornithine decarboxylase 1	Rattus norvegicus	99-122
2547010-2	1989	The effect of difluoromethyl ornithine (DFMO), a specific inhibitor of ODC activity, on AVP-stimulated Na+ K+ ATPase activity was evaluated using a cytochemical bioassay.	Eflornithine	14-38	ornithine decarboxylase 1	Rattus norvegicus	71-74
2547010-2	1989	The effect of difluoromethyl ornithine (DFMO), a specific inhibitor of ODC activity, on AVP-stimulated Na+ K+ ATPase activity was evaluated using a cytochemical bioassay.	Eflornithine	40-44	ornithine decarboxylase 1	Rattus norvegicus	71-74
2498115-10	1989	A single dose of the ODC inhibitor DL-alpha-difluoromethylornithine given to infected rats or mice suppressed trypanosome ODC activity greater than 90% for more than 7 hr.	Eflornithine	35-67	ornithine decarboxylase 1	Rattus norvegicus	21-24
2498115-10	1989	A single dose of the ODC inhibitor DL-alpha-difluoromethylornithine given to infected rats or mice suppressed trypanosome ODC activity greater than 90% for more than 7 hr.	Eflornithine	35-67	ornithine decarboxylase, structural 1	Mus musculus	122-125
2497738-1	1989	The effects of chronic inhibition of ornithine decarboxylase (ODC) by the specific inhibitor difluoromethylornithine (DFMO) in the rat colon and small intestine on mucosal contents of polyamines, decarboxylated S-adenosylmethionine (decarboxylated AdoMet) and S-adenosylmethionine decarboxylase (AdoMet decarboxylase) activity were studied.	Eflornithine	93-116	ornithine decarboxylase 1	Rattus norvegicus	37-60
2497738-1	1989	The effects of chronic inhibition of ornithine decarboxylase (ODC) by the specific inhibitor difluoromethylornithine (DFMO) in the rat colon and small intestine on mucosal contents of polyamines, decarboxylated S-adenosylmethionine (decarboxylated AdoMet) and S-adenosylmethionine decarboxylase (AdoMet decarboxylase) activity were studied.	Eflornithine	93-116	ornithine decarboxylase 1	Rattus norvegicus	62-65
2497738-1	1989	The effects of chronic inhibition of ornithine decarboxylase (ODC) by the specific inhibitor difluoromethylornithine (DFMO) in the rat colon and small intestine on mucosal contents of polyamines, decarboxylated S-adenosylmethionine (decarboxylated AdoMet) and S-adenosylmethionine decarboxylase (AdoMet decarboxylase) activity were studied.	Eflornithine	118-122	ornithine decarboxylase 1	Rattus norvegicus	37-60
2497738-1	1989	The effects of chronic inhibition of ornithine decarboxylase (ODC) by the specific inhibitor difluoromethylornithine (DFMO) in the rat colon and small intestine on mucosal contents of polyamines, decarboxylated S-adenosylmethionine (decarboxylated AdoMet) and S-adenosylmethionine decarboxylase (AdoMet decarboxylase) activity were studied.	Eflornithine	118-122	ornithine decarboxylase 1	Rattus norvegicus	62-65
2497738-2	1989	Administration of 1% DFMO in the drinking water for 10 or 15 weeks resulted in inhibition of ODC and decreases in intracellular putrescine and spermidine contents in both proximal and distal segments of small intestine and colon.	Eflornithine	21-25	ornithine decarboxylase 1	Rattus norvegicus	93-96
2501085-0	1989	Rearrangement between ornithine decarboxylase and the switch region of the gamma 1 immunoglobulin gene in alpha-difluoromethylornithine resistant mouse myeloma cells.	Eflornithine	106-135	ornithine decarboxylase, structural 1	Mus musculus	22-45
2501085-1	1989	We demonstrate here that the functional ornithine decarboxylase (ODC) gene of alpha-difluoromethylornithine (alpha-DFMO, a suicide inhibitor of ODC) resistant mouse myeloma 653-1 cells has been rearranged with the immunoglobulin heavy chain locus in a c-myc like manner.	Eflornithine	78-107	ornithine decarboxylase, structural 1	Mus musculus	40-63
2501085-1	1989	We demonstrate here that the functional ornithine decarboxylase (ODC) gene of alpha-difluoromethylornithine (alpha-DFMO, a suicide inhibitor of ODC) resistant mouse myeloma 653-1 cells has been rearranged with the immunoglobulin heavy chain locus in a c-myc like manner.	Eflornithine	78-107	ornithine decarboxylase, structural 1	Mus musculus	65-68
2501085-1	1989	We demonstrate here that the functional ornithine decarboxylase (ODC) gene of alpha-difluoromethylornithine (alpha-DFMO, a suicide inhibitor of ODC) resistant mouse myeloma 653-1 cells has been rearranged with the immunoglobulin heavy chain locus in a c-myc like manner.	Eflornithine	78-107	ornithine decarboxylase, structural 1	Mus musculus	144-147
2501085-1	1989	We demonstrate here that the functional ornithine decarboxylase (ODC) gene of alpha-difluoromethylornithine (alpha-DFMO, a suicide inhibitor of ODC) resistant mouse myeloma 653-1 cells has been rearranged with the immunoglobulin heavy chain locus in a c-myc like manner.	Eflornithine	109-119	ornithine decarboxylase, structural 1	Mus musculus	40-63
2501085-1	1989	We demonstrate here that the functional ornithine decarboxylase (ODC) gene of alpha-difluoromethylornithine (alpha-DFMO, a suicide inhibitor of ODC) resistant mouse myeloma 653-1 cells has been rearranged with the immunoglobulin heavy chain locus in a c-myc like manner.	Eflornithine	109-119	ornithine decarboxylase, structural 1	Mus musculus	65-68
2501085-1	1989	We demonstrate here that the functional ornithine decarboxylase (ODC) gene of alpha-difluoromethylornithine (alpha-DFMO, a suicide inhibitor of ODC) resistant mouse myeloma 653-1 cells has been rearranged with the immunoglobulin heavy chain locus in a c-myc like manner.	Eflornithine	109-119	ornithine decarboxylase, structural 1	Mus musculus	144-147
2494298-4	1989	Hyperosmolal mannitol in physiological buffer evoked a rapid (less than 15 s), concentration- and time-dependent increase in capillary ODC activity and an accumulation of putrescine and spermidine which was blocked by the specific ODC inhibitor, alpha-difluoromethylornithine (DFMO, 10 mM).	Eflornithine	246-275	ornithine decarboxylase 1	Rattus norvegicus	231-234
2494298-4	1989	Hyperosmolal mannitol in physiological buffer evoked a rapid (less than 15 s), concentration- and time-dependent increase in capillary ODC activity and an accumulation of putrescine and spermidine which was blocked by the specific ODC inhibitor, alpha-difluoromethylornithine (DFMO, 10 mM).	Eflornithine	277-281	ornithine decarboxylase 1	Rattus norvegicus	231-234
2494298-9	1989	This PMA effect was abolished by DFMO, suggesting involvement of rapid, ODC-controlled polyamine synthesis.	Eflornithine	33-37	ornithine decarboxylase 1	Rattus norvegicus	72-75
2492471-0	1989	Downregulation of T cell growth factor production by ornithine decarboxylase and its product putrescine: D,L-alpha-difluoromethylornithine suppresses general protein synthesis but augments simultaneously the production of interleukin-2.	Eflornithine	105-138	ornithine decarboxylase, structural 1	Mus musculus	53-76
2507897-0	1989	[Antitumor effect of alpha-difluoromethylornithine (DFMO) changes in ornithine decarboxylase (ODC) activity and polyamine (PA) levels in human tumor transplanted into nude mice].	Eflornithine	21-50	ornithine decarboxylase 1	Homo sapiens	94-97
2507897-0	1989	[Antitumor effect of alpha-difluoromethylornithine (DFMO) changes in ornithine decarboxylase (ODC) activity and polyamine (PA) levels in human tumor transplanted into nude mice].	Eflornithine	52-56	ornithine decarboxylase 1	Homo sapiens	69-92
2507897-0	1989	[Antitumor effect of alpha-difluoromethylornithine (DFMO) changes in ornithine decarboxylase (ODC) activity and polyamine (PA) levels in human tumor transplanted into nude mice].	Eflornithine	52-56	ornithine decarboxylase 1	Homo sapiens	94-97
2492471-0	1989	Downregulation of T cell growth factor production by ornithine decarboxylase and its product putrescine: D,L-alpha-difluoromethylornithine suppresses general protein synthesis but augments simultaneously the production of interleukin-2.	Eflornithine	105-138	interleukin 2	Mus musculus	222-235
2507897-6	1989	The antitumor effects (the lowest value of TRW/CRW) of 2% DFMO against MX-1, Exp-42 and Co-3 were 4.83%, 35.8% and 73.4% respectively.	Eflornithine	58-62	MX dynamin-like GTPase 1	Mus musculus	71-75
2492471-4	1989	Putrescine has rather a counter-regulatory effect as concluded from the observation that the TPA-induced TCGF production and IL-2-specific mRNA expression are augmented (superinduced) by the ODC inhibitor D,L-alpha-difluoromethylornithine (DFMO) and again suppressed after the administration of putrescine or polyamines to DFMO-treated cultures.	Eflornithine	205-238	interleukin 2	Mus musculus	105-109
2492471-4	1989	Putrescine has rather a counter-regulatory effect as concluded from the observation that the TPA-induced TCGF production and IL-2-specific mRNA expression are augmented (superinduced) by the ODC inhibitor D,L-alpha-difluoromethylornithine (DFMO) and again suppressed after the administration of putrescine or polyamines to DFMO-treated cultures.	Eflornithine	205-238	interleukin 2	Mus musculus	125-129
2507897-8	1989	With 2% DFMO, ODC and PUT levels were decreased to 16.4%, 2.89% of control in MX-1, 14.8%, 6.62% in Exp-42, 4.18%, 11.2% in Co-3 respectively.	Eflornithine	8-12	ornithine decarboxylase, structural 1	Mus musculus	14-17
2492471-4	1989	Putrescine has rather a counter-regulatory effect as concluded from the observation that the TPA-induced TCGF production and IL-2-specific mRNA expression are augmented (superinduced) by the ODC inhibitor D,L-alpha-difluoromethylornithine (DFMO) and again suppressed after the administration of putrescine or polyamines to DFMO-treated cultures.	Eflornithine	205-238	ornithine decarboxylase, structural 1	Mus musculus	191-194
2507897-8	1989	With 2% DFMO, ODC and PUT levels were decreased to 16.4%, 2.89% of control in MX-1, 14.8%, 6.62% in Exp-42, 4.18%, 11.2% in Co-3 respectively.	Eflornithine	8-12	MX dynamin-like GTPase 1	Mus musculus	78-82
2494281-5	1989	The ODC response to AVP was totally blocked by specific antiserum to AVP and reduced by 70% with the specific inhibitor to ODC, difluoromethyl ornithine.	Eflornithine	128-152	ornithine decarboxylase 1	Rattus norvegicus	4-7
2492471-4	1989	Putrescine has rather a counter-regulatory effect as concluded from the observation that the TPA-induced TCGF production and IL-2-specific mRNA expression are augmented (superinduced) by the ODC inhibitor D,L-alpha-difluoromethylornithine (DFMO) and again suppressed after the administration of putrescine or polyamines to DFMO-treated cultures.	Eflornithine	240-244	ornithine decarboxylase, structural 1	Mus musculus	191-194
2492471-4	1989	Putrescine has rather a counter-regulatory effect as concluded from the observation that the TPA-induced TCGF production and IL-2-specific mRNA expression are augmented (superinduced) by the ODC inhibitor D,L-alpha-difluoromethylornithine (DFMO) and again suppressed after the administration of putrescine or polyamines to DFMO-treated cultures.	Eflornithine	323-327	ornithine decarboxylase, structural 1	Mus musculus	191-194
2494758-1	1989	Eflornithine hydrochloride (DFMO) is a highly selective, enzyme-activated, irreversible inhibitor of the enzyme L-ornithine decarboxylase (ODC).	Eflornithine	0-26	ornithine decarboxylase 1	Rattus norvegicus	112-137
2494758-1	1989	Eflornithine hydrochloride (DFMO) is a highly selective, enzyme-activated, irreversible inhibitor of the enzyme L-ornithine decarboxylase (ODC).	Eflornithine	0-26	ornithine decarboxylase 1	Rattus norvegicus	139-142
2494758-1	1989	Eflornithine hydrochloride (DFMO) is a highly selective, enzyme-activated, irreversible inhibitor of the enzyme L-ornithine decarboxylase (ODC).	Eflornithine	28-32	ornithine decarboxylase 1	Rattus norvegicus	112-137
2494758-1	1989	Eflornithine hydrochloride (DFMO) is a highly selective, enzyme-activated, irreversible inhibitor of the enzyme L-ornithine decarboxylase (ODC).	Eflornithine	28-32	ornithine decarboxylase 1	Rattus norvegicus	139-142
2495841-6	1989	The specific ODC inhibitor alpha-difluoromethylornithine (DFMO) blocked the 1.6 M mannitol-induced increase in ODC activity and the accumulation of polyamines, and concurrently prevented BBB breakdown, monitored by transport of intravenously administered Evans blue and alpha-[3H]aminoisobutyrate into cerebral tissue.	Eflornithine	27-56	ornithine decarboxylase 1	Homo sapiens	13-16
2495841-6	1989	The specific ODC inhibitor alpha-difluoromethylornithine (DFMO) blocked the 1.6 M mannitol-induced increase in ODC activity and the accumulation of polyamines, and concurrently prevented BBB breakdown, monitored by transport of intravenously administered Evans blue and alpha-[3H]aminoisobutyrate into cerebral tissue.	Eflornithine	27-56	ornithine decarboxylase 1	Homo sapiens	111-114
2495841-6	1989	The specific ODC inhibitor alpha-difluoromethylornithine (DFMO) blocked the 1.6 M mannitol-induced increase in ODC activity and the accumulation of polyamines, and concurrently prevented BBB breakdown, monitored by transport of intravenously administered Evans blue and alpha-[3H]aminoisobutyrate into cerebral tissue.	Eflornithine	58-62	ornithine decarboxylase 1	Homo sapiens	13-16
2495841-6	1989	The specific ODC inhibitor alpha-difluoromethylornithine (DFMO) blocked the 1.6 M mannitol-induced increase in ODC activity and the accumulation of polyamines, and concurrently prevented BBB breakdown, monitored by transport of intravenously administered Evans blue and alpha-[3H]aminoisobutyrate into cerebral tissue.	Eflornithine	58-62	ornithine decarboxylase 1	Homo sapiens	111-114
2494281-5	1989	The ODC response to AVP was totally blocked by specific antiserum to AVP and reduced by 70% with the specific inhibitor to ODC, difluoromethyl ornithine.	Eflornithine	128-152	ornithine decarboxylase 1	Rattus norvegicus	123-126
2495754-3	1989	Consequently, combined treatment of tumor-bearing animals with an inhibitor of ornithine decarboxylase (e.g. alpha-difluoromethylornithine) and polyamine oxidase (e.g. N,N"- bis-allenylputrescine) has an antitumoral effect superior to that of either drug alone.	Eflornithine	109-138	ornithine decarboxylase, structural 1	Mus musculus	79-102
2492900-3	1989	The ODC inhibitor difluoromethylornithine (DFMO), which is active as a single agent did not enhance growth inhibition induced by the biological response modifiers.	Eflornithine	18-41	ornithine decarboxylase 1	Homo sapiens	4-7
2492900-4	1989	The substitution of the BT-20 cells with putrescine, the product of the enzymatic reaction mediated by ODC, reversed DFMO induced antiproliferative action.	Eflornithine	117-121	ornithine decarboxylase 1	Homo sapiens	103-106
2509268-2	1989	alpha-Difluoromethylornithine, an irreversible and specific inhibitor of ornithine decarboxylase, was applied simultaneously to elucidate the essential role of polyamines in pancreatic growth.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	73-96
2501116-4	1989	Inhibition of L-ornithine decarboxylase (ODC) by 2-difluoromethylornithine (DFMO) had no effect on Orn concentrations.	Eflornithine	49-74	ornithine decarboxylase 1	Homo sapiens	14-39
2501116-4	1989	Inhibition of L-ornithine decarboxylase (ODC) by 2-difluoromethylornithine (DFMO) had no effect on Orn concentrations.	Eflornithine	49-74	ornithine decarboxylase 1	Homo sapiens	41-44
2501116-4	1989	Inhibition of L-ornithine decarboxylase (ODC) by 2-difluoromethylornithine (DFMO) had no effect on Orn concentrations.	Eflornithine	76-80	ornithine decarboxylase 1	Homo sapiens	14-39
2501116-4	1989	Inhibition of L-ornithine decarboxylase (ODC) by 2-difluoromethylornithine (DFMO) had no effect on Orn concentrations.	Eflornithine	76-80	ornithine decarboxylase 1	Homo sapiens	41-44
2509268-6	1989	alpha-Difluoromethylornithine significantly delayed and reduced the camostate-induced increase in ornithine decarboxylase activity and polyamine concentrations as well as the trophic parameters.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	98-121
2489234-0	1989	Fluorescent location of ornithine decarboxylase employing derivatives of the specific inhibitor alpha-difluoromethyl ornithine.	Eflornithine	96-126	ornithine decarboxylase 1	Homo sapiens	24-47
2489234-2	1989	alpha-difluoromethyl ornithine is a potent inhibitor of ornithine decarboxylase, an enzyme which plays an essential role in cell division.	Eflornithine	0-30	ornithine decarboxylase 1	Homo sapiens	56-79
2462023-1	1989	Postnatal administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), is known to curtail replication of granule cells in the cerebellum of the rat, but its effects on post-proliferative neurons is unknown.	Eflornithine	28-57	ornithine decarboxylase 1	Rattus norvegicus	95-118
2497140-4	1989	ODC inactivated by alpha- difluoro-methylornithine (DFMO) could also be assayed with this method similarly to active ODC protein.	Eflornithine	19-50	ornithine decarboxylase 1	Rattus norvegicus	0-3
2497140-4	1989	ODC inactivated by alpha- difluoro-methylornithine (DFMO) could also be assayed with this method similarly to active ODC protein.	Eflornithine	52-56	ornithine decarboxylase 1	Rattus norvegicus	0-3
2462023-1	1989	Postnatal administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), is known to curtail replication of granule cells in the cerebellum of the rat, but its effects on post-proliferative neurons is unknown.	Eflornithine	28-57	ornithine decarboxylase 1	Rattus norvegicus	120-123
2462023-1	1989	Postnatal administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), is known to curtail replication of granule cells in the cerebellum of the rat, but its effects on post-proliferative neurons is unknown.	Eflornithine	59-63	ornithine decarboxylase 1	Rattus norvegicus	95-118
2462023-1	1989	Postnatal administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), is known to curtail replication of granule cells in the cerebellum of the rat, but its effects on post-proliferative neurons is unknown.	Eflornithine	59-63	ornithine decarboxylase 1	Rattus norvegicus	120-123
2494400-1	1989	alpha-Difluoromethylornithine (DFMO) directly infused into a brain-lateral ventricle (12.5, 25 and 50 micrograms/rat) dose- and time-dependently inhibited brain ODC activity.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	161-164
2498505-10	1989	ODC induced by two doses of Co2+ was insensitive to exogenous putrescine, but sensitive to alpha-difluoromethylornithine and 1,3-diaminopropane.	Eflornithine	91-120	ornithine decarboxylase 1	Rattus norvegicus	0-3
2494400-1	1989	alpha-Difluoromethylornithine (DFMO) directly infused into a brain-lateral ventricle (12.5, 25 and 50 micrograms/rat) dose- and time-dependently inhibited brain ODC activity.	Eflornithine	31-35	ornithine decarboxylase 1	Rattus norvegicus	161-164
3056933-7	1988	T. brucei ornithine decarboxylase appears similar to mouse ornithine decarboxylase, further supporting our previous suggestion that the selective toxicity of DFMO to the parasite is not due to catalytic differences between the two proteins.	Eflornithine	158-162	ornithine decarboxylase, structural 1	Mus musculus	10-33
16666499-4	1989	DFMA inhibits the fresh and dry weight increases of tobacco calli, whereas DFMO even promoted the fresh and dry weight increases, thus supporting the view that ADC is important for cell division and callus induction.	Eflornithine	75-79	arginine decarboxylase	Nicotiana tabacum	160-163
16666499-5	1989	Inhibition of ODC activity by DFMO resulting in an amide deficiency after 4 weeks of culture facilates the expression of differentiated cell functions.	Eflornithine	30-34	ornithine decarboxylase	Nicotiana tabacum	14-17
3142887-2	1988	When exponentially growing A31 cells are placed for greater than or equal to 2 days in a medium containing the alpha-difluoromethylornithine (alpha DFMO), an irreversible inhibitor of ornithine decarboxylase, they become arrested in G1 phase as a consequence of polyamine depletion (Medrano et al., 1983).	Eflornithine	142-152	ornithine decarboxylase 1	Homo sapiens	184-207
3142887-5	1988	After addition of putrescine in FCS-containing medium, these mRNAs continue to be present for at least 3 h. A large proportion of alpha DFMO-arrested cells can be induced to progress to S phase by insulin (1 microM, acting via IGF1 receptor) plus putrescine in a serum-free medium (greater than or equal to 50% of FCS effect).	Eflornithine	136-140	insulin	Homo sapiens	197-204
3142887-5	1988	After addition of putrescine in FCS-containing medium, these mRNAs continue to be present for at least 3 h. A large proportion of alpha DFMO-arrested cells can be induced to progress to S phase by insulin (1 microM, acting via IGF1 receptor) plus putrescine in a serum-free medium (greater than or equal to 50% of FCS effect).	Eflornithine	136-140	insulin like growth factor 1	Homo sapiens	227-231
3142887-6	1988	In this case, the levels of "competence" mRNAs become low or undetectable within 3 h, EGF (10 nM) plus insulin had only slightly greater effect than insulin alone on the progression of alpha DFMO-arrested cells.	Eflornithine	191-195	epidermal growth factor	Homo sapiens	86-89
3142887-6	1988	In this case, the levels of "competence" mRNAs become low or undetectable within 3 h, EGF (10 nM) plus insulin had only slightly greater effect than insulin alone on the progression of alpha DFMO-arrested cells.	Eflornithine	191-195	insulin	Homo sapiens	103-110
3142887-7	1988	When the alpha DFMO-arrested cells are subsequently incubated during 3 days in a low-serum-containing medium (0.25% FCS), they do not replenish their supply of polyamines, and then continue to express the c-myc gene.	Eflornithine	15-19	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	205-210
3142887-10	1988	During the subsequent serum deprivation, the alpha DFMO-arrested cells remain "competent" (PDGF-independent), probably as a consequence of their continued expression of c-myc (and possibly other PDGF-inducible genes).	Eflornithine	51-55	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	169-174
3141045-1	1988	Ornithine decarboxylase, the first regulatory enzyme in polyamine biosynthesis, is inhibited by alpha-difluoromethylornithine (DFMO), a specific enzyme-activated irreversible inhibitor.	Eflornithine	96-125	ornithine decarboxylase 1	Rattus norvegicus	0-23
3141045-1	1988	Ornithine decarboxylase, the first regulatory enzyme in polyamine biosynthesis, is inhibited by alpha-difluoromethylornithine (DFMO), a specific enzyme-activated irreversible inhibitor.	Eflornithine	127-131	ornithine decarboxylase 1	Rattus norvegicus	0-23
3141045-12	1988	At necropsy, tumor ornithine decarboxylase activity was 115 +/- 22 pmol/h/mg of protein in DFMO rats as compared with 842 +/- 576 in controls.	Eflornithine	91-95	ornithine decarboxylase 1	Rattus norvegicus	19-42
3141298-3	1988	In addition, we attempted to control tumor growth during TPN with alpha-difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase (ODC), in a fibrosarcoma-bearing rat model.	Eflornithine	66-95	ornithine decarboxylase 1	Rattus norvegicus	127-150
3141298-3	1988	In addition, we attempted to control tumor growth during TPN with alpha-difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase (ODC), in a fibrosarcoma-bearing rat model.	Eflornithine	66-95	ornithine decarboxylase 1	Rattus norvegicus	152-155
3141298-3	1988	In addition, we attempted to control tumor growth during TPN with alpha-difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase (ODC), in a fibrosarcoma-bearing rat model.	Eflornithine	97-101	ornithine decarboxylase 1	Rattus norvegicus	127-150
3141298-3	1988	In addition, we attempted to control tumor growth during TPN with alpha-difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase (ODC), in a fibrosarcoma-bearing rat model.	Eflornithine	97-101	ornithine decarboxylase 1	Rattus norvegicus	152-155
3141298-9	1988	Despite DFMO treatment, liver ODC activity in RI----TPN + DFMO group was unaffected.	Eflornithine	58-62	ornithine decarboxylase 1	Rattus norvegicus	30-33
3146032-2	1988	Polyamines appear to play a critical role in the development of the rat cerebellar cortex, since postnatal treatment with the specific irreversible ornithine decarboxylase inhibitor, alpha-difluoromethylornithine, arrests cell division and migration in this region.	Eflornithine	183-212	ornithine decarboxylase 1	Rattus norvegicus	148-171
3143119-3	1988	In these studies we determined whether inhibition of ODC activity and subsequent polyamine biosynthesis with the specific enzyme inhibitor difluoromethyornithine (DFMO) would attenuate prostaglandin-mediated trophic effects in the rat duodenum.	Eflornithine	163-167	ornithine decarboxylase 1	Rattus norvegicus	53-56
3146234-2	1988	True ODC activity was determined by two methods: (a) addition of the inhibitors alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ODC, or aminooxyacetate (AOA), an inhibitor that blocks the decarboxylation of ornithine by mitochondrial enzymes; and (b) chromatographic analysis of the reaction products.	Eflornithine	80-109	ornithine decarboxylase 1	Rattus norvegicus	5-8
3146234-2	1988	True ODC activity was determined by two methods: (a) addition of the inhibitors alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ODC, or aminooxyacetate (AOA), an inhibitor that blocks the decarboxylation of ornithine by mitochondrial enzymes; and (b) chromatographic analysis of the reaction products.	Eflornithine	111-115	ornithine decarboxylase 1	Rattus norvegicus	5-8
3146234-4	1988	Kidney and spleen ODC activity was inhibited 90-100% by DFMO, but apparent liver ODC activity was inhibited only 60-75%.	Eflornithine	56-60	ornithine decarboxylase 1	Rattus norvegicus	18-21
3146234-6	1988	After 23 days, DFMO did not inhibit apparent ODC activity in supernatants from frozen liver and inhibited ODC in frozen kidney by only 49%.	Eflornithine	15-19	ornithine decarboxylase 1	Rattus norvegicus	106-109
3143356-1	1988	Inhibition of ornithine decarboxylase activity after arginase-mediated hydrolysis of DL-alpha-difluoromethylarginine to DL-alpha-difluoromethylornithine.	Eflornithine	120-152	ornithine decarboxylase	Nicotiana tabacum	14-37
2458948-0	1988	Transcriptional and post-transcriptional regulation of c-myc, c-myb, and p53 during proliferation and differentiation of murine erythroleukemia cells treated with DFMO and DMSO.	Eflornithine	163-167	myeloblastosis oncogene	Mus musculus	62-67
2458948-0	1988	Transcriptional and post-transcriptional regulation of c-myc, c-myb, and p53 during proliferation and differentiation of murine erythroleukemia cells treated with DFMO and DMSO.	Eflornithine	163-167	transformation related protein 53, pseudogene	Mus musculus	73-76
2458948-4	1988	In contrast, treatment of the cells with DFMO resulted in gradual cessation of cell replication and a decrease in transcription of c-myc, c-myb and p53.	Eflornithine	41-45	myeloblastosis oncogene	Mus musculus	138-143
2458948-4	1988	In contrast, treatment of the cells with DFMO resulted in gradual cessation of cell replication and a decrease in transcription of c-myc, c-myb and p53.	Eflornithine	41-45	transformation related protein 53, pseudogene	Mus musculus	148-151
2458948-7	1988	From these experiments we conclude that (i) c-myc, c-myb, and p53 are regulated independently at both the transcriptional and post-transcriptional levels, (ii) DFMO inhibits MEL cell proliferation and expression of several genes, including c-myc, c-myb and p53, and (iii) DFMO suppresses terminal differentiation but is unable to alter proto-oncogene changes associated with the early stages of differentiation.	Eflornithine	160-164	myeloblastosis oncogene	Mus musculus	51-56
2458948-7	1988	From these experiments we conclude that (i) c-myc, c-myb, and p53 are regulated independently at both the transcriptional and post-transcriptional levels, (ii) DFMO inhibits MEL cell proliferation and expression of several genes, including c-myc, c-myb and p53, and (iii) DFMO suppresses terminal differentiation but is unable to alter proto-oncogene changes associated with the early stages of differentiation.	Eflornithine	160-164	transformation related protein 53, pseudogene	Mus musculus	62-65
2458948-7	1988	From these experiments we conclude that (i) c-myc, c-myb, and p53 are regulated independently at both the transcriptional and post-transcriptional levels, (ii) DFMO inhibits MEL cell proliferation and expression of several genes, including c-myc, c-myb and p53, and (iii) DFMO suppresses terminal differentiation but is unable to alter proto-oncogene changes associated with the early stages of differentiation.	Eflornithine	160-164	myeloblastosis oncogene	Mus musculus	247-252
2458948-7	1988	From these experiments we conclude that (i) c-myc, c-myb, and p53 are regulated independently at both the transcriptional and post-transcriptional levels, (ii) DFMO inhibits MEL cell proliferation and expression of several genes, including c-myc, c-myb and p53, and (iii) DFMO suppresses terminal differentiation but is unable to alter proto-oncogene changes associated with the early stages of differentiation.	Eflornithine	160-164	transformation related protein 53, pseudogene	Mus musculus	257-260
3139441-6	1988	DL-alpha-difluoromethylornithine efficiently and irreversibly inhibited ornithine decarboxylase activity from P. falciparum grown in vitro or Plasmodium berghei grown in vivo.	Eflornithine	0-32	ornithine decarboxylase, structural 1	Mus musculus	72-95
2840461-5	1988	The early rise in ODC activity is followed by a protracted increase in enzyme activity, apparent protein measured by [3H]difluoromethylornithine binding, and by accumulation of steady state ODC mRNA.	Eflornithine	121-144	ornithine decarboxylase, structural 1	Mus musculus	18-21
2971724-3	1988	The proliferation of all cell types used in these experiments was markedly suppressed by a specific ODC inhibitor, alpha-difluoromethyl ornithine (DFMO), substantiating the crucial role of ODC activity for cell proliferation.	Eflornithine	115-145	ornithine decarboxylase 1	Homo sapiens	100-103
2971724-3	1988	The proliferation of all cell types used in these experiments was markedly suppressed by a specific ODC inhibitor, alpha-difluoromethyl ornithine (DFMO), substantiating the crucial role of ODC activity for cell proliferation.	Eflornithine	115-145	ornithine decarboxylase 1	Homo sapiens	189-192
2971724-3	1988	The proliferation of all cell types used in these experiments was markedly suppressed by a specific ODC inhibitor, alpha-difluoromethyl ornithine (DFMO), substantiating the crucial role of ODC activity for cell proliferation.	Eflornithine	147-151	ornithine decarboxylase 1	Homo sapiens	100-103
2971724-3	1988	The proliferation of all cell types used in these experiments was markedly suppressed by a specific ODC inhibitor, alpha-difluoromethyl ornithine (DFMO), substantiating the crucial role of ODC activity for cell proliferation.	Eflornithine	147-151	ornithine decarboxylase 1	Homo sapiens	189-192
3137699-2	1988	When D,L-alpha-difluoromethyl ornithine (DFMO), an inhibitor of ODC activity, was coadministered with TCAOB, it decreased the frequency of cleft palate compared with TCAOB alone.	Eflornithine	5-39	ornithine decarboxylase, structural 1	Mus musculus	64-67
3137699-2	1988	When D,L-alpha-difluoromethyl ornithine (DFMO), an inhibitor of ODC activity, was coadministered with TCAOB, it decreased the frequency of cleft palate compared with TCAOB alone.	Eflornithine	41-45	ornithine decarboxylase, structural 1	Mus musculus	64-67
3134356-0	1988	Control of ornithine decarboxylase activity in alpha-difluoromethylornithine-resistant L1210 cells by polyamines and synthetic analogues.	Eflornithine	47-76	ornithine decarboxylase, structural 1	Mus musculus	11-34
3134356-1	1988	The regulation of ornithine decarboxylase (ODC) activity by the polyamine derivatives N1,N8-bis(ethyl)-spermidine and N1,N12-bis(ethyl)spermine was studied using a line of L1210 cells resistant to alpha-difluoromethylornithine (D-R cells), which contain very high levels of ODC, and a synthetic mRNA prepared from a plasmid containing an insert corresponding to ODC mRNA adjacent to an SP6 RNA polymerase promoter.	Eflornithine	197-226	ornithine decarboxylase, structural 1	Mus musculus	18-41
3134356-1	1988	The regulation of ornithine decarboxylase (ODC) activity by the polyamine derivatives N1,N8-bis(ethyl)-spermidine and N1,N12-bis(ethyl)spermine was studied using a line of L1210 cells resistant to alpha-difluoromethylornithine (D-R cells), which contain very high levels of ODC, and a synthetic mRNA prepared from a plasmid containing an insert corresponding to ODC mRNA adjacent to an SP6 RNA polymerase promoter.	Eflornithine	197-226	ornithine decarboxylase, structural 1	Mus musculus	43-46
2839169-4	1988	The ODC inhibitor alpha-difluoromethylornithine (DFMO, 5-10 mM) blocks the isoproterenol-evoked increase in ODC activity and polyamine levels and the changes in 45Ca fluxes, [Ca2+]i and membrane transport.	Eflornithine	18-47	ornithine decarboxylase 1	Rattus norvegicus	4-7
2839169-4	1988	The ODC inhibitor alpha-difluoromethylornithine (DFMO, 5-10 mM) blocks the isoproterenol-evoked increase in ODC activity and polyamine levels and the changes in 45Ca fluxes, [Ca2+]i and membrane transport.	Eflornithine	18-47	ornithine decarboxylase 1	Rattus norvegicus	108-111
2839169-4	1988	The ODC inhibitor alpha-difluoromethylornithine (DFMO, 5-10 mM) blocks the isoproterenol-evoked increase in ODC activity and polyamine levels and the changes in 45Ca fluxes, [Ca2+]i and membrane transport.	Eflornithine	49-53	ornithine decarboxylase 1	Rattus norvegicus	4-7
2839169-4	1988	The ODC inhibitor alpha-difluoromethylornithine (DFMO, 5-10 mM) blocks the isoproterenol-evoked increase in ODC activity and polyamine levels and the changes in 45Ca fluxes, [Ca2+]i and membrane transport.	Eflornithine	49-53	ornithine decarboxylase 1	Rattus norvegicus	108-111
3135921-7	1988	DFMO-treatment significantly reduced ODC activity after 8 h recirculation and following 24 h recirculation.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	37-40
3135921-9	1988	The discrepancy between reduction in ODC activity and putrescine levels in DFMO-treated animals was most prominent in the hippocampus after 8 h recirculation: here DFMO reduced ODC activity to control values without affecting putrescine levels.	Eflornithine	75-79	ornithine decarboxylase 1	Rattus norvegicus	177-180
3135921-9	1988	The discrepancy between reduction in ODC activity and putrescine levels in DFMO-treated animals was most prominent in the hippocampus after 8 h recirculation: here DFMO reduced ODC activity to control values without affecting putrescine levels.	Eflornithine	164-168	ornithine decarboxylase 1	Rattus norvegicus	37-40
3135921-9	1988	The discrepancy between reduction in ODC activity and putrescine levels in DFMO-treated animals was most prominent in the hippocampus after 8 h recirculation: here DFMO reduced ODC activity to control values without affecting putrescine levels.	Eflornithine	164-168	ornithine decarboxylase 1	Rattus norvegicus	177-180
3129184-1	1988	L1210 cells were selected for resistance to the ornithine decarboxylase (ODC) inhibitor, alpha-difluoromethylornithine.	Eflornithine	89-118	ornithine decarboxylase, structural 1	Mus musculus	48-71
3129184-1	1988	L1210 cells were selected for resistance to the ornithine decarboxylase (ODC) inhibitor, alpha-difluoromethylornithine.	Eflornithine	89-118	ornithine decarboxylase, structural 1	Mus musculus	73-76
3132336-1	1988	When Ehrlich ascites tumour cells are induced to proliferate by serum stimulation, the ornithine decarboxylase (ODC) activity increases rapidly and reaches two to three peaks during the first 24 h. Inhibition of the first peak in ODC activity (occurring at 4 h) by adding alpha-difluoromethylornithine (DFMO) within 2 h of serum stimulation, results in maximal growth inhibition.	Eflornithine	272-301	ornithine decarboxylase, structural 1	Mus musculus	87-110
3132336-1	1988	When Ehrlich ascites tumour cells are induced to proliferate by serum stimulation, the ornithine decarboxylase (ODC) activity increases rapidly and reaches two to three peaks during the first 24 h. Inhibition of the first peak in ODC activity (occurring at 4 h) by adding alpha-difluoromethylornithine (DFMO) within 2 h of serum stimulation, results in maximal growth inhibition.	Eflornithine	272-301	ornithine decarboxylase, structural 1	Mus musculus	112-115
3132336-1	1988	When Ehrlich ascites tumour cells are induced to proliferate by serum stimulation, the ornithine decarboxylase (ODC) activity increases rapidly and reaches two to three peaks during the first 24 h. Inhibition of the first peak in ODC activity (occurring at 4 h) by adding alpha-difluoromethylornithine (DFMO) within 2 h of serum stimulation, results in maximal growth inhibition.	Eflornithine	272-301	ornithine decarboxylase, structural 1	Mus musculus	230-233
3132336-1	1988	When Ehrlich ascites tumour cells are induced to proliferate by serum stimulation, the ornithine decarboxylase (ODC) activity increases rapidly and reaches two to three peaks during the first 24 h. Inhibition of the first peak in ODC activity (occurring at 4 h) by adding alpha-difluoromethylornithine (DFMO) within 2 h of serum stimulation, results in maximal growth inhibition.	Eflornithine	303-307	ornithine decarboxylase, structural 1	Mus musculus	87-110
3132336-1	1988	When Ehrlich ascites tumour cells are induced to proliferate by serum stimulation, the ornithine decarboxylase (ODC) activity increases rapidly and reaches two to three peaks during the first 24 h. Inhibition of the first peak in ODC activity (occurring at 4 h) by adding alpha-difluoromethylornithine (DFMO) within 2 h of serum stimulation, results in maximal growth inhibition.	Eflornithine	303-307	ornithine decarboxylase, structural 1	Mus musculus	112-115
3132336-1	1988	When Ehrlich ascites tumour cells are induced to proliferate by serum stimulation, the ornithine decarboxylase (ODC) activity increases rapidly and reaches two to three peaks during the first 24 h. Inhibition of the first peak in ODC activity (occurring at 4 h) by adding alpha-difluoromethylornithine (DFMO) within 2 h of serum stimulation, results in maximal growth inhibition.	Eflornithine	303-307	ornithine decarboxylase, structural 1	Mus musculus	230-233
3132336-3	1988	When DFMO is added 3 h after seeding, however, enough polyamines have already accumulated during the initial burst in ODC activity to reduce the antiproliferative effect of the drug.	Eflornithine	5-9	ornithine decarboxylase, structural 1	Mus musculus	118-121
3142219-1	1988	Both mouse interferon-beta (MuIFN-beta) and the inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethyl ornithine (DFMO), inhibited the differentiation of mouse 3T3-L1 fibroblasts into adipocytes in a dose-dependent manner.	Eflornithine	92-122	ornithine decarboxylase, structural 1	Mus musculus	61-84
3142219-1	1988	Both mouse interferon-beta (MuIFN-beta) and the inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethyl ornithine (DFMO), inhibited the differentiation of mouse 3T3-L1 fibroblasts into adipocytes in a dose-dependent manner.	Eflornithine	92-122	ornithine decarboxylase, structural 1	Mus musculus	86-89
3142219-1	1988	Both mouse interferon-beta (MuIFN-beta) and the inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethyl ornithine (DFMO), inhibited the differentiation of mouse 3T3-L1 fibroblasts into adipocytes in a dose-dependent manner.	Eflornithine	124-128	interferon beta 1, fibroblast	Mus musculus	11-26
3142219-1	1988	Both mouse interferon-beta (MuIFN-beta) and the inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethyl ornithine (DFMO), inhibited the differentiation of mouse 3T3-L1 fibroblasts into adipocytes in a dose-dependent manner.	Eflornithine	124-128	ornithine decarboxylase, structural 1	Mus musculus	61-84
3142219-1	1988	Both mouse interferon-beta (MuIFN-beta) and the inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethyl ornithine (DFMO), inhibited the differentiation of mouse 3T3-L1 fibroblasts into adipocytes in a dose-dependent manner.	Eflornithine	124-128	ornithine decarboxylase, structural 1	Mus musculus	86-89
3365395-7	1988	The combined application of 100 microM MAOEA and 5 mM alpha-(difluoromethyl)ornithine (an ornithine decarboxylase inhibitor) to L1210 cells completely prevented the synthesis of putrescine, spermidine, and spermine for up to 48 h. The reduction in polyamine content brought about by MHZPA or MAOEA could be partially prevented by the addition of decarboxylated S-adenosylmethionine to the culture medium.	Eflornithine	54-85	ornithine decarboxylase, structural 1	Mus musculus	90-113
3138918-3	1988	Difluoromethylornithine (DFMO), a potent inhibitor of ODC, blocks the mucosal growth response, indicating that ODC activity is necessary for growth.	Eflornithine	0-23	ornithine decarboxylase 1	Rattus norvegicus	54-57
3138918-3	1988	Difluoromethylornithine (DFMO), a potent inhibitor of ODC, blocks the mucosal growth response, indicating that ODC activity is necessary for growth.	Eflornithine	0-23	ornithine decarboxylase 1	Rattus norvegicus	111-114
3138918-3	1988	Difluoromethylornithine (DFMO), a potent inhibitor of ODC, blocks the mucosal growth response, indicating that ODC activity is necessary for growth.	Eflornithine	25-29	ornithine decarboxylase 1	Rattus norvegicus	54-57
3138918-3	1988	Difluoromethylornithine (DFMO), a potent inhibitor of ODC, blocks the mucosal growth response, indicating that ODC activity is necessary for growth.	Eflornithine	25-29	ornithine decarboxylase 1	Rattus norvegicus	111-114
2852723-8	1988	The ODC inhibitor alpha-difluoromethylornithine (DFMO, 5 mM) suppressed the isoproterenol-induced increase in ODC and polyamine levels and the stimulation of 45Ca influx, endocytosis, hexose transport, and amino acid transport.	Eflornithine	18-47	ornithine decarboxylase 1	Rattus norvegicus	4-7
2852723-8	1988	The ODC inhibitor alpha-difluoromethylornithine (DFMO, 5 mM) suppressed the isoproterenol-induced increase in ODC and polyamine levels and the stimulation of 45Ca influx, endocytosis, hexose transport, and amino acid transport.	Eflornithine	18-47	ornithine decarboxylase 1	Rattus norvegicus	110-113
2852723-8	1988	The ODC inhibitor alpha-difluoromethylornithine (DFMO, 5 mM) suppressed the isoproterenol-induced increase in ODC and polyamine levels and the stimulation of 45Ca influx, endocytosis, hexose transport, and amino acid transport.	Eflornithine	49-53	ornithine decarboxylase 1	Rattus norvegicus	4-7
2852723-8	1988	The ODC inhibitor alpha-difluoromethylornithine (DFMO, 5 mM) suppressed the isoproterenol-induced increase in ODC and polyamine levels and the stimulation of 45Ca influx, endocytosis, hexose transport, and amino acid transport.	Eflornithine	49-53	ornithine decarboxylase 1	Rattus norvegicus	110-113
3137935-1	1988	We have selected mouse myeloma and leukemia cell lines overproducing ornithine decarboxylase (ODC) under the pressure of alpha-difluoromethylornithine (DFMO), a mechanism-based inhibitor of the enzyme.	Eflornithine	121-150	ornithine decarboxylase, structural 1	Mus musculus	69-92
3137935-1	1988	We have selected mouse myeloma and leukemia cell lines overproducing ornithine decarboxylase (ODC) under the pressure of alpha-difluoromethylornithine (DFMO), a mechanism-based inhibitor of the enzyme.	Eflornithine	121-150	ornithine decarboxylase, structural 1	Mus musculus	94-97
3137935-1	1988	We have selected mouse myeloma and leukemia cell lines overproducing ornithine decarboxylase (ODC) under the pressure of alpha-difluoromethylornithine (DFMO), a mechanism-based inhibitor of the enzyme.	Eflornithine	152-156	ornithine decarboxylase, structural 1	Mus musculus	69-92
3137935-1	1988	We have selected mouse myeloma and leukemia cell lines overproducing ornithine decarboxylase (ODC) under the pressure of alpha-difluoromethylornithine (DFMO), a mechanism-based inhibitor of the enzyme.	Eflornithine	152-156	ornithine decarboxylase, structural 1	Mus musculus	94-97
3137935-4	1988	The DFMO-resistant cells exhibited ODC activity that was 8 to 25 times higher than the enzyme activity in the parental cells.	Eflornithine	4-8	ornithine decarboxylase, structural 1	Mus musculus	35-38
3136663-4	1988	Pretreatment with difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, as a 1% drinking water solution inhibited both base-line renal ODC activity and putrescine concentration as well as increases stimulated by UN, although concentrations of spermidine and spermine were not decreased.	Eflornithine	18-41	ornithine decarboxylase 1	Rattus norvegicus	79-82
3136663-4	1988	Pretreatment with difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, as a 1% drinking water solution inhibited both base-line renal ODC activity and putrescine concentration as well as increases stimulated by UN, although concentrations of spermidine and spermine were not decreased.	Eflornithine	18-41	ornithine decarboxylase 1	Rattus norvegicus	147-150
3136663-4	1988	Pretreatment with difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, as a 1% drinking water solution inhibited both base-line renal ODC activity and putrescine concentration as well as increases stimulated by UN, although concentrations of spermidine and spermine were not decreased.	Eflornithine	43-47	ornithine decarboxylase 1	Rattus norvegicus	79-82
3136663-4	1988	Pretreatment with difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, as a 1% drinking water solution inhibited both base-line renal ODC activity and putrescine concentration as well as increases stimulated by UN, although concentrations of spermidine and spermine were not decreased.	Eflornithine	43-47	ornithine decarboxylase 1	Rattus norvegicus	147-150
3136663-8	1988	Although increased renal ODC activity and CRH after UN are correlated in normal and hypophysectomized rats, CRH takes place in rats treated with DFMO despite inhibition of ODC activity and depletion of polyamines.	Eflornithine	145-149	ornithine decarboxylase 1	Rattus norvegicus	172-175
3135955-7	1988	A 0.5 or 0.25% supplement of alpha-difluoromethylornithine (alpha-DFMO) in the drinking water inhibited the induction of epidermal ODC following chrysarobin (220 nmol/mouse) treatment by 85 or 70%, respectively.	Eflornithine	29-58	ornithine decarboxylase, structural 1	Mus musculus	131-134
3135955-7	1988	A 0.5 or 0.25% supplement of alpha-difluoromethylornithine (alpha-DFMO) in the drinking water inhibited the induction of epidermal ODC following chrysarobin (220 nmol/mouse) treatment by 85 or 70%, respectively.	Eflornithine	60-70	ornithine decarboxylase, structural 1	Mus musculus	131-134
3140710-3	1988	The observed antitumor activity of the compound was potentiated by administration of a - difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	89-112	ornithine decarboxylase, structural 1	Mus musculus	150-173
3140710-3	1988	The observed antitumor activity of the compound was potentiated by administration of a - difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	114-118	ornithine decarboxylase, structural 1	Mus musculus	150-173
3134121-5	1988	DEGBG was also found to potentiate the antiproliferative effect of the ornithine decarboxylase inhibitor alpha-difluoromethyl ornithine against mouse L1210 leukemia cells in vitro.	Eflornithine	105-135	ornithine decarboxylase, structural 1	Mus musculus	71-94
3130188-6	1988	alpha-Difluoromethylornithine inhibits ornithine decarboxylase, the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	39-62
3130189-5	1988	Nevertheless, cell strains derived from the metaplastic tissue were growth inhibited by alpha-difluoromethylornithine, an enzyme-activated, suicide inhibitor of ODC.	Eflornithine	88-117	ornithine decarboxylase 1	Homo sapiens	161-164
3131549-1	1988	Previous studies have reported that alpha difluoromethylornithine (DFMO), an enzyme-activated, irreversible inhibitor of ornithine decarboxylase (ODC), has anti-tumor activity in several tumor systems.	Eflornithine	36-65	ornithine decarboxylase, structural 1	Mus musculus	121-144
3131549-1	1988	Previous studies have reported that alpha difluoromethylornithine (DFMO), an enzyme-activated, irreversible inhibitor of ornithine decarboxylase (ODC), has anti-tumor activity in several tumor systems.	Eflornithine	36-65	ornithine decarboxylase, structural 1	Mus musculus	146-149
3131549-1	1988	Previous studies have reported that alpha difluoromethylornithine (DFMO), an enzyme-activated, irreversible inhibitor of ornithine decarboxylase (ODC), has anti-tumor activity in several tumor systems.	Eflornithine	67-71	ornithine decarboxylase, structural 1	Mus musculus	121-144
3131549-1	1988	Previous studies have reported that alpha difluoromethylornithine (DFMO), an enzyme-activated, irreversible inhibitor of ornithine decarboxylase (ODC), has anti-tumor activity in several tumor systems.	Eflornithine	67-71	ornithine decarboxylase, structural 1	Mus musculus	146-149
3128541-3	1988	In the present study, we demonstrate that polyamine depletion induced by 2-difluoromethylornithine in COLO 320 human colon carcinoma cells results in a greater than 90% decrease in expression of a key gene in the maintenance of cell growth, the c-myc protooncogene.	Eflornithine	73-98	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	245-250
3378315-4	1988	However, inhibition of ODC activity by alpha-difluoromethylornithine does not prevent the increase of the microsomal activity caused by thioacetamide.	Eflornithine	39-68	ornithine decarboxylase 1	Homo sapiens	23-26
3123076-6	1988	In direct comparison with another ODC inhibitor, alpha-difluoromethylornithine (DFMO), MAP was five- to sixfold more potent in reducing CTL induction.	Eflornithine	49-78	ornithine decarboxylase 1	Homo sapiens	34-37
3275019-3	1988	Treatment of laboratory animals bearing transplantable tumours with alpha-difluoromethylornithine, an inhibitor of ornithine decarboxylase, followed by 2,2-difluoroputrescine allows the partial replacement of the endogenous polyamines spermidine and spermine by their fluorine-containing analogs 6,6-difluorospermidine and 6,6-difluorospermine.	Eflornithine	68-97	ornithine decarboxylase, structural 1	Mus musculus	115-138
3348786-1	1988	Ornithine decarboxylase in the crude extract from the kidney of androgen-treated mice was labeled by reaction with radioactive alpha-difluoromethylornithine and analyzed by sodium dodecylsulfate-polyacrylamide gel electrophoresis followed by autoradiography.	Eflornithine	127-156	ornithine decarboxylase, structural 1	Mus musculus	0-23
16665927-3	1988	One cell line, resistant to difluoromethylornithine (Dfr1) had a very low level of ornithine decarboxylase activity which was half insensitive to the inhibitor in vitro.	Eflornithine	28-51	dihydroflavonol-4-reductase	Nicotiana tabacum	53-57
16665927-3	1988	One cell line, resistant to difluoromethylornithine (Dfr1) had a very low level of ornithine decarboxylase activity which was half insensitive to the inhibitor in vitro.	Eflornithine	28-51	ornithine decarboxylase	Nicotiana tabacum	83-106
3341033-7	1988	The administrations of alpha-difluoromethylornithine and 1,3-diaminopropane resulted in the inhibition of DEM-mediated induction of ODC, but not heme oxygenase.	Eflornithine	23-52	ornithine decarboxylase 1	Rattus norvegicus	132-135
3124839-5	1988	The proenzyme form was readily detectable in control prostates (about 4% of the total) and this proportion was increased to 25% when the rats were pretreated for 3 days with the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine.	Eflornithine	213-242	ornithine decarboxylase 1	Rattus norvegicus	178-201
3275496-2	1988	All four human TCC cell lines tested were quite sensitive to the specific inhibitor of ornithine decarboxylase, alpha-difluoromethylornithine (DFMO), requiring less than or equal to 1.0 mM DFMO to double generation time.	Eflornithine	112-141	ornithine decarboxylase 1	Homo sapiens	87-110
3275496-2	1988	All four human TCC cell lines tested were quite sensitive to the specific inhibitor of ornithine decarboxylase, alpha-difluoromethylornithine (DFMO), requiring less than or equal to 1.0 mM DFMO to double generation time.	Eflornithine	143-147	ornithine decarboxylase 1	Homo sapiens	87-110
3275496-2	1988	All four human TCC cell lines tested were quite sensitive to the specific inhibitor of ornithine decarboxylase, alpha-difluoromethylornithine (DFMO), requiring less than or equal to 1.0 mM DFMO to double generation time.	Eflornithine	189-193	ornithine decarboxylase 1	Homo sapiens	87-110
3250232-11	1988	The precursor could also be detected by immunoblotting of extracts from prostates of rats depleted of putrescine by treatment with the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine.	Eflornithine	170-199	ornithine decarboxylase 1	Rattus norvegicus	135-158
3250233-12	1988	(93, 94) and others (95) reported that, among a spectrum of human lung carcinoma lines, small cell carcinoma was exquisitely sensitive to the ODC inhibitor, DFMO.	Eflornithine	157-161	ornithine decarboxylase 1	Homo sapiens	142-145
3255234-4	1988	alpha-difluoromethylornithine (DFMO), an irreversible and specific inhibitor of ODC, was applied simultaneously to elucidate the essential role of polyamines in pancreatic growth.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	80-83
3255234-4	1988	alpha-difluoromethylornithine (DFMO), an irreversible and specific inhibitor of ODC, was applied simultaneously to elucidate the essential role of polyamines in pancreatic growth.	Eflornithine	31-35	ornithine decarboxylase 1	Rattus norvegicus	80-83
2848638-3	1988	It was therefore best to give the melarsoprol towards the end of the DFMO regimen, and as a guanylhydrazone (TBG) also blocks trypanothione (polyamine) biosynthesis, if TBG/DFMO are given together the treatment period can be reduced to 8 days.	Eflornithine	173-177	serine (or cysteine) peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7	Mus musculus	109-112
2840221-3	1988	Difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase (ODC) which produces minimal toxicity in animals and humans, has shown antiproliferative effect against human SCC in culture but a much smaller effect (cytostatic) against NSCC.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	73-96
2840221-3	1988	Difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase (ODC) which produces minimal toxicity in animals and humans, has shown antiproliferative effect against human SCC in culture but a much smaller effect (cytostatic) against NSCC.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	98-101
2840221-3	1988	Difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase (ODC) which produces minimal toxicity in animals and humans, has shown antiproliferative effect against human SCC in culture but a much smaller effect (cytostatic) against NSCC.	Eflornithine	0-23	serpin family B member 3	Homo sapiens	207-210
2840221-3	1988	Difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase (ODC) which produces minimal toxicity in animals and humans, has shown antiproliferative effect against human SCC in culture but a much smaller effect (cytostatic) against NSCC.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	73-96
2840221-3	1988	Difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase (ODC) which produces minimal toxicity in animals and humans, has shown antiproliferative effect against human SCC in culture but a much smaller effect (cytostatic) against NSCC.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	98-101
2840221-3	1988	Difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase (ODC) which produces minimal toxicity in animals and humans, has shown antiproliferative effect against human SCC in culture but a much smaller effect (cytostatic) against NSCC.	Eflornithine	25-29	serpin family B member 3	Homo sapiens	207-210
3130336-6	1988	At 60 min after injection, 11% of the 14C was present in the acid-precipitable fraction of the FM3A, which suggests the formation of an irreversible complex of [14C]DFMO with ODC.	Eflornithine	165-169	ornithine decarboxylase, structural 1	Mus musculus	175-178
3143490-1	1988	alpha-Difluoromethyl ornithine (DFMO) irreversibly inhibits ornithine decarboxylase (ODC), an essential enzyme for the synthesis of polyamines, and results in decreased biosynthesis of putrescine and spermidine, factors necessary for cellular multiplication.	Eflornithine	0-30	ornithine decarboxylase 1	Homo sapiens	60-83
3143490-1	1988	alpha-Difluoromethyl ornithine (DFMO) irreversibly inhibits ornithine decarboxylase (ODC), an essential enzyme for the synthesis of polyamines, and results in decreased biosynthesis of putrescine and spermidine, factors necessary for cellular multiplication.	Eflornithine	0-30	ornithine decarboxylase 1	Homo sapiens	85-88
3143490-1	1988	alpha-Difluoromethyl ornithine (DFMO) irreversibly inhibits ornithine decarboxylase (ODC), an essential enzyme for the synthesis of polyamines, and results in decreased biosynthesis of putrescine and spermidine, factors necessary for cellular multiplication.	Eflornithine	32-36	ornithine decarboxylase 1	Homo sapiens	60-83
3143490-1	1988	alpha-Difluoromethyl ornithine (DFMO) irreversibly inhibits ornithine decarboxylase (ODC), an essential enzyme for the synthesis of polyamines, and results in decreased biosynthesis of putrescine and spermidine, factors necessary for cellular multiplication.	Eflornithine	32-36	ornithine decarboxylase 1	Homo sapiens	85-88
3147916-5	1988	The results presented here provide additional in vitro evidence on the characteristic changes in the metabolic imbalance of ornithine in tumor cells induced by DFMO via inhibition of ornithine decarboxylase and ornithine carbamoyl transferase activities.	Eflornithine	160-164	ornithine decarboxylase, structural 1	Mus musculus	183-206
3145970-1	1988	DFMO (difluoromethylornithine) and DFMA (difluoromethylarginine), irreversible suicide inhibitors of ornithine and arginine decarboxylase activities (ODC and ADC) respectively, inhibit the growth of six species of Microsporum and six species of Trichophyton.	Eflornithine	0-4	antizyme inhibitor 2	Homo sapiens	115-137
3127398-4	1988	Tissue polyamine concentrations were more effectively depleted by combined treatment with D,L-alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, and N1,N4-bis-allenylputrescine, an inactivator of polyamine oxidase, than with either inhibitor alone.	Eflornithine	90-123	ornithine decarboxylase 1	Homo sapiens	154-177
3125950-2	1987	Subcellular fractionation showed the enzyme associated with the post-mitochondrial supernatant fraction in each of the tissues: Specific activities of ODC, defined as alpha-difluoromethylornithine (DFMO)-sensitive decarboxylation of ornithine, in the supernatant fractions of combined inner ear tissues were: guinea pig = 44 +/- 4 pmoles CO2 produced/hour/mg protein, and rat = 133 +/- 30.	Eflornithine	167-196	ornithine decarboxylase 1	Homo sapiens	151-154
3125950-2	1987	Subcellular fractionation showed the enzyme associated with the post-mitochondrial supernatant fraction in each of the tissues: Specific activities of ODC, defined as alpha-difluoromethylornithine (DFMO)-sensitive decarboxylation of ornithine, in the supernatant fractions of combined inner ear tissues were: guinea pig = 44 +/- 4 pmoles CO2 produced/hour/mg protein, and rat = 133 +/- 30.	Eflornithine	198-202	ornithine decarboxylase 1	Homo sapiens	151-154
3125950-6	1987	Since both the ODC-inhibitors, DFMO and neomycin, can cause hearing loss in patients and experimental animals it is suggested that inhibition of ODC may be an important factor in the ototoxicity of these drugs.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	15-18
3125950-6	1987	Since both the ODC-inhibitors, DFMO and neomycin, can cause hearing loss in patients and experimental animals it is suggested that inhibition of ODC may be an important factor in the ototoxicity of these drugs.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	145-148
3117792-4	1987	Only lysates from cells treated with alpha-difluoromethylornithine, to deplete endogenous polyamine pools, supported the formation of deoxyhypusine, suggesting that unmodified eIF-4D accumulated in spermidine deficient cells.	Eflornithine	37-66	eukaryotic translation initiation factor 5A	Homo sapiens	176-182
3122732-1	1987	We recently selected a variant mouse L1210 leukaemia-cell line overproducing ornithine decarboxylase (ODC) (EC 4.1.1.17) as a result of chronic exposure to 2-difluoromethylornithine (DFMO) in the presence of micromolar concentrations of cadaverine.	Eflornithine	156-181	ornithine decarboxylase, structural 1	Mus musculus	77-100
3122732-1	1987	We recently selected a variant mouse L1210 leukaemia-cell line overproducing ornithine decarboxylase (ODC) (EC 4.1.1.17) as a result of chronic exposure to 2-difluoromethylornithine (DFMO) in the presence of micromolar concentrations of cadaverine.	Eflornithine	156-181	ornithine decarboxylase, structural 1	Mus musculus	102-105
3122732-1	1987	We recently selected a variant mouse L1210 leukaemia-cell line overproducing ornithine decarboxylase (ODC) (EC 4.1.1.17) as a result of chronic exposure to 2-difluoromethylornithine (DFMO) in the presence of micromolar concentrations of cadaverine.	Eflornithine	183-187	ornithine decarboxylase, structural 1	Mus musculus	77-100
3122732-1	1987	We recently selected a variant mouse L1210 leukaemia-cell line overproducing ornithine decarboxylase (ODC) (EC 4.1.1.17) as a result of chronic exposure to 2-difluoromethylornithine (DFMO) in the presence of micromolar concentrations of cadaverine.	Eflornithine	183-187	ornithine decarboxylase, structural 1	Mus musculus	102-105
3115562-0	1987	Changes in the glutathione content of rat 9L cells induced by treatment with the ornithine decarboxylase inhibitor alpha-difluoromethylornithine.	Eflornithine	115-144	ornithine decarboxylase 1	Rattus norvegicus	81-104
3115562-1	1987	Treatment of 9L cells with the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) depletes cells of putrescine and spermidine and sensitizes cells to the cytotoxic effects of the alkylating agent 1,3-bis(2-chloroethyl)-1-nitrosourea.	Eflornithine	65-94	ornithine decarboxylase 1	Rattus norvegicus	31-54
3115562-1	1987	Treatment of 9L cells with the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) depletes cells of putrescine and spermidine and sensitizes cells to the cytotoxic effects of the alkylating agent 1,3-bis(2-chloroethyl)-1-nitrosourea.	Eflornithine	96-100	ornithine decarboxylase 1	Rattus norvegicus	31-54
3038303-1	1987	Difluoromethylornithine (DFMO), an enzyme activated irreversible inhibitor of ornithine decarboxylase (ODC), depletes intracellular putrescine, and spermidine (Spd), but not spermine, and generally leads to an inhibition of cell proliferation, without cell death, in both normal and neoplastic cells.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	78-101
3038303-1	1987	Difluoromethylornithine (DFMO), an enzyme activated irreversible inhibitor of ornithine decarboxylase (ODC), depletes intracellular putrescine, and spermidine (Spd), but not spermine, and generally leads to an inhibition of cell proliferation, without cell death, in both normal and neoplastic cells.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	103-106
3038303-1	1987	Difluoromethylornithine (DFMO), an enzyme activated irreversible inhibitor of ornithine decarboxylase (ODC), depletes intracellular putrescine, and spermidine (Spd), but not spermine, and generally leads to an inhibition of cell proliferation, without cell death, in both normal and neoplastic cells.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	78-101
3038303-1	1987	Difluoromethylornithine (DFMO), an enzyme activated irreversible inhibitor of ornithine decarboxylase (ODC), depletes intracellular putrescine, and spermidine (Spd), but not spermine, and generally leads to an inhibition of cell proliferation, without cell death, in both normal and neoplastic cells.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	103-106
3111681-13	1987	These data concur with the established molecular actions of the two enzyme inhibitors as blockers of ornithine decarboxylase (difluoromethylornithine) and spermidine synthase (dicyclohexylammonium sulfate).	Eflornithine	126-149	ornithine decarboxylase, structural 1	Mus musculus	101-124
3115786-1	1987	Alpha-difluoromethylornithine (DFMO) is an enzyme-activated, irreversible inhibitor of ornithine decarboxylase, the first enzyme in the synthesis of the polyamines putrescine, spermidine and spermine.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	87-110
3115786-1	1987	Alpha-difluoromethylornithine (DFMO) is an enzyme-activated, irreversible inhibitor of ornithine decarboxylase, the first enzyme in the synthesis of the polyamines putrescine, spermidine and spermine.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	87-110
3114562-2	1987	Treatment of MCF-7 cells with difluoromethylornithine (DFMO), the irreversible inhibitor of the enzyme ornithine decarboxylase (ODC), prevented estradiol-induced cell proliferation in a dose-dependent fashion.	Eflornithine	30-53	ornithine decarboxylase 1	Homo sapiens	103-126
3114562-2	1987	Treatment of MCF-7 cells with difluoromethylornithine (DFMO), the irreversible inhibitor of the enzyme ornithine decarboxylase (ODC), prevented estradiol-induced cell proliferation in a dose-dependent fashion.	Eflornithine	30-53	ornithine decarboxylase 1	Homo sapiens	128-131
3114562-2	1987	Treatment of MCF-7 cells with difluoromethylornithine (DFMO), the irreversible inhibitor of the enzyme ornithine decarboxylase (ODC), prevented estradiol-induced cell proliferation in a dose-dependent fashion.	Eflornithine	55-59	ornithine decarboxylase 1	Homo sapiens	103-126
3114562-2	1987	Treatment of MCF-7 cells with difluoromethylornithine (DFMO), the irreversible inhibitor of the enzyme ornithine decarboxylase (ODC), prevented estradiol-induced cell proliferation in a dose-dependent fashion.	Eflornithine	55-59	ornithine decarboxylase 1	Homo sapiens	128-131
3114562-4	1987	ODC activity was 4-fold greater in estrogen-treated cells and DFMO (5 mM) fully inhibited ODC activity.	Eflornithine	62-66	ornithine decarboxylase 1	Homo sapiens	90-93
3113732-4	1987	The cultures were treated with alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase, the first and rate-limiting enzyme in polyamine synthesis.	Eflornithine	31-60	ornithine decarboxylase	Gallus gallus	115-138
3113732-4	1987	The cultures were treated with alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase, the first and rate-limiting enzyme in polyamine synthesis.	Eflornithine	62-66	ornithine decarboxylase	Gallus gallus	115-138
3114026-2	1987	This stimulation of citric acid levels was not blocked by pretreatment of the animals with the ornithine decarboxylase (ODC) inhibitor, alpha-difluoromethyl ornithine (DFMO), suggesting that the prolactin induction of citric acid in this organ is not mediated through activation of the ODC.	Eflornithine	136-166	ornithine decarboxylase 1	Rattus norvegicus	120-123
3036823-10	1987	The lack of turnover of ornithine decarboxylase in trypanosomes may constitute the basis of selective antitrypanosomal action of the irreversible enzyme inhibitor DL-alpha-difluoromethylornithine.	Eflornithine	163-195	ornithine decarboxylase 1	Homo sapiens	24-47
3112598-3	1987	The addition of 2 mM difluoromethylornithine (DFMO; an inhibitor of ornithine decarboxylase) to the perifusion medium completely inhibited the response to all volleys of LHRH.	Eflornithine	21-44	ornithine decarboxylase 1	Rattus norvegicus	68-91
3112598-3	1987	The addition of 2 mM difluoromethylornithine (DFMO; an inhibitor of ornithine decarboxylase) to the perifusion medium completely inhibited the response to all volleys of LHRH.	Eflornithine	21-44	gonadotropin releasing hormone 1	Rattus norvegicus	170-174
3112598-3	1987	The addition of 2 mM difluoromethylornithine (DFMO; an inhibitor of ornithine decarboxylase) to the perifusion medium completely inhibited the response to all volleys of LHRH.	Eflornithine	46-50	ornithine decarboxylase 1	Rattus norvegicus	68-91
3112598-3	1987	The addition of 2 mM difluoromethylornithine (DFMO; an inhibitor of ornithine decarboxylase) to the perifusion medium completely inhibited the response to all volleys of LHRH.	Eflornithine	46-50	gonadotropin releasing hormone 1	Rattus norvegicus	170-174
3112598-7	1987	Unstimulated pituitary tissues showed constant low levels of carbon dioxide release during 5 h of incubation, but those given hourly volleys of LHRH showed progressively increasing release of radioactivity, which was blocked by the addition of DFMO.	Eflornithine	244-248	gonadotropin releasing hormone 1	Rattus norvegicus	144-148
2436752-0	1987	Altered expression of beta-globin, transferrin receptor, and ornithine decarboxylase in Friend murine erythroleukemia cells inhibited by alpha-difluoromethylornithine.	Eflornithine	137-166	hemoglobin beta chain complex	Mus musculus	22-33
2436752-0	1987	Altered expression of beta-globin, transferrin receptor, and ornithine decarboxylase in Friend murine erythroleukemia cells inhibited by alpha-difluoromethylornithine.	Eflornithine	137-166	transferrin receptor	Mus musculus	35-55
3036086-4	1987	It is possible that the amplification of ODC genes in Ehrlich ascites-carcinoma cells in response to 2-difluoromethylornithine (DFMO) was associated with hypomethylation, or that less-methylated genes were amplified.	Eflornithine	101-126	ornithine decarboxylase 1	Homo sapiens	41-44
3036086-4	1987	It is possible that the amplification of ODC genes in Ehrlich ascites-carcinoma cells in response to 2-difluoromethylornithine (DFMO) was associated with hypomethylation, or that less-methylated genes were amplified.	Eflornithine	128-132	ornithine decarboxylase 1	Homo sapiens	41-44
3100028-0	1987	Decarboxylated-S-adenosylmethionine excretion: a biochemical marker of ornithine decarboxylase inhibition by alpha-difluoromethylornithine.	Eflornithine	109-138	ornithine decarboxylase 1	Homo sapiens	71-94
3100897-2	1987	alpha-Difluoromethylornithine (DFMO), is a specific and irreversible inhibitor of ornithine decarboxylase (ODC); the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	82-105
3100897-2	1987	alpha-Difluoromethylornithine (DFMO), is a specific and irreversible inhibitor of ornithine decarboxylase (ODC); the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	107-110
3101980-2	1987	After preincubation of rat brain synaptosomes with 5 mM difluormethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, the K+-induced increase of [Ca2+]i was 33% less than that in non-treated synaptosomes.	Eflornithine	80-84	ornithine decarboxylase 1	Rattus norvegicus	116-139
3118650-6	1987	DFMO, a specific irreversible inhibitor of ODC, has been used extensively in studies which have shed light on the role of polyamines in cell proliferation and differentiation.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	43-46
3105526-0	1987	Decarboxylation of alpha-difluoromethylornithine by ornithine decarboxylase.	Eflornithine	19-48	ornithine decarboxylase 1	Homo sapiens	52-75
3105526-1	1987	The mechanism of inactivation of rodent ornithine decarboxylase by alpha-difluoromethylornithine (DFMO) was studied using the inhibitor labelled with 14C in both the 1 and the 5 positions.	Eflornithine	67-96	ornithine decarboxylase 1	Homo sapiens	40-63
3105526-1	1987	The mechanism of inactivation of rodent ornithine decarboxylase by alpha-difluoromethylornithine (DFMO) was studied using the inhibitor labelled with 14C in both the 1 and the 5 positions.	Eflornithine	98-102	ornithine decarboxylase 1	Homo sapiens	40-63
3105968-1	1987	Difluoromethylornithine (DFMO) is a nonreversible inhibitor of ornithine decarboxylase (ODC), the initial rate-limiting enzyme in the polyamine biosynthetic pathway.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	63-86
3105968-1	1987	Difluoromethylornithine (DFMO) is a nonreversible inhibitor of ornithine decarboxylase (ODC), the initial rate-limiting enzyme in the polyamine biosynthetic pathway.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	88-91
3105968-1	1987	Difluoromethylornithine (DFMO) is a nonreversible inhibitor of ornithine decarboxylase (ODC), the initial rate-limiting enzyme in the polyamine biosynthetic pathway.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	63-86
3105968-1	1987	Difluoromethylornithine (DFMO) is a nonreversible inhibitor of ornithine decarboxylase (ODC), the initial rate-limiting enzyme in the polyamine biosynthetic pathway.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	88-91
3105968-2	1987	When HL60 leukemic cells were incubated in the presence of concentrations of DFMO from 0.05 mM to 5 mM, there was a concentration-dependent inhibition of ODC activity apparent within 24 h. Likewise, cellular polyamine levels were reduced by the presence of DFMO in a concentration-dependent manner after 4 days.	Eflornithine	77-81	ornithine decarboxylase 1	Homo sapiens	154-157
3023035-7	1987	Addition of alpha-difluoromethylornithine, an irreversible inhibitor of ODC, blocked increases in both ODC activity and PA in cells stimulated with FSH or Bu2cAMP.	Eflornithine	12-41	ornithine decarboxylase 1	Rattus norvegicus	72-75
3023035-7	1987	Addition of alpha-difluoromethylornithine, an irreversible inhibitor of ODC, blocked increases in both ODC activity and PA in cells stimulated with FSH or Bu2cAMP.	Eflornithine	12-41	ornithine decarboxylase 1	Rattus norvegicus	103-106
3121452-2	1987	Polyamine synthesis is rate limited by ornithine decarboxylase (ODC) and ODC activity is specifically inhibited by -difluoromethyl ornithine (DFMO).	Eflornithine	115-140	ornithine decarboxylase 1	Rattus norvegicus	73-76
3121452-2	1987	Polyamine synthesis is rate limited by ornithine decarboxylase (ODC) and ODC activity is specifically inhibited by -difluoromethyl ornithine (DFMO).	Eflornithine	142-146	ornithine decarboxylase 1	Rattus norvegicus	73-76
3121456-9	1987	Difluoromethyl ornithine (DFMO) (1 mM), an irreversible inhibitor of ODC, inhibits cell growth from day 3 up to day 7.	Eflornithine	0-24	ornithine decarboxylase 1	Rattus norvegicus	69-72
3121456-9	1987	Difluoromethyl ornithine (DFMO) (1 mM), an irreversible inhibitor of ODC, inhibits cell growth from day 3 up to day 7.	Eflornithine	26-30	ornithine decarboxylase 1	Rattus norvegicus	69-72
3121457-7	1987	With administration of the specific inhibitor of ODC (difluoromethylornithine, DFMO) the increases in ODC and polyamines are suppressed, and intestinal adaptation is abrogated.	Eflornithine	54-77	ornithine decarboxylase 1	Homo sapiens	49-52
3121457-7	1987	With administration of the specific inhibitor of ODC (difluoromethylornithine, DFMO) the increases in ODC and polyamines are suppressed, and intestinal adaptation is abrogated.	Eflornithine	54-77	ornithine decarboxylase 1	Homo sapiens	102-105
3121457-7	1987	With administration of the specific inhibitor of ODC (difluoromethylornithine, DFMO) the increases in ODC and polyamines are suppressed, and intestinal adaptation is abrogated.	Eflornithine	79-83	ornithine decarboxylase 1	Homo sapiens	49-52
3121457-7	1987	With administration of the specific inhibitor of ODC (difluoromethylornithine, DFMO) the increases in ODC and polyamines are suppressed, and intestinal adaptation is abrogated.	Eflornithine	79-83	ornithine decarboxylase 1	Homo sapiens	102-105
3115911-1	1987	Eflornithine-HCl (alpha-difluoromethylornithine or DFMO), an irreversible inhibitor of ornithine decarboxylase, blocks polyamine synthesis and has demonstrated antitumor activity in cell culture and animal tumor models.	Eflornithine	0-16	ornithine decarboxylase 1	Homo sapiens	87-110
3115911-1	1987	Eflornithine-HCl (alpha-difluoromethylornithine or DFMO), an irreversible inhibitor of ornithine decarboxylase, blocks polyamine synthesis and has demonstrated antitumor activity in cell culture and animal tumor models.	Eflornithine	18-47	ornithine decarboxylase 1	Homo sapiens	87-110
3115911-1	1987	Eflornithine-HCl (alpha-difluoromethylornithine or DFMO), an irreversible inhibitor of ornithine decarboxylase, blocks polyamine synthesis and has demonstrated antitumor activity in cell culture and animal tumor models.	Eflornithine	51-55	ornithine decarboxylase 1	Homo sapiens	87-110
3117720-1	1987	alpha-Difluoromethylornithine (DFMO) is a known irreversible inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	74-97
3117720-1	1987	alpha-Difluoromethylornithine (DFMO) is a known irreversible inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	99-102
3117720-1	1987	alpha-Difluoromethylornithine (DFMO) is a known irreversible inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	74-97
3117720-1	1987	alpha-Difluoromethylornithine (DFMO) is a known irreversible inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	99-102
3114741-1	1987	The current study examines the effects of alpha-difluoromethylornithine (DFMO), an irreversible ornithine decarboxylase inhibitor, on pancreatic growth and development of rat neonates.	Eflornithine	42-71	ornithine decarboxylase 1	Rattus norvegicus	96-119
3114741-1	1987	The current study examines the effects of alpha-difluoromethylornithine (DFMO), an irreversible ornithine decarboxylase inhibitor, on pancreatic growth and development of rat neonates.	Eflornithine	73-77	ornithine decarboxylase 1	Rattus norvegicus	96-119
3116512-2	1987	Formation is dependent on the enzyme ornithine decarboxylase (ODC) which is irreversibly inhibited by alpha-difluoromethylornithine (DFMO).	Eflornithine	102-131	ornithine decarboxylase 1	Rattus norvegicus	37-60
3116512-2	1987	Formation is dependent on the enzyme ornithine decarboxylase (ODC) which is irreversibly inhibited by alpha-difluoromethylornithine (DFMO).	Eflornithine	102-131	ornithine decarboxylase 1	Rattus norvegicus	62-65
3116512-2	1987	Formation is dependent on the enzyme ornithine decarboxylase (ODC) which is irreversibly inhibited by alpha-difluoromethylornithine (DFMO).	Eflornithine	133-137	ornithine decarboxylase 1	Rattus norvegicus	37-60
3116512-2	1987	Formation is dependent on the enzyme ornithine decarboxylase (ODC) which is irreversibly inhibited by alpha-difluoromethylornithine (DFMO).	Eflornithine	133-137	ornithine decarboxylase 1	Rattus norvegicus	62-65
3096554-2	1986	Recently, insight into the role of ODC and thus into the physiology of polyamines has been gained by the use of an inhibitor of ODC, difluoromethylornithine (DFMO).	Eflornithine	133-156	ornithine decarboxylase, structural 1	Mus musculus	35-38
3096554-2	1986	Recently, insight into the role of ODC and thus into the physiology of polyamines has been gained by the use of an inhibitor of ODC, difluoromethylornithine (DFMO).	Eflornithine	133-156	ornithine decarboxylase, structural 1	Mus musculus	128-131
3096554-2	1986	Recently, insight into the role of ODC and thus into the physiology of polyamines has been gained by the use of an inhibitor of ODC, difluoromethylornithine (DFMO).	Eflornithine	158-162	ornithine decarboxylase, structural 1	Mus musculus	35-38
3096554-2	1986	Recently, insight into the role of ODC and thus into the physiology of polyamines has been gained by the use of an inhibitor of ODC, difluoromethylornithine (DFMO).	Eflornithine	158-162	ornithine decarboxylase, structural 1	Mus musculus	128-131
3096554-7	1986	Because of the apparent selectivity of the antimitotic activity of DFMO towards tumors, ODC inhibitors may prove to be useful anticancer drugs.	Eflornithine	67-71	ornithine decarboxylase, structural 1	Mus musculus	88-91
3096557-1	1986	alpha-Difluoromethylornithine (DFMO) and methyl acetylene putrescine (MAP) are inhibitors of the rate limiting enzyme in polyamine synthesis, ornithine decarboxylase.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	142-165
3096557-1	1986	alpha-Difluoromethylornithine (DFMO) and methyl acetylene putrescine (MAP) are inhibitors of the rate limiting enzyme in polyamine synthesis, ornithine decarboxylase.	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	142-165
3096559-2	1986	Treatment with DFMO together with rec-IFN-gamma synergistically inhibited KO-RCC-1 cell growth in monolayer culture and in soft agar.	Eflornithine	15-19	regulator of chromosome condensation 1	Homo sapiens	77-82
3096559-5	1986	The polyamine content in KO-RCC-1 cells was decreased to a greater extent by combined treatment with DFMO and rec-IFN-gamma than that in Bewo and HT-1197 cells.	Eflornithine	101-105	regulator of chromosome condensation 1	Homo sapiens	28-33
3096587-2	1986	The second objective of this work was to determine whether treatment with D,L-2-difluoromethylornithine (DFMO), a synthetic inhibitor of the enzyme ornithine decarboxylase, would reduce the occurrence of mammary cancers in tamoxifen-treated or ovariectomized rats.	Eflornithine	105-109	ornithine decarboxylase 1	Rattus norvegicus	148-171
3097421-9	1986	The ODC inhibitor alpha-difluoromethylornithine blocked the cryoinjury-induced changes in ODC, polyamines, fluorescein uptake, and capillary ultrastructure.	Eflornithine	18-47	ornithine decarboxylase 1	Rattus norvegicus	4-7
3097421-9	1986	The ODC inhibitor alpha-difluoromethylornithine blocked the cryoinjury-induced changes in ODC, polyamines, fluorescein uptake, and capillary ultrastructure.	Eflornithine	18-47	ornithine decarboxylase 1	Rattus norvegicus	90-93
3093066-1	1986	The objective of the present investigation was to examine the effect of in vivo polyamine depletion by DL-alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase, on cell-mediated tumoricidal activity in normal and tumor-bearing (B16 melanoma) mice.	Eflornithine	103-135	ornithine decarboxylase, structural 1	Mus musculus	181-204
3093066-1	1986	The objective of the present investigation was to examine the effect of in vivo polyamine depletion by DL-alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase, on cell-mediated tumoricidal activity in normal and tumor-bearing (B16 melanoma) mice.	Eflornithine	137-141	ornithine decarboxylase, structural 1	Mus musculus	181-204
3096943-6	1986	The specific irreversible ODC inhibitor, alpha-difluoromethylornithine, significantly reduced lung-ODC activity and putrescine and spermidine specific content; it also caused significant early reductions in lung DNA and protein content without simultaneously affecting body weight and appearance.	Eflornithine	41-70	ornithine decarboxylase 1	Rattus norvegicus	26-29
3096943-6	1986	The specific irreversible ODC inhibitor, alpha-difluoromethylornithine, significantly reduced lung-ODC activity and putrescine and spermidine specific content; it also caused significant early reductions in lung DNA and protein content without simultaneously affecting body weight and appearance.	Eflornithine	41-70	ornithine decarboxylase 1	Rattus norvegicus	99-102
3096321-3	1986	We report here that alpha-difluoromethylornithine, a specific enzyme-activated inhibitor of ornithine decarboxylase activity, can induce differentiation in human embryonal carcinoma cells.	Eflornithine	20-49	ornithine decarboxylase 1	Homo sapiens	92-115
3094378-4	1986	Inhibition of ODC with difluoromethylornithine lead to mucosal atrophy in ileum but not in duodenum.	Eflornithine	23-46	ornithine decarboxylase 1	Rattus norvegicus	14-17
3802047-1	1986	We previously demonstrated that repeated instillation of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), inhibits (or retards) urinary bladder carcinogenesis in rats.	Eflornithine	57-86	ornithine decarboxylase 1	Rattus norvegicus	124-147
3802047-1	1986	We previously demonstrated that repeated instillation of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), inhibits (or retards) urinary bladder carcinogenesis in rats.	Eflornithine	57-86	ornithine decarboxylase 1	Rattus norvegicus	149-152
3802047-1	1986	We previously demonstrated that repeated instillation of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), inhibits (or retards) urinary bladder carcinogenesis in rats.	Eflornithine	88-92	ornithine decarboxylase 1	Rattus norvegicus	124-147
3802047-1	1986	We previously demonstrated that repeated instillation of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), inhibits (or retards) urinary bladder carcinogenesis in rats.	Eflornithine	88-92	ornithine decarboxylase 1	Rattus norvegicus	149-152
3802047-2	1986	Since ODC catalyzes the first step in polyamine synthesis, the inhibition of polyamine formation may be responsible for tumor inhibition by DFMO.	Eflornithine	140-144	ornithine decarboxylase 1	Rattus norvegicus	6-9
3100403-4	1986	MNNG-induced tumours were inhibited by selenium or by difluoromethylornithine, an ornithine decarboxylase inhibitor.	Eflornithine	54-77	ornithine decarboxylase 1	Rattus norvegicus	82-105
2433364-1	1986	The effect of human interferon (IFN) and alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of eukaryotic ornithine decarboxylase, on the rate of DNA synthesis and the increase of ornithine decarboxylase activity of T47D cells was examined.	Eflornithine	41-70	ornithine decarboxylase 1	Homo sapiens	136-159
2433364-1	1986	The effect of human interferon (IFN) and alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of eukaryotic ornithine decarboxylase, on the rate of DNA synthesis and the increase of ornithine decarboxylase activity of T47D cells was examined.	Eflornithine	41-70	ornithine decarboxylase 1	Homo sapiens	210-233
2433364-1	1986	The effect of human interferon (IFN) and alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of eukaryotic ornithine decarboxylase, on the rate of DNA synthesis and the increase of ornithine decarboxylase activity of T47D cells was examined.	Eflornithine	72-76	ornithine decarboxylase 1	Homo sapiens	136-159
2433364-5	1986	The biological implication of IFN and DFMO is discussed with regard to the regulation of ornithine decarboxylase activity and the antiproliferative effects of the two drugs.	Eflornithine	38-42	ornithine decarboxylase 1	Homo sapiens	89-112
3095679-1	1986	The roles of ornithine decarboxylase and the polyamines in behavioral development were examined through the use of alpha-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase.	Eflornithine	115-144	ornithine decarboxylase 1	Homo sapiens	183-206
3095679-5	1986	Thus, the behavioral effects of alpha-difluoromethylornithine exposure are highly dependent upon the age at which the drug is administered, a finding in keeping with the participation of the ornithine decarboxylase/polyamine system in cell replication and differentiation during discrete periods of neural development.	Eflornithine	32-61	ornithine decarboxylase 1	Homo sapiens	191-214
3094839-4	1986	More recently, the replication of neuronal cells in developing brain has been shown to require the maintenance of polyamine levels and consequently, depletion of polyamines by alpha-difluoromethylornithine (DFMO, an ODC inhibitor) arrests brain cell maturation.	Eflornithine	176-205	ornithine decarboxylase 1	Homo sapiens	216-219
3094839-6	1986	Indeed, [3H]DFMO-autoradiographic localization of ODC in developing cerebellar lamina indicates high levels of activity associated with neuropil, areas of axonal outgrowth, and post-mitotic granule cells.	Eflornithine	12-16	ornithine decarboxylase 1	Homo sapiens	50-53
3090896-5	1986	In the ileum ODC activity increased dramatically in refed rats and was essentially eliminated in rats fed DFMO.	Eflornithine	106-110	ornithine decarboxylase 1	Rattus norvegicus	13-16
3015379-4	1986	L1210 murine leukemia and 8226 human myeloma cells were treated with alpha-difluoromethylornithine (DFMO) to reduce intracellular polyamine levels via inhibition of ornithine decarboxylase.	Eflornithine	69-98	ornithine decarboxylase 1	Homo sapiens	165-188
3015379-4	1986	L1210 murine leukemia and 8226 human myeloma cells were treated with alpha-difluoromethylornithine (DFMO) to reduce intracellular polyamine levels via inhibition of ornithine decarboxylase.	Eflornithine	100-104	ornithine decarboxylase 1	Homo sapiens	165-188
3023951-6	1986	Variants were selected for resistance to 0.1 mM difluoromethylornithine, an inhibitor of ODC, by either a single or a multistep process.	Eflornithine	48-71	ornithine decarboxylase, structural 1	Mus musculus	89-92
3091023-2	1986	Hormonal effects were measured in female mice maintained on the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO), which results in a 85-90% reduction of ODC enzyme levels and a depletion of putrescine concentrations in kidney.	Eflornithine	104-133	ornithine decarboxylase, structural 1	Mus musculus	64-87
3091023-2	1986	Hormonal effects were measured in female mice maintained on the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO), which results in a 85-90% reduction of ODC enzyme levels and a depletion of putrescine concentrations in kidney.	Eflornithine	104-133	ornithine decarboxylase, structural 1	Mus musculus	89-92
3091023-2	1986	Hormonal effects were measured in female mice maintained on the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO), which results in a 85-90% reduction of ODC enzyme levels and a depletion of putrescine concentrations in kidney.	Eflornithine	104-133	ornithine decarboxylase, structural 1	Mus musculus	181-184
3091023-2	1986	Hormonal effects were measured in female mice maintained on the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO), which results in a 85-90% reduction of ODC enzyme levels and a depletion of putrescine concentrations in kidney.	Eflornithine	135-139	ornithine decarboxylase, structural 1	Mus musculus	64-87
3091023-2	1986	Hormonal effects were measured in female mice maintained on the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO), which results in a 85-90% reduction of ODC enzyme levels and a depletion of putrescine concentrations in kidney.	Eflornithine	135-139	ornithine decarboxylase, structural 1	Mus musculus	89-92
3091023-2	1986	Hormonal effects were measured in female mice maintained on the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO), which results in a 85-90% reduction of ODC enzyme levels and a depletion of putrescine concentrations in kidney.	Eflornithine	135-139	ornithine decarboxylase, structural 1	Mus musculus	181-184
3087889-2	1986	CAL 18 A cells, derived from a breast carcinoma, were incubated with alpha-difluoromethylornithine (DFMO)--a specific and irreversible inhibitor of ornithine decarboxylase (ODC)--at a 1 mM or 10-mM concentration for either 1 hr or 24 hr and irradiated thereafter.	Eflornithine	69-98	ornithine decarboxylase 1	Homo sapiens	148-171
3087889-2	1986	CAL 18 A cells, derived from a breast carcinoma, were incubated with alpha-difluoromethylornithine (DFMO)--a specific and irreversible inhibitor of ornithine decarboxylase (ODC)--at a 1 mM or 10-mM concentration for either 1 hr or 24 hr and irradiated thereafter.	Eflornithine	69-98	ornithine decarboxylase 1	Homo sapiens	173-176
3087889-2	1986	CAL 18 A cells, derived from a breast carcinoma, were incubated with alpha-difluoromethylornithine (DFMO)--a specific and irreversible inhibitor of ornithine decarboxylase (ODC)--at a 1 mM or 10-mM concentration for either 1 hr or 24 hr and irradiated thereafter.	Eflornithine	100-104	ornithine decarboxylase 1	Homo sapiens	148-171
3087889-2	1986	CAL 18 A cells, derived from a breast carcinoma, were incubated with alpha-difluoromethylornithine (DFMO)--a specific and irreversible inhibitor of ornithine decarboxylase (ODC)--at a 1 mM or 10-mM concentration for either 1 hr or 24 hr and irradiated thereafter.	Eflornithine	100-104	ornithine decarboxylase 1	Homo sapiens	173-176
3087889-7	1986	Measurement of ODC indicated that this enzyme was markedly inactivated upon brief incubation of CAL 18 A cells with DFMO, reflecting a depletion of polyamine synthesis.	Eflornithine	116-120	ornithine decarboxylase 1	Homo sapiens	15-18
3085924-1	1986	alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, was examined as a single and combined agent in growth studies using P3J, a Burkitt"s lymphoma cell line.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	67-90
3085924-1	1986	alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, was examined as a single and combined agent in growth studies using P3J, a Burkitt"s lymphoma cell line.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	67-90
3934157-3	1985	Here we report that ornithine decarboxylase is regulated at the translational level by polyamines in difluoromethylornithine-resistant mouse myeloma cells that overproduce the enzyme due to amplification of an ornithine decarboxylase gene.	Eflornithine	101-124	ornithine decarboxylase, structural 1	Mus musculus	20-43
3934157-3	1985	Here we report that ornithine decarboxylase is regulated at the translational level by polyamines in difluoromethylornithine-resistant mouse myeloma cells that overproduce the enzyme due to amplification of an ornithine decarboxylase gene.	Eflornithine	101-124	ornithine decarboxylase, structural 1	Mus musculus	210-233
3935643-5	1985	Difluoromethylornithine (DFMO) and sodium molybdate had marked antiproliferative effects in HEC-50 cultures, reducing cell numbers to 10 to 20% of control values 11 d after plating and inhibiting ODC activity by approximately 80% on Day 7.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	196-199
3935643-5	1985	Difluoromethylornithine (DFMO) and sodium molybdate had marked antiproliferative effects in HEC-50 cultures, reducing cell numbers to 10 to 20% of control values 11 d after plating and inhibiting ODC activity by approximately 80% on Day 7.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	196-199
3935643-6	1985	The antiproliferative effect of DFMO, but not that of molybdate, was reversed by 10 microM putrescine, the product of ODC activity.	Eflornithine	32-36	ornithine decarboxylase 1	Homo sapiens	118-121
3935643-9	1985	These results indicate that ODC activity, present in both epithelial and stromal cells, as shown analytically and also by autoradiography after labeling with [3H]DFMO, may be related to cell proliferation in vivo and that proliferation of human endometrial cancer cells in culture can be arrested by DFMO and by molybdate.	Eflornithine	162-166	ornithine decarboxylase 1	Homo sapiens	28-31
3935643-9	1985	These results indicate that ODC activity, present in both epithelial and stromal cells, as shown analytically and also by autoradiography after labeling with [3H]DFMO, may be related to cell proliferation in vivo and that proliferation of human endometrial cancer cells in culture can be arrested by DFMO and by molybdate.	Eflornithine	300-304	ornithine decarboxylase 1	Homo sapiens	28-31
3931086-2	1985	At concentrations of 0.5 mM and above alpha-difluoromethyl ornithine (DFMO), which inhibits ornithine decarboxylase and the conversion of ornithine to putrescine, significantly attenuated the mitogenic effect of prolactin.	Eflornithine	38-68	ornithine decarboxylase 1	Homo sapiens	92-115
3931086-2	1985	At concentrations of 0.5 mM and above alpha-difluoromethyl ornithine (DFMO), which inhibits ornithine decarboxylase and the conversion of ornithine to putrescine, significantly attenuated the mitogenic effect of prolactin.	Eflornithine	38-68	prolactin	Homo sapiens	212-221
3931086-2	1985	At concentrations of 0.5 mM and above alpha-difluoromethyl ornithine (DFMO), which inhibits ornithine decarboxylase and the conversion of ornithine to putrescine, significantly attenuated the mitogenic effect of prolactin.	Eflornithine	70-74	ornithine decarboxylase 1	Homo sapiens	92-115
3931086-2	1985	At concentrations of 0.5 mM and above alpha-difluoromethyl ornithine (DFMO), which inhibits ornithine decarboxylase and the conversion of ornithine to putrescine, significantly attenuated the mitogenic effect of prolactin.	Eflornithine	70-74	prolactin	Homo sapiens	212-221
2998352-2	1985	alpha-Difluoromethylornithine, a specific inhibitor of ornithine decarboxylase, suppressed the isoproterenol-induced increase in submandibular polyamines and inhibited mucin secretion.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	55-78
2998352-2	1985	alpha-Difluoromethylornithine, a specific inhibitor of ornithine decarboxylase, suppressed the isoproterenol-induced increase in submandibular polyamines and inhibited mucin secretion.	Eflornithine	0-29	solute carrier family 13 member 2	Rattus norvegicus	168-173
2998352-3	1985	Exogenous putrescine restored tissue polyamine levels and partially reversed the inhibitory effect of alpha-difluoromethylornithine on mucin secretion.	Eflornithine	102-131	solute carrier family 13 member 2	Rattus norvegicus	135-140
3930296-4	1985	alpha-DFMO, an enzyme-activated irreversible inhibitor of ODC, does not react with the monomeric form and therefore the influence of substrate and salts on the aggregation equilibrium must be taken into account in titration experiments with alpha-DFMO of the total amount of ODC in tissue preparations.	Eflornithine	0-10	ornithine decarboxylase 1	Rattus norvegicus	58-61
3930296-4	1985	alpha-DFMO, an enzyme-activated irreversible inhibitor of ODC, does not react with the monomeric form and therefore the influence of substrate and salts on the aggregation equilibrium must be taken into account in titration experiments with alpha-DFMO of the total amount of ODC in tissue preparations.	Eflornithine	0-10	ornithine decarboxylase 1	Rattus norvegicus	275-278
3931300-1	1985	Previous work in our laboratory has shown that the continuous administration of alpha-difluoromethylornithine (DFMO), a highly specific irreversible inhibitor of ornithine decarboxylase (ODC), which is the rate-limiting enzyme in polyamine biosynthesis, prevented the development of pulmonary hypertension and right ventricular hypertrophy induced in rats 21 days after a single injection of monocrotaline (MCT).	Eflornithine	80-109	ornithine decarboxylase 1	Rattus norvegicus	162-185
3931300-1	1985	Previous work in our laboratory has shown that the continuous administration of alpha-difluoromethylornithine (DFMO), a highly specific irreversible inhibitor of ornithine decarboxylase (ODC), which is the rate-limiting enzyme in polyamine biosynthesis, prevented the development of pulmonary hypertension and right ventricular hypertrophy induced in rats 21 days after a single injection of monocrotaline (MCT).	Eflornithine	80-109	ornithine decarboxylase 1	Rattus norvegicus	187-190
3931300-1	1985	Previous work in our laboratory has shown that the continuous administration of alpha-difluoromethylornithine (DFMO), a highly specific irreversible inhibitor of ornithine decarboxylase (ODC), which is the rate-limiting enzyme in polyamine biosynthesis, prevented the development of pulmonary hypertension and right ventricular hypertrophy induced in rats 21 days after a single injection of monocrotaline (MCT).	Eflornithine	111-115	ornithine decarboxylase 1	Rattus norvegicus	162-185
3931300-1	1985	Previous work in our laboratory has shown that the continuous administration of alpha-difluoromethylornithine (DFMO), a highly specific irreversible inhibitor of ornithine decarboxylase (ODC), which is the rate-limiting enzyme in polyamine biosynthesis, prevented the development of pulmonary hypertension and right ventricular hypertrophy induced in rats 21 days after a single injection of monocrotaline (MCT).	Eflornithine	111-115	ornithine decarboxylase 1	Rattus norvegicus	187-190
2413987-1	1985	The in vitro effects of alpha-difluoromethyl ornithine (DFMO) on the growth and the secretion of alpha-fetoprotein (AFP) and albumin in human hepatoma cell line PLC/PRF/5 were studied.	Eflornithine	24-54	alpha fetoprotein	Homo sapiens	97-114
2413987-1	1985	The in vitro effects of alpha-difluoromethyl ornithine (DFMO) on the growth and the secretion of alpha-fetoprotein (AFP) and albumin in human hepatoma cell line PLC/PRF/5 were studied.	Eflornithine	24-54	alpha fetoprotein	Homo sapiens	116-119
2413987-1	1985	The in vitro effects of alpha-difluoromethyl ornithine (DFMO) on the growth and the secretion of alpha-fetoprotein (AFP) and albumin in human hepatoma cell line PLC/PRF/5 were studied.	Eflornithine	56-60	alpha fetoprotein	Homo sapiens	97-114
2413987-1	1985	The in vitro effects of alpha-difluoromethyl ornithine (DFMO) on the growth and the secretion of alpha-fetoprotein (AFP) and albumin in human hepatoma cell line PLC/PRF/5 were studied.	Eflornithine	56-60	alpha fetoprotein	Homo sapiens	116-119
2413987-1	1985	The in vitro effects of alpha-difluoromethyl ornithine (DFMO) on the growth and the secretion of alpha-fetoprotein (AFP) and albumin in human hepatoma cell line PLC/PRF/5 were studied.	Eflornithine	56-60	heparan sulfate proteoglycan 2	Homo sapiens	161-164
3931903-0	1985	Inhibition of ornithine decarboxylase activity by small doses of alpha-difluoromethylornithine.	Eflornithine	65-94	ornithine decarboxylase, structural 1	Mus musculus	14-37
3931903-3	1985	We studied the dose and dose schedule of alpha-difluoromethylornithine (DFMO), a suicide inhibitor of ODC, needed to effectively inhibit ODC activity in mice.	Eflornithine	41-70	ornithine decarboxylase, structural 1	Mus musculus	102-105
3931903-3	1985	We studied the dose and dose schedule of alpha-difluoromethylornithine (DFMO), a suicide inhibitor of ODC, needed to effectively inhibit ODC activity in mice.	Eflornithine	41-70	ornithine decarboxylase, structural 1	Mus musculus	137-140
3931903-3	1985	We studied the dose and dose schedule of alpha-difluoromethylornithine (DFMO), a suicide inhibitor of ODC, needed to effectively inhibit ODC activity in mice.	Eflornithine	72-76	ornithine decarboxylase, structural 1	Mus musculus	102-105
3931903-3	1985	We studied the dose and dose schedule of alpha-difluoromethylornithine (DFMO), a suicide inhibitor of ODC, needed to effectively inhibit ODC activity in mice.	Eflornithine	72-76	ornithine decarboxylase, structural 1	Mus musculus	137-140
3928149-1	1985	The objective of the present study was to investigate the effect of polyamine depletion by alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase, on the growth and differentiation of B16 melanoma cells grown in culture and also as solid tumors in mice.	Eflornithine	91-120	ornithine decarboxylase, structural 1	Mus musculus	166-189
3928149-1	1985	The objective of the present study was to investigate the effect of polyamine depletion by alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase, on the growth and differentiation of B16 melanoma cells grown in culture and also as solid tumors in mice.	Eflornithine	122-126	ornithine decarboxylase, structural 1	Mus musculus	166-189
3928149-6	1985	Administration of different doses of DFMO in drinking water to B16 melanoma tumor bearing mice also resulted in an increase in tyrosinase activity and a dose dependent inhibition (86-90%) of tumor growth.	Eflornithine	37-41	tyrosinase	Mus musculus	127-137
3930245-1	1985	alpha-Difluoromethylornithine (DFMO), a highly selective inhibitor of ornithine decarboxylase (ODC), induced terminal differentiation of F9 mouse embryonal carcinoma cells in culture.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	95-98
3930245-1	1985	alpha-Difluoromethylornithine (DFMO), a highly selective inhibitor of ornithine decarboxylase (ODC), induced terminal differentiation of F9 mouse embryonal carcinoma cells in culture.	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	70-93
3930245-1	1985	alpha-Difluoromethylornithine (DFMO), a highly selective inhibitor of ornithine decarboxylase (ODC), induced terminal differentiation of F9 mouse embryonal carcinoma cells in culture.	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	95-98
3926303-4	1985	The ornithine decarboxylase inhibitor alpha-difluoromethylornithine blocked the MTA-triggered accumulation of putrescine but not decarboxylated SAM.	Eflornithine	38-67	ornithine decarboxylase, structural 1	Mus musculus	4-27
2864658-0	1985	Postnatal development of brain alpha 1-adrenergic receptors: in vitro autoradiography with [125I]HEAT in normal rats and rats treated with alpha-difluoromethylornithine, a specific, irreversible inhibitor of ornithine decarboxylase.	Eflornithine	139-168	ornithine decarboxylase 1	Rattus norvegicus	208-231
2864658-6	1985	The two patterns could be distinguished by their sensitivity to alpha-difluoromethylornithine, a drug that inhibits ornithine decarboxylase, leading to a slowing of cellular replication, differentiation and migration.	Eflornithine	64-93	ornithine decarboxylase 1	Rattus norvegicus	116-139
3931214-9	1985	When polyamine synthesis is blocked with the ODC inhibitor difluoromethyl ornithine (DFMO), the adaptive intestinal hyperplasia of pancreaticobiliary diversion is either inhibited or completely prevented.	Eflornithine	59-83	ornithine decarboxylase 1	Homo sapiens	45-48
3931214-9	1985	When polyamine synthesis is blocked with the ODC inhibitor difluoromethyl ornithine (DFMO), the adaptive intestinal hyperplasia of pancreaticobiliary diversion is either inhibited or completely prevented.	Eflornithine	85-89	ornithine decarboxylase 1	Homo sapiens	45-48
2409817-4	1985	Rats were maintained on a liquid diet for 5 days and treated with difluoromethylornithine (DFMO, 200 mg/kg ip, 3 times/day), a selective, irreversible inhibitor of ODC, for 5 days.	Eflornithine	66-89	ornithine decarboxylase 1	Rattus norvegicus	164-167
2409817-4	1985	Rats were maintained on a liquid diet for 5 days and treated with difluoromethylornithine (DFMO, 200 mg/kg ip, 3 times/day), a selective, irreversible inhibitor of ODC, for 5 days.	Eflornithine	91-95	ornithine decarboxylase 1	Rattus norvegicus	164-167
3859699-7	1985	Increased ODC activity was the result of the increase in enzymatically active ODC protein, quantitated by a [3H]difluoromethylornithine-binding assay.	Eflornithine	112-135	ornithine decarboxylase 1	Homo sapiens	10-13
3859699-7	1985	Increased ODC activity was the result of the increase in enzymatically active ODC protein, quantitated by a [3H]difluoromethylornithine-binding assay.	Eflornithine	112-135	ornithine decarboxylase 1	Homo sapiens	78-81
3924051-0	1985	Potentiation by alpha-difluoromethylornithine of the activity of 3,4-dihydroxybenzylamine, a tyrosinase-dependent melanolytic agent, against B16 melanoma.	Eflornithine	16-45	tyrosinase	Mus musculus	93-103
3924051-1	1985	Continuous exposure for 96 hr of B16 melanoma cells in culture to 2.5 mM alpha-difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase, resulted in a marked increase in the activity of the enzyme tyrosinase, and also 20% cell kill as assessed by clonogenic assay.	Eflornithine	73-102	ornithine decarboxylase, structural 1	Mus musculus	152-175
3924051-1	1985	Continuous exposure for 96 hr of B16 melanoma cells in culture to 2.5 mM alpha-difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase, resulted in a marked increase in the activity of the enzyme tyrosinase, and also 20% cell kill as assessed by clonogenic assay.	Eflornithine	73-102	tyrosinase	Mus musculus	237-247
3924051-1	1985	Continuous exposure for 96 hr of B16 melanoma cells in culture to 2.5 mM alpha-difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase, resulted in a marked increase in the activity of the enzyme tyrosinase, and also 20% cell kill as assessed by clonogenic assay.	Eflornithine	104-108	ornithine decarboxylase, structural 1	Mus musculus	152-175
3924051-4	1985	This observed cytotoxicity with the combination suggests that induction of tyrosinase by DFMO sensitizes B16 melanoma cells to the melanolytic activity of DHBA.	Eflornithine	89-93	tyrosinase	Mus musculus	75-85
3924051-5	1985	Oral administration of DFMO to mice bearing subcutaneous B16 melanomas also resulted in marked increases in the activity of tyrosinase in the tumor tissue.	Eflornithine	23-27	tyrosinase	Mus musculus	124-134
3921243-5	1985	alpha-Difluoromethylornithine (DFMO, 0.1 mM), a specific inhibitor of ODC, blocked the estradiol-induced cell proliferation and ODC activity.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	70-73
3921243-5	1985	alpha-Difluoromethylornithine (DFMO, 0.1 mM), a specific inhibitor of ODC, blocked the estradiol-induced cell proliferation and ODC activity.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	128-131
3921243-5	1985	alpha-Difluoromethylornithine (DFMO, 0.1 mM), a specific inhibitor of ODC, blocked the estradiol-induced cell proliferation and ODC activity.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	70-73
3921243-5	1985	alpha-Difluoromethylornithine (DFMO, 0.1 mM), a specific inhibitor of ODC, blocked the estradiol-induced cell proliferation and ODC activity.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	128-131
3921243-9	1985	Hormone-responsive cells exhibited differential sensitivity to DFMO; resistant cell lines (e.g., MCF-7) were found to possess higher endogeneous levels of ODC than sensitive cell lines (e.g., T-47D and ZR-75-1).	Eflornithine	63-67	ornithine decarboxylase 1	Homo sapiens	155-158
3925242-4	1985	TPN + DFMO resulted in a higher plasma albumin level and lower tumor ODC activity compared with chow feeding or TPN.	Eflornithine	6-10	ornithine decarboxylase 1	Rattus norvegicus	69-72
3921237-1	1985	We have investigated the effect of pretreatment with the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) on the cytocidal efficacy of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a series of five cultured human adenocarcinoma cell lines.	Eflornithine	91-120	ornithine decarboxylase 1	Homo sapiens	57-80
3921237-1	1985	We have investigated the effect of pretreatment with the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) on the cytocidal efficacy of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a series of five cultured human adenocarcinoma cell lines.	Eflornithine	122-126	ornithine decarboxylase 1	Homo sapiens	57-80
3921237-11	1985	These results suggest that DFMO-induced chemosensitization to BCNU in the four cell lines other than ME-180 is a specific consequence of the inhibition of ornithine decarboxylase by DFMO and the resulting depletion of intracellular polyamine content.	Eflornithine	27-31	ornithine decarboxylase 1	Homo sapiens	155-178
3921237-11	1985	These results suggest that DFMO-induced chemosensitization to BCNU in the four cell lines other than ME-180 is a specific consequence of the inhibition of ornithine decarboxylase by DFMO and the resulting depletion of intracellular polyamine content.	Eflornithine	182-186	ornithine decarboxylase 1	Homo sapiens	155-178
2582110-1	1985	The addition of DL-alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, to human Plasmodium falciparum-infected red cells in continuous culture decreased both parasite growth and intracellular polyamine concentrations.	Eflornithine	16-48	ornithine decarboxylase 1	Homo sapiens	79-102
2582110-4	1985	Concentrations of DL-alpha-difluoromethylornithine greater than 0.3 mM decreased intracellular levels of putrescine and spermidine, reduced ornithine decarboxylase activity and inhibited growth and maturation of the intracellular parasite at the trophozoite stage.	Eflornithine	18-50	ornithine decarboxylase 1	Homo sapiens	140-163
3925368-1	1985	alpha-Difluoromethylornithine specifically and irreversibly inhibits the enzyme ornithine decarboxylase.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	80-103
2859859-6	1985	alpha-Difluoromethylornithine (alpha-DFMO), an irreversible inhibitor of ODC, given orally or subcutaneously, almost completely abolished the induction of ODC by APM or immobilization, and inhibited the increase of putrescine in both cases, but did not affect spermidine after APM.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	73-76
2859859-6	1985	alpha-Difluoromethylornithine (alpha-DFMO), an irreversible inhibitor of ODC, given orally or subcutaneously, almost completely abolished the induction of ODC by APM or immobilization, and inhibited the increase of putrescine in both cases, but did not affect spermidine after APM.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	155-158
2859859-6	1985	alpha-Difluoromethylornithine (alpha-DFMO), an irreversible inhibitor of ODC, given orally or subcutaneously, almost completely abolished the induction of ODC by APM or immobilization, and inhibited the increase of putrescine in both cases, but did not affect spermidine after APM.	Eflornithine	31-41	ornithine decarboxylase 1	Rattus norvegicus	73-76
2859859-6	1985	alpha-Difluoromethylornithine (alpha-DFMO), an irreversible inhibitor of ODC, given orally or subcutaneously, almost completely abolished the induction of ODC by APM or immobilization, and inhibited the increase of putrescine in both cases, but did not affect spermidine after APM.	Eflornithine	31-41	ornithine decarboxylase 1	Rattus norvegicus	155-158
3919940-2	1985	The stimulation of tyrosinase (EC 1.10.3.1) activity and melanin formation by DFMO was closely associated with intracellular depletion of putrescine and spermidine developed in response to the drug.	Eflornithine	78-82	tyrosinase	Mus musculus	19-29
3857388-3	1985	The effect of oPRL and oGH was blocked by alpha-difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase, the rate-limiting enzyme of polyamine biosynthesis.	Eflornithine	42-71	ornithine decarboxylase 1	Rattus norvegicus	103-126
3857388-3	1985	The effect of oPRL and oGH was blocked by alpha-difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase, the rate-limiting enzyme of polyamine biosynthesis.	Eflornithine	73-77	ornithine decarboxylase 1	Rattus norvegicus	103-126
3923382-5	1985	Pretreatment of the animals with D,L-alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase reduced both, polyamine turnover rate and the extent of putrescine reutilization.	Eflornithine	33-66	ornithine decarboxylase 1	Homo sapiens	97-120
3921019-2	1985	Pretreatment of cells with a specific ornithine decarboxylase inhibitor, DL-alpha-difluoromethyl-ornithine significantly inhibited the effect of the mitogen on DNA synthesis.	Eflornithine	73-106	ornithine decarboxylase 1	Homo sapiens	38-61
3925717-1	1985	In adult rats, the intracerebroventricular injection of alpha-difluoromethylornithine (DFMO), a polyamine antimetabolite which specifically inhibits ornithine-decarboxylase, induces a typical convulsive syndrome (ED50 = 100 micrograms/rat) and death (LD50 = 300 micrograms/rat).	Eflornithine	56-85	ornithine decarboxylase 1	Rattus norvegicus	149-172
3925717-1	1985	In adult rats, the intracerebroventricular injection of alpha-difluoromethylornithine (DFMO), a polyamine antimetabolite which specifically inhibits ornithine-decarboxylase, induces a typical convulsive syndrome (ED50 = 100 micrograms/rat) and death (LD50 = 300 micrograms/rat).	Eflornithine	87-91	ornithine decarboxylase 1	Rattus norvegicus	149-172
3917869-4	1985	DFMO effectively inhibited the growth of 804G cells stimulated by Fraction I or by 10% FCS, and the inhibition was associated with suppression of ODC activity and partial depletion of intracellular putrescine and spermidine.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	146-149
3934106-1	1985	Difluoromethylornithine (DFMO), a non-competitive inhibitor of ornithine decarboxylase (ODC), the rate limiting enzyme of the polyamine synthetic pathway was evaluated in a Phase I trial.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	63-86
3934106-1	1985	Difluoromethylornithine (DFMO), a non-competitive inhibitor of ornithine decarboxylase (ODC), the rate limiting enzyme of the polyamine synthetic pathway was evaluated in a Phase I trial.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	88-91
3934106-1	1985	Difluoromethylornithine (DFMO), a non-competitive inhibitor of ornithine decarboxylase (ODC), the rate limiting enzyme of the polyamine synthetic pathway was evaluated in a Phase I trial.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	63-86
3934106-1	1985	Difluoromethylornithine (DFMO), a non-competitive inhibitor of ornithine decarboxylase (ODC), the rate limiting enzyme of the polyamine synthetic pathway was evaluated in a Phase I trial.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	88-91
3917438-4	1985	Three different classes of embryonal carcinoma cell lines reflect differential changes in polyamine levels resulting from inhibition of ornithine decarboxylase enzyme activity by DFMO.	Eflornithine	179-183	ornithine decarboxylase, structural 1	Mus musculus	136-159
3934184-4	1985	Despite the fact that 1,3-diaminopropane and putrescine inhibited the ODC activity more effectively than did alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ODC, they were considerably less antiproliferative in action.	Eflornithine	109-138	ornithine decarboxylase, structural 1	Mus musculus	193-196
3934184-4	1985	Despite the fact that 1,3-diaminopropane and putrescine inhibited the ODC activity more effectively than did alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ODC, they were considerably less antiproliferative in action.	Eflornithine	140-144	ornithine decarboxylase, structural 1	Mus musculus	193-196
3923379-1	1985	Rats were treated with alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), at a dose of 200 mg/kg/day SC, either prenatally (to the mothers, on days 16 to 20 of gestation) or neonatally (to the pups, on days 1 to 10 after birth).	Eflornithine	23-52	ornithine decarboxylase 1	Rattus norvegicus	90-113
3923379-1	1985	Rats were treated with alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), at a dose of 200 mg/kg/day SC, either prenatally (to the mothers, on days 16 to 20 of gestation) or neonatally (to the pups, on days 1 to 10 after birth).	Eflornithine	23-52	ornithine decarboxylase 1	Rattus norvegicus	115-118
3923379-1	1985	Rats were treated with alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), at a dose of 200 mg/kg/day SC, either prenatally (to the mothers, on days 16 to 20 of gestation) or neonatally (to the pups, on days 1 to 10 after birth).	Eflornithine	54-58	ornithine decarboxylase 1	Rattus norvegicus	115-118
3923379-7	1985	ODC activity in brains of DFMO-exposed offspring was substantially inhibited throughout treatment (-72 to -41%, compared with respective controls), but showed a strong rebound after termination of treatment (up to +400%, compared with respective controls).	Eflornithine	26-30	ornithine decarboxylase 1	Rattus norvegicus	0-3
3133375-1	1988	We previously demonstrated that repeated intravesical instillation of DFMO, an irreversible inhibitor of ornithine decarboxylase, inhibits (or retards) urinary bladder carcinogenesis in rats.	Eflornithine	70-74	ornithine decarboxylase 1	Rattus norvegicus	105-128
3140600-1	1988	Both mouse interferon-beta (MuIFN-beta) and the inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethyl ornithine (DFMO), inhibited the differentiation of mouse 3T3-L1 fibroblasts into adipocytes in a dose-dependent manner.	Eflornithine	92-122	ornithine decarboxylase, structural 1	Mus musculus	61-84
3140600-1	1988	Both mouse interferon-beta (MuIFN-beta) and the inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethyl ornithine (DFMO), inhibited the differentiation of mouse 3T3-L1 fibroblasts into adipocytes in a dose-dependent manner.	Eflornithine	92-122	ornithine decarboxylase, structural 1	Mus musculus	86-89
3140600-1	1988	Both mouse interferon-beta (MuIFN-beta) and the inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethyl ornithine (DFMO), inhibited the differentiation of mouse 3T3-L1 fibroblasts into adipocytes in a dose-dependent manner.	Eflornithine	124-128	interferon beta 1, fibroblast	Mus musculus	11-26
3140600-1	1988	Both mouse interferon-beta (MuIFN-beta) and the inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethyl ornithine (DFMO), inhibited the differentiation of mouse 3T3-L1 fibroblasts into adipocytes in a dose-dependent manner.	Eflornithine	124-128	ornithine decarboxylase, structural 1	Mus musculus	61-84
3140600-1	1988	Both mouse interferon-beta (MuIFN-beta) and the inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethyl ornithine (DFMO), inhibited the differentiation of mouse 3T3-L1 fibroblasts into adipocytes in a dose-dependent manner.	Eflornithine	124-128	ornithine decarboxylase, structural 1	Mus musculus	86-89
3125429-3	1988	High performance liquid chromatography analysis of methionine cycle intermediates in cells from untreated rats and from rats treated with the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine (DFMO) indicated that the inhibitor causes pronounced changes in concentrations of these intermediates and dramatically alters the methylation index of the cell.	Eflornithine	176-208	ornithine decarboxylase 1	Rattus norvegicus	142-165
3125429-3	1988	High performance liquid chromatography analysis of methionine cycle intermediates in cells from untreated rats and from rats treated with the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine (DFMO) indicated that the inhibitor causes pronounced changes in concentrations of these intermediates and dramatically alters the methylation index of the cell.	Eflornithine	210-214	ornithine decarboxylase 1	Rattus norvegicus	142-165
3131785-5	1988	injection of 50 mgkg-1) and of alpha-di fluoromethylornithine (DFMO) (100 mgkg-1 every 12 h for 7 consecutive days) caused a 62.5% inhibition of ventricular ODC activity, and a significant decrease of the ventricular content of putrescine and spermidine (-59.5%, and -40.1%, respectively).	Eflornithine	31-61	ornithine decarboxylase 1	Rattus norvegicus	157-160
3131785-5	1988	injection of 50 mgkg-1) and of alpha-di fluoromethylornithine (DFMO) (100 mgkg-1 every 12 h for 7 consecutive days) caused a 62.5% inhibition of ventricular ODC activity, and a significant decrease of the ventricular content of putrescine and spermidine (-59.5%, and -40.1%, respectively).	Eflornithine	63-67	ornithine decarboxylase 1	Rattus norvegicus	157-160
2824033-1	1987	The effects of alpha-difluoromethylornithine (DFMO), an ornithine analogue which is an ornithine decarboxylase inhibitor, on the actions of the topoisomerase II-reactive agents 4"-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide (VP-16) were investigated in 2 murine L1210 leukemia lines and 2 human HL-60 leukemia lines.	Eflornithine	15-44	ornithine decarboxylase, structural 1	Mus musculus	87-110
3119414-2	1987	DFMO is an irreversible inhibitor of ornithine decarboxylase (ODC), the initial enzyme in the production of polyamines.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	37-60
3119414-2	1987	DFMO is an irreversible inhibitor of ornithine decarboxylase (ODC), the initial enzyme in the production of polyamines.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	62-65
3119414-12	1987	Protein synthesis and ornithine decarboxylase activity in the skin were both significantly decreased by DFMO.	Eflornithine	104-108	ornithine decarboxylase 1	Rattus norvegicus	22-45
3129415-1	1987	DL-alpha-Difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase [EC 4.1.1.17] (ODC), inhibited concanavalin A-induced proliferation of splenic mononuclear cells (SMNC).	Eflornithine	0-32	ornithine decarboxylase 1	Homo sapiens	104-107
3129415-1	1987	DL-alpha-Difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase [EC 4.1.1.17] (ODC), inhibited concanavalin A-induced proliferation of splenic mononuclear cells (SMNC).	Eflornithine	34-38	ornithine decarboxylase 1	Homo sapiens	104-107
3117796-8	1987	Inhibition of ornithine decarboxylase by 5 mM difluoromethylornithine completely abolished glycolytic enzyme induction.	Eflornithine	46-69	ornithine decarboxylase 1	Rattus norvegicus	14-37
3117718-2	1987	Difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase, was administered as a 2% aqueous solution in the drinking water.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	69-92
3117718-2	1987	Difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase, was administered as a 2% aqueous solution in the drinking water.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	69-92
3119663-5	1987	alpha-Difluoromethylornithine (DFMO), a specific suicide inhibitor of ODC, suppressed the calcium reperfusion-induced increase in polyamines and the concomitant increase in myocardial cellular 45Ca influx, loss of contractility, release of cytosolic enzymes, myoglobin, and protein, and structural lesions.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	70-73
3119663-5	1987	alpha-Difluoromethylornithine (DFMO), a specific suicide inhibitor of ODC, suppressed the calcium reperfusion-induced increase in polyamines and the concomitant increase in myocardial cellular 45Ca influx, loss of contractility, release of cytosolic enzymes, myoglobin, and protein, and structural lesions.	Eflornithine	0-29	myoglobin	Rattus norvegicus	259-268
3119663-5	1987	alpha-Difluoromethylornithine (DFMO), a specific suicide inhibitor of ODC, suppressed the calcium reperfusion-induced increase in polyamines and the concomitant increase in myocardial cellular 45Ca influx, loss of contractility, release of cytosolic enzymes, myoglobin, and protein, and structural lesions.	Eflornithine	31-35	ornithine decarboxylase 1	Rattus norvegicus	70-73
3119663-5	1987	alpha-Difluoromethylornithine (DFMO), a specific suicide inhibitor of ODC, suppressed the calcium reperfusion-induced increase in polyamines and the concomitant increase in myocardial cellular 45Ca influx, loss of contractility, release of cytosolic enzymes, myoglobin, and protein, and structural lesions.	Eflornithine	31-35	myoglobin	Rattus norvegicus	259-268
3119663-6	1987	Putrescine, the product of ODC activity, nullified DFMO inhibition and restored the calcium reperfusion-induced increment in polyamines and the full expression of the calcium paradox.	Eflornithine	51-55	ornithine decarboxylase 1	Rattus norvegicus	27-30
3115898-6	1987	That the effects of DFMO on the macrophages probably resulted from a reduction in polyamine levels caused by inhibition of ornithine decarboxylase was indicated by the fact that these effects were not seen when the macrophages were incubated with DFMO in the presence of putrescine, the product of ornithine decarboxylation by ornithine decarboxylase.	Eflornithine	20-24	ornithine decarboxylase, structural 1	Mus musculus	123-146
3115898-6	1987	That the effects of DFMO on the macrophages probably resulted from a reduction in polyamine levels caused by inhibition of ornithine decarboxylase was indicated by the fact that these effects were not seen when the macrophages were incubated with DFMO in the presence of putrescine, the product of ornithine decarboxylation by ornithine decarboxylase.	Eflornithine	20-24	ornithine decarboxylase, structural 1	Mus musculus	327-350
3109985-9	1987	Stimulation of GAG synthesis was significantly inhibited by the administration of 5 mM DFMO (an irreversible inhibitor of ODC), indicating that the marked increase in GAG production was dependent, in part, on the induction of ODC activity by EGF and PGE2.	Eflornithine	87-91	ornithine decarboxylase, structural 1	Mus musculus	122-125
3109985-9	1987	Stimulation of GAG synthesis was significantly inhibited by the administration of 5 mM DFMO (an irreversible inhibitor of ODC), indicating that the marked increase in GAG production was dependent, in part, on the induction of ODC activity by EGF and PGE2.	Eflornithine	87-91	ornithine decarboxylase, structural 1	Mus musculus	226-229
3109985-9	1987	Stimulation of GAG synthesis was significantly inhibited by the administration of 5 mM DFMO (an irreversible inhibitor of ODC), indicating that the marked increase in GAG production was dependent, in part, on the induction of ODC activity by EGF and PGE2.	Eflornithine	87-91	epidermal growth factor	Mus musculus	242-245
3111804-9	1987	DFMO-treated weanling rats showed less than 5% of ornithine decarboxylase (ODC) activity when compared to age-matched control animals.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	50-73
3111804-9	1987	DFMO-treated weanling rats showed less than 5% of ornithine decarboxylase (ODC) activity when compared to age-matched control animals.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	75-78
3111804-10	1987	The effects observed on the small intestinal mucosa are presumably due to inhibition of ornithine decarboxylase activities by DFMO which prevents the proliferation, regeneration, and maturation of epithelial cells.	Eflornithine	126-130	ornithine decarboxylase 1	Rattus norvegicus	88-111
3111273-6	1987	DNA, RNA, and protein content were decreased by 3.4 M NaCl, and these decreases were much greater if ODC was inhibited by pretreatment with alpha-difluoromethylornithine (DFMO).	Eflornithine	140-169	ornithine decarboxylase 1	Rattus norvegicus	101-104
3111273-6	1987	DNA, RNA, and protein content were decreased by 3.4 M NaCl, and these decreases were much greater if ODC was inhibited by pretreatment with alpha-difluoromethylornithine (DFMO).	Eflornithine	171-175	ornithine decarboxylase 1	Rattus norvegicus	101-104
3111477-1	1987	We investigated the cytotoxic effects of nitrosoureas with and without a 42-hr preincubation with the ornithine decarboxylase (EC 4.1.1.17) inhibitor alpha-difluoromethylornithine (DFMO, 1 mM) in a MER+ (methylation excision repair positive) human cell line.	Eflornithine	150-179	ornithine decarboxylase 1	Homo sapiens	102-125
2436752-0	1987	Altered expression of beta-globin, transferrin receptor, and ornithine decarboxylase in Friend murine erythroleukemia cells inhibited by alpha-difluoromethylornithine.	Eflornithine	137-166	ornithine decarboxylase, structural 1	Mus musculus	61-84
2436752-1	1987	alpha-Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC) and restricts the proliferation and differentiation of Friend murine erythroleukemia cells.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	69-92
2436752-1	1987	alpha-Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC) and restricts the proliferation and differentiation of Friend murine erythroleukemia cells.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	94-97
2436752-1	1987	alpha-Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC) and restricts the proliferation and differentiation of Friend murine erythroleukemia cells.	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	69-92
2436752-1	1987	alpha-Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC) and restricts the proliferation and differentiation of Friend murine erythroleukemia cells.	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	94-97
2436752-4	1987	However, in the presence of DFMO the levels of ODC remained elevated even when the cells had stopped dividing; this appears to be a feedback mechanism to overcome the effects of the inhibitor.	Eflornithine	28-32	ornithine decarboxylase, structural 1	Mus musculus	47-50
2436752-5	1987	TFR expression paralleled regular cell division and was curtailed when replication was reduced by DFMO.	Eflornithine	98-102	transferrin receptor	Mus musculus	0-3
3105898-3	1987	Polyamine depletion was achieved utilizing the specific irreversible inhibitor of ornithine decarboxylase (ODC), DL-alpha-difluoromethylornithine (DFMO).	Eflornithine	113-145	ornithine decarboxylase 1	Homo sapiens	82-105
3105898-3	1987	Polyamine depletion was achieved utilizing the specific irreversible inhibitor of ornithine decarboxylase (ODC), DL-alpha-difluoromethylornithine (DFMO).	Eflornithine	147-151	ornithine decarboxylase 1	Homo sapiens	82-105
3106075-4	1987	The rise in enzyme activity was blocked by actinomycin D and cycloheximide, suggesting control at the transcriptional and translational levels, alpha-Difluoromethylornithine (DFMO), a catalytic and irreversible inhibitor of ODC, prevented the appearance of enzyme activity.	Eflornithine	144-173	ornithine decarboxylase 1	Homo sapiens	224-227
3106075-4	1987	The rise in enzyme activity was blocked by actinomycin D and cycloheximide, suggesting control at the transcriptional and translational levels, alpha-Difluoromethylornithine (DFMO), a catalytic and irreversible inhibitor of ODC, prevented the appearance of enzyme activity.	Eflornithine	175-179	ornithine decarboxylase 1	Homo sapiens	224-227
3107550-1	1987	An exposure of a human myeloma cell line to 2-difluoromethylornithine the mechanism-based inhibitor of ornithine decarboxylase (EC 4.1.1.17), resulted in a selection of tumor cells readily growing in the presence of 4 mM difluoromethylornithine, a concentration that swiftly halted the growth of the parental cells.	Eflornithine	44-69	ornithine decarboxylase 1	Homo sapiens	103-126
3107550-1	1987	An exposure of a human myeloma cell line to 2-difluoromethylornithine the mechanism-based inhibitor of ornithine decarboxylase (EC 4.1.1.17), resulted in a selection of tumor cells readily growing in the presence of 4 mM difluoromethylornithine, a concentration that swiftly halted the growth of the parental cells.	Eflornithine	46-69	ornithine decarboxylase 1	Homo sapiens	103-126
3105330-8	1987	DFMO significantly reduced ODC activity at every age except 40 days, where there was no difference from control values.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	27-30
3102048-1	1987	The antiproliferative effects of the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) are limited by the inability of the compound to deplete completely cellular polyamine pools.	Eflornithine	71-100	ornithine decarboxylase, structural 1	Mus musculus	37-60
3102048-1	1987	The antiproliferative effects of the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) are limited by the inability of the compound to deplete completely cellular polyamine pools.	Eflornithine	102-106	ornithine decarboxylase, structural 1	Mus musculus	37-60
3102048-4	1987	It therefore seemed possible that DFMO and MeSAdo could interact synergistically to inhibit polyamine synthesis in MeSAdo phosphorylase-deficient malignant cells.	Eflornithine	34-38	methylthioadenosine phosphorylase	Homo sapiens	115-135
3102050-11	1987	Although normal host tissue weights were not affected by treatment with DFMO, the putrescine and spermidine levels of liver, spleen, and kidney and ornithine decarboxylase activity of the liver and kidney were decreased.	Eflornithine	72-76	ornithine decarboxylase 1	Rattus norvegicus	148-171
3110101-0	1987	The effect of alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on mitogen-induced interleukin 2 production.	Eflornithine	14-43	interleukin 2	Mus musculus	104-117
3110101-1	1987	The objective of the present investigation was to examine the effect of DL-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, on mitogen-induced interleukin 2 production.	Eflornithine	72-104	ornithine decarboxylase, structural 1	Mus musculus	142-165
3110101-1	1987	The objective of the present investigation was to examine the effect of DL-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, on mitogen-induced interleukin 2 production.	Eflornithine	72-104	interleukin 2	Mus musculus	186-199
3110101-1	1987	The objective of the present investigation was to examine the effect of DL-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, on mitogen-induced interleukin 2 production.	Eflornithine	106-110	ornithine decarboxylase, structural 1	Mus musculus	142-165
3110101-1	1987	The objective of the present investigation was to examine the effect of DL-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, on mitogen-induced interleukin 2 production.	Eflornithine	106-110	interleukin 2	Mus musculus	186-199
3110101-3	1987	In contrast, DFMO treatment enhanced, greater than two-fold, detectable levels of concanavalin A-induced interleukin 2 activity.	Eflornithine	13-17	interleukin 2	Mus musculus	105-118
3110101-4	1987	This observed augmentation was not limited to in vitro DFMO treatment, since oral administration of DFMO to C57BL/6 mice also enhanced concanavalin A-induced interleukin 2 levels in vitro.	Eflornithine	100-104	interleukin 2	Mus musculus	158-171
3110101-5	1987	Treatment with exogenous putrescine reversed the effect of DFMO on interleukin 2 levels.	Eflornithine	59-63	interleukin 2	Mus musculus	67-80
3110101-6	1987	These results suggest that the effect of DFMO on interleukin 2 levels is mediated through polyamines.	Eflornithine	41-45	interleukin 2	Mus musculus	49-62
3106317-1	1987	A difference was observed in the effect of difluoromethlyornithine (DFMO), a specific inhibitor of ornithine decarboxylase, on human and murine granulocyte-macrophage precursor cell (CFU-C) proliferation in vitro, in the presence of fetal bovine serum (FBS) and horse serum (HS).	Eflornithine	68-72	ornithine decarboxylase 1	Homo sapiens	99-122
3106317-4	1987	The importance of DAO in the assessment of polyamine effects is also suggested by decreased colony formation in cultures containing HS and DFMO only after the addition of this enzyme.	Eflornithine	139-143	amine oxidase copper containing 1	Homo sapiens	18-21
3108836-1	1987	Alpha-difluoromethylornithine (DFMO) is a specific irreversible inhibitor of ornithine-decarboxylase (ODC), key enzyme in the biosynthesis of polyamines, physiological compounds involved in cell multiplication.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	77-100
3108836-1	1987	Alpha-difluoromethylornithine (DFMO) is a specific irreversible inhibitor of ornithine-decarboxylase (ODC), key enzyme in the biosynthesis of polyamines, physiological compounds involved in cell multiplication.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	102-105
3108836-1	1987	Alpha-difluoromethylornithine (DFMO) is a specific irreversible inhibitor of ornithine-decarboxylase (ODC), key enzyme in the biosynthesis of polyamines, physiological compounds involved in cell multiplication.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	77-100
3108836-1	1987	Alpha-difluoromethylornithine (DFMO) is a specific irreversible inhibitor of ornithine-decarboxylase (ODC), key enzyme in the biosynthesis of polyamines, physiological compounds involved in cell multiplication.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	102-105
3109315-0	1987	Increased survival of CD1 mice bearing dimethylhydrazine induced primary colon and anal cancers by difluoromethylornithine with concomitant increase in angiosarcoma incidence.	Eflornithine	99-122	CD1 antigen complex	Mus musculus	22-25
3102080-2	1987	In this regard, we have utilized alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC.	Eflornithine	33-62	ornithine decarboxylase 1	Homo sapiens	100-103
3102080-2	1987	In this regard, we have utilized alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC.	Eflornithine	64-68	ornithine decarboxylase 1	Homo sapiens	100-103
3102080-3	1987	DFMO treatment completely abrogated Con A-induced NW T-cell ODC activity.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	60-63
3109382-0	1987	Human myeloma cells acquire resistance to difluoromethylornithine by amplification of ornithine decarboxylase gene.	Eflornithine	42-65	ornithine decarboxylase 1	Homo sapiens	86-109
3109382-1	1987	Stepwise increments of the concentration of 2-difluoromethylornithine (DFMO), a mechanism-based irreversible inhibitor of mammalian ornithine decarboxylase (ODC), resulted in a selection of cultured human IgG-myeloma cells (Sultan cell line) capable of growing in the presence of up to 3 mM-DFMO.	Eflornithine	44-69	ornithine decarboxylase 1	Homo sapiens	132-155
3109382-1	1987	Stepwise increments of the concentration of 2-difluoromethylornithine (DFMO), a mechanism-based irreversible inhibitor of mammalian ornithine decarboxylase (ODC), resulted in a selection of cultured human IgG-myeloma cells (Sultan cell line) capable of growing in the presence of up to 3 mM-DFMO.	Eflornithine	44-69	ornithine decarboxylase 1	Homo sapiens	157-160
3109382-1	1987	Stepwise increments of the concentration of 2-difluoromethylornithine (DFMO), a mechanism-based irreversible inhibitor of mammalian ornithine decarboxylase (ODC), resulted in a selection of cultured human IgG-myeloma cells (Sultan cell line) capable of growing in the presence of up to 3 mM-DFMO.	Eflornithine	71-75	ornithine decarboxylase 1	Homo sapiens	132-155
3109382-1	1987	Stepwise increments of the concentration of 2-difluoromethylornithine (DFMO), a mechanism-based irreversible inhibitor of mammalian ornithine decarboxylase (ODC), resulted in a selection of cultured human IgG-myeloma cells (Sultan cell line) capable of growing in the presence of up to 3 mM-DFMO.	Eflornithine	71-75	ornithine decarboxylase 1	Homo sapiens	157-160
3109383-1	1987	DL-alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, prevented the increases in putrescine and spermidine, but not in spermine, in human erythrocytes infected with the malarial parasite Plasmodium falciparum.	Eflornithine	0-32	ornithine decarboxylase 1	Homo sapiens	70-93
3109383-1	1987	DL-alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, prevented the increases in putrescine and spermidine, but not in spermine, in human erythrocytes infected with the malarial parasite Plasmodium falciparum.	Eflornithine	34-38	ornithine decarboxylase 1	Homo sapiens	70-93
3104728-1	1987	Copenhagen rats with implanted metastatic prostate carcinomas have been treated with the drug alpha-difluoromethylornithine (DFMO), an inhibitor of the enzyme ornithine decarboxylase.	Eflornithine	94-123	ornithine decarboxylase 1	Rattus norvegicus	159-182
3104728-1	1987	Copenhagen rats with implanted metastatic prostate carcinomas have been treated with the drug alpha-difluoromethylornithine (DFMO), an inhibitor of the enzyme ornithine decarboxylase.	Eflornithine	125-129	ornithine decarboxylase 1	Rattus norvegicus	159-182
3100897-2	1987	alpha-Difluoromethylornithine (DFMO), is a specific and irreversible inhibitor of ornithine decarboxylase (ODC); the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	82-105
3100897-2	1987	alpha-Difluoromethylornithine (DFMO), is a specific and irreversible inhibitor of ornithine decarboxylase (ODC); the rate-limiting enzyme in polyamine biosynthesis.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	107-110
2427159-1	1986	Difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC; 200-800 mg/kg, s.c.), to rats has no detectable behavioral effects using a battery of tests to assess sensorimotor function.	Eflornithine	0-23	ornithine decarboxylase 1	Rattus norvegicus	48-71
2427159-1	1986	Difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC; 200-800 mg/kg, s.c.), to rats has no detectable behavioral effects using a battery of tests to assess sensorimotor function.	Eflornithine	0-23	ornithine decarboxylase 1	Rattus norvegicus	73-76
2427159-1	1986	Difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC; 200-800 mg/kg, s.c.), to rats has no detectable behavioral effects using a battery of tests to assess sensorimotor function.	Eflornithine	25-29	ornithine decarboxylase 1	Rattus norvegicus	48-71
3089220-1	1986	alpha-Difluoromethylornithine (DFMO) has been widely used for determining the amounts of ornithine decarboxylase (ODC) in cells.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	89-112
3089220-1	1986	alpha-Difluoromethylornithine (DFMO) has been widely used for determining the amounts of ornithine decarboxylase (ODC) in cells.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	114-117
3089220-1	1986	alpha-Difluoromethylornithine (DFMO) has been widely used for determining the amounts of ornithine decarboxylase (ODC) in cells.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	89-112
3089220-1	1986	alpha-Difluoromethylornithine (DFMO) has been widely used for determining the amounts of ornithine decarboxylase (ODC) in cells.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	114-117
3011686-6	1986	On the other hand, an inhibitor of ODC, DFMO, the protein kinase inhibitors, the calmodulin inhibitor and retinoic acid suppressed TPA-induced HTLV-I p19 expression but did not suppress multinucleated cell formation.	Eflornithine	40-44	interleukin 23 subunit alpha	Homo sapiens	150-153
3085964-9	1986	The retinoid and DFMO preclude TPA-increased ornithine decarboxylase (ODC) activity and the accumulation of putrescine by differential effects on ODC, an enzyme associated with skin tumor promotion by TPA.	Eflornithine	17-21	ornithine decarboxylase, structural 1	Mus musculus	45-68
3085964-9	1986	The retinoid and DFMO preclude TPA-increased ornithine decarboxylase (ODC) activity and the accumulation of putrescine by differential effects on ODC, an enzyme associated with skin tumor promotion by TPA.	Eflornithine	17-21	ornithine decarboxylase, structural 1	Mus musculus	70-73
3085964-9	1986	The retinoid and DFMO preclude TPA-increased ornithine decarboxylase (ODC) activity and the accumulation of putrescine by differential effects on ODC, an enzyme associated with skin tumor promotion by TPA.	Eflornithine	17-21	ornithine decarboxylase, structural 1	Mus musculus	146-149
3091371-1	1986	Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, and human leukocyte interferon (IFN-alpha) have synergistic anti-tumor activities in vivo in B 16 melanoma and in vitro against several human cancer cell lines.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	61-84
3091371-1	1986	Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, and human leukocyte interferon (IFN-alpha) have synergistic anti-tumor activities in vivo in B 16 melanoma and in vitro against several human cancer cell lines.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	61-84
3086160-6	1986	Experiments performed with DFMO, a specific and irreversible inhibitor of ODC, show that this compound can prevent the stimulation of growth by oestradiol and that this may be overcome by the addition of putrescine to the cells.	Eflornithine	27-31	ornithine decarboxylase 1	Homo sapiens	74-77
2424111-0	1986	Inhibition of ileal and colonic ornithine decarboxylase activity by alpha-difluoromethylornithine in rats: transient atrophic changes and loss of postresectional adaptive growth.	Eflornithine	68-97	ornithine decarboxylase 1	Rattus norvegicus	32-55
2424111-1	1986	To determine the role of putrescine synthesis in adaptive hyperplasia of the ileum and colon, DL-alpha-difluoromethylornithine (DFMO), an enzyme-activated, irreversible inhibitor of ornithine decarboxylase (ODC), the enzyme controlling putrescine biosynthesis, was fed to rats after excision of the proximal half of the small bowel.	Eflornithine	128-132	ornithine decarboxylase 1	Rattus norvegicus	182-205
2424111-3	1986	Inclusion of 1% DFMO (2.1 gm/kg/day) in drinking water for 12 hours before operation and for 14 days thereafter decreased ODC activity by 85% to 96%, reduced levels of putrescine and spermidine and measurements of the adaptive response by 50% in the ileum, and abolished the adaptive response in the colon.	Eflornithine	16-20	ornithine decarboxylase 1	Rattus norvegicus	122-125
3087389-4	1986	However, prolonged suppression of ODC activity by DL-alpha-difluoromethylornithine (DFMO) (200 microM) attenuated the growth of Nb2 cells (50-60% inhibition), indicating that normal cell growth was dependent on ODC and polyamine biosynthesis.	Eflornithine	50-82	ornithine decarboxylase 1	Homo sapiens	34-37
3087389-4	1986	However, prolonged suppression of ODC activity by DL-alpha-difluoromethylornithine (DFMO) (200 microM) attenuated the growth of Nb2 cells (50-60% inhibition), indicating that normal cell growth was dependent on ODC and polyamine biosynthesis.	Eflornithine	84-88	ornithine decarboxylase 1	Homo sapiens	34-37
3087389-4	1986	However, prolonged suppression of ODC activity by DL-alpha-difluoromethylornithine (DFMO) (200 microM) attenuated the growth of Nb2 cells (50-60% inhibition), indicating that normal cell growth was dependent on ODC and polyamine biosynthesis.	Eflornithine	84-88	ornithine decarboxylase 1	Homo sapiens	211-214
3084121-5	1986	Whereas the mammary tumors of DFMO-treated rats had reduced ODC activity and lower polyamine concentrations in comparison to the tumors of untreated animals, tamoxifen had no effect on these parameters independent of its effect on tumor growth status.	Eflornithine	30-34	ornithine decarboxylase 1	Rattus norvegicus	60-63
3082705-3	1986	The specific ODC inhibitor, alpha-difluoromethylornithine was given as a 3% oral solution (5.4 g/kg X day intake) to hepatectomized rats as well as sham-operated controls.	Eflornithine	28-57	ornithine decarboxylase 1	Rattus norvegicus	13-16
3082705-4	1986	alpha-Difluoromethylornithine had no effect other than inhibition of the low basal levels of ODC in sham-operated rats, but it markedly inhibited increases in ODC by 85% in hepatectomized rats.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	159-162
3082705-5	1986	alpha-Difluoromethylornithine reduced hepatic deoxyribonucleic acid synthesis by 61%, protein synthesis by 46%, and liver weight increased by 83%, showing that alpha-difluoromethylornithine inhibition of ODC inhibits liver regeneration.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	204-207
3082705-5	1986	alpha-Difluoromethylornithine reduced hepatic deoxyribonucleic acid synthesis by 61%, protein synthesis by 46%, and liver weight increased by 83%, showing that alpha-difluoromethylornithine inhibition of ODC inhibits liver regeneration.	Eflornithine	160-189	ornithine decarboxylase 1	Rattus norvegicus	204-207
3082705-8	1986	In rats given alpha-difluoromethylornithine, putrescine markedly reversed the inhibitory effect of alpha-difluoromethylornithine on ODC (83%), deoxyribonucleic acid synthesis (94%), protein synthesis (95%), and liver regeneration (85%).	Eflornithine	99-128	ornithine decarboxylase 1	Rattus norvegicus	132-135
3009500-2	1986	It was found that these triamines did lead to a restoration of growth in cells in which spermidine content had been depleted by exposure to the ornithine decarboxylase inhibitor 2-difluoromethylornithine.	Eflornithine	178-203	ornithine decarboxylase, structural 1	Mus musculus	144-167
3083692-3	1986	In 19-day pregnant rats DL-alpha-difluoromethylornithine treatment inhibited the expression of enhanced ODC activity occurring normally at this stage of pregnancy.	Eflornithine	24-56	ornithine decarboxylase 1	Rattus norvegicus	104-107
3004707-4	1986	Moreover, in the spectrum of human lung carcinoma cells in culture, the SCC cells respond in a cytotoxic manner to DFMO, whereas the non-small cell lung carcinoma (non-SCC) cells, which are anchorage dependent, show only growth inhibition, without actual cell loss.	Eflornithine	115-119	serpin family B member 3	Homo sapiens	72-75
3004707-6	1986	Two non-SCC lung cancer cell lines, which normally grow as anchorage-dependent monolayers, show growth inhibition but no cell loss with the addition of DFMO.	Eflornithine	152-156	serpin family B member 3	Homo sapiens	8-11
3093095-6	1986	Treatment with D,L-alpha-difluoromethylornithine X HCl X H2O (DFMO), a specific irreversible inhibitor of ODC activity, completely abrogated lymphokine-dependent ODC induction in both the CTLL-20 and FDC-P1 cell lines.	Eflornithine	62-66	ornithine decarboxylase, structural 1	Mus musculus	106-109
3093095-6	1986	Treatment with D,L-alpha-difluoromethylornithine X HCl X H2O (DFMO), a specific irreversible inhibitor of ODC activity, completely abrogated lymphokine-dependent ODC induction in both the CTLL-20 and FDC-P1 cell lines.	Eflornithine	62-66	ornithine decarboxylase, structural 1	Mus musculus	162-165
3093095-8	1986	DFMO treatment reduced both IL-2- and IL-3-dependent proliferation in a dose-dependent manner.	Eflornithine	0-4	interleukin 2	Mus musculus	28-42
3757919-4	1986	The inhibition of ornithine decarboxylase activity in SC 115 by injecting alpha-difluoromethylornithine did not affect the enhancement of RNA polymerase I activity by androgen, showing independent elevation of the levels of the two enzymes by androgen.	Eflornithine	74-103	ornithine decarboxylase, structural 1	Mus musculus	18-41
3082276-3	1986	In 1978 alpha-difluoromethylornithine (DFMO), a powerful inhibitor of ornithine decarboxylase, the rate limiting enzyme in polyamine synthesis, was synthesized by Metcalf.	Eflornithine	8-37	ornithine decarboxylase 1	Homo sapiens	70-93
3082276-3	1986	In 1978 alpha-difluoromethylornithine (DFMO), a powerful inhibitor of ornithine decarboxylase, the rate limiting enzyme in polyamine synthesis, was synthesized by Metcalf.	Eflornithine	39-43	ornithine decarboxylase 1	Homo sapiens	70-93
3008983-1	1986	The intracisternal injection of either all-trans-retinoic acid or [alpha]-difluoromethylornithine (DFMO) into the brain of 9-day-old mice blocked (greater than 90%) phorbol ester-induced ornithine decarboxylase (ODC, EC 4.1.1.17) activity in a concentration-dependent fashion; this inhibition was not evident with the use of the biologically impotent furyl analog of retinoic acid.	Eflornithine	66-97	ornithine decarboxylase, structural 1	Mus musculus	187-210
3008983-1	1986	The intracisternal injection of either all-trans-retinoic acid or [alpha]-difluoromethylornithine (DFMO) into the brain of 9-day-old mice blocked (greater than 90%) phorbol ester-induced ornithine decarboxylase (ODC, EC 4.1.1.17) activity in a concentration-dependent fashion; this inhibition was not evident with the use of the biologically impotent furyl analog of retinoic acid.	Eflornithine	66-97	ornithine decarboxylase, structural 1	Mus musculus	212-215
3008983-1	1986	The intracisternal injection of either all-trans-retinoic acid or [alpha]-difluoromethylornithine (DFMO) into the brain of 9-day-old mice blocked (greater than 90%) phorbol ester-induced ornithine decarboxylase (ODC, EC 4.1.1.17) activity in a concentration-dependent fashion; this inhibition was not evident with the use of the biologically impotent furyl analog of retinoic acid.	Eflornithine	99-103	ornithine decarboxylase, structural 1	Mus musculus	187-210
3008983-1	1986	The intracisternal injection of either all-trans-retinoic acid or [alpha]-difluoromethylornithine (DFMO) into the brain of 9-day-old mice blocked (greater than 90%) phorbol ester-induced ornithine decarboxylase (ODC, EC 4.1.1.17) activity in a concentration-dependent fashion; this inhibition was not evident with the use of the biologically impotent furyl analog of retinoic acid.	Eflornithine	99-103	ornithine decarboxylase, structural 1	Mus musculus	212-215
3080230-1	1986	We compared L-phenylalanine mustard (L-PAM)-induced cytotoxicity and DNA cross-linking with and without a 42-h preincubation with the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO, 1 mM) in a human lymphoma cell line.	Eflornithine	168-197	ornithine decarboxylase 1	Homo sapiens	134-157
3080235-1	1986	We have studied the effect of pretreatment with difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, on the cytocidal responses of four human adenocarcinoma cell lines to Adriamycin (ADR).	Eflornithine	48-71	ornithine decarboxylase 1	Homo sapiens	83-106
3080235-1	1986	We have studied the effect of pretreatment with difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, on the cytocidal responses of four human adenocarcinoma cell lines to Adriamycin (ADR).	Eflornithine	73-77	ornithine decarboxylase 1	Homo sapiens	83-106
2422585-0	1986	Effects of alpha-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase, on nucleic acids and proteins in developing rat brain: critical perinatal periods for regional selectivity.	Eflornithine	11-40	ornithine decarboxylase 1	Rattus norvegicus	79-102
2422585-1	1986	Ornithine decarboxylase and its metabolic products, the polyamines, are known to coordinate macromolecule synthesis in developing neural tissues; consequently, inhibition of this enzyme by alpha-difluoromethylornithine interferes with cellular replication and differentiation.	Eflornithine	189-218	ornithine decarboxylase 1	Rattus norvegicus	0-23
3004454-0	1986	Human lung tumor sensitivity to difluoromethylornithine as related to ornithine decarboxylase messenger RNA levels.	Eflornithine	32-55	ornithine decarboxylase 1	Homo sapiens	70-93
3006760-3	1986	The acetylation of decarboxylated S-adenosylmethionine occurred in vivo in SV-3T3 cells exposed to the ornithine decarboxylase inhibitor 2-(difluoromethyl)ornithine.	Eflornithine	137-164	ornithine decarboxylase, structural 1	Mus musculus	103-126
3080004-6	1986	Similarly, the methyl and the ethyl esters of (E)-2-(fluoromethyl)dehydroornithine used at 10 times lower doses are as effective as the parent amino acid and as DFMO at inhibiting ODC in the ventral prostate of rat, 6 hr after oral administration.	Eflornithine	161-165	ornithine decarboxylase 1	Rattus norvegicus	180-183
3754136-10	1986	The inhibitors of ODC, 1,3-diaminopropane and alpha-difluoromethylornithine, were able to inhibit the induction of the enzyme, without affecting the induction of haem oxygenase by Co2+.	Eflornithine	46-75	ornithine decarboxylase 1	Rattus norvegicus	18-21
3098011-0	1986	The effect of alpha-difluoromethylornithine on ornithine decarboxylase activity in compensatory growth of mouse lung.	Eflornithine	14-43	ornithine decarboxylase, structural 1	Mus musculus	47-70
3098011-3	1986	The effect of alpha-difluoromethylornithine was studied on the ornithine decarboxylase (E.C.4.1.1.17.)	Eflornithine	14-43	ornithine decarboxylase, structural 1	Mus musculus	63-86
3098011-5	1986	Although a single injection of alpha-difluoromethylornithine inhibited ornithine decarboxylase activity, the compensatory growth of lung still occurred in spite of continuous alpha-difluoromethylornithine treatment.	Eflornithine	31-60	ornithine decarboxylase, structural 1	Mus musculus	71-94
3084110-1	1986	We investigated the effect of pretreatment with difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, on the cytocidal responses of four human adenocarcinoma cell lines to two alkylating and crosslinking agents: chlorambucil and N,N",N"-triethylenethiophosphoramide (thiotepa).	Eflornithine	48-71	ornithine decarboxylase 1	Homo sapiens	83-106
3084110-1	1986	We investigated the effect of pretreatment with difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, on the cytocidal responses of four human adenocarcinoma cell lines to two alkylating and crosslinking agents: chlorambucil and N,N",N"-triethylenethiophosphoramide (thiotepa).	Eflornithine	73-77	ornithine decarboxylase 1	Homo sapiens	83-106
3087732-1	1986	The inhibitory effect of difluoromethylornithine (DFMO) synthesized by the authors on the activity of the ornithine decarboxylase (ODC) and proliferation of microbial and mammalian cells in vitro was studied.	Eflornithine	25-48	ornithine decarboxylase 1	Homo sapiens	106-129
3087732-1	1986	The inhibitory effect of difluoromethylornithine (DFMO) synthesized by the authors on the activity of the ornithine decarboxylase (ODC) and proliferation of microbial and mammalian cells in vitro was studied.	Eflornithine	25-48	ornithine decarboxylase 1	Homo sapiens	131-134
3087732-1	1986	The inhibitory effect of difluoromethylornithine (DFMO) synthesized by the authors on the activity of the ornithine decarboxylase (ODC) and proliferation of microbial and mammalian cells in vitro was studied.	Eflornithine	50-54	ornithine decarboxylase 1	Homo sapiens	106-129
3087732-1	1986	The inhibitory effect of difluoromethylornithine (DFMO) synthesized by the authors on the activity of the ornithine decarboxylase (ODC) and proliferation of microbial and mammalian cells in vitro was studied.	Eflornithine	50-54	ornithine decarboxylase 1	Homo sapiens	131-134
3079592-2	1986	On the contrary, conditions are described, where inhibition of the ODC activity with alpha-difluoromethyl ornithine (DFMO) stimulated the induced differentiation.	Eflornithine	85-115	ornithine decarboxylase, structural 1	Mus musculus	67-70
3079592-2	1986	On the contrary, conditions are described, where inhibition of the ODC activity with alpha-difluoromethyl ornithine (DFMO) stimulated the induced differentiation.	Eflornithine	117-121	ornithine decarboxylase, structural 1	Mus musculus	67-70
3082689-2	1986	Inhibiting the ornithine decarboxylase (ODC) activity DFMO depleted putrescine and spermidine to 30-50 and 50-60%, respectively, and increased spermine to 25-60% compared with the controls, when given as 2% solution in drinking water of the tumor-bearing animals.	Eflornithine	54-58	ornithine decarboxylase, structural 1	Mus musculus	15-38
3082689-2	1986	Inhibiting the ornithine decarboxylase (ODC) activity DFMO depleted putrescine and spermidine to 30-50 and 50-60%, respectively, and increased spermine to 25-60% compared with the controls, when given as 2% solution in drinking water of the tumor-bearing animals.	Eflornithine	54-58	ornithine decarboxylase, structural 1	Mus musculus	40-43
3084872-3	1986	alpha-Difluoromethylornithine (DFMO), a specific inhibitor of ODC, blocked the estradiol-induced cell proliferation and ODC activity.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	62-65
3084872-3	1986	alpha-Difluoromethylornithine (DFMO), a specific inhibitor of ODC, blocked the estradiol-induced cell proliferation and ODC activity.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	120-123
3084872-3	1986	alpha-Difluoromethylornithine (DFMO), a specific inhibitor of ODC, blocked the estradiol-induced cell proliferation and ODC activity.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	62-65
3084872-3	1986	alpha-Difluoromethylornithine (DFMO), a specific inhibitor of ODC, blocked the estradiol-induced cell proliferation and ODC activity.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	120-123
3084872-4	1986	Exogenous addition of putrescine, the natural product of ODC, rescued the inhibitory effect of DFMO.	Eflornithine	95-99	ornithine decarboxylase 1	Homo sapiens	57-60
3106959-3	1986	Difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC) that produces antiproliferative effects by polyamine depletion, was combined with the cytotoxic agent doxorubicin (DOX) in vitro.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	56-79
3106959-3	1986	Difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC) that produces antiproliferative effects by polyamine depletion, was combined with the cytotoxic agent doxorubicin (DOX) in vitro.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	81-84
3106959-3	1986	Difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC) that produces antiproliferative effects by polyamine depletion, was combined with the cytotoxic agent doxorubicin (DOX) in vitro.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	56-79
3787115-7	1986	The HTB system has been demonstrated to be useful for other investigations; for example, alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ODC, when instilled repeatedly to the bladder lumen, inhibited tumorigenesis in HTBs.	Eflornithine	89-118	ornithine decarboxylase 1	Rattus norvegicus	166-169
2867766-2	1985	The ornithine decarboxylase inhibitor alpha-difluoromethylornithine blocked the K+-stimulated increase in enzyme activity and polyamines and also suppressed the increase in 45Ca2+ influx and efflux and the Ca2+-dependent release of GABA and norepinephrine.	Eflornithine	38-67	ornithine decarboxylase 1	Rattus norvegicus	4-27
3936139-4	1985	Adult male rats were given a subcutaneous injection of either 105 mg/kg monocrotaline or its vehicle and were treated concurrently with either alpha-difluoromethylornithine (DFMO), a specific, irreversible inhibitor of ODC, or saline.	Eflornithine	174-178	ornithine decarboxylase 1	Rattus norvegicus	219-222
3932087-8	1985	DFMO inhibited both CSF-induced proliferation and differentiation of myeloblasts, but had no effect on TPA-induced differentiation.	Eflornithine	0-4	colony stimulating factor 2	Homo sapiens	20-23
3931682-3	1985	Both the crude and the purified enzyme preparations are inactivated irreversibly by alpha-difluoromethylornithine, a suicide inhibitor of mammalian ornithine decarboxylase.	Eflornithine	84-113	ornithine decarboxylase 1	Homo sapiens	148-171
3930245-1	1985	alpha-Difluoromethylornithine (DFMO), a highly selective inhibitor of ornithine decarboxylase (ODC), induced terminal differentiation of F9 mouse embryonal carcinoma cells in culture.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	70-93
3919709-1	1985	A new method was developed for the assay of ornithine decarboxylase (ODC)-antizyme complex, in which alpha-difluoromethylornithine (DFMO)-inactivated ODC was used to release active ODC competitively from the complex.	Eflornithine	101-130	ornithine decarboxylase 1	Homo sapiens	44-67
3919709-1	1985	A new method was developed for the assay of ornithine decarboxylase (ODC)-antizyme complex, in which alpha-difluoromethylornithine (DFMO)-inactivated ODC was used to release active ODC competitively from the complex.	Eflornithine	132-136	ornithine decarboxylase 1	Homo sapiens	44-67
2983688-0	1985	Difluoromethylornithine-induced amplification of ornithine decarboxylase genes in Ehrlich ascites carcinoma cells.	Eflornithine	0-23	ornithine decarboxylase, structural 1	Mus musculus	49-72
2983688-1	1985	Stepwise increments of the concentration of 2-difluoromethylornithine, a mechanism-based irreversible inhibitor of mammalian ornithine decarboxylase (EC 4.1.1.17), resulted in a selection of cultured Ehrlich ascites carcinoma cells capable of growing in the presence of up to 50 mM difluoromethylornithine.	Eflornithine	44-69	ornithine decarboxylase 1	Homo sapiens	125-148
2983688-1	1985	Stepwise increments of the concentration of 2-difluoromethylornithine, a mechanism-based irreversible inhibitor of mammalian ornithine decarboxylase (EC 4.1.1.17), resulted in a selection of cultured Ehrlich ascites carcinoma cells capable of growing in the presence of up to 50 mM difluoromethylornithine.	Eflornithine	46-69	ornithine decarboxylase 1	Homo sapiens	125-148
2983688-4	1985	The overproduction of ornithine decarboxylase by the tumor cells grown under the pressure of difluoromethylornithine was at least partly attributable to a 10 to 20-fold increase in the total gene dosage of ornithine decarboxylase involving an amplification of several genes of the gene family.	Eflornithine	93-116	ornithine decarboxylase, structural 1	Mus musculus	22-45
2983688-4	1985	The overproduction of ornithine decarboxylase by the tumor cells grown under the pressure of difluoromethylornithine was at least partly attributable to a 10 to 20-fold increase in the total gene dosage of ornithine decarboxylase involving an amplification of several genes of the gene family.	Eflornithine	93-116	ornithine decarboxylase, structural 1	Mus musculus	206-229
2983688-6	1985	The overproduction of ornithine decarboxylase was accompanied by an enhanced resistance of the enzyme towards difluoromethylornithine in vitro.	Eflornithine	110-133	ornithine decarboxylase, structural 1	Mus musculus	22-45
3918535-2	1985	Ornithine decarboxylase from Paju was resistant to inhibition in vitro by difluoromethylornithine, and required 10 microM of the compound for 50% inhibition, whereas ornithine decarboxylase from SH-SY5Y cells (another human neuroblastoma) and from rat liver needed only 0.5 microM difluoromethylornithine.	Eflornithine	74-97	ornithine decarboxylase 1	Homo sapiens	0-23
3918535-2	1985	Ornithine decarboxylase from Paju was resistant to inhibition in vitro by difluoromethylornithine, and required 10 microM of the compound for 50% inhibition, whereas ornithine decarboxylase from SH-SY5Y cells (another human neuroblastoma) and from rat liver needed only 0.5 microM difluoromethylornithine.	Eflornithine	281-304	ornithine decarboxylase 1	Homo sapiens	0-23
3918535-11	1985	These results suggest that Paju ornithine decarboxylase has an altered molecular conformation, rendering it resistant to (i) difluoromethylornithine and (ii) proteolytic degradation both in vivo and in vitro.	Eflornithine	125-148	ornithine decarboxylase 1	Homo sapiens	32-55
3939097-1	1985	Specific, irreversible, inhibition of ODC activity with DFMO and resultant low levels of intracellular polyamines markedly suppress the induction of experimental colonic and mammary cancers and hold promise for augmenting the multidrug chemotherapy of established colonic, pancreatic, renal and mammary cancers without increasing systemic toxicity.	Eflornithine	56-60	ornithine decarboxylase 1	Homo sapiens	38-41
3917400-1	1985	Murine embryonal carcinoma F9 cells can be induced to differentiate by 2-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC).	Eflornithine	71-96	ornithine decarboxylase, structural 1	Mus musculus	134-157
3917400-1	1985	Murine embryonal carcinoma F9 cells can be induced to differentiate by 2-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC).	Eflornithine	71-96	ornithine decarboxylase, structural 1	Mus musculus	159-162
3917400-1	1985	Murine embryonal carcinoma F9 cells can be induced to differentiate by 2-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC).	Eflornithine	98-102	ornithine decarboxylase, structural 1	Mus musculus	134-157
3917400-1	1985	Murine embryonal carcinoma F9 cells can be induced to differentiate by 2-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC).	Eflornithine	98-102	ornithine decarboxylase, structural 1	Mus musculus	159-162
3917400-4	1985	Both DFMO and RA reduce ornithine decarboxylase activity, polyamine levels and inhibit cell proliferation of F9 cells.	Eflornithine	5-9	ornithine decarboxylase, structural 1	Mus musculus	24-47
11539696-2	1985	DL-alpha-Difluoromethylornithine (DFMO) and DL-alpha-difluoromethylarginine (DFMA), specific, irreversible ("suicide") inhibitors of ODC and ADC in vitro, were used to modulate PA biosynthesis in excised flowers.	Eflornithine	0-32	ornithine decarboxylase	Nicotiana tabacum	133-136
11539696-4	1985	In vivo inhibition of ODC with DFMO resulted in a significant decrease in PA titers, ovary fresh weight and protein content.	Eflornithine	31-35	ornithine decarboxylase	Nicotiana tabacum	22-25
11539696-5	1985	Simultaneous inhibition of both decarboxylases by DFMO and DFMA produced only a marginally greater depression in growth and PA titers, indicating that ODC activity is rate-limiting for PA biosynthesis in these tissues.	Eflornithine	50-54	ornithine decarboxylase	Nicotiana tabacum	151-154
11539696-7	1985	In vivo inhibition of ODC by DFMA appears to result from arginase-mediated hydrolysis of this inhibitor to urea and DFMO, the suicide substrate for ODC.	Eflornithine	116-120	ornithine decarboxylase	Nicotiana tabacum	22-25
11539696-7	1985	In vivo inhibition of ODC by DFMA appears to result from arginase-mediated hydrolysis of this inhibitor to urea and DFMO, the suicide substrate for ODC.	Eflornithine	116-120	ornithine decarboxylase	Nicotiana tabacum	148-151
3925543-8	1985	When polyamine synthesis is blocked with the ODC inhibitor, difluoromethyl ornithine (DFMO), the adaptive intestinal hyperplasia of pancreatico-biliary diversion is either inhibited or completely prevented.	Eflornithine	60-84	ornithine decarboxylase 1	Homo sapiens	45-48
3925543-8	1985	When polyamine synthesis is blocked with the ODC inhibitor, difluoromethyl ornithine (DFMO), the adaptive intestinal hyperplasia of pancreatico-biliary diversion is either inhibited or completely prevented.	Eflornithine	86-90	ornithine decarboxylase 1	Homo sapiens	45-48
2412277-2	1985	In Experiment 1, the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine (DFMO), was administered by gavage to one group only during AFB1 administration; another group received DFMO during AFB1 administration and for 2 months after carcinogen administration.	Eflornithine	56-85	ornithine decarboxylase 1	Rattus norvegicus	21-44
2412277-2	1985	In Experiment 1, the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine (DFMO), was administered by gavage to one group only during AFB1 administration; another group received DFMO during AFB1 administration and for 2 months after carcinogen administration.	Eflornithine	87-91	ornithine decarboxylase 1	Rattus norvegicus	21-44
2412277-7	1985	However, at 10 months following AFB1 and DFMO administration, the [3H]thymidine-labeling index and glucose-6-phosphatase staining were significantly increased.	Eflornithine	41-45	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	99-120
6438117-3	1984	DFMO, a specific inhibitor of ornithine decarboxylase, halts continued polyamine biosynthesis and the Spd analog serves as a functional substitute for Spd.	Eflornithine	0-4	ornithine decarboxylase, structural 1	Mus musculus	30-53
3145970-1	1988	DFMO (difluoromethylornithine) and DFMA (difluoromethylarginine), irreversible suicide inhibitors of ornithine and arginine decarboxylase activities (ODC and ADC) respectively, inhibit the growth of six species of Microsporum and six species of Trichophyton.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	150-153
3145970-1	1988	DFMO (difluoromethylornithine) and DFMA (difluoromethylarginine), irreversible suicide inhibitors of ornithine and arginine decarboxylase activities (ODC and ADC) respectively, inhibit the growth of six species of Microsporum and six species of Trichophyton.	Eflornithine	6-29	antizyme inhibitor 2	Homo sapiens	115-137
3145970-4	1988	Inhibition is specific, as a number of substrates and end products of ODC and ADC activities antagonize DFMA and DFMO (i.e. ornithine greater than putrescine = spermidine greater than agmatine).	Eflornithine	113-117	ornithine decarboxylase 1	Homo sapiens	70-73
6435861-4	1984	It prolonged the survival of mice bearing L1210 or P388 leukemias and inhibited the development of Lewis lung carcinoma in mice at doses 10- to 20-fold lower than those of alpha-difluoromethylornithine, the most widely used irreversible inhibitor of ornithine decarboxylase.	Eflornithine	172-201	ornithine decarboxylase, structural 1	Mus musculus	250-273
6439194-1	1984	The effects of alpha-difluoromethylornithine, a specific inhibitor of ornithine decarboxylase, on cell growth rate, polyamine content and the content of decarboxylated S-adenosylmethionine in SV-3T3 transformed mouse fibroblasts were studied.	Eflornithine	15-44	ornithine decarboxylase, structural 1	Mus musculus	70-93
6435867-3	1984	In the presence of ethylglyoxal bis(guanylhydrazone) and the ornithine decarboxylase inhibitor alpha-difluoromethylornithine, the cellular contents of putrescine, spermidine, and spermine were decreased by 75 to 90, 65 to 80, and 40 to 60%, respectively, compared with control cultures.	Eflornithine	95-124	ornithine decarboxylase	Bos taurus	61-84
6436005-8	1984	This observation should serve as a warning against uncritical acceptance of the notion that all effects of alpha-difluoromethylornithine are the result of inhibition of ornithine decarboxylase.	Eflornithine	107-136	ornithine decarboxylase	Bos taurus	169-192
6440787-8	1984	alpha-Difluoromethylornithine (DFMO) is an enzyme-activated irreversible inhibitor of ODC and binds covalently to the active enzyme.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	86-89
6440787-8	1984	alpha-Difluoromethylornithine (DFMO) is an enzyme-activated irreversible inhibitor of ODC and binds covalently to the active enzyme.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	86-89
6436232-2	1984	Ornithine decarboxylase from Paju was very resistant to inhibition by difluoromethylornithine in vitro (Ki = 10 microM compared to 0.5 microM for mouse kidney ornithine decarboxylase).	Eflornithine	70-93	ornithine decarboxylase, structural 1	Mus musculus	0-23
6437245-5	1984	Continuous treatment with alpha-difluoromethylornithine, a highly specific enzyme-activated, irreversible inhibitor of ODC activity, prevented the development of MCT-induced pulmonary toxicity.	Eflornithine	26-55	ornithine decarboxylase 1	Rattus norvegicus	119-122
6432307-3	1984	The frequency of 6-thioguanine-resistant mutant cells increased by approximately 9-fold as a result of the treatment with alpha-difluoromethylornithine, a potent inhibitor of ornithine decarboxylase (EC 4.1.1.17).	Eflornithine	122-151	ornithine decarboxylase 1	Homo sapiens	175-198
6432313-2	1984	The cell kill produced by a 24-hr treatment with VCR or MTX was decreased in 9L cells pretreated with 1 mM alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	107-136	ornithine decarboxylase 1	Rattus norvegicus	167-190
6084857-1	1984	The role of ornithine decarboxylase and of polyamines was investigated on caerulein-induced pancreatic growth by the use of alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase.	Eflornithine	124-153	ornithine decarboxylase 1	Homo sapiens	208-231
6208628-0	1984	Control of nucleic acid and protein synthesis in developing brain, kidney, and heart of the neonatal rat: effects of alpha-difluoromethylornithine, a specific, irreversible inhibitor of ornithine decarboxylase.	Eflornithine	117-146	ornithine decarboxylase 1	Rattus norvegicus	186-209
6437251-4	1984	In animals given the specific inhibitor of ODC, alpha-difluoromethylornithine (DFMO), intestinal mucosal ODC activity was inhibited, and intestinal adaptation was suppressed, with marked diminution of the adaptive increase in mucosal weight and thickness especially in crypt depth.	Eflornithine	79-83	ornithine decarboxylase 1	Rattus norvegicus	43-46
6437251-4	1984	In animals given the specific inhibitor of ODC, alpha-difluoromethylornithine (DFMO), intestinal mucosal ODC activity was inhibited, and intestinal adaptation was suppressed, with marked diminution of the adaptive increase in mucosal weight and thickness especially in crypt depth.	Eflornithine	79-83	ornithine decarboxylase 1	Rattus norvegicus	105-108
6208628-2	1984	Daily postnatal administration of alpha-difluoromethylornithine (DFMO, a specific inhibitor of ODC) to newborn rats caused organ-specific deficits in tissue weight gain, with brain and kidney as the major targets.	Eflornithine	34-63	ornithine decarboxylase 1	Rattus norvegicus	95-98
6208628-2	1984	Daily postnatal administration of alpha-difluoromethylornithine (DFMO, a specific inhibitor of ODC) to newborn rats caused organ-specific deficits in tissue weight gain, with brain and kidney as the major targets.	Eflornithine	65-69	ornithine decarboxylase 1	Rattus norvegicus	95-98
6430555-1	1984	Polyamine depletion by pretreatment with alpha-difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase, potentiates the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in L1210 leukemia cells grown in a modified soft agar system.	Eflornithine	41-70	ornithine decarboxylase, structural 1	Mus musculus	120-143
6435607-4	1984	DL-alpha-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, did not interfere with merozoite invasion and with ring-form development, but prevented the transformation of trophozoites to schizonts.	Eflornithine	0-32	ornithine decarboxylase 1	Homo sapiens	63-86
6430555-1	1984	Polyamine depletion by pretreatment with alpha-difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase, potentiates the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in L1210 leukemia cells grown in a modified soft agar system.	Eflornithine	72-76	ornithine decarboxylase, structural 1	Mus musculus	120-143
6430921-4	1984	Addition of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, caused a dramatic decrease in differentiation.	Eflornithine	12-41	ornithine decarboxylase 1	Homo sapiens	79-82
6434889-3	1984	alpha-Difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, had a much more profound and persistent effect on spermidine and also depleted putrescine throughout drug administration; furthermore, DFMO prevented both the elevation of putrescine caused by DCHA and the eventual restitution of spermidine levels.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	54-77
6434889-3	1984	alpha-Difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, had a much more profound and persistent effect on spermidine and also depleted putrescine throughout drug administration; furthermore, DFMO prevented both the elevation of putrescine caused by DCHA and the eventual restitution of spermidine levels.	Eflornithine	31-35	ornithine decarboxylase 1	Rattus norvegicus	54-77
6434889-3	1984	alpha-Difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, had a much more profound and persistent effect on spermidine and also depleted putrescine throughout drug administration; furthermore, DFMO prevented both the elevation of putrescine caused by DCHA and the eventual restitution of spermidine levels.	Eflornithine	214-218	ornithine decarboxylase 1	Rattus norvegicus	54-77
6438490-1	1984	Treatment with alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase (ODC), depletes the putrescine and spermidine content, and reduces the growth rate of Ehrlich ascites tumor cells.	Eflornithine	15-44	ornithine decarboxylase, structural 1	Mus musculus	99-122
6438490-1	1984	Treatment with alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase (ODC), depletes the putrescine and spermidine content, and reduces the growth rate of Ehrlich ascites tumor cells.	Eflornithine	15-44	ornithine decarboxylase, structural 1	Mus musculus	124-127
6438490-1	1984	Treatment with alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase (ODC), depletes the putrescine and spermidine content, and reduces the growth rate of Ehrlich ascites tumor cells.	Eflornithine	46-50	ornithine decarboxylase, structural 1	Mus musculus	99-122
6438490-1	1984	Treatment with alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase (ODC), depletes the putrescine and spermidine content, and reduces the growth rate of Ehrlich ascites tumor cells.	Eflornithine	46-50	ornithine decarboxylase, structural 1	Mus musculus	124-127
6150759-2	1984	The results clearly demonstrated an association between DFMO and BHA treatment with reduction in numbers of persisting nodules as assayed histopathologically and by analysis of gamma-glutamyltranspeptidase (gamma GT) and glucose-6-phosphate dehydrogenase (G6PDH) positive populations.	Eflornithine	56-60	gamma-glutamyltransferase 1	Rattus norvegicus	177-205
6150759-2	1984	The results clearly demonstrated an association between DFMO and BHA treatment with reduction in numbers of persisting nodules as assayed histopathologically and by analysis of gamma-glutamyltranspeptidase (gamma GT) and glucose-6-phosphate dehydrogenase (G6PDH) positive populations.	Eflornithine	56-60	gamma-glutamyltransferase 1	Rattus norvegicus	207-215
6150759-2	1984	The results clearly demonstrated an association between DFMO and BHA treatment with reduction in numbers of persisting nodules as assayed histopathologically and by analysis of gamma-glutamyltranspeptidase (gamma GT) and glucose-6-phosphate dehydrogenase (G6PDH) positive populations.	Eflornithine	56-60	glucose-6-phosphate dehydrogenase	Rattus norvegicus	221-254
6150759-2	1984	The results clearly demonstrated an association between DFMO and BHA treatment with reduction in numbers of persisting nodules as assayed histopathologically and by analysis of gamma-glutamyltranspeptidase (gamma GT) and glucose-6-phosphate dehydrogenase (G6PDH) positive populations.	Eflornithine	56-60	glucose-6-phosphate dehydrogenase	Rattus norvegicus	256-261
6433909-3	1984	When DFMO was administered to either intact or ovariectomized immature (20 day-old) rats for 2 or 6 days prior to and then during the 1 or 3 days of estradiol treatment, uterine ODC activity was completely suppressed as was the associated increase in spermidine concentration, but the magnitude of uterine growth stimulated by estradiol was equally great in the presence or absence of DFMO.	Eflornithine	5-9	ornithine decarboxylase 1	Rattus norvegicus	178-181
6430921-4	1984	Addition of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, caused a dramatic decrease in differentiation.	Eflornithine	43-47	ornithine decarboxylase 1	Homo sapiens	79-82
6432848-5	1984	In the present study, we gave rats the specific irreversible ODC inhibitor, alpha-difluoromethyl ornithine (DFMO), beginning 3 d before jejunectomy.	Eflornithine	76-106	ornithine decarboxylase 1	Rattus norvegicus	61-64
6432848-5	1984	In the present study, we gave rats the specific irreversible ODC inhibitor, alpha-difluoromethyl ornithine (DFMO), beginning 3 d before jejunectomy.	Eflornithine	108-112	ornithine decarboxylase 1	Rattus norvegicus	61-64
6432848-6	1984	DFMO completely suppressed the increases in ODC activity and polyamine content in the intestinal mucosa.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	44-47
6431170-2	1984	Inhibition of polyamine biosynthesis with alpha-difluoromethylornithine (DFMO) (1 mM), an irreversible inhibitor of ornithine decarboxylase, completely blocked the growth-promoting effect of E2 (10(-8) M) in this system.	Eflornithine	42-71	ornithine decarboxylase 1	Rattus norvegicus	116-139
6430546-12	1984	DFMO was observed to inhibit ornithine decarboxylase activity in JDF-1 tumors by 78%, IFN-alpha 2 by 18%, and the combination by 78%.	Eflornithine	0-4	ornithine decarboxylase, structural 1	Mus musculus	29-52
6430546-12	1984	DFMO was observed to inhibit ornithine decarboxylase activity in JDF-1 tumors by 78%, IFN-alpha 2 by 18%, and the combination by 78%.	Eflornithine	0-4	interferon alpha 2	Mus musculus	86-97
6430547-1	1984	We have investigated the effect of age, a high-fat diet, sodium deoxycholate, and the ornithine analogue alpha-difluoromethylornithine on ornithine decarboxylase (ODC) activity in the rat colon.	Eflornithine	105-134	ornithine decarboxylase 1	Rattus norvegicus	138-161
6430547-1	1984	We have investigated the effect of age, a high-fat diet, sodium deoxycholate, and the ornithine analogue alpha-difluoromethylornithine on ornithine decarboxylase (ODC) activity in the rat colon.	Eflornithine	105-134	ornithine decarboxylase 1	Rattus norvegicus	163-166
6430547-5	1984	alpha-Difluoromethylornithine given in drinking water inhibited, in a dose-dependent fashion, deoxycholate-induced ODC activity.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	115-118
6431170-2	1984	Inhibition of polyamine biosynthesis with alpha-difluoromethylornithine (DFMO) (1 mM), an irreversible inhibitor of ornithine decarboxylase, completely blocked the growth-promoting effect of E2 (10(-8) M) in this system.	Eflornithine	73-77	ornithine decarboxylase 1	Rattus norvegicus	116-139
6087190-3	1984	The present study shows that pretreatment with alpha-difluoromethylornithine (DFMO), and irreversible inhibitor of mammalian ornithine decarboxylase (ODC), antagonizes these behavioral effects in a dose-dependent way, in rats.	Eflornithine	47-76	ornithine decarboxylase 1	Homo sapiens	125-148
6430095-11	1984	Finally, treatment of rats with difluoromethylornithine, a selective, irreversible inhibitor of ODC, partially prevented the trophic response to intestinal obstruction.	Eflornithine	32-55	ornithine decarboxylase 1	Rattus norvegicus	96-99
6426779-1	1984	alpha-Difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, was administered in combination with human leukocyte interferon to human lymphoblastoid (Daudi) cells in culture.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	77-100
6428422-0	1984	Mode of interaction of ornithine decarboxylase with antizyme and alpha-difluoromethylornithine.	Eflornithine	65-94	ornithine decarboxylase 1	Homo sapiens	23-46
6087190-3	1984	The present study shows that pretreatment with alpha-difluoromethylornithine (DFMO), and irreversible inhibitor of mammalian ornithine decarboxylase (ODC), antagonizes these behavioral effects in a dose-dependent way, in rats.	Eflornithine	47-76	ornithine decarboxylase 1	Homo sapiens	150-153
6087190-3	1984	The present study shows that pretreatment with alpha-difluoromethylornithine (DFMO), and irreversible inhibitor of mammalian ornithine decarboxylase (ODC), antagonizes these behavioral effects in a dose-dependent way, in rats.	Eflornithine	78-82	ornithine decarboxylase 1	Homo sapiens	125-148
6423275-3	1984	The ornithine decarboxylase inhibitor, alpha-difluoromethylornithine, has been used to inhibit MEL proliferation by depleting intracellular putrescine and spermidine.	Eflornithine	39-68	ornithine decarboxylase, structural 1	Mus musculus	4-27
6426969-1	1984	Depletion of intracellular levels of polyamines in 9L rat brain tumor cells by alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase, significantly enhanced the cytotoxicity of 1-(2-chloroethyl)-3-trans-4-methylcyclohexyl-1-nitrosourea (MeCCNU) in vitro as measured by a colony-forming efficiency assay.	Eflornithine	110-114	ornithine decarboxylase 1	Rattus norvegicus	163-186
6421997-8	1984	All increases in ODC activity were blocked by difluoromethylornithine, an irreversible inhibitor of ODC.	Eflornithine	46-69	ornithine decarboxylase 1	Rattus norvegicus	17-20
6421997-8	1984	All increases in ODC activity were blocked by difluoromethylornithine, an irreversible inhibitor of ODC.	Eflornithine	46-69	ornithine decarboxylase 1	Rattus norvegicus	100-103
6321786-1	1984	D,L-alpha-Difluoromethylornithine (DFMO) is an inhibitor of ornithine decarboxylase, the first enzyme in the polyamine biosynthetic pathway.	Eflornithine	0-33	ornithine decarboxylase 1	Homo sapiens	60-83
6321786-1	1984	D,L-alpha-Difluoromethylornithine (DFMO) is an inhibitor of ornithine decarboxylase, the first enzyme in the polyamine biosynthetic pathway.	Eflornithine	35-39	ornithine decarboxylase 1	Homo sapiens	60-83
6420041-4	1984	Since alpha-difluoromethylornithine (DFMO) and methylglyoxal-bis-guanylhydrazone (MGBG) are irreversible and competitive inhibitors of ODC and SAMDC, respectively, they were tested as single agents and in combination on a transplantable rapidly growing and hormone-resistant G subline of the Dunning R-3327 rat prostatic adenocarcinoma.	Eflornithine	6-35	ornithine decarboxylase 1	Rattus norvegicus	135-138
6420041-4	1984	Since alpha-difluoromethylornithine (DFMO) and methylglyoxal-bis-guanylhydrazone (MGBG) are irreversible and competitive inhibitors of ODC and SAMDC, respectively, they were tested as single agents and in combination on a transplantable rapidly growing and hormone-resistant G subline of the Dunning R-3327 rat prostatic adenocarcinoma.	Eflornithine	6-35	adenosylmethionine decarboxylase 1	Rattus norvegicus	143-148
6420041-4	1984	Since alpha-difluoromethylornithine (DFMO) and methylglyoxal-bis-guanylhydrazone (MGBG) are irreversible and competitive inhibitors of ODC and SAMDC, respectively, they were tested as single agents and in combination on a transplantable rapidly growing and hormone-resistant G subline of the Dunning R-3327 rat prostatic adenocarcinoma.	Eflornithine	37-41	ornithine decarboxylase 1	Rattus norvegicus	135-138
6420041-4	1984	Since alpha-difluoromethylornithine (DFMO) and methylglyoxal-bis-guanylhydrazone (MGBG) are irreversible and competitive inhibitors of ODC and SAMDC, respectively, they were tested as single agents and in combination on a transplantable rapidly growing and hormone-resistant G subline of the Dunning R-3327 rat prostatic adenocarcinoma.	Eflornithine	37-41	adenosylmethionine decarboxylase 1	Rattus norvegicus	143-148
6240915-6	1984	On the other hand, alpha-DFMO--which inhibits the elevated activity of ODC--has not effect on rRNA transcription.	Eflornithine	19-29	ornithine decarboxylase, structural 1	Mus musculus	71-74
6424664-3	1984	The frequently reported restoration of difluoromethylornithine-induced polyamine depletion on administration of methylglyoxal bis(guanylhydrazone) is in all likelihood attributable to a profound inhibition of intestinal diamine oxidase (EC 1.4.3.6), resulting in an enhanced entry of intestinal (bacterial) diamines into general circulation and finally into tumour cells.	Eflornithine	39-62	amine oxidase, copper-containing 1	Mus musculus	220-235
6424650-1	1984	Hepatoma tissue-culture (HTC) cells were exposed to DL-alpha-difluoromethylornithine (DFMeOrn), a specific irreversible inhibitor of ornithine decarboxylase.	Eflornithine	52-84	ornithine decarboxylase 1	Rattus norvegicus	133-156
6424650-1	1984	Hepatoma tissue-culture (HTC) cells were exposed to DL-alpha-difluoromethylornithine (DFMeOrn), a specific irreversible inhibitor of ornithine decarboxylase.	Eflornithine	86-93	ornithine decarboxylase 1	Rattus norvegicus	133-156
6692368-8	1984	These cytostatic effects were clearly enhanced when MFMH was combined in therapy with the specific ornithine decarboxylase inhibitor, DL-alpha-difluoromethylornithine.	Eflornithine	134-166	ornithine decarboxylase 1	Rattus norvegicus	99-122
6323434-1	1984	HeLa cells were made strictly dependent upon polyamine by growth in the presence of alpha-difluoromethylornithine, a specific inhibitor of ornithine decarboxylase.	Eflornithine	84-113	ornithine decarboxylase 1	Homo sapiens	139-162
6703477-7	1984	The DFMO treatment lowered ODC activities below baseline, reduced the increase in polyamine content, and also reduced the morphometric parameters described above to only 60 to 70% of the values during normal repair.	Eflornithine	4-8	ornithine decarboxylase 1	Rattus norvegicus	27-30
6442954-0	1984	Successful treatment of lethal protozoal infections with the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine.	Eflornithine	96-125	ornithine decarboxylase 1	Homo sapiens	61-84
6423285-0	1984	Autoradiographic localization of ornithine decarboxylase in mouse kidney by use of radiolabeled alpha-difluoromethylornithine.	Eflornithine	96-125	ornithine decarboxylase, structural 1	Mus musculus	33-56
6423285-1	1984	Ornithine decarboxylase, a key enzyme in polyamine biosynthesis and cell growth, has been localized in mouse kidney by autoradiography after administration of radiolabeled alpha-difluoromethylornithine.	Eflornithine	172-201	ornithine decarboxylase, structural 1	Mus musculus	0-23
6440309-3	1984	The mice were then treated with DFMO, an irreversible inhibitor of ornithine decarboxylase, which inhibits polyamine synthesis.	Eflornithine	32-36	ornithine decarboxylase, structural 1	Mus musculus	67-90
6435895-0	1984	CNS toxicity and CSF pharmacokinetics of intraventricular DFMO and MGBG in beagle dogs.	Eflornithine	58-62	colony stimulating factor 2	Canis lupus familiaris	17-20
6416890-0	1983	Intestinal changes caused by DL-alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase.	Eflornithine	29-61	ornithine decarboxylase 1	Canis lupus familiaris	86-109
6416890-0	1983	Intestinal changes caused by DL-alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase.	Eflornithine	63-67	ornithine decarboxylase 1	Canis lupus familiaris	86-109
6416890-1	1983	Subacute (2 week) oral or intravenous administration of DL-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), caused diarrhea and frequent emesis as early as 4 to 5 days in dogs (dose greater than or equal to 200 mg/kg/day).	Eflornithine	56-88	ornithine decarboxylase 1	Canis lupus familiaris	126-149
6416890-1	1983	Subacute (2 week) oral or intravenous administration of DL-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), caused diarrhea and frequent emesis as early as 4 to 5 days in dogs (dose greater than or equal to 200 mg/kg/day).	Eflornithine	56-88	ornithine decarboxylase 1	Canis lupus familiaris	151-154
6416890-1	1983	Subacute (2 week) oral or intravenous administration of DL-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), caused diarrhea and frequent emesis as early as 4 to 5 days in dogs (dose greater than or equal to 200 mg/kg/day).	Eflornithine	90-94	ornithine decarboxylase 1	Canis lupus familiaris	126-149
6418170-4	1983	The ornithine decarboxylase inhibitor alpha-difluoromethylornithine suppressed the injury-induced increment in spermidine and spermine and microvascular permeability.	Eflornithine	38-67	ornithine decarboxylase 1	Rattus norvegicus	4-27
6196591-4	1983	In the latter organ, there is a transient increase of N1-acetylspermidine, followed by a decrease of spermidine, alpha-Difluoromethylornithine (DFMO), a potent ODC inhibitor, impairs the accumulation of putrescine in liver but not in pancreas.	Eflornithine	113-142	ornithine decarboxylase 1	Rattus norvegicus	160-163
6196591-4	1983	In the latter organ, there is a transient increase of N1-acetylspermidine, followed by a decrease of spermidine, alpha-Difluoromethylornithine (DFMO), a potent ODC inhibitor, impairs the accumulation of putrescine in liver but not in pancreas.	Eflornithine	144-148	ornithine decarboxylase 1	Rattus norvegicus	160-163
6580640-5	1983	The ornithine decarboxylase inhibitor alpha-difluoromethylornithine (5 mM) suppressed the testosterone-induced increase in polyamine levels and rates of endocytosis, hexose transport, and amino acid transport, measured by horseradish peroxidase, [14C]aminoisobutyric acid, and deoxy[3H]glucose uptake.	Eflornithine	38-67	ornithine decarboxylase, structural 1	Mus musculus	4-27
6195664-3	1983	alpha-Difluoro methyl ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase activity, reduces the PRL-stimulated ornithine decarboxylase (ODC) activity by more than 95%, and yet does not suppress the effects of PRL on RNA, casein or lipid synthesis.	Eflornithine	0-31	prolactin	Mus musculus	115-118
6415048-1	1983	Mutant mouse lymphoma cells that overproduce ornithine decarboxylase have been generated by selection for resistance to difluoromethylornithine, an inhibitor of the enzyme.	Eflornithine	120-143	ornithine decarboxylase, structural 1	Mus musculus	45-68
6411329-0	1983	Influence of polyamine depletion caused by alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on alkylation- and carbamoylation-induced cytotoxicity in 9L rat brain tumor cells in vitro.	Eflornithine	43-72	ornithine decarboxylase 1	Rattus norvegicus	120-143
6195664-3	1983	alpha-Difluoro methyl ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase activity, reduces the PRL-stimulated ornithine decarboxylase (ODC) activity by more than 95%, and yet does not suppress the effects of PRL on RNA, casein or lipid synthesis.	Eflornithine	0-31	ornithine decarboxylase, structural 1	Mus musculus	69-92
6307502-2	1983	DFMO is a specific enzyme-activated irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme controlling polyamine biosynthesis.	Eflornithine	0-4	ornithine decarboxylase, structural 1	Mus musculus	62-85
6307502-6	1983	DFMO caused 72 to 75% inactivation of ornithine decarboxylase activity and reduced putrescine levels in renal carcinoma and Wilms" tumor, reduced spermidine levels in Wilms" tumor, and apparently raised spermine levels in the latter as a consequence.	Eflornithine	0-4	ornithine decarboxylase, structural 1	Mus musculus	38-61
6412710-1	1983	Exposure to alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, inhibited the insulin induced differentiation of L6 myoblast cells.	Eflornithine	12-41	ornithine decarboxylase 1	Rattus norvegicus	89-112
6407751-1	1983	alpha-Difluoromethylornithine, an enzyme-activated, irreversible inhibitor of ornithine decarboxylase, inhibited the growth of both chloroethylnitrosourea-sensitive and -resistant 9L rat brain tumor cells in vitro.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	78-101
6407752-2	1983	The relevance of these TPA-induced changes to the mechanism of tumor promotion was investigated using alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC.	Eflornithine	102-131	ornithine decarboxylase 1	Homo sapiens	169-172
6407752-2	1983	The relevance of these TPA-induced changes to the mechanism of tumor promotion was investigated using alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC.	Eflornithine	133-137	ornithine decarboxylase 1	Homo sapiens	169-172
6407752-9	1983	These results provide evidence for an essential role of ODC induction and the accumulation of putrescine in tumor promotion by TPA and add strength to the proposal that DFMO may be a promising drug for the prevention and treatment of cancer in human beings.	Eflornithine	169-173	ornithine decarboxylase 1	Homo sapiens	56-59
6410400-1	1983	The specific ornithine decarboxylase inhibitor alpha-difluoromethylornithine, when given to adult rats in vivo for 5 wk, resulted in a decrease in peripheral blood cell elements in normal rats and a marked suppression of marrow recovery in rats with chemotherapy-induced marrow hypoplasia.	Eflornithine	47-76	ornithine decarboxylase 1	Rattus norvegicus	13-36
6411082-2	1983	We report here that inhibition of ornithine decarboxylase activity with a specific enzyme-activated inhibitor, alpha-difluoromethylornithine, can induce differentiation in embryonal carcinoma cells.	Eflornithine	111-140	ornithine decarboxylase, structural 1	Mus musculus	34-57
6408089-0	1983	Ornithine decarboxylase in difluoromethylornithine-resistant mouse lymphoma cells.	Eflornithine	27-50	ornithine decarboxylase, structural 1	Mus musculus	0-23
6408089-2	1983	Variant S49 mouse lymphoma cells with increased ornithine decarboxylase activity were obtained by selecting for resistance to alpha-difluoromethylornithine (DFMO), a specific inhibitor of the enzyme.	Eflornithine	126-155	ornithine decarboxylase, structural 1	Mus musculus	48-71
6408089-2	1983	Variant S49 mouse lymphoma cells with increased ornithine decarboxylase activity were obtained by selecting for resistance to alpha-difluoromethylornithine (DFMO), a specific inhibitor of the enzyme.	Eflornithine	157-161	ornithine decarboxylase, structural 1	Mus musculus	48-71
6408089-7	1983	This charge alteration and the inactivation of ornithine decarboxylase showed the same dependence on DFMO concentration and both effects were prevented by addition of either ornithine or putrescine.	Eflornithine	101-105	ornithine decarboxylase, structural 1	Mus musculus	47-70
6414762-3	1983	0.5 mg/kg of DL-alpha-difluoromethylornithine (DFMO) (irreversible inhibitor of ODC) was administered to uterine horns of Long-Evans adult rats during the 4th day of pregnancy.	Eflornithine	13-45	ornithine decarboxylase 1	Homo sapiens	80-83
6414762-3	1983	0.5 mg/kg of DL-alpha-difluoromethylornithine (DFMO) (irreversible inhibitor of ODC) was administered to uterine horns of Long-Evans adult rats during the 4th day of pregnancy.	Eflornithine	47-51	ornithine decarboxylase 1	Homo sapiens	80-83
6411077-1	1983	Treatment of mice bearing L1210 leukaemia with 2-difluoromethylornithine, a specific inhibitor of ornithine decarboxylase (EC 4.1.1.17), produced a profound depletion of putrescine and spermidine in the tumour cells.	Eflornithine	47-72	ornithine decarboxylase, structural 1	Mus musculus	98-121
6411077-3	1983	Experiments carried out with the combination of difluoromethylornithine and aminoguanidine, a potent inhibitor of diamine oxidase (EC 1.4.3.6), indicated that the methylglyoxal bis(guanylhydrazone)-induced reversal of polyamine depletion was mediated by the known inhibition of diamine oxidase by the diguanidine.	Eflornithine	48-71	amine oxidase, copper-containing 1	Mus musculus	114-129
6406046-1	1983	The effect of pretreating 9L rat brain tumor cells in vitro with 10 mM alpha-difluoromethylornithine (DFMO), an enzyme-activated, irreversible inhibitor of ornithine decarboxylase, on the cytotoxicity of 1-beta-D-arabinofuranosylcytosine (ara-C) was investigated using a colony-forming assay.	Eflornithine	71-100	ornithine decarboxylase 1	Rattus norvegicus	156-179
6406046-1	1983	The effect of pretreating 9L rat brain tumor cells in vitro with 10 mM alpha-difluoromethylornithine (DFMO), an enzyme-activated, irreversible inhibitor of ornithine decarboxylase, on the cytotoxicity of 1-beta-D-arabinofuranosylcytosine (ara-C) was investigated using a colony-forming assay.	Eflornithine	102-106	ornithine decarboxylase 1	Rattus norvegicus	156-179
6195664-3	1983	alpha-Difluoro methyl ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase activity, reduces the PRL-stimulated ornithine decarboxylase (ODC) activity by more than 95%, and yet does not suppress the effects of PRL on RNA, casein or lipid synthesis.	Eflornithine	0-31	ornithine decarboxylase, structural 1	Mus musculus	130-153
6195664-3	1983	alpha-Difluoro methyl ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase activity, reduces the PRL-stimulated ornithine decarboxylase (ODC) activity by more than 95%, and yet does not suppress the effects of PRL on RNA, casein or lipid synthesis.	Eflornithine	0-31	ornithine decarboxylase, structural 1	Mus musculus	155-158
6195664-3	1983	alpha-Difluoro methyl ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase activity, reduces the PRL-stimulated ornithine decarboxylase (ODC) activity by more than 95%, and yet does not suppress the effects of PRL on RNA, casein or lipid synthesis.	Eflornithine	0-31	prolactin	Mus musculus	228-231
6195664-3	1983	alpha-Difluoro methyl ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase activity, reduces the PRL-stimulated ornithine decarboxylase (ODC) activity by more than 95%, and yet does not suppress the effects of PRL on RNA, casein or lipid synthesis.	Eflornithine	33-37	ornithine decarboxylase, structural 1	Mus musculus	69-92
6195664-3	1983	alpha-Difluoro methyl ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase activity, reduces the PRL-stimulated ornithine decarboxylase (ODC) activity by more than 95%, and yet does not suppress the effects of PRL on RNA, casein or lipid synthesis.	Eflornithine	33-37	prolactin	Mus musculus	115-118
6195664-3	1983	alpha-Difluoro methyl ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase activity, reduces the PRL-stimulated ornithine decarboxylase (ODC) activity by more than 95%, and yet does not suppress the effects of PRL on RNA, casein or lipid synthesis.	Eflornithine	33-37	ornithine decarboxylase, structural 1	Mus musculus	130-153
6195664-3	1983	alpha-Difluoro methyl ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase activity, reduces the PRL-stimulated ornithine decarboxylase (ODC) activity by more than 95%, and yet does not suppress the effects of PRL on RNA, casein or lipid synthesis.	Eflornithine	33-37	ornithine decarboxylase, structural 1	Mus musculus	155-158
6195664-3	1983	alpha-Difluoro methyl ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase activity, reduces the PRL-stimulated ornithine decarboxylase (ODC) activity by more than 95%, and yet does not suppress the effects of PRL on RNA, casein or lipid synthesis.	Eflornithine	33-37	prolactin	Mus musculus	228-231
6831037-1	1983	Under the influence of a selective irreversible inhibitor of ornithine decarboxylase (ODC), DL-alpha-difluoromethylornithine (DFMO), early hematopoiesis was enhanced.	Eflornithine	92-124	ornithine decarboxylase, structural 1	Mus musculus	61-84
6405745-2	1983	Although luteinizing hormone enhanced both ornithine decarboxylase activity and testosterone production at a similar physiological dose range, we found dissociation in the two responses in terms of their temporal aspect and the way they were affected by an irreversible inhibitor of ornithine decarboxylase, alpha-difluoromethylornithine, and protein synthesis inhibitor cycloheximide.	Eflornithine	308-337	ornithine decarboxylase 1	Rattus norvegicus	283-306
6831037-1	1983	Under the influence of a selective irreversible inhibitor of ornithine decarboxylase (ODC), DL-alpha-difluoromethylornithine (DFMO), early hematopoiesis was enhanced.	Eflornithine	92-124	ornithine decarboxylase, structural 1	Mus musculus	86-89
6831037-1	1983	Under the influence of a selective irreversible inhibitor of ornithine decarboxylase (ODC), DL-alpha-difluoromethylornithine (DFMO), early hematopoiesis was enhanced.	Eflornithine	126-130	ornithine decarboxylase, structural 1	Mus musculus	61-84
6403787-0	1983	Subcellular distribution of ornithine decarboxylase in rat liver and accessibility of the enzyme to alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	100-129	ornithine decarboxylase 1	Rattus norvegicus	160-183
6407845-1	1983	The effects of DL-alpha-difluoromethylornithine (DFMO), a specific, irreversible inhibitor of ornithine decarboxylase (ODC), on tumors induced in the muscle of C57BL mice by Lewis lung (LL) carcinoma cells and on the development of lung metastases have been investigated.	Eflornithine	15-47	ornithine decarboxylase, structural 1	Mus musculus	94-117
6407845-1	1983	The effects of DL-alpha-difluoromethylornithine (DFMO), a specific, irreversible inhibitor of ornithine decarboxylase (ODC), on tumors induced in the muscle of C57BL mice by Lewis lung (LL) carcinoma cells and on the development of lung metastases have been investigated.	Eflornithine	15-47	ornithine decarboxylase, structural 1	Mus musculus	119-122
6407845-1	1983	The effects of DL-alpha-difluoromethylornithine (DFMO), a specific, irreversible inhibitor of ornithine decarboxylase (ODC), on tumors induced in the muscle of C57BL mice by Lewis lung (LL) carcinoma cells and on the development of lung metastases have been investigated.	Eflornithine	49-53	ornithine decarboxylase, structural 1	Mus musculus	119-122
6407845-3	1983	Oral treatment with DFMO (2% aqueous solution as sole drinking fluid, equivalent to 4 g DFMO/kg/day) decreased markedly the ODC activity and the putrescine and spermidine concentrations of the primary tumor, and stimulated S-adenosyl-L-methionine decarboxylase activity.	Eflornithine	20-24	ornithine decarboxylase, structural 1	Mus musculus	124-127
6407845-4	1983	ODC activity and putrescine and spermidine concentrations were similarly markedly reduced in the metastatic lung by DFMO treatment.	Eflornithine	116-120	ornithine decarboxylase, structural 1	Mus musculus	0-3
6137572-0	1983	Effect of alpha-difluoromethylornithine, an irreversible ornithine decarboxylase inhibitor, on formation of GGTase-positive foci.	Eflornithine	10-39	ornithine decarboxylase 1	Homo sapiens	57-80
6137572-2	1983	This was accomplished by examining the complete foci system in the presence and absence of alpha-DFMO, an irreversible inhibitor of ornithine decarboxylase, at concentrations capable of inhibiting both phenobarbital stimulated and control levels of the enzyme.	Eflornithine	91-101	ornithine decarboxylase 1	Homo sapiens	132-155
6300139-1	1983	Treatment of mouse lymphoma S49 cells with D,L-alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, depleted cellular polyamine levels and stopped cell growth.	Eflornithine	43-76	ornithine decarboxylase, structural 1	Mus musculus	101-124
6300139-1	1983	Treatment of mouse lymphoma S49 cells with D,L-alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, depleted cellular polyamine levels and stopped cell growth.	Eflornithine	78-82	ornithine decarboxylase, structural 1	Mus musculus	101-124
6300139-8	1983	DFMO diminishes ODC activity and augments SAMD activity in both untreated and Bt2cAMP-treated cells, leading to polyamine depletion in both cases.	Eflornithine	0-4	ornithine decarboxylase, structural 1	Mus musculus	16-19
6402774-1	1983	Mitochondrial structure and function were studied in 9L rat brain tumor cells depleted of polyamines by alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase.	Eflornithine	104-133	ornithine decarboxylase 1	Rattus norvegicus	181-204
6401167-1	1983	Treatment of mice with DL-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (EC 4.1.1.17), produced a significant spermidine depletion in liver, small intestine, and bone marrow among eight tissues studied.	Eflornithine	23-55	ornithine decarboxylase, structural 1	Mus musculus	93-116
6617953-6	1983	Ornithine decarboxylase is inhibited in vitro by alpha-difluoromethylornithine, but not in vivo.	Eflornithine	49-78	ornithine decarboxylase	Gallus gallus	0-23
24875723-1	1983	The roles of ornithine decarboxylase (ODC) and the polyamines in fetal and neonatal development were examined through the use of alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ODC.	Eflornithine	129-158	ornithine decarboxylase 1	Rattus norvegicus	204-207
24875723-6	1983	The separable sensitivities were apparent even though the effects of DFMO on ODC and the polyamines for any given treatment period were fairly uniform in all tissues studied.	Eflornithine	69-73	ornithine decarboxylase 1	Rattus norvegicus	77-80
24875723-7	1983	These results indicate that the ODC/polyamine system plays multiple roles in fetal survival and in tissue growth during discrete periods of development; because the time course of cellular maturation differs for each tissue or cell population, DFMO administered during any one brief period can produce organ-specific developmental deficits.	Eflornithine	244-248	ornithine decarboxylase 1	Rattus norvegicus	32-35
24875948-1	1983	Specific inhibition of ornithine decarboxylase selectively in the developing rat cerebellum was achieved within 10 min after intrathecal injection of alpha-difluoromethylornithine.	Eflornithine	150-179	ornithine decarboxylase 1	Rattus norvegicus	23-46
6423794-1	1983	The drug DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase, was studied as an antitrypanosomal drug.	Eflornithine	9-41	ornithine decarboxylase, structural 1	Mus musculus	74-97
6423794-1	1983	The drug DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase, was studied as an antitrypanosomal drug.	Eflornithine	43-47	ornithine decarboxylase, structural 1	Mus musculus	74-97
24875600-0	1983	Role of ornithine decarboxylase and the polyamines in nervous system development: Short-term postnatal administration of alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	121-150	ornithine decarboxylase 1	Rattus norvegicus	181-204
24875600-1	1983	The role of ornithine decarboxylase (ODC) and the polyamines in development of central and peripheral catecholaminergic neurons was examined through the use of alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ODC.	Eflornithine	160-189	ornithine decarboxylase 1	Rattus norvegicus	235-238
24875600-2	1983	Short-term postnatal administration of DFMO (500 mg/kg daily on days 1-6) to neonatal rats resulted in effective inhibition of ODC and depletion of both putrescine and spermidine in brain, heart and kidney; after cessation of DFMO administration, polyamine levels returned to normal by 10-13 days of age.	Eflornithine	39-43	ornithine decarboxylase 1	Rattus norvegicus	127-130
6401167-1	1983	Treatment of mice with DL-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (EC 4.1.1.17), produced a significant spermidine depletion in liver, small intestine, and bone marrow among eight tissues studied.	Eflornithine	57-61	ornithine decarboxylase, structural 1	Mus musculus	93-116
6815870-6	1982	Treatment of three of the six inoculated pigs with the ornithine decarboxylase inhibitor, DL-alpha-difluoromethylornithine, orally for ten days had no apparent effect on the infection.	Eflornithine	90-122	ornithine decarboxylase 1	Sus scrofa	55-78
6401860-2	1983	Inhibition of either ornithine decarboxylase or S-adenosyl-L-methionine decarboxylase (AMDC) by alpha-difluormethylornithine (DFMO) or methylglyoxal-bis[guanylhydrazone] (MGBG), respectively, was associated with significant antitumor effect.	Eflornithine	126-130	ornithine decarboxylase 1	Homo sapiens	21-44
6813433-1	1982	We studied the effect of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, on putrescine uptake by the rat prostate.	Eflornithine	56-60	ornithine decarboxylase 1	Rattus norvegicus	92-115
6813433-2	1982	Using C-14 putrescine, we found a several-fold increase in uptake by both the dorsal and ventral prostates of DFMO-pretreated intact animals, compared with untreated controls.	Eflornithine	110-114	anti-Mullerian hormone receptor type 2	Rattus norvegicus	6-10
6813433-3	1982	When previously castrated animals were treated with a combination of testosterone and DFMO, the prostatic uptake of exogenously administered C-14 putrescine increased more than tenfold.	Eflornithine	86-90	anti-Mullerian hormone receptor type 2	Rattus norvegicus	141-145
6240487-3	1983	The irreversible inhibitor of ODC activity, alpha-difluoromethylornithine, not only prevented ODC activity in a dose-dependent manner following skin application, it also prevented skin tumor promotion by TPA.	Eflornithine	44-73	ornithine decarboxylase, structural 1	Mus musculus	30-33
6240487-3	1983	The irreversible inhibitor of ODC activity, alpha-difluoromethylornithine, not only prevented ODC activity in a dose-dependent manner following skin application, it also prevented skin tumor promotion by TPA.	Eflornithine	44-73	ornithine decarboxylase, structural 1	Mus musculus	94-97
6814770-0	1982	Ornithine decarboxylase activity in nucleolus and nucleoplasm demonstrated autoradiographically with tritium-labeled alpha-difluoromethylornithine.	Eflornithine	117-146	ornithine decarboxylase 1	Homo sapiens	0-23
6813381-5	1982	DL-alpha-difluoromethyl ornithine, a specific irreversible inhibitor of ODC, almost completely abolished ODC activity but did not inhibit DMBA- or TCDD-induced AHH activity.	Eflornithine	0-33	ornithine decarboxylase 1	Rattus norvegicus	72-75
6813381-5	1982	DL-alpha-difluoromethyl ornithine, a specific irreversible inhibitor of ODC, almost completely abolished ODC activity but did not inhibit DMBA- or TCDD-induced AHH activity.	Eflornithine	0-33	ornithine decarboxylase 1	Rattus norvegicus	105-108
6125588-0	1982	Impaired development of central and peripheral catecholamine neurotransmitter systems in preweanling rats treated with alpha-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase.	Eflornithine	119-148	ornithine decarboxylase 1	Rattus norvegicus	187-210
6125588-1	1982	Daily administration of alpha-difluoromethylornithine (DFMO) to neonatal rats results in persistent inhibition of ornithine decarboxylase, depletion of polyamines and rapid onset of brain growth deficits.	Eflornithine	24-53	ornithine decarboxylase 1	Rattus norvegicus	114-137
6809932-0	1982	Ornithine decarboxylase and polyamines in tissues of the neonatal rat: effects of alpha-difluoromethylornithine, a specific, irreversible inhibitor of ornithine decarboxylase.	Eflornithine	82-111	ornithine decarboxylase 1	Rattus norvegicus	151-174
6809932-1	1982	To evaluate the role of ornithine decarboxylase (ODC) and the polyamines in tissue growth and development, neonatal rats were given daily injections of alpha-difluoromethylornithine, a specific, irreversible inhibitor of ODC.	Eflornithine	152-181	ornithine decarboxylase 1	Rattus norvegicus	221-224
6125588-1	1982	Daily administration of alpha-difluoromethylornithine (DFMO) to neonatal rats results in persistent inhibition of ornithine decarboxylase, depletion of polyamines and rapid onset of brain growth deficits.	Eflornithine	55-59	ornithine decarboxylase 1	Rattus norvegicus	114-137
6125588-7	1982	These results support the view that ornithine decarboxylase and the polyamines play an obligatory role in synaptic maturation, with the greatest sensitivity to DFMO-induced alterations occurring during periods of rapid development.	Eflornithine	160-164	ornithine decarboxylase 1	Rattus norvegicus	36-59
6816220-11	1982	These results indicate that titration with alpha-difluoromethylornithine provides a valuable method by which to quantify the amount of active ornithine decarboxylase present in mammalian tissues, and that the androgen-treated mouse kidney is a much better source for purification of the enzyme than is rat liver.	Eflornithine	43-72	ornithine decarboxylase 1	Homo sapiens	142-165
6816220-0	1982	Measurement of the number of ornithine decarboxylase molecules in rat and mouse tissues under various physiological conditions by binding of radiolabelled alpha-difluoromethylornithine.	Eflornithine	155-184	ornithine decarboxylase 1	Rattus norvegicus	29-52
6816220-1	1982	The binding of alpha-difluoromethylornithine, an irreversible inhibitor, to ornithine decarboxylase was used to investigate the amount of enzyme present in rat liver under various conditions and in mouse kidney after treatment with androgens.	Eflornithine	15-44	ornithine decarboxylase 1	Rattus norvegicus	76-99
16662530-4	1982	Further evidence is provided by the use of two ODC inhibitors, alpha-difluoromethylornithine (alpha-DFMO) and alpha-methylornithine (alpha-MO).	Eflornithine	94-104	ornithine decarboxylase	Solanum lycopersicum	47-50
6812635-0	1982	Affinity labeling of purified ornithine decarboxylase by alpha-difluoromethylornithine.	Eflornithine	57-86	ornithine decarboxylase 1	Rattus norvegicus	30-53
6217347-0	1982	Role of polyamines in isoproterenol-induced cardiac hypertrophy: effects of alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	76-105	ornithine decarboxylase 1	Homo sapiens	136-159
16662530-7	1982	When applied in vivo, alpha-DFMO, a catalytic irreversible inhibitor, caused 97.1% reduction of ODC activity in the dialyzed extract from the treated ovaries, while it had no effect on ADC.	Eflornithine	22-32	ornithine decarboxylase	Solanum lycopersicum	96-99
6806278-6	1982	These results indicate that steroid hormones can affect the level of certain proteins by changing the rate of degradation and that the labeling of ornithine decarboxylase by reaction with radioactive alpha-difluoromethylornithine in vivo provides a useful method for studying the degradation of this protein.	Eflornithine	200-229	ornithine decarboxylase, structural 1	Mus musculus	147-170
6806900-1	1982	alpha-Difluoromethylornithine is an enzyme-activated irreversible inhibitor of ornithine decarboxylase that forms a covalent bond with the enzyme.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	79-102
6811956-0	1982	Effects of DL-alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, on the rat mammary tumour induced by 7,12-dimethylbenz[a]anthracene.	Eflornithine	11-43	ornithine decarboxylase 1	Rattus norvegicus	74-97
6811956-7	1982	Tumour ornithine decarboxylase activities and putrescine concentrations were reduced by treatment with DFMO; the activity of S-adenosyl-L-methionine decarboxylase was increased and the concentration of spermine either remained unchanged or increased depending on the length of treatment.	Eflornithine	103-107	ornithine decarboxylase 1	Rattus norvegicus	7-30
6125941-5	1982	A broad peak of TGase activity also occurred after the addition of alpha-difluoromethylornithine, an irreversible inhibitor of ODCase, and after addition of alpha-difluoromethylornithine plus retinol.	Eflornithine	67-96	transglutaminase 1	Homo sapiens	16-21
6125941-5	1982	A broad peak of TGase activity also occurred after the addition of alpha-difluoromethylornithine, an irreversible inhibitor of ODCase, and after addition of alpha-difluoromethylornithine plus retinol.	Eflornithine	157-186	transglutaminase 1	Homo sapiens	16-21
6809478-0	1982	Enhancement of ovulation in the rat by DL-alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	39-71	ornithine decarboxylase 1	Rattus norvegicus	102-125
6809478-1	1982	Spontaneously cycling Sprague-Dawley Rats were treated with the irreversible ornithine decarboxylase (ODC) inhibitor DL-alpha-difluoromethylornithine (DFMO) on the day of proestrus.	Eflornithine	117-149	ornithine decarboxylase 1	Rattus norvegicus	77-100
6809478-1	1982	Spontaneously cycling Sprague-Dawley Rats were treated with the irreversible ornithine decarboxylase (ODC) inhibitor DL-alpha-difluoromethylornithine (DFMO) on the day of proestrus.	Eflornithine	117-149	ornithine decarboxylase 1	Rattus norvegicus	102-105
6809478-1	1982	Spontaneously cycling Sprague-Dawley Rats were treated with the irreversible ornithine decarboxylase (ODC) inhibitor DL-alpha-difluoromethylornithine (DFMO) on the day of proestrus.	Eflornithine	151-155	ornithine decarboxylase 1	Rattus norvegicus	102-105
7116338-3	1982	Acute (10 h) exposure of the cells to DL-alpha-difluoromethyl ornithine (DFMO) led to a marked inhibition of ODC activity without any significant effect on induced AHH activity.	Eflornithine	38-71	ornithine decarboxylase, structural 1	Mus musculus	109-112
6821130-0	1982	alpha-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	60-83
7116338-3	1982	Acute (10 h) exposure of the cells to DL-alpha-difluoromethyl ornithine (DFMO) led to a marked inhibition of ODC activity without any significant effect on induced AHH activity.	Eflornithine	73-77	ornithine decarboxylase, structural 1	Mus musculus	109-112
7116338-3	1982	Acute (10 h) exposure of the cells to DL-alpha-difluoromethyl ornithine (DFMO) led to a marked inhibition of ODC activity without any significant effect on induced AHH activity.	Eflornithine	73-77	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	164-167
6807294-2	1982	The content of decarboxylated S-adenosylmethionine (AdoMet) in transformed mouse fibroblasts (SV-3T3 cells) was increased 500-fold to about 0.4fmol/cell when ornithine decarboxylase was inhibited by alpha-difluoromethylornithine.	Eflornithine	199-228	ornithine decarboxylase, structural 1	Mus musculus	158-181
6950518-1	1982	The ornithine decarboxylase inhibitor DL-alpha-difluoromethyl ornithine inhibited a proliferation-associated increase in ornithine decarboxylase activity in cultured human promyelocytic leukemia cells, resulting in a marked suppression of cell proliferation and subsequent cell loss.	Eflornithine	38-71	ornithine decarboxylase 1	Homo sapiens	4-27
6950518-1	1982	The ornithine decarboxylase inhibitor DL-alpha-difluoromethyl ornithine inhibited a proliferation-associated increase in ornithine decarboxylase activity in cultured human promyelocytic leukemia cells, resulting in a marked suppression of cell proliferation and subsequent cell loss.	Eflornithine	38-71	ornithine decarboxylase 1	Homo sapiens	121-144
6800405-1	1982	The possibility that alpha-difluoromethylornithine, a specific, irreversible inhibitor of ornithine decarboxylase could be used to prevent the rise in hepatic putrescine and spermidine content following partial hepatectomy was tested.	Eflornithine	21-50	ornithine decarboxylase 1	Rattus norvegicus	90-113
6800405-7	1982	Experiments with lower doses of alpha-difluoromethylornithine showed that a substantial part of the rise in hepatic ornithine decarboxylase activity could be abolished without affecting either the rise in spermidine content or the increase in DNA synthesis after partial hepatectomy.	Eflornithine	32-61	ornithine decarboxylase 1	Rattus norvegicus	116-139
6801066-5	1982	The procedure is applied to the study in rats and in hepatoma tissue culture cells of the biochemical effects of alpha difluoromethylornithine, a potent enzyme-activated irreversible inhibitor of ornithine decarboxylase.	Eflornithine	113-142	ornithine decarboxylase 1	Rattus norvegicus	196-219
6802862-2	1982	Both an irreversible inhibitor of ornithine decarboxylase--difluoromethyl-ornithine (DFMO)--and a competitive inhibitor of S-adenosyl-methionine decarboxylase--methylglyoxal-bis(guanylhydrazone) (MGBG)--depressed spermidine levels and inhibited myoblast proliferation.	Eflornithine	59-83	ornithine decarboxylase 1	Rattus norvegicus	34-57
6802862-2	1982	Both an irreversible inhibitor of ornithine decarboxylase--difluoromethyl-ornithine (DFMO)--and a competitive inhibitor of S-adenosyl-methionine decarboxylase--methylglyoxal-bis(guanylhydrazone) (MGBG)--depressed spermidine levels and inhibited myoblast proliferation.	Eflornithine	85-89	ornithine decarboxylase 1	Rattus norvegicus	34-57
6177318-0	1982	Effect on prostatic growth of 2-difluoromethylornithine, an effective inhibitor of ornithine decarboxylase.	Eflornithine	30-55	ornithine decarboxylase 1	Rattus norvegicus	83-106
6177318-1	1982	2-Difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase, causes marked changes in the polyamine metabolism of ventral prostate when given to adult rats in drinking water (20 g/l) for 3 consecutive days.	Eflornithine	0-25	ornithine decarboxylase 1	Rattus norvegicus	80-103
6177318-1	1982	2-Difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase, causes marked changes in the polyamine metabolism of ventral prostate when given to adult rats in drinking water (20 g/l) for 3 consecutive days.	Eflornithine	27-31	ornithine decarboxylase 1	Rattus norvegicus	80-103
6812032-2	1982	We have found the ornithine decarboxylase (ODC) activity of this tumor to be as sensitive to inhibition by alpha-difluoromethylornithine (DFMO) as normal rat prostate.	Eflornithine	107-136	ornithine decarboxylase 1	Rattus norvegicus	18-41
6812032-2	1982	We have found the ornithine decarboxylase (ODC) activity of this tumor to be as sensitive to inhibition by alpha-difluoromethylornithine (DFMO) as normal rat prostate.	Eflornithine	107-136	ornithine decarboxylase 1	Rattus norvegicus	43-46
6812032-2	1982	We have found the ornithine decarboxylase (ODC) activity of this tumor to be as sensitive to inhibition by alpha-difluoromethylornithine (DFMO) as normal rat prostate.	Eflornithine	138-142	ornithine decarboxylase 1	Rattus norvegicus	18-41
6812032-2	1982	We have found the ornithine decarboxylase (ODC) activity of this tumor to be as sensitive to inhibition by alpha-difluoromethylornithine (DFMO) as normal rat prostate.	Eflornithine	138-142	ornithine decarboxylase 1	Rattus norvegicus	43-46
6812032-4	1982	The in vivo inhibition of ODC by DFMO allowed increased uptake of exogenously administered putrescine by the R3327AT tumor.	Eflornithine	33-37	ornithine decarboxylase 1	Rattus norvegicus	26-29
6186061-7	1982	The combination of 1% DFMO and 11 mg/kg MGBG distinctly reduces the activity of ODC and SAMDC and significantly lowers the levels of putrescine, spermidine and spermine in the tumor.	Eflornithine	22-26	ornithine decarboxylase 1	Homo sapiens	80-83
16662530-4	1982	Further evidence is provided by the use of two ODC inhibitors, alpha-difluoromethylornithine (alpha-DFMO) and alpha-methylornithine (alpha-MO).	Eflornithine	63-92	ornithine decarboxylase	Solanum lycopersicum	47-50
6186061-2	1982	The therapeutic concept of irreversible inhibition of both ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (SAMDC) by alpha-difluoromethylornithine (DFMO) and methylglyoxal bis-guanylhydrazone (MGBG) is based on pathologic activities of these enzymes in tumor tissue.	Eflornithine	139-168	ornithine decarboxylase 1	Homo sapiens	59-82
6186061-7	1982	The combination of 1% DFMO and 11 mg/kg MGBG distinctly reduces the activity of ODC and SAMDC and significantly lowers the levels of putrescine, spermidine and spermine in the tumor.	Eflornithine	22-26	adenosylmethionine decarboxylase 1	Homo sapiens	88-93
6186061-2	1982	The therapeutic concept of irreversible inhibition of both ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (SAMDC) by alpha-difluoromethylornithine (DFMO) and methylglyoxal bis-guanylhydrazone (MGBG) is based on pathologic activities of these enzymes in tumor tissue.	Eflornithine	139-168	adenosylmethionine decarboxylase 1	Homo sapiens	93-127
6186061-2	1982	The therapeutic concept of irreversible inhibition of both ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (SAMDC) by alpha-difluoromethylornithine (DFMO) and methylglyoxal bis-guanylhydrazone (MGBG) is based on pathologic activities of these enzymes in tumor tissue.	Eflornithine	139-168	adenosylmethionine decarboxylase 1	Homo sapiens	129-134
6175860-1	1981	DL-alpha-Difluoromethylornithine (DFMO), a specific enzyme-activated irreversible inhibitor of ornithine decarboxylase (ODC) was previously shown to cure mice infected with Trypanosoma brucei brucei, a parasite of game and cattle in Africa and Trypanosoma brucei rhodesiense, a human African Sleeping Sickness pathogen.	Eflornithine	0-32	ornithine decarboxylase, structural 1	Mus musculus	95-118
6186061-2	1982	The therapeutic concept of irreversible inhibition of both ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (SAMDC) by alpha-difluoromethylornithine (DFMO) and methylglyoxal bis-guanylhydrazone (MGBG) is based on pathologic activities of these enzymes in tumor tissue.	Eflornithine	170-174	ornithine decarboxylase 1	Homo sapiens	59-82
6186061-2	1982	The therapeutic concept of irreversible inhibition of both ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (SAMDC) by alpha-difluoromethylornithine (DFMO) and methylglyoxal bis-guanylhydrazone (MGBG) is based on pathologic activities of these enzymes in tumor tissue.	Eflornithine	170-174	ornithine decarboxylase 1	Homo sapiens	84-87
6186061-2	1982	The therapeutic concept of irreversible inhibition of both ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (SAMDC) by alpha-difluoromethylornithine (DFMO) and methylglyoxal bis-guanylhydrazone (MGBG) is based on pathologic activities of these enzymes in tumor tissue.	Eflornithine	170-174	adenosylmethionine decarboxylase 1	Homo sapiens	93-127
6186061-2	1982	The therapeutic concept of irreversible inhibition of both ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (SAMDC) by alpha-difluoromethylornithine (DFMO) and methylglyoxal bis-guanylhydrazone (MGBG) is based on pathologic activities of these enzymes in tumor tissue.	Eflornithine	170-174	adenosylmethionine decarboxylase 1	Homo sapiens	129-134
6175860-2	1981	Our studies now indicate that DFMO blocks ornithine decarboxylase and lowers trypanosome polyamine levels in vivo.	Eflornithine	30-34	ornithine decarboxylase 1	Homo sapiens	42-65
6175860-1	1981	DL-alpha-Difluoromethylornithine (DFMO), a specific enzyme-activated irreversible inhibitor of ornithine decarboxylase (ODC) was previously shown to cure mice infected with Trypanosoma brucei brucei, a parasite of game and cattle in Africa and Trypanosoma brucei rhodesiense, a human African Sleeping Sickness pathogen.	Eflornithine	0-32	ornithine decarboxylase, structural 1	Mus musculus	120-123
6175860-1	1981	DL-alpha-Difluoromethylornithine (DFMO), a specific enzyme-activated irreversible inhibitor of ornithine decarboxylase (ODC) was previously shown to cure mice infected with Trypanosoma brucei brucei, a parasite of game and cattle in Africa and Trypanosoma brucei rhodesiense, a human African Sleeping Sickness pathogen.	Eflornithine	34-38	ornithine decarboxylase, structural 1	Mus musculus	95-118
6175860-1	1981	DL-alpha-Difluoromethylornithine (DFMO), a specific enzyme-activated irreversible inhibitor of ornithine decarboxylase (ODC) was previously shown to cure mice infected with Trypanosoma brucei brucei, a parasite of game and cattle in Africa and Trypanosoma brucei rhodesiense, a human African Sleeping Sickness pathogen.	Eflornithine	34-38	ornithine decarboxylase, structural 1	Mus musculus	120-123
6796258-0	1981	Potentiation of the antitumor therapeutic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor.	Eflornithine	93-122	ornithine decarboxylase 1	Rattus norvegicus	127-150
7339299-2	1981	Putrescine can be produced by the action of L-ornithine decarboxylase, an inducible enzyme which can be irreversibly inhibited by the drug, alpha-difluoromethylornithine.	Eflornithine	140-169	ornithine decarboxylase 1	Rattus norvegicus	46-69
6796258-1	1981	alpha-Difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase, was used alone and in combination with various single doses of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) to treat animals bearing murine glioma 26 and rat 9L gliosarcoma intracerebral tumors.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	84-107
6796258-1	1981	alpha-Difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase, was used alone and in combination with various single doses of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) to treat animals bearing murine glioma 26 and rat 9L gliosarcoma intracerebral tumors.	Eflornithine	31-35	ornithine decarboxylase 1	Rattus norvegicus	84-107
6794570-0	1981	Binding of radioactive alpha-difluoromethylornithine to rat liver ornithine decarboxylase.	Eflornithine	23-52	ornithine decarboxylase 1	Rattus norvegicus	66-89
6271245-5	1981	In shift-down experiments a change towards the permissive temperature pattern of polyamine metabolism was evident within 2-3 h. Difluoromethylornithine, a specific and irreversible inhibitor of ornithine decarboxylase efficiently reduced the enzyme activity as well as the levels of both putrescine and spermidine in all culture types and temperatures.	Eflornithine	128-151	ornithine decarboxylase 1	Homo sapiens	194-217
7075668-5	1982	In support of this hypothesis, alpha-difluoromethylornithine, an irreversible ODC inhibitor, displayed identical ID50 values in control and isoproterenol-treated animals, a situation which would not occur if more enzyme were present.	Eflornithine	31-60	ornithine decarboxylase 1	Rattus norvegicus	78-81
6788425-0	1981	Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	12-41	ornithine decarboxylase 1	Homo sapiens	72-95
6788425-1	1981	We gave alpha-difluoromethylornithine (DFMO), a selective, irreversible inhibitor of ornithine decarboxylase, to six health men in single intravenous doses of 5 and 10 mg/kg body weight and oral doses of 10 and 20 mg/kg.	Eflornithine	8-37	ornithine decarboxylase 1	Homo sapiens	85-108
6788425-1	1981	We gave alpha-difluoromethylornithine (DFMO), a selective, irreversible inhibitor of ornithine decarboxylase, to six health men in single intravenous doses of 5 and 10 mg/kg body weight and oral doses of 10 and 20 mg/kg.	Eflornithine	39-43	ornithine decarboxylase 1	Homo sapiens	85-108
6794981-4	1981	It was observed that DFMO completely abolished ornithine decarboxylase levels in the pregnant uterus.	Eflornithine	21-25	ornithine decarboxylase 1	Rattus norvegicus	47-70
6797408-6	1981	Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, although powerfully inhibiting ornithine decarboxylase, produced a gradual enhancement of adenosylmethionine decarboxylase activity during lymphocyte activation, without influencing the activities of the two propylamine transferases (spermidine synthase and spermine synthase).	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	54-77
6797408-6	1981	Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, although powerfully inhibiting ornithine decarboxylase, produced a gradual enhancement of adenosylmethionine decarboxylase activity during lymphocyte activation, without influencing the activities of the two propylamine transferases (spermidine synthase and spermine synthase).	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	110-133
6788788-1	1981	A procedure is described for the measurement of DL-alpha-difluoromethylornithine (DFMO), a selective irreversible inhibitor of ornithine decarboxylase, in biological specimens.	Eflornithine	48-80	ornithine decarboxylase 1	Homo sapiens	127-150
6788836-0	1981	Cytochemical localization of ornithine decarboxylase with rhodamine or biotin-labeled alpha-difluoromethylornithine.	Eflornithine	86-115	ornithine decarboxylase 1	Rattus norvegicus	29-52
6264474-3	1981	alpha-Difluoromethylornithine, a specific enzyme-activated, irreversible ornithine decarboxylase inhibitor, blocks the increase in ornithine decarboxylase activity and in polyamines and inhibits human small-cell lung carcinoma cell growth.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	73-96
6264474-3	1981	alpha-Difluoromethylornithine, a specific enzyme-activated, irreversible ornithine decarboxylase inhibitor, blocks the increase in ornithine decarboxylase activity and in polyamines and inhibits human small-cell lung carcinoma cell growth.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	131-154
6788362-0	1981	Sensitization of 9L rat brain gliosarcoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor.	Eflornithine	91-120	ornithine decarboxylase 1	Rattus norvegicus	125-148
6113790-1	1981	The inactivation of ornithine decarboxylase, a polyamine biosynthetic enzyme, by alpha-difluoromethylornithine (alpha-DFMO) was studied in patients with chronic non-suppurative prostatitis.	Eflornithine	81-110	ornithine decarboxylase 1	Homo sapiens	20-43
6113790-1	1981	The inactivation of ornithine decarboxylase, a polyamine biosynthetic enzyme, by alpha-difluoromethylornithine (alpha-DFMO) was studied in patients with chronic non-suppurative prostatitis.	Eflornithine	112-122	ornithine decarboxylase 1	Homo sapiens	20-43
6788788-1	1981	A procedure is described for the measurement of DL-alpha-difluoromethylornithine (DFMO), a selective irreversible inhibitor of ornithine decarboxylase, in biological specimens.	Eflornithine	82-86	ornithine decarboxylase 1	Homo sapiens	127-150
6794904-1	1981	In in vitro studies with the Copenhagen rat prostate-derived tumor cell lines, the activity of ornithine decarboxylase (ODC) of these lines were as sensitive to inhibition by alpha-difluoromethylornithine (alpha-DFMO) as normal prostatic tissue.	Eflornithine	175-204	ornithine decarboxylase 1	Rattus norvegicus	95-118
6794904-1	1981	In in vitro studies with the Copenhagen rat prostate-derived tumor cell lines, the activity of ornithine decarboxylase (ODC) of these lines were as sensitive to inhibition by alpha-difluoromethylornithine (alpha-DFMO) as normal prostatic tissue.	Eflornithine	175-204	ornithine decarboxylase 1	Rattus norvegicus	120-123
6794904-1	1981	In in vitro studies with the Copenhagen rat prostate-derived tumor cell lines, the activity of ornithine decarboxylase (ODC) of these lines were as sensitive to inhibition by alpha-difluoromethylornithine (alpha-DFMO) as normal prostatic tissue.	Eflornithine	206-216	ornithine decarboxylase 1	Rattus norvegicus	95-118
6794904-1	1981	In in vitro studies with the Copenhagen rat prostate-derived tumor cell lines, the activity of ornithine decarboxylase (ODC) of these lines were as sensitive to inhibition by alpha-difluoromethylornithine (alpha-DFMO) as normal prostatic tissue.	Eflornithine	206-216	ornithine decarboxylase 1	Rattus norvegicus	120-123
6794904-2	1981	The in vitro growth of the tumor in calf serum was inhibited by ODC inhibitors alpha-methylornithine and alpha-difluoromethylornithine.	Eflornithine	105-134	ornithine decarboxylase 1	Rattus norvegicus	64-67
6794904-4	1981	Further, alpha-DFMO was not inhibitory to the growth of these cells in sera which lacked diamine oxidase activity, but was inhibitory when diamine oxidase was added.	Eflornithine	9-19	amine oxidase, copper containing 1	Rattus norvegicus	139-154
6449079-1	1980	Inhibition of cardiac ornithine decarboxylase (ODC) by alpha-difluoromethylornithine (DFMO) did not prevent normal cardiac growth in mature rats but attenuated isoproterenol-induced hypertrophy.	Eflornithine	55-84	ornithine decarboxylase 1	Rattus norvegicus	22-45
6789780-4	1981	A single topical dose of alpha-difluoromethylornithine, a selective inhibitor or ornithine decarboxylase, prevented the UV-induced increase of polyamine excretion in agreement with its effect on UV-induced epidermal polyamine turnover.	Eflornithine	25-54	ornithine decarboxylase, structural 1	Mus musculus	81-104
6169180-3	1981	Increased excretion of hydroxyproline and beta2-microglobulin were measured 1 month following alpha-DFMO treatment suggesting initial tumor necrosis and degradation.	Eflornithine	94-104	beta-2-microglobulin	Homo sapiens	42-61
7310281-6	1980	The ODC activity was blocked by alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor.	Eflornithine	32-61	ornithine decarboxylase	Gallus gallus	4-7
6449079-1	1980	Inhibition of cardiac ornithine decarboxylase (ODC) by alpha-difluoromethylornithine (DFMO) did not prevent normal cardiac growth in mature rats but attenuated isoproterenol-induced hypertrophy.	Eflornithine	55-84	ornithine decarboxylase 1	Rattus norvegicus	47-50
6449079-1	1980	Inhibition of cardiac ornithine decarboxylase (ODC) by alpha-difluoromethylornithine (DFMO) did not prevent normal cardiac growth in mature rats but attenuated isoproterenol-induced hypertrophy.	Eflornithine	86-90	ornithine decarboxylase 1	Rattus norvegicus	22-45
6449079-1	1980	Inhibition of cardiac ornithine decarboxylase (ODC) by alpha-difluoromethylornithine (DFMO) did not prevent normal cardiac growth in mature rats but attenuated isoproterenol-induced hypertrophy.	Eflornithine	86-90	ornithine decarboxylase 1	Rattus norvegicus	47-50
6449079-3	1980	There appear to be both ODC-dependent and ODC-independent processes contributing to the subcellular mechanisms associated with growth, which must be considered in the potential laboratory and clinical use of DFMO.	Eflornithine	208-212	ornithine decarboxylase 1	Rattus norvegicus	24-27
6449079-3	1980	There appear to be both ODC-dependent and ODC-independent processes contributing to the subcellular mechanisms associated with growth, which must be considered in the potential laboratory and clinical use of DFMO.	Eflornithine	208-212	ornithine decarboxylase 1	Rattus norvegicus	42-45
7305994-8	1981	alpha-Difluoromethylornithine, which is an irreversible inhibitor of ornithine decarboxylase, was a more potent inhibitor of growth and polyamine production (depleting spermidine almost completely and spermine significantly) than alpha-methylornithine, which is a competitive inhibitor.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	69-92
6781485-2	1980	The mechanism of stimulation of S-adenosylmethionine decarboxylase (EC 4.1.1.50) activity by inhibitors of ornithine decarboxylase (EC 4.1.1.17), namely dl-alpha-difluoromethylornithine, 1,3-diaminopropane and 1,3-diaminopropan-2-ol, was studied in Ehrlich ascites-tumour cells grown in suspension cultures.	Eflornithine	153-185	ornithine decarboxylase 1	Homo sapiens	107-130
6774420-4	1980	In vivo, alpha-difluoromethyl ornithine, a highly selective, enzyme-activated, irreversible inhibitor, suppresses these increases in mucosal ornithine decarboxylase and delays both intestinal mucosal maturation and recovery from injury.	Eflornithine	9-39	ornithine decarboxylase 1	Rattus norvegicus	141-164
6768132-1	1980	The highly selective, enzyme-activated, irreversible inhibitor of L-ornithine decarboxylase, DL-alpha-difluoromethylornithine, suppresses the increase in uterine L-ornithine decarboxylase activity associated with early embryogenesis in the mouse and arrests embryonic development at that stage.	Eflornithine	93-125	ornithine decarboxylase 1	Homo sapiens	68-91
6773783-0	1980	Inhibition of murine embryonic development by alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	46-75	ornithine decarboxylase, structural 1	Mus musculus	106-129
6773783-3	1980	Administration of the irreversible inhibitor of ODC, alpha-difluoromethylornithine, DFMO, 2% inthe drinking water during days 5-8 of gestation, abolished the inareases in uterine ODC activity, putrescine and spermidine concentrations and enhanced the activity of SAMDC.	Eflornithine	53-82	ornithine decarboxylase, structural 1	Mus musculus	179-182
6773783-3	1980	Administration of the irreversible inhibitor of ODC, alpha-difluoromethylornithine, DFMO, 2% inthe drinking water during days 5-8 of gestation, abolished the inareases in uterine ODC activity, putrescine and spermidine concentrations and enhanced the activity of SAMDC.	Eflornithine	53-82	S-adenosylmethionine decarboxylase 1	Mus musculus	263-268
6773783-3	1980	Administration of the irreversible inhibitor of ODC, alpha-difluoromethylornithine, DFMO, 2% inthe drinking water during days 5-8 of gestation, abolished the inareases in uterine ODC activity, putrescine and spermidine concentrations and enhanced the activity of SAMDC.	Eflornithine	84-88	ornithine decarboxylase, structural 1	Mus musculus	48-51
6773783-3	1980	Administration of the irreversible inhibitor of ODC, alpha-difluoromethylornithine, DFMO, 2% inthe drinking water during days 5-8 of gestation, abolished the inareases in uterine ODC activity, putrescine and spermidine concentrations and enhanced the activity of SAMDC.	Eflornithine	84-88	ornithine decarboxylase, structural 1	Mus musculus	179-182
6773783-3	1980	Administration of the irreversible inhibitor of ODC, alpha-difluoromethylornithine, DFMO, 2% inthe drinking water during days 5-8 of gestation, abolished the inareases in uterine ODC activity, putrescine and spermidine concentrations and enhanced the activity of SAMDC.	Eflornithine	84-88	S-adenosylmethionine decarboxylase 1	Mus musculus	263-268
6773783-6	1980	Treatment on single days with DFMO, 200 mg/kg every six h, revealed optimal contragestational effects on day 8 which corresponded exactly to the time of the peak in deciduomal ODC activity.	Eflornithine	30-34	ornithine decarboxylase, structural 1	Mus musculus	176-179
6768132-1	1980	The highly selective, enzyme-activated, irreversible inhibitor of L-ornithine decarboxylase, DL-alpha-difluoromethylornithine, suppresses the increase in uterine L-ornithine decarboxylase activity associated with early embryogenesis in the mouse and arrests embryonic development at that stage.	Eflornithine	93-125	ornithine decarboxylase 1	Homo sapiens	164-187
6781187-0	1980	Inhibition of cell proliferation by DL-alpha-difluoromethylornithine, a catalytic irreversible inhibitor of ornithine decarboxylase.	Eflornithine	36-68	ornithine decarboxylase 1	Homo sapiens	108-131
7360002-0	1980	Inhibition of EMT6 tumor growth by interference with polyamine biosynthesis; effects of alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	88-117	ornithine decarboxylase 1	Homo sapiens	148-171
227464-0	1979	Inhibition of cytomegalovirus-stimulated human cell ornithine decarboxylase by alpha-difluoromethylornithine.	Eflornithine	79-108	ornithine decarboxylase 1	Homo sapiens	52-75
227464-4	1979	Stimulation of ornithine decarboxylase activity by shifting low serum-arrested whole human embryo cells to high serum medium is inhibited more than 99% by 2.5 mM DL-alpha-difluoromethylornithine.	Eflornithine	162-194	ornithine decarboxylase 1	Homo sapiens	15-38
227464-5	1979	The addition of DL-alpha-difluoromethylornithine to human cells arrested in low serum and subsequently stimulated by the addition of fresh high serum-containing medium, causes a greater percent inhibition of ornithine decarboxylase activity than when the drug is added to growing human cells.	Eflornithine	16-48	ornithine decarboxylase 1	Homo sapiens	208-231
227464-7	1979	Increased ornithine decarboxylase activity produced by infection of low serum-arrested human cells was inhibited by 5.0 mM of DL-alpha-difluoromethylornithine.	Eflornithine	126-158	ornithine decarboxylase 1	Homo sapiens	10-33
486129-10	1979	Repeated doses of alpha-difluoromethylornithine, a potent enzyme-activated irreversible inhibitor of ornithine decarboxylase, totally blocked the testosterone-induced increase of putrescine and spermidine in the ventral prostate and of putrescine in the seminal vesicle.	Eflornithine	18-47	ornithine decarboxylase 1	Rattus norvegicus	101-124
679213-0	1978	Effect of alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on L1210 leukemia in mice.	Eflornithine	10-39	ornithine decarboxylase, structural 1	Mus musculus	87-110
486492-5	1979	Lysine and ornithine decarboxylase activities were lost to similar extents on inhibition of protein synthesis by cycloheximide and on exposure to alpha-difluoromethylornithine.	Eflornithine	146-175	ornithine decarboxylase 1	Rattus norvegicus	11-34
431333-0	1979	Effect of alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on polyamine levels in rat tissues.	Eflornithine	10-39	ornithine decarboxylase 1	Rattus norvegicus	87-110
228925-9	1979	Specific inhibition (up to 90%) of gonadotropin-induced ornithine decarboxylase activity by difluoromethyl ornithine or 1,3-diamino-2-propanol had little effect on the ability of the ovarian cells to respond to the hormone with increasing production of cyclic AMP and progesterone.	Eflornithine	92-116	ornithine decarboxylase 1	Rattus norvegicus	56-79
6775372-1	1980	alpha-Difluoromethylornithine (RMI 71,782), a specific irreversible inhibitor of the first step in polyamine biosynthesis, that is, the formation of putrescine from ornithine by ornithine decarboxylase, cures mice infected with a virulent, rodent-passaged strain of Trypanosoma brucei brucei.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	178-201
33621898-7	2021	The N5-[18F]FPO exhibited fast uptake in HepG2 cells and the cellular uptake ability of N5-[18F]FPO can be inhibited by L-ornithine and DFMO, which indicated that the transport pathway of N5-[18F]FPO is similar to that of L-ornithine, interacting with ODC after being transported into the cell.	Eflornithine	136-140	ornithine decarboxylase 1	Homo sapiens	252-255
34029478-12	2021	Here, we investigated difluoromethylornithine (DFMO), which has antitumor effects on MCF-7 cells by inhibiting ODC activity.	Eflornithine	22-45	ornithine decarboxylase 1	Homo sapiens	111-114
34029478-12	2021	Here, we investigated difluoromethylornithine (DFMO), which has antitumor effects on MCF-7 cells by inhibiting ODC activity.	Eflornithine	47-51	ornithine decarboxylase 1	Homo sapiens	111-114
34055746-2	2021	Difluoromethylornithine (DFMO, eflornithine) is the best-known inhibitor of ODC and a broad-spectrum, unique therapeutical agent.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	76-79
34055746-2	2021	Difluoromethylornithine (DFMO, eflornithine) is the best-known inhibitor of ODC and a broad-spectrum, unique therapeutical agent.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	76-79
34055746-2	2021	Difluoromethylornithine (DFMO, eflornithine) is the best-known inhibitor of ODC and a broad-spectrum, unique therapeutical agent.	Eflornithine	31-43	ornithine decarboxylase 1	Homo sapiens	76-79
33991460-8	2021	In contrast, depletion of cellular polyamines by treatment with alpha-difluoromethylornithine reduced alpha4/PP2Ac complexes and repressed cell migration.	Eflornithine	64-93	immunoglobulin kappa variable 1D-27 (pseudogene)	Homo sapiens	102-108
33991460-8	2021	In contrast, depletion of cellular polyamines by treatment with alpha-difluoromethylornithine reduced alpha4/PP2Ac complexes and repressed cell migration.	Eflornithine	64-93	protein phosphatase 2 catalytic subunit alpha	Homo sapiens	109-114
33579942-3	2021	Ornithine decarboxylase 1 (ODC1), the rate-limiting enzyme in polyamine synthesis, is irreversibly inhibited by difluoromethylornithine (DFMO).	Eflornithine	112-135	ornithine decarboxylase 1	Homo sapiens	0-25
33579942-3	2021	Ornithine decarboxylase 1 (ODC1), the rate-limiting enzyme in polyamine synthesis, is irreversibly inhibited by difluoromethylornithine (DFMO).	Eflornithine	112-135	ornithine decarboxylase 1	Homo sapiens	27-31
33579942-3	2021	Ornithine decarboxylase 1 (ODC1), the rate-limiting enzyme in polyamine synthesis, is irreversibly inhibited by difluoromethylornithine (DFMO).	Eflornithine	137-141	ornithine decarboxylase 1	Homo sapiens	0-25
33579942-3	2021	Ornithine decarboxylase 1 (ODC1), the rate-limiting enzyme in polyamine synthesis, is irreversibly inhibited by difluoromethylornithine (DFMO).	Eflornithine	137-141	ornithine decarboxylase 1	Homo sapiens	27-31
33244237-10	2020	DFMO and compound 3k synergistically inhibited HCC cell proliferation, induced apoptosis, and suppressed cell mobility, as well as the EMT phenotype and the AKT/GSK-3beta/beta-catenin pathway.	Eflornithine	0-4	glycogen synthase kinase 3 alpha	Mus musculus	161-170
33934471-6	2021	Only eflornithine hydrochloride, an inhibitor of ODC1, showed to be partially effective in the management of acquired HT.	Eflornithine	5-31	ornithine decarboxylase 1	Homo sapiens	49-53
33934471-21	2021	DFMO completely abolished the enzymatic activity (100 +- 5% inhibition, equivalent to 0 +- 5% ODC1 activity).	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	94-98
33452997-4	2021	We observed that the reduction of putrescine biosynthesis by treatment with difluormethylornithine (DFMO), a specific nontoxic inhibitor of ODC1, or with in vitro synthesized dsRNAs targeting ODC1 mRNA could inhibit viral infection.	Eflornithine	100-104	ornithine decarboxylase 1	Homo sapiens	140-144
33452997-4	2021	We observed that the reduction of putrescine biosynthesis by treatment with difluormethylornithine (DFMO), a specific nontoxic inhibitor of ODC1, or with in vitro synthesized dsRNAs targeting ODC1 mRNA could inhibit viral infection.	Eflornithine	100-104	ornithine decarboxylase 1	Homo sapiens	192-196
33403098-6	2020	Additional mice with and without endotoxemia were pretreated with the ornithine decarboxylase-inhibitor difluoromethylornithine before examination of hypoxic pulmonary vasoconstriction.	Eflornithine	104-127	ornithine decarboxylase, structural 1	Mus musculus	70-93
33229544-7	2020	Pharmacological inhibition of intracellular polyamine synthesis with alpha-difluoromethylornithine (DFMO) also increased MitoROS and ATF4 when ATP13A2 was deficient.	Eflornithine	69-98	activating transcription factor 4	Homo sapiens	133-137
33229544-7	2020	Pharmacological inhibition of intracellular polyamine synthesis with alpha-difluoromethylornithine (DFMO) also increased MitoROS and ATF4 when ATP13A2 was deficient.	Eflornithine	69-98	ATPase cation transporting 13A2	Homo sapiens	143-150
33229544-7	2020	Pharmacological inhibition of intracellular polyamine synthesis with alpha-difluoromethylornithine (DFMO) also increased MitoROS and ATF4 when ATP13A2 was deficient.	Eflornithine	100-104	activating transcription factor 4	Homo sapiens	133-137
33229544-7	2020	Pharmacological inhibition of intracellular polyamine synthesis with alpha-difluoromethylornithine (DFMO) also increased MitoROS and ATF4 when ATP13A2 was deficient.	Eflornithine	100-104	ATPase cation transporting 13A2	Homo sapiens	143-150
33229544-8	2020	The polyamine transport activity of ATP13A2 was required for lowering rotenone/DFMO-induced MitoROS, whereas exogenous spermine quenched rotenone-induced MitoROS via ATP13A2.	Eflornithine	79-83	ATPase cation transporting 13A2	Homo sapiens	36-43
33364460-8	2020	In comparison with the Pro group, the combined administration of Pro and DFMO reduced the expression of ODC protein and spermine concentration in the fetal intestine, as well as the concentrations of putrescine, spermidine and spermine in IPEC-J2 cells (P < 0.05).	Eflornithine	73-77	ornithine decarboxylase 1	Sus scrofa	104-107
33244237-10	2020	DFMO and compound 3k synergistically inhibited HCC cell proliferation, induced apoptosis, and suppressed cell mobility, as well as the EMT phenotype and the AKT/GSK-3beta/beta-catenin pathway.	Eflornithine	0-4	catenin (cadherin associated protein), beta 1	Mus musculus	171-183
33244237-13	2020	The simultaneous inhibition of ODC1 and PKM2 using DFMO and compound 3k exerts synergistic effects against HCC cells via the AKT/GSK-3beta/beta-catenin pathway.	Eflornithine	51-55	ornithine decarboxylase, structural 1	Mus musculus	31-35
33244237-13	2020	The simultaneous inhibition of ODC1 and PKM2 using DFMO and compound 3k exerts synergistic effects against HCC cells via the AKT/GSK-3beta/beta-catenin pathway.	Eflornithine	51-55	pyruvate kinase, muscle	Mus musculus	40-44
33244237-13	2020	The simultaneous inhibition of ODC1 and PKM2 using DFMO and compound 3k exerts synergistic effects against HCC cells via the AKT/GSK-3beta/beta-catenin pathway.	Eflornithine	51-55	thymoma viral proto-oncogene 1	Mus musculus	125-128
33244237-13	2020	The simultaneous inhibition of ODC1 and PKM2 using DFMO and compound 3k exerts synergistic effects against HCC cells via the AKT/GSK-3beta/beta-catenin pathway.	Eflornithine	51-55	glycogen synthase kinase 3 alpha	Mus musculus	129-138
33244237-13	2020	The simultaneous inhibition of ODC1 and PKM2 using DFMO and compound 3k exerts synergistic effects against HCC cells via the AKT/GSK-3beta/beta-catenin pathway.	Eflornithine	51-55	catenin (cadherin associated protein), beta 1	Mus musculus	139-151
33292222-6	2020	As an irreversible suicide inhibitor of the ornithine decarboxylase (a vital enzyme of polyamine synthesis), Difluoro-methylornithine had been shown to have the chemoprevention effect on cancer.	Eflornithine	109-133	ornithine decarboxylase 1	Homo sapiens	44-67
33216820-6	2020	To that end, this study was designed to test viability of decreasing secondary mutations by disrupting the cell division cycle using eflornithine, a specific inhibitor of ornithine decarboxylase.	Eflornithine	133-145	ornithine decarboxylase 1	Homo sapiens	171-194
32984708-5	2020	The eflornithine enantiomers, d- and l-eflornithine, have different affinities to the target enzyme ornithine decarboxylase, suggesting that the pharmacodynamics of the enantiomers may differ.	Eflornithine	4-16	ornithine decarboxylase 1	Homo sapiens	100-123
32799616-10	2020	Exposure to 100 microM D-Arg and 100 microM DFMO could each decrease the activities of Arginine decarboxylase (ADC), Ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (SAMDC) in all maize tissues.	Eflornithine	44-48	ornithine decarboxylase	Zea mays	117-140
32799616-10	2020	Exposure to 100 microM D-Arg and 100 microM DFMO could each decrease the activities of Arginine decarboxylase (ADC), Ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (SAMDC) in all maize tissues.	Eflornithine	44-48	ornithine decarboxylase	Zea mays	142-145
32799616-11	2020	However, the decrease of the ADC activity was more prominent in 100 microM D-Arg-treated seedlings, while the decrease of SAMDC and ODC activities was prominent in 100 microM DFMO-treated seedlings.	Eflornithine	175-179	ornithine decarboxylase	Zea mays	132-135
32946839-6	2020	Treatment with DL-2-difluoromethylornithine (DFMO), an inhibitor of polyamine biosynthesis, diminished GATA3 expression in CD4+ T cells under Th2-skewed conditions.	Eflornithine	45-49	GATA binding protein 3	Mus musculus	103-108
32946839-6	2020	Treatment with DL-2-difluoromethylornithine (DFMO), an inhibitor of polyamine biosynthesis, diminished GATA3 expression in CD4+ T cells under Th2-skewed conditions.	Eflornithine	45-49	CD4 antigen	Mus musculus	123-126
32946839-7	2020	Supplementation of exogenous polyamines rescued GATA3 downregulation caused by DFMO treatment in CD4+ T cells.	Eflornithine	79-83	GATA binding protein 3	Mus musculus	48-53
32946839-7	2020	Supplementation of exogenous polyamines rescued GATA3 downregulation caused by DFMO treatment in CD4+ T cells.	Eflornithine	79-83	CD4 antigen	Mus musculus	97-100
32946839-10	2020	Furthermore, oral administration of DFMO increased IL-9-producing CD4+ T cells in small intestine in mice.	Eflornithine	36-40	interleukin 9	Mus musculus	51-55
32946839-10	2020	Furthermore, oral administration of DFMO increased IL-9-producing CD4+ T cells in small intestine in mice.	Eflornithine	36-40	CD4 antigen	Mus musculus	66-69
32697811-12	2020	Consistent with the known actions of DFMO on ornithine decarboxylase (ODC), serum putrescene and spermidine levels were significantly reduced by DFMO, though the decrease in endpoint polyamine levels did not directly correlate with the behavioral changes.	Eflornithine	37-41	ornithine decarboxylase 1	Homo sapiens	45-68
32911426-5	2020	This study aimed to determine the treatment effects of alpha-difluoromethylornithine (DFMO), a specific ODC inhibitor, in MPM xenografts.	Eflornithine	55-84	ornithine decarboxylase, structural 1	Mus musculus	104-107
32911426-5	2020	This study aimed to determine the treatment effects of alpha-difluoromethylornithine (DFMO), a specific ODC inhibitor, in MPM xenografts.	Eflornithine	86-90	ornithine decarboxylase, structural 1	Mus musculus	104-107
32911426-10	2020	Furthermore, increase in nitrosocysteine, intratumoral IL-6, keratinocyte chemoattractant and TNFalpha, DNA lesion and inhibition of the Akt/mTOR pathway were induced by DFMO in H226 xenograft.	Eflornithine	170-174	interleukin 6	Mus musculus	55-59
32911426-10	2020	Furthermore, increase in nitrosocysteine, intratumoral IL-6, keratinocyte chemoattractant and TNFalpha, DNA lesion and inhibition of the Akt/mTOR pathway were induced by DFMO in H226 xenograft.	Eflornithine	170-174	tumor necrosis factor	Mus musculus	94-102
32911426-10	2020	Furthermore, increase in nitrosocysteine, intratumoral IL-6, keratinocyte chemoattractant and TNFalpha, DNA lesion and inhibition of the Akt/mTOR pathway were induced by DFMO in H226 xenograft.	Eflornithine	170-174	thymoma viral proto-oncogene 1	Mus musculus	137-140
32911426-10	2020	Furthermore, increase in nitrosocysteine, intratumoral IL-6, keratinocyte chemoattractant and TNFalpha, DNA lesion and inhibition of the Akt/mTOR pathway were induced by DFMO in H226 xenograft.	Eflornithine	170-174	mechanistic target of rapamycin kinase	Mus musculus	141-145
32697811-12	2020	Consistent with the known actions of DFMO on ornithine decarboxylase (ODC), serum putrescene and spermidine levels were significantly reduced by DFMO, though the decrease in endpoint polyamine levels did not directly correlate with the behavioral changes.	Eflornithine	37-41	ornithine decarboxylase 1	Homo sapiens	70-73
33318864-8	2021	Furthermore, inhibited hippocampal ODC/Spd pathway by difluoromethylornithine (DFMO) markedly reversed the protections of NaHS against the hippocampal autophagic flux impairment as well as the cognitive dysfunction in STZ-exposed rats.	Eflornithine	54-77	ornithine decarboxylase 1	Rattus norvegicus	35-38
33318864-8	2021	Furthermore, inhibited hippocampal ODC/Spd pathway by difluoromethylornithine (DFMO) markedly reversed the protections of NaHS against the hippocampal autophagic flux impairment as well as the cognitive dysfunction in STZ-exposed rats.	Eflornithine	79-83	ornithine decarboxylase 1	Rattus norvegicus	35-38
32373551-2	2020	In this study, we explored the anti-HBV effect of difluoromethylornithine (DFMO), an irreversibly inhibitor of decarboxylase 1(ODC1) on HBV replication.	Eflornithine	50-73	ornithine decarboxylase 1	Homo sapiens	127-131
32139506-6	2020	Treatment with the ODC inhibitor difluoromethylornithine (DFMO) sensitized TNBC cells to chemotherapy, but this was not observed in receptor-positive breast cancer cells.	Eflornithine	33-56	ornithine decarboxylase 1	Homo sapiens	19-22
32139506-6	2020	Treatment with the ODC inhibitor difluoromethylornithine (DFMO) sensitized TNBC cells to chemotherapy, but this was not observed in receptor-positive breast cancer cells.	Eflornithine	58-62	ornithine decarboxylase 1	Homo sapiens	19-22
32139506-8	2020	The alterations in polyamine metabolism in response to chemotherapy, as well as DFMO-induced preferential sensitization of TNBC cells to chemotherapy, reported here suggest that ODC may be a targetable metabolic vulnerability in TNBC.	Eflornithine	80-84	ornithine decarboxylase 1	Homo sapiens	178-181
32373551-2	2020	In this study, we explored the anti-HBV effect of difluoromethylornithine (DFMO), an irreversibly inhibitor of decarboxylase 1(ODC1) on HBV replication.	Eflornithine	75-79	ornithine decarboxylase 1	Homo sapiens	127-131
32373551-6	2020	Taken together, our findings demonstrate that DFMO inhibits HBV replication by reducing HBc stability and this may provide a new approach for HBV therapeutics.	Eflornithine	46-50	hbc	None	88-91
32256343-14	2019	This observation correlated with relative resistance to polyamine synthesis inhibitors eflornithine and SAM486 (inhibitors of ornithine decarboxylase and S-adenosyl-L-methionine decarboxylase, respectively), and MDL72527 (inhibitor of polyamine oxidase and spermine oxidase).	Eflornithine	87-99	ornithine decarboxylase 1	Homo sapiens	126-149
31249027-8	2019	Exposure of primary dermal fibroblasts to ODC inhibitor alpha-difluoromethylornithine (DFMO) reduced the ODC activity and putrescine to levels observed in controls without adversely affecting cell morphology or inducing cell death.	Eflornithine	56-85	ornithine decarboxylase 1	Homo sapiens	42-45
32101568-5	2020	Polyamine depletion was induced using alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	38-67	ornithine decarboxylase, structural 1	Mus musculus	105-128
32101568-5	2020	Polyamine depletion was induced using alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	69-73	ornithine decarboxylase, structural 1	Mus musculus	105-128
32101568-8	2020	Levels of the transcription factor kruppel-like factor 4 (KLF4) greatly decreased upon DFMO treatment; however, Klf4 mRNA was expressed at levels similar to controls.	Eflornithine	87-91	Kruppel-like factor 4 (gut)	Mus musculus	35-56
32101568-8	2020	Levels of the transcription factor kruppel-like factor 4 (KLF4) greatly decreased upon DFMO treatment; however, Klf4 mRNA was expressed at levels similar to controls.	Eflornithine	87-91	Kruppel-like factor 4 (gut)	Mus musculus	58-62
32101568-10	2020	We found that the efficiency of KLF4 synthesis in response to DFMO treatment was enhanced by the existence of a GC-rich 5"-untranslated region (5"-UTR) on Klf4 mRNA, regardless of the recognition of the initiation codon.	Eflornithine	62-66	Kruppel-like factor 4 (gut)	Mus musculus	32-36
32101568-10	2020	We found that the efficiency of KLF4 synthesis in response to DFMO treatment was enhanced by the existence of a GC-rich 5"-untranslated region (5"-UTR) on Klf4 mRNA, regardless of the recognition of the initiation codon.	Eflornithine	62-66	Kruppel-like factor 4 (gut)	Mus musculus	155-159
32101568-11	2020	Taken together, these results indicate that the enhancement of histamine synthesis by DFMO depends on the up-regulation of Hdc expression, achieved by removal of transcriptional suppression of KLF4, during differentiation.	Eflornithine	86-90	histidine decarboxylase	Mus musculus	123-126
32101568-11	2020	Taken together, these results indicate that the enhancement of histamine synthesis by DFMO depends on the up-regulation of Hdc expression, achieved by removal of transcriptional suppression of KLF4, during differentiation.	Eflornithine	86-90	Kruppel-like factor 4 (gut)	Mus musculus	193-197
31793679-8	2020	Difluoromethylornithine (DFMO) is an ODC inhibitor, which inhibits NMBA-induced activation of p38 alpha, ERK1/2 and AKT/mTOR/p70S6K pathways; this has been verified by Western blotting.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	37-40
31793679-8	2020	Difluoromethylornithine (DFMO) is an ODC inhibitor, which inhibits NMBA-induced activation of p38 alpha, ERK1/2 and AKT/mTOR/p70S6K pathways; this has been verified by Western blotting.	Eflornithine	0-23	mitogen-activated protein kinase 14	Homo sapiens	94-103
31793679-8	2020	Difluoromethylornithine (DFMO) is an ODC inhibitor, which inhibits NMBA-induced activation of p38 alpha, ERK1/2 and AKT/mTOR/p70S6K pathways; this has been verified by Western blotting.	Eflornithine	0-23	mitogen-activated protein kinase 3	Homo sapiens	105-111
31793679-8	2020	Difluoromethylornithine (DFMO) is an ODC inhibitor, which inhibits NMBA-induced activation of p38 alpha, ERK1/2 and AKT/mTOR/p70S6K pathways; this has been verified by Western blotting.	Eflornithine	0-23	AKT serine/threonine kinase 1	Homo sapiens	116-119
31793679-8	2020	Difluoromethylornithine (DFMO) is an ODC inhibitor, which inhibits NMBA-induced activation of p38 alpha, ERK1/2 and AKT/mTOR/p70S6K pathways; this has been verified by Western blotting.	Eflornithine	0-23	mechanistic target of rapamycin kinase	Homo sapiens	120-124
31793679-8	2020	Difluoromethylornithine (DFMO) is an ODC inhibitor, which inhibits NMBA-induced activation of p38 alpha, ERK1/2 and AKT/mTOR/p70S6K pathways; this has been verified by Western blotting.	Eflornithine	0-23	ribosomal protein S6 kinase B1	Homo sapiens	125-131
31793679-8	2020	Difluoromethylornithine (DFMO) is an ODC inhibitor, which inhibits NMBA-induced activation of p38 alpha, ERK1/2 and AKT/mTOR/p70S6K pathways; this has been verified by Western blotting.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	37-40
31793679-8	2020	Difluoromethylornithine (DFMO) is an ODC inhibitor, which inhibits NMBA-induced activation of p38 alpha, ERK1/2 and AKT/mTOR/p70S6K pathways; this has been verified by Western blotting.	Eflornithine	25-29	mitogen-activated protein kinase 14	Homo sapiens	94-103
31793679-8	2020	Difluoromethylornithine (DFMO) is an ODC inhibitor, which inhibits NMBA-induced activation of p38 alpha, ERK1/2 and AKT/mTOR/p70S6K pathways; this has been verified by Western blotting.	Eflornithine	25-29	mitogen-activated protein kinase 3	Homo sapiens	105-111
31793679-8	2020	Difluoromethylornithine (DFMO) is an ODC inhibitor, which inhibits NMBA-induced activation of p38 alpha, ERK1/2 and AKT/mTOR/p70S6K pathways; this has been verified by Western blotting.	Eflornithine	25-29	AKT serine/threonine kinase 1	Homo sapiens	116-119
31793679-8	2020	Difluoromethylornithine (DFMO) is an ODC inhibitor, which inhibits NMBA-induced activation of p38 alpha, ERK1/2 and AKT/mTOR/p70S6K pathways; this has been verified by Western blotting.	Eflornithine	25-29	mechanistic target of rapamycin kinase	Homo sapiens	120-124
31793679-8	2020	Difluoromethylornithine (DFMO) is an ODC inhibitor, which inhibits NMBA-induced activation of p38 alpha, ERK1/2 and AKT/mTOR/p70S6K pathways; this has been verified by Western blotting.	Eflornithine	25-29	ribosomal protein S6 kinase B1	Homo sapiens	125-131
31793679-9	2020	DFMO was also found to suppress the development of esophageal precancerous lesions in an NMBA-induced rat model; IHC demonstrated p38 alpha, ERK1/2, and AKT/mTOR/p70S6K pathways to be downregulated in these rats.	Eflornithine	0-4	mitogen activated protein kinase 14	Rattus norvegicus	130-139
31793679-9	2020	DFMO was also found to suppress the development of esophageal precancerous lesions in an NMBA-induced rat model; IHC demonstrated p38 alpha, ERK1/2, and AKT/mTOR/p70S6K pathways to be downregulated in these rats.	Eflornithine	0-4	mitogen activated protein kinase 3	Rattus norvegicus	141-147
31793679-9	2020	DFMO was also found to suppress the development of esophageal precancerous lesions in an NMBA-induced rat model; IHC demonstrated p38 alpha, ERK1/2, and AKT/mTOR/p70S6K pathways to be downregulated in these rats.	Eflornithine	0-4	AKT serine/threonine kinase 1	Rattus norvegicus	153-156
31793679-9	2020	DFMO was also found to suppress the development of esophageal precancerous lesions in an NMBA-induced rat model; IHC demonstrated p38 alpha, ERK1/2, and AKT/mTOR/p70S6K pathways to be downregulated in these rats.	Eflornithine	0-4	mechanistic target of rapamycin kinase	Rattus norvegicus	157-161
31793679-9	2020	DFMO was also found to suppress the development of esophageal precancerous lesions in an NMBA-induced rat model; IHC demonstrated p38 alpha, ERK1/2, and AKT/mTOR/p70S6K pathways to be downregulated in these rats.	Eflornithine	0-4	ribosomal protein S6 kinase B1	Rattus norvegicus	162-168
32912061-5	2020	RNA-sequencing showed that many key epigenetic players including Ubiquitin-like containing PHD and Ring finger 1 (UHRF1) and its 2 partners DNA methyltransferase 1 (DNMT1) and histone deacetylase 1 (HDAC1) were down-regulated in DFMO-treated Jurkat cells.	Eflornithine	229-233	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	65-112
32912061-5	2020	RNA-sequencing showed that many key epigenetic players including Ubiquitin-like containing PHD and Ring finger 1 (UHRF1) and its 2 partners DNA methyltransferase 1 (DNMT1) and histone deacetylase 1 (HDAC1) were down-regulated in DFMO-treated Jurkat cells.	Eflornithine	229-233	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	114-119
32912061-5	2020	RNA-sequencing showed that many key epigenetic players including Ubiquitin-like containing PHD and Ring finger 1 (UHRF1) and its 2 partners DNA methyltransferase 1 (DNMT1) and histone deacetylase 1 (HDAC1) were down-regulated in DFMO-treated Jurkat cells.	Eflornithine	229-233	DNA methyltransferase 1	Homo sapiens	140-163
32912061-5	2020	RNA-sequencing showed that many key epigenetic players including Ubiquitin-like containing PHD and Ring finger 1 (UHRF1) and its 2 partners DNA methyltransferase 1 (DNMT1) and histone deacetylase 1 (HDAC1) were down-regulated in DFMO-treated Jurkat cells.	Eflornithine	229-233	DNA methyltransferase 1	Homo sapiens	165-170
32912061-5	2020	RNA-sequencing showed that many key epigenetic players including Ubiquitin-like containing PHD and Ring finger 1 (UHRF1) and its 2 partners DNA methyltransferase 1 (DNMT1) and histone deacetylase 1 (HDAC1) were down-regulated in DFMO-treated Jurkat cells.	Eflornithine	229-233	histone deacetylase 1	Homo sapiens	176-197
32912061-5	2020	RNA-sequencing showed that many key epigenetic players including Ubiquitin-like containing PHD and Ring finger 1 (UHRF1) and its 2 partners DNA methyltransferase 1 (DNMT1) and histone deacetylase 1 (HDAC1) were down-regulated in DFMO-treated Jurkat cells.	Eflornithine	229-233	histone deacetylase 1	Homo sapiens	199-204
32912061-6	2020	The combination of DFMO and TQ dramatically decreased the expression of UHRF1, DNMT1 and HDAC1 genes compared to either DFMO or TQ alone.	Eflornithine	19-23	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	72-77
32912061-6	2020	The combination of DFMO and TQ dramatically decreased the expression of UHRF1, DNMT1 and HDAC1 genes compared to either DFMO or TQ alone.	Eflornithine	19-23	DNA methyltransferase 1	Homo sapiens	79-84
32912061-6	2020	The combination of DFMO and TQ dramatically decreased the expression of UHRF1, DNMT1 and HDAC1 genes compared to either DFMO or TQ alone.	Eflornithine	19-23	histone deacetylase 1	Homo sapiens	89-94
32912061-6	2020	The combination of DFMO and TQ dramatically decreased the expression of UHRF1, DNMT1 and HDAC1 genes compared to either DFMO or TQ alone.	Eflornithine	120-124	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	72-77
32912061-6	2020	The combination of DFMO and TQ dramatically decreased the expression of UHRF1, DNMT1 and HDAC1 genes compared to either DFMO or TQ alone.	Eflornithine	120-124	histone deacetylase 1	Homo sapiens	89-94
31545969-0	2019	Improving Eflornithine Oral Bioavailability and Brain Uptake by Modulating Intercellular Junctions With an E-cadherin Peptide.	Eflornithine	10-22	cadherin 1	Homo sapiens	107-117
31545969-3	2019	Here, we investigated the feasibility of using an intercellular junction-modulating E-cadherin peptide HAV6 to enhance the oral bioavailability and blood-brain barrier permeation of eflornithine.	Eflornithine	182-194	cadherin 1	Homo sapiens	84-94
31249027-8	2019	Exposure of primary dermal fibroblasts to ODC inhibitor alpha-difluoromethylornithine (DFMO) reduced the ODC activity and putrescine to levels observed in controls without adversely affecting cell morphology or inducing cell death.	Eflornithine	56-85	ornithine decarboxylase 1	Homo sapiens	105-108
31249027-8	2019	Exposure of primary dermal fibroblasts to ODC inhibitor alpha-difluoromethylornithine (DFMO) reduced the ODC activity and putrescine to levels observed in controls without adversely affecting cell morphology or inducing cell death.	Eflornithine	87-91	ornithine decarboxylase 1	Homo sapiens	42-45
31249027-8	2019	Exposure of primary dermal fibroblasts to ODC inhibitor alpha-difluoromethylornithine (DFMO) reduced the ODC activity and putrescine to levels observed in controls without adversely affecting cell morphology or inducing cell death.	Eflornithine	87-91	ornithine decarboxylase 1	Homo sapiens	105-108
31249027-9	2019	In conclusion, our patient and potentially other patients that carry a similar ODC1 gain-of-function mutation might benefit from treatment with DFMO, a drug with a good safety profile, to suppress the exceptionally high ODC activity and putrescine levels in the body.	Eflornithine	144-148	ornithine decarboxylase 1	Homo sapiens	79-83
31249027-9	2019	In conclusion, our patient and potentially other patients that carry a similar ODC1 gain-of-function mutation might benefit from treatment with DFMO, a drug with a good safety profile, to suppress the exceptionally high ODC activity and putrescine levels in the body.	Eflornithine	144-148	ornithine decarboxylase 1	Homo sapiens	79-82
31088836-3	2019	To improve the efficacy of epigenetic therapy, we hypothesized that the addition of alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, may further decrease immunosuppressive cell populations improving outcome.	Eflornithine	84-113	ornithine decarboxylase, structural 1	Mus musculus	125-148
31088836-3	2019	To improve the efficacy of epigenetic therapy, we hypothesized that the addition of alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, may further decrease immunosuppressive cell populations improving outcome.	Eflornithine	115-119	ornithine decarboxylase, structural 1	Mus musculus	125-148
31088836-4	2019	We tested this hypothesis in an immunocompetent mouse model for ovarian cancer and found that in vivo, 5AZA-C and DFMO, either alone or in combination, significantly increased survival, decreased tumor burden, and caused recruitment of activated (IFNgamma+) CD4+ T cells, CD8+ T cells, and NK cells.	Eflornithine	114-118	interferon gamma	Mus musculus	247-255
31088836-4	2019	We tested this hypothesis in an immunocompetent mouse model for ovarian cancer and found that in vivo, 5AZA-C and DFMO, either alone or in combination, significantly increased survival, decreased tumor burden, and caused recruitment of activated (IFNgamma+) CD4+ T cells, CD8+ T cells, and NK cells.	Eflornithine	114-118	CD4 antigen	Mus musculus	258-261
31088836-7	2019	In this model, depletion of macrophages with a CSF1R-blocking antibody reduced the efficacy of 5AZA-C + DFMO treatment and resulted in fewer M1 macrophages in the tumor microenvironment.	Eflornithine	104-108	colony stimulating factor 1 receptor	Mus musculus	47-52
31156441-2	2019	We found that GA could promote the proliferation, decrease the apoptotic rate, and attenuate DFMO-elicited growth arrest and delay in restitution after wounding in IEC-6 cells via HuR.	Eflornithine	93-97	ELAV like RNA binding protein 1	Rattus norvegicus	180-183
31203007-14	2019	On the other hand, DFMO inhibits the expression of TRPC1 channels in colon cancer cells, eliminating their contribution to SOCE.	Eflornithine	19-23	transient receptor potential cation channel subfamily C member 1	Homo sapiens	51-56
29452772-13	2019	In vitro treatment of RCC cells with the ornithine-decarboxylase inhibitor difluoromethylornithine resulted in reduced cell viability and mitochondrial activity.	Eflornithine	75-98	ornithine decarboxylase 1	Homo sapiens	41-64
30927735-1	2019	OBJECTIVES: The chemopreventive drug alpha-difluoromethylornithine (DFMO) has been shown to have an antinociceptive effect on mechanical allodynia in inflammatory arthritis by directly inhibiting ornithine decarboxylase (ODC) and decreasing polyamine production in inflammatory sites.	Eflornithine	37-66	ornithine decarboxylase, structural 1	Mus musculus	196-219
30927735-1	2019	OBJECTIVES: The chemopreventive drug alpha-difluoromethylornithine (DFMO) has been shown to have an antinociceptive effect on mechanical allodynia in inflammatory arthritis by directly inhibiting ornithine decarboxylase (ODC) and decreasing polyamine production in inflammatory sites.	Eflornithine	37-66	ornithine decarboxylase, structural 1	Mus musculus	221-224
30927735-1	2019	OBJECTIVES: The chemopreventive drug alpha-difluoromethylornithine (DFMO) has been shown to have an antinociceptive effect on mechanical allodynia in inflammatory arthritis by directly inhibiting ornithine decarboxylase (ODC) and decreasing polyamine production in inflammatory sites.	Eflornithine	68-72	ornithine decarboxylase, structural 1	Mus musculus	196-219
30927735-1	2019	OBJECTIVES: The chemopreventive drug alpha-difluoromethylornithine (DFMO) has been shown to have an antinociceptive effect on mechanical allodynia in inflammatory arthritis by directly inhibiting ornithine decarboxylase (ODC) and decreasing polyamine production in inflammatory sites.	Eflornithine	68-72	ornithine decarboxylase, structural 1	Mus musculus	221-224
30700572-5	2019	Knockdown of SLC3A2 in neuroblastoma cells reduced the uptake of the radiolabeled polyamine spermidine, and DFMO treatment increased SLC3A2 protein.	Eflornithine	108-112	solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2	Mus musculus	133-139
30871110-3	2019	Jurkat cells and human mammary epithelial cells were cultured with spermine and/or D,L-alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase.	Eflornithine	83-116	ornithine decarboxylase 1	Homo sapiens	141-164
30871110-6	2019	In Jurkat cells cultured with DFMO, the protein levels of DNA methyltransferases (DNMTs) 1, 3A and 3B were not changed, however the activity of the three enzymes markedly decreased.	Eflornithine	30-34	DNA methyltransferase 1	Homo sapiens	58-101
29436980-0	2019	Virtual screening of natural inhibitors targeting ornithine decarboxylase with pharmacophore scaffolding of DFMO and validation by molecular dynamics simulation studies.	Eflornithine	108-112	ornithine decarboxylase 1	Homo sapiens	50-73
29436980-4	2019	As per earlier studies, di-flouro-methyl-orninthine (DFMO) is a proven efficient inhibitor ODC targeting the catalytic activity, however, its usage is limited due to side effects.	Eflornithine	53-57	ornithine decarboxylase 1	Homo sapiens	91-94
29436980-9	2019	Finally, molecular dynamics simulations were performed for the natural molecule hit and DFMO in complex with ODC using Desmond.	Eflornithine	88-92	ornithine decarboxylase 1	Homo sapiens	109-112
29436980-10	2019	Among the hits shortlisted, 2-amino-5, 9, 13, 17-tetramethyloctadeca-8, 16-diene-1, 3, 14-triol (UNPD208110) was found to be highly potential, as it showed a higher binding affinity in terms of interactions with key active cavity residues, and also showed better ADMET property, HUMO-LUMO gap energy and more stable complex formation with ODC compared to DFMO.	Eflornithine	355-359	ornithine decarboxylase 1	Homo sapiens	339-342
30642111-5	2019	Difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase (ODC), the limiting step in polyamine biosynthesis, strongly prevents CRC, particularly when combined with sulindac.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	55-78
30642111-5	2019	Difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase (ODC), the limiting step in polyamine biosynthesis, strongly prevents CRC, particularly when combined with sulindac.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	80-83
30642111-5	2019	Difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase (ODC), the limiting step in polyamine biosynthesis, strongly prevents CRC, particularly when combined with sulindac.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	55-78
30642111-5	2019	Difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase (ODC), the limiting step in polyamine biosynthesis, strongly prevents CRC, particularly when combined with sulindac.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	80-83
30642111-9	2019	Moreover, DFMO abolish selectively the TRPC1-dependent component of SOCs characteristic of CRC cells and this effect is reversed by the polyamine putrescine.	Eflornithine	10-14	transient receptor potential cation channel subfamily C member 1	Homo sapiens	39-44
30642111-11	2019	Finally, DFMO treatment inhibits expression of TRPC1 and stromal interaction protein 1 (STIM1) in CRC cells.	Eflornithine	9-13	transient receptor potential cation channel subfamily C member 1	Homo sapiens	47-52
30642111-11	2019	Finally, DFMO treatment inhibits expression of TRPC1 and stromal interaction protein 1 (STIM1) in CRC cells.	Eflornithine	9-13	stromal interaction molecule 1	Homo sapiens	88-93
30355744-4	2019	Because the ODC inhibitor difluoromethylornithine (DFMO) acts like RS1-Reg(S20E), and DFMO and RS1-Reg(S20E) are not cumulative, we raised the hypothesis that RS1-Reg(S20E) down-regulates the exocytotic pathway of SGLT1 at the trans-Golgi by inhibiting ODC.	Eflornithine	26-49	ornithine decarboxylase 1	Homo sapiens	12-15
30700572-3	2019	Treatment of neuroblastoma cells with the ODC1 inhibitor difluoromethylornithine (DFMO), although a promising therapeutic strategy, is only partially effective at impeding neuroblastoma cell growth due to activation of compensatory mechanisms resulting in increased polyamine uptake from the surrounding microenvironment.	Eflornithine	57-80	ornithine decarboxylase, structural 1	Mus musculus	42-46
30700572-3	2019	Treatment of neuroblastoma cells with the ODC1 inhibitor difluoromethylornithine (DFMO), although a promising therapeutic strategy, is only partially effective at impeding neuroblastoma cell growth due to activation of compensatory mechanisms resulting in increased polyamine uptake from the surrounding microenvironment.	Eflornithine	82-86	ornithine decarboxylase, structural 1	Mus musculus	42-46
30355744-4	2019	Because the ODC inhibitor difluoromethylornithine (DFMO) acts like RS1-Reg(S20E), and DFMO and RS1-Reg(S20E) are not cumulative, we raised the hypothesis that RS1-Reg(S20E) down-regulates the exocytotic pathway of SGLT1 at the trans-Golgi by inhibiting ODC.	Eflornithine	51-55	ornithine decarboxylase 1	Homo sapiens	12-15
30239107-8	2018	Our autosomal dominant patient who carries this gain-of-function ODC1 mutation may benefit from treatment with alpha-difluoromethylornithine, a well-tolerated, U.S. Food and Drug Administration (FDA).	Eflornithine	111-140	ornithine decarboxylase 1	Homo sapiens	65-69
30475806-3	2018	This is the case for four of five current drugs used to treat Human African Trypanosomiasis (HAT); eflornithine is a specific inhibitor of ornithine decarboxylase.	Eflornithine	99-111	ornithine decarboxylase 1	Homo sapiens	139-162
30404920-6	2018	We therefore had proposed to repurpose alpha-difluoromethylornithine (DFMO), an FDA-approved, orally available ODC inhibitor, for management of neuroblastoma, and this intervention is now being pursued in several clinical trials.	Eflornithine	39-68	ornithine decarboxylase 1	Homo sapiens	111-114
30404920-6	2018	We therefore had proposed to repurpose alpha-difluoromethylornithine (DFMO), an FDA-approved, orally available ODC inhibitor, for management of neuroblastoma, and this intervention is now being pursued in several clinical trials.	Eflornithine	70-74	ornithine decarboxylase 1	Homo sapiens	111-114
30138353-7	2018	Combination treatments using curcumin with the ODC inhibitor 2-difluoromethylornithine (DFMO), an agent currently in clinical chemoprevention trials, significantly enhanced inhibition of ODC activity and decreased growth of GI cancer cell lines beyond that observed with either agent alone.	Eflornithine	61-86	ornithine decarboxylase 1	Homo sapiens	47-50
30066894-10	2018	The action of an ODC1 inhibitor (alpha-difluoromethylornithine, DFMO) was studied in the restoration of the anticancer effects of BCT-100 in lung adenocarcinoma.	Eflornithine	33-62	ornithine decarboxylase 1	Homo sapiens	17-21
30066894-10	2018	The action of an ODC1 inhibitor (alpha-difluoromethylornithine, DFMO) was studied in the restoration of the anticancer effects of BCT-100 in lung adenocarcinoma.	Eflornithine	64-68	ornithine decarboxylase 1	Homo sapiens	17-21
30066894-16	2018	In conclusion, inhibition of ODC1 by DFMO was crucial in facilitating BCT-100 treatment in lung adenocarcinoma that was partially mediated by depleting arginine and polyamines with consequent apoptosis.	Eflornithine	37-41	ornithine decarboxylase 1	Homo sapiens	29-33
30262852-3	2018	This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent relapse following completion of standard therapy (Stratum 1) or after salvage therapy for relapsed/refractory disease (Stratum 2).	Eflornithine	59-82	ornithine decarboxylase 1	Homo sapiens	25-48
30262852-3	2018	This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent relapse following completion of standard therapy (Stratum 1) or after salvage therapy for relapsed/refractory disease (Stratum 2).	Eflornithine	84-88	ornithine decarboxylase 1	Homo sapiens	25-48
30026114-8	2018	Therefore, the interaction of Cpd2 and Cpd3 with the ornithine decarboxylase inhibitor eflornithine was determined.	Eflornithine	87-99	spinocerebellar ataxia, autosomal recessive 2	Homo sapiens	39-43
30138353-7	2018	Combination treatments using curcumin with the ODC inhibitor 2-difluoromethylornithine (DFMO), an agent currently in clinical chemoprevention trials, significantly enhanced inhibition of ODC activity and decreased growth of GI cancer cell lines beyond that observed with either agent alone.	Eflornithine	61-86	ornithine decarboxylase 1	Homo sapiens	187-190
30138353-7	2018	Combination treatments using curcumin with the ODC inhibitor 2-difluoromethylornithine (DFMO), an agent currently in clinical chemoprevention trials, significantly enhanced inhibition of ODC activity and decreased growth of GI cancer cell lines beyond that observed with either agent alone.	Eflornithine	88-92	ornithine decarboxylase 1	Homo sapiens	47-50
30138353-7	2018	Combination treatments using curcumin with the ODC inhibitor 2-difluoromethylornithine (DFMO), an agent currently in clinical chemoprevention trials, significantly enhanced inhibition of ODC activity and decreased growth of GI cancer cell lines beyond that observed with either agent alone.	Eflornithine	88-92	ornithine decarboxylase 1	Homo sapiens	187-190
29626790-2	2018	Difluoromethylornithine (DFMO, an irreversible inhibitor of ornithine decarboxylase) is reported to modulate polyamines to potentially attenuate proliferation of neuroblastoma cells.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	60-83
30115881-3	2018	In other pediatric cancer models, inhibition of the PA biosynthesis pathway with ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO) results in decreased cell proliferation and differentiation.	Eflornithine	121-150	ornithine decarboxylase 1	Homo sapiens	81-104
30115881-3	2018	In other pediatric cancer models, inhibition of the PA biosynthesis pathway with ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO) results in decreased cell proliferation and differentiation.	Eflornithine	121-150	ornithine decarboxylase 1	Homo sapiens	106-109
30115881-3	2018	In other pediatric cancer models, inhibition of the PA biosynthesis pathway with ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO) results in decreased cell proliferation and differentiation.	Eflornithine	152-156	ornithine decarboxylase 1	Homo sapiens	81-104
30115881-3	2018	In other pediatric cancer models, inhibition of the PA biosynthesis pathway with ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO) results in decreased cell proliferation and differentiation.	Eflornithine	152-156	ornithine decarboxylase 1	Homo sapiens	106-109
29635516-10	2018	Treatment of Tsc2+/- mice with the ornithine decarboxylase inhibitor alpha-difluoromethylornithine, to reduce putrescine synthesis dose-dependently reduced hippocampal astrogliosis.	Eflornithine	69-98	TSC complex subunit 2	Mus musculus	13-17
29635516-10	2018	Treatment of Tsc2+/- mice with the ornithine decarboxylase inhibitor alpha-difluoromethylornithine, to reduce putrescine synthesis dose-dependently reduced hippocampal astrogliosis.	Eflornithine	69-98	ornithine decarboxylase, structural 1	Mus musculus	35-58
29626790-2	2018	Difluoromethylornithine (DFMO, an irreversible inhibitor of ornithine decarboxylase) is reported to modulate polyamines to potentially attenuate proliferation of neuroblastoma cells.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	60-83
29378419-1	2018	This review covers the literature between 1989 and 2007 on studies relevant to the neuro-oncology usage of eflornithine (alpha-difluoromethylornithine), an oral agent that irreversibly inhibits the enzyme ornithine decarboxylase.	Eflornithine	107-119	ornithine decarboxylase 1	Homo sapiens	205-228
29378419-1	2018	This review covers the literature between 1989 and 2007 on studies relevant to the neuro-oncology usage of eflornithine (alpha-difluoromethylornithine), an oral agent that irreversibly inhibits the enzyme ornithine decarboxylase.	Eflornithine	121-150	ornithine decarboxylase 1	Homo sapiens	205-228
29559907-5	2018	We report results from a single-case study in which DFMO was administered, for the first time, in an attempt to slow progression of AD in a single woman with multi-domain, amnestic MCI who was unable to tolerate an acetylcholinesterase inhibitor.	Eflornithine	52-56	acetylcholinesterase (Cartwright blood group)	Homo sapiens	215-235
29215586-9	2017	A combination therapy containing difluoromethylornithine (DFMO, an ODC inhibitor) and a polyamine transport inhibitor (PTI) were shown to significantly deplete intracellular polyamine pools.	Eflornithine	33-56	ornithine decarboxylase 1	Homo sapiens	67-70
29419804-1	2018	The fluorinated ornithine analog alpha-difluoromethylornithine (DFMO, eflornithine, ornidyl) is an irreversible suicide inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme of polyamine biosynthesis.	Eflornithine	33-62	ornithine decarboxylase 1	Homo sapiens	133-156
29419804-1	2018	The fluorinated ornithine analog alpha-difluoromethylornithine (DFMO, eflornithine, ornidyl) is an irreversible suicide inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme of polyamine biosynthesis.	Eflornithine	33-62	ornithine decarboxylase 1	Homo sapiens	158-161
29419804-1	2018	The fluorinated ornithine analog alpha-difluoromethylornithine (DFMO, eflornithine, ornidyl) is an irreversible suicide inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme of polyamine biosynthesis.	Eflornithine	64-68	ornithine decarboxylase 1	Homo sapiens	133-156
29419804-1	2018	The fluorinated ornithine analog alpha-difluoromethylornithine (DFMO, eflornithine, ornidyl) is an irreversible suicide inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme of polyamine biosynthesis.	Eflornithine	64-68	ornithine decarboxylase 1	Homo sapiens	158-161
29419804-1	2018	The fluorinated ornithine analog alpha-difluoromethylornithine (DFMO, eflornithine, ornidyl) is an irreversible suicide inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme of polyamine biosynthesis.	Eflornithine	70-82	ornithine decarboxylase 1	Homo sapiens	133-156
29419804-1	2018	The fluorinated ornithine analog alpha-difluoromethylornithine (DFMO, eflornithine, ornidyl) is an irreversible suicide inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme of polyamine biosynthesis.	Eflornithine	70-82	ornithine decarboxylase 1	Homo sapiens	158-161
29419804-1	2018	The fluorinated ornithine analog alpha-difluoromethylornithine (DFMO, eflornithine, ornidyl) is an irreversible suicide inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme of polyamine biosynthesis.	Eflornithine	84-91	ornithine decarboxylase 1	Homo sapiens	133-156
29419804-1	2018	The fluorinated ornithine analog alpha-difluoromethylornithine (DFMO, eflornithine, ornidyl) is an irreversible suicide inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme of polyamine biosynthesis.	Eflornithine	84-91	ornithine decarboxylase 1	Homo sapiens	158-161
29299930-6	2018	DFMO alone and with Trimer44NMe also inhibited in vivo orthotopic PDAC growth and resulted in decreased c-Myc expression, a readout of polyamine pathway dysfunction.	Eflornithine	0-4	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	104-109
29240775-5	2017	Difluoromethylornithine (DFMO) a specific inhibitor of ODC significantly reduced cell proliferation, cell viability, and colony formation in cell line models derived from undifferentiated, endometrioid, serous, carcinosarcoma (mixed mesodermal tumor; MMT) and clear cell endometrial cancers.	Eflornithine	0-23	ornithine decarboxylase, structural 1	Mus musculus	55-58
29240775-5	2017	Difluoromethylornithine (DFMO) a specific inhibitor of ODC significantly reduced cell proliferation, cell viability, and colony formation in cell line models derived from undifferentiated, endometrioid, serous, carcinosarcoma (mixed mesodermal tumor; MMT) and clear cell endometrial cancers.	Eflornithine	25-29	ornithine decarboxylase, structural 1	Mus musculus	55-58
29240775-7	2017	ODC-regulated polyamines (putrescine [Put] and/or spermidine [Spd]) known activators of cell proliferation were strongly decreased in response to DFMO, in both tumor tissue ([Put] (p = 0.0006), [Spd] (p&lt;0.0001)) and blood plasma ([Put] (p&lt;0.0001), [Spd] (p = 0.0049)) of treated mice.	Eflornithine	146-150	ornithine decarboxylase, structural 1	Mus musculus	0-3
28346093-5	2017	This enables real-time monitoring of the enzymatic reaction through a continuous fluorescence change caused by dye displacement from the macrocycle by the formed product, which allowed a straightforward determination of enzyme kinetic parameters ( kcat = 0.12 s-1 and KM = 24 microM) and inhibition constants of the two ODC inhibitors alpha-difluoromethylornithine (DFMO) and epigallocatechin gallate (EGCG).	Eflornithine	335-364	ornithine decarboxylase 1	Homo sapiens	320-323
29135915-2	2017	Polyamine levels can be depleted by difluoromethylornithine (DFMO), an inhibitor of the key polyamine biosynthesis enzyme ornithine decarboxylase (ODC).	Eflornithine	36-59	Ornithine decarboxylase 1	Drosophila melanogaster	122-145
29135915-2	2017	Polyamine levels can be depleted by difluoromethylornithine (DFMO), an inhibitor of the key polyamine biosynthesis enzyme ornithine decarboxylase (ODC).	Eflornithine	36-59	Ornithine decarboxylase 1	Drosophila melanogaster	147-150
29135915-2	2017	Polyamine levels can be depleted by difluoromethylornithine (DFMO), an inhibitor of the key polyamine biosynthesis enzyme ornithine decarboxylase (ODC).	Eflornithine	61-65	Ornithine decarboxylase 1	Drosophila melanogaster	122-145
29135915-2	2017	Polyamine levels can be depleted by difluoromethylornithine (DFMO), an inhibitor of the key polyamine biosynthesis enzyme ornithine decarboxylase (ODC).	Eflornithine	61-65	Ornithine decarboxylase 1	Drosophila melanogaster	147-150
28679527-2	2017	Indeed, ODC is the target of the WHO "essential medicine" eflornithine, which is antagonistic to another anti-HAT drug, suramin.	Eflornithine	58-70	ornithine decarboxylase 1	Homo sapiens	8-11
28346093-5	2017	This enables real-time monitoring of the enzymatic reaction through a continuous fluorescence change caused by dye displacement from the macrocycle by the formed product, which allowed a straightforward determination of enzyme kinetic parameters ( kcat = 0.12 s-1 and KM = 24 microM) and inhibition constants of the two ODC inhibitors alpha-difluoromethylornithine (DFMO) and epigallocatechin gallate (EGCG).	Eflornithine	366-370	ornithine decarboxylase 1	Homo sapiens	320-323
28478810-12	2017	Depletion of cellular polyamines by DL-a-difluoromethylornithine (DFMO, an inhibitor of polyamine synthesis) suppressed cell migration and proliferation, decreased polyamines content, and reduced [Ca2+]c, which was paralleled by a decrease in TRPC1 and PLC-gamma1 mRNA and protein expression in IEC-6 cells.	Eflornithine	66-70	transient receptor potential cation channel, subfamily C, member 1	Rattus norvegicus	243-248
28478810-12	2017	Depletion of cellular polyamines by DL-a-difluoromethylornithine (DFMO, an inhibitor of polyamine synthesis) suppressed cell migration and proliferation, decreased polyamines content, and reduced [Ca2+]c, which was paralleled by a decrease in TRPC1 and PLC-gamma1 mRNA and protein expression in IEC-6 cells.	Eflornithine	66-70	phospholipase C, gamma 1	Rattus norvegicus	253-263
28707668-8	2017	It has been demonstrated that, in cells transfected with HCV genes, DFMO reduces the production of three out of four tested cytokines, namely, TNF-alpha and TGF-beta in cells that express HCV core, E1E2, NS3, NS5A, and NS5B proteins, and IL-1beta in the cells that express HCV core, E1E2, and NS3 proteins.	Eflornithine	68-72	tumor necrosis factor	Homo sapiens	143-152
28707668-8	2017	It has been demonstrated that, in cells transfected with HCV genes, DFMO reduces the production of three out of four tested cytokines, namely, TNF-alpha and TGF-beta in cells that express HCV core, E1E2, NS3, NS5A, and NS5B proteins, and IL-1beta in the cells that express HCV core, E1E2, and NS3 proteins.	Eflornithine	68-72	transforming growth factor beta 1	Homo sapiens	157-165
28707668-8	2017	It has been demonstrated that, in cells transfected with HCV genes, DFMO reduces the production of three out of four tested cytokines, namely, TNF-alpha and TGF-beta in cells that express HCV core, E1E2, NS3, NS5A, and NS5B proteins, and IL-1beta in the cells that express HCV core, E1E2, and NS3 proteins.	Eflornithine	68-72	interleukin 1 beta	Homo sapiens	238-246
29872701-3	2017	Then we investigated the function of ornithine decarboxylase in ESCC cells by using shRNA and an irreversible inhibitor of ornithine decarboxylase, difluoromethylornithine.	Eflornithine	148-171	ornithine decarboxylase 1	Homo sapiens	37-60
28125906-1	2017	Difluoromethylornithine (DFMO; eflornithine) is an irreversible suicide inhibitor of the enzyme ornithine decarboxylase which is involved in polyamine synthesis.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	96-119
28478810-13	2017	AT-I reversed the effects of DFMO on polyamines content, [Ca2+]c, TRPC1 and PLC-gamma1 mRNA and protein expression, and restored IEC-6 cell migration and proliferation to near normal levels.	Eflornithine	29-33	transient receptor potential cation channel, subfamily C, member 1	Rattus norvegicus	66-71
28478810-13	2017	AT-I reversed the effects of DFMO on polyamines content, [Ca2+]c, TRPC1 and PLC-gamma1 mRNA and protein expression, and restored IEC-6 cell migration and proliferation to near normal levels.	Eflornithine	29-33	phospholipase C, gamma 1	Rattus norvegicus	76-86
28125906-1	2017	Difluoromethylornithine (DFMO; eflornithine) is an irreversible suicide inhibitor of the enzyme ornithine decarboxylase which is involved in polyamine synthesis.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	96-119
28125906-1	2017	Difluoromethylornithine (DFMO; eflornithine) is an irreversible suicide inhibitor of the enzyme ornithine decarboxylase which is involved in polyamine synthesis.	Eflornithine	31-43	ornithine decarboxylase 1	Homo sapiens	96-119
27001865-5	2016	Moreover, it completely prevented alpha-difluoromethylornithine (DFMO)-induced increase in [(14)C] Spd uptake, and inhibited [(14)C] putrescine (Put) uptake and ODC activity in vivo Seven-day treatment of DU145 cells with TETA caused growth cessation by reducing intracellular polyamine levels and suppressing the formation of hypusinated eukaryotic translation initiation factor 5A (eIF5A).	Eflornithine	65-69	ornithine decarboxylase 1	Homo sapiens	161-164
27841323-8	2016	DFMO, Rosuvastatin and/or combinations significantly decreased polyamine content and increased intra-tumoral NK cells expressing perforin plus IFN-gamma compared to untreated colon tumors.	Eflornithine	0-4	interferon gamma	Rattus norvegicus	143-152
27555600-9	2016	Inhibition of ODC1 activity by RS1-Reg mutants and the ODC1 inhibitor difluoromethylornithine (DFMO) was measured in the absence and presence of glucose.	Eflornithine	70-93	ornithine decarboxylase 1 L homeolog	Xenopus laevis	55-59
27555600-9	2016	Inhibition of ODC1 activity by RS1-Reg mutants and the ODC1 inhibitor difluoromethylornithine (DFMO) was measured in the absence and presence of glucose.	Eflornithine	95-99	ornithine decarboxylase 1 L homeolog	Xenopus laevis	14-18
27535047-6	2016	Here, we describe the antiviral effects of two molecules that alter polyamine levels: difluoromethylornithine (DFMO; also called eflornithine), which is a suicide inhibitor of ornithine decarboxylase 1 (ODC1), and diethylnorspermine (DENSpm), an activator of spermidine/spermine N1-acetyltransferase (SAT1).	Eflornithine	86-109	ornithine decarboxylase 1	Homo sapiens	176-201
27535047-6	2016	Here, we describe the antiviral effects of two molecules that alter polyamine levels: difluoromethylornithine (DFMO; also called eflornithine), which is a suicide inhibitor of ornithine decarboxylase 1 (ODC1), and diethylnorspermine (DENSpm), an activator of spermidine/spermine N1-acetyltransferase (SAT1).	Eflornithine	86-109	ornithine decarboxylase 1	Homo sapiens	203-207
27535047-6	2016	Here, we describe the antiviral effects of two molecules that alter polyamine levels: difluoromethylornithine (DFMO; also called eflornithine), which is a suicide inhibitor of ornithine decarboxylase 1 (ODC1), and diethylnorspermine (DENSpm), an activator of spermidine/spermine N1-acetyltransferase (SAT1).	Eflornithine	86-109	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	301-305
27535047-6	2016	Here, we describe the antiviral effects of two molecules that alter polyamine levels: difluoromethylornithine (DFMO; also called eflornithine), which is a suicide inhibitor of ornithine decarboxylase 1 (ODC1), and diethylnorspermine (DENSpm), an activator of spermidine/spermine N1-acetyltransferase (SAT1).	Eflornithine	111-115	ornithine decarboxylase 1	Homo sapiens	176-201
27535047-6	2016	Here, we describe the antiviral effects of two molecules that alter polyamine levels: difluoromethylornithine (DFMO; also called eflornithine), which is a suicide inhibitor of ornithine decarboxylase 1 (ODC1), and diethylnorspermine (DENSpm), an activator of spermidine/spermine N1-acetyltransferase (SAT1).	Eflornithine	111-115	ornithine decarboxylase 1	Homo sapiens	203-207
27535047-6	2016	Here, we describe the antiviral effects of two molecules that alter polyamine levels: difluoromethylornithine (DFMO; also called eflornithine), which is a suicide inhibitor of ornithine decarboxylase 1 (ODC1), and diethylnorspermine (DENSpm), an activator of spermidine/spermine N1-acetyltransferase (SAT1).	Eflornithine	111-115	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	301-305
27535047-6	2016	Here, we describe the antiviral effects of two molecules that alter polyamine levels: difluoromethylornithine (DFMO; also called eflornithine), which is a suicide inhibitor of ornithine decarboxylase 1 (ODC1), and diethylnorspermine (DENSpm), an activator of spermidine/spermine N1-acetyltransferase (SAT1).	Eflornithine	129-141	ornithine decarboxylase 1	Homo sapiens	176-201
27535047-6	2016	Here, we describe the antiviral effects of two molecules that alter polyamine levels: difluoromethylornithine (DFMO; also called eflornithine), which is a suicide inhibitor of ornithine decarboxylase 1 (ODC1), and diethylnorspermine (DENSpm), an activator of spermidine/spermine N1-acetyltransferase (SAT1).	Eflornithine	129-141	ornithine decarboxylase 1	Homo sapiens	203-207
27535047-6	2016	Here, we describe the antiviral effects of two molecules that alter polyamine levels: difluoromethylornithine (DFMO; also called eflornithine), which is a suicide inhibitor of ornithine decarboxylase 1 (ODC1), and diethylnorspermine (DENSpm), an activator of spermidine/spermine N1-acetyltransferase (SAT1).	Eflornithine	129-141	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	301-305
27480131-2	2016	Inhibition of ornithine decarboxylase (ODC) using low-dose eflornithine (DFMO, CPP-1X), combined with maximal PA export using low-dose sulindac, results in greatly reduced levels of normal mucosal PAs.	Eflornithine	59-71	ornithine decarboxylase 1	Homo sapiens	14-37
27480131-2	2016	Inhibition of ornithine decarboxylase (ODC) using low-dose eflornithine (DFMO, CPP-1X), combined with maximal PA export using low-dose sulindac, results in greatly reduced levels of normal mucosal PAs.	Eflornithine	59-71	ornithine decarboxylase 1	Homo sapiens	39-42
27480131-2	2016	Inhibition of ornithine decarboxylase (ODC) using low-dose eflornithine (DFMO, CPP-1X), combined with maximal PA export using low-dose sulindac, results in greatly reduced levels of normal mucosal PAs.	Eflornithine	73-77	ornithine decarboxylase 1	Homo sapiens	14-37
27480131-2	2016	Inhibition of ornithine decarboxylase (ODC) using low-dose eflornithine (DFMO, CPP-1X), combined with maximal PA export using low-dose sulindac, results in greatly reduced levels of normal mucosal PAs.	Eflornithine	73-77	ornithine decarboxylase 1	Homo sapiens	39-42
27012811-7	2016	Furthermore, the combination of DFMO with celecoxib was found to be highly active, alone, and combined with numerous chemotherapy regimens, in regressing established tumors in both models, including tumors harboring highest risk genetic lesions such as MYCN amplification, ALK mutation, and TP53 mutation with multidrug resistance.	Eflornithine	32-36	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	253-257
27012811-7	2016	Furthermore, the combination of DFMO with celecoxib was found to be highly active, alone, and combined with numerous chemotherapy regimens, in regressing established tumors in both models, including tumors harboring highest risk genetic lesions such as MYCN amplification, ALK mutation, and TP53 mutation with multidrug resistance.	Eflornithine	32-36	anaplastic lymphoma kinase	Mus musculus	273-276
27012811-7	2016	Furthermore, the combination of DFMO with celecoxib was found to be highly active, alone, and combined with numerous chemotherapy regimens, in regressing established tumors in both models, including tumors harboring highest risk genetic lesions such as MYCN amplification, ALK mutation, and TP53 mutation with multidrug resistance.	Eflornithine	32-36	transformation related protein 53	Mus musculus	291-295
29897188-5	2016	The specific ODC inhibitor difluoromethylornithine (DFMO) increased ROS levels and weakened the ability of sodium nitrite and ammonium chloride mixture in the regulation of invasion of SMMC-7721 cells.	Eflornithine	27-50	ornithine decarboxylase 1	Homo sapiens	13-16
29897188-5	2016	The specific ODC inhibitor difluoromethylornithine (DFMO) increased ROS levels and weakened the ability of sodium nitrite and ammonium chloride mixture in the regulation of invasion of SMMC-7721 cells.	Eflornithine	52-56	ornithine decarboxylase 1	Homo sapiens	13-16
27429841-0	2016	ATP13A3 and caveolin-1 as potential biomarkers for difluoromethylornithine-based therapies in pancreatic cancers.	Eflornithine	51-74	ATPase 13A3	Homo sapiens	0-7
27429841-0	2016	ATP13A3 and caveolin-1 as potential biomarkers for difluoromethylornithine-based therapies in pancreatic cancers.	Eflornithine	51-74	caveolin 1	Homo sapiens	12-22
27429841-2	2016	Cell lines with low polyamine import activity and low ATP13A3 protein levels appear committed to polyamine biosynthesis and required high concentrations of the polyamine biosynthesis inhibitor, difluoromethylornithine (DFMO) to inhibit their growth (e.g., AsPC-1 and Capan 1).	Eflornithine	194-217	ATPase 13A3	Homo sapiens	54-61
27429841-2	2016	Cell lines with low polyamine import activity and low ATP13A3 protein levels appear committed to polyamine biosynthesis and required high concentrations of the polyamine biosynthesis inhibitor, difluoromethylornithine (DFMO) to inhibit their growth (e.g., AsPC-1 and Capan 1).	Eflornithine	219-223	ATPase 13A3	Homo sapiens	54-61
27429841-3	2016	In contrast, cell lines with high polyamine import activity and high ATP13A3 protein expression (e.g., L3.6pl) demonstrated a commitment to polyamine transport and required lower DFMO concentrations to inhibit their growth.	Eflornithine	179-183	ATPase 13A3	Homo sapiens	69-76
27429841-6	2016	High ATP13A3 protein expression and moderate to low Cav-1 protein expression was shown to be predictive of tumors which effectively escape DFMO via polyamine import.	Eflornithine	139-143	ATPase 13A3	Homo sapiens	5-12
27429841-6	2016	High ATP13A3 protein expression and moderate to low Cav-1 protein expression was shown to be predictive of tumors which effectively escape DFMO via polyamine import.	Eflornithine	139-143	caveolin 1	Homo sapiens	52-57
27429841-7	2016	In summary, this report demonstrates for the first time the role of ATP13A3 in polyamine transport and its use as a potential biomarker along with Cav-1 to select tumors most susceptible to DFMO.	Eflornithine	190-194	ATPase 13A3	Homo sapiens	68-75
26529275-2	2016	Inhibition of polyamine synthesis by alpha-difluoro-methylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, attenuates VSMC proliferation with high sensitivity and specificity.	Eflornithine	37-67	ornithine decarboxylase, structural 1	Mus musculus	105-128
26529275-2	2016	Inhibition of polyamine synthesis by alpha-difluoro-methylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, attenuates VSMC proliferation with high sensitivity and specificity.	Eflornithine	69-73	ornithine decarboxylase, structural 1	Mus musculus	105-128
27293987-10	2016	DFMO and combination-treated mice lung tumors exhibited modulated ODC pathway components (Oat, Oaz, SRM, SMS, and SAT, p &lt; 0.05) along with decreased proliferation (PCNA, Cyclin D1 and Cyclin A) and increased expression of p53, p21 and p27 compared to mice fed control diet.	Eflornithine	0-4	ornithine decarboxylase, structural 1	Mus musculus	66-69
27293987-10	2016	DFMO and combination-treated mice lung tumors exhibited modulated ODC pathway components (Oat, Oaz, SRM, SMS, and SAT, p &lt; 0.05) along with decreased proliferation (PCNA, Cyclin D1 and Cyclin A) and increased expression of p53, p21 and p27 compared to mice fed control diet.	Eflornithine	0-4	ornithine decarboxylase antizyme 1	Mus musculus	95-98
27293987-10	2016	DFMO and combination-treated mice lung tumors exhibited modulated ODC pathway components (Oat, Oaz, SRM, SMS, and SAT, p &lt; 0.05) along with decreased proliferation (PCNA, Cyclin D1 and Cyclin A) and increased expression of p53, p21 and p27 compared to mice fed control diet.	Eflornithine	0-4	cyclin D1	Mus musculus	174-183
27293987-10	2016	DFMO and combination-treated mice lung tumors exhibited modulated ODC pathway components (Oat, Oaz, SRM, SMS, and SAT, p &lt; 0.05) along with decreased proliferation (PCNA, Cyclin D1 and Cyclin A) and increased expression of p53, p21 and p27 compared to mice fed control diet.	Eflornithine	0-4	cyclin A2	Mus musculus	188-196
27293987-10	2016	DFMO and combination-treated mice lung tumors exhibited modulated ODC pathway components (Oat, Oaz, SRM, SMS, and SAT, p &lt; 0.05) along with decreased proliferation (PCNA, Cyclin D1 and Cyclin A) and increased expression of p53, p21 and p27 compared to mice fed control diet.	Eflornithine	0-4	transformation related protein 53, pseudogene	Mus musculus	226-229
27293987-10	2016	DFMO and combination-treated mice lung tumors exhibited modulated ODC pathway components (Oat, Oaz, SRM, SMS, and SAT, p &lt; 0.05) along with decreased proliferation (PCNA, Cyclin D1 and Cyclin A) and increased expression of p53, p21 and p27 compared to mice fed control diet.	Eflornithine	0-4	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	231-234
27293987-10	2016	DFMO and combination-treated mice lung tumors exhibited modulated ODC pathway components (Oat, Oaz, SRM, SMS, and SAT, p &lt; 0.05) along with decreased proliferation (PCNA, Cyclin D1 and Cyclin A) and increased expression of p53, p21 and p27 compared to mice fed control diet.	Eflornithine	0-4	cyclin-dependent kinase inhibitor 1B	Mus musculus	239-242
26663722-0	2016	Targeting Ornithine Decarboxylase by alpha-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells.	Eflornithine	37-66	ornithine decarboxylase, structural 1	Mus musculus	10-33
26663722-2	2016	However, little is known about the effect of ornithine decarboxylase (ODC) inhibition by DFMO on antitumor immune responses.	Eflornithine	89-93	ornithine decarboxylase, structural 1	Mus musculus	45-68
26663722-2	2016	However, little is known about the effect of ornithine decarboxylase (ODC) inhibition by DFMO on antitumor immune responses.	Eflornithine	89-93	ornithine decarboxylase, structural 1	Mus musculus	70-73
26663722-3	2016	We showed in this study that pharmacologic blockade of ODC by DFMO inhibited tumor growth in intact immunocompetent mice, but abrogated in the immunodeficient Rag1(-/-) mice, suggesting that antitumor effect of DFMO is dependent on the induction of adaptive antitumor T cell immune responses.	Eflornithine	62-66	ornithine decarboxylase, structural 1	Mus musculus	55-58
26663722-3	2016	We showed in this study that pharmacologic blockade of ODC by DFMO inhibited tumor growth in intact immunocompetent mice, but abrogated in the immunodeficient Rag1(-/-) mice, suggesting that antitumor effect of DFMO is dependent on the induction of adaptive antitumor T cell immune responses.	Eflornithine	211-215	ornithine decarboxylase, structural 1	Mus musculus	55-58
26663722-5	2016	Moreover, DFMO treatment enhanced antitumor CD8(+) T cell infiltration and IFN-gamma production and augmented the efficacy of adoptive T cell therapy.	Eflornithine	10-14	interferon gamma	Mus musculus	75-84
26663722-6	2016	Importantly, DFMO impaired Gr1(+)CD11b(+) myeloid-derived suppressor cells (MDSCs) suppressive activity through at least two mechanisms, including reducing arginase expression and activity and inhibiting the CD39/CD73-mediated pathway.	Eflornithine	13-17	integrin subunit alpha M	Homo sapiens	33-38
26663722-6	2016	Importantly, DFMO impaired Gr1(+)CD11b(+) myeloid-derived suppressor cells (MDSCs) suppressive activity through at least two mechanisms, including reducing arginase expression and activity and inhibiting the CD39/CD73-mediated pathway.	Eflornithine	13-17	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	208-212
26663722-6	2016	Importantly, DFMO impaired Gr1(+)CD11b(+) myeloid-derived suppressor cells (MDSCs) suppressive activity through at least two mechanisms, including reducing arginase expression and activity and inhibiting the CD39/CD73-mediated pathway.	Eflornithine	13-17	5'-nucleotidase ecto	Homo sapiens	213-217
26663722-8	2016	Our findings establish a new role of ODC inhibition by DFMO as a viable and effective immunological adjunct in effective cancer treatment, thereby adding to the growing list of chemoimmunotherapeutic applications of these agents.	Eflornithine	55-59	ornithine decarboxylase, structural 1	Mus musculus	37-40
26426536-6	2015	Furthermore, testosterone administered to castrated male mice restores prostate secretory activity, whereas administering testosterone and the ornithine decarboxylase inhibitor D,L-alpha-difluromethylornithine (DFMO) to castrated males does not restore prostate secretory activity, suggesting that polyamines are required for androgens to exert their effects.	Eflornithine	211-215	ornithine decarboxylase, structural 1	Mus musculus	143-166
27074051-3	2016	Difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, has attracted considerable interest for its antiproliferative role, which it exerts through inhibition of the polyamine pathway and cell turnover.	Eflornithine	0-23	ornithine decarboxylase 1	Rattus norvegicus	61-64
27074051-3	2016	Difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, has attracted considerable interest for its antiproliferative role, which it exerts through inhibition of the polyamine pathway and cell turnover.	Eflornithine	25-29	ornithine decarboxylase 1	Rattus norvegicus	61-64
27074051-12	2016	DFMO down-regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up-regulated the expression of SSAT and Bcl-2.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	38-41
27074051-12	2016	DFMO down-regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up-regulated the expression of SSAT and Bcl-2.	Eflornithine	0-4	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	43-71
27074051-12	2016	DFMO down-regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up-regulated the expression of SSAT and Bcl-2.	Eflornithine	0-4	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	73-78
27074051-12	2016	DFMO down-regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up-regulated the expression of SSAT and Bcl-2.	Eflornithine	0-4	DNA-damage inducible transcript 3	Rattus norvegicus	81-105
27074051-12	2016	DFMO down-regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up-regulated the expression of SSAT and Bcl-2.	Eflornithine	0-4	DNA-damage inducible transcript 3	Rattus norvegicus	107-111
27074051-12	2016	DFMO down-regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up-regulated the expression of SSAT and Bcl-2.	Eflornithine	0-4	caspase 12	Rattus norvegicus	122-132
27074051-12	2016	DFMO down-regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up-regulated the expression of SSAT and Bcl-2.	Eflornithine	0-4	BCL2 associated X, apoptosis regulator	Rattus norvegicus	138-141
27074051-12	2016	DFMO down-regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up-regulated the expression of SSAT and Bcl-2.	Eflornithine	0-4	spermidine/spermine N1-acetyl transferase 1	Rattus norvegicus	177-181
27074051-12	2016	DFMO down-regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up-regulated the expression of SSAT and Bcl-2.	Eflornithine	0-4	BCL2, apoptosis regulator	Rattus norvegicus	186-191
26884982-9	2015	CHOP expression was significantly lower in DFMO group than in I/R group at each time point (P&lt;0.05).	Eflornithine	43-47	DNA-damage inducible transcript 3	Rattus norvegicus	0-4
26426536-10	2015	Inhibiting ornithine decarboxylase using DFMO in UGS organ culture blocked the induction of prostatic buds by androgens, and significantly decreased expression of key prostate transcription factor, Nkx3.1, by androgens.	Eflornithine	41-45	ornithine decarboxylase, structural 1	Mus musculus	11-34
26426536-10	2015	Inhibiting ornithine decarboxylase using DFMO in UGS organ culture blocked the induction of prostatic buds by androgens, and significantly decreased expression of key prostate transcription factor, Nkx3.1, by androgens.	Eflornithine	41-45	NK3 homeobox 1	Mus musculus	198-204
26426536-11	2015	DFMO also significantly decreased the expression of developmental regulatory gene Notch1.	Eflornithine	0-4	notch 1	Mus musculus	82-88
26396545-7	2015	DFMO alone or in combination with sulindac suppressed both the tumor number and tumor burden growth rate in the CP setting because of DFMO-mediated decrease in cell proliferation (Ki-67, P &lt; 0.001) and K-RAS mutations frequency (P = 0.04).	Eflornithine	0-4	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	205-210
26396545-7	2015	DFMO alone or in combination with sulindac suppressed both the tumor number and tumor burden growth rate in the CP setting because of DFMO-mediated decrease in cell proliferation (Ki-67, P &lt; 0.001) and K-RAS mutations frequency (P = 0.04).	Eflornithine	134-138	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	205-210
26396545-9	2015	A decrease in COX-2 staining in DFMO/sulindac CT groups (COX-2, P &lt; 0.01) confirmed the treatment effect.	Eflornithine	32-36	cytochrome c oxidase II, mitochondrial	Mus musculus	14-19
26396545-9	2015	A decrease in COX-2 staining in DFMO/sulindac CT groups (COX-2, P &lt; 0.01) confirmed the treatment effect.	Eflornithine	32-36	cytochrome c oxidase II, mitochondrial	Mus musculus	57-62
26835380-4	2015	DFMO is an irreversible inhibitor of ornithine decarboxylase (Odc), a MYC target gene, bona fide oncogene, and the rate-limiting enzyme in polyamine synthesis.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	37-60
26140984-2	2015	Suppression of ODC by its irreversible inhibitor, alpha-difluoromethylornithine (DFMO), or by RNA interference through siRNA, enhanced osteogenic gene expression and alkaline phosphatase activity, and accelerated matrix mineralization of human bone marrow-derived mesenchymal stem cells (hBMSCs).	Eflornithine	50-79	ornithine decarboxylase 1	Homo sapiens	15-18
26140984-2	2015	Suppression of ODC by its irreversible inhibitor, alpha-difluoromethylornithine (DFMO), or by RNA interference through siRNA, enhanced osteogenic gene expression and alkaline phosphatase activity, and accelerated matrix mineralization of human bone marrow-derived mesenchymal stem cells (hBMSCs).	Eflornithine	81-85	ornithine decarboxylase 1	Homo sapiens	15-18
25818703-4	2015	The suitability of this methodology is further corroborated through the examination of the metabolic changes in the polyamines pathway produced in colon cancer HT-29 cells by difluoromethylornithine (DFMO), a known potent ornithine decarboxylase inhibitor.	Eflornithine	175-198	ornithine decarboxylase 1	Homo sapiens	222-245
25818703-4	2015	The suitability of this methodology is further corroborated through the examination of the metabolic changes in the polyamines pathway produced in colon cancer HT-29 cells by difluoromethylornithine (DFMO), a known potent ornithine decarboxylase inhibitor.	Eflornithine	200-204	ornithine decarboxylase 1	Homo sapiens	222-245
26112945-6	2015	Determination of ODC - the key enzyme of the polyamine synthesis - in the samples of experimental tumors was performed by method of Luqman S. RESULTS: Administration of DFMO or it"s combination with nor-NOHA resulted in the decrease of tumor growth rate, number and volume of lung metastases and was accompanied with reduced ODC activity in tumor tissue.	Eflornithine	169-173	ornithine decarboxylase, structural 1	Mus musculus	17-20
26112945-6	2015	Determination of ODC - the key enzyme of the polyamine synthesis - in the samples of experimental tumors was performed by method of Luqman S. RESULTS: Administration of DFMO or it"s combination with nor-NOHA resulted in the decrease of tumor growth rate, number and volume of lung metastases and was accompanied with reduced ODC activity in tumor tissue.	Eflornithine	169-173	ornithine decarboxylase, structural 1	Mus musculus	325-328
25935110-2	2015	Another promising cancer therapy is difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, which is oraly administered and well tolerated.	Eflornithine	36-59	ornithine decarboxylase 1	Homo sapiens	84-107
25935110-2	2015	Another promising cancer therapy is difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, which is oraly administered and well tolerated.	Eflornithine	61-65	ornithine decarboxylase 1	Homo sapiens	84-107
26835380-4	2015	DFMO is an irreversible inhibitor of ornithine decarboxylase (Odc), a MYC target gene, bona fide oncogene, and the rate-limiting enzyme in polyamine synthesis.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	62-65
26835380-4	2015	DFMO is an irreversible inhibitor of ornithine decarboxylase (Odc), a MYC target gene, bona fide oncogene, and the rate-limiting enzyme in polyamine synthesis.	Eflornithine	0-4	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	70-73
26835380-12	2015	Putative DFMO activities that are both cancer cell intrinsic (targeting the principal oncogenic driver, MYC) and cancer cell extrinsic (altering the tumor microenvironment to support anti-tumor immunity) will be discussed.	Eflornithine	9-13	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	104-107
26018967-3	2015	This study investigated safety, response, pharmacokinetics, genetic and metabolic factors associated with ODC in a clinical trial of the ODC inhibitor difluoromethylornithine (DFMO) +- etoposide for patients with relapsed or refractory NB.	Eflornithine	151-174	ornithine decarboxylase 1	Homo sapiens	137-140
26018967-8	2015	Patients with the minor T-allele at rs2302616 of the ODC gene had higher baseline levels (p=0.02) of, and larger decreases in, total urinary polyamines during the first cycle of DFMO therapy (p=0.003) and had median progression free survival (PFS) that was over three times longer, compared to patients with the major G allele at this locus although this last result was not statistically significant (p=0.07).	Eflornithine	178-182	ornithine decarboxylase 1	Homo sapiens	53-56
26018967-12	2015	Children with the minor T allele at rs2302616 of the ODC gene with relapsed or refractory NB had higher levels of urinary polyamine markers and responded better to therapy containing DFMO, compared to those with the major G allele at this locus.	Eflornithine	183-187	ornithine decarboxylase 1	Homo sapiens	53-56
26323151-1	2015	To study the effect of the combined administration of different doses of Glycyrrhizae Radix et Rhizoma and Atractylodis Macrocephalae Rhizoma on the proliferation of DFMO-treated intestinal epithelial cells (IEC-6) and p53, p21 mRNA and protein expressions, in order to define the molecular basis for the effect of the combined administration of different doses of Glycyrrhizae Radix et Rhizoma and Atractylodis Macrocephalae Rhizoma on the cell proliferation.	Eflornithine	166-170	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	219-222
26323151-1	2015	To study the effect of the combined administration of different doses of Glycyrrhizae Radix et Rhizoma and Atractylodis Macrocephalae Rhizoma on the proliferation of DFMO-treated intestinal epithelial cells (IEC-6) and p53, p21 mRNA and protein expressions, in order to define the molecular basis for the effect of the combined administration of different doses of Glycyrrhizae Radix et Rhizoma and Atractylodis Macrocephalae Rhizoma on the cell proliferation.	Eflornithine	166-170	KRAS proto-oncogene, GTPase	Rattus norvegicus	224-227
26323151-5	2015	Atractylodis Macrocephalae Rhizoma could increase p53, p21 mRNA and proteins expression in DFMO-treated IEC-6 cells.	Eflornithine	91-95	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	50-53
26323151-5	2015	Atractylodis Macrocephalae Rhizoma could increase p53, p21 mRNA and proteins expression in DFMO-treated IEC-6 cells.	Eflornithine	91-95	KRAS proto-oncogene, GTPase	Rattus norvegicus	55-58
26323151-6	2015	The combined administration of different ratios of Atractylodis Macrocephalae Rhizoma and Glycyrrhizae Radix et Rhizoma could significantly down-regulate Atractylodis Macrocephalae Rhizoma"s effect on p53, p21 mRNA and proteins expression in DFMO-treated IEC-6 cells and promote the proliferation of IEC-6 cells.	Eflornithine	242-246	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	201-204
26323151-6	2015	The combined administration of different ratios of Atractylodis Macrocephalae Rhizoma and Glycyrrhizae Radix et Rhizoma could significantly down-regulate Atractylodis Macrocephalae Rhizoma"s effect on p53, p21 mRNA and proteins expression in DFMO-treated IEC-6 cells and promote the proliferation of IEC-6 cells.	Eflornithine	242-246	KRAS proto-oncogene, GTPase	Rattus norvegicus	206-209
25415050-7	2015	In vitro experiments using NB cell lines, BE(2)-C, SMS-KCNR, and CHLA90 show that DFMO treatment reduced LIN28B and MYCN protein levels and increased Let-7 miRNA and decreased neurosphere formation.	Eflornithine	82-86	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	116-120
25415050-6	2015	Difluoromethylornithine (DFMO) is an inhibitor of ODC in clinical trials for children with NB.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	50-53
25415050-6	2015	Difluoromethylornithine (DFMO) is an inhibitor of ODC in clinical trials for children with NB.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	50-53
25415050-7	2015	In vitro experiments using NB cell lines, BE(2)-C, SMS-KCNR, and CHLA90 show that DFMO treatment reduced LIN28B and MYCN protein levels and increased Let-7 miRNA and decreased neurosphere formation.	Eflornithine	82-86	lin-28 homolog B	Homo sapiens	105-111
25248858-0	2014	Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.	Eflornithine	0-12	ornithine decarboxylase, structural 1	Mus musculus	76-99
25248858-0	2014	Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.	Eflornithine	14-18	ornithine decarboxylase, structural 1	Mus musculus	76-99
25248858-3	2014	Interest in use of the ODC inhibitor eflornithine (DFMO) as a cancer chemopreventive agent has increased in recent years since ODC was shown to be transactivated by the c-myc oncogene and to cooperate with the ras oncogene in malignant transformation of epithelial tissues.	Eflornithine	37-49	ornithine decarboxylase, structural 1	Mus musculus	23-26
25248858-3	2014	Interest in use of the ODC inhibitor eflornithine (DFMO) as a cancer chemopreventive agent has increased in recent years since ODC was shown to be transactivated by the c-myc oncogene and to cooperate with the ras oncogene in malignant transformation of epithelial tissues.	Eflornithine	37-49	ornithine decarboxylase, structural 1	Mus musculus	127-130
25248858-3	2014	Interest in use of the ODC inhibitor eflornithine (DFMO) as a cancer chemopreventive agent has increased in recent years since ODC was shown to be transactivated by the c-myc oncogene and to cooperate with the ras oncogene in malignant transformation of epithelial tissues.	Eflornithine	51-55	ornithine decarboxylase, structural 1	Mus musculus	23-26
25248858-3	2014	Interest in use of the ODC inhibitor eflornithine (DFMO) as a cancer chemopreventive agent has increased in recent years since ODC was shown to be transactivated by the c-myc oncogene and to cooperate with the ras oncogene in malignant transformation of epithelial tissues.	Eflornithine	51-55	ornithine decarboxylase, structural 1	Mus musculus	127-130
25248858-5	2014	The Kras(G12D/+) mice fed DFMO at 0.1% and 0.2% in the diet showed a significant inhibition (P &lt; 0.0001) of PDAC incidence compared with mice fed control diet.	Eflornithine	26-30	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	4-8
25248858-8	2014	DFMO-treated pancreas exhibited modulated ODC pathway components along with decreased proliferation and increased expression of p21/p27 as compared with pancreatic tissues derived from mice fed control diet.	Eflornithine	0-4	ornithine decarboxylase, structural 1	Mus musculus	42-45
25248858-8	2014	DFMO-treated pancreas exhibited modulated ODC pathway components along with decreased proliferation and increased expression of p21/p27 as compared with pancreatic tissues derived from mice fed control diet.	Eflornithine	0-4	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	128-131
25248858-8	2014	DFMO-treated pancreas exhibited modulated ODC pathway components along with decreased proliferation and increased expression of p21/p27 as compared with pancreatic tissues derived from mice fed control diet.	Eflornithine	0-4	dynactin 6	Mus musculus	132-135
26093909-4	2015	We and others previously showed that polyamines (PA) like spermidine and spermine are essential for NB tumorigenesis and that DFMO, an inhibitor of the key PA synthesis gene product ODC, is effective both in vitro and in vivo, securing its evaluation in NB clinical trials.	Eflornithine	126-130	ornithine decarboxylase 1	Homo sapiens	182-185
25730793-2	2015	In these methods eflornithine hydrochloride react with bromocresol green (buffer of pH 4), bromophenol blue (buffer pH 4.5), methyl orange (buffer of pH 5.5) and bromothymol blue (buffer of pH 5) respectively.	Eflornithine	17-43	prolyl 4-hydroxylase, transmembrane	Homo sapiens	84-88
25730793-2	2015	In these methods eflornithine hydrochloride react with bromocresol green (buffer of pH 4), bromophenol blue (buffer pH 4.5), methyl orange (buffer of pH 5.5) and bromothymol blue (buffer of pH 5) respectively.	Eflornithine	17-43	prolyl 4-hydroxylase, transmembrane	Homo sapiens	116-120
25449949-10	2015	Therefore, we demonstrated cross-talk with the use of alpha-difluoromethylornithine which can reduce the activity of ornithine decarboxylase of L. donovani, eliminating the parasite-induced immune suppression and inducing collateral host protective responses in visceral leishmaniasis.	Eflornithine	54-83	ornithine decarboxylase 1	Homo sapiens	117-140
25415050-9	2015	Additionally, sensitivity to DFMO treatment correlated with LIN28B overexpression (BE(2)-C&gt;SMS-KCNR&gt;CHLA90).	Eflornithine	29-33	lin-28 homolog B	Homo sapiens	60-66
25415050-10	2015	This is the first study to demonstrate that DFMO treatment restores balance to the LIN28/Let-7 axis and inhibits glycolytic metabolism and neurosphere formation in NB and that PET scans may be a meaningful imaging tool to evaluate the therapeutic effects of DFMO treatment.	Eflornithine	44-48	lin-28 homolog A	Homo sapiens	83-88
24666424-5	2014	Treatment with alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, reduced DNA synthesis in primary rat VSMCs in a concentration-dependent manner with an IC50 value of 100 muM.	Eflornithine	15-44	ornithine decarboxylase 1	Rattus norvegicus	82-85
24666424-5	2014	Treatment with alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, reduced DNA synthesis in primary rat VSMCs in a concentration-dependent manner with an IC50 value of 100 muM.	Eflornithine	46-50	ornithine decarboxylase 1	Rattus norvegicus	82-85
25253735-7	2014	Our results indicate that putrescine promotes cell proliferation and protein synthesis in a dose- and time-dependent manner, which was inhibited by difluoro-methylornithine (an inhibitor of ornithine decarboxylase).	Eflornithine	148-172	Ornithine decarboxylase 1	Drosophila melanogaster	190-213
24077669-5	2014	2-Difluoromethylornithine (DFMO), an inhibitor of polyamine synthesis, increased both transcription from the canonical transcription start site and the ratio of the full-length mRNA to Azin1-X mRNA, whereas polyamines show the opposite effect.	Eflornithine	0-25	antizyme inhibitor 1	Homo sapiens	185-190
25375198-11	2014	Further analyses also revealed that DFMO increased hippocampal protein levels of the antioxidants thioredoxin 1 and peroxiredoxin 3 compared to vehicle treated animals.	Eflornithine	36-40	thioredoxin 1	Mus musculus	98-111
25375198-11	2014	Further analyses also revealed that DFMO increased hippocampal protein levels of the antioxidants thioredoxin 1 and peroxiredoxin 3 compared to vehicle treated animals.	Eflornithine	36-40	peroxiredoxin 3	Mus musculus	116-131
24921942-4	2014	In this study we show here that interruption of NMDAR modulation by polyamines through blockade of its binding site at NMDAR by arcaine (0.02 nmol/site), or inhibition of polyamine synthesis by DFMO (2.7 nmol/site), reverses Abeta25-35-induced memory impairment in mice in a novel object recognition task.	Eflornithine	194-198	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	48-53
24921942-6	2014	The Abeta-induced nuclear translocation of Jacob was blocked upon application of traxoprodil (4 nM), arcaine (4 microM) or DFMO (5 microM), suggesting that activation of the polyamine binding site at NMDAR located probably at extrasynaptic sites might underlie the cognitive deficits of Abeta25-35-treated mice.	Eflornithine	123-127	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	200-205
23846959-3	2014	To test a role for polyamines in type 1 diabetes pathogenesis, we administered the ornithine decarboxylase inhibitor difluoromethylornithine to two mouse models--the low-dose streptozotocin model and the NOD model--to deplete intracellular polyamines, and administered streptozotocin to a third model, which was haploinsufficient for the gene encoding the hypusination enzyme deoxyhypusine synthase.	Eflornithine	117-140	ornithine decarboxylase, structural 1	Mus musculus	83-106
23846959-6	2014	Difluoromethylornithine treatment reduced hypusinated eIF5A levels in both immune cells and islets.	Eflornithine	0-23	eukaryotic translation initiation factor 5A	Mus musculus	54-59
25315710-4	2014	We and others previously showed that polyamines such as spermidine play an essential role in NB tumorigenesis and that DFMO, an inhibitor of the central polyamine synthesis gene ODC, is effective in vitro and in vivo, prompting its evaluation in NB clinical trials.	Eflornithine	119-123	ornithine decarboxylase 1	Homo sapiens	178-181
24824458-9	2014	Surprisingly, addition of DENSpm along with DFMO restored AZ1 induction by putrescine in polyamine-depleted cells suggesting that the increased SSAT activity in response to DENSpm converted SPM to SPD, leading to the expression of AZ1.	Eflornithine	44-48	spermidine/spermine N1-acetyl transferase 1	Rattus norvegicus	144-148
24464033-5	2014	An inhibitor of ODC, alpha-difluoromethylornithine (DFMO), abolished the IPC-induced cardioprotection.	Eflornithine	21-50	ornithine decarboxylase 1	Rattus norvegicus	16-19
24464033-5	2014	An inhibitor of ODC, alpha-difluoromethylornithine (DFMO), abolished the IPC-induced cardioprotection.	Eflornithine	52-56	ornithine decarboxylase 1	Rattus norvegicus	16-19
24077669-5	2014	2-Difluoromethylornithine (DFMO), an inhibitor of polyamine synthesis, increased both transcription from the canonical transcription start site and the ratio of the full-length mRNA to Azin1-X mRNA, whereas polyamines show the opposite effect.	Eflornithine	27-31	antizyme inhibitor 1	Homo sapiens	185-190
24405276-7	2014	This PTI exhibited decreased sensitivity to amine oxidases and low toxicity as well as high potency (EC50 = 1.4 muM) in inhibiting the uptake of spermidine (1 muM) in DFMO-treated L3.6pl human pancreatic cancer cells.	Eflornithine	167-171	latexin	Homo sapiens	112-115
24305501-8	2014	Accordingly, we administered testosterone with and without alpha-difluoromethylornithine (DFMO), an Odc1 inhibitor, to castrated mice.	Eflornithine	59-88	ornithine decarboxylase, structural 1	Mus musculus	100-104
24305501-8	2014	Accordingly, we administered testosterone with and without alpha-difluoromethylornithine (DFMO), an Odc1 inhibitor, to castrated mice.	Eflornithine	90-94	ornithine decarboxylase, structural 1	Mus musculus	100-104
24778323-3	2014	A polyamine-blocking therapy (PBT) that combines the well-characterized ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) with AMXT 1501, a novel inhibitor of the polyamine transport system, blocked tumor growth in immunocompetent mice but not in athymic nude mice lacking T cells.	Eflornithine	112-135	ornithine decarboxylase, structural 1	Mus musculus	72-95
24405276-7	2014	This PTI exhibited decreased sensitivity to amine oxidases and low toxicity as well as high potency (EC50 = 1.4 muM) in inhibiting the uptake of spermidine (1 muM) in DFMO-treated L3.6pl human pancreatic cancer cells.	Eflornithine	167-171	latexin	Homo sapiens	159-162
25323967-12	2014	In addition, DFMO (0.5 mM) down regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up regulated the expression of SSAT and Bcl-2.	Eflornithine	13-17	ornithine decarboxylase 1	Rattus norvegicus	60-63
25323967-12	2014	In addition, DFMO (0.5 mM) down regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up regulated the expression of SSAT and Bcl-2.	Eflornithine	13-17	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	65-93
25323967-12	2014	In addition, DFMO (0.5 mM) down regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up regulated the expression of SSAT and Bcl-2.	Eflornithine	13-17	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	95-100
25323967-12	2014	In addition, DFMO (0.5 mM) down regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up regulated the expression of SSAT and Bcl-2.	Eflornithine	13-17	DNA-damage inducible transcript 3	Rattus norvegicus	103-127
25323967-12	2014	In addition, DFMO (0.5 mM) down regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up regulated the expression of SSAT and Bcl-2.	Eflornithine	13-17	DNA-damage inducible transcript 3	Rattus norvegicus	129-133
25323967-12	2014	In addition, DFMO (0.5 mM) down regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up regulated the expression of SSAT and Bcl-2.	Eflornithine	13-17	caspase 12	Rattus norvegicus	144-154
25323967-12	2014	In addition, DFMO (0.5 mM) down regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up regulated the expression of SSAT and Bcl-2.	Eflornithine	13-17	BCL2 associated X, apoptosis regulator	Rattus norvegicus	160-163
25323967-12	2014	In addition, DFMO (0.5 mM) down regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up regulated the expression of SSAT and Bcl-2.	Eflornithine	13-17	spermidine/spermine N1-acetyl transferase 1	Rattus norvegicus	199-203
25323967-12	2014	In addition, DFMO (0.5 mM) down regulated the expression of ODC, glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and Bax and up regulated the expression of SSAT and Bcl-2.	Eflornithine	13-17	BCL2, apoptosis regulator	Rattus norvegicus	208-213
23701543-15	2014	Although roscovitine was less effective in DU145 cells, pre-treatment with alpha-difluoromethylornithine (DFMO), an inhibitor of ODC, enhanced the roscovitine-induced apoptotic cell death through the cleavage of caspase-9 and caspase-3.	Eflornithine	75-104	caspase 9	Homo sapiens	212-221
23701543-15	2014	Although roscovitine was less effective in DU145 cells, pre-treatment with alpha-difluoromethylornithine (DFMO), an inhibitor of ODC, enhanced the roscovitine-induced apoptotic cell death through the cleavage of caspase-9 and caspase-3.	Eflornithine	75-104	caspase 3	Homo sapiens	226-235
23701543-15	2014	Although roscovitine was less effective in DU145 cells, pre-treatment with alpha-difluoromethylornithine (DFMO), an inhibitor of ODC, enhanced the roscovitine-induced apoptotic cell death through the cleavage of caspase-9 and caspase-3.	Eflornithine	106-110	caspase 9	Homo sapiens	212-221
23701543-15	2014	Although roscovitine was less effective in DU145 cells, pre-treatment with alpha-difluoromethylornithine (DFMO), an inhibitor of ODC, enhanced the roscovitine-induced apoptotic cell death through the cleavage of caspase-9 and caspase-3.	Eflornithine	106-110	caspase 3	Homo sapiens	226-235
24260338-0	2013	Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis.	Eflornithine	71-100	ornithine decarboxylase, structural 1	Mus musculus	29-52
23737330-7	2014	Locked nucleic acid (LNA) oligonucleotides targeting the seed region of the let-7 family rescued the expression of HMGA2, but not LIN28, in both DFMO-treated and eIF5A1/2 knockdown cultures.	Eflornithine	145-149	high mobility group AT-hook 2	Homo sapiens	115-120
25404991-9	2014	An ODC inhibitor, alpha-difluoromethylornithine, abolished the recovery of preconditioning protection mediated by exercise.	Eflornithine	18-47	ornithine decarboxylase 1	Rattus norvegicus	3-6
24260338-0	2013	Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis.	Eflornithine	71-100	thymoma viral proto-oncogene 1	Mus musculus	136-139
24260338-0	2013	Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis.	Eflornithine	71-100	mitogen-activated protein kinase 1	Mus musculus	140-143
24260338-5	2013	Here, we show that combined blockade of ODC and COX-2 using their potent inhibitors, DFMO and diclofenac respectively abrogates growth of A431 epidermal xenograft tumors in nu/nu mice by more than 90%.	Eflornithine	85-89	ornithine decarboxylase, structural 1	Mus musculus	40-43
24260338-5	2013	Here, we show that combined blockade of ODC and COX-2 using their potent inhibitors, DFMO and diclofenac respectively abrogates growth of A431 epidermal xenograft tumors in nu/nu mice by more than 90%.	Eflornithine	85-89	cytochrome c oxidase II, mitochondrial	Mus musculus	48-53
24260338-12	2013	Akt activation by ODC+COX-2 over-expression was the key player in this regard as Akt inhibition manifested effects similar to those observed by the combined inhibition of ODC+COX-2 whereas forced over-expression of Akt resisted against DFMO+diclofenac treatment.	Eflornithine	236-240	thymoma viral proto-oncogene 1	Mus musculus	0-3
24260338-12	2013	Akt activation by ODC+COX-2 over-expression was the key player in this regard as Akt inhibition manifested effects similar to those observed by the combined inhibition of ODC+COX-2 whereas forced over-expression of Akt resisted against DFMO+diclofenac treatment.	Eflornithine	236-240	ornithine decarboxylase, structural 1	Mus musculus	18-21
24260338-12	2013	Akt activation by ODC+COX-2 over-expression was the key player in this regard as Akt inhibition manifested effects similar to those observed by the combined inhibition of ODC+COX-2 whereas forced over-expression of Akt resisted against DFMO+diclofenac treatment.	Eflornithine	236-240	cytochrome c oxidase II, mitochondrial	Mus musculus	22-27
23457004-0	2013	AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.	Eflornithine	66-70	ornithine decarboxylase 1	Homo sapiens	136-159
23680596-3	2013	We aimed to test the effect of alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, on vascular cell pathophysiology in vitro and in a rat model of carotid arteriotomy-induced (re)stenosis.	Eflornithine	31-60	ornithine decarboxylase 1	Rattus norvegicus	85-108
23680596-3	2013	We aimed to test the effect of alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, on vascular cell pathophysiology in vitro and in a rat model of carotid arteriotomy-induced (re)stenosis.	Eflornithine	62-66	ornithine decarboxylase 1	Rattus norvegicus	85-108
23457004-4	2013	Alpha-difluoromethylornithine (DFMO), an ODC inhibitor, is currently being used in a Phase I clinical trial for treatment of NB.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	41-44
23457004-4	2013	Alpha-difluoromethylornithine (DFMO), an ODC inhibitor, is currently being used in a Phase I clinical trial for treatment of NB.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	41-44
23457004-7	2013	We propose that inhibiting ODC with DFMO, coupled with polyamine transport inhibition by AMXT-1501 will result in enhanced NB growth inhibition.	Eflornithine	36-40	ornithine decarboxylase 1	Homo sapiens	27-30
23771434-5	2013	We hypothesized that unrestrained SAM consumption/regeneration constitutes a futile DFMO-triggered cascade that can steal tetrahydrofolate from thymidylate synthase and thereby diminish thymidine pools.	Eflornithine	84-88	thymidylate synthetase	Homo sapiens	144-164
23771434-1	2013	UNLABELLED: The ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) is a highly effective chemopreventive agent for colorectal cancer thought to act via polyamine depletion.	Eflornithine	50-79	ornithine decarboxylase 1	Homo sapiens	16-39
23771434-1	2013	UNLABELLED: The ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) is a highly effective chemopreventive agent for colorectal cancer thought to act via polyamine depletion.	Eflornithine	81-85	ornithine decarboxylase 1	Homo sapiens	16-39
23181218-5	2012	Inhibition of ODC1 by difluoromethylornithine (DFMO) decreased tumor penetrance in TH-MYCN mice treated pre-emptively, and extended survival and synergized with chemotherapy in treating established tumors in both TH-MYCN and xenograft models.	Eflornithine	22-45	ornithine decarboxylase, structural 1	Mus musculus	14-18
23440295-0	2013	DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.	Eflornithine	0-4	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	64-68
23440295-0	2013	DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.	Eflornithine	0-4	cyclin dependent kinase inhibitor 1B	Homo sapiens	82-89
23440295-0	2013	DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.	Eflornithine	5-17	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	64-68
23440295-0	2013	DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.	Eflornithine	5-17	cyclin dependent kinase inhibitor 1B	Homo sapiens	82-89
23440295-5	2013	DFMO treatment leads to the accumulation of the cyclin-dependent kinase inhibitor p27(Kip1) protein and causes p27(Kip1)/Rb-coupled G(1) cell cycle arrest in MYCN-amplified NB tumor cells through a process that involves p27(Kip1) phosphorylation at residues Ser10 and Thr198.	Eflornithine	0-4	zinc ribbon domain containing 2	Homo sapiens	82-85
23440295-5	2013	DFMO treatment leads to the accumulation of the cyclin-dependent kinase inhibitor p27(Kip1) protein and causes p27(Kip1)/Rb-coupled G(1) cell cycle arrest in MYCN-amplified NB tumor cells through a process that involves p27(Kip1) phosphorylation at residues Ser10 and Thr198.	Eflornithine	0-4	cyclin dependent kinase inhibitor 1B	Homo sapiens	86-90
23440295-5	2013	DFMO treatment leads to the accumulation of the cyclin-dependent kinase inhibitor p27(Kip1) protein and causes p27(Kip1)/Rb-coupled G(1) cell cycle arrest in MYCN-amplified NB tumor cells through a process that involves p27(Kip1) phosphorylation at residues Ser10 and Thr198.	Eflornithine	0-4	zinc ribbon domain containing 2	Homo sapiens	111-114
23440295-5	2013	DFMO treatment leads to the accumulation of the cyclin-dependent kinase inhibitor p27(Kip1) protein and causes p27(Kip1)/Rb-coupled G(1) cell cycle arrest in MYCN-amplified NB tumor cells through a process that involves p27(Kip1) phosphorylation at residues Ser10 and Thr198.	Eflornithine	0-4	cyclin dependent kinase inhibitor 1B	Homo sapiens	115-119
23440295-5	2013	DFMO treatment leads to the accumulation of the cyclin-dependent kinase inhibitor p27(Kip1) protein and causes p27(Kip1)/Rb-coupled G(1) cell cycle arrest in MYCN-amplified NB tumor cells through a process that involves p27(Kip1) phosphorylation at residues Ser10 and Thr198.	Eflornithine	0-4	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	158-162
23440295-5	2013	DFMO treatment leads to the accumulation of the cyclin-dependent kinase inhibitor p27(Kip1) protein and causes p27(Kip1)/Rb-coupled G(1) cell cycle arrest in MYCN-amplified NB tumor cells through a process that involves p27(Kip1) phosphorylation at residues Ser10 and Thr198.	Eflornithine	0-4	zinc ribbon domain containing 2	Homo sapiens	111-114
23440295-5	2013	DFMO treatment leads to the accumulation of the cyclin-dependent kinase inhibitor p27(Kip1) protein and causes p27(Kip1)/Rb-coupled G(1) cell cycle arrest in MYCN-amplified NB tumor cells through a process that involves p27(Kip1) phosphorylation at residues Ser10 and Thr198.	Eflornithine	0-4	cyclin dependent kinase inhibitor 1B	Homo sapiens	115-119
23440295-8	2013	DFMO treatments induced MYCN protein downregulation and phosphorylation of Akt/PKB (Ser473) and GSK3-beta (Ser9), and polyamine supplementation alleviated the DFMO-induced effects.	Eflornithine	0-4	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	24-28
23440295-8	2013	DFMO treatments induced MYCN protein downregulation and phosphorylation of Akt/PKB (Ser473) and GSK3-beta (Ser9), and polyamine supplementation alleviated the DFMO-induced effects.	Eflornithine	0-4	glycogen synthase kinase 3 beta	Homo sapiens	96-105
23440295-8	2013	DFMO treatments induced MYCN protein downregulation and phosphorylation of Akt/PKB (Ser473) and GSK3-beta (Ser9), and polyamine supplementation alleviated the DFMO-induced effects.	Eflornithine	159-163	glycogen synthase kinase 3 beta	Homo sapiens	96-105
23053023-6	2013	The alpha-difluoromethyl ornithine, an irreversible inhibitor of ODC, amplified ethanol toxicity on cell viability, protein level, and DNA synthesis through accentuation of polyamine depletion in proliferating HepaRG cells.	Eflornithine	4-34	ornithine decarboxylase 1	Homo sapiens	65-68
23340449-9	2013	Significant metachronous adenoma risk reduction was observed after DFMO+sulindac treatment in dietary polyamine quartiles 1-3 (risk ratio (RR) 0.19; 95% confidence interval (CI) 0.08-0.42; P&lt;0.0001) but not in quartile 4 (RR 1.51; 95% CI 0.53-4.29; P=0.44).	Eflornithine	67-71	ribonucleotide reductase catalytic subunit M1	Homo sapiens	225-229
23418509-2	2013	Inhibition of ornithine decarboxylase, which is required for polyamine synthesis, in Jurkat cells by 3 mM D,L-alpha-difluoromethylornithine hydrochloride (DFMO) significantly decreased spermine and spermidine concentrations and was associated with decreased DNA methyltransferase (Dnmt) activity, enhanced demethylation of the LFA-1 gene (ITGAL) promoter area, and increased CD11a expression.	Eflornithine	155-159	ornithine decarboxylase 1	Homo sapiens	14-37
23418509-2	2013	Inhibition of ornithine decarboxylase, which is required for polyamine synthesis, in Jurkat cells by 3 mM D,L-alpha-difluoromethylornithine hydrochloride (DFMO) significantly decreased spermine and spermidine concentrations and was associated with decreased DNA methyltransferase (Dnmt) activity, enhanced demethylation of the LFA-1 gene (ITGAL) promoter area, and increased CD11a expression.	Eflornithine	155-159	DNA methyltransferase 1	Homo sapiens	258-279
23418509-2	2013	Inhibition of ornithine decarboxylase, which is required for polyamine synthesis, in Jurkat cells by 3 mM D,L-alpha-difluoromethylornithine hydrochloride (DFMO) significantly decreased spermine and spermidine concentrations and was associated with decreased DNA methyltransferase (Dnmt) activity, enhanced demethylation of the LFA-1 gene (ITGAL) promoter area, and increased CD11a expression.	Eflornithine	155-159	DNA methyltransferase 1	Homo sapiens	281-285
23418509-2	2013	Inhibition of ornithine decarboxylase, which is required for polyamine synthesis, in Jurkat cells by 3 mM D,L-alpha-difluoromethylornithine hydrochloride (DFMO) significantly decreased spermine and spermidine concentrations and was associated with decreased DNA methyltransferase (Dnmt) activity, enhanced demethylation of the LFA-1 gene (ITGAL) promoter area, and increased CD11a expression.	Eflornithine	155-159	integrin subunit alpha L	Homo sapiens	327-332
23418509-2	2013	Inhibition of ornithine decarboxylase, which is required for polyamine synthesis, in Jurkat cells by 3 mM D,L-alpha-difluoromethylornithine hydrochloride (DFMO) significantly decreased spermine and spermidine concentrations and was associated with decreased DNA methyltransferase (Dnmt) activity, enhanced demethylation of the LFA-1 gene (ITGAL) promoter area, and increased CD11a expression.	Eflornithine	155-159	integrin subunit alpha L	Homo sapiens	339-344
23418509-2	2013	Inhibition of ornithine decarboxylase, which is required for polyamine synthesis, in Jurkat cells by 3 mM D,L-alpha-difluoromethylornithine hydrochloride (DFMO) significantly decreased spermine and spermidine concentrations and was associated with decreased DNA methyltransferase (Dnmt) activity, enhanced demethylation of the LFA-1 gene (ITGAL) promoter area, and increased CD11a expression.	Eflornithine	155-159	integrin subunit alpha L	Homo sapiens	375-380
23300995-8	2013	An ODC inhibitor, difluoromethylornithine (DFMO), prevented the proliferation of transformed cells by JAK2 (V617F).	Eflornithine	18-41	ornithine decarboxylase, structural 1	Mus musculus	3-6
23300995-8	2013	An ODC inhibitor, difluoromethylornithine (DFMO), prevented the proliferation of transformed cells by JAK2 (V617F).	Eflornithine	18-41	Janus kinase 2	Mus musculus	102-106
23300995-8	2013	An ODC inhibitor, difluoromethylornithine (DFMO), prevented the proliferation of transformed cells by JAK2 (V617F).	Eflornithine	43-47	ornithine decarboxylase, structural 1	Mus musculus	3-6
23300995-8	2013	An ODC inhibitor, difluoromethylornithine (DFMO), prevented the proliferation of transformed cells by JAK2 (V617F).	Eflornithine	43-47	Janus kinase 2	Mus musculus	102-106
23300995-9	2013	Importantly, administration of DFMO effectively delayed tumor formation in nude mice inoculated with transformed cells by JAK2 (V617F), resulting in prolonged survival; therefore, ODC expression through c-Myc is a critical step for JAK2 (V617F)-induced transformation and DFMO could be used as effective therapy for MPNs.	Eflornithine	31-35	Janus kinase 2	Mus musculus	122-126
23300995-9	2013	Importantly, administration of DFMO effectively delayed tumor formation in nude mice inoculated with transformed cells by JAK2 (V617F), resulting in prolonged survival; therefore, ODC expression through c-Myc is a critical step for JAK2 (V617F)-induced transformation and DFMO could be used as effective therapy for MPNs.	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	180-183
23300995-9	2013	Importantly, administration of DFMO effectively delayed tumor formation in nude mice inoculated with transformed cells by JAK2 (V617F), resulting in prolonged survival; therefore, ODC expression through c-Myc is a critical step for JAK2 (V617F)-induced transformation and DFMO could be used as effective therapy for MPNs.	Eflornithine	31-35	Janus kinase 2	Mus musculus	232-236
23300995-9	2013	Importantly, administration of DFMO effectively delayed tumor formation in nude mice inoculated with transformed cells by JAK2 (V617F), resulting in prolonged survival; therefore, ODC expression through c-Myc is a critical step for JAK2 (V617F)-induced transformation and DFMO could be used as effective therapy for MPNs.	Eflornithine	272-276	ornithine decarboxylase, structural 1	Mus musculus	180-183
23181218-5	2012	Inhibition of ODC1 by difluoromethylornithine (DFMO) decreased tumor penetrance in TH-MYCN mice treated pre-emptively, and extended survival and synergized with chemotherapy in treating established tumors in both TH-MYCN and xenograft models.	Eflornithine	22-45	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	86-90
23181218-5	2012	Inhibition of ODC1 by difluoromethylornithine (DFMO) decreased tumor penetrance in TH-MYCN mice treated pre-emptively, and extended survival and synergized with chemotherapy in treating established tumors in both TH-MYCN and xenograft models.	Eflornithine	47-51	ornithine decarboxylase, structural 1	Mus musculus	14-18
23181218-5	2012	Inhibition of ODC1 by difluoromethylornithine (DFMO) decreased tumor penetrance in TH-MYCN mice treated pre-emptively, and extended survival and synergized with chemotherapy in treating established tumors in both TH-MYCN and xenograft models.	Eflornithine	47-51	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	86-90
23181218-5	2012	Inhibition of ODC1 by difluoromethylornithine (DFMO) decreased tumor penetrance in TH-MYCN mice treated pre-emptively, and extended survival and synergized with chemotherapy in treating established tumors in both TH-MYCN and xenograft models.	Eflornithine	47-51	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	216-220
22555848-5	2012	In contrast, depletion of cellular polyamines by inhibiting ornithine decarboxylase with alpha-difluoromethylornithine increased cytoplasmic eukaryotic initiation factor 3b and TIA-1 related protein abundance and enhanced arsenite-induced SG assembly.	Eflornithine	89-118	ornithine decarboxylase 1	Homo sapiens	60-83
23418509-3	2013	Supplementation with extracellular spermine (500 microM) of cells pretreated with DFMO significantly increased polyamine concentrations, increased Dnmt activity, enhanced methylation of the ITGAL promoter, and decreased CD11a expression.	Eflornithine	82-86	DNA methyltransferase 1	Homo sapiens	147-151
23418509-3	2013	Supplementation with extracellular spermine (500 microM) of cells pretreated with DFMO significantly increased polyamine concentrations, increased Dnmt activity, enhanced methylation of the ITGAL promoter, and decreased CD11a expression.	Eflornithine	82-86	integrin subunit alpha L	Homo sapiens	190-195
23418509-3	2013	Supplementation with extracellular spermine (500 microM) of cells pretreated with DFMO significantly increased polyamine concentrations, increased Dnmt activity, enhanced methylation of the ITGAL promoter, and decreased CD11a expression.	Eflornithine	82-86	integrin subunit alpha L	Homo sapiens	220-225
22555848-5	2012	In contrast, depletion of cellular polyamines by inhibiting ornithine decarboxylase with alpha-difluoromethylornithine increased cytoplasmic eukaryotic initiation factor 3b and TIA-1 related protein abundance and enhanced arsenite-induced SG assembly.	Eflornithine	89-118	TIA1 cytotoxic granule associated RNA binding protein	Homo sapiens	177-182
21809075-7	2012	Transient silencing of ornithine decarboxylase, polyamine biosynthesis enzyme and special target of DFMO also increased roscovitine-induced apoptosis in HCT116 cells.	Eflornithine	100-104	ornithine decarboxylase 1	Homo sapiens	23-46
22132744-7	2012	In the present paper we report the synergistic effects of specific oligoamines in combination with DFMO (2-difluoromethylornithine), an inhibitor of ornithine decarboxylase, in human colorectal cancer cells.	Eflornithine	99-103	ornithine decarboxylase 1	Homo sapiens	149-172
22132744-7	2012	In the present paper we report the synergistic effects of specific oligoamines in combination with DFMO (2-difluoromethylornithine), an inhibitor of ornithine decarboxylase, in human colorectal cancer cells.	Eflornithine	105-130	ornithine decarboxylase 1	Homo sapiens	149-172
22132744-9	2012	The combination of oligoamines and DFMO results in a synergistic re-expression of aberrantly silenced tumour-suppressor genes, including SFRP2 (secreted frizzled-related protein 2), which encodes a Wnt signalling pathway antagonist and plays an anti-tumorigenic role in colorectal cancer.	Eflornithine	35-39	secreted frizzled related protein 2	Homo sapiens	137-142
22132744-9	2012	The combination of oligoamines and DFMO results in a synergistic re-expression of aberrantly silenced tumour-suppressor genes, including SFRP2 (secreted frizzled-related protein 2), which encodes a Wnt signalling pathway antagonist and plays an anti-tumorigenic role in colorectal cancer.	Eflornithine	35-39	secreted frizzled related protein 2	Homo sapiens	144-179
22309684-1	2012	Despite the fact that eflornithine was considered as the safer drug to treat human African trypanosomiasis (HAT) and has been freely available since 2001, the difficulties in logistics and cost burden associated with this drug meant that the toxic melarsoprol remained the drug of choice.	Eflornithine	22-34	transmembrane serine protease 11D	Homo sapiens	108-111
22344475-3	2012	alpha-difluoromethylornithine (DFMO) is the ODC inhibitor, which has been shown to act as an antiproliferative agent in human cancer cells by irreversibly inhibiting ODC, which is overexpressed in breast cancer cells.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	44-47
22344475-3	2012	alpha-difluoromethylornithine (DFMO) is the ODC inhibitor, which has been shown to act as an antiproliferative agent in human cancer cells by irreversibly inhibiting ODC, which is overexpressed in breast cancer cells.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	166-169
22344475-3	2012	alpha-difluoromethylornithine (DFMO) is the ODC inhibitor, which has been shown to act as an antiproliferative agent in human cancer cells by irreversibly inhibiting ODC, which is overexpressed in breast cancer cells.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	44-47
22344475-3	2012	alpha-difluoromethylornithine (DFMO) is the ODC inhibitor, which has been shown to act as an antiproliferative agent in human cancer cells by irreversibly inhibiting ODC, which is overexpressed in breast cancer cells.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	166-169
22344475-12	2012	The ODC specific inhibitor, DFMO, altered the apoptotic effects of ROSC by increasing the generation of reactive oxygen species, decreasing the PA intracellular pool and modulating pro-apoptotic and anti-apoptotic Bcl-2 family members.	Eflornithine	28-32	ornithine decarboxylase 1	Homo sapiens	4-7
22344475-12	2012	The ODC specific inhibitor, DFMO, altered the apoptotic effects of ROSC by increasing the generation of reactive oxygen species, decreasing the PA intracellular pool and modulating pro-apoptotic and anti-apoptotic Bcl-2 family members.	Eflornithine	28-32	BCL2 apoptosis regulator	Homo sapiens	214-219
22421154-7	2012	Ribonuclease activity is enhanced in cytoplasmic extracts of HCT116 (p53+/+) cells exposed to gamma-irradiation or treated by the non-genotoxic drug AS101 but decreased following treatment by genotoxic (e.g., doxorubicin) or non-genotoxic (e.g., DFMO) agents, thus indicating that p53 exonuclease activity is dependent on the specific stress and nature of the substrate.	Eflornithine	246-250	tumor protein p53	Homo sapiens	69-72
21861168-3	2012	Here, we report the ability of novel mono-methylated spermidine analogs (alpha-MeSpd, beta-MeSpd, gamma-MeSpd, and omega-MeSpd) to function in the hypusination of eIF5A and in supporting the growth of DFMO-treated DU145 cells.	Eflornithine	201-205	eukaryotic translation initiation factor 5A	Homo sapiens	163-168
21809076-2	2012	Alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC) a limiting enzyme of polyamine biosynthesis, depleted the cellular polyamines and prevented triglyceride accumulation and differentiation in 3T3-L1 cells.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	54-77
21809076-2	2012	Alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC) a limiting enzyme of polyamine biosynthesis, depleted the cellular polyamines and prevented triglyceride accumulation and differentiation in 3T3-L1 cells.	Eflornithine	0-29	ornithine decarboxylase, structural 1	Mus musculus	79-82
21809076-2	2012	Alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC) a limiting enzyme of polyamine biosynthesis, depleted the cellular polyamines and prevented triglyceride accumulation and differentiation in 3T3-L1 cells.	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	54-77
21809076-2	2012	Alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC) a limiting enzyme of polyamine biosynthesis, depleted the cellular polyamines and prevented triglyceride accumulation and differentiation in 3T3-L1 cells.	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	79-82
21730362-6	2011	Treatment with alpha-difluoromethylornithine, a specific inhibitor of ODC activity, normalized the wound response in transgenic mice and decreased wound-induced inflammation if administered from the time of abrasion but not if initiated 4 days following abrasion.	Eflornithine	15-44	ornithine decarboxylase, structural 1	Mus musculus	70-73
21861168-8	2012	The long-term growth of DFMO-treated cells correlated with the hypusine modification of eIF5A by intracellular methylated spermidine analogs.	Eflornithine	24-28	eukaryotic translation initiation factor 5A	Homo sapiens	88-93
21901470-8	2012	Nuclear extracts of cells treated with DFMO + TGF-beta(1) revealed the presence of Snai1 immunopositive bands in a range of molecular weight between 55 and 72 kDa, with additional positive bands detected at MW greater than 170 kDa.	Eflornithine	39-43	snail family transcriptional repressor 1	Canis lupus familiaris	83-88
22024160-4	2012	DFMO treatment resulted in approximately 80-90% and 20% of reductions in the putrescine and spermidine levels, respectively, in the four brain regions examined, and a small reduction in agmatine level in the CA2/3, with no effects on spermine, glutamate and gamma-aminobutyrate.	Eflornithine	0-4	carbonic anhydrase 2	Rattus norvegicus	208-213
23123718-9	2012	In addition, we found that ODC inhibitor, DL-alpha-difluoromethylornithine (DFMO) prevented the proliferation of the JAK2 V617F mutant-induced transformed cells.	Eflornithine	42-74	ornithine decarboxylase, structural 1	Mus musculus	27-30
23123718-9	2012	In addition, we found that ODC inhibitor, DL-alpha-difluoromethylornithine (DFMO) prevented the proliferation of the JAK2 V617F mutant-induced transformed cells.	Eflornithine	42-74	Janus kinase 2	Mus musculus	117-121
23123718-9	2012	In addition, we found that ODC inhibitor, DL-alpha-difluoromethylornithine (DFMO) prevented the proliferation of the JAK2 V617F mutant-induced transformed cells.	Eflornithine	76-80	ornithine decarboxylase, structural 1	Mus musculus	27-30
23123718-9	2012	In addition, we found that ODC inhibitor, DL-alpha-difluoromethylornithine (DFMO) prevented the proliferation of the JAK2 V617F mutant-induced transformed cells.	Eflornithine	76-80	Janus kinase 2	Mus musculus	117-121
22384556-13	2011	When compared with the control group, significantly elevated expression levels of p53 protein and mRNA in cells of the DFMO group were detected after 6-day treatment (P &lt; 0.05).	Eflornithine	119-123	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	82-85
22384556-14	2011	When compared with the DFMO group, the expression levels of p53 protein and mRNA were significantly down-regulated in the low dose licorice and the high dose licorice groups (P &lt; 0.05).	Eflornithine	23-27	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	60-63
21464038-8	2011	Importantly, P-S/DFMO decreased putrescine and spermidine levels and the expression of Trx-1, TrxR, and cyclooxygenase (COX) 2.	Eflornithine	17-21	thioredoxin 1	Mus musculus	87-92
22122775-4	2011	Reports of cardiovascular risks of some NSAIDs and selective COX-2 inhibitors have led to promising studies of lower doses in combination with ursodeoxycholic acid, statin, and difluoromethylornithine.	Eflornithine	177-200	prostaglandin-endoperoxide synthase 2	Homo sapiens	61-66
21512157-7	2011	When ODC was inhibited by alpha-difluoromethylornithine (DFMO), an irreversible ODC inhibitor, the heat stress induction of Hsp70 and Hsp25 was decreased significantly, even in the presence of glutamine.	Eflornithine	26-55	ornithine decarboxylase 1	Rattus norvegicus	5-8
21512157-7	2011	When ODC was inhibited by alpha-difluoromethylornithine (DFMO), an irreversible ODC inhibitor, the heat stress induction of Hsp70 and Hsp25 was decreased significantly, even in the presence of glutamine.	Eflornithine	26-55	ornithine decarboxylase 1	Rattus norvegicus	80-83
21512157-7	2011	When ODC was inhibited by alpha-difluoromethylornithine (DFMO), an irreversible ODC inhibitor, the heat stress induction of Hsp70 and Hsp25 was decreased significantly, even in the presence of glutamine.	Eflornithine	26-55	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	124-129
21512157-7	2011	When ODC was inhibited by alpha-difluoromethylornithine (DFMO), an irreversible ODC inhibitor, the heat stress induction of Hsp70 and Hsp25 was decreased significantly, even in the presence of glutamine.	Eflornithine	26-55	heat shock protein family B (small) member 1	Rattus norvegicus	134-139
21512157-7	2011	When ODC was inhibited by alpha-difluoromethylornithine (DFMO), an irreversible ODC inhibitor, the heat stress induction of Hsp70 and Hsp25 was decreased significantly, even in the presence of glutamine.	Eflornithine	57-61	ornithine decarboxylase 1	Rattus norvegicus	5-8
21512157-7	2011	When ODC was inhibited by alpha-difluoromethylornithine (DFMO), an irreversible ODC inhibitor, the heat stress induction of Hsp70 and Hsp25 was decreased significantly, even in the presence of glutamine.	Eflornithine	57-61	ornithine decarboxylase 1	Rattus norvegicus	80-83
21512157-7	2011	When ODC was inhibited by alpha-difluoromethylornithine (DFMO), an irreversible ODC inhibitor, the heat stress induction of Hsp70 and Hsp25 was decreased significantly, even in the presence of glutamine.	Eflornithine	57-61	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	124-129
21512157-7	2011	When ODC was inhibited by alpha-difluoromethylornithine (DFMO), an irreversible ODC inhibitor, the heat stress induction of Hsp70 and Hsp25 was decreased significantly, even in the presence of glutamine.	Eflornithine	57-61	heat shock protein family B (small) member 1	Rattus norvegicus	134-139
21512157-9	2011	However, DFMO dramatically reduced glutamine-dependent HSF-1 binding to an oligonucleotide with heat shock elements (HSE), which was increased by glutamine.	Eflornithine	9-13	heat shock transcription factor 1	Rattus norvegicus	55-60
21464038-1	2011	The nonsteroidal anti-inflammatory drug (NSAID) sulindac and the ornithine decarboxylase (ODC) antagonist difluoromethylornithine (DFMO), individually and together, are effective inhibitors of colon carcinogenesis.	Eflornithine	106-129	ornithine decarboxylase, structural 1	Mus musculus	65-88
21464038-1	2011	The nonsteroidal anti-inflammatory drug (NSAID) sulindac and the ornithine decarboxylase (ODC) antagonist difluoromethylornithine (DFMO), individually and together, are effective inhibitors of colon carcinogenesis.	Eflornithine	106-129	ornithine decarboxylase, structural 1	Mus musculus	90-93
21464038-1	2011	The nonsteroidal anti-inflammatory drug (NSAID) sulindac and the ornithine decarboxylase (ODC) antagonist difluoromethylornithine (DFMO), individually and together, are effective inhibitors of colon carcinogenesis.	Eflornithine	131-135	ornithine decarboxylase, structural 1	Mus musculus	65-88
21464038-1	2011	The nonsteroidal anti-inflammatory drug (NSAID) sulindac and the ornithine decarboxylase (ODC) antagonist difluoromethylornithine (DFMO), individually and together, are effective inhibitors of colon carcinogenesis.	Eflornithine	131-135	ornithine decarboxylase, structural 1	Mus musculus	90-93
21636549-11	2011	DFMO downregulated Kruppel-like factor 5 (KLF5), a transcription factor promoting cell proliferation, and suppressed RFC5 whose protein interacts with proliferating cell nuclear antigen.	Eflornithine	0-4	Kruppel like factor 5	Homo sapiens	19-40
21636549-11	2011	DFMO downregulated Kruppel-like factor 5 (KLF5), a transcription factor promoting cell proliferation, and suppressed RFC5 whose protein interacts with proliferating cell nuclear antigen.	Eflornithine	0-4	Kruppel like factor 5	Homo sapiens	42-46
21636549-11	2011	DFMO downregulated Kruppel-like factor 5 (KLF5), a transcription factor promoting cell proliferation, and suppressed RFC5 whose protein interacts with proliferating cell nuclear antigen.	Eflornithine	0-4	replication factor C subunit 5	Homo sapiens	117-121
21237263-5	2011	Inhibiting ODC by co-injecting DFMO decreased LPS-induced CCL2 expression and macrophage influx into the CNS, without altering LPS-induced microglial or macrophage activation.	Eflornithine	31-35	ornithine decarboxylase, structural 1	Mus musculus	11-14
21237263-5	2011	Inhibiting ODC by co-injecting DFMO decreased LPS-induced CCL2 expression and macrophage influx into the CNS, without altering LPS-induced microglial or macrophage activation.	Eflornithine	31-35	chemokine (C-C motif) ligand 2	Mus musculus	58-62
21570380-5	2011	Administration of the selective ODC inhibitor DFMO (10 mumol/paw) attenuated the development of allodynia and edema and decreased ODC activity in both control and CFA-treated animals.	Eflornithine	46-50	ornithine decarboxylase 1	Homo sapiens	32-35
21570380-5	2011	Administration of the selective ODC inhibitor DFMO (10 mumol/paw) attenuated the development of allodynia and edema and decreased ODC activity in both control and CFA-treated animals.	Eflornithine	46-50	ornithine decarboxylase 1	Homo sapiens	130-133
21639123-5	2011	All the analogs induced the splicing of the productive mRNA splice variant of SSAT, overcame growth arrest induced by 72-h treatment with ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine, and were transported via the polyamine transporter.	Eflornithine	178-207	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	78-82
21639123-5	2011	All the analogs induced the splicing of the productive mRNA splice variant of SSAT, overcame growth arrest induced by 72-h treatment with ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine, and were transported via the polyamine transporter.	Eflornithine	178-207	ornithine decarboxylase 1	Homo sapiens	138-161
21639123-5	2011	All the analogs induced the splicing of the productive mRNA splice variant of SSAT, overcame growth arrest induced by 72-h treatment with ornithine decarboxylase (ODC) inhibitor alpha-difluoromethylornithine, and were transported via the polyamine transporter.	Eflornithine	178-207	ornithine decarboxylase 1	Homo sapiens	163-166
21505150-7	2011	Inhibition of ODC activity in C(2)C(12) myoblasts by alpha-difluoromethylornithine decreases myoblast number by 40% and 66% following 48 and 72 h of treatment, respectively.	Eflornithine	53-82	ornithine decarboxylase, structural 1	Mus musculus	14-17
21464038-8	2011	Importantly, P-S/DFMO decreased putrescine and spermidine levels and the expression of Trx-1, TrxR, and cyclooxygenase (COX) 2.	Eflornithine	17-21	peroxiredoxin 2	Mus musculus	94-98
21464038-8	2011	Importantly, P-S/DFMO decreased putrescine and spermidine levels and the expression of Trx-1, TrxR, and cyclooxygenase (COX) 2.	Eflornithine	17-21	cytochrome c oxidase II, mitochondrial	Mus musculus	104-126
21464038-11	2011	P-S/DFMO has an intricate mechanism of action extending beyond polyamines and including the thioredoxin system, an emerging regulator of chemoprevention.	Eflornithine	4-8	thioredoxin 1	Mus musculus	92-103
20844550-7	2011	The specific ODC inhibitor, alpha-difluoromethylornithine, abrogated all suppressive effects of ODC in CHS reactions.	Eflornithine	28-57	ornithine decarboxylase, structural 1	Mus musculus	13-16
20835736-6	2011	This effect was prevented in the presence of alpha-difluoromethylornithine, an irreversible inhibitor of ODC.	Eflornithine	45-74	ornithine decarboxylase 1	Homo sapiens	105-108
20844550-7	2011	The specific ODC inhibitor, alpha-difluoromethylornithine, abrogated all suppressive effects of ODC in CHS reactions.	Eflornithine	28-57	ornithine decarboxylase, structural 1	Mus musculus	96-99
20406645-8	2010	Phytomonas ODC required pyridoxal 5"-phosphate for maximum activity and was specifically inhibited by alpha-difluoromethylornithine.	Eflornithine	102-131	ornithine decarboxylase 1	Homo sapiens	11-14
21253788-4	2011	A clinical trial of difluoromethylornithine (DFMO), a selective inhibitor of polyamine synthesis, showed that the 1 year treatment duration reduced prostate volume and serum prostate-specific antigen doubling time in men with a family history of prostate cancer.	Eflornithine	20-43	kallikrein related peptidase 3	Homo sapiens	174-199
21253788-4	2011	A clinical trial of difluoromethylornithine (DFMO), a selective inhibitor of polyamine synthesis, showed that the 1 year treatment duration reduced prostate volume and serum prostate-specific antigen doubling time in men with a family history of prostate cancer.	Eflornithine	45-49	kallikrein related peptidase 3	Homo sapiens	174-199
20838207-7	2010	By contrast, DFMO slightly increased the CD44+CD24- subpopulation, increased cell motility and the level of mesenchymal-related proteins.	Eflornithine	13-17	CD44 molecule (Indian blood group)	Homo sapiens	41-45
20838207-7	2010	By contrast, DFMO slightly increased the CD44+CD24- subpopulation, increased cell motility and the level of mesenchymal-related proteins.	Eflornithine	13-17	CD24 molecule	Homo sapiens	46-50
20838207-9	2010	Both PG11047 and DFMO reduced the expression of the human epidermal growth factor receptor 2 protein, which is correlated to malignancy and resistance to trastuzumab in JIMT-1 cells.	Eflornithine	17-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-92
20937024-10	2010	Genistein, alpha-difluoromethylornithine, toremifene, R-flurbiprofen, celecoxib, and green tea polyphenols have been shown to prevent prostate cancer development in TRAMP mice.	Eflornithine	11-40	tumor necrosis factor receptor superfamily, member 25	Mus musculus	165-170
21151498-6	2010	Further, depletion of polyamines by culturing BMMCs with alpha-difluoromethylornithine (DFMO) caused aberrant secretory granule ultrastructure, impaired histamine storage, reduced serotonin levels and increased beta-hexosaminidase content.	Eflornithine	57-86	O-GlcNAcase	Mus musculus	211-230
21151498-6	2010	Further, depletion of polyamines by culturing BMMCs with alpha-difluoromethylornithine (DFMO) caused aberrant secretory granule ultrastructure, impaired histamine storage, reduced serotonin levels and increased beta-hexosaminidase content.	Eflornithine	88-92	O-GlcNAcase	Mus musculus	211-230
20627873-11	2010	Similar to sulindac, OXT-922 enhanced spermidine/spermine N(1)-acetyltransferase activity, reduced the cellular polyamine content and synergized with difluoromethylornithine to inhibit cancer cell proliferation and induce apoptosis.	Eflornithine	150-173	oxytocin/neurophysin I prepropeptide	Homo sapiens	21-24
20600019-7	2010	The ODC inhibitor, alpha-difluoromethylornithine, was administered to H pylori-infected mice for 4 months after inoculation.	Eflornithine	19-48	ornithine decarboxylase, structural 1	Mus musculus	4-7
20600019-12	2010	alpha-Difluoromethylornithine treatment of infected mice restored L-Arg uptake, iNOS protein expression, and NO production in gastric macrophages, and significantly reduced both H pylori colonization levels and gastritis severity.	Eflornithine	0-29	nitric oxide synthase 2, inducible	Mus musculus	80-84
20594968-2	2010	Targeted inhibition of ornithine decarboxylase (ODC), i.e. a key enzyme of polyamine biosynthesis, by alpha-difluoromethylornithine (DFMO) has shown anti-neoplastic activity in various experimental models.	Eflornithine	102-131	ornithine decarboxylase 1	Homo sapiens	23-46
20594968-2	2010	Targeted inhibition of ornithine decarboxylase (ODC), i.e. a key enzyme of polyamine biosynthesis, by alpha-difluoromethylornithine (DFMO) has shown anti-neoplastic activity in various experimental models.	Eflornithine	102-131	ornithine decarboxylase 1	Homo sapiens	48-51
20594968-2	2010	Targeted inhibition of ornithine decarboxylase (ODC), i.e. a key enzyme of polyamine biosynthesis, by alpha-difluoromethylornithine (DFMO) has shown anti-neoplastic activity in various experimental models.	Eflornithine	133-137	ornithine decarboxylase 1	Homo sapiens	23-46
20594968-2	2010	Targeted inhibition of ornithine decarboxylase (ODC), i.e. a key enzyme of polyamine biosynthesis, by alpha-difluoromethylornithine (DFMO) has shown anti-neoplastic activity in various experimental models.	Eflornithine	133-137	ornithine decarboxylase 1	Homo sapiens	48-51
20594968-5	2010	DFMO-mediated ODC inhibition was reversed by extracellular polyamine supplementation, showing that anti-angiogenic effects of DFMO were specifically related to polyamine levels.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	14-17
20594968-5	2010	DFMO-mediated ODC inhibition was reversed by extracellular polyamine supplementation, showing that anti-angiogenic effects of DFMO were specifically related to polyamine levels.	Eflornithine	126-130	ornithine decarboxylase 1	Homo sapiens	14-17
20594968-7	2010	Moreover, our data suggest that de-regulated actin cytoskeleton dynamics in DFMO treated endothelial cells may be related to constitutive activation of the small GTPase CDC42, i.e. a well-known regulator of cell motility and actin cytoskeleton remodeling.	Eflornithine	76-80	cell division cycle 42	Homo sapiens	169-174
20629736-3	2010	Indeed, growing (anagen) HFs show the highest activity of ornithine decarboxylase (ODC), the rate-limiting enzyme of polyamine biosynthesis, while inhibition of ODC, using eflornithine, results in a decreased rate of excessive facial hair growth in vivo and inhibits human scalp hair growth in organ culture.	Eflornithine	172-184	ornithine decarboxylase 1	Homo sapiens	161-164
20522643-9	2010	Knocking down the solute carrier transporter SLC3A2 in HCT116-derived Hkh2 cells reduced the accumulation of exogenous putrescine and total polyamine contents in DFMO treated cells, relative to non-DFMO-treated cells.	Eflornithine	162-166	solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2	Mus musculus	45-51
20522643-9	2010	Knocking down the solute carrier transporter SLC3A2 in HCT116-derived Hkh2 cells reduced the accumulation of exogenous putrescine and total polyamine contents in DFMO treated cells, relative to non-DFMO-treated cells.	Eflornithine	198-202	solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2	Mus musculus	45-51
20651378-4	2010	RESULTS: Significant increases in apoptosis, MMP-9 and uPA (tumor) were observed in 7 patients &gt;or=50 years who received DFMO for &gt;or=14 days relative to patients &lt;50 years and/or who received &lt;14 days of treatment (n=11).	Eflornithine	124-128	matrix metallopeptidase 9	Homo sapiens	45-50
20219382-8	2010	alpha-Diflouromethylornithine (DFMO) was synthesized by Merrell-Dow and became a potent inhibitor of ornithine decarboxylase.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	101-124
20651378-4	2010	RESULTS: Significant increases in apoptosis, MMP-9 and uPA (tumor) were observed in 7 patients &gt;or=50 years who received DFMO for &gt;or=14 days relative to patients &lt;50 years and/or who received &lt;14 days of treatment (n=11).	Eflornithine	124-128	plasminogen activator, urokinase	Homo sapiens	55-58
19538475-5	2010	Polyamine depletion caused by alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, prevented adipocyte differentiation by suppressing the expression of its key regulators, peroxisome proliferator-activated receptor gamma and CCAAT/enhancer binding protein alpha.	Eflornithine	30-59	ornithine decarboxylase 1	Homo sapiens	97-120
19538475-5	2010	Polyamine depletion caused by alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, prevented adipocyte differentiation by suppressing the expression of its key regulators, peroxisome proliferator-activated receptor gamma and CCAAT/enhancer binding protein alpha.	Eflornithine	30-59	peroxisome proliferator activated receptor gamma	Homo sapiens	211-300
19538475-5	2010	Polyamine depletion caused by alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, prevented adipocyte differentiation by suppressing the expression of its key regulators, peroxisome proliferator-activated receptor gamma and CCAAT/enhancer binding protein alpha.	Eflornithine	61-65	ornithine decarboxylase 1	Homo sapiens	97-120
19538475-5	2010	Polyamine depletion caused by alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, prevented adipocyte differentiation by suppressing the expression of its key regulators, peroxisome proliferator-activated receptor gamma and CCAAT/enhancer binding protein alpha.	Eflornithine	61-65	peroxisome proliferator activated receptor gamma	Homo sapiens	211-300
19953281-7	2010	Interestingly, both SpmTrien and Trien were able to partially overcome growth arrest induced by an ODC inhibitor, alpha-difluoromethylornithine, indicating that they are able to mimic some functions of the natural polyamines.	Eflornithine	114-143	ornithine decarboxylase 1	Homo sapiens	99-102
21175041-1	2010	The purpose of this study was to synthesize a series of delta-amide derivatives of the antitrypanosomal drug eflornithine (2,5-diamino-2-(difluoromethyl)pentanoic acid hydrochloride, DMFO, CAS 70052-12-9), to determine their physicochemical properties and to assess whether they convert to eflornithine in vivo and if so, whether higher systemic exposure to eflornithine could be achieved by increase intestinal absorption, suggesting an oral treatment to be possible.	Eflornithine	109-121	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	189-192
20013009-8	2010	Polyamine depletion-by means of alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase-abolished the differentiation process.	Eflornithine	32-61	ornithine decarboxylase 1	Rattus norvegicus	92-115
19479373-8	2009	Furthermore the glypican-1 proteoglycan produced in the presence of polyamine synthesis inhibitor, alpha-difluoromethylornithine, was endogenously S-nitrosylated and release of nitric oxide induced deaminative autocleavage of the HS side chains of glypican-1.	Eflornithine	99-128	glypican 1	Homo sapiens	16-26
20051367-4	2010	DFMO is an inhibitor of ornithine decarboxylase, a key enzyme in the polyamine biosynthetic pathway.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	24-47
20051371-1	2010	Preclinical studies have shown that the inhibition of ornithine decarboxylase (ODC) by alpha-difluoromethylornithine (DFMO) and resultant decreases in tissue concentrations of polyamines (putrescine and spermidine) prevents neoplastic developments in many tissue types.	Eflornithine	87-116	ornithine decarboxylase 1	Homo sapiens	54-77
20051371-1	2010	Preclinical studies have shown that the inhibition of ornithine decarboxylase (ODC) by alpha-difluoromethylornithine (DFMO) and resultant decreases in tissue concentrations of polyamines (putrescine and spermidine) prevents neoplastic developments in many tissue types.	Eflornithine	87-116	ornithine decarboxylase 1	Homo sapiens	79-82
20051371-1	2010	Preclinical studies have shown that the inhibition of ornithine decarboxylase (ODC) by alpha-difluoromethylornithine (DFMO) and resultant decreases in tissue concentrations of polyamines (putrescine and spermidine) prevents neoplastic developments in many tissue types.	Eflornithine	118-122	ornithine decarboxylase 1	Homo sapiens	54-77
20051371-1	2010	Preclinical studies have shown that the inhibition of ornithine decarboxylase (ODC) by alpha-difluoromethylornithine (DFMO) and resultant decreases in tissue concentrations of polyamines (putrescine and spermidine) prevents neoplastic developments in many tissue types.	Eflornithine	118-122	ornithine decarboxylase 1	Homo sapiens	79-82
20051371-2	2010	Clinical studies of oral DFMO at 500 mg/m(2)/day revealed it to be safe and tolerable and resulted in significant inhibition of phorbol ester-induced skin ODC activity.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	155-158
19479373-8	2009	Furthermore the glypican-1 proteoglycan produced in the presence of polyamine synthesis inhibitor, alpha-difluoromethylornithine, was endogenously S-nitrosylated and release of nitric oxide induced deaminative autocleavage of the HS side chains of glypican-1.	Eflornithine	99-128	glypican 1	Homo sapiens	248-258
19427401-3	2009	Polyamine deficiency was induced by adding an inhibitor of ornithine decarboxylase, alpha-difluoromethylornithine, to the medium.	Eflornithine	84-113	ornithine decarboxylase, structural 1	Mus musculus	59-82
20095973-3	2009	Preclinical studies have demonstrated that DFMO (difluoromethylornithine), an irreversible inhibitor of ODC (ornithine decarboxylase) which is the first enzyme in polyamine biosynthesis, combined with NSAIDs (non-steroidal anti-inflammatory drugs) suppresses colorectal carcinogenesis in murine models.	Eflornithine	43-47	ornithine decarboxylase, structural 1	Mus musculus	104-107
20095973-3	2009	Preclinical studies have demonstrated that DFMO (difluoromethylornithine), an irreversible inhibitor of ODC (ornithine decarboxylase) which is the first enzyme in polyamine biosynthesis, combined with NSAIDs (non-steroidal anti-inflammatory drugs) suppresses colorectal carcinogenesis in murine models.	Eflornithine	43-47	ornithine decarboxylase, structural 1	Mus musculus	109-132
20095973-3	2009	Preclinical studies have demonstrated that DFMO (difluoromethylornithine), an irreversible inhibitor of ODC (ornithine decarboxylase) which is the first enzyme in polyamine biosynthesis, combined with NSAIDs (non-steroidal anti-inflammatory drugs) suppresses colorectal carcinogenesis in murine models.	Eflornithine	49-72	ornithine decarboxylase, structural 1	Mus musculus	104-107
20095973-3	2009	Preclinical studies have demonstrated that DFMO (difluoromethylornithine), an irreversible inhibitor of ODC (ornithine decarboxylase) which is the first enzyme in polyamine biosynthesis, combined with NSAIDs (non-steroidal anti-inflammatory drugs) suppresses colorectal carcinogenesis in murine models.	Eflornithine	49-72	ornithine decarboxylase, structural 1	Mus musculus	109-132
20095973-4	2009	The preclinical rationale for combination chemoprevention with DFMO and the NSAID sulindac, was strengthened by the observation that a SNP (single nucleotide polymorphism) in the ODC promoter was prognostic for adenoma recurrence in patients with prior sporadic colon polyps and predicted reduced risk of adenoma in those patients taking aspirin.	Eflornithine	63-67	ornithine decarboxylase 1	Homo sapiens	179-182
19136059-10	2009	Inhibition of ornithine decarboxylase (ODC) with alpha-difluromethylornithine (DFMO) and subsequent depletion of intracellular polyamines increased p53 protein, Mdm2 Ser166 phosphorylation and conferred resistance to CPT-induced apoptosis.	Eflornithine	79-83	ornithine decarboxylase 1	Rattus norvegicus	14-37
19562674-6	2009	alpha-Difluoromethylornithine (DFMO)-induced polyamine depletion resulted in an upregulation of histidine decarboxylase (HDC, the histamine-synthesizing enzyme) expression and activity, accompanied by increased histamine levels, specifically during early stages of these cell cultures, where an active histamine synthesis process occurs.	Eflornithine	0-29	histidine decarboxylase	Mus musculus	96-119
19562674-6	2009	alpha-Difluoromethylornithine (DFMO)-induced polyamine depletion resulted in an upregulation of histidine decarboxylase (HDC, the histamine-synthesizing enzyme) expression and activity, accompanied by increased histamine levels, specifically during early stages of these cell cultures, where an active histamine synthesis process occurs.	Eflornithine	0-29	histidine decarboxylase	Mus musculus	121-124
19562674-6	2009	alpha-Difluoromethylornithine (DFMO)-induced polyamine depletion resulted in an upregulation of histidine decarboxylase (HDC, the histamine-synthesizing enzyme) expression and activity, accompanied by increased histamine levels, specifically during early stages of these cell cultures, where an active histamine synthesis process occurs.	Eflornithine	31-35	histidine decarboxylase	Mus musculus	96-119
19562674-6	2009	alpha-Difluoromethylornithine (DFMO)-induced polyamine depletion resulted in an upregulation of histidine decarboxylase (HDC, the histamine-synthesizing enzyme) expression and activity, accompanied by increased histamine levels, specifically during early stages of these cell cultures, where an active histamine synthesis process occurs.	Eflornithine	31-35	histidine decarboxylase	Mus musculus	121-124
19562674-8	2009	Sequence-specific DNA methylation analysis revealed that the DFMO-induced HDC mRNA upregulation observed in early bone marrow cell cultures is not attributable to a demethylation of the gene promoter caused by the pharmacological polyamine depletion.	Eflornithine	61-65	histidine decarboxylase	Mus musculus	74-77
19348875-8	2009	DFMO treatment at both doses resulted in an 80%-90% reduction of putrescine level in the CA1, CA2/3 and dentate gyrus (DG) sub-regions of the hippocampus and the prefrontal cortex with minimal effects on the spermidine and spermine levels.	Eflornithine	0-4	carbonic anhydrase 1	Rattus norvegicus	89-92
19348875-8	2009	DFMO treatment at both doses resulted in an 80%-90% reduction of putrescine level in the CA1, CA2/3 and dentate gyrus (DG) sub-regions of the hippocampus and the prefrontal cortex with minimal effects on the spermidine and spermine levels.	Eflornithine	0-4	carbonic anhydrase 2	Rattus norvegicus	94-97
19136059-10	2009	Inhibition of ornithine decarboxylase (ODC) with alpha-difluromethylornithine (DFMO) and subsequent depletion of intracellular polyamines increased p53 protein, Mdm2 Ser166 phosphorylation and conferred resistance to CPT-induced apoptosis.	Eflornithine	79-83	ornithine decarboxylase 1	Rattus norvegicus	39-42
19136059-10	2009	Inhibition of ornithine decarboxylase (ODC) with alpha-difluromethylornithine (DFMO) and subsequent depletion of intracellular polyamines increased p53 protein, Mdm2 Ser166 phosphorylation and conferred resistance to CPT-induced apoptosis.	Eflornithine	79-83	MDM2 proto-oncogene	Rattus norvegicus	161-165
20524478-12	2009	DFMO can thus be employed for anti-neoplastic clinical trials on account of interference with activity of ODC (Ornithine Decarboxylase) fundamental for polyamine biosynthesis.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	106-109
20524478-12	2009	DFMO can thus be employed for anti-neoplastic clinical trials on account of interference with activity of ODC (Ornithine Decarboxylase) fundamental for polyamine biosynthesis.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	111-134
19047162-0	2008	Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma.	Eflornithine	38-67	ornithine decarboxylase 1	Homo sapiens	0-23
18368465-7	2009	The ODC inhibitor DFMO (1-10 mM) reduced polyamine concentration and attenuated proliferation in A7r5 cells and rat tail artery.	Eflornithine	18-22	ornithine decarboxylase 1	Rattus norvegicus	4-7
19001365-0	2009	Spermine synthase deficiency leads to deafness and a profound sensitivity to alpha-difluoromethylornithine.	Eflornithine	77-106	spermine synthase	Mus musculus	0-17
19001365-5	2009	Gy mice showed a striking toxic response to treatment with the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	97-126	ornithine decarboxylase, structural 1	Mus musculus	63-86
19001365-5	2009	Gy mice showed a striking toxic response to treatment with the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	128-132	ornithine decarboxylase, structural 1	Mus musculus	63-86
19055734-10	2008	alpha-difluoromethylornithine, a specific inhibitor of ornithine decarboxylase, partially protected hypoxic flies from amino acid toxicity but not from polyamine toxicity.	Eflornithine	0-29	Ornithine decarboxylase 1	Drosophila melanogaster	55-78
19047152-7	2008	The Odc inhibitor alpha-difluoromethylornithine (DFMO) inhibited neuroblast proliferation in vitro and suppressed oncogenesis in vivo.	Eflornithine	18-47	ornithine decarboxylase, structural 1	Mus musculus	4-7
19047152-7	2008	The Odc inhibitor alpha-difluoromethylornithine (DFMO) inhibited neuroblast proliferation in vitro and suppressed oncogenesis in vivo.	Eflornithine	49-53	ornithine decarboxylase, structural 1	Mus musculus	4-7
19047152-8	2008	DFMO treatment of neuroblastoma-prone genetically engineered mice (TH-MYCN) extended tumor latency and survival in homozygous mice and prevented oncogenesis in hemizygous mice.	Eflornithine	0-4	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	70-74
19147568-4	2009	Indeed, sustained treatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity markedly impairs lymphoma development in Emicro-Myc transgenic mice, and these effects are linked to the induction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1), which is normally repressed by Myc.	Eflornithine	59-88	ornithine decarboxylase, structural 1	Mus musculus	37-40
19147568-4	2009	Indeed, sustained treatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity markedly impairs lymphoma development in Emicro-Myc transgenic mice, and these effects are linked to the induction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1), which is normally repressed by Myc.	Eflornithine	59-88	myelocytomatosis oncogene	Mus musculus	166-169
19147568-4	2009	Indeed, sustained treatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity markedly impairs lymphoma development in Emicro-Myc transgenic mice, and these effects are linked to the induction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1), which is normally repressed by Myc.	Eflornithine	59-88	cyclin-dependent kinase inhibitor 1B	Mus musculus	280-283
19147568-4	2009	Indeed, sustained treatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity markedly impairs lymphoma development in Emicro-Myc transgenic mice, and these effects are linked to the induction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1), which is normally repressed by Myc.	Eflornithine	59-88	cyclin-dependent kinase inhibitor 1B	Mus musculus	284-288
19147568-4	2009	Indeed, sustained treatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity markedly impairs lymphoma development in Emicro-Myc transgenic mice, and these effects are linked to the induction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1), which is normally repressed by Myc.	Eflornithine	59-88	myelocytomatosis oncogene	Mus musculus	322-325
19147568-4	2009	Indeed, sustained treatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity markedly impairs lymphoma development in Emicro-Myc transgenic mice, and these effects are linked to the induction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1), which is normally repressed by Myc.	Eflornithine	90-94	ornithine decarboxylase, structural 1	Mus musculus	37-40
19147568-4	2009	Indeed, sustained treatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity markedly impairs lymphoma development in Emicro-Myc transgenic mice, and these effects are linked to the induction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1), which is normally repressed by Myc.	Eflornithine	90-94	myelocytomatosis oncogene	Mus musculus	166-169
19147568-4	2009	Indeed, sustained treatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity markedly impairs lymphoma development in Emicro-Myc transgenic mice, and these effects are linked to the induction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1), which is normally repressed by Myc.	Eflornithine	90-94	cyclin-dependent kinase inhibitor 1B	Mus musculus	280-283
19147568-4	2009	Indeed, sustained treatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity markedly impairs lymphoma development in Emicro-Myc transgenic mice, and these effects are linked to the induction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1), which is normally repressed by Myc.	Eflornithine	90-94	cyclin-dependent kinase inhibitor 1B	Mus musculus	284-288
19147568-4	2009	Indeed, sustained treatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity markedly impairs lymphoma development in Emicro-Myc transgenic mice, and these effects are linked to the induction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1), which is normally repressed by Myc.	Eflornithine	90-94	myelocytomatosis oncogene	Mus musculus	322-325
19147568-5	2009	Here, we report that DFMO treatment, but not Odc heterozygosity, impairs MYCN-induced neuroblastoma and that, in this malignancy, transient DFMO treatment is sufficient to confer protection.	Eflornithine	21-25	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	73-77
19147568-6	2009	The selective anticancer effects of DFMO on mouse and human MYCN-amplified neuroblastoma also rely on its ability to disable the proliferative response of Myc, yet in this tumor context, DFMO targets the expression of the p21(Cip1) Cdk inhibitor, which is also suppressed by Myc oncoproteins.	Eflornithine	36-40	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	60-64
19147568-6	2009	The selective anticancer effects of DFMO on mouse and human MYCN-amplified neuroblastoma also rely on its ability to disable the proliferative response of Myc, yet in this tumor context, DFMO targets the expression of the p21(Cip1) Cdk inhibitor, which is also suppressed by Myc oncoproteins.	Eflornithine	36-40	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	155-158
19147568-6	2009	The selective anticancer effects of DFMO on mouse and human MYCN-amplified neuroblastoma also rely on its ability to disable the proliferative response of Myc, yet in this tumor context, DFMO targets the expression of the p21(Cip1) Cdk inhibitor, which is also suppressed by Myc oncoproteins.	Eflornithine	36-40	cyclin dependent kinase inhibitor 1A	Homo sapiens	222-225
19147568-6	2009	The selective anticancer effects of DFMO on mouse and human MYCN-amplified neuroblastoma also rely on its ability to disable the proliferative response of Myc, yet in this tumor context, DFMO targets the expression of the p21(Cip1) Cdk inhibitor, which is also suppressed by Myc oncoproteins.	Eflornithine	36-40	cyclin dependent kinase inhibitor 1A	Homo sapiens	226-230
19147568-6	2009	The selective anticancer effects of DFMO on mouse and human MYCN-amplified neuroblastoma also rely on its ability to disable the proliferative response of Myc, yet in this tumor context, DFMO targets the expression of the p21(Cip1) Cdk inhibitor, which is also suppressed by Myc oncoproteins.	Eflornithine	36-40	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	275-278
19147568-6	2009	The selective anticancer effects of DFMO on mouse and human MYCN-amplified neuroblastoma also rely on its ability to disable the proliferative response of Myc, yet in this tumor context, DFMO targets the expression of the p21(Cip1) Cdk inhibitor, which is also suppressed by Myc oncoproteins.	Eflornithine	187-191	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	60-64
19147568-6	2009	The selective anticancer effects of DFMO on mouse and human MYCN-amplified neuroblastoma also rely on its ability to disable the proliferative response of Myc, yet in this tumor context, DFMO targets the expression of the p21(Cip1) Cdk inhibitor, which is also suppressed by Myc oncoproteins.	Eflornithine	187-191	cyclin dependent kinase inhibitor 1A	Homo sapiens	222-225
19147568-7	2009	These findings suggest that agents, such as DFMO, that target the polyamine pathway may show efficacy in high-risk, MYCN-amplified neuroblastoma.	Eflornithine	44-48	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	116-120
19047162-5	2008	In the present study, we found that the inhibition of ODC by DFMO promotes cell survival by inducing the phosphorylation of Akt/PKB at residue Ser473 and glycogen synthase kinase-3beta at Ser9.	Eflornithine	61-65	ornithine decarboxylase 1	Homo sapiens	54-57
19047162-5	2008	In the present study, we found that the inhibition of ODC by DFMO promotes cell survival by inducing the phosphorylation of Akt/PKB at residue Ser473 and glycogen synthase kinase-3beta at Ser9.	Eflornithine	61-65	AKT serine/threonine kinase 1	Homo sapiens	124-127
19047162-5	2008	In the present study, we found that the inhibition of ODC by DFMO promotes cell survival by inducing the phosphorylation of Akt/PKB at residue Ser473 and glycogen synthase kinase-3beta at Ser9.	Eflornithine	61-65	AKT serine/threonine kinase 1	Homo sapiens	128-131
19047162-5	2008	In the present study, we found that the inhibition of ODC by DFMO promotes cell survival by inducing the phosphorylation of Akt/PKB at residue Ser473 and glycogen synthase kinase-3beta at Ser9.	Eflornithine	61-65	glycogen synthase kinase 3 beta	Homo sapiens	154-184
19047162-6	2008	Intriguingly, DFMO also induced the phosphorylation of p27Kip1 at residues Ser10 (nuclear export) and Thr198 (protein stabilization) but not Thr187 (proteasomal degradation).	Eflornithine	14-18	cyclin dependent kinase inhibitor 1B	Homo sapiens	55-62
19047162-8	2008	The data suggest that inhibition of ODC by DFMO induces two opposing pathways in NB: one promoting cell survival by activating Akt/PKB via the PI3K/Akt pathway and one inducing p27Kip1/retinoblastoma-coupled G1 cell cycle arrest via a mechanism that regulates the phosphorylation and stabilization of p27Kip1.	Eflornithine	43-47	ornithine decarboxylase 1	Homo sapiens	36-39
19047162-8	2008	The data suggest that inhibition of ODC by DFMO induces two opposing pathways in NB: one promoting cell survival by activating Akt/PKB via the PI3K/Akt pathway and one inducing p27Kip1/retinoblastoma-coupled G1 cell cycle arrest via a mechanism that regulates the phosphorylation and stabilization of p27Kip1.	Eflornithine	43-47	AKT serine/threonine kinase 1	Homo sapiens	127-134
19047162-8	2008	The data suggest that inhibition of ODC by DFMO induces two opposing pathways in NB: one promoting cell survival by activating Akt/PKB via the PI3K/Akt pathway and one inducing p27Kip1/retinoblastoma-coupled G1 cell cycle arrest via a mechanism that regulates the phosphorylation and stabilization of p27Kip1.	Eflornithine	43-47	AKT serine/threonine kinase 1	Homo sapiens	127-130
19047162-8	2008	The data suggest that inhibition of ODC by DFMO induces two opposing pathways in NB: one promoting cell survival by activating Akt/PKB via the PI3K/Akt pathway and one inducing p27Kip1/retinoblastoma-coupled G1 cell cycle arrest via a mechanism that regulates the phosphorylation and stabilization of p27Kip1.	Eflornithine	43-47	cyclin dependent kinase inhibitor 1B	Homo sapiens	177-184
19047162-8	2008	The data suggest that inhibition of ODC by DFMO induces two opposing pathways in NB: one promoting cell survival by activating Akt/PKB via the PI3K/Akt pathway and one inducing p27Kip1/retinoblastoma-coupled G1 cell cycle arrest via a mechanism that regulates the phosphorylation and stabilization of p27Kip1.	Eflornithine	43-47	cyclin dependent kinase inhibitor 1B	Homo sapiens	301-308
19047162-0	2008	Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma.	Eflornithine	38-67	AKT serine/threonine kinase 1	Homo sapiens	134-137
19047162-0	2008	Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma.	Eflornithine	38-67	protein tyrosine kinase 2 beta	Homo sapiens	138-154
19047162-0	2008	Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma.	Eflornithine	38-67	cyclin dependent kinase inhibitor 1B	Homo sapiens	159-166
19047162-2	2008	We previously showed that treating human neuroblastoma (NB) cells with the ODC inhibitor alpha-difluoromethylornithine (DFMO) depleted polyamine pools and induced G1 cell cycle arrest without causing apoptosis.	Eflornithine	89-118	ornithine decarboxylase 1	Homo sapiens	75-78
19047162-2	2008	We previously showed that treating human neuroblastoma (NB) cells with the ODC inhibitor alpha-difluoromethylornithine (DFMO) depleted polyamine pools and induced G1 cell cycle arrest without causing apoptosis.	Eflornithine	120-124	ornithine decarboxylase 1	Homo sapiens	75-78
19010902-7	2008	These results were supported by experiments in an in vivo glioma tumor model, showing significantly enhanced antitumor effects of the antiangiogenic, humanized anti-vascular endothelial growth factor (VEGF) antibody bevacizumab when used in combination with the well-established, irreversible inhibitor of ODC, alpha-difluoromethylornithine.	Eflornithine	311-340	vascular endothelial growth factor A	Homo sapiens	160-199
18755180-9	2008	alpha-Difluoromethylornithine, an inhibitor of ornithine decarboxylase, antagonized the effect of isoproterenol on inotropism and cAMP increase.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	47-70
19010902-7	2008	These results were supported by experiments in an in vivo glioma tumor model, showing significantly enhanced antitumor effects of the antiangiogenic, humanized anti-vascular endothelial growth factor (VEGF) antibody bevacizumab when used in combination with the well-established, irreversible inhibitor of ODC, alpha-difluoromethylornithine.	Eflornithine	311-340	vascular endothelial growth factor A	Homo sapiens	201-205
18097746-8	2008	Therefore, we tested the effect of DFMO on the HGF/c-Met pathway which is strongly implicated in the progression of human breast cancer.	Eflornithine	35-39	hepatocyte growth factor	Homo sapiens	47-50
18097746-8	2008	Therefore, we tested the effect of DFMO on the HGF/c-Met pathway which is strongly implicated in the progression of human breast cancer.	Eflornithine	35-39	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	51-56
18097746-9	2008	We found that DFMO treatment blocked HGF-induced c-Met phosphorylation in MDA-MB-435 cells, suggesting that its anti-invasion action may be mediated, at least in part, by blocking c-Met signaling.	Eflornithine	14-18	hepatocyte growth factor	Homo sapiens	37-40
18097746-9	2008	We found that DFMO treatment blocked HGF-induced c-Met phosphorylation in MDA-MB-435 cells, suggesting that its anti-invasion action may be mediated, at least in part, by blocking c-Met signaling.	Eflornithine	14-18	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	49-54
18097746-9	2008	We found that DFMO treatment blocked HGF-induced c-Met phosphorylation in MDA-MB-435 cells, suggesting that its anti-invasion action may be mediated, at least in part, by blocking c-Met signaling.	Eflornithine	14-18	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	180-185
18097746-10	2008	Next, we showed that 1 mM DFMO suppressed HGF induced invasiveness of MDA-MB-435 cells in matrigel.	Eflornithine	26-30	hepatocyte growth factor	Homo sapiens	42-45
18097746-11	2008	Combination administration of DFMO with suboptimal doses of PHA-665752, a specific c-Met inhibitor, reduced invasiveness to an even greater extent than the individual treatment.	Eflornithine	30-34	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	83-88
18097746-13	2008	Our data also point to inhibition of HGF/c-Met pathway as a possible novel approach to enhancing the antitumor action of DFMO.	Eflornithine	121-125	hepatocyte growth factor	Homo sapiens	37-40
18097746-13	2008	Our data also point to inhibition of HGF/c-Met pathway as a possible novel approach to enhancing the antitumor action of DFMO.	Eflornithine	121-125	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	41-46
18583422-3	2008	Our present results demonstrate that the contragestational effect of alpha-difluoromethylornithine (DFMO), a suicide inhibitor of ODC, when given at d 7-9 of pregnancy, is associated with embryo growth arrest and marked alterations in the development of yolk sac and placenta.	Eflornithine	69-98	ornithine decarboxylase, structural 1	Mus musculus	130-133
18583422-3	2008	Our present results demonstrate that the contragestational effect of alpha-difluoromethylornithine (DFMO), a suicide inhibitor of ODC, when given at d 7-9 of pregnancy, is associated with embryo growth arrest and marked alterations in the development of yolk sac and placenta.	Eflornithine	100-104	ornithine decarboxylase, structural 1	Mus musculus	130-133
18670363-3	2008	This effect was antagonized by an inhibitor of ornithine decarboxylase, alpha-difluoromethylornithine (10 mM), suggesting enzyme activation.	Eflornithine	72-101	ornithine decarboxylase 1	Rattus norvegicus	47-70
18240140-3	2008	The percentage of GFP+MSCs showing cardiac myofibril proteins (cMLC2, cTnI) was about threefold higher after DFMO addition (3%) relative to the untreated control (1%).	Eflornithine	109-113	troponin I3, cardiac type	Rattus norvegicus	70-74
18455248-1	2008	More than 30 years ago the potent ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) was designed as new anticancer drug.	Eflornithine	68-91	ornithine decarboxylase 1	Homo sapiens	34-57
18455248-1	2008	More than 30 years ago the potent ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) was designed as new anticancer drug.	Eflornithine	93-97	ornithine decarboxylase 1	Homo sapiens	34-57
18097746-1	2008	We have shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis, reduces the invasive and metastatic properties of MDA-MB-435 breast cancer cells while activating multiple signal transduction pathways, including MAPK, Stat3, Stat1, and JNK.	Eflornithine	37-66	ornithine decarboxylase 1	Homo sapiens	104-127
18097746-1	2008	We have shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis, reduces the invasive and metastatic properties of MDA-MB-435 breast cancer cells while activating multiple signal transduction pathways, including MAPK, Stat3, Stat1, and JNK.	Eflornithine	37-66	ornithine decarboxylase 1	Homo sapiens	129-132
18097746-1	2008	We have shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis, reduces the invasive and metastatic properties of MDA-MB-435 breast cancer cells while activating multiple signal transduction pathways, including MAPK, Stat3, Stat1, and JNK.	Eflornithine	37-66	mitogen-activated protein kinase 1	Homo sapiens	349-353
18097746-1	2008	We have shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis, reduces the invasive and metastatic properties of MDA-MB-435 breast cancer cells while activating multiple signal transduction pathways, including MAPK, Stat3, Stat1, and JNK.	Eflornithine	37-66	signal transducer and activator of transcription 3	Homo sapiens	355-360
18097746-1	2008	We have shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis, reduces the invasive and metastatic properties of MDA-MB-435 breast cancer cells while activating multiple signal transduction pathways, including MAPK, Stat3, Stat1, and JNK.	Eflornithine	37-66	signal transducer and activator of transcription 1	Homo sapiens	362-367
18097746-1	2008	We have shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis, reduces the invasive and metastatic properties of MDA-MB-435 breast cancer cells while activating multiple signal transduction pathways, including MAPK, Stat3, Stat1, and JNK.	Eflornithine	37-66	mitogen-activated protein kinase 8	Homo sapiens	373-376
18097746-1	2008	We have shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis, reduces the invasive and metastatic properties of MDA-MB-435 breast cancer cells while activating multiple signal transduction pathways, including MAPK, Stat3, Stat1, and JNK.	Eflornithine	68-72	ornithine decarboxylase 1	Homo sapiens	104-127
18097746-1	2008	We have shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis, reduces the invasive and metastatic properties of MDA-MB-435 breast cancer cells while activating multiple signal transduction pathways, including MAPK, Stat3, Stat1, and JNK.	Eflornithine	68-72	ornithine decarboxylase 1	Homo sapiens	129-132
18097746-1	2008	We have shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis, reduces the invasive and metastatic properties of MDA-MB-435 breast cancer cells while activating multiple signal transduction pathways, including MAPK, Stat3, Stat1, and JNK.	Eflornithine	68-72	mitogen-activated protein kinase 1	Homo sapiens	349-353
18097746-1	2008	We have shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis, reduces the invasive and metastatic properties of MDA-MB-435 breast cancer cells while activating multiple signal transduction pathways, including MAPK, Stat3, Stat1, and JNK.	Eflornithine	68-72	signal transducer and activator of transcription 3	Homo sapiens	355-360
18097746-1	2008	We have shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis, reduces the invasive and metastatic properties of MDA-MB-435 breast cancer cells while activating multiple signal transduction pathways, including MAPK, Stat3, Stat1, and JNK.	Eflornithine	68-72	signal transducer and activator of transcription 1	Homo sapiens	362-367
18097746-1	2008	We have shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis, reduces the invasive and metastatic properties of MDA-MB-435 breast cancer cells while activating multiple signal transduction pathways, including MAPK, Stat3, Stat1, and JNK.	Eflornithine	68-72	mitogen-activated protein kinase 8	Homo sapiens	373-376
18202119-7	2008	Embryo implantation was significantly inhibited by alpha-difluoromethylornithine, an Odc inhibitor.	Eflornithine	51-80	ornithine decarboxylase, structural 1	Mus musculus	85-88
18202119-8	2008	Moreover, the reduction of Odc activity caused by alpha-difluoromethylornithine treatment was compensated by the up-regulation of S-adenosylmethionine decarboxylase gene expression.	Eflornithine	50-79	ornithine decarboxylase, structural 1	Mus musculus	27-30
18381427-5	2008	ATM activation is polyamine dependent because alpha-difluoromethylornithine, a specific inhibitor of ODC activity, blocks its phosphorylation.	Eflornithine	46-75	ataxia telangiectasia mutated	Mus musculus	0-3
18381427-5	2008	ATM activation is polyamine dependent because alpha-difluoromethylornithine, a specific inhibitor of ODC activity, blocks its phosphorylation.	Eflornithine	46-75	ornithine decarboxylase, structural 1	Mus musculus	101-104
18360702-5	2008	Conversely, depletion of intracellular polyamines by the specific ODC-inhibitor alpha-difluoromethylornithine (DFMO) resulted in increased cellular binding of polyamine and anti-HS antibody.	Eflornithine	80-109	ornithine decarboxylase 1	Homo sapiens	66-69
18360702-5	2008	Conversely, depletion of intracellular polyamines by the specific ODC-inhibitor alpha-difluoromethylornithine (DFMO) resulted in increased cellular binding of polyamine and anti-HS antibody.	Eflornithine	111-115	ornithine decarboxylase 1	Homo sapiens	66-69
18268112-2	2008	Difluoromethylornithine (DFMO) is an antiproliferative agent, inhibiting ornithine decarboxylase, the first enzyme in the polyamine pathway, and has been studied as a therapeutic and chemopreventive agent.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	73-96
18208615-2	2008	DL-alpha-difluoromethylornithine (DFMO), a synthetic inhibitor of ODC, induces G1 arrest through dephosphorylation of retinoblastoma protein (pRb).	Eflornithine	0-32	ornithine decarboxylase 1	Homo sapiens	66-69
18208615-2	2008	DL-alpha-difluoromethylornithine (DFMO), a synthetic inhibitor of ODC, induces G1 arrest through dephosphorylation of retinoblastoma protein (pRb).	Eflornithine	0-32	RB transcriptional corepressor 1	Homo sapiens	142-145
18208615-2	2008	DL-alpha-difluoromethylornithine (DFMO), a synthetic inhibitor of ODC, induces G1 arrest through dephosphorylation of retinoblastoma protein (pRb).	Eflornithine	34-38	ornithine decarboxylase 1	Homo sapiens	66-69
18208615-2	2008	DL-alpha-difluoromethylornithine (DFMO), a synthetic inhibitor of ODC, induces G1 arrest through dephosphorylation of retinoblastoma protein (pRb).	Eflornithine	34-38	RB transcriptional corepressor 1	Homo sapiens	142-145
18208615-3	2008	The effect of DFMO on cell growth of pRb deficient cells is not known.	Eflornithine	14-18	RB transcriptional corepressor 1	Homo sapiens	37-40
18208615-4	2008	We examined the effects of DFMO on pRb deficient human retinoblastoma Y79 cell proliferation and its molecular mechanism.	Eflornithine	27-31	RB transcriptional corepressor 1	Homo sapiens	35-38
18208615-7	2008	DFMO induced p27/Kip1 protein expression, p107 dephosphorylation and accumulation of p107/E2F-4 complex in Y79 cells.	Eflornithine	0-4	cyclin-dependent kinase inhibitor 1B (p27, Kip1) S homeolog	Xenopus laevis	17-21
18208615-7	2008	DFMO induced p27/Kip1 protein expression, p107 dephosphorylation and accumulation of p107/E2F-4 complex in Y79 cells.	Eflornithine	0-4	retinoblastoma-like 1 L homeolog	Xenopus laevis	42-46
18208615-7	2008	DFMO induced p27/Kip1 protein expression, p107 dephosphorylation and accumulation of p107/E2F-4 complex in Y79 cells.	Eflornithine	0-4	retinoblastoma-like 1 L homeolog	Xenopus laevis	85-95
18208615-8	2008	CONCLUSION: These results indicate that p107 dephosphorylation and accumulation of p107/E2F-4 complex is involved in G1 and S phase arrest of DFMO treated Y79 cells.	Eflornithine	142-146	RB transcriptional corepressor like 1	Homo sapiens	40-44
18208615-8	2008	CONCLUSION: These results indicate that p107 dephosphorylation and accumulation of p107/E2F-4 complex is involved in G1 and S phase arrest of DFMO treated Y79 cells.	Eflornithine	142-146	RB transcriptional corepressor like 1	Homo sapiens	83-93
17919121-4	2008	Decreased levels of cellular polyamines as a result of inhibiting ODC (ornithine decarboxylase) with DFMO (D,L-alpha-difluoromethylornithine) repressed AMPK activity and reduced Impalpha1 levels, whereas increased levels of polyamines as a result of ODC overexpression induced both AMPK and Impalpha1 levels.	Eflornithine	101-105	ornithine decarboxylase 1	Homo sapiens	66-69
17919121-4	2008	Decreased levels of cellular polyamines as a result of inhibiting ODC (ornithine decarboxylase) with DFMO (D,L-alpha-difluoromethylornithine) repressed AMPK activity and reduced Impalpha1 levels, whereas increased levels of polyamines as a result of ODC overexpression induced both AMPK and Impalpha1 levels.	Eflornithine	101-105	ornithine decarboxylase 1	Homo sapiens	71-94
17919121-4	2008	Decreased levels of cellular polyamines as a result of inhibiting ODC (ornithine decarboxylase) with DFMO (D,L-alpha-difluoromethylornithine) repressed AMPK activity and reduced Impalpha1 levels, whereas increased levels of polyamines as a result of ODC overexpression induced both AMPK and Impalpha1 levels.	Eflornithine	101-105	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	152-156
17919121-4	2008	Decreased levels of cellular polyamines as a result of inhibiting ODC (ornithine decarboxylase) with DFMO (D,L-alpha-difluoromethylornithine) repressed AMPK activity and reduced Impalpha1 levels, whereas increased levels of polyamines as a result of ODC overexpression induced both AMPK and Impalpha1 levels.	Eflornithine	101-105	ornithine decarboxylase 1	Homo sapiens	250-253
17919121-4	2008	Decreased levels of cellular polyamines as a result of inhibiting ODC (ornithine decarboxylase) with DFMO (D,L-alpha-difluoromethylornithine) repressed AMPK activity and reduced Impalpha1 levels, whereas increased levels of polyamines as a result of ODC overexpression induced both AMPK and Impalpha1 levels.	Eflornithine	101-105	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	282-286
17919121-4	2008	Decreased levels of cellular polyamines as a result of inhibiting ODC (ornithine decarboxylase) with DFMO (D,L-alpha-difluoromethylornithine) repressed AMPK activity and reduced Impalpha1 levels, whereas increased levels of polyamines as a result of ODC overexpression induced both AMPK and Impalpha1 levels.	Eflornithine	107-140	ornithine decarboxylase 1	Homo sapiens	66-69
17919121-4	2008	Decreased levels of cellular polyamines as a result of inhibiting ODC (ornithine decarboxylase) with DFMO (D,L-alpha-difluoromethylornithine) repressed AMPK activity and reduced Impalpha1 levels, whereas increased levels of polyamines as a result of ODC overexpression induced both AMPK and Impalpha1 levels.	Eflornithine	107-140	ornithine decarboxylase 1	Homo sapiens	71-94
17919121-4	2008	Decreased levels of cellular polyamines as a result of inhibiting ODC (ornithine decarboxylase) with DFMO (D,L-alpha-difluoromethylornithine) repressed AMPK activity and reduced Impalpha1 levels, whereas increased levels of polyamines as a result of ODC overexpression induced both AMPK and Impalpha1 levels.	Eflornithine	107-140	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	152-156
17919121-4	2008	Decreased levels of cellular polyamines as a result of inhibiting ODC (ornithine decarboxylase) with DFMO (D,L-alpha-difluoromethylornithine) repressed AMPK activity and reduced Impalpha1 levels, whereas increased levels of polyamines as a result of ODC overexpression induced both AMPK and Impalpha1 levels.	Eflornithine	107-140	ornithine decarboxylase 1	Homo sapiens	250-253
17919121-4	2008	Decreased levels of cellular polyamines as a result of inhibiting ODC (ornithine decarboxylase) with DFMO (D,L-alpha-difluoromethylornithine) repressed AMPK activity and reduced Impalpha1 levels, whereas increased levels of polyamines as a result of ODC overexpression induced both AMPK and Impalpha1 levels.	Eflornithine	107-140	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	282-286
18235846-9	2008	Difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ODC, had no effect on the recombinant putative ODC from E. histolytica.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	78-81
18235846-10	2008	Comparative modeling of the three-dimensional structure of E. histolytica putative ODC shows that the putative binding site for DFMO is disrupted by the substitution of three amino acids-aspartate-332, aspartate-361, and tyrosine-323-by histidine-296, phenylalanine-305, and asparagine-334, through which this inhibitor interacts with the protein.	Eflornithine	128-132	ornithine decarboxylase 1	Homo sapiens	83-86
18235846-14	2008	Computer modeling revealed that three of the critical residues required for binding of DFMO to the ODC enzyme are substituted in E. histolytica, resulting in the likely loss of interactions between the enzyme and DFMO.	Eflornithine	87-91	ornithine decarboxylase 1	Homo sapiens	99-102
18235846-14	2008	Computer modeling revealed that three of the critical residues required for binding of DFMO to the ODC enzyme are substituted in E. histolytica, resulting in the likely loss of interactions between the enzyme and DFMO.	Eflornithine	213-217	ornithine decarboxylase 1	Homo sapiens	99-102
17333334-1	2008	We have shown that alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, the first and rate-limiting enzyme in polyamine synthesis, has significant antiproliferative and antiinvasive effects in breast cancer cells.	Eflornithine	19-48	ornithine decarboxylase 1	Homo sapiens	73-96
17333334-1	2008	We have shown that alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, the first and rate-limiting enzyme in polyamine synthesis, has significant antiproliferative and antiinvasive effects in breast cancer cells.	Eflornithine	50-54	ornithine decarboxylase 1	Homo sapiens	73-96
17333334-4	2008	We found that DFMO administration (1 mM) to MDA-MB-435 breast cancer cells significantly increased cAMP response element (CRE)-binding protein (CREB) phosphorylation as well as the transactivation of pCRE-luc, a CREB-dependent promoter activated by PKA.	Eflornithine	14-18	cAMP responsive element binding protein 1	Homo sapiens	144-148
17333334-4	2008	We found that DFMO administration (1 mM) to MDA-MB-435 breast cancer cells significantly increased cAMP response element (CRE)-binding protein (CREB) phosphorylation as well as the transactivation of pCRE-luc, a CREB-dependent promoter activated by PKA.	Eflornithine	14-18	cAMP responsive element binding protein 1	Homo sapiens	212-216
17333334-5	2008	To determine the significance of this biochemical effect of DFMO, we used the PKA inhibitor H89 which, as expected, suppressed in a dose-dependent manner (1 and 10 microM) basal and DFMO-induced CREB phosphorylation in our system.	Eflornithine	60-64	cAMP responsive element binding protein 1	Homo sapiens	195-199
17333334-5	2008	To determine the significance of this biochemical effect of DFMO, we used the PKA inhibitor H89 which, as expected, suppressed in a dose-dependent manner (1 and 10 microM) basal and DFMO-induced CREB phosphorylation in our system.	Eflornithine	182-186	cAMP responsive element binding protein 1	Homo sapiens	195-199
17333334-7	2008	At concentrations of 0.5 and 1 muM, H89 treatment, while having no antiproliferative effect of its own, potentiated in a dose-dependent fashion the growth inhibitory action of a suboptimal concentration of DFMO (0.01 mM).	Eflornithine	206-210	latexin	Homo sapiens	31-34
17333334-10	2008	H89 treatment (10 microM) partially reduced DFMO-induced phosphorylation of STAT-3 but not that of STAT-1, Extracellular regulated kinase (ERK), and JNK.	Eflornithine	44-48	signal transducer and activator of transcription 3	Homo sapiens	76-82
17333334-13	2008	Our data are also consistent with the notion that STAT-3 activation by DFMO is at least in part mediated through the PKA pathway.	Eflornithine	71-75	signal transducer and activator of transcription 3	Homo sapiens	50-56
17333337-5	2008	In contrast to our previous findings with MDA-MB-435 cells, DFMO did not affect the activation of signal transducers and activator of transcription 3, c-Jun N-terminal kinase, and extracellular signal-regulated kinase, but decreased phosphorylation of p38.	Eflornithine	60-64	mitogen-activated protein kinase 14	Homo sapiens	252-255
18268112-9	2008	Stratification by ornithine decarboxylase genotype showed that DFMO reduced prostate volume (P = 0.029) and putrescine levels (P = 0.0053) in the AA + GA group but not in the GG group.	Eflornithine	63-67	ornithine decarboxylase 1	Homo sapiens	18-41
17825525-1	2007	Intracellular polyamine synthesis is regulated by the enzyme ornithine decarboxylase (ODC), and its inhibition by alpha-difluromethylornithine (DFMO), confers resistance to apoptosis.	Eflornithine	144-148	ornithine decarboxylase 1	Homo sapiens	61-84
17825525-1	2007	Intracellular polyamine synthesis is regulated by the enzyme ornithine decarboxylase (ODC), and its inhibition by alpha-difluromethylornithine (DFMO), confers resistance to apoptosis.	Eflornithine	144-148	ornithine decarboxylase 1	Homo sapiens	86-89
17825525-2	2007	We have previously shown that DFMO leads to the inhibition of de novo polyamine synthesis, which in turn rapidly activates Src, STAT3 and NF-kappaB via integrin beta3 in intestinal epithelial cells.	Eflornithine	30-34	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	123-126
17825525-2	2007	We have previously shown that DFMO leads to the inhibition of de novo polyamine synthesis, which in turn rapidly activates Src, STAT3 and NF-kappaB via integrin beta3 in intestinal epithelial cells.	Eflornithine	30-34	signal transducer and activator of transcription 3	Homo sapiens	128-133
17825525-2	2007	We have previously shown that DFMO leads to the inhibition of de novo polyamine synthesis, which in turn rapidly activates Src, STAT3 and NF-kappaB via integrin beta3 in intestinal epithelial cells.	Eflornithine	30-34	nuclear factor kappa B subunit 1	Homo sapiens	138-147
17825525-2	2007	We have previously shown that DFMO leads to the inhibition of de novo polyamine synthesis, which in turn rapidly activates Src, STAT3 and NF-kappaB via integrin beta3 in intestinal epithelial cells.	Eflornithine	30-34	integrin subunit beta 3	Homo sapiens	152-166
17825525-5	2007	DFMO increased EGFR phosphorylation on tyrosine residues 1173 (pY1173) and 845 (pY845) within 5 min.	Eflornithine	0-4	epidermal growth factor receptor	Homo sapiens	15-19
17825525-8	2007	Pretreatment with either DFMO or EGF for 1 h protected cells from TNF-alpha/CHX-induced apoptosis.	Eflornithine	25-29	tumor necrosis factor	Homo sapiens	66-75
17825525-10	2007	In addition, inhibition of integrin beta3 activity (with RGDS), Src activity (with PP2), or EGFR kinase activity (with AG1478), increased basal apoptosis and prevented protection conferred by either DFMO or EGF.	Eflornithine	199-203	integrin subunit beta 3	Homo sapiens	27-41
17825525-10	2007	In addition, inhibition of integrin beta3 activity (with RGDS), Src activity (with PP2), or EGFR kinase activity (with AG1478), increased basal apoptosis and prevented protection conferred by either DFMO or EGF.	Eflornithine	199-203	epidermal growth factor receptor	Homo sapiens	92-96
18268112-2	2008	Difluoromethylornithine (DFMO) is an antiproliferative agent, inhibiting ornithine decarboxylase, the first enzyme in the polyamine pathway, and has been studied as a therapeutic and chemopreventive agent.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	73-96
17600044-5	2007	Depletion of cellular polyamines by inhibiting ornithine decarboxylase (ODC) with alpha-difluoromethylornithine decreased levels of TLR2 mRNA and protein, whereas increased polyamines by ectopic overexpression of the ODC gene enhanced TLR2 expression.	Eflornithine	82-111	ornithine decarboxylase 1	Homo sapiens	47-70
17582600-9	2007	This study shows that Ab-ODC-Alexa 647 fluorescence intensity can be used as a surrogate marker of ODC biochemical activity in AGs and can predict PFS to DFMO-based chemotherapy.	Eflornithine	154-158	ornithine decarboxylase 1	Homo sapiens	25-28
17582600-9	2007	This study shows that Ab-ODC-Alexa 647 fluorescence intensity can be used as a surrogate marker of ODC biochemical activity in AGs and can predict PFS to DFMO-based chemotherapy.	Eflornithine	154-158	ornithine decarboxylase 1	Homo sapiens	99-102
17675337-6	2007	In addition, treatment of tumor-bearing K6-SSAT mice with the ODC inhibitor, alpha-difluoromethylornithine, resulted in the complete regression of established tumors.	Eflornithine	77-106	ornithine decarboxylase, structural 1	Mus musculus	62-65
17912446-0	2007	Effects of alpha-difluoromethylornithine on thrombospondin-1 production by human breast cancer cells.	Eflornithine	11-40	thrombospondin 1	Homo sapiens	44-60
17912446-1	2007	We have previously observed that inhibition of polyamine biosynthesis with alpha-difluoromethylornithine (DFMO) upregulates production of thrombospondin-1 (TSP-1), an extracellular matrix protein with potent anti-angiogenic and antimetastatic properties, by MDA-MB-435 human breast cancer cells in culture.	Eflornithine	75-104	thrombospondin 1	Homo sapiens	138-154
17912446-1	2007	We have previously observed that inhibition of polyamine biosynthesis with alpha-difluoromethylornithine (DFMO) upregulates production of thrombospondin-1 (TSP-1), an extracellular matrix protein with potent anti-angiogenic and antimetastatic properties, by MDA-MB-435 human breast cancer cells in culture.	Eflornithine	75-104	thrombospondin 1	Homo sapiens	156-161
17912446-1	2007	We have previously observed that inhibition of polyamine biosynthesis with alpha-difluoromethylornithine (DFMO) upregulates production of thrombospondin-1 (TSP-1), an extracellular matrix protein with potent anti-angiogenic and antimetastatic properties, by MDA-MB-435 human breast cancer cells in culture.	Eflornithine	106-110	thrombospondin 1	Homo sapiens	138-154
17912446-1	2007	We have previously observed that inhibition of polyamine biosynthesis with alpha-difluoromethylornithine (DFMO) upregulates production of thrombospondin-1 (TSP-1), an extracellular matrix protein with potent anti-angiogenic and antimetastatic properties, by MDA-MB-435 human breast cancer cells in culture.	Eflornithine	106-110	thrombospondin 1	Homo sapiens	156-161
17912446-2	2007	The present experiments were designed to investigate the mechanisms by which DFMO regulates TSP-1 production in this system.	Eflornithine	77-81	thrombospondin 1	Homo sapiens	92-97
17714450-8	2007	Importantly, we also demonstrate that NMDA leads to activation of both the Erk1/2 and PI3 K/Akt pathways, but only the PI3 K/Akt kinase was required for di-fluoro-methyl-ornithine-induced RGC survival.	Eflornithine	153-179	AKT serine/threonine kinase 1	Homo sapiens	125-128
17675337-6	2007	In addition, treatment of tumor-bearing K6-SSAT mice with the ODC inhibitor, alpha-difluoromethylornithine, resulted in the complete regression of established tumors.	Eflornithine	77-106	keratin 6	Mus musculus	40-47
17912446-3	2007	35S-methionine pulse chase experiments indicated that DFMO administration increased TSP-1 synthesis by approximately 6-fold, while it slightly but significantly decreased protein half-life from 35 to 28 min.	Eflornithine	54-58	thrombospondin 1	Homo sapiens	84-89
17912446-4	2007	DFMO treatment increased steady state TSP-1 mRNA levels by 2-fold in MDA-MB-435 cells.	Eflornithine	0-4	thrombospondin 1	Homo sapiens	38-43
17912446-6	2007	Analysis of distribution of TSP-1 mRNA levels between non-polysomal, subpolysomal and polysomal fractions in control and DFMO-treated cells suggested a major stimulatory effect of the drug on TSP-1 translation.	Eflornithine	121-125	thrombospondin 1	Homo sapiens	28-33
17912446-6	2007	Analysis of distribution of TSP-1 mRNA levels between non-polysomal, subpolysomal and polysomal fractions in control and DFMO-treated cells suggested a major stimulatory effect of the drug on TSP-1 translation.	Eflornithine	121-125	thrombospondin 1	Homo sapiens	192-197
17912446-7	2007	A similar increase in TSP-1 transcription and translation in response to DFMO treatment was also observed in vivo in MDA-MB-435 breast cancer xenografts.	Eflornithine	73-77	thrombospondin 1	Homo sapiens	22-27
17912446-9	2007	The reason for this unexpected finding is unknown but may be due to DFMO-induced stimulation of TSP-1 secretion into the systemic circulation, thus preventing its accumulation within the tumor.	Eflornithine	68-72	thrombospondin 1	Homo sapiens	96-101
17600044-5	2007	Depletion of cellular polyamines by inhibiting ornithine decarboxylase (ODC) with alpha-difluoromethylornithine decreased levels of TLR2 mRNA and protein, whereas increased polyamines by ectopic overexpression of the ODC gene enhanced TLR2 expression.	Eflornithine	82-111	ornithine decarboxylase 1	Homo sapiens	72-75
17600044-5	2007	Depletion of cellular polyamines by inhibiting ornithine decarboxylase (ODC) with alpha-difluoromethylornithine decreased levels of TLR2 mRNA and protein, whereas increased polyamines by ectopic overexpression of the ODC gene enhanced TLR2 expression.	Eflornithine	82-111	toll like receptor 2	Homo sapiens	132-136
17143592-5	2007	In contrast to our previous findings with MDA-MB-435 cells, DFMO did not affect the activation of STAT3, JNK, and ERK, but decreased phosphorylation of p38.	Eflornithine	60-64	mitogen-activated protein kinase 14	Homo sapiens	152-155
17407445-4	2007	We also show that L. donovani ODC binds the substrate, the co-enzyme pyridoxal 5"-phosphate and the irreversible inhibitor alpha-difluoromethylornithine (a curative agent of West African sleeping sickness) with less affinity than human ODC.	Eflornithine	123-152	ornithine decarboxylase 1	Homo sapiens	30-33
17494634-2	2007	We showed here that CAT-1 mRNA expression was increased by ornithne in OAT-deficient RPE cells, which was reversed by an inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethylornithine (DFMO).	Eflornithine	165-194	solute carrier family 7 member 1	Homo sapiens	20-25
17494634-2	2007	We showed here that CAT-1 mRNA expression was increased by ornithne in OAT-deficient RPE cells, which was reversed by an inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethylornithine (DFMO).	Eflornithine	196-200	solute carrier family 7 member 1	Homo sapiens	20-25
17494634-2	2007	We showed here that CAT-1 mRNA expression was increased by ornithne in OAT-deficient RPE cells, which was reversed by an inhibitor of ornithine decarboxylase (ODC), alpha-difluoromethylornithine (DFMO).	Eflornithine	196-200	ornithine decarboxylase 1	Homo sapiens	159-162
17396214-2	2007	Inhibitors of ornithine decarboxylase, such as difluoromethylornithine (DFMO), and agents that stimulate polyamine acetylation and export, such as non-steroidal anti-inflammatory drugs (NSAIDS), act at least additively to arrest growth in human cell models and suppress intestinal carcinogenesis in mice.	Eflornithine	47-70	ornithine decarboxylase 1	Homo sapiens	14-37
17443268-5	2007	The ODC irreversible inactivator DFMO has proven to be not only a valuable tool in the study of ODC in cancer, but also shows promise as a chemopreventive and chemotherapeutic agent in certain types of malignancies.	Eflornithine	33-37	ornithine decarboxylase 1	Homo sapiens	4-7
17443268-5	2007	The ODC irreversible inactivator DFMO has proven to be not only a valuable tool in the study of ODC in cancer, but also shows promise as a chemopreventive and chemotherapeutic agent in certain types of malignancies.	Eflornithine	33-37	ornithine decarboxylase 1	Homo sapiens	96-99
17610127-3	2007	The ODC inhibitor alpha-difluoromethylornithine (DFMO) is about to become a first-line drug against human late-stage gambiense sleeping sickness.	Eflornithine	18-47	ornithine decarboxylase 1	Homo sapiens	4-7
17610127-3	2007	The ODC inhibitor alpha-difluoromethylornithine (DFMO) is about to become a first-line drug against human late-stage gambiense sleeping sickness.	Eflornithine	49-53	ornithine decarboxylase 1	Homo sapiens	4-7
17442733-5	2007	Depletion of cellular polyamines by inhibiting ornithine decarboxylase (ODC) with alpha-difluoromethylornithine not only induced p53 but also increased NDRG1 transcription as indicated by induction of the NDRG1 promoter activity and increased levels of NDRG1 mRNA and protein, all of which were prevented by using specific p53 siRNA and in cells with a targeted deletion of p53.	Eflornithine	82-111	ornithine decarboxylase 1	Homo sapiens	47-70
17442733-5	2007	Depletion of cellular polyamines by inhibiting ornithine decarboxylase (ODC) with alpha-difluoromethylornithine not only induced p53 but also increased NDRG1 transcription as indicated by induction of the NDRG1 promoter activity and increased levels of NDRG1 mRNA and protein, all of which were prevented by using specific p53 siRNA and in cells with a targeted deletion of p53.	Eflornithine	82-111	ornithine decarboxylase 1	Homo sapiens	72-75
17442733-5	2007	Depletion of cellular polyamines by inhibiting ornithine decarboxylase (ODC) with alpha-difluoromethylornithine not only induced p53 but also increased NDRG1 transcription as indicated by induction of the NDRG1 promoter activity and increased levels of NDRG1 mRNA and protein, all of which were prevented by using specific p53 siRNA and in cells with a targeted deletion of p53.	Eflornithine	82-111	tumor protein p53	Homo sapiens	129-132
17442733-5	2007	Depletion of cellular polyamines by inhibiting ornithine decarboxylase (ODC) with alpha-difluoromethylornithine not only induced p53 but also increased NDRG1 transcription as indicated by induction of the NDRG1 promoter activity and increased levels of NDRG1 mRNA and protein, all of which were prevented by using specific p53 siRNA and in cells with a targeted deletion of p53.	Eflornithine	82-111	N-myc downstream regulated 1	Homo sapiens	152-157
17442733-5	2007	Depletion of cellular polyamines by inhibiting ornithine decarboxylase (ODC) with alpha-difluoromethylornithine not only induced p53 but also increased NDRG1 transcription as indicated by induction of the NDRG1 promoter activity and increased levels of NDRG1 mRNA and protein, all of which were prevented by using specific p53 siRNA and in cells with a targeted deletion of p53.	Eflornithine	82-111	N-myc downstream regulated 1	Homo sapiens	205-210
17442733-5	2007	Depletion of cellular polyamines by inhibiting ornithine decarboxylase (ODC) with alpha-difluoromethylornithine not only induced p53 but also increased NDRG1 transcription as indicated by induction of the NDRG1 promoter activity and increased levels of NDRG1 mRNA and protein, all of which were prevented by using specific p53 siRNA and in cells with a targeted deletion of p53.	Eflornithine	82-111	N-myc downstream regulated 1	Homo sapiens	205-210
17442733-5	2007	Depletion of cellular polyamines by inhibiting ornithine decarboxylase (ODC) with alpha-difluoromethylornithine not only induced p53 but also increased NDRG1 transcription as indicated by induction of the NDRG1 promoter activity and increased levels of NDRG1 mRNA and protein, all of which were prevented by using specific p53 siRNA and in cells with a targeted deletion of p53.	Eflornithine	82-111	tumor protein p53	Homo sapiens	323-326
17442733-5	2007	Depletion of cellular polyamines by inhibiting ornithine decarboxylase (ODC) with alpha-difluoromethylornithine not only induced p53 but also increased NDRG1 transcription as indicated by induction of the NDRG1 promoter activity and increased levels of NDRG1 mRNA and protein, all of which were prevented by using specific p53 siRNA and in cells with a targeted deletion of p53.	Eflornithine	82-111	tumor protein p53	Homo sapiens	323-326
17549408-8	2007	Animals of the aspirin/DFMO group exhibited an inactivation of ornithine decarboxylase, a key enzyme in polyamine biosynthesis, and a two-fold reduction in the prostaglandin E2 content of the colonic mucosa (p&lt;0.01).	Eflornithine	23-27	ornithine decarboxylase 1	Rattus norvegicus	63-86
17121924-6	2006	To determine if polyamines contribute to the cellular response to HDAC inhibitors, we inhibited ODC activity with alpha-difluoromethylornithine.	Eflornithine	114-143	ornithine decarboxylase 1	Homo sapiens	96-99
17183546-1	2007	Polyamine depletion with the ornithine decarboxylase inhibitor alpha-difluoromethyl ornithine (DFMO), prevents Rac1 activation causing the formation of a thick actin cortex at the cell periphery and inhibits migration of intestinal epithelial cells.	Eflornithine	63-93	ornithine decarboxylase 1	Homo sapiens	29-52
17183546-1	2007	Polyamine depletion with the ornithine decarboxylase inhibitor alpha-difluoromethyl ornithine (DFMO), prevents Rac1 activation causing the formation of a thick actin cortex at the cell periphery and inhibits migration of intestinal epithelial cells.	Eflornithine	63-93	Rac family small GTPase 1	Homo sapiens	111-115
17183546-1	2007	Polyamine depletion with the ornithine decarboxylase inhibitor alpha-difluoromethyl ornithine (DFMO), prevents Rac1 activation causing the formation of a thick actin cortex at the cell periphery and inhibits migration of intestinal epithelial cells.	Eflornithine	95-99	ornithine decarboxylase 1	Homo sapiens	29-52
17183546-1	2007	Polyamine depletion with the ornithine decarboxylase inhibitor alpha-difluoromethyl ornithine (DFMO), prevents Rac1 activation causing the formation of a thick actin cortex at the cell periphery and inhibits migration of intestinal epithelial cells.	Eflornithine	95-99	Rac family small GTPase 1	Homo sapiens	111-115
17116678-5	2007	The ODC, ADOMETDC, and SPDSYN overproducer strains exhibited a high level of resistance to difluoromethylornithine, 5"-{[(Z)-4-amino-2-butenyl]methylamino}-5"-deoxyadenosine, and n-butylamine, respectively, confirming previous observations that these agents specifically target polyamine enzymes.	Eflornithine	91-114	S-adenosylmethionine decarboxylase	Leishmania donovani	9-17
17235241-4	2007	Annexin V was induced by nimesulide, 4-hydroxyphenylretinamide, and difluoromethylornithine in ultraviolet-B-treated radial growth-phase-like melanoma cells.	Eflornithine	68-91	annexin A5	Homo sapiens	0-9
17235241-6	2007	E-cadherin was only induced by difluoromethylornithine in ultraviolet-B-treated radial growth-phase-like melanoma cells.	Eflornithine	31-54	cadherin 1	Homo sapiens	0-10
16973916-5	2007	Depletion of cellular polyamines by alpha-difluoromethylornithine inhibited PLC-gamma1 expression in differentiated IECs (stable Cdx2-transfected IEC-6 cells), as indicated by substantial decreases in levels of PLC-gamma1 mRNA and protein and its enzyme product IP3.	Eflornithine	36-65	phospholipase C, gamma 1	Rattus norvegicus	76-86
16944279-1	2006	The antiproliferative effects of the iron chelator O-trensox and the ornithine-decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO) were characterized in the rat hepatoma cell line FAO, the rat liver epithelial cell line (RLEC) and the primary rat hepatocyte cultures stimulated by EGF.	Eflornithine	109-138	ornithine decarboxylase 1	Rattus norvegicus	69-92
16944279-1	2006	The antiproliferative effects of the iron chelator O-trensox and the ornithine-decarboxylase (ODC) inhibitor alpha-difluoromethylornithine (DFMO) were characterized in the rat hepatoma cell line FAO, the rat liver epithelial cell line (RLEC) and the primary rat hepatocyte cultures stimulated by EGF.	Eflornithine	109-138	ornithine decarboxylase 1	Rattus norvegicus	94-97
17148758-7	2007	Combination treatment of mice with alpha-difluoromethylornithine (a suicide inhibitor of ODC) and a polyamine-deficient diet produced a marked decrease in adrenal polyamine and catecholamine levels and a significant reduction in plasma corticosterone and aldosterone concentrations that were not associated with a decrease in the mRNA levels of steroidogenic proteins.	Eflornithine	35-64	ornithine decarboxylase, structural 1	Mus musculus	89-92
17371277-2	2007	Among the inhibitors of polyamine-related enzymes, the ODC inactivator DFMO [2-(difluoromethyl)ornithine] became the most well-known.	Eflornithine	71-75	ornithine decarboxylase 1	Homo sapiens	55-58
17371277-2	2007	Among the inhibitors of polyamine-related enzymes, the ODC inactivator DFMO [2-(difluoromethyl)ornithine] became the most well-known.	Eflornithine	77-104	ornithine decarboxylase 1	Homo sapiens	55-58
16973916-5	2007	Depletion of cellular polyamines by alpha-difluoromethylornithine inhibited PLC-gamma1 expression in differentiated IECs (stable Cdx2-transfected IEC-6 cells), as indicated by substantial decreases in levels of PLC-gamma1 mRNA and protein and its enzyme product IP3.	Eflornithine	36-65	caudal type homeo box 2	Rattus norvegicus	129-133
16973916-5	2007	Depletion of cellular polyamines by alpha-difluoromethylornithine inhibited PLC-gamma1 expression in differentiated IECs (stable Cdx2-transfected IEC-6 cells), as indicated by substantial decreases in levels of PLC-gamma1 mRNA and protein and its enzyme product IP3.	Eflornithine	36-65	phospholipase C, gamma 1	Rattus norvegicus	211-221
16883568-6	2006	DFMO treatment and SPD rescues also changed the ratio of total cellular PI(4,5)P2 to PIP suggesting involvement of a SPD-sensitive PI(4)P5K.	Eflornithine	0-4	prolactin induced protein	Homo sapiens	85-88
16669788-4	2006	Inhibition of ODC by DFMO (alpha-difluoromethylornithine) increased the activity of Src and ERK1/2 (extracellular-signal-regulated kinase 1/2) within 30 min, which was prevented by exogenous polyamines added to the DFMO-containing medium.	Eflornithine	21-25	ornithine decarboxylase 1	Rattus norvegicus	14-17
16870157-5	2006	To determine if MTOB exerts its effects primarily via ODC inhibition, we compared the effects of MTOB with the ODC-specific inhibitor difluoromethylornithine (DFMO).	Eflornithine	134-157	ornithine decarboxylase 1	Homo sapiens	111-114
16706751-6	2006	In contrast, depletion of cellular polyamines by inhibiting ODC enzyme activity with alpha-difluoromethylornithine decreased c-Myc, but increased p21Cip1 transcription.	Eflornithine	85-114	ornithine decarboxylase 1	Homo sapiens	60-63
16706751-6	2006	In contrast, depletion of cellular polyamines by inhibiting ODC enzyme activity with alpha-difluoromethylornithine decreased c-Myc, but increased p21Cip1 transcription.	Eflornithine	85-114	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	125-130
16706751-6	2006	In contrast, depletion of cellular polyamines by inhibiting ODC enzyme activity with alpha-difluoromethylornithine decreased c-Myc, but increased p21Cip1 transcription.	Eflornithine	85-114	cyclin dependent kinase inhibitor 1A	Homo sapiens	146-153
16669788-4	2006	Inhibition of ODC by DFMO (alpha-difluoromethylornithine) increased the activity of Src and ERK1/2 (extracellular-signal-regulated kinase 1/2) within 30 min, which was prevented by exogenous polyamines added to the DFMO-containing medium.	Eflornithine	21-25	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	84-87
16669788-4	2006	Inhibition of ODC by DFMO (alpha-difluoromethylornithine) increased the activity of Src and ERK1/2 (extracellular-signal-regulated kinase 1/2) within 30 min, which was prevented by exogenous polyamines added to the DFMO-containing medium.	Eflornithine	21-25	mitogen activated protein kinase 3	Rattus norvegicus	92-98
16669788-4	2006	Inhibition of ODC by DFMO (alpha-difluoromethylornithine) increased the activity of Src and ERK1/2 (extracellular-signal-regulated kinase 1/2) within 30 min, which was prevented by exogenous polyamines added to the DFMO-containing medium.	Eflornithine	21-25	mitogen activated protein kinase 3	Rattus norvegicus	100-141
16669788-4	2006	Inhibition of ODC by DFMO (alpha-difluoromethylornithine) increased the activity of Src and ERK1/2 (extracellular-signal-regulated kinase 1/2) within 30 min, which was prevented by exogenous polyamines added to the DFMO-containing medium.	Eflornithine	27-56	ornithine decarboxylase 1	Rattus norvegicus	14-17
16669788-4	2006	Inhibition of ODC by DFMO (alpha-difluoromethylornithine) increased the activity of Src and ERK1/2 (extracellular-signal-regulated kinase 1/2) within 30 min, which was prevented by exogenous polyamines added to the DFMO-containing medium.	Eflornithine	27-56	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	84-87
16669788-4	2006	Inhibition of ODC by DFMO (alpha-difluoromethylornithine) increased the activity of Src and ERK1/2 (extracellular-signal-regulated kinase 1/2) within 30 min, which was prevented by exogenous polyamines added to the DFMO-containing medium.	Eflornithine	27-56	mitogen activated protein kinase 3	Rattus norvegicus	92-98
16669788-4	2006	Inhibition of ODC by DFMO (alpha-difluoromethylornithine) increased the activity of Src and ERK1/2 (extracellular-signal-regulated kinase 1/2) within 30 min, which was prevented by exogenous polyamines added to the DFMO-containing medium.	Eflornithine	27-56	mitogen activated protein kinase 3	Rattus norvegicus	100-141
16669788-4	2006	Inhibition of ODC by DFMO (alpha-difluoromethylornithine) increased the activity of Src and ERK1/2 (extracellular-signal-regulated kinase 1/2) within 30 min, which was prevented by exogenous polyamines added to the DFMO-containing medium.	Eflornithine	215-219	ornithine decarboxylase 1	Rattus norvegicus	14-17
16669788-4	2006	Inhibition of ODC by DFMO (alpha-difluoromethylornithine) increased the activity of Src and ERK1/2 (extracellular-signal-regulated kinase 1/2) within 30 min, which was prevented by exogenous polyamines added to the DFMO-containing medium.	Eflornithine	215-219	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	84-87
16669788-4	2006	Inhibition of ODC by DFMO (alpha-difluoromethylornithine) increased the activity of Src and ERK1/2 (extracellular-signal-regulated kinase 1/2) within 30 min, which was prevented by exogenous polyamines added to the DFMO-containing medium.	Eflornithine	215-219	mitogen activated protein kinase 3	Rattus norvegicus	92-98
16669788-4	2006	Inhibition of ODC by DFMO (alpha-difluoromethylornithine) increased the activity of Src and ERK1/2 (extracellular-signal-regulated kinase 1/2) within 30 min, which was prevented by exogenous polyamines added to the DFMO-containing medium.	Eflornithine	215-219	mitogen activated protein kinase 3	Rattus norvegicus	100-141
16669788-8	2006	Polyamine depletion by DFMO increased integrin beta3 Tyr785 phosphorylation.	Eflornithine	23-27	integrin subunit beta 3	Rattus norvegicus	38-52
16274854-3	2006	In the present study, we found that depletion of polyamines with alpha-difluromethylornithine (DFMO) significantly reduced the efficacy of GLP-2 in preserving gut mucosa in rats maintained on TPN for 8 days.	Eflornithine	95-99	mast cell protease 10	Rattus norvegicus	139-144
16678846-7	2006	Pharmacological inhibition of ornithine decarboxylase by alpha-difluoromethylornithine (DFMO) depletes H9c2 cardiomyoblasts of polyamines and protects the cells against ischemia-induced apoptosis.	Eflornithine	57-86	ornithine decarboxylase, structural 1	Mus musculus	30-53
16678846-7	2006	Pharmacological inhibition of ornithine decarboxylase by alpha-difluoromethylornithine (DFMO) depletes H9c2 cardiomyoblasts of polyamines and protects the cells against ischemia-induced apoptosis.	Eflornithine	88-92	ornithine decarboxylase, structural 1	Mus musculus	30-53
16678846-8	2006	DFMO inhibits several of the molecular events of apoptosis that follow simulated ischemia, such as the release of cytochrome c from mitochondria, caspase activation, downregulation of Bcl-xL, and DNA fragmentation.	Eflornithine	0-4	BCL2-like 1	Mus musculus	184-190
16813878-1	2006	PURPOSE: Ornithine decarboxylase catalyzes the rate limiting step in polyamine synthesis and its activity can be inhibited by difluoromethylornithine, which has been shown in preclinical studies, to prevent bladder cancer.	Eflornithine	126-149	ornithine decarboxylase 1	Homo sapiens	9-32
16690610-4	2006	Depletion of cellular polyamines by inhibiting ornithine decarboxylase with alpha-difluoromethylornithine dramatically enhanced the cytoplasmic abundance of HuR, whereas ectopic ornithine decarboxylase overexpression decreased cytoplasmic HuR; neither intervention changed whole-cell HuR levels.	Eflornithine	76-105	ornithine decarboxylase 1	Homo sapiens	47-70
16690610-4	2006	Depletion of cellular polyamines by inhibiting ornithine decarboxylase with alpha-difluoromethylornithine dramatically enhanced the cytoplasmic abundance of HuR, whereas ectopic ornithine decarboxylase overexpression decreased cytoplasmic HuR; neither intervention changed whole-cell HuR levels.	Eflornithine	76-105	ELAV like RNA binding protein 1	Homo sapiens	157-160
16274854-5	2006	Addition of DFMO to the infusate prevented the protective effects of GLP-2 in the duodenum and jejunum.	Eflornithine	12-16	mast cell protease 10	Rattus norvegicus	69-74
16532286-5	2006	DFMO-treated cells also showed a low level of thioredoxin, which is a high-level determinant of the cellular fate.	Eflornithine	0-4	thioredoxin	Homo sapiens	46-57
16520895-11	2006	However, Bcl-2 is further enhanced following prolactin stimulation for 4 h and this enhancement is blocked by DFMO.	Eflornithine	110-114	BCL2 apoptosis regulator	Homo sapiens	9-14
16520895-12	2006	Bcl-2 has no effect on ODC activity and protein levels, but ODC upregulates Bcl-2, which is inhibited by DFMO.	Eflornithine	105-109	ornithine decarboxylase 1	Homo sapiens	60-63
16520895-12	2006	Bcl-2 has no effect on ODC activity and protein levels, but ODC upregulates Bcl-2, which is inhibited by DFMO.	Eflornithine	105-109	BCL2 apoptosis regulator	Homo sapiens	76-81
15965903-4	2006	Pre-treatment of chondrocytes with alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, markedly reduced putrescine and spermidine content as well as the caspase-3 activation and DNA fragmentation induced by TNF and CHX.	Eflornithine	35-64	ornithine decarboxylase 1	Homo sapiens	76-99
16052528-7	2006	Finally, DENSPM could rescue cells from growth arrest by the ornithine decarboxylase inhibitor difluoromethylornithine, which depletes intracellular polyamines.	Eflornithine	95-118	ornithine decarboxylase 1	Homo sapiens	61-84
16406751-7	2006	Another strong indication of apoptosis was the finding that one of the key enzymes in the apoptotic process, caspase-3, was induced when DFMO was omitted from the growth medium.	Eflornithine	137-141	caspase-3	Cricetulus griseus	109-118
15965903-4	2006	Pre-treatment of chondrocytes with alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, markedly reduced putrescine and spermidine content as well as the caspase-3 activation and DNA fragmentation induced by TNF and CHX.	Eflornithine	35-64	tumor necrosis factor	Homo sapiens	237-240
15965903-4	2006	Pre-treatment of chondrocytes with alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, markedly reduced putrescine and spermidine content as well as the caspase-3 activation and DNA fragmentation induced by TNF and CHX.	Eflornithine	66-70	ornithine decarboxylase 1	Homo sapiens	76-99
15965903-4	2006	Pre-treatment of chondrocytes with alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, markedly reduced putrescine and spermidine content as well as the caspase-3 activation and DNA fragmentation induced by TNF and CHX.	Eflornithine	66-70	ornithine decarboxylase 1	Homo sapiens	101-104
15965903-4	2006	Pre-treatment of chondrocytes with alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, markedly reduced putrescine and spermidine content as well as the caspase-3 activation and DNA fragmentation induced by TNF and CHX.	Eflornithine	66-70	caspase 3	Homo sapiens	183-192
15965903-4	2006	Pre-treatment of chondrocytes with alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, markedly reduced putrescine and spermidine content as well as the caspase-3 activation and DNA fragmentation induced by TNF and CHX.	Eflornithine	66-70	tumor necrosis factor	Homo sapiens	237-240
15965903-5	2006	DFMO treatment also inhibited the increase in effector caspase activity provoked by TNF plus MG132, a proteasome inhibitor.	Eflornithine	0-4	tumor necrosis factor	Homo sapiens	84-87
15965903-6	2006	DFMO decreased caspase-8 activity and procaspase-8 content, an apical caspase essential for TNF-induced apoptosis.	Eflornithine	0-4	caspase 8	Homo sapiens	15-24
15965903-6	2006	DFMO decreased caspase-8 activity and procaspase-8 content, an apical caspase essential for TNF-induced apoptosis.	Eflornithine	0-4	tumor necrosis factor	Homo sapiens	92-95
15965903-7	2006	Although DFMO increased the amount of active, phosphorylated Akt, inhibitors of the Akt pathway failed to restore the TNF-induced increase in caspase activity blunted by DFMO.	Eflornithine	9-13	AKT serine/threonine kinase 1	Homo sapiens	61-64
15965903-8	2006	DFMO also reduced the increase in caspase activity induced by staurosporine, but in this case Akt inhibition prevented the DFMO effect.	Eflornithine	123-127	AKT serine/threonine kinase 1	Homo sapiens	94-97
16439861-8	2006	Myc-induced apoptosis operates through ODC and can be prevented with the ODC inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	88-117	ornithine decarboxylase 1	Homo sapiens	73-76
16439861-8	2006	Myc-induced apoptosis operates through ODC and can be prevented with the ODC inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	119-123	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-3
16439861-8	2006	Myc-induced apoptosis operates through ODC and can be prevented with the ODC inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	119-123	ornithine decarboxylase 1	Homo sapiens	39-42
16439861-8	2006	Myc-induced apoptosis operates through ODC and can be prevented with the ODC inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	119-123	ornithine decarboxylase 1	Homo sapiens	73-76
15965903-4	2006	Pre-treatment of chondrocytes with alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, markedly reduced putrescine and spermidine content as well as the caspase-3 activation and DNA fragmentation induced by TNF and CHX.	Eflornithine	35-64	ornithine decarboxylase 1	Homo sapiens	101-104
15965903-4	2006	Pre-treatment of chondrocytes with alpha-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, markedly reduced putrescine and spermidine content as well as the caspase-3 activation and DNA fragmentation induced by TNF and CHX.	Eflornithine	35-64	caspase 3	Homo sapiens	183-192
16048438-3	2005	Polyamine depletion by DFMO (alpha-difluoromethylornithine) caused phosphorylation of STAT3 at Tyr-705 and Ser-727.	Eflornithine	23-27	signal transducer and activator of transcription 3	Homo sapiens	86-91
16048438-3	2005	Polyamine depletion by DFMO (alpha-difluoromethylornithine) caused phosphorylation of STAT3 at Tyr-705 and Ser-727.	Eflornithine	29-58	signal transducer and activator of transcription 3	Homo sapiens	86-91
16322252-4	2005	We found that DFMO caused a p53-independent increase in p21 and its association with cyclin-dependent kinase (cdk)-2 and decreased cdk-2 protein as well as its phosphorylation on Thr160.	Eflornithine	14-18	tumor protein p53	Homo sapiens	28-31
16322252-4	2005	We found that DFMO caused a p53-independent increase in p21 and its association with cyclin-dependent kinase (cdk)-2 and decreased cdk-2 protein as well as its phosphorylation on Thr160.	Eflornithine	14-18	cyclin dependent kinase inhibitor 1A	Homo sapiens	56-59
16322252-4	2005	We found that DFMO caused a p53-independent increase in p21 and its association with cyclin-dependent kinase (cdk)-2 and decreased cdk-2 protein as well as its phosphorylation on Thr160.	Eflornithine	14-18	cyclin dependent kinase 2	Homo sapiens	85-116
16322252-4	2005	We found that DFMO caused a p53-independent increase in p21 and its association with cyclin-dependent kinase (cdk)-2 and decreased cdk-2 protein as well as its phosphorylation on Thr160.	Eflornithine	14-18	cyclin dependent kinase 2	Homo sapiens	131-136
16322252-6	2005	Cdk-2 activity was drastically reduced in DFMO-treated breast cancer cells which exhibited a reduction in retinoblastoma (Rb) phosphorylation and protein.	Eflornithine	42-46	cyclin dependent kinase 2	Homo sapiens	0-5
16322252-8	2005	In addition, DFMO inhibited G2-M transition, most likely as a result of its induction of p21 expression.	Eflornithine	13-17	cyclin dependent kinase inhibitor 1A	Homo sapiens	89-92
16322252-9	2005	Inhibition of the MAPK pathway with PD98059 or U0126 blocked the DFMO-induced induction of p21 and the reduction of cdk-2 protein.	Eflornithine	65-69	cyclin dependent kinase inhibitor 1A	Homo sapiens	91-94
16322252-9	2005	Inhibition of the MAPK pathway with PD98059 or U0126 blocked the DFMO-induced induction of p21 and the reduction of cdk-2 protein.	Eflornithine	65-69	cyclin dependent kinase 2	Homo sapiens	116-121
16322252-10	2005	PD98059 reversed the G2-M block induced by DFMO (probably as a result of suppression of p21) but not the G1-S arrest.	Eflornithine	43-47	cyclin dependent kinase inhibitor 1A	Homo sapiens	88-91
16322252-11	2005	MDA-MB-435 cells treated with PD98059 or U0126 in the presence and absence of DFMO exhibited a marked increase in the expression of p27 and its association with cdk-2, a decrease in phosphorylation of cdk-2 on Thr160, and a decrease in cyclin E expression.	Eflornithine	78-82	interferon alpha inducible protein 27	Homo sapiens	132-135
16322252-11	2005	MDA-MB-435 cells treated with PD98059 or U0126 in the presence and absence of DFMO exhibited a marked increase in the expression of p27 and its association with cdk-2, a decrease in phosphorylation of cdk-2 on Thr160, and a decrease in cyclin E expression.	Eflornithine	78-82	cyclin dependent kinase 2	Homo sapiens	161-166
16322252-11	2005	MDA-MB-435 cells treated with PD98059 or U0126 in the presence and absence of DFMO exhibited a marked increase in the expression of p27 and its association with cdk-2, a decrease in phosphorylation of cdk-2 on Thr160, and a decrease in cyclin E expression.	Eflornithine	78-82	cyclin dependent kinase 2	Homo sapiens	201-206
16322252-13	2005	Neither DFMO nor PD98059, either alone or in combination, reduced cdk-4 activity despite a marked induction in p15 expression caused by DFMO.	Eflornithine	136-140	cyclin dependent kinase inhibitor 2B	Homo sapiens	111-114
16382048-8	2005	Difluoromethylornithine (DFMO), a selective inhibitor of ODC, is under clinical evaluation as a colorectal cancer chemopreventive agent.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	57-60
16048438-7	2005	Expression of DN-STAT3 (dominant negative-STAT3) completely eliminated the protective effect of DFMO against TNF-alpha-induced apoptosis.	Eflornithine	96-100	signal transducer and activator of transcription 3	Homo sapiens	17-22
16048438-7	2005	Expression of DN-STAT3 (dominant negative-STAT3) completely eliminated the protective effect of DFMO against TNF-alpha-induced apoptosis.	Eflornithine	96-100	signal transducer and activator of transcription 3	Homo sapiens	42-47
16048438-7	2005	Expression of DN-STAT3 (dominant negative-STAT3) completely eliminated the protective effect of DFMO against TNF-alpha-induced apoptosis.	Eflornithine	96-100	tumor necrosis factor	Homo sapiens	109-118
16320593-0	2005	[Effect of alpha-difluoromethylornithine on the expression of ODC mRNA in the cortex and hippocampus in rats after cerebral ischemia reperfusion].	Eflornithine	11-40	ornithine decarboxylase 1	Rattus norvegicus	62-65
16320593-4	2005	The variations of the expression of ODC mRNA were studied in the DFMO pretreatment group and the ischemal control group respectively.	Eflornithine	65-69	ornithine decarboxylase 1	Rattus norvegicus	36-39
16320593-6	2005	CONCLUSION: DFMO suppressed the expression of ODC mRNA after different lengths of reperfusion following 10-minute global cerebral ischemia in rats and it may be one of the ways for DFMO to inhibit ODC activity.	Eflornithine	12-16	ornithine decarboxylase 1	Rattus norvegicus	46-49
16320593-6	2005	CONCLUSION: DFMO suppressed the expression of ODC mRNA after different lengths of reperfusion following 10-minute global cerebral ischemia in rats and it may be one of the ways for DFMO to inhibit ODC activity.	Eflornithine	12-16	ornithine decarboxylase 1	Rattus norvegicus	197-200
16320593-6	2005	CONCLUSION: DFMO suppressed the expression of ODC mRNA after different lengths of reperfusion following 10-minute global cerebral ischemia in rats and it may be one of the ways for DFMO to inhibit ODC activity.	Eflornithine	181-185	ornithine decarboxylase 1	Rattus norvegicus	46-49
16320593-6	2005	CONCLUSION: DFMO suppressed the expression of ODC mRNA after different lengths of reperfusion following 10-minute global cerebral ischemia in rats and it may be one of the ways for DFMO to inhibit ODC activity.	Eflornithine	181-185	ornithine decarboxylase 1	Rattus norvegicus	197-200
15994315-5	2005	Bad Ser112 phosphorylation in response to tumor necrosis factor (TNF)-alpha treatment decreased with time in cells grown in control as well as those grown in the presence of alpha-difluoromethylornithine plus putrescine.	Eflornithine	174-203	tumor necrosis factor	Homo sapiens	42-75
15994315-6	2005	However, a sustained increase in the levels of Bad Ser112 phosphorylation was maintained in response to TNF-alpha treatment in cells grown in the presence of alpha-difluoromethylornithine.	Eflornithine	158-187	tumor necrosis factor	Homo sapiens	104-113
15860639-3	2005	Pretreatment of IEC-6 cells with 5 mM alpha-difluoromethylornithine (DFMO) for 4 days significantly reduced radiation-induced caspase-3 activity and DNA fragmentation.	Eflornithine	38-67	caspase 3	Rattus norvegicus	126-135
15860639-3	2005	Pretreatment of IEC-6 cells with 5 mM alpha-difluoromethylornithine (DFMO) for 4 days significantly reduced radiation-induced caspase-3 activity and DNA fragmentation.	Eflornithine	69-73	caspase 3	Rattus norvegicus	126-135
15860639-6	2005	Pretreatment of mice with 2% DFMO in drinking water significantly reduced apoptotic cells from approximately 2.75 to 1.61 per crypt-villus unit, accompanied by significant decreases in caspase-3 levels.	Eflornithine	29-33	caspase 3	Mus musculus	185-194
15860639-7	2005	Further examination showed that DFMO pretreatment inhibited the radiation-induced increase in the proapoptotic protein Bax.	Eflornithine	32-36	BCL2 associated X, apoptosis regulator	Rattus norvegicus	119-122
15860639-9	2005	We conclude that polyamine depletion by DFMO inhibits gamma-irradiation-induced apoptosis of intestinal epithelial cells both in vitro and in vivo through inhibition of Bax and caspase-3 activity, which leads to attenuation of radiation-inflicted intestinal injury.	Eflornithine	40-44	BCL2 associated X, apoptosis regulator	Rattus norvegicus	169-172
15860639-9	2005	We conclude that polyamine depletion by DFMO inhibits gamma-irradiation-induced apoptosis of intestinal epithelial cells both in vitro and in vivo through inhibition of Bax and caspase-3 activity, which leads to attenuation of radiation-inflicted intestinal injury.	Eflornithine	40-44	caspase 3	Rattus norvegicus	177-186
15828019-6	2005	Pre-treatment of chondrocytes with DFMO, while causing polyamine depletion, significantly reduced NF-kappaB DNA binding activity.	Eflornithine	35-39	nuclear factor kappa B subunit 1	Homo sapiens	98-107
15828019-7	2005	Moreover, DFMO also decreased IL-8 production without affecting cellular viability.	Eflornithine	10-14	C-X-C motif chemokine ligand 8	Homo sapiens	30-34
16439861-8	2006	Myc-induced apoptosis operates through ODC and can be prevented with the ODC inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	88-117	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-3
15872011-4	2005	Depletion of cellular polyamines by alpha-difluoromethylornithine, the specific inhibitor of polyamine biosynthesis, stimulated expression of the NPM gene and induced nuclear translocation of NPM protein.	Eflornithine	36-65	nucleophosmin 1	Rattus norvegicus	146-149
15872011-4	2005	Depletion of cellular polyamines by alpha-difluoromethylornithine, the specific inhibitor of polyamine biosynthesis, stimulated expression of the NPM gene and induced nuclear translocation of NPM protein.	Eflornithine	36-65	nucleophosmin 1	Rattus norvegicus	192-195
16007177-1	2005	Alpha-difluoromethylornithine (DFMO) inhibits the proto-oncogene ornithine decarboxylase (ODC) and is known to induce cell cycle arrest.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	65-88
16007177-1	2005	Alpha-difluoromethylornithine (DFMO) inhibits the proto-oncogene ornithine decarboxylase (ODC) and is known to induce cell cycle arrest.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	90-93
16007177-1	2005	Alpha-difluoromethylornithine (DFMO) inhibits the proto-oncogene ornithine decarboxylase (ODC) and is known to induce cell cycle arrest.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	65-88
16007177-1	2005	Alpha-difluoromethylornithine (DFMO) inhibits the proto-oncogene ornithine decarboxylase (ODC) and is known to induce cell cycle arrest.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	90-93
16007177-3	2005	Treatment with DFMO in combination with SAM486A, an S-adenosylmethionine decarboxylase (AdoMetDC) inhibitor, has been shown to enhance polyamine pool depletion.	Eflornithine	15-19	adenosylmethionine decarboxylase 1	Homo sapiens	52-86
16007177-3	2005	Treatment with DFMO in combination with SAM486A, an S-adenosylmethionine decarboxylase (AdoMetDC) inhibitor, has been shown to enhance polyamine pool depletion.	Eflornithine	15-19	adenosylmethionine decarboxylase 1	Homo sapiens	88-96
16007177-11	2005	We show for the first time that DFMO and SAM486A induce G1 cell cycle arrest in NB cells through p27Kip1 and Rb hypophosphorylation.	Eflornithine	32-36	cyclin dependent kinase inhibitor 1B	Homo sapiens	97-104
15941855-5	2005	BMSCs were grown for an additional 2 days in the presence of 1 mM alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, which reduced the content of both putrescine and spermidine by nearly 90%.	Eflornithine	66-95	ornithine decarboxylase 1	Homo sapiens	120-143
15941855-5	2005	BMSCs were grown for an additional 2 days in the presence of 1 mM alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, which reduced the content of both putrescine and spermidine by nearly 90%.	Eflornithine	97-101	ornithine decarboxylase 1	Homo sapiens	120-143
15941855-9	2005	The effect of DFMO on TNFalpha/MG132-induced upregulation of caspase-3 activity was reversed by the addition of 100 microM putrescine, confirming that polyamines were really involved in the apoptotic process.	Eflornithine	14-18	tumor necrosis factor	Homo sapiens	22-30
15941855-9	2005	The effect of DFMO on TNFalpha/MG132-induced upregulation of caspase-3 activity was reversed by the addition of 100 microM putrescine, confirming that polyamines were really involved in the apoptotic process.	Eflornithine	14-18	caspase 3	Homo sapiens	61-70
16382048-8	2005	Difluoromethylornithine (DFMO), a selective inhibitor of ODC, is under clinical evaluation as a colorectal cancer chemopreventive agent.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	57-60
15909119-3	2005	Previous studies have demonstrated that decreasing the activity of ODC by difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, causes the accumulation of intracellular reactive oxygen species (ROS) and cell arrest, thus inducing cell death.	Eflornithine	74-97	ornithine decarboxylase 1	Homo sapiens	67-70
15691870-5	2005	Polyamine depletion by alpha-difluoromethylornithine (DFMO) decreased levels of occludin protein but failed to affect expression of its mRNA.	Eflornithine	23-52	occludin	Rattus norvegicus	80-88
15691870-5	2005	Polyamine depletion by alpha-difluoromethylornithine (DFMO) decreased levels of occludin protein but failed to affect expression of its mRNA.	Eflornithine	54-58	occludin	Rattus norvegicus	80-88
16342411-4	2005	ODC overexpression also increased CK2 kinase activity 2-fold at the nuclear matrix, a response which could be abrogated by treatment of K6/ODC transgenic keratinocytes with the ODC inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	191-220	ornithine decarboxylase 1	Homo sapiens	0-3
16342411-4	2005	ODC overexpression also increased CK2 kinase activity 2-fold at the nuclear matrix, a response which could be abrogated by treatment of K6/ODC transgenic keratinocytes with the ODC inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	191-220	ornithine decarboxylase 1	Homo sapiens	136-142
16342411-4	2005	ODC overexpression also increased CK2 kinase activity 2-fold at the nuclear matrix, a response which could be abrogated by treatment of K6/ODC transgenic keratinocytes with the ODC inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	191-220	ornithine decarboxylase 1	Homo sapiens	139-142
16342411-4	2005	ODC overexpression also increased CK2 kinase activity 2-fold at the nuclear matrix, a response which could be abrogated by treatment of K6/ODC transgenic keratinocytes with the ODC inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	222-226	ornithine decarboxylase 1	Homo sapiens	0-3
16342411-4	2005	ODC overexpression also increased CK2 kinase activity 2-fold at the nuclear matrix, a response which could be abrogated by treatment of K6/ODC transgenic keratinocytes with the ODC inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	222-226	ornithine decarboxylase 1	Homo sapiens	136-142
16342411-5	2005	Levels of B23 protein were also elevated in ODC-overexpressing cells compared to normal cells or transgenic cells treated with DFMO.	Eflornithine	127-131	nucleophosmin 1	Homo sapiens	10-13
16342411-5	2005	Levels of B23 protein were also elevated in ODC-overexpressing cells compared to normal cells or transgenic cells treated with DFMO.	Eflornithine	127-131	ornithine decarboxylase 1	Homo sapiens	44-47
15909119-3	2005	Previous studies have demonstrated that decreasing the activity of ODC by difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, causes the accumulation of intracellular reactive oxygen species (ROS) and cell arrest, thus inducing cell death.	Eflornithine	74-97	ornithine decarboxylase 1	Homo sapiens	135-138
15909119-3	2005	Previous studies have demonstrated that decreasing the activity of ODC by difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, causes the accumulation of intracellular reactive oxygen species (ROS) and cell arrest, thus inducing cell death.	Eflornithine	99-103	ornithine decarboxylase 1	Homo sapiens	67-70
15909119-3	2005	Previous studies have demonstrated that decreasing the activity of ODC by difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, causes the accumulation of intracellular reactive oxygen species (ROS) and cell arrest, thus inducing cell death.	Eflornithine	99-103	ornithine decarboxylase 1	Homo sapiens	135-138
15909119-9	2005	Inhibition of ODC by DFMO in HL-60 cells only could increase ROS generation, but did not disrupt Delta psi(m) or induce apoptosis.	Eflornithine	21-25	ornithine decarboxylase 1	Homo sapiens	14-17
15909119-10	2005	However, DFMO enhanced the accumulation of ROS, disruption of Delta psi(m) and apoptosis when cells were treated with TNF-alpha .	Eflornithine	9-13	tumor necrosis factor	Homo sapiens	118-127
15894264-4	2005	Moreover, lymphoma development was markedly delayed in E mu-Myc;Odc(+/-) transgenic mice and in E mu-Myc mice treated with the Odc inhibitor difluoromethylornithine (DFMO).	Eflornithine	141-164	ornithine decarboxylase, structural 1	Mus musculus	64-67
15894264-4	2005	Moreover, lymphoma development was markedly delayed in E mu-Myc;Odc(+/-) transgenic mice and in E mu-Myc mice treated with the Odc inhibitor difluoromethylornithine (DFMO).	Eflornithine	141-164	myelocytomatosis oncogene	Mus musculus	101-104
15894264-4	2005	Moreover, lymphoma development was markedly delayed in E mu-Myc;Odc(+/-) transgenic mice and in E mu-Myc mice treated with the Odc inhibitor difluoromethylornithine (DFMO).	Eflornithine	141-164	ornithine decarboxylase, structural 1	Mus musculus	127-130
15894264-4	2005	Moreover, lymphoma development was markedly delayed in E mu-Myc;Odc(+/-) transgenic mice and in E mu-Myc mice treated with the Odc inhibitor difluoromethylornithine (DFMO).	Eflornithine	166-170	ornithine decarboxylase, structural 1	Mus musculus	127-130
15925780-2	2005	BBB disturbances may be almost completely prevented by treating animals with the ornithine decarboxylase (ODC) inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	122-151	ornithine decarboxylase 1	Homo sapiens	81-104
16138831-3	2005	We found that inhibition of ODC results in a systematic kidney organogenesis phenotype, in that the DFMO-treated kidney specimens were of smaller size, had less epithelial ureteric bud branches, and their mesenchymal-derived tubule formation was retarded.	Eflornithine	100-104	ornithine decarboxylase, structural 1	Mus musculus	28-31
16138831-6	2005	We studied regulation of the Pax-2 gene by analyzing a mouse line in which lacZ was driven by an 8.5 kb Pax-2 enhancer in the epithelial ureteric bud, and found that Pax-2 expression, as indicated by lacZ expression, increased after DFMO treatment.	Eflornithine	233-237	paired box 2	Mus musculus	29-34
15925780-2	2005	BBB disturbances may be almost completely prevented by treating animals with the ornithine decarboxylase (ODC) inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	122-151	ornithine decarboxylase 1	Homo sapiens	106-109
15925780-2	2005	BBB disturbances may be almost completely prevented by treating animals with the ornithine decarboxylase (ODC) inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	153-157	ornithine decarboxylase 1	Homo sapiens	81-104
15925780-2	2005	BBB disturbances may be almost completely prevented by treating animals with the ornithine decarboxylase (ODC) inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	153-157	ornithine decarboxylase 1	Homo sapiens	106-109
15840035-11	2005	alpha-Difluoromethylornithine (DFMO), an ODC inhibitor, reduced intracellular polyamine concentrations and rHSA-induced cell proliferation to control levels.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	41-44
15840035-11	2005	alpha-Difluoromethylornithine (DFMO), an ODC inhibitor, reduced intracellular polyamine concentrations and rHSA-induced cell proliferation to control levels.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	41-44
15718247-7	2005	Here, we show that the ototoxicity of DFMO may be mediated by alteration of the inward rectification of Kir4.1 channels, resulting in a marked reduction in EP.	Eflornithine	38-42	potassium inwardly rectifying channel subfamily J member 10	Homo sapiens	104-110
15711175-4	2005	The best-characterized inhibitor is alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	36-65	ornithine decarboxylase 1	Homo sapiens	103-126
15711175-4	2005	The best-characterized inhibitor is alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase.	Eflornithine	67-71	ornithine decarboxylase 1	Homo sapiens	103-126
15546879-5	2005	By contrast, simultaneous combination of 5-FU with DFMO, an inhibitor of the polyamine biosynthetic enzyme ornithine decarboxylase, depleted putrescine but did not produce synergistic cell killing.	Eflornithine	51-55	ornithine decarboxylase 1	Homo sapiens	107-130
15857080-4	2005	Difluoromethylornithine (DFMO) selectively inhibits ornithine decarboxylase, thus depleting polyamine content and preventing cell proliferation and synthesis activity.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	52-75
15857080-4	2005	Difluoromethylornithine (DFMO) selectively inhibits ornithine decarboxylase, thus depleting polyamine content and preventing cell proliferation and synthesis activity.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	52-75
15857080-8	2005	RESULTS: Fibroblasts treated with DFMO significantly decreased cell proliferation, ornithine decarboxylase activity, and putrescine levels at all treatment times, spermidine after 72 and 96 hours, and spermine after 96 hours of culture.	Eflornithine	34-38	ornithine decarboxylase 1	Homo sapiens	83-106
15857080-12	2005	Transforming growth factor-beta1 and c-myc mRNA expression were related and correlated to MMP-1 and 2, COL-I and TIMP-1 mRNA trend after DFMO treatment.	Eflornithine	137-141	transforming growth factor beta 1	Homo sapiens	0-32
15857080-12	2005	Transforming growth factor-beta1 and c-myc mRNA expression were related and correlated to MMP-1 and 2, COL-I and TIMP-1 mRNA trend after DFMO treatment.	Eflornithine	137-141	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	37-42
15857080-12	2005	Transforming growth factor-beta1 and c-myc mRNA expression were related and correlated to MMP-1 and 2, COL-I and TIMP-1 mRNA trend after DFMO treatment.	Eflornithine	137-141	matrix metallopeptidase 1	Homo sapiens	90-101
15857080-12	2005	Transforming growth factor-beta1 and c-myc mRNA expression were related and correlated to MMP-1 and 2, COL-I and TIMP-1 mRNA trend after DFMO treatment.	Eflornithine	137-141	TIMP metallopeptidase inhibitor 1	Homo sapiens	113-119
15546879-6	2005	Some pre-treatment and post-treatment regimens of DENSPM and DFMO were antagonistic to 5-FU depending on cellular p53 status.	Eflornithine	61-65	tumor protein p53	Homo sapiens	114-117
15377278-5	2005	DFMO considerably decreased the levels of putrescine and spermidine, and the formation of active eIF5A began to decrease when the level of spermidine fell below 8 nmol/mg of protein after 12 h of incubation with DFMO.	Eflornithine	212-216	eukaryotic translation initiation factor 5A	Mus musculus	97-102
15514084-3	2005	Our study reveals that the blockade of the induction of ovarian ODC by means of the specific inhibitor alpha-difluoromethylornithine (DFMO) affects folliculogenesis and luteinization.	Eflornithine	103-132	ornithine decarboxylase, structural 1	Mus musculus	64-67
15514084-3	2005	Our study reveals that the blockade of the induction of ovarian ODC by means of the specific inhibitor alpha-difluoromethylornithine (DFMO) affects folliculogenesis and luteinization.	Eflornithine	134-138	ornithine decarboxylase, structural 1	Mus musculus	64-67
15514084-5	2005	In adult cycling females, the administration of DFMO on the evening/night of proestrus markedly decreased plasma progesterone levels at diestrus, which was associated to the decrease in the expression of steroidogenic factor 1, cytochrome cholesterol side chain cleavage enzyme, and steroidogenic acute regulatory protein in the ovary and to a reduced vascularization of the corpora lutea.	Eflornithine	48-52	nuclear receptor subfamily 5, group A, member 1	Mus musculus	204-226
16168128-2	2005	Ornithine decarboxylase converts ornithine to putrescine and is the rate-limiting step in polyamine synthesis.alpha-Difluoromethylornithine (DFMO) irreversibly inhibits ornithine decarboxylase and MDA-MB-435 human breast cancer metastasis to the lung without blocking orthotopic tumor growth.	Eflornithine	110-139	ornithine decarboxylase 1	Homo sapiens	0-23
15695401-5	2005	When K14-MEK mice were given alpha-difluoromethylornithine (DFMO), a suicide inactivator of ODC, in the drinking water from birth, there was a dramatic delay in the onset of tumor growth ( approximately 6 weeks), and only 25% of DFMO-treated mice developed tumors by 15 weeks of age.	Eflornithine	29-58	keratin 14	Mus musculus	5-8
15695401-5	2005	When K14-MEK mice were given alpha-difluoromethylornithine (DFMO), a suicide inactivator of ODC, in the drinking water from birth, there was a dramatic delay in the onset of tumor growth ( approximately 6 weeks), and only 25% of DFMO-treated mice developed tumors by 15 weeks of age.	Eflornithine	29-58	midkine	Mus musculus	9-12
15695401-5	2005	When K14-MEK mice were given alpha-difluoromethylornithine (DFMO), a suicide inactivator of ODC, in the drinking water from birth, there was a dramatic delay in the onset of tumor growth ( approximately 6 weeks), and only 25% of DFMO-treated mice developed tumors by 15 weeks of age.	Eflornithine	29-58	ornithine decarboxylase, structural 1	Mus musculus	92-95
15695401-5	2005	When K14-MEK mice were given alpha-difluoromethylornithine (DFMO), a suicide inactivator of ODC, in the drinking water from birth, there was a dramatic delay in the onset of tumor growth ( approximately 6 weeks), and only 25% of DFMO-treated mice developed tumors by 15 weeks of age.	Eflornithine	60-64	keratin 14	Mus musculus	5-8
15695401-5	2005	When K14-MEK mice were given alpha-difluoromethylornithine (DFMO), a suicide inactivator of ODC, in the drinking water from birth, there was a dramatic delay in the onset of tumor growth ( approximately 6 weeks), and only 25% of DFMO-treated mice developed tumors by 15 weeks of age.	Eflornithine	60-64	midkine	Mus musculus	9-12
15695401-5	2005	When K14-MEK mice were given alpha-difluoromethylornithine (DFMO), a suicide inactivator of ODC, in the drinking water from birth, there was a dramatic delay in the onset of tumor growth ( approximately 6 weeks), and only 25% of DFMO-treated mice developed tumors by 15 weeks of age.	Eflornithine	60-64	ornithine decarboxylase, structural 1	Mus musculus	92-95
15695401-5	2005	When K14-MEK mice were given alpha-difluoromethylornithine (DFMO), a suicide inactivator of ODC, in the drinking water from birth, there was a dramatic delay in the onset of tumor growth ( approximately 6 weeks), and only 25% of DFMO-treated mice developed tumors by 15 weeks of age.	Eflornithine	229-233	keratin 14	Mus musculus	5-8
16168128-2	2005	Ornithine decarboxylase converts ornithine to putrescine and is the rate-limiting step in polyamine synthesis.alpha-Difluoromethylornithine (DFMO) irreversibly inhibits ornithine decarboxylase and MDA-MB-435 human breast cancer metastasis to the lung without blocking orthotopic tumor growth.	Eflornithine	110-139	ornithine decarboxylase 1	Homo sapiens	169-192
16168128-2	2005	Ornithine decarboxylase converts ornithine to putrescine and is the rate-limiting step in polyamine synthesis.alpha-Difluoromethylornithine (DFMO) irreversibly inhibits ornithine decarboxylase and MDA-MB-435 human breast cancer metastasis to the lung without blocking orthotopic tumor growth.	Eflornithine	141-145	ornithine decarboxylase 1	Homo sapiens	0-23
16168128-2	2005	Ornithine decarboxylase converts ornithine to putrescine and is the rate-limiting step in polyamine synthesis.alpha-Difluoromethylornithine (DFMO) irreversibly inhibits ornithine decarboxylase and MDA-MB-435 human breast cancer metastasis to the lung without blocking orthotopic tumor growth.	Eflornithine	141-145	ornithine decarboxylase 1	Homo sapiens	169-192
16170669-1	2005	Inhibition of ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, by the irreversible inhibitor alpha-difluoromethylornithine (DFMO) has been shown to decrease the invasiveness of metastatic human breast cancer cell lines.	Eflornithine	115-144	ornithine decarboxylase 1	Homo sapiens	14-37
15355849-6	2005	Depletion of cellular polyamines by pretreatment with alpha-difluoromethylornithine (DFMO) prevented increases in c-myc expression and DNA synthesis induced by 5% dFBS.	Eflornithine	54-83	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	114-119
15355849-6	2005	Depletion of cellular polyamines by pretreatment with alpha-difluoromethylornithine (DFMO) prevented increases in c-myc expression and DNA synthesis induced by 5% dFBS.	Eflornithine	85-89	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	114-119
15355849-7	2005	c-Myc gene transcription and cell proliferation decreased in polyamine-deficient cells, whereas the natural polyamine spermidine given together with DFMO maintained c-myc gene expression and cell growth at normal levels.	Eflornithine	149-153	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	165-170
15355849-8	2005	Disruption of c-myc expression using specific c-myc antisense oligomers not only inhibited normal cell growth (without DFMO) but also prevented the restoration of cell proliferation by spermidine in polyamine-deficient cells.	Eflornithine	119-123	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	14-19
16158253-9	2005	DFMO also increased tyrosine phosphorylation of STAT-3 and expression of STAT-1 and JNK proteins.	Eflornithine	0-4	signal transducer and activator of transcription 3	Homo sapiens	48-54
16170669-1	2005	Inhibition of ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, by the irreversible inhibitor alpha-difluoromethylornithine (DFMO) has been shown to decrease the invasiveness of metastatic human breast cancer cell lines.	Eflornithine	115-144	ornithine decarboxylase 1	Homo sapiens	39-42
16158253-9	2005	DFMO also increased tyrosine phosphorylation of STAT-3 and expression of STAT-1 and JNK proteins.	Eflornithine	0-4	signal transducer and activator of transcription 1	Homo sapiens	73-79
16170669-1	2005	Inhibition of ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, by the irreversible inhibitor alpha-difluoromethylornithine (DFMO) has been shown to decrease the invasiveness of metastatic human breast cancer cell lines.	Eflornithine	146-150	ornithine decarboxylase 1	Homo sapiens	14-37
16158253-9	2005	DFMO also increased tyrosine phosphorylation of STAT-3 and expression of STAT-1 and JNK proteins.	Eflornithine	0-4	mitogen-activated protein kinase 8	Homo sapiens	84-87
16170669-1	2005	Inhibition of ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, by the irreversible inhibitor alpha-difluoromethylornithine (DFMO) has been shown to decrease the invasiveness of metastatic human breast cancer cell lines.	Eflornithine	146-150	ornithine decarboxylase 1	Homo sapiens	39-42
16170669-5	2005	Expression of MMP-7 mRNA was reduced by DFMO, while MMPs-1, -2, -3, -14, and meprin beta were unaffected.	Eflornithine	40-44	matrix metallopeptidase 7	Homo sapiens	14-19
16170669-9	2005	The decrease in meprin alpha expression was reversed with the MEK inhibitor PD98059, demonstrating that MAP kinase signaling mediates the effect of DFMO and SAM486A.	Eflornithine	148-152	mitogen-activated protein kinase kinase 7	Homo sapiens	62-65
15534104-11	2004	We also show that inhibition of ODC by difluoromethylornithine caused decreased cell growth and increased apoptosis in two MTAP-deleted pancreatic adenocarcinoma-derived cell lines.	Eflornithine	39-62	ornithine decarboxylase 1	Homo sapiens	32-35
15611981-6	2005	The increases in mutant frequency were clearly due to ODC transgene activity, since treatment of mice with the ODC inhibitor, alpha-difluoromethylornithine, completely abolished the difference in mutant frequencies between double-transgenic and Big Blue mice.	Eflornithine	126-155	ornithine decarboxylase, structural 1	Mus musculus	54-57
15611981-6	2005	The increases in mutant frequency were clearly due to ODC transgene activity, since treatment of mice with the ODC inhibitor, alpha-difluoromethylornithine, completely abolished the difference in mutant frequencies between double-transgenic and Big Blue mice.	Eflornithine	126-155	ornithine decarboxylase, structural 1	Mus musculus	111-114
15704548-2	2004	DFMO and SAM486A are specific inhibitors of ODC and AdoMetDC, respectively, and are the only two PA inhibitors, which have been clinically evaluated in Phase II and III cancer trials.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	44-47
15704548-2	2004	DFMO and SAM486A are specific inhibitors of ODC and AdoMetDC, respectively, and are the only two PA inhibitors, which have been clinically evaluated in Phase II and III cancer trials.	Eflornithine	0-4	adenosylmethionine decarboxylase 1	Homo sapiens	52-60
15547724-5	2004	Combined administration of SAM486A and alpha-difluoromethylornithine (DFMO), a selective inhibitor of ornithine decarboxylase (ODC), exerted greater antiproliferative and anti-invasive effects and induced an overall greater suppression of cellular PA levels than the individual treatments.	Eflornithine	39-68	ornithine decarboxylase 1	Homo sapiens	102-125
15547724-5	2004	Combined administration of SAM486A and alpha-difluoromethylornithine (DFMO), a selective inhibitor of ornithine decarboxylase (ODC), exerted greater antiproliferative and anti-invasive effects and induced an overall greater suppression of cellular PA levels than the individual treatments.	Eflornithine	39-68	ornithine decarboxylase 1	Homo sapiens	127-130
15547724-5	2004	Combined administration of SAM486A and alpha-difluoromethylornithine (DFMO), a selective inhibitor of ornithine decarboxylase (ODC), exerted greater antiproliferative and anti-invasive effects and induced an overall greater suppression of cellular PA levels than the individual treatments.	Eflornithine	70-74	ornithine decarboxylase 1	Homo sapiens	102-125
15547724-5	2004	Combined administration of SAM486A and alpha-difluoromethylornithine (DFMO), a selective inhibitor of ornithine decarboxylase (ODC), exerted greater antiproliferative and anti-invasive effects and induced an overall greater suppression of cellular PA levels than the individual treatments.	Eflornithine	70-74	ornithine decarboxylase 1	Homo sapiens	127-130
15547724-6	2004	Both SAM486A and DFMO increased phosphorylation of STAT-1, -3, ERK1/2 and p38, thus indicating activation of both STAT signaling and the MAPK pathway.	Eflornithine	17-21	signal transducer and activator of transcription 1	Homo sapiens	51-61
15547724-6	2004	Both SAM486A and DFMO increased phosphorylation of STAT-1, -3, ERK1/2 and p38, thus indicating activation of both STAT signaling and the MAPK pathway.	Eflornithine	17-21	mitogen-activated protein kinase 3	Homo sapiens	63-69
15547724-6	2004	Both SAM486A and DFMO increased phosphorylation of STAT-1, -3, ERK1/2 and p38, thus indicating activation of both STAT signaling and the MAPK pathway.	Eflornithine	17-21	mitogen-activated protein kinase 1	Homo sapiens	74-77
15547724-6	2004	Both SAM486A and DFMO increased phosphorylation of STAT-1, -3, ERK1/2 and p38, thus indicating activation of both STAT signaling and the MAPK pathway.	Eflornithine	17-21	mitogen-activated protein kinase 3	Homo sapiens	137-141
15534104-11	2004	We also show that inhibition of ODC by difluoromethylornithine caused decreased cell growth and increased apoptosis in two MTAP-deleted pancreatic adenocarcinoma-derived cell lines.	Eflornithine	39-62	methylthioadenosine phosphorylase	Homo sapiens	123-127
15505341-0	2004	Tissue-based assay for ornithine decarboxylase to identify patients likely to respond to difluoromethylornithine.	Eflornithine	89-112	ornithine decarboxylase 1	Homo sapiens	23-46
15505341-10	2004	We conclude that we can measure levels of ODC in formalin-fixed tumor tissue using an antibody to ODC coupled to Alexa 647 dye, and this will enable us to conduct a future study to correlate survival of patients with gliomas of different histologies treated with DFMO to tumor ODC levels.	Eflornithine	263-267	ornithine decarboxylase 1	Homo sapiens	42-45
15351722-1	2004	Difluoromethylornithine-induced polyamine depletion produced a significant fall in the rate of 4E-BP1 gene transcription in IEC-6 cells, without a change in stability of the 4E-BP1 message.	Eflornithine	0-23	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	95-101
15378410-4	2004	A two days pre-treatment of fibroblasts with alpha-difluoromethylornithine (DFMO), which caused polyamine depletion, provoked a slight activating effect when given alone, but markedly inhibited the etoposide-induced increases in p65 DNA binding and phosphorylation.	Eflornithine	45-74	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	229-232
15378410-4	2004	A two days pre-treatment of fibroblasts with alpha-difluoromethylornithine (DFMO), which caused polyamine depletion, provoked a slight activating effect when given alone, but markedly inhibited the etoposide-induced increases in p65 DNA binding and phosphorylation.	Eflornithine	76-80	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	229-232
15205357-1	2004	The ability of celecoxib and alpha-difluoromethylornithine (DFMO) to modulate the DNA hypomethylation and the hypermethylation of the estrogen receptor (ER)-alpha gene in colon tumors was evaluated as potential biomarkers for chemoprevention.	Eflornithine	29-58	estrogen receptor 1	Rattus norvegicus	134-162
15494691-5	2004	Upon addition of alpha-DFMO + putrescine to the culture medium of MCF-7 cells, the decrease of the levels of p50 and p65 proteins in the nuclei has been observed.	Eflornithine	17-27	nuclear factor kappa B subunit 1	Homo sapiens	109-112
16416654-5	2005	Specific inhibitors of ODC, most notably 2-difluoromethylornithine (DFMO), have been used experimentally to validate polyamine metabolism as an antineoplastic strategy.	Eflornithine	41-66	ornithine decarboxylase 1	Homo sapiens	23-26
16416654-5	2005	Specific inhibitors of ODC, most notably 2-difluoromethylornithine (DFMO), have been used experimentally to validate polyamine metabolism as an antineoplastic strategy.	Eflornithine	68-72	ornithine decarboxylase 1	Homo sapiens	23-26
15494691-5	2004	Upon addition of alpha-DFMO + putrescine to the culture medium of MCF-7 cells, the decrease of the levels of p50 and p65 proteins in the nuclei has been observed.	Eflornithine	17-27	RELA proto-oncogene, NF-kB subunit	Homo sapiens	117-120
15265947-9	2004	In addition, in vivo inhibition of ODC with alpha-difluoromethylornithine also exacerbated the colitis.	Eflornithine	44-73	ornithine decarboxylase, structural 1	Mus musculus	35-38
15306645-8	2004	Inhibition of ODC by difluoromethylornithine prevented basal and induced cell death in Q57 cells, demonstrating a central role for polyamines in this process.	Eflornithine	21-44	ornithine decarboxylase 1	Homo sapiens	14-17
15247138-1	2004	Difluoromethylornithine (DFMO) is a potent, irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme in the synthesis of polyamines that promote cellular proliferation.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	70-93
15247138-1	2004	Difluoromethylornithine (DFMO) is a potent, irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme in the synthesis of polyamines that promote cellular proliferation.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	70-93
15175104-3	2004	We have investigated the utility of polyamine-based therapy against SCCs in this model using the ODC inhibitor 2-difluoromethylornithine delivered orally.	Eflornithine	111-136	ornithine decarboxylase, structural 1	Mus musculus	97-100
15205357-1	2004	The ability of celecoxib and alpha-difluoromethylornithine (DFMO) to modulate the DNA hypomethylation and the hypermethylation of the estrogen receptor (ER)-alpha gene in colon tumors was evaluated as potential biomarkers for chemoprevention.	Eflornithine	60-64	estrogen receptor 1	Rattus norvegicus	134-162
15205357-9	2004	DFMO for 7-days decreased the number of methylated CpG sites in the ER-alpha gene from 5.00 +/- 0.95 to 3.83 +/- 0.75 and 1.75 +/- 0.49 these levels were further reduced to 0.50 +/- 0.26 following administration of 1000 mg/kg for 28 days.	Eflornithine	0-4	estrogen receptor 1	Rattus norvegicus	68-76
15205357-12	2004	In parallel with the hypermethylation of the ER-alpha gene, the mRNA expression of the gene was decreased in colon tumors and was increased by celecoxib, DFMO or the combination.	Eflornithine	154-158	estrogen receptor 1	Rattus norvegicus	45-53
15205357-13	2004	Celecoxib and DFMO reversed DNA hypomethylation and the hypermethylation of the ER-alpha gene in colon tumors supporting the hypothesis that modulation of methylation is a biomarker of chemoprevention.	Eflornithine	14-18	estrogen receptor 1	Rattus norvegicus	80-88
15175104-8	2004	The enzymatic activity of ODC, the target of DFMO, was substantially reduced after treatment with 1% DFMO and the high SCC polyamine levels, especially putrescine, were also significantly lowered.	Eflornithine	45-49	ornithine decarboxylase, structural 1	Mus musculus	26-29
15175104-8	2004	The enzymatic activity of ODC, the target of DFMO, was substantially reduced after treatment with 1% DFMO and the high SCC polyamine levels, especially putrescine, were also significantly lowered.	Eflornithine	101-105	ornithine decarboxylase, structural 1	Mus musculus	26-29
15067319-7	2004	Furthermore, oral administration of the suicidal ODC inhibitor alpha-difluoromethylornithine reduced UVB-induced BCCs in Ptch1+/- mice.	Eflornithine	63-92	ornithine decarboxylase, structural 1	Mus musculus	49-52
15024023-5	2004	Depletion of cellular polyamines by alpha-difluoromethylornithine induced levels of phosphorylated Akt and increased Akt kinase activity, although it had no effect on expression of total Akt, pERK, p38, and Bcl-2 proteins.	Eflornithine	36-65	AKT serine/threonine kinase 1	Homo sapiens	99-102
15024023-5	2004	Depletion of cellular polyamines by alpha-difluoromethylornithine induced levels of phosphorylated Akt and increased Akt kinase activity, although it had no effect on expression of total Akt, pERK, p38, and Bcl-2 proteins.	Eflornithine	36-65	AKT serine/threonine kinase 1	Homo sapiens	117-120
15024023-5	2004	Depletion of cellular polyamines by alpha-difluoromethylornithine induced levels of phosphorylated Akt and increased Akt kinase activity, although it had no effect on expression of total Akt, pERK, p38, and Bcl-2 proteins.	Eflornithine	36-65	AKT serine/threonine kinase 1	Homo sapiens	117-120
15024023-8	2004	Phosphorylation of glycogen synthase kinase-3, a downstream target of Akt, was also increased in alpha-difluoromethylornithine-treated cells, which was prevented by inactivation of Akt by LY294002 or DNMAkt overexpression.	Eflornithine	97-126	AKT serine/threonine kinase 1	Homo sapiens	70-73
15024023-8	2004	Phosphorylation of glycogen synthase kinase-3, a downstream target of Akt, was also increased in alpha-difluoromethylornithine-treated cells, which was prevented by inactivation of Akt by LY294002 or DNMAkt overexpression.	Eflornithine	97-126	AKT serine/threonine kinase 1	Homo sapiens	181-184
15075199-4	2004	Depletion of cellular polyamines by alpha-difluoromethylornithine not only activated NF-kappaB activity but also increased expression of c-IAP2 and XIAP.	Eflornithine	36-65	X-linked inhibitor of apoptosis	Rattus norvegicus	148-152
15057874-0	2004	The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells.	Eflornithine	26-55	KRAS proto-oncogene, GTPase	Homo sapiens	63-69
15057874-2	2004	alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme, ornithine decarboxylase (ODC), inhibits Ki-ras transformation and colon tumorigenesis in carcinogen-treated animal models by mechanisms yet to be elucidated.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	102-125
15057874-2	2004	alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme, ornithine decarboxylase (ODC), inhibits Ki-ras transformation and colon tumorigenesis in carcinogen-treated animal models by mechanisms yet to be elucidated.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	127-130
15057874-2	2004	alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme, ornithine decarboxylase (ODC), inhibits Ki-ras transformation and colon tumorigenesis in carcinogen-treated animal models by mechanisms yet to be elucidated.	Eflornithine	0-29	KRAS proto-oncogene, GTPase	Homo sapiens	142-148
15057874-2	2004	alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme, ornithine decarboxylase (ODC), inhibits Ki-ras transformation and colon tumorigenesis in carcinogen-treated animal models by mechanisms yet to be elucidated.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	102-125
15057874-2	2004	alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme, ornithine decarboxylase (ODC), inhibits Ki-ras transformation and colon tumorigenesis in carcinogen-treated animal models by mechanisms yet to be elucidated.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	127-130
15057874-2	2004	alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme, ornithine decarboxylase (ODC), inhibits Ki-ras transformation and colon tumorigenesis in carcinogen-treated animal models by mechanisms yet to be elucidated.	Eflornithine	31-35	KRAS proto-oncogene, GTPase	Homo sapiens	142-148
15057874-11	2004	Other Ki-ras-dependent, but DFMO-independent, genes included transglutaminase (TGase) and kallikrein 6 (KLK6).	Eflornithine	28-32	transglutaminase 1	Homo sapiens	61-77
15057874-11	2004	Other Ki-ras-dependent, but DFMO-independent, genes included transglutaminase (TGase) and kallikrein 6 (KLK6).	Eflornithine	28-32	transglutaminase 1	Homo sapiens	79-84
15057874-11	2004	Other Ki-ras-dependent, but DFMO-independent, genes included transglutaminase (TGase) and kallikrein 6 (KLK6).	Eflornithine	28-32	kallikrein related peptidase 6	Homo sapiens	90-102
15057874-11	2004	Other Ki-ras-dependent, but DFMO-independent, genes included transglutaminase (TGase) and kallikrein 6 (KLK6).	Eflornithine	28-32	kallikrein related peptidase 6	Homo sapiens	104-108
15057874-14	2004	The results indicated that the Ki-ras oncogene caused changes in experimental cell migration and cell-cell communication genes and that some of these changes could be reversed by DFMO.	Eflornithine	179-183	KRAS proto-oncogene, GTPase	Homo sapiens	31-37
14563673-4	2004	Polyamine depletion by alpha-difluromethylornithine (DFMO) resulted in the sustained activation of ERK in response to TNF-alpha/CHX treatment.	Eflornithine	53-57	Eph receptor B1	Rattus norvegicus	99-102
14563673-4	2004	Polyamine depletion by alpha-difluromethylornithine (DFMO) resulted in the sustained activation of ERK in response to TNF-alpha/CHX treatment.	Eflornithine	53-57	tumor necrosis factor	Rattus norvegicus	118-127
14563673-6	2004	Moreover, the dose dependency of U-0126-mediated inhibition of TNF-alpha/ CHX-induced ERK phosphorylation correlated with the reversal of the antiapoptotic effect of DFMO.	Eflornithine	166-170	tumor necrosis factor	Rattus norvegicus	63-72
14563673-6	2004	Moreover, the dose dependency of U-0126-mediated inhibition of TNF-alpha/ CHX-induced ERK phosphorylation correlated with the reversal of the antiapoptotic effect of DFMO.	Eflornithine	166-170	Eph receptor B1	Rattus norvegicus	86-89
15067319-7	2004	Furthermore, oral administration of the suicidal ODC inhibitor alpha-difluoromethylornithine reduced UVB-induced BCCs in Ptch1+/- mice.	Eflornithine	63-92	patched 1	Mus musculus	121-126
33873730-3	2004	alpha-Difluoromethylornithine inhibited ornithine decarboxylase and decreased free spermidine levels, but had no effect on ascospore germination.	Eflornithine	0-29	ornithine decarboxylase	Nicotiana tabacum	40-63
14962510-6	2004	Both antisense of c-myc and alpha-difluoromethylornithine (DFMO, specific ODC inhibitor) inhibited cell proliferation without affecting COX-2 expression in response to cigarette smoke extracts (CSE).	Eflornithine	28-57	ornithine decarboxylase 1	Homo sapiens	74-77
14962510-6	2004	Both antisense of c-myc and alpha-difluoromethylornithine (DFMO, specific ODC inhibitor) inhibited cell proliferation without affecting COX-2 expression in response to cigarette smoke extracts (CSE).	Eflornithine	59-63	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	18-23
14962510-6	2004	Both antisense of c-myc and alpha-difluoromethylornithine (DFMO, specific ODC inhibitor) inhibited cell proliferation without affecting COX-2 expression in response to cigarette smoke extracts (CSE).	Eflornithine	59-63	ornithine decarboxylase 1	Homo sapiens	74-77
14693047-0	2003	[Apoptotic induction of human lung carcinoma A549 cells by DFMO through Fas/FasL pathway].	Eflornithine	59-63	Fas ligand	Homo sapiens	76-80
15672871-0	2004	Cellular mechanisms mediating the anti-invasive properties of the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) in human breast cancer cells.	Eflornithine	100-129	ornithine decarboxylase 1	Homo sapiens	66-89
15672871-0	2004	Cellular mechanisms mediating the anti-invasive properties of the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) in human breast cancer cells.	Eflornithine	131-135	ornithine decarboxylase 1	Homo sapiens	66-89
15672871-3	2004	DFMO did not affect phosphorylation of FAK or Akt, but increased ERK phosphorylation by approximately threefold.	Eflornithine	0-4	mitogen-activated protein kinase 1	Homo sapiens	65-68
15672871-6	2004	Next, we tested the influence of DFMO on the production of the prometastatic peptide osteopontin (OPN) and the anti-metastatic protein thrombospondin-1 (TSP-1).	Eflornithine	33-37	secreted phosphoprotein 1	Homo sapiens	85-96
15672871-7	2004	DFMO treatment, while not affecting OPN production, markedly increased the TSP-1 level in the conditioned media.	Eflornithine	0-4	thrombospondin 1	Homo sapiens	75-80
15672871-9	2004	PD98059 completely blocked the stimulatory effect of DFMO on TSP-1 production, which supports a mediatory role for activation of the MAPK pathway in the upregulation of this anti-metastatic peptide by DFMO.	Eflornithine	53-57	thrombospondin 1	Homo sapiens	61-66
15672871-9	2004	PD98059 completely blocked the stimulatory effect of DFMO on TSP-1 production, which supports a mediatory role for activation of the MAPK pathway in the upregulation of this anti-metastatic peptide by DFMO.	Eflornithine	53-57	mitogen-activated protein kinase 1	Homo sapiens	133-137
15672871-9	2004	PD98059 completely blocked the stimulatory effect of DFMO on TSP-1 production, which supports a mediatory role for activation of the MAPK pathway in the upregulation of this anti-metastatic peptide by DFMO.	Eflornithine	201-205	thrombospondin 1	Homo sapiens	61-66
15672871-9	2004	PD98059 completely blocked the stimulatory effect of DFMO on TSP-1 production, which supports a mediatory role for activation of the MAPK pathway in the upregulation of this anti-metastatic peptide by DFMO.	Eflornithine	201-205	mitogen-activated protein kinase 1	Homo sapiens	133-137
15672871-10	2004	In summary, our results show that the increase in ERK phosphorylation induced by DFMO plays a critical role in the anti-invasive action of the drug and in its ability to upregulate TSP-1 production.	Eflornithine	81-85	mitogen-activated protein kinase 1	Homo sapiens	50-53
15672871-10	2004	In summary, our results show that the increase in ERK phosphorylation induced by DFMO plays a critical role in the anti-invasive action of the drug and in its ability to upregulate TSP-1 production.	Eflornithine	81-85	thrombospondin 1	Homo sapiens	181-186
14693047-7	2003	CONCLUSION: DFMO induce apoptosis of human lung carcinoma A549 cells through Fas/FasL pathway.	Eflornithine	12-16	Fas ligand	Homo sapiens	81-85
14600289-9	2003	The decrease in PTK activity after the first day, even in the presence of alpha-D-Difluoromethylornithine (DFMO), an inhibitor of ODC activity, suggests that it is not regulated by polyamines.	Eflornithine	107-111	ornithine decarboxylase 1	Rattus norvegicus	130-133
14649727-11	2003	0.25 mM alpha-difluoromethylornithine (DFMO) inhibited ischemia-induced ODC activity, whereas a 10-mM dose of DFMO appears to provide some neuroprotection by suppressing both ODC activity and LDH release in neuronal cultures, suggesting the involvement of polyamines in the development of neuronal cell death.	Eflornithine	8-37	ornithine decarboxylase 1	Rattus norvegicus	72-75
14649727-11	2003	0.25 mM alpha-difluoromethylornithine (DFMO) inhibited ischemia-induced ODC activity, whereas a 10-mM dose of DFMO appears to provide some neuroprotection by suppressing both ODC activity and LDH release in neuronal cultures, suggesting the involvement of polyamines in the development of neuronal cell death.	Eflornithine	39-43	ornithine decarboxylase 1	Rattus norvegicus	72-75
14649727-11	2003	0.25 mM alpha-difluoromethylornithine (DFMO) inhibited ischemia-induced ODC activity, whereas a 10-mM dose of DFMO appears to provide some neuroprotection by suppressing both ODC activity and LDH release in neuronal cultures, suggesting the involvement of polyamines in the development of neuronal cell death.	Eflornithine	110-114	ornithine decarboxylase 1	Rattus norvegicus	175-178
12855402-5	2003	Depletion of cellular polyamines by alpha-difluoromethylornithine (DFMO) increased basal levels of Smad3 and Smad4 proteins, induced their nuclear translocation, and stimulated Smad sequence-specific DNA-binding activity.	Eflornithine	36-65	SMAD family member 3	Rattus norvegicus	99-104
12853285-5	2003	Depletion of cellular polyamines by alpha-difluoromethylornithine (DFMO) reduced intracellular free Ca2+ concentration ([Ca2+]cyt), decreased E-cadherin expression, and increased paracellular permeability in normal intestinal epithelial cells (IEC-6 line).	Eflornithine	36-65	cadherin 1	Homo sapiens	142-152
12853285-5	2003	Depletion of cellular polyamines by alpha-difluoromethylornithine (DFMO) reduced intracellular free Ca2+ concentration ([Ca2+]cyt), decreased E-cadherin expression, and increased paracellular permeability in normal intestinal epithelial cells (IEC-6 line).	Eflornithine	67-71	cadherin 1	Homo sapiens	142-152
12853285-7	2003	Addition of exogenous polyamine spermidine reversed the effects of DFMO on [Ca2+]cyt and E-cadherin expression and restored paracellular permeability to near normal.	Eflornithine	67-71	cadherin 1	Homo sapiens	89-99
14568000-4	2003	This could reflect tighter tethering of nucleosomes to DNA or a more compacted chromatin structure due to elevated intracellular concentrations of polyamines since this effect is reversible upon treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC enzymatic activity.	Eflornithine	210-239	ornithine decarboxylase, structural 1	Mus musculus	272-275
14568000-4	2003	This could reflect tighter tethering of nucleosomes to DNA or a more compacted chromatin structure due to elevated intracellular concentrations of polyamines since this effect is reversible upon treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC enzymatic activity.	Eflornithine	241-245	ornithine decarboxylase, structural 1	Mus musculus	272-275
12869386-6	2003	Polyamine depletion by treatment with alpha-difluoromethylornithine significantly reduced the level of apoptosis, as judged by DNA fragmentation and the caspase-3 activity of attached cells.	Eflornithine	38-67	caspase 3	Rattus norvegicus	153-162
12855402-5	2003	Depletion of cellular polyamines by alpha-difluoromethylornithine (DFMO) increased basal levels of Smad3 and Smad4 proteins, induced their nuclear translocation, and stimulated Smad sequence-specific DNA-binding activity.	Eflornithine	36-65	SMAD family member 4	Rattus norvegicus	109-114
12855402-5	2003	Depletion of cellular polyamines by alpha-difluoromethylornithine (DFMO) increased basal levels of Smad3 and Smad4 proteins, induced their nuclear translocation, and stimulated Smad sequence-specific DNA-binding activity.	Eflornithine	67-71	SMAD family member 3	Rattus norvegicus	99-104
12855402-5	2003	Depletion of cellular polyamines by alpha-difluoromethylornithine (DFMO) increased basal levels of Smad3 and Smad4 proteins, induced their nuclear translocation, and stimulated Smad sequence-specific DNA-binding activity.	Eflornithine	67-71	SMAD family member 4	Rattus norvegicus	109-114
12855402-7	2003	Inhibition of Smads by a dominant-negative mutant Smad4 in the DFMO-treated cells prevented the increased Smad transcription activation.	Eflornithine	63-67	SMAD family member 4	Rattus norvegicus	50-55
12885432-2	2003	We administered alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, to neonatal rats on postnatal days 5-12, during the mitotic peak of the cerebellum, a treatment regimen that achieves a chemical knockout of ODC activity and polyamine depletion limited to the treatment period.	Eflornithine	16-45	ornithine decarboxylase 1	Rattus norvegicus	83-86
12859253-0	2003	Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.	Eflornithine	71-94	ornithine decarboxylase 1	Homo sapiens	20-43
12859253-1	2003	Racemic difluoromethylornithine (D/L-DFMO) is an inhibitor of ODC (ornithine decarboxylase), the first enzyme in eukaryotic polyamine biosynthesis.	Eflornithine	8-31	ornithine decarboxylase 1	Homo sapiens	62-65
12859253-1	2003	Racemic difluoromethylornithine (D/L-DFMO) is an inhibitor of ODC (ornithine decarboxylase), the first enzyme in eukaryotic polyamine biosynthesis.	Eflornithine	8-31	ornithine decarboxylase 1	Homo sapiens	67-90
12859253-4	2003	However, both DFMO enantiomers suppressed ODC activity in a time- and concentration-dependent manner.	Eflornithine	14-18	ornithine decarboxylase 1	Homo sapiens	42-45
12859253-12	2003	These results show that both enantiomers of DFMO irreversibly inactivate ODC and suggest that this inactivation occurs by a common mechanism.	Eflornithine	44-48	ornithine decarboxylase 1	Homo sapiens	73-76
12816757-5	2003	Constitutively active RhoA and vector-transfected IEC-6 cell lines were grown in the presence or absence of DFMO, which causes polyamine depletion by inhibiting ornithine decarboxylase, the first rate-limiting step in polyamine synthesis.	Eflornithine	108-112	ornithine decarboxylase 1	Rattus norvegicus	161-184
14535654-11	2003	Among the inhibitors of PA-related enzymes, the ODC inactivator (R, S)-2-(difluoromethyl)ornithine (DFMO) became most famous.	Eflornithine	100-104	ornithine decarboxylase 1	Homo sapiens	48-51
12885432-2	2003	We administered alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, to neonatal rats on postnatal days 5-12, during the mitotic peak of the cerebellum, a treatment regimen that achieves a chemical knockout of ODC activity and polyamine depletion limited to the treatment period.	Eflornithine	16-45	ornithine decarboxylase 1	Rattus norvegicus	229-232
12885432-2	2003	We administered alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, to neonatal rats on postnatal days 5-12, during the mitotic peak of the cerebellum, a treatment regimen that achieves a chemical knockout of ODC activity and polyamine depletion limited to the treatment period.	Eflornithine	47-51	ornithine decarboxylase 1	Rattus norvegicus	83-86
12885432-6	2003	DFMO"s effects on both nAChR expression and cellular biomarkers resembled those of developmental exposure to nicotine.	Eflornithine	0-4	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	23-28
12801231-4	2003	The most sensitive derivatives to DFMO treatment were the Ant-4,4,3- and Ant-4,4,4-tetraamine analogues, which were 7 and 5 times more cytotoxic in DFMO-treated L1210 cells, respectively.	Eflornithine	34-38	solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 31	Mus musculus	58-63
12909191-9	2003	Alpha-difluoromethylornithine (DFMO), the irreversible inhibitor of ornithine decarboxylase, also induced apoptosis to a similar extent.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	68-91
12909191-9	2003	Alpha-difluoromethylornithine (DFMO), the irreversible inhibitor of ornithine decarboxylase, also induced apoptosis to a similar extent.	Eflornithine	31-35	ornithine decarboxylase 1	Rattus norvegicus	68-91
12873989-11	2003	Treatment of ZD:Wt mice with alpha-difluoromethylornithine, an inhibitor of ornithine decarboxylase, had similar results to AZ in reducing tumor incidence, spermidine content, decreasing cell proliferation, and increasing apoptosis.	Eflornithine	29-58	ornithine decarboxylase, structural 1	Mus musculus	76-99
12801231-4	2003	The most sensitive derivatives to DFMO treatment were the Ant-4,4,3- and Ant-4,4,4-tetraamine analogues, which were 7 and 5 times more cytotoxic in DFMO-treated L1210 cells, respectively.	Eflornithine	148-152	solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 31	Mus musculus	58-63
12801231-4	2003	The most sensitive derivatives to DFMO treatment were the Ant-4,4,3- and Ant-4,4,4-tetraamine analogues, which were 7 and 5 times more cytotoxic in DFMO-treated L1210 cells, respectively.	Eflornithine	148-152	solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 31	Mus musculus	73-78
12810623-0	2003	Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by alpha-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss.	Eflornithine	115-144	protein kinase C, epsilon	Mus musculus	71-95
12810623-4	2003	However, DFMO treatment led to marked hair loss in PKC epsilon transgenic mice.	Eflornithine	9-13	protein kinase C, epsilon	Mus musculus	51-62
12810623-7	2003	Severe hair loss observed in PKC epsilon transgenic mice on DFMO during skin tumor promotion has not been reported before in the prevention of cancer in other animal models or in human cancer prevention trials.	Eflornithine	60-64	protein kinase C, epsilon	Mus musculus	29-40
12801231-4	2003	The most sensitive derivatives to DFMO treatment were the Ant-4,4,3- and Ant-4,4,4-tetraamine analogues, which were 7 and 5 times more cytotoxic in DFMO-treated L1210 cells, respectively.	Eflornithine	34-38	solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 31	Mus musculus	73-78
12624736-9	2003	Depletion of putrescine and spermidine due to inactivation of ODC by DFMO causes accumulation of cells in G1, and a proportional decrease of S-phase cells in both cell lines.	Eflornithine	69-73	ornithine decarboxylase 1	Homo sapiens	62-65
12771040-1	2003	The cyclooxygenase-2 (COX-2) inhibitor celecoxib and the ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) were each previously shown to prevent skin tumor development when administered throughout the course of UV irradiation.	Eflornithine	97-120	ornithine decarboxylase, structural 1	Mus musculus	57-80
12771040-1	2003	The cyclooxygenase-2 (COX-2) inhibitor celecoxib and the ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) were each previously shown to prevent skin tumor development when administered throughout the course of UV irradiation.	Eflornithine	97-120	ornithine decarboxylase, structural 1	Mus musculus	82-85
12771040-1	2003	The cyclooxygenase-2 (COX-2) inhibitor celecoxib and the ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) were each previously shown to prevent skin tumor development when administered throughout the course of UV irradiation.	Eflornithine	122-126	prostaglandin-endoperoxide synthase 2	Mus musculus	4-20
12771040-1	2003	The cyclooxygenase-2 (COX-2) inhibitor celecoxib and the ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) were each previously shown to prevent skin tumor development when administered throughout the course of UV irradiation.	Eflornithine	122-126	ornithine decarboxylase, structural 1	Mus musculus	57-80
12653645-8	2003	Pharmacological strategies for suppressing ODC (e.g. the enzyme-activated inhibitor alpha-difluoromethylornithine) and activating SSAT (e.g. NSAIDs) are potent inhibitors of intestinal carcinogenesis in rodent models.	Eflornithine	84-113	ornithine decarboxylase 1	Homo sapiens	43-46
12730671-0	2003	Chemoprevention of mammary carcinogenesis in a transgenic mouse model by alpha-difluoromethylornithine (DFMO) in the diet is associated with decreased cyclin D1 activity.	Eflornithine	73-102	cyclin D1	Mus musculus	151-160
12730671-0	2003	Chemoprevention of mammary carcinogenesis in a transgenic mouse model by alpha-difluoromethylornithine (DFMO) in the diet is associated with decreased cyclin D1 activity.	Eflornithine	104-108	cyclin D1	Mus musculus	151-160
12730671-5	2003	Analyses of preneoplastic mammary tissue collected 1 month after DFMO treatment demonstrated that DFMO (10 g/kg diet) significantly increased the ratio of apoptotic to proliferative indices (P=0.013) and significantly reduced the percentage of cells demonstrating nuclear localized cyclin D1 (P=0.013).	Eflornithine	98-102	cyclin D1	Mus musculus	282-291
12574162-5	2003	Polyamine depletion with alpha-difluoromethylornithine inhibited the activities of RhoA, Rac1, and Cdc42.	Eflornithine	25-54	ras homolog family member A	Rattus norvegicus	83-87
12574162-5	2003	Polyamine depletion with alpha-difluoromethylornithine inhibited the activities of RhoA, Rac1, and Cdc42.	Eflornithine	25-54	Rac family small GTPase 1	Rattus norvegicus	89-93
12574162-5	2003	Polyamine depletion with alpha-difluoromethylornithine inhibited the activities of RhoA, Rac1, and Cdc42.	Eflornithine	25-54	cell division cycle 42	Rattus norvegicus	99-104
12527115-5	2003	When HGF was added to the culture medium, such denuded area was significantly reduced in size compared with the control, but the reduction was inhibited by addition of D,L-alpha-difluoromethylornithine (DFMO), an inhibitor of a rate-limiting enzyme (ornithine decarboxylase) of polyamine biosynthesis, to the culture medium.	Eflornithine	168-201	hepatocyte growth factor	Oryctolagus cuniculus	5-8
12527115-5	2003	When HGF was added to the culture medium, such denuded area was significantly reduced in size compared with the control, but the reduction was inhibited by addition of D,L-alpha-difluoromethylornithine (DFMO), an inhibitor of a rate-limiting enzyme (ornithine decarboxylase) of polyamine biosynthesis, to the culture medium.	Eflornithine	203-207	hepatocyte growth factor	Oryctolagus cuniculus	5-8
12529543-7	2003	Application of alpha-difluoromethyl-ornithine (-Orn) and/or alpha-difluoromethyl-arginine (-Arg), irreversible inhibitors of the putrescine biosynthesis enzymes Orn decarboxylase (ODC) and Arg decarboxylase, respectively, prevented growth of unpollinated MA/pat-2 ovaries.	Eflornithine	15-45	ornithine decarboxylase	Solanum lycopersicum	161-178
12525265-2	2003	In animal models of colon carcinogenesis, inhibition of ODC activity by difluoromethylornithine (DFMO) has been shown to reduce the number and size of colon adenomas and carcinomas.	Eflornithine	72-95	ornithine decarboxylase 1	Homo sapiens	56-59
12525265-2	2003	In animal models of colon carcinogenesis, inhibition of ODC activity by difluoromethylornithine (DFMO) has been shown to reduce the number and size of colon adenomas and carcinomas.	Eflornithine	97-101	ornithine decarboxylase 1	Homo sapiens	56-59
12856719-1	2003	We have recently shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis reduces pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice.	Eflornithine	46-75	ornithine decarboxylase, structural 1	Mus musculus	113-136
12856719-1	2003	We have recently shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis reduces pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice.	Eflornithine	46-75	ornithine decarboxylase, structural 1	Mus musculus	138-141
12856719-1	2003	We have recently shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis reduces pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice.	Eflornithine	77-81	ornithine decarboxylase, structural 1	Mus musculus	113-136
12856719-1	2003	We have recently shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis reduces pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice.	Eflornithine	77-81	ornithine decarboxylase, structural 1	Mus musculus	138-141
12529543-7	2003	Application of alpha-difluoromethyl-ornithine (-Orn) and/or alpha-difluoromethyl-arginine (-Arg), irreversible inhibitors of the putrescine biosynthesis enzymes Orn decarboxylase (ODC) and Arg decarboxylase, respectively, prevented growth of unpollinated MA/pat-2 ovaries.	Eflornithine	15-45	ornithine decarboxylase	Solanum lycopersicum	180-183
12438261-8	2002	Consistent with this observation, the polyamine biosynthesis inhibitor alpha-difluoromethylornithine inhibits the ability of MTAP-deficient cells to form colonies in soft agar, whereas addition of the polyamine putrescine stimulates colony formation in MTAP-expressing cells.	Eflornithine	71-100	methylthioadenosine phosphorylase	Homo sapiens	125-129
12903851-13	2003	For example, a phase II randomized trial of topical DFMO reduced AK number, suppressed polyamines, and reduced p53 protein.	Eflornithine	52-56	tumor protein p53	Homo sapiens	111-114
12597149-1	2002	In the present study the chemopreventive activities of DFMO, the irreversible inhibitor of ornithine decarboxylase, and finasteride, the inhibitor of prostatic 5a-reductase, against the development of chemically induced prostate adenocarcinoma by methylnitrosourea/testosterone propionate in male Wistar rats were investigated.	Eflornithine	55-59	ornithine decarboxylase 1	Rattus norvegicus	91-114
12441138-1	2002	Accumulation of putrescine in ornithine decarboxylase overproducing cells provokes apoptotic death that is inhibited by 2-difluoromethylornithine, a specific inhibitor of ODC.	Eflornithine	120-145	ornithine decarboxylase, structural 1	Mus musculus	30-53
12220664-4	2002	Both ERK and caspase activation were blocked in cells depleted of polyamines by the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	118-147	mitogen-activated protein kinase 1	Mus musculus	5-8
12374678-2	2002	DFMO is an irreversible inhibitor of ornithine decarboxylase, the limiting enzyme of polyamine synthesis that is often up-regulated in breast cancer.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	37-60
12220664-4	2002	Both ERK and caspase activation were blocked in cells depleted of polyamines by the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	118-147	ornithine decarboxylase, structural 1	Mus musculus	84-107
12220664-4	2002	Both ERK and caspase activation were blocked in cells depleted of polyamines by the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	149-153	mitogen-activated protein kinase 1	Mus musculus	5-8
12220664-4	2002	Both ERK and caspase activation were blocked in cells depleted of polyamines by the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO).	Eflornithine	149-153	ornithine decarboxylase, structural 1	Mus musculus	84-107
12220664-5	2002	In etoposide-treated cells, DFMO also abolished phosphorylation of c-Jun NH(2)-terminal kinases triggered by the drug.	Eflornithine	28-32	jun proto-oncogene	Mus musculus	67-72
12220664-7	2002	Ornithine decarboxylase activity decreased after etoposide, indicating that DFMO exerts its effect by depleting cellular polyamines before induction of apoptosis.	Eflornithine	76-80	ornithine decarboxylase, structural 1	Mus musculus	0-23
12189186-6	2002	Calcium chloride, DFMO, piroxicam and sulindac administered for 7 days decreased the mitotic index and reduced the protein and mRNA levels of c-myc in colon tumors.	Eflornithine	18-22	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	142-147
12176729-6	2002	Polyamine depletion by alpha-difluoromethylornithine reduced cytoplasmic free Ca(2+) concentration ([Ca(2+)](cyt)), prevented induction of beta-catenin phosphorylation, and decreased cell migration.	Eflornithine	23-52	catenin beta 1	Homo sapiens	139-151
12189186-7	2002	Calcium chloride, DFMO and piroxicam increased the protein and mRNA levels of p16 and along with sulindac increased the protein level of p27, but not its mRNA.	Eflornithine	18-22	cyclin-dependent kinase inhibitor 2A	Rattus norvegicus	78-81
12189186-7	2002	Calcium chloride, DFMO and piroxicam increased the protein and mRNA levels of p16 and along with sulindac increased the protein level of p27, but not its mRNA.	Eflornithine	18-22	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	137-140
12198703-6	2002	RESULTS: Depletion of cellular polyamines by DL-alpha-difluoromethylornithine (DFMO) induced levels of JunD mRNA and protein, which was associated with an increase in G(1) phase growth arrest.	Eflornithine	45-77	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	103-107
12198703-6	2002	RESULTS: Depletion of cellular polyamines by DL-alpha-difluoromethylornithine (DFMO) induced levels of JunD mRNA and protein, which was associated with an increase in G(1) phase growth arrest.	Eflornithine	79-83	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	103-107
12198703-10	2002	Treatment with JunD antisense oligomers inhibited the p21 promoter and prevented the increase in p21 expression in the presence of DFMO.	Eflornithine	131-135	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	15-19
12198703-10	2002	Treatment with JunD antisense oligomers inhibited the p21 promoter and prevented the increase in p21 expression in the presence of DFMO.	Eflornithine	131-135	H3 histone pseudogene 16	Homo sapiens	97-100
12452334-2	2002	We also examined the effects of spermidine and difluoromethylornithine (DFMO: a specific inhibitor of ODC) on the systolic blood pressure and ODC protein expression in SS rats fed a high salt diet.	Eflornithine	72-76	ornithine decarboxylase 1	Rattus norvegicus	142-145
12452334-8	2002	Spermidine down-regulated and DFMO up-regulated renal ODC protein in SS rats on a high salt diet.	Eflornithine	30-34	ornithine decarboxylase 1	Rattus norvegicus	54-57
12105848-3	2002	METHODS: Polyamines were depleted in intestinal epithelial cell (IEC)-6 cells by incubating them for 4 days with 5 mmol/L alpha-difluoromethylornithine (DFMO), which inhibits ornithine decarboxylase, the first rate-limiting enzyme in the synthesis of polyamines.	Eflornithine	122-151	ornithine decarboxylase 1	Rattus norvegicus	175-198
12223177-9	2002	These observations confirm previous findings that DFMO and NO interfere with RASMC proliferation by inhibiting ODC and polyamine production and provide evidence that nebivolol works by the same mechanism.	Eflornithine	50-54	ornithine decarboxylase 1	Homo sapiens	111-114
12457568-6	2002	Depletion of polyamines by DL-alpha-difluoromethylornithine (DFMO) treatment caused an induction of COX-2 mRNA steady-state levels.	Eflornithine	27-59	prostaglandin-endoperoxide synthase 2	Homo sapiens	100-105
12457568-6	2002	Depletion of polyamines by DL-alpha-difluoromethylornithine (DFMO) treatment caused an induction of COX-2 mRNA steady-state levels.	Eflornithine	61-65	prostaglandin-endoperoxide synthase 2	Homo sapiens	100-105
12467913-8	2002	However, these effects were abrogated by the addition of the ODC inhibitor, DL-alpha-difluoromethyl-ornithine (DFMO).	Eflornithine	76-109	ornithine decarboxylase 1	Rattus norvegicus	61-64
12467913-8	2002	However, these effects were abrogated by the addition of the ODC inhibitor, DL-alpha-difluoromethyl-ornithine (DFMO).	Eflornithine	111-115	ornithine decarboxylase 1	Rattus norvegicus	61-64
12105848-11	2002	In the presence of DFMO, the HA-V14-RhoA cells lost stress fibers and gained the appearance of HA-N19-RhoA cells or wild-type cells treated with DFMO.	Eflornithine	19-23	ras homolog family member A	Rattus norvegicus	36-40
12105848-11	2002	In the presence of DFMO, the HA-V14-RhoA cells lost stress fibers and gained the appearance of HA-N19-RhoA cells or wild-type cells treated with DFMO.	Eflornithine	19-23	ras homolog family member A	Rattus norvegicus	102-106
12105848-11	2002	In the presence of DFMO, the HA-V14-RhoA cells lost stress fibers and gained the appearance of HA-N19-RhoA cells or wild-type cells treated with DFMO.	Eflornithine	145-149	ras homolog family member A	Rattus norvegicus	36-40
12089346-7	2002	We also found that GR1P1 and DRIP205 synergistically activated HNF4alpha-mediated transcription and that a specific inhibitor of polyamine biosynthesis, alpha-difluoromethylornithine (DFMO), decreased the ability of HNF4alpha to activate transcription in vivo.	Eflornithine	153-182	hepatocyte nuclear factor 4 alpha	Homo sapiens	216-225
12089346-7	2002	We also found that GR1P1 and DRIP205 synergistically activated HNF4alpha-mediated transcription and that a specific inhibitor of polyamine biosynthesis, alpha-difluoromethylornithine (DFMO), decreased the ability of HNF4alpha to activate transcription in vivo.	Eflornithine	184-188	mediator complex subunit 1	Homo sapiens	29-36
12089346-7	2002	We also found that GR1P1 and DRIP205 synergistically activated HNF4alpha-mediated transcription and that a specific inhibitor of polyamine biosynthesis, alpha-difluoromethylornithine (DFMO), decreased the ability of HNF4alpha to activate transcription in vivo.	Eflornithine	184-188	hepatocyte nuclear factor 4 alpha	Homo sapiens	63-72
12089346-7	2002	We also found that GR1P1 and DRIP205 synergistically activated HNF4alpha-mediated transcription and that a specific inhibitor of polyamine biosynthesis, alpha-difluoromethylornithine (DFMO), decreased the ability of HNF4alpha to activate transcription in vivo.	Eflornithine	184-188	hepatocyte nuclear factor 4 alpha	Homo sapiens	216-225
11997243-6	2002	We inhibited ornithine decarboxylase, the first rate-limiting enzyme in polyamine synthesis, with alpha-difluoromethylornithine (DFMO) to deplete cells of polyamines.	Eflornithine	98-127	ornithine decarboxylase 1	Rattus norvegicus	13-36
11997243-6	2002	We inhibited ornithine decarboxylase, the first rate-limiting enzyme in polyamine synthesis, with alpha-difluoromethylornithine (DFMO) to deplete cells of polyamines.	Eflornithine	129-133	ornithine decarboxylase 1	Rattus norvegicus	13-36
11997243-10	2002	The expression of antiapoptotic proteins Bcl-x(L) and Bcl-2 was increased in DFMO-treated cells.	Eflornithine	77-81	Bcl2-like 1	Rattus norvegicus	41-49
11997243-10	2002	The expression of antiapoptotic proteins Bcl-x(L) and Bcl-2 was increased in DFMO-treated cells.	Eflornithine	77-81	BCL2, apoptosis regulator	Rattus norvegicus	54-59
12054570-2	2002	Our results show that blockade of the preovulatory rise of ovarian ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, by treatment with the specific inhibitor alpha-difluoromethylornithine (DFMO) leads to a significant decrease in the ovarian progesterone content and a dramatic fall in the plasma levels of this hormone during the following diestrus.	Eflornithine	179-208	ornithine decarboxylase, structural 1	Mus musculus	67-90
11972386-1	2002	OBJECTIVE: Difluoromethylornithine(DFMO), an irreversible inhibitor of ornithine decarboxylase and an angiogenesis inhibitor, has been used in phase I cervical intraepithelial neoplasia (CIN) trials, producing a 50% regression of CIN 3 lesions.	Eflornithine	11-34	ornithine decarboxylase 1	Homo sapiens	71-94
11972386-1	2002	OBJECTIVE: Difluoromethylornithine(DFMO), an irreversible inhibitor of ornithine decarboxylase and an angiogenesis inhibitor, has been used in phase I cervical intraepithelial neoplasia (CIN) trials, producing a 50% regression of CIN 3 lesions.	Eflornithine	35-39	ornithine decarboxylase 1	Homo sapiens	71-94
12054570-2	2002	Our results show that blockade of the preovulatory rise of ovarian ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, by treatment with the specific inhibitor alpha-difluoromethylornithine (DFMO) leads to a significant decrease in the ovarian progesterone content and a dramatic fall in the plasma levels of this hormone during the following diestrus.	Eflornithine	179-208	ornithine decarboxylase, structural 1	Mus musculus	92-95
12054570-2	2002	Our results show that blockade of the preovulatory rise of ovarian ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, by treatment with the specific inhibitor alpha-difluoromethylornithine (DFMO) leads to a significant decrease in the ovarian progesterone content and a dramatic fall in the plasma levels of this hormone during the following diestrus.	Eflornithine	210-214	ornithine decarboxylase, structural 1	Mus musculus	67-90
12054570-2	2002	Our results show that blockade of the preovulatory rise of ovarian ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, by treatment with the specific inhibitor alpha-difluoromethylornithine (DFMO) leads to a significant decrease in the ovarian progesterone content and a dramatic fall in the plasma levels of this hormone during the following diestrus.	Eflornithine	210-214	ornithine decarboxylase, structural 1	Mus musculus	92-95
11911991-12	2002	alpha-Difluoromethylornithine (a specific and irreversible inhibitor of ornithine decarboxylase) decreases PUT and SPD, increased SPM and AGM remain unchanged in the hypothalamus and pituitary.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	72-95
11801552-10	2002	In skin biopsies from the same study, we demonstrate that topical DFMO significantly reduces the percentage of p53-positive cells (22%; P = 0.04); however, there were no significant changes in proliferating cell nuclear antigen or apoptotic indices, or in the frequency of p53 mutations (25% at baseline, 21% after placebo, and 26% after DFMO).	Eflornithine	66-70	tumor protein p53	Homo sapiens	111-114
11888902-0	2002	Suppression of UV carcinogenesis by difluoromethylornithine in nucleotide excision repair-deficient Xpa knockout mice.	Eflornithine	36-59	xeroderma pigmentosum, complementation group A	Mus musculus	100-103
11888902-6	2002	To simulate the situation in XPA patients, we used a hairless Xpa knockout mouse model and down-regulated the ODC activity by difluoromethylornithine (DFMO) administered in the drinking water.	Eflornithine	126-149	XPA, DNA damage recognition and repair factor	Homo sapiens	62-65
11888902-6	2002	To simulate the situation in XPA patients, we used a hairless Xpa knockout mouse model and down-regulated the ODC activity by difluoromethylornithine (DFMO) administered in the drinking water.	Eflornithine	126-149	ornithine decarboxylase, structural 1	Mus musculus	110-113
11888902-6	2002	To simulate the situation in XPA patients, we used a hairless Xpa knockout mouse model and down-regulated the ODC activity by difluoromethylornithine (DFMO) administered in the drinking water.	Eflornithine	151-155	XPA, DNA damage recognition and repair factor	Homo sapiens	29-32
11888902-6	2002	To simulate the situation in XPA patients, we used a hairless Xpa knockout mouse model and down-regulated the ODC activity by difluoromethylornithine (DFMO) administered in the drinking water.	Eflornithine	151-155	XPA, DNA damage recognition and repair factor	Homo sapiens	62-65
11888902-6	2002	To simulate the situation in XPA patients, we used a hairless Xpa knockout mouse model and down-regulated the ODC activity by difluoromethylornithine (DFMO) administered in the drinking water.	Eflornithine	151-155	ornithine decarboxylase, structural 1	Mus musculus	110-113
11888902-9	2002	Late-stage DFMO treatment significantly reduced the number of carcinomas by a factor of 2-3, and it appeared to select for carcinomas with high ODC activity.	Eflornithine	11-15	ornithine decarboxylase 1	Homo sapiens	144-147
11853879-7	2002	Irreversible inhibition of ODC with the active site-directed inhibitor alpha-difluoromethylornithine (DFMO) did not block TPA-mediated inhibition of tyr.	Eflornithine	102-106	ornithine decarboxylase, structural 1	Mus musculus	27-30
11853879-8	2002	Conversely, prolonged treatment of B16 cells with DFMO stimulated tyr activity by a posttranslational mechanism, probably requiring polyamine depletion.	Eflornithine	50-54	tyrosinase	Mus musculus	66-69
11853879-9	2002	Combination treatment with alphaMSH and DFMO synergistically activated tyr.	Eflornithine	40-44	tyrosinase	Mus musculus	71-74
11782361-6	2002	Treatment with the ODC enzyme inhibitor alpha-difluoromethylornithine, which results in regression of ODC/Ras tumors, reverses the effects on HAT and deacetylase enzyme function, implicating polyamine biosynthesis in the regulation of histone acetylation.	Eflornithine	40-69	ornithine decarboxylase, structural 1	Mus musculus	19-22
11782361-6	2002	Treatment with the ODC enzyme inhibitor alpha-difluoromethylornithine, which results in regression of ODC/Ras tumors, reverses the effects on HAT and deacetylase enzyme function, implicating polyamine biosynthesis in the regulation of histone acetylation.	Eflornithine	40-69	ornithine decarboxylase, structural 1	Mus musculus	102-105
11801552-3	2002	Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, suppresses increased polyamine synthesis and inhibits tumors in models of skin carcinogenesis.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	61-84
11801552-3	2002	Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, suppresses increased polyamine synthesis and inhibits tumors in models of skin carcinogenesis.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	61-84
11883715-0	2002	Inhibition of placental ornithine decarboxylase by DL-alpha-difluoro-methyl ornithine causes fetal growth restriction in rat.	Eflornithine	51-85	ornithine decarboxylase 1	Rattus norvegicus	24-47
11883715-2	2002	The DL-alpha-difluoromethyl ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC) which is a rate limiting enzyme of polyamine synthesis was administrated to pregnant rats so that we obtained rat fetuses with IUGR.	Eflornithine	4-37	ornithine decarboxylase 1	Rattus norvegicus	75-98
11883715-2	2002	The DL-alpha-difluoromethyl ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC) which is a rate limiting enzyme of polyamine synthesis was administrated to pregnant rats so that we obtained rat fetuses with IUGR.	Eflornithine	4-37	ornithine decarboxylase 1	Rattus norvegicus	100-103
11883715-2	2002	The DL-alpha-difluoromethyl ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC) which is a rate limiting enzyme of polyamine synthesis was administrated to pregnant rats so that we obtained rat fetuses with IUGR.	Eflornithine	39-43	ornithine decarboxylase 1	Rattus norvegicus	75-98
11883715-2	2002	The DL-alpha-difluoromethyl ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC) which is a rate limiting enzyme of polyamine synthesis was administrated to pregnant rats so that we obtained rat fetuses with IUGR.	Eflornithine	39-43	ornithine decarboxylase 1	Rattus norvegicus	100-103
11883715-7	2002	Depression of ODC activity in the placenta may be the major cause of IUGR induced by DFMO administration, and polyamines play important roles to carry pregnancy.	Eflornithine	85-89	ornithine decarboxylase 1	Rattus norvegicus	14-17
11853879-7	2002	Irreversible inhibition of ODC with the active site-directed inhibitor alpha-difluoromethylornithine (DFMO) did not block TPA-mediated inhibition of tyr.	Eflornithine	71-100	ornithine decarboxylase, structural 1	Mus musculus	27-30
12444804-11	2002	A novel treatment for slowing excessive hair growth is topical eflornithine, an inhibitor of the enzyme ornithine decarboxylase present in hair follicles that is important in hair growth.	Eflornithine	63-75	ornithine decarboxylase 1	Homo sapiens	104-127
12025870-13	2002	Inhibitors of ODC, like alpha-difluoromethylornithine (DFMO) have long been used for cancer prevention and therapy.	Eflornithine	24-53	ornithine decarboxylase 1	Homo sapiens	14-17
12025870-13	2002	Inhibitors of ODC, like alpha-difluoromethylornithine (DFMO) have long been used for cancer prevention and therapy.	Eflornithine	55-59	ornithine decarboxylase 1	Homo sapiens	14-17
11876528-0	2002	The ornithine decarboxylase inhibitor, difluoromethylornithine, inhibits casein kinase II activity, c-Myc expression and normal human keratinocyte proliferation.	Eflornithine	39-62	ornithine decarboxylase 1	Homo sapiens	4-27
11876528-0	2002	The ornithine decarboxylase inhibitor, difluoromethylornithine, inhibits casein kinase II activity, c-Myc expression and normal human keratinocyte proliferation.	Eflornithine	39-62	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	100-105
11964084-3	2002	Administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, significantly reduced, in a dose-dependent manner, the invasiveness in matrigel of both MDA-MB-435 and MDA-MB-231 cells by approximately 70%.	Eflornithine	18-47	ornithine decarboxylase 1	Homo sapiens	85-88
11964084-3	2002	Administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, significantly reduced, in a dose-dependent manner, the invasiveness in matrigel of both MDA-MB-435 and MDA-MB-231 cells by approximately 70%.	Eflornithine	49-53	ornithine decarboxylase 1	Homo sapiens	85-88
12021483-8	2002	Simultaneously administered alpha-difluoromethylornithine significantly (p &lt; 0.005) abolished the IGF-I-induced trophic effects in small intestine and spleen.	Eflornithine	28-57	insulin-like growth factor 1	Rattus norvegicus	101-106
11922393-8	2002	Pretreatment with the ODC inhibitor DFMO, followed by addition of Dex, enhances steroid-evoked kill slightly.	Eflornithine	36-40	ornithine decarboxylase 1	Homo sapiens	22-25
12458962-5	2002	The compound has anticancer and contragestational effects, and it improves the anticancer effect of the ornithine decarboxylase inactivator (D,L)-2-(difluoromethyl)ornithine (DFMO).	Eflornithine	175-179	ornithine decarboxylase 1	Homo sapiens	104-127
11736657-6	2001	ODC activity was completely and irreversibly inhibited by alpha-difluoromethylornithine (K(i) 1.15 microM), showing a competitive inhibition pattern.	Eflornithine	58-87	ornithine decarboxylase 1	Homo sapiens	0-3
11590175-5	2001	We found that the inhibition of ODC by alpha-difluoromethylornithine (DFMO) resulted in a approximately 50% decrease in intracellular putrescine levels within 1 h. NF-kappa B is activated by DFMO through the degradation of the inhibitory protein I kappa B alpha that sequesters NF-kappa B in the cytoplasm.	Eflornithine	39-68	ornithine decarboxylase 1	Rattus norvegicus	32-35
11590175-5	2001	We found that the inhibition of ODC by alpha-difluoromethylornithine (DFMO) resulted in a approximately 50% decrease in intracellular putrescine levels within 1 h. NF-kappa B is activated by DFMO through the degradation of the inhibitory protein I kappa B alpha that sequesters NF-kappa B in the cytoplasm.	Eflornithine	39-68	NFKB inhibitor alpha	Rattus norvegicus	246-261
11590175-5	2001	We found that the inhibition of ODC by alpha-difluoromethylornithine (DFMO) resulted in a approximately 50% decrease in intracellular putrescine levels within 1 h. NF-kappa B is activated by DFMO through the degradation of the inhibitory protein I kappa B alpha that sequesters NF-kappa B in the cytoplasm.	Eflornithine	70-74	ornithine decarboxylase 1	Rattus norvegicus	32-35
11590175-5	2001	We found that the inhibition of ODC by alpha-difluoromethylornithine (DFMO) resulted in a approximately 50% decrease in intracellular putrescine levels within 1 h. NF-kappa B is activated by DFMO through the degradation of the inhibitory protein I kappa B alpha that sequesters NF-kappa B in the cytoplasm.	Eflornithine	70-74	NFKB inhibitor alpha	Rattus norvegicus	246-261
11590175-5	2001	We found that the inhibition of ODC by alpha-difluoromethylornithine (DFMO) resulted in a approximately 50% decrease in intracellular putrescine levels within 1 h. NF-kappa B is activated by DFMO through the degradation of the inhibitory protein I kappa B alpha that sequesters NF-kappa B in the cytoplasm.	Eflornithine	191-195	ornithine decarboxylase 1	Rattus norvegicus	32-35
11590175-5	2001	We found that the inhibition of ODC by alpha-difluoromethylornithine (DFMO) resulted in a approximately 50% decrease in intracellular putrescine levels within 1 h. NF-kappa B is activated by DFMO through the degradation of the inhibitory protein I kappa B alpha that sequesters NF-kappa B in the cytoplasm.	Eflornithine	191-195	NFKB inhibitor alpha	Rattus norvegicus	246-261
11590175-6	2001	The DFMO-induced NF-kappa B complexes contain the p65 and p50 members of the Rel protein family.	Eflornithine	4-8	synaptotagmin 1	Rattus norvegicus	50-53
11590175-7	2001	DFMO-induced NF-kappa B activation was accompanied by the translocation of p65 from the cytoplasm into the nucleus.	Eflornithine	0-4	synaptotagmin 1	Rattus norvegicus	75-78
11728444-1	2001	Trypanosomatid parasites containing a metabolically unstable ornithine decarboxylase (ODC) are naturally resistant to high levels of alpha-difluoromethylornithine (DFMO) because this ODC inhibitor, though causing a drastic reduction of intracellular putrescine, elicits only a moderate decrease of the spermidine endogenous pool.	Eflornithine	133-162	ornithine decarboxylase 1	Homo sapiens	61-84
11728444-1	2001	Trypanosomatid parasites containing a metabolically unstable ornithine decarboxylase (ODC) are naturally resistant to high levels of alpha-difluoromethylornithine (DFMO) because this ODC inhibitor, though causing a drastic reduction of intracellular putrescine, elicits only a moderate decrease of the spermidine endogenous pool.	Eflornithine	133-162	ornithine decarboxylase 1	Homo sapiens	86-89
11728444-1	2001	Trypanosomatid parasites containing a metabolically unstable ornithine decarboxylase (ODC) are naturally resistant to high levels of alpha-difluoromethylornithine (DFMO) because this ODC inhibitor, though causing a drastic reduction of intracellular putrescine, elicits only a moderate decrease of the spermidine endogenous pool.	Eflornithine	133-162	ornithine decarboxylase 1	Homo sapiens	183-186
11728444-1	2001	Trypanosomatid parasites containing a metabolically unstable ornithine decarboxylase (ODC) are naturally resistant to high levels of alpha-difluoromethylornithine (DFMO) because this ODC inhibitor, though causing a drastic reduction of intracellular putrescine, elicits only a moderate decrease of the spermidine endogenous pool.	Eflornithine	164-168	ornithine decarboxylase 1	Homo sapiens	61-84
11728444-1	2001	Trypanosomatid parasites containing a metabolically unstable ornithine decarboxylase (ODC) are naturally resistant to high levels of alpha-difluoromethylornithine (DFMO) because this ODC inhibitor, though causing a drastic reduction of intracellular putrescine, elicits only a moderate decrease of the spermidine endogenous pool.	Eflornithine	164-168	ornithine decarboxylase 1	Homo sapiens	86-89
11728444-1	2001	Trypanosomatid parasites containing a metabolically unstable ornithine decarboxylase (ODC) are naturally resistant to high levels of alpha-difluoromethylornithine (DFMO) because this ODC inhibitor, though causing a drastic reduction of intracellular putrescine, elicits only a moderate decrease of the spermidine endogenous pool.	Eflornithine	164-168	ornithine decarboxylase 1	Homo sapiens	183-186
11691789-3	2001	Treatment of MALME-3M cells with either the ornithine decarboxylase inhibitor alpha-difluoromethylornithine or the S-adenosylmethionine decarboxylase inhibitor MDL-73811 lowered specific polyamine pools and slowed cell growth but did not induce cell cycle arrest.	Eflornithine	78-107	ornithine decarboxylase 1	Homo sapiens	44-67
11698350-3	2001	In order to further explore this possibility, we used SAM-486A and alpha-difluoromethylornithine (DFMO), which are inhibitors of S-adenosylmethionine decarboxylase (SAMDC), and ornithine decarboxylase (ODC), respectively, either alone or in combination to reduce the intracellular polyamine levels.	Eflornithine	67-96	adenosylmethionine decarboxylase 1	Homo sapiens	129-163
11698350-3	2001	In order to further explore this possibility, we used SAM-486A and alpha-difluoromethylornithine (DFMO), which are inhibitors of S-adenosylmethionine decarboxylase (SAMDC), and ornithine decarboxylase (ODC), respectively, either alone or in combination to reduce the intracellular polyamine levels.	Eflornithine	67-96	adenosylmethionine decarboxylase 1	Homo sapiens	165-170
11698350-3	2001	In order to further explore this possibility, we used SAM-486A and alpha-difluoromethylornithine (DFMO), which are inhibitors of S-adenosylmethionine decarboxylase (SAMDC), and ornithine decarboxylase (ODC), respectively, either alone or in combination to reduce the intracellular polyamine levels.	Eflornithine	67-96	ornithine decarboxylase 1	Homo sapiens	202-205
11698350-3	2001	In order to further explore this possibility, we used SAM-486A and alpha-difluoromethylornithine (DFMO), which are inhibitors of S-adenosylmethionine decarboxylase (SAMDC), and ornithine decarboxylase (ODC), respectively, either alone or in combination to reduce the intracellular polyamine levels.	Eflornithine	98-102	adenosylmethionine decarboxylase 1	Homo sapiens	129-163
11698350-3	2001	In order to further explore this possibility, we used SAM-486A and alpha-difluoromethylornithine (DFMO), which are inhibitors of S-adenosylmethionine decarboxylase (SAMDC), and ornithine decarboxylase (ODC), respectively, either alone or in combination to reduce the intracellular polyamine levels.	Eflornithine	98-102	adenosylmethionine decarboxylase 1	Homo sapiens	165-170
11698350-3	2001	In order to further explore this possibility, we used SAM-486A and alpha-difluoromethylornithine (DFMO), which are inhibitors of S-adenosylmethionine decarboxylase (SAMDC), and ornithine decarboxylase (ODC), respectively, either alone or in combination to reduce the intracellular polyamine levels.	Eflornithine	98-102	ornithine decarboxylase 1	Homo sapiens	177-200
11698350-3	2001	In order to further explore this possibility, we used SAM-486A and alpha-difluoromethylornithine (DFMO), which are inhibitors of S-adenosylmethionine decarboxylase (SAMDC), and ornithine decarboxylase (ODC), respectively, either alone or in combination to reduce the intracellular polyamine levels.	Eflornithine	98-102	ornithine decarboxylase 1	Homo sapiens	202-205
11698350-5	2001	We observed that both SAM-486A and DFMO, either alone or in combination, inhibited cell proliferation, induced p21 and arrested cells in the G(0)-G(1) phase of the cell cycle but failed to activate caspase-3 as assessed by enzymatic assay of caspase-3, western blot analysis of the proteolytic cleavage of caspase-3 protein as well as TUNEL assay.	Eflornithine	35-39	H3 histone pseudogene 16	Homo sapiens	111-114
11698350-5	2001	We observed that both SAM-486A and DFMO, either alone or in combination, inhibited cell proliferation, induced p21 and arrested cells in the G(0)-G(1) phase of the cell cycle but failed to activate caspase-3 as assessed by enzymatic assay of caspase-3, western blot analysis of the proteolytic cleavage of caspase-3 protein as well as TUNEL assay.	Eflornithine	35-39	caspase 3	Homo sapiens	242-251
11698350-5	2001	We observed that both SAM-486A and DFMO, either alone or in combination, inhibited cell proliferation, induced p21 and arrested cells in the G(0)-G(1) phase of the cell cycle but failed to activate caspase-3 as assessed by enzymatic assay of caspase-3, western blot analysis of the proteolytic cleavage of caspase-3 protein as well as TUNEL assay.	Eflornithine	35-39	caspase 3	Homo sapiens	242-251
11698350-6	2001	Furthermore, pre-incubation of the cells with SAM-486A and DFMO for 4 days, either alone or in combination significantly inhibited the activation of caspase-3 and apoptosis by NOHA when compared with that observed with cells treated with NOHA alone.	Eflornithine	59-63	caspase 3	Homo sapiens	149-158
11592976-2	2001	NO, like alpha-difluoromethylornithine (DFMO), interferes with cell proliferation by inhibiting ornithine decarboxylase (ODC) and, therefore, polyamine synthesis.	Eflornithine	9-38	ornithine decarboxylase 1	Rattus norvegicus	96-119
11592976-2	2001	NO, like alpha-difluoromethylornithine (DFMO), interferes with cell proliferation by inhibiting ornithine decarboxylase (ODC) and, therefore, polyamine synthesis.	Eflornithine	9-38	ornithine decarboxylase 1	Rattus norvegicus	121-124
11592976-2	2001	NO, like alpha-difluoromethylornithine (DFMO), interferes with cell proliferation by inhibiting ornithine decarboxylase (ODC) and, therefore, polyamine synthesis.	Eflornithine	40-44	ornithine decarboxylase 1	Rattus norvegicus	96-119
11592976-2	2001	NO, like alpha-difluoromethylornithine (DFMO), interferes with cell proliferation by inhibiting ornithine decarboxylase (ODC) and, therefore, polyamine synthesis.	Eflornithine	40-44	ornithine decarboxylase 1	Rattus norvegicus	121-124
11592976-4	2001	The cytostatic effect of NO and DFMO was prevented by the MAPK kinase 1/2 inhibitors PD 098,059 or U0126.	Eflornithine	32-36	mitogen activated protein kinase 3	Rattus norvegicus	58-62
11592976-6	2001	Western blot analysis revealed that treatment of RASMC with NO or DFMO leads to activation of p42/p44 MAPK and induction of p21(waf1/cip1).	Eflornithine	66-70	mitogen activated protein kinase 3	Rattus norvegicus	98-106
11592976-6	2001	Western blot analysis revealed that treatment of RASMC with NO or DFMO leads to activation of p42/p44 MAPK and induction of p21(waf1/cip1).	Eflornithine	66-70	cyclin-dependent kinase inhibitor 1A	Rattus norvegicus	124-137
11592976-8	2001	Moreover, activation of p42/p44 and induction of p21(waf1/cip1) were prevented by exogenous putrescine but not ornithine, suggesting this effect was due to the inhibition of ODC by NO or DFMO.	Eflornithine	187-191	cyclin-dependent kinase inhibitor 1A	Rattus norvegicus	49-62
11592976-8	2001	Moreover, activation of p42/p44 and induction of p21(waf1/cip1) were prevented by exogenous putrescine but not ornithine, suggesting this effect was due to the inhibition of ODC by NO or DFMO.	Eflornithine	187-191	ornithine decarboxylase 1	Rattus norvegicus	174-177
11592976-11	2001	These observations suggest that inhibition of ODC and accompanying putrescine production are the underlying mechanisms by which NO and DFMO activate the MAPK pathway to promote induction of p21(waf1/cip1) and consequent inhibition of cell proliferation.	Eflornithine	135-139	ornithine decarboxylase 1	Rattus norvegicus	46-49
11592976-11	2001	These observations suggest that inhibition of ODC and accompanying putrescine production are the underlying mechanisms by which NO and DFMO activate the MAPK pathway to promote induction of p21(waf1/cip1) and consequent inhibition of cell proliferation.	Eflornithine	135-139	mitogen activated protein kinase 3	Rattus norvegicus	153-157
11592976-11	2001	These observations suggest that inhibition of ODC and accompanying putrescine production are the underlying mechanisms by which NO and DFMO activate the MAPK pathway to promote induction of p21(waf1/cip1) and consequent inhibition of cell proliferation.	Eflornithine	135-139	cyclin-dependent kinase inhibitor 1A	Rattus norvegicus	190-203
11801552-10	2002	In skin biopsies from the same study, we demonstrate that topical DFMO significantly reduces the percentage of p53-positive cells (22%; P = 0.04); however, there were no significant changes in proliferating cell nuclear antigen or apoptotic indices, or in the frequency of p53 mutations (25% at baseline, 21% after placebo, and 26% after DFMO).	Eflornithine	66-70	tumor protein p53	Homo sapiens	273-276
11801552-11	2002	We conclude that inhibition of the premalignant AK lesions as well as a reduction in the expression of p53 and in spermidine concentrations may serve as surrogate endpoint biomarkers of DFMO and possibly other topically administered skin cancer chemopreventive agents.	Eflornithine	186-190	tumor protein p53	Homo sapiens	103-106
11502571-6	2001	Depletion of cellular polyamines by treatment with alpha-difluoromethylornithine (DFMO) increased p53 gene expression and caused growth inhibition in the intact small intestinal mucosa and the cultured cells.	Eflornithine	51-80	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	98-101
11502571-6	2001	Depletion of cellular polyamines by treatment with alpha-difluoromethylornithine (DFMO) increased p53 gene expression and caused growth inhibition in the intact small intestinal mucosa and the cultured cells.	Eflornithine	82-86	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	98-101
11502571-8	2001	Induction of p53 mRNA levels in DFMO-treated cells was paralleled by an increase in the rate of newly synthesized p53 protein.	Eflornithine	32-36	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	13-16
11549581-12	2001	Oral consumption of alpha-difluoromethylornithine, an irreversible specific inhibitor of ODC, in the drinking water (1% w/v) to the transgenic mice resulted in complete prevention of UVB-mediated tumorigenesis and a substantial decrease in the formation of pigmented cysts (&lt;10 per mouse).	Eflornithine	20-49	ornithine decarboxylase, structural 1	Mus musculus	89-92
11502571-8	2001	Induction of p53 mRNA levels in DFMO-treated cells was paralleled by an increase in the rate of newly synthesized p53 protein.	Eflornithine	32-36	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	114-117
11502571-11	2001	Inhibition of the p53 gene expression by using p53 antisense oligodeoxyribonucleotides significantly promoted cell growth in the presence of DFMO.	Eflornithine	141-145	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	18-21
11502571-11	2001	Inhibition of the p53 gene expression by using p53 antisense oligodeoxyribonucleotides significantly promoted cell growth in the presence of DFMO.	Eflornithine	141-145	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	47-50
11688517-3	2001	To further explore the interaction between the polyamine pathway and EGF/HER-2neu signalling in this system, we inhibited endogenous ODC activity with alpha-difluoromethylornithine (DFMO) and assessed the effects of this blockade on the expression of EGF receptors (EGFR) and HER-2neu as well as activation of downstream EGF target genes.	Eflornithine	151-180	ornithine decarboxylase 1	Homo sapiens	133-136
11598794-6	2001	Moreover we show that alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC enzymatic activity, effectively reduces, while exogenous added polyamines enhance apoptosis in starved cells.	Eflornithine	22-51	ornithine decarboxylase 1	Homo sapiens	89-92
11598794-6	2001	Moreover we show that alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC enzymatic activity, effectively reduces, while exogenous added polyamines enhance apoptosis in starved cells.	Eflornithine	53-57	ornithine decarboxylase 1	Homo sapiens	89-92
11688517-0	2001	Effect of alpha-difluoromethyl-ornithine on the expression and function of the epidermal growth factor receptor in human breast epithelial cells in culture.	Eflornithine	10-40	epidermal growth factor receptor	Homo sapiens	79-111
11688517-3	2001	To further explore the interaction between the polyamine pathway and EGF/HER-2neu signalling in this system, we inhibited endogenous ODC activity with alpha-difluoromethylornithine (DFMO) and assessed the effects of this blockade on the expression of EGF receptors (EGFR) and HER-2neu as well as activation of downstream EGF target genes.	Eflornithine	182-186	ornithine decarboxylase 1	Homo sapiens	133-136
11688517-4	2001	We found that DFMO administration to MCF-10A cells increased EGF-R mRNA and protein levels in a dose-response fashion, while HER-2neu expression was not affected.	Eflornithine	14-18	epidermal growth factor	Homo sapiens	61-64
11688517-6	2001	Our results also indicated that the increase in EGFR induced by DFMO was not a non-specific consequence of inhibition of cell proliferation.	Eflornithine	64-68	epidermal growth factor receptor	Homo sapiens	48-52
11688517-8	2001	We propose that physiologic levels of ODC activity may be critical for regulation of a yet undefined signalling pathway, whose blockade by DFMO leads to a compensatory increase in functional EGFR.	Eflornithine	139-143	ornithine decarboxylase 1	Homo sapiens	38-41
11688517-8	2001	We propose that physiologic levels of ODC activity may be critical for regulation of a yet undefined signalling pathway, whose blockade by DFMO leads to a compensatory increase in functional EGFR.	Eflornithine	139-143	epidermal growth factor receptor	Homo sapiens	191-195
11430920-6	2001	Incubation in the organ bath with an inhibitor of ornithine decarboxylase activity, alpha-difluoromethylornithine 10 mM, significantly decreased the positive inotropism induced by 5alpha- and 5beta-dihydrotestosterone (0.1-100 microM).	Eflornithine	84-113	ornithine decarboxylase 1	Rattus norvegicus	50-73
11292609-5	2001	In contrast, polyamine depletion by DFMO promoted resistance to apoptotic cell death induced by the combination of tumor necrosis factor-alpha (TNF-alpha) and cycloheximide.	Eflornithine	36-40	tumor necrosis factor	Rattus norvegicus	115-142
11331080-8	2001	DL-alpha-difluoromethyl-ornithine repressed the [3H]thymidine incorporation and ODC activity induced by ASCE.	Eflornithine	0-33	ornithine decarboxylase 1	Rattus norvegicus	80-83
11401916-4	2001	Difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase (ODC), is a known experimental cancer prevention agent that is being evaluated in a number of human cancer prevention trials.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	55-78
11401916-4	2001	Difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase (ODC), is a known experimental cancer prevention agent that is being evaluated in a number of human cancer prevention trials.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	80-83
11401916-4	2001	Difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase (ODC), is a known experimental cancer prevention agent that is being evaluated in a number of human cancer prevention trials.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	55-78
11401916-4	2001	Difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase (ODC), is a known experimental cancer prevention agent that is being evaluated in a number of human cancer prevention trials.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	80-83
11292609-5	2001	In contrast, polyamine depletion by DFMO promoted resistance to apoptotic cell death induced by the combination of tumor necrosis factor-alpha (TNF-alpha) and cycloheximide.	Eflornithine	36-40	tumor necrosis factor	Rattus norvegicus	144-153
11245616-3	2001	Depletion of cellular polyamines by alpha-difluoromethylornithine (DFMO) reduced whole cell K+ currents [I(K(v))] through Kv channels and caused membrane depolarization, which was associated with decreases in ([Ca2+](cyt)), RhoA protein, and cell migration.	Eflornithine	67-71	ras homolog family member A	Rattus norvegicus	224-228
11245616-4	2001	Exogenous polyamine spermidine reversed the effects of DFMO on I(K(v)), E(m), ([Ca2+](cyt)), and RhoA protein and restored cell migration to normal.	Eflornithine	55-59	ras homolog family member A	Rattus norvegicus	97-101
11259671-5	2001	The cytostatic action of the NO donor agents as well as alpha-difluoromethylornithine (DFMO), a known ODC inhibitor, was prevented by addition of putrescine but not ornithine.	Eflornithine	56-85	ornithine decarboxylase 1	Homo sapiens	102-105
11408253-3	2001	Cells were grown in the presence or absence of alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase, the first rate-limiting enzyme in the synthesis of polyamines.	Eflornithine	47-76	ornithine decarboxylase 1	Rattus norvegicus	109-132
11303587-9	2001	Importantly, DFMO-treated ZD esophagi display increased rate of apoptosis accompanied by intense bax expression and greatly reduced cell proliferation by proliferating cell nuclear antigen expression.	Eflornithine	13-17	BCL2 associated X, apoptosis regulator	Rattus norvegicus	97-100
11408253-3	2001	Cells were grown in the presence or absence of alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase, the first rate-limiting enzyme in the synthesis of polyamines.	Eflornithine	78-82	ornithine decarboxylase 1	Rattus norvegicus	109-132
11408253-10	2001	However, the activity of Cdk2 was significantly inhibited by DFMO in IEC-6 cells.	Eflornithine	61-65	cyclin dependent kinase 2	Rattus norvegicus	25-29
11303587-1	2001	Alpha-difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase, the first enzyme in polyamine synthesis.	Eflornithine	0-29	ornithine decarboxylase 1	Rattus norvegicus	69-92
11259671-5	2001	The cytostatic action of the NO donor agents as well as alpha-difluoromethylornithine (DFMO), a known ODC inhibitor, was prevented by addition of putrescine but not ornithine.	Eflornithine	87-91	ornithine decarboxylase 1	Homo sapiens	102-105
11259671-6	2001	These observations suggested that NO, like DFMO, may directly inhibit ODC.	Eflornithine	43-47	ornithine decarboxylase 1	Homo sapiens	70-73
11303587-10	2001	In addition, the p16(ink4a)/retinoblastoma control at G1 to S, deregulated in ZD esophagi, is restored after DFMO treatment.	Eflornithine	109-113	cyclin-dependent kinase inhibitor 2A	Rattus norvegicus	17-20
11303587-1	2001	Alpha-difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase, the first enzyme in polyamine synthesis.	Eflornithine	31-35	ornithine decarboxylase 1	Rattus norvegicus	69-92
11303587-10	2001	In addition, the p16(ink4a)/retinoblastoma control at G1 to S, deregulated in ZD esophagi, is restored after DFMO treatment.	Eflornithine	109-113	cyclin-dependent kinase inhibitor 2A	Rattus norvegicus	21-26
11142412-1	2000	Alpha-2-(Difluoromethyl)-dl-ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, has been shown to suppress skin carcinogenesis in murine models after oral or topical administration.	Eflornithine	39-43	ornithine decarboxylase, structural 1	Mus musculus	75-98
11222476-8	2001	Furthermore, the formation of putrescine was inhibited by the ODC inhibitor alpha-difluoromethylornithine, and L-proline generation was blocked by the OAT inhibitor L-canaline.	Eflornithine	76-105	ornithine decarboxylase 1	Homo sapiens	62-65
11160858-8	2001	However, the spermine-deficient cells were significantly more sensitive to the growth inhibition exerted by 2-difluoromethylornithine, an inhibitor of ornithine decarboxylase.	Eflornithine	108-133	ornithine decarboxylase, structural 1	Mus musculus	151-174
11162600-0	2001	p53 independent G(1) arrest induced by DL-alpha-difluoromethylornithine.	Eflornithine	39-71	tumor protein p53	Homo sapiens	0-3
11162600-2	2001	DL-alpha-Difluoromethylornithine (DFMO), a synthetic inhibitor of ODC, inhibits cell growth.	Eflornithine	0-32	ornithine decarboxylase 1	Homo sapiens	66-69
11162600-2	2001	DL-alpha-Difluoromethylornithine (DFMO), a synthetic inhibitor of ODC, inhibits cell growth.	Eflornithine	34-38	ornithine decarboxylase 1	Homo sapiens	66-69
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	0-4	H3 histone pseudogene 16	Homo sapiens	142-145
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	0-4	signal transducer and activator of transcription 1	Homo sapiens	169-174
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	0-4	signal transducer and activator of transcription 1	Homo sapiens	283-288
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	0-4	H3 histone pseudogene 16	Homo sapiens	296-299
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	0-4	tumor protein p53	Homo sapiens	376-379
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	0-4	H3 histone pseudogene 16	Homo sapiens	296-299
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	205-209	H3 histone pseudogene 16	Homo sapiens	142-145
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	205-209	signal transducer and activator of transcription 1	Homo sapiens	169-174
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	205-209	signal transducer and activator of transcription 1	Homo sapiens	283-288
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	205-209	H3 histone pseudogene 16	Homo sapiens	296-299
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	205-209	tumor protein p53	Homo sapiens	376-379
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	205-209	H3 histone pseudogene 16	Homo sapiens	296-299
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	205-209	H3 histone pseudogene 16	Homo sapiens	142-145
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	205-209	signal transducer and activator of transcription 1	Homo sapiens	169-174
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	205-209	signal transducer and activator of transcription 1	Homo sapiens	283-288
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	205-209	H3 histone pseudogene 16	Homo sapiens	296-299
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	205-209	tumor protein p53	Homo sapiens	376-379
11162600-5	2001	DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively.	Eflornithine	205-209	H3 histone pseudogene 16	Homo sapiens	296-299
11162600-6	2001	These results suggest that DFMO induced MKN45 cell arrest at G(1) phase in a p53 independent manner, and Stat1 is, at least in part, involved in G(1) arrest.	Eflornithine	27-31	tumor protein p53	Homo sapiens	77-80
11705097-1	2001	Eflornithine is a specific, irreversible inhibitor of the enzyme ornithine decarboxylase which is thought to slow hair growth by inhibiting this enzyme in hair follicles.	Eflornithine	0-12	ornithine decarboxylase 1	Homo sapiens	65-88
11435720-5	2001	alpha-Difluoromethyl ornithine (DFMO), a specific ODC inhibitor, was given orally to early-weaned pups and its resultant effects were assessed on days 1 and 6 after early weaning.	Eflornithine	0-30	ornithine decarboxylase 1	Rattus norvegicus	50-53
11435720-5	2001	alpha-Difluoromethyl ornithine (DFMO), a specific ODC inhibitor, was given orally to early-weaned pups and its resultant effects were assessed on days 1 and 6 after early weaning.	Eflornithine	32-36	ornithine decarboxylase 1	Rattus norvegicus	50-53
11435720-8	2001	The increases of ODC activity, DNA and protein contents as induced by early weaning were significantly suppressed when pups were exposed to DFMO.	Eflornithine	140-144	ornithine decarboxylase 1	Rattus norvegicus	17-20
11160138-5	2001	Kidney weight, ODC activity, and GFR were correlated in diabetic and control rats given difluoromethylornithine (DFMO; Marion Merrell Dow, Cincinnati, Ohio, USA) to inhibit ODC.	Eflornithine	88-111	ornithine decarboxylase 1	Rattus norvegicus	173-176
11160138-5	2001	Kidney weight, ODC activity, and GFR were correlated in diabetic and control rats given difluoromethylornithine (DFMO; Marion Merrell Dow, Cincinnati, Ohio, USA) to inhibit ODC.	Eflornithine	113-117	ornithine decarboxylase 1	Rattus norvegicus	173-176
11160138-7	2001	ODC activity was elevated 15-fold in diabetic kidneys and normalized by DFMO, which also attenuated hyperfiltration and hypertrophy.	Eflornithine	72-76	ornithine decarboxylase 1	Rattus norvegicus	0-3
11134585-2	2000	We administered alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, to neonatal rats on postnatal days 5-12, during the mitotic peak of the cerebellum, a treatment regimen that leads to selective growth inhibition and dysmorphology.	Eflornithine	16-45	ornithine decarboxylase 1	Rattus norvegicus	83-86
11134585-2	2000	We administered alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, to neonatal rats on postnatal days 5-12, during the mitotic peak of the cerebellum, a treatment regimen that leads to selective growth inhibition and dysmorphology.	Eflornithine	47-51	ornithine decarboxylase 1	Rattus norvegicus	83-86
11201656-1	2000	DFMO is an irreversible inhibitor of ornithine decarboxilase (ODC), the key enzyme in mammalian polyamine biosynthesis, and has been shown to induce apoptosis.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	37-60
11201656-1	2000	DFMO is an irreversible inhibitor of ornithine decarboxilase (ODC), the key enzyme in mammalian polyamine biosynthesis, and has been shown to induce apoptosis.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	62-65
11059762-2	2000	Treatment of ODC/Ras double transgenic mice with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC enzyme activity, causes a rapid regression of these spontaneous tumors.	Eflornithine	49-78	ornithine decarboxylase, structural 1	Mus musculus	13-16
11003584-4	2000	Administration of alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (the rate-limiting enzyme for polyamine synthesis), for 4 and 6 days depleted cellular polyamines putrescine, spermidine, and spermine in IEC-6 cells.	Eflornithine	18-47	ornithine decarboxylase 1	Rattus norvegicus	80-103
11003584-4	2000	Administration of alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (the rate-limiting enzyme for polyamine synthesis), for 4 and 6 days depleted cellular polyamines putrescine, spermidine, and spermine in IEC-6 cells.	Eflornithine	49-53	ornithine decarboxylase 1	Rattus norvegicus	80-103
11003584-5	2000	Polyamine depletion by DFMO increased levels of the TGF-beta type I receptor (TGF-betaRI) mRNA and protein but had no effect on the TGF-beta type II receptor expression.	Eflornithine	23-27	transforming growth factor, beta receptor 1	Rattus norvegicus	52-76
11003584-10	2000	These results indicate that 1) depletion of cellular polyamines by DFMO increases expression of the TGF-betaRI gene and 2) increased TGF-betaRI expression plays an important role in the process through which polyamine depletion sensitizes intestinal epithelial cells to growth inhibition induced by TGF-beta.	Eflornithine	67-71	transforming growth factor, beta 1	Rattus norvegicus	100-108
12497077-5	2000	We report here studies utilizing polyamine depletion by means of a combination of blockade of polyamine synthesis with DFMO (alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase, the rate limiting enzyme in the polyamine synthetic pathway, and ORI 1202, a novel inhibitor of polyamine transport into the cell.	Eflornithine	119-123	ornithine decarboxylase 1	Homo sapiens	173-196
12497077-5	2000	We report here studies utilizing polyamine depletion by means of a combination of blockade of polyamine synthesis with DFMO (alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase, the rate limiting enzyme in the polyamine synthetic pathway, and ORI 1202, a novel inhibitor of polyamine transport into the cell.	Eflornithine	125-154	ornithine decarboxylase 1	Homo sapiens	173-196
11097222-0	2000	Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine.	Eflornithine	115-138	KRAS proto-oncogene, GTPase	Homo sapiens	13-18
11097222-1	2000	The nonsteroidal anti-inflammatory drug sulindac and the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) are both potent inhibitors of colon carcinogenesis in experimental models of this disease.	Eflornithine	91-114	ornithine decarboxylase 1	Homo sapiens	57-80
11097222-1	2000	The nonsteroidal anti-inflammatory drug sulindac and the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) are both potent inhibitors of colon carcinogenesis in experimental models of this disease.	Eflornithine	116-120	ornithine decarboxylase 1	Homo sapiens	57-80
11097222-7	2000	A 24-h treatment with DFMO caused a dose-dependent decrease in the colony-forming ability of cells expressing an activated K-ras but had no effect on the viability of the parental Caco-2 cells.	Eflornithine	22-26	KRAS proto-oncogene, GTPase	Homo sapiens	123-128
11097222-8	2000	The DFMO-dependent decrease in colony formation in K-ras-activated cells occurred in the absence of apoptosis.	Eflornithine	4-8	KRAS proto-oncogene, GTPase	Homo sapiens	51-56
11097222-10	2000	These data indicate that K-ras can influence the kinetics of apoptosis induction by sulindac metabolites and cell survival in response to DFMO.	Eflornithine	138-142	KRAS proto-oncogene, GTPase	Homo sapiens	25-30
11059762-2	2000	Treatment of ODC/Ras double transgenic mice with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC enzyme activity, causes a rapid regression of these spontaneous tumors.	Eflornithine	49-78	ornithine decarboxylase, structural 1	Mus musculus	111-114
11059762-2	2000	Treatment of ODC/Ras double transgenic mice with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC enzyme activity, causes a rapid regression of these spontaneous tumors.	Eflornithine	80-84	ornithine decarboxylase, structural 1	Mus musculus	13-16
11059762-2	2000	Treatment of ODC/Ras double transgenic mice with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ODC enzyme activity, causes a rapid regression of these spontaneous tumors.	Eflornithine	80-84	ornithine decarboxylase, structural 1	Mus musculus	111-114
11059762-3	2000	DFMO treatment led to dramatic decreases in ODC activity and putrescine levels, but v-Ha-ras expression was not affected in the regressed tumors.	Eflornithine	0-4	ornithine decarboxylase, structural 1	Mus musculus	44-47
11051233-2	2000	In the current study, we sought to determine whether the addition of alpha-difluoromethylornithine (eflornithine), an inhibitor of ornithine decarboxylase, which has shown encouraging results in the setting of recurrent glioma patients, to a nitrosourea-based therapy (PCV) would constitute a more effective adjuvant therapy in the treatment of glioblastoma multiforme patients in the postradiation therapy setting.	Eflornithine	69-98	ornithine decarboxylase 1	Homo sapiens	131-154
11051233-2	2000	In the current study, we sought to determine whether the addition of alpha-difluoromethylornithine (eflornithine), an inhibitor of ornithine decarboxylase, which has shown encouraging results in the setting of recurrent glioma patients, to a nitrosourea-based therapy (PCV) would constitute a more effective adjuvant therapy in the treatment of glioblastoma multiforme patients in the postradiation therapy setting.	Eflornithine	100-112	ornithine decarboxylase 1	Homo sapiens	131-154
11091138-5	2000	Combined exposure of cells to 2-(difluoromethyl)ornithine (DFMO) (a selective inactivator of ornithine decarboxylase), MDL 72527 and N(1)OSSpm produced a synergistic cytotoxic effect.	Eflornithine	30-57	ornithine decarboxylase 1	Homo sapiens	93-116
11091138-5	2000	Combined exposure of cells to 2-(difluoromethyl)ornithine (DFMO) (a selective inactivator of ornithine decarboxylase), MDL 72527 and N(1)OSSpm produced a synergistic cytotoxic effect.	Eflornithine	59-63	ornithine decarboxylase 1	Homo sapiens	93-116
11064274-3	2000	In this investigation, we used alpha-difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ODC activity and polyamine synthesis to test the hypothesis that polyamines contribute to myocardial injury in rat.	Eflornithine	31-60	ornithine decarboxylase 1	Rattus norvegicus	110-113
11016639-3	2000	In these animals, ornithine decarboxylase (ODC) activity (&gt;3-fold) as well as protein expression (&gt;4-fold) was found to be markedly higher in the dorsolateral prostate as compared with the nontransgenic littermates, suggesting their suitability to determine the chemopreventive effect of alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ODC, against prostate cancer.	Eflornithine	299-323	ornithine decarboxylase, structural 1	Mus musculus	18-41
11016639-3	2000	In these animals, ornithine decarboxylase (ODC) activity (&gt;3-fold) as well as protein expression (&gt;4-fold) was found to be markedly higher in the dorsolateral prostate as compared with the nontransgenic littermates, suggesting their suitability to determine the chemopreventive effect of alpha-difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ODC, against prostate cancer.	Eflornithine	325-329	ornithine decarboxylase, structural 1	Mus musculus	18-41
11016639-6	2000	Oral consumption of 1% DFMO (w/v) in the drinking water to TRAMP mice from 8 to 28 weeks of age resulted in a significant decrease in (a) weight (59%) and volume (66%) of prostate, (b) genitourinary weight (63%), and (c) ODC enzyme activity (52%) in the dorsolateral prostate.	Eflornithine	23-27	ornithine decarboxylase 1	Homo sapiens	221-224
11016639-8	2000	Furthermore, DFMO treatment resulted in the marked reduction in the protein expression of proliferation cell nuclear antigen, ODC, and probasin in the dorsolateral prostate.	Eflornithine	13-17	ornithine decarboxylase, structural 1	Mus musculus	126-129
11016639-9	2000	The protein expression of antimetastases markers, i.e., E-cadherin and alpha- and beta-catenin, was found to be restored in DFMO-fed animals as compared with the non-DFMO-fed mice.	Eflornithine	124-128	cadherin 1	Mus musculus	56-66
11016639-9	2000	The protein expression of antimetastases markers, i.e., E-cadherin and alpha- and beta-catenin, was found to be restored in DFMO-fed animals as compared with the non-DFMO-fed mice.	Eflornithine	124-128	catenin (cadherin associated protein), beta 1	Mus musculus	71-94
11064274-3	2000	In this investigation, we used alpha-difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ODC activity and polyamine synthesis to test the hypothesis that polyamines contribute to myocardial injury in rat.	Eflornithine	62-66	ornithine decarboxylase 1	Rattus norvegicus	110-113
11064274-8	2000	DFMO treatment inhibited ISO-induced increases in (i) ODC activity and putrescine and spermidine levels in heart, (ii) CPK and LDH activity in plasma, and (iii) the area of subendocardial lesions.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	54-57
10913016-7	2000	Inhibition of ODC by the ODC antagonist difluoromethylornithine (1 mM) attenuated this hypertrophic response, indicating that ODC induction is causally involved.	Eflornithine	40-63	ornithine decarboxylase 1	Rattus norvegicus	14-17
10913016-7	2000	Inhibition of ODC by the ODC antagonist difluoromethylornithine (1 mM) attenuated this hypertrophic response, indicating that ODC induction is causally involved.	Eflornithine	40-63	ornithine decarboxylase 1	Rattus norvegicus	25-28
10913016-7	2000	Inhibition of ODC by the ODC antagonist difluoromethylornithine (1 mM) attenuated this hypertrophic response, indicating that ODC induction is causally involved.	Eflornithine	40-63	ornithine decarboxylase 1	Rattus norvegicus	25-28
10869460-1	2000	Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC), the essential enzyme in mammalian polyamine biosynthesis (Pasic et al., 1997, Arch.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	63-86
10869460-1	2000	Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC), the essential enzyme in mammalian polyamine biosynthesis (Pasic et al., 1997, Arch.	Eflornithine	0-23	ornithine decarboxylase 1	Homo sapiens	88-91
10869460-1	2000	Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC), the essential enzyme in mammalian polyamine biosynthesis (Pasic et al., 1997, Arch.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	63-86
10869460-1	2000	Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC), the essential enzyme in mammalian polyamine biosynthesis (Pasic et al., 1997, Arch.	Eflornithine	25-29	ornithine decarboxylase 1	Homo sapiens	88-91
10705873-1	2000	Human breast adenocarcinoma cells MCF-7 were selected for resistance to ornithine decarboxylase (ODC) inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	113-142	ornithine decarboxylase 1	Homo sapiens	72-95
10903418-7	2000	A similar response was observed with the ODC inhibitor 2-difluoromethylornithine (DFMO), which served as a positive control.	Eflornithine	55-80	ornithine decarboxylase, structural 1	Mus musculus	41-44
10903418-7	2000	A similar response was observed with the ODC inhibitor 2-difluoromethylornithine (DFMO), which served as a positive control.	Eflornithine	82-86	ornithine decarboxylase, structural 1	Mus musculus	41-44
11174068-8	2000	Inhibition of ODC activity (about 2-fold by 24 h DFMO 5 mM), ERK activation (almost completely by 20 min PD 098059 50 microM), or both these enzymes simultaneously led to a reduction by about half in levels of MT1-MMP mRNA, 59/62-kD MMP-2 activity, and invasion in untreated as well as PMA-stimulated cells.	Eflornithine	49-53	ornithine decarboxylase 1	Homo sapiens	14-17
10782045-5	2000	Two drugs were employed in these studies: DFMO (difluoromethylornithine), which inhibits ornithine decarboxylase, and MGBG [methylglyoxal bis(guanyl-hydrazone)], which inhibits S-adenosyl methionine decarboxylase.	Eflornithine	48-71	ornithine decarboxylase, structural 1	Mus musculus	89-112
10766173-0	2000	Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.	Eflornithine	51-74	APC, WNT signaling pathway regulator	Mus musculus	88-91
10760944-8	2000	The ODC-mediated increase in acetylated histones was abrogated when cells were treated with alpha-difluoromethylornithine, a specific inhibitor of ODC activity, implying a distinct role for polyamines.	Eflornithine	92-121	ornithine decarboxylase 1	Homo sapiens	4-7
10760944-8	2000	The ODC-mediated increase in acetylated histones was abrogated when cells were treated with alpha-difluoromethylornithine, a specific inhibitor of ODC activity, implying a distinct role for polyamines.	Eflornithine	92-121	ornithine decarboxylase 1	Homo sapiens	147-150
10712236-6	2000	Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.	Eflornithine	53-85	ornithine decarboxylase 1	Rattus norvegicus	118-141
10712236-6	2000	Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.	Eflornithine	53-85	ornithine decarboxylase 1	Rattus norvegicus	143-146
10712236-6	2000	Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.	Eflornithine	87-91	ornithine decarboxylase 1	Rattus norvegicus	118-141
10712236-6	2000	Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.	Eflornithine	87-91	ornithine decarboxylase 1	Rattus norvegicus	143-146
11776633-6	2000	In addition, transfection with antisense bcl-2 did not induce marked apoptosis whereas treatment of the transfectant with low concentration (0.2 mmol/L) of DFMO resulted in enhanced expression inhibition of bcl-2 protein, inhibition of cell growth and induction of apoptosis.	Eflornithine	156-160	BCL2 apoptosis regulator	Homo sapiens	207-212
10728361-8	2000	In the presence of ODC inhibitors (alpha-methylornithine or difluoromethylornithine) this increase remained absent and the increases in 14C-phenylalanine incorporation, protein and RNA mass under isoprenaline were abolished.	Eflornithine	60-83	ornithine decarboxylase, structural 1	Mus musculus	19-22
10769640-2	2000	Complete polyamine deprivation, using 2 alpha-difluoromethyl-ornithine (DFMO, Eflornithine), a specific inactivator of ornithine decarboxylase (key-enzyme of the polyamine biosynthesis) combined with inhibition of the bacterial production of gastrointestinal polyamine and a polyamine free regimen, was demonstrated to exhibit a cytostatic effect and a decrease of the three tumoral polyamine concentrations in a MCF-7 tumor model.	Eflornithine	72-76	ornithine decarboxylase 1	Homo sapiens	119-142
10769640-2	2000	Complete polyamine deprivation, using 2 alpha-difluoromethyl-ornithine (DFMO, Eflornithine), a specific inactivator of ornithine decarboxylase (key-enzyme of the polyamine biosynthesis) combined with inhibition of the bacterial production of gastrointestinal polyamine and a polyamine free regimen, was demonstrated to exhibit a cytostatic effect and a decrease of the three tumoral polyamine concentrations in a MCF-7 tumor model.	Eflornithine	78-90	ornithine decarboxylase 1	Homo sapiens	119-142
10840185-1	2000	Postnatal treatment with alpha-difluoromethylornithine (DFMO), a potent inhibitor of ornithine decarboxylase, reduces polyamine levels in rats.	Eflornithine	25-54	ornithine decarboxylase 1	Rattus norvegicus	85-108
10840185-1	2000	Postnatal treatment with alpha-difluoromethylornithine (DFMO), a potent inhibitor of ornithine decarboxylase, reduces polyamine levels in rats.	Eflornithine	56-60	ornithine decarboxylase 1	Rattus norvegicus	85-108
10893799-0	2000	Effects of alpha-difluoromethylornithine on the cyclin A expression in Hep-2 cells.	Eflornithine	11-40	cyclin A2	Homo sapiens	48-56
10893799-0	2000	Effects of alpha-difluoromethylornithine on the cyclin A expression in Hep-2 cells.	Eflornithine	11-40	DNL-type zinc finger	Homo sapiens	71-74
10893799-1	2000	DFMO is an irreversible inhibitor of ornithine decarboxilase (ODC), the key enzyme in mammalian polyamine biosynthesis.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	37-60
10893799-1	2000	DFMO is an irreversible inhibitor of ornithine decarboxilase (ODC), the key enzyme in mammalian polyamine biosynthesis.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	62-65
10893799-2	2000	The goal of this study was to determine the effects of DFMO on the expression of cyclin A at different stages of the cell cycle of Hep-2 cells.	Eflornithine	55-59	cyclin A2	Homo sapiens	81-89
10893799-2	2000	The goal of this study was to determine the effects of DFMO on the expression of cyclin A at different stages of the cell cycle of Hep-2 cells.	Eflornithine	55-59	DNL-type zinc finger	Homo sapiens	131-134
10893799-4	2000	The expression of cyclin A increased in the phases S and G2 in control cells, almost disappearing in phase M. However, in DFMO treated cultures, the expression of cyclin A was increased in M and this effect remained still after 48 h treatment.	Eflornithine	122-126	cyclin A2	Homo sapiens	18-26
10893799-4	2000	The expression of cyclin A increased in the phases S and G2 in control cells, almost disappearing in phase M. However, in DFMO treated cultures, the expression of cyclin A was increased in M and this effect remained still after 48 h treatment.	Eflornithine	122-126	cyclin A2	Homo sapiens	163-171
10766173-15	2000	Apc(min)/+ progeny of pregnant dams treated with piroxicam and/or DFMO were reduced in number and their ratio to Apc+/+ progeny was decreased to approximately 0.28:1.	Eflornithine	66-70	APC, WNT signaling pathway regulator	Mus musculus	0-3
10766173-15	2000	Apc(min)/+ progeny of pregnant dams treated with piroxicam and/or DFMO were reduced in number and their ratio to Apc+/+ progeny was decreased to approximately 0.28:1.	Eflornithine	66-70	APC, WNT signaling pathway regulator	Mus musculus	113-116
10666025-4	2000	The specific inhibitor of polyamine synthesis, alpha-difluoromethylornithine (DFMO, 5 mM), depleted cellular polyamines (putrescine, spermidine, and spermine), selectively inhibited Kv1.1 channel (a delayed-rectifier Kv channel) expression, and resulted in membrane depolarization.	Eflornithine	47-76	potassium voltage-gated channel subfamily A member 1	Rattus norvegicus	182-187
10666025-4	2000	The specific inhibitor of polyamine synthesis, alpha-difluoromethylornithine (DFMO, 5 mM), depleted cellular polyamines (putrescine, spermidine, and spermine), selectively inhibited Kv1.1 channel (a delayed-rectifier Kv channel) expression, and resulted in membrane depolarization.	Eflornithine	78-82	potassium voltage-gated channel subfamily A member 1	Rattus norvegicus	182-187
10666025-7	2000	Exogenous spermidine not only reversed the effects of DFMO on Kv1.1 channel expression, E(m), and [Ca(2+)](cyt) but also restored cell migration to normal.	Eflornithine	54-58	potassium voltage-gated channel subfamily A member 1	Rattus norvegicus	62-67
10654447-3	2000	DFMO, which depleted cellular polyamines by inhibiting ornithine decarboxylase, induced G1 arrest but without apoptosis, though it enhanced dexamethasone-induced G1 arrest and apoptosis.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	55-78
10654447-6	2000	The p27Kip1, level was increased by dexamethasone or and DFMO in line with the kinetics of G1 arrest.	Eflornithine	57-61	cyclin dependent kinase inhibitor 1B	Homo sapiens	4-11
10629084-2	2000	alpha-Difluoromethylornithine (DFMO) is a specific irreversible inhibitor of ornithine decarboxylase, a key enzyme in polyamine biosynthesis, and has been used for clinical chemotherapy and chemoprevention trials against several tumors with various effects.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	77-100
10629084-2	2000	alpha-Difluoromethylornithine (DFMO) is a specific irreversible inhibitor of ornithine decarboxylase, a key enzyme in polyamine biosynthesis, and has been used for clinical chemotherapy and chemoprevention trials against several tumors with various effects.	Eflornithine	31-35	ornithine decarboxylase 1	Homo sapiens	77-100
11128555-0	2000	Inhibition of ornithine decarboxylase by alpha-difluoromethylornithine induces apoptosis of HC11 mouse mammary epithelial cells.	Eflornithine	41-70	ornithine decarboxylase, structural 1	Mus musculus	14-37
11128555-0	2000	Inhibition of ornithine decarboxylase by alpha-difluoromethylornithine induces apoptosis of HC11 mouse mammary epithelial cells.	Eflornithine	41-70	heterochromatin, Chr 11	Mus musculus	92-96
11128555-1	2000	The effect of a-difluoromethylornithine (DFMO) on the apoptosis of HC11 mouse mammary epithelial cells was investigated.	Eflornithine	41-45	heterochromatin, Chr 11	Mus musculus	67-71
11128555-3	2000	DFMO (0.1, 1 and 5mM) induced apoptosis of HC11 cells in dose- and time-dependent manner.	Eflornithine	0-4	heterochromatin, Chr 11	Mus musculus	43-47
11128555-6	2000	Apoptosis induced by ODC inhibition was associated with a rapid increase in ROS concentration in HC11 cells observed within 1 h after DFMO treatment.	Eflornithine	134-138	ornithine decarboxylase, structural 1	Mus musculus	21-24
11128555-6	2000	Apoptosis induced by ODC inhibition was associated with a rapid increase in ROS concentration in HC11 cells observed within 1 h after DFMO treatment.	Eflornithine	134-138	heterochromatin, Chr 11	Mus musculus	97-101
10705873-1	2000	Human breast adenocarcinoma cells MCF-7 were selected for resistance to ornithine decarboxylase (ODC) inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	113-142	ornithine decarboxylase 1	Homo sapiens	97-100
10705873-1	2000	Human breast adenocarcinoma cells MCF-7 were selected for resistance to ornithine decarboxylase (ODC) inhibitor, alpha-difluoromethylornithine (DFMO).	Eflornithine	144-148	ornithine decarboxylase 1	Homo sapiens	72-95
10607762-6	2000	Rats were treated with difluoromethylornithine (0.5-2% in the drinking water), a selective inhibitor of the rate-limiting enzyme of polyamine synthesis, ornithine decarboxylase (ODC).	Eflornithine	23-46	ornithine decarboxylase 1	Rattus norvegicus	153-176
10607762-6	2000	Rats were treated with difluoromethylornithine (0.5-2% in the drinking water), a selective inhibitor of the rate-limiting enzyme of polyamine synthesis, ornithine decarboxylase (ODC).	Eflornithine	23-46	ornithine decarboxylase 1	Rattus norvegicus	178-181
10607308-4	1999	However, addition of alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, to the cultures did not enhance apoptosis but rather caused inhibition of thymocyte apoptosis.	Eflornithine	21-50	ornithine decarboxylase, structural 1	Mus musculus	81-104
10695713-6	1999	The ornithine decarboxylase inhibitor eflornithine prevents the induction, and ameliorates the severity, of the PTRE, and also reduces the degree of astrocyte activation.	Eflornithine	38-50	ornithine decarboxylase 1	Homo sapiens	4-27
10469614-6	1999	Treatment of Min mice with the specific ODC inhibitor difluoromethylornithine (DFMO) suppressed small intestinal, but not colonic, polyamine content and tumor number.	Eflornithine	54-77	ornithine decarboxylase, structural 1	Mus musculus	40-43
10581530-6	1999	Cleavage of poly(ADP-ribose) polymerase (PARP) illustrated that the staurosporine treatment induced apoptosis in the cells within 6 h. Analysis of PARP cleavage indicated that treatment with DFMO accelerated the kinetics of progression of apoptosis but did not influence the sensitivity of cells to 10 nM-1 microM staurosporine.	Eflornithine	191-195	poly(ADP-ribose) polymerase 1	Homo sapiens	12-39
10581530-6	1999	Cleavage of poly(ADP-ribose) polymerase (PARP) illustrated that the staurosporine treatment induced apoptosis in the cells within 6 h. Analysis of PARP cleavage indicated that treatment with DFMO accelerated the kinetics of progression of apoptosis but did not influence the sensitivity of cells to 10 nM-1 microM staurosporine.	Eflornithine	191-195	poly(ADP-ribose) polymerase 1	Homo sapiens	41-45
10581530-6	1999	Cleavage of poly(ADP-ribose) polymerase (PARP) illustrated that the staurosporine treatment induced apoptosis in the cells within 6 h. Analysis of PARP cleavage indicated that treatment with DFMO accelerated the kinetics of progression of apoptosis but did not influence the sensitivity of cells to 10 nM-1 microM staurosporine.	Eflornithine	191-195	poly(ADP-ribose) polymerase 1	Homo sapiens	147-151
10589756-1	1999	DFMO (alpha-difluoromethylornithine) is an oral irreversible inhibitor of ornithine decarboxylase, the first rate-limiting enzyme in polyamine synthesis.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	74-97
10589756-1	1999	DFMO (alpha-difluoromethylornithine) is an oral irreversible inhibitor of ornithine decarboxylase, the first rate-limiting enzyme in polyamine synthesis.	Eflornithine	6-35	ornithine decarboxylase 1	Homo sapiens	74-97
10523861-6	1999	alpha-Difluoromethylornithine, an irreversible inhibitor of ODC, attenuated, at an equivalent IC50, both TPA-induced ODC activity and anchorage-independent growth of JB6 P+ cells, despite no inhibition of AP-1 transactivation.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	60-63
10523861-6	1999	alpha-Difluoromethylornithine, an irreversible inhibitor of ODC, attenuated, at an equivalent IC50, both TPA-induced ODC activity and anchorage-independent growth of JB6 P+ cells, despite no inhibition of AP-1 transactivation.	Eflornithine	0-29	promotion susceptibility QTL 1	Mus musculus	105-108
10523861-6	1999	alpha-Difluoromethylornithine, an irreversible inhibitor of ODC, attenuated, at an equivalent IC50, both TPA-induced ODC activity and anchorage-independent growth of JB6 P+ cells, despite no inhibition of AP-1 transactivation.	Eflornithine	0-29	ornithine decarboxylase 1	Homo sapiens	117-120
10497162-4	1999	Cells of the human leukemic cell line, HL-60, were incubated with or without the ornithine decarboxylase inhibitor, difluoromethylornithine (DFMO), and induced to undergo apoptosis by ultraviolet irradiation.	Eflornithine	116-139	ornithine decarboxylase 1	Homo sapiens	81-104
10563800-3	1999	One of the currently used drugs, alpha-difluoromethylornithine (DFMO), is a suicide inhibitor of ODC.	Eflornithine	33-62	ornithine decarboxylase, structural 1	Mus musculus	97-100
10563800-3	1999	One of the currently used drugs, alpha-difluoromethylornithine (DFMO), is a suicide inhibitor of ODC.	Eflornithine	64-68	ornithine decarboxylase, structural 1	Mus musculus	97-100
10563800-4	1999	The structure of the T. brucei ODC (TbODC) mutant K69A bound to DFMO has been determined by X-ray crystallography to 2.0 A resolution.	Eflornithine	64-68	ornithine decarboxylase, structural 1	Mus musculus	31-34
10469614-6	1999	Treatment of Min mice with the specific ODC inhibitor difluoromethylornithine (DFMO) suppressed small intestinal, but not colonic, polyamine content and tumor number.	Eflornithine	79-83	ornithine decarboxylase, structural 1	Mus musculus	40-43
10469614-8	1999	Further, ODC enzyme activity, which is influenced by both ODC and AZ RNA levels and inhibited by DFMO, is consequential for small intestinal tumorigenesis in this model.	Eflornithine	97-101	ornithine decarboxylase, structural 1	Mus musculus	9-12
10510592-3	1999	Type I diabetes is associated with jejunal mucosal hyperplasia, and administration of diflouromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), causes hypoplasia.	Eflornithine	111-115	ornithine decarboxylase 1	Rattus norvegicus	147-170
10510592-3	1999	Type I diabetes is associated with jejunal mucosal hyperplasia, and administration of diflouromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), causes hypoplasia.	Eflornithine	111-115	ornithine decarboxylase 1	Rattus norvegicus	172-175
10446971-2	1999	This study elucidated site-specific histopathological and biochemical surrogate endpoint biomarkers of spontaneous epidermal carcinogenesis in K14-HPV16 transgenic mice and demonstrated that the incidence and severity of these markers were decreased by the ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO).	Eflornithine	297-320	ornithine decarboxylase, structural 1	Mus musculus	257-280
10446971-2	1999	This study elucidated site-specific histopathological and biochemical surrogate endpoint biomarkers of spontaneous epidermal carcinogenesis in K14-HPV16 transgenic mice and demonstrated that the incidence and severity of these markers were decreased by the ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO).	Eflornithine	322-326	ornithine decarboxylase, structural 1	Mus musculus	257-280
10446971-7	1999	ODC activity and tissue putrescine content were markedly diminished by DFMO chemoprevention in ear skin, whereas there was a more modest decline of these parameters in chest skin.	Eflornithine	71-75	ornithine decarboxylase, structural 1	Mus musculus	0-3
10430362-8	1999	The increase in DNA synthesis caused by transforming growth factor-alpha, hepatocyte growth factor, or both was completely inhibited by alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone).	Eflornithine	136-165	transforming growth factor alpha	Rattus norvegicus	40-72
10393094-2	1999	In d,l-alpha-difluoromethylornithine (DFMO)-resistant L1210 cells stimulated to grow from quiescence, treatment with PD98059 inhibited p44/42 MAPK phosphorylation and the induction of ODC activity and protein.	Eflornithine	3-36	mitogen-activated protein kinase 3	Mus musculus	135-138
10393094-2	1999	In d,l-alpha-difluoromethylornithine (DFMO)-resistant L1210 cells stimulated to grow from quiescence, treatment with PD98059 inhibited p44/42 MAPK phosphorylation and the induction of ODC activity and protein.	Eflornithine	3-36	mitogen-activated protein kinase 3	Mus musculus	142-146
10393094-2	1999	In d,l-alpha-difluoromethylornithine (DFMO)-resistant L1210 cells stimulated to grow from quiescence, treatment with PD98059 inhibited p44/42 MAPK phosphorylation and the induction of ODC activity and protein.	Eflornithine	3-36	ornithine decarboxylase, structural 1	Mus musculus	184-187
10393094-2	1999	In d,l-alpha-difluoromethylornithine (DFMO)-resistant L1210 cells stimulated to grow from quiescence, treatment with PD98059 inhibited p44/42 MAPK phosphorylation and the induction of ODC activity and protein.	Eflornithine	38-42	mitogen-activated protein kinase 3	Mus musculus	135-138
10393094-2	1999	In d,l-alpha-difluoromethylornithine (DFMO)-resistant L1210 cells stimulated to grow from quiescence, treatment with PD98059 inhibited p44/42 MAPK phosphorylation and the induction of ODC activity and protein.	Eflornithine	38-42	mitogen-activated protein kinase 3	Mus musculus	142-146
10393094-2	1999	In d,l-alpha-difluoromethylornithine (DFMO)-resistant L1210 cells stimulated to grow from quiescence, treatment with PD98059 inhibited p44/42 MAPK phosphorylation and the induction of ODC activity and protein.	Eflornithine	38-42	ornithine decarboxylase, structural 1	Mus musculus	184-187
10393094-7	1999	Cells kept in a DFMO-free medium, and thus containing high levels of putrescine and spermidine, showed enhanced MAPK phosphorylation and lower sensitivity to PD98059, compared with cells maintained in the presence of DFMO.	Eflornithine	16-20	mitogen-activated protein kinase 3	Mus musculus	112-116
10445853-5	1999	Furthermore, CD437-induced apoptosis could be blocked by the ODC inhibitor difluoromethylornithine, the caspase inhibitors Z-VAD FMK and Z-DEVD FMK, and c-Myc antisense oligodeoxynucleotide, respectively.	Eflornithine	75-98	ornithine decarboxylase 1	Homo sapiens	61-64
10430362-8	1999	The increase in DNA synthesis caused by transforming growth factor-alpha, hepatocyte growth factor, or both was completely inhibited by alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone).	Eflornithine	136-165	myotrophin	Rattus norvegicus	53-66
10199827-5	1999	Polyamine depletion by DFMO was accompanied by a significant increase in expression of the p53 gene.	Eflornithine	23-27	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	91-94
10445761-1	1999	DFMO, an irreversible inhibitor of ornithine decarboxylase (ODC), is under development as a chemopreventive drug against cancers with pronounced proliferative phases.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	35-58
10445761-1	1999	DFMO, an irreversible inhibitor of ornithine decarboxylase (ODC), is under development as a chemopreventive drug against cancers with pronounced proliferative phases.	Eflornithine	0-4	ornithine decarboxylase 1	Rattus norvegicus	60-63
10198235-3	1999	Conversely, the G1 block induced by alpha-difluoromethylornithine (DFMO) is associated with a protective effect against dRib-induced cell suicide.	Eflornithine	36-65	ribbon	Drosophila melanogaster	120-124
10198235-3	1999	Conversely, the G1 block induced by alpha-difluoromethylornithine (DFMO) is associated with a protective effect against dRib-induced cell suicide.	Eflornithine	67-71	ribbon	Drosophila melanogaster	120-124
10535358-10	1999	DFMO, a well defined polyamine biosynthesis inhibitor, completely blocks ODC activity, resulting in growth inhibition but not apoptosis.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	73-76
10199827-6	1999	The p53 mRNA levels increased 4 days after exposure to DFMO, and the maximum increases occurred at 6 and 12 days after exposure.	Eflornithine	55-59	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	4-7
10199827-7	1999	Increased levels of p53 mRNA in DFMO-treated cells were paralleled by increases in p53 protein.	Eflornithine	32-36	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	20-23
10199827-7	1999	Increased levels of p53 mRNA in DFMO-treated cells were paralleled by increases in p53 protein.	Eflornithine	32-36	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	83-86
10199827-8	1999	Polyamines given together with DFMO completely prevented increased expression of the p53 gene.	Eflornithine	31-35	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	85-88
10199827-9	1999	Increased expression of the p53 gene in DFMO-treated cells was associated with a significant increase in G1 phase growth arrest.	Eflornithine	40-44	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	28-31
10069996-3	1999	IEC-6 cells were grown in the presence or absence of DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase, which is the first rate-limiting enzyme for polyamine synthesis.	Eflornithine	53-85	ornithine decarboxylase 1	Rattus norvegicus	118-141
10194516-2	1999	Estrogen receptor (ER) linked to glutathione-S-transferase (GST) was used to examine the effects of two polyamine biosynthesis inhibitors, difluoromethylornithine (DFMO) and CGP 48664.	Eflornithine	139-162	estrogen receptor 1	Homo sapiens	0-17
10194516-2	1999	Estrogen receptor (ER) linked to glutathione-S-transferase (GST) was used to examine the effects of two polyamine biosynthesis inhibitors, difluoromethylornithine (DFMO) and CGP 48664.	Eflornithine	164-168	estrogen receptor 1	Homo sapiens	19-21
10194516-2	1999	Estrogen receptor (ER) linked to glutathione-S-transferase (GST) was used to examine the effects of two polyamine biosynthesis inhibitors, difluoromethylornithine (DFMO) and CGP 48664.	Eflornithine	164-168	glutathione S-transferase kappa 1	Homo sapiens	60-63
10194516-6	1999	When samples from the estradiol+DFMO treatment group were incubated with spermidine prior to GST-ER pull down assay, an increased association of several proteins with ER was detected.	Eflornithine	32-36	glutathione S-transferase kappa 1	Homo sapiens	93-96
10194516-6	1999	When samples from the estradiol+DFMO treatment group were incubated with spermidine prior to GST-ER pull down assay, an increased association of several proteins with ER was detected.	Eflornithine	32-36	estrogen receptor 1	Homo sapiens	97-99
10194516-6	1999	When samples from the estradiol+DFMO treatment group were incubated with spermidine prior to GST-ER pull down assay, an increased association of several proteins with ER was detected.	Eflornithine	32-36	estrogen receptor 1	Homo sapiens	167-169
10069996-3	1999	IEC-6 cells were grown in the presence or absence of DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase, which is the first rate-limiting enzyme for polyamine synthesis.	Eflornithine	87-91	ornithine decarboxylase 1	Rattus norvegicus	118-141
10069996-10	1999	Activation of JNK-1 was the earliest event; within 5 h after DFMO treatment, JNK activity was increased by 150%.	Eflornithine	61-65	mitogen-activated protein kinase 8	Rattus norvegicus	14-17
10069996-10	1999	Activation of JNK-1 was the earliest event; within 5 h after DFMO treatment, JNK activity was increased by 150%.	Eflornithine	61-65	mitogen-activated protein kinase 8	Rattus norvegicus	77-80
9950818-6	1999	Administration of alpha-difluoromethylornithine (DFMO), a specific inhibitor for polyamine synthesis, for 4 and 6 days completely depleted cellular polyamine levels, while AP-1 binding activity was significantly increased.	Eflornithine	18-47	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	172-176
9989776-10	1999	Cotreatment with alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ODC, did not reduced growth rate.	Eflornithine	17-46	ornithine decarboxylase	Gallus gallus	94-97
9950774-3	1999	DFMO reduced F-actin in the cell interior, increased it in the cell cortex, redistributed G-actin, and increased nuclear staining of Tbeta4.	Eflornithine	0-4	thymosin beta 4, X-linked	Rattus norvegicus	133-139
9950774-7	1999	We propose that DFMO reduces migration by interfering with the sequestration of G-actin by Tbeta4 and the association of F-actin with activated EGF receptors.	Eflornithine	16-20	thymosin beta 4, X-linked	Rattus norvegicus	91-97
9950818-6	1999	Administration of alpha-difluoromethylornithine (DFMO), a specific inhibitor for polyamine synthesis, for 4 and 6 days completely depleted cellular polyamine levels, while AP-1 binding activity was significantly increased.	Eflornithine	49-53	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	172-176
9950818-7	1999	Spermidine, when given together with DFMO, restored AP-1 binding activity toward normal.	Eflornithine	37-41	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	52-56
9950818-9	1999	There were significant increases in JunD mRNA and protein in DFMO-treated cells, although expression of the c-fos, c-jun, and junB genes decreased.	Eflornithine	61-65	JunD proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	36-40
9950818-9	1999	There were significant increases in JunD mRNA and protein in DFMO-treated cells, although expression of the c-fos, c-jun, and junB genes decreased.	Eflornithine	61-65	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	108-113
9950818-9	1999	There were significant increases in JunD mRNA and protein in DFMO-treated cells, although expression of the c-fos, c-jun, and junB genes decreased.	Eflornithine	61-65	JunB proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	126-130
9950818-10	1999	The increase in JunD/AP-1 activity in DFMO-treated cells was associated with a significant decrease in cell division.	Eflornithine	38-42	JunD proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	16-20
9950818-10	1999	The increase in JunD/AP-1 activity in DFMO-treated cells was associated with a significant decrease in cell division.	Eflornithine	38-42	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	21-25
9950818-12	1999	DFMO prevented the stimulation of c-Jun/AP-1 activity induced by 5% dialyzed serum.	Eflornithine	0-4	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	40-44
9950818-13	1999	These results indicate that 1) polyamine depletion is associated with an increase in AP-1 binding activity and 2) the increase in AP-1 activity in the DFMO-treated cells was primarily contributed by an increase in the JunD/AP-1.	Eflornithine	151-155	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	85-89
9950818-13	1999	These results indicate that 1) polyamine depletion is associated with an increase in AP-1 binding activity and 2) the increase in AP-1 activity in the DFMO-treated cells was primarily contributed by an increase in the JunD/AP-1.	Eflornithine	151-155	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	130-134
9950818-13	1999	These results indicate that 1) polyamine depletion is associated with an increase in AP-1 binding activity and 2) the increase in AP-1 activity in the DFMO-treated cells was primarily contributed by an increase in the JunD/AP-1.	Eflornithine	151-155	JunD proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	218-222
9950818-13	1999	These results indicate that 1) polyamine depletion is associated with an increase in AP-1 binding activity and 2) the increase in AP-1 activity in the DFMO-treated cells was primarily contributed by an increase in the JunD/AP-1.	Eflornithine	151-155	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	130-134
10709674-3	1999	As discussed above, all six potential chemopreventive agents, aspirin, 2-CPR, DFMO, 4-HPR, piroxicam, and 9-cis-retinoic acid, decreased the level of AOM-induced ACF.	Eflornithine	78-82	ACF	Homo sapiens	162-165
10319188-7	1999	This last effect was blocked by a NOS inhibitor and was strongly reduced by difluoromethylornithine (DFMO), an irreversible inhibitor of ODC.	Eflornithine	76-99	ornithine decarboxylase 1	Homo sapiens	137-140
10319188-7	1999	This last effect was blocked by a NOS inhibitor and was strongly reduced by difluoromethylornithine (DFMO), an irreversible inhibitor of ODC.	Eflornithine	101-105	ornithine decarboxylase 1	Homo sapiens	137-140
9795249-9	1998	Differences in the temporal relationship between IL-2 production and polyamine induction in mitogen- versus superantigen-stimulated cells may account for the significant inhibition of the proliferative response by alpha-difluoromethylornithine following PHA but not SEB stimulation.	Eflornithine	214-243	interleukin 2	Homo sapiens	49-53
10433086-3	1999	We studied the in vivo effects of difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme, ornithine decarboxylase (ODC), on the expression of fas in MRL-lpr/lpr mice as well as in congenic MRL- + / + and autoimmune NZB/W strains.	Eflornithine	34-57	ornithine decarboxylase, structural 1	Mus musculus	130-153
10433086-3	1999	We studied the in vivo effects of difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme, ornithine decarboxylase (ODC), on the expression of fas in MRL-lpr/lpr mice as well as in congenic MRL- + / + and autoimmune NZB/W strains.	Eflornithine	34-57	ornithine decarboxylase, structural 1	Mus musculus	155-158
10433086-3	1999	We studied the in vivo effects of difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme, ornithine decarboxylase (ODC), on the expression of fas in MRL-lpr/lpr mice as well as in congenic MRL- + / + and autoimmune NZB/W strains.	Eflornithine	34-57	Fas (TNF receptor superfamily member 6)	Mus musculus	193-196
10433086-3	1999	We studied the in vivo effects of difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme, ornithine decarboxylase (ODC), on the expression of fas in MRL-lpr/lpr mice as well as in congenic MRL- + / + and autoimmune NZB/W strains.	Eflornithine	59-63	ornithine decarboxylase, structural 1	Mus musculus	130-153
10433086-3	1999	We studied the in vivo effects of difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme, ornithine decarboxylase (ODC), on the expression of fas in MRL-lpr/lpr mice as well as in congenic MRL- + / + and autoimmune NZB/W strains.	Eflornithine	59-63	ornithine decarboxylase, structural 1	Mus musculus	155-158
10433086-3	1999	We studied the in vivo effects of difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme, ornithine decarboxylase (ODC), on the expression of fas in MRL-lpr/lpr mice as well as in congenic MRL- + / + and autoimmune NZB/W strains.	Eflornithine	59-63	Fas (TNF receptor superfamily member 6)	Mus musculus	193-196
10433086-3	1999	We studied the in vivo effects of difluoromethylornithine (DFMO), an irreversible inhibitor of the polyamine biosynthetic enzyme, ornithine decarboxylase (ODC), on the expression of fas in MRL-lpr/lpr mice as well as in congenic MRL- + / + and autoimmune NZB/W strains.	Eflornithine	59-63	Fas (TNF receptor superfamily member 6)	Mus musculus	197-200
10433086-4	1999	Using Northern blot hybridization and reverse transcription polymerase chain reaction (RT-PCR), we found that DFMO treatment resulted in an increase in the expression of fas mRNA in the thymus of MRL-lpr/lpr mice.	Eflornithine	110-114	Fas (TNF receptor superfamily member 6)	Mus musculus	200-203
10433086-4	1999	Using Northern blot hybridization and reverse transcription polymerase chain reaction (RT-PCR), we found that DFMO treatment resulted in an increase in the expression of fas mRNA in the thymus of MRL-lpr/lpr mice.	Eflornithine	110-114	Fas (TNF receptor superfamily member 6)	Mus musculus	204-207
10433086-6	1999	With fractionated CD4 + and CD8 + T cells, we found a cell-specific effect of DFMO on chimeric ETn/fas expression in CD8 + cells.	Eflornithine	78-82	CD4 antigen	Mus musculus	18-21
10433086-9	1999	These results indicate that DFMO-mediated polyamine depletion is linked to the regulation of fas and chimeric ETn/fas in MRL-lpr/lpr mice.	Eflornithine	28-32	Fas (TNF receptor superfamily member 6)	Mus musculus	125-128
10433086-9	1999	These results indicate that DFMO-mediated polyamine depletion is linked to the regulation of fas and chimeric ETn/fas in MRL-lpr/lpr mice.	Eflornithine	28-32	Fas (TNF receptor superfamily member 6)	Mus musculus	129-132
10321508-2	1999	Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme in the biosynthesis of polyamines.	Eflornithine	0-23	ornithine decarboxylase 1	Canis lupus familiaris	63-86
10321508-2	1999	Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme in the biosynthesis of polyamines.	Eflornithine	25-29	ornithine decarboxylase 1	Canis lupus familiaris	63-86
10550568-2	1999	Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme in the biosynthesis of polyamines.	Eflornithine	0-23	ornithine decarboxylase 1	Rattus norvegicus	63-86
10550568-2	1999	Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme in the biosynthesis of polyamines.	Eflornithine	25-29	ornithine decarboxylase 1	Rattus norvegicus	63-86
10353628-6	1999	Co-administration of difluoromethylornithine, an irreversible inhibitor of ODC, or propranolol, a nonspecific beta-antagonist, with clenbuterol completely prevented the induction of ODC activity as well as the increase in polyamine levels in heart.	Eflornithine	21-44	ornithine decarboxylase, structural 1	Mus musculus	75-78
10353628-6	1999	Co-administration of difluoromethylornithine, an irreversible inhibitor of ODC, or propranolol, a nonspecific beta-antagonist, with clenbuterol completely prevented the induction of ODC activity as well as the increase in polyamine levels in heart.	Eflornithine	21-44	ornithine decarboxylase, structural 1	Mus musculus	182-185
9884080-1	1998	We have examined whether modulation of the polyamine biosynthetic pathway, through inhibition by alpha-difluoromethylornithine (DFMO) of the rate limiting enzyme, ornithine decarboxylase (ODC), modulates NO synthesis in J774 macrophages.	Eflornithine	97-126	ornithine decarboxylase, structural 1	Mus musculus	163-186
9884080-1	1998	We have examined whether modulation of the polyamine biosynthetic pathway, through inhibition by alpha-difluoromethylornithine (DFMO) of the rate limiting enzyme, ornithine decarboxylase (ODC), modulates NO synthesis in J774 macrophages.	Eflornithine	97-126	ornithine decarboxylase, structural 1	Mus musculus	188-191
9884080-1	1998	We have examined whether modulation of the polyamine biosynthetic pathway, through inhibition by alpha-difluoromethylornithine (DFMO) of the rate limiting enzyme, ornithine decarboxylase (ODC), modulates NO synthesis in J774 macrophages.	Eflornithine	128-132	ornithine decarboxylase, structural 1	Mus musculus	163-186
9884080-1	1998	We have examined whether modulation of the polyamine biosynthetic pathway, through inhibition by alpha-difluoromethylornithine (DFMO) of the rate limiting enzyme, ornithine decarboxylase (ODC), modulates NO synthesis in J774 macrophages.	Eflornithine	128-132	ornithine decarboxylase, structural 1	Mus musculus	188-191
9884080-8	1998	Pre-incubation of cells with DFMO (10 mM; 24 h) prior to activation with LPS resulted in enhanced (approximately 2 fold) iNOS protein expression.	Eflornithine	29-33	nitric oxide synthase 2, inducible	Mus musculus	121-125
9884080-10	1998	Since the only known mechanism of action of DFMO is inhibition of ODC, and thus polyamine biosynthesis, we conclude that expression of iNOS can be critically regulated by endogenous polyamines.	Eflornithine	44-48	ornithine decarboxylase, structural 1	Mus musculus	66-69
9884080-10	1998	Since the only known mechanism of action of DFMO is inhibition of ODC, and thus polyamine biosynthesis, we conclude that expression of iNOS can be critically regulated by endogenous polyamines.	Eflornithine	44-48	nitric oxide synthase 2, inducible	Mus musculus	135-139
28976672-3	1998	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme for polyamine synthesis, for 4 days totally inhibited ODC activity and depleted intracellular polyamines in the intestinal epithelial cells (IEC-6) derived from rat small intestinal crypt cells.	Eflornithine	15-44	ornithine decarboxylase 1	Rattus norvegicus	77-100
28976672-3	1998	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme for polyamine synthesis, for 4 days totally inhibited ODC activity and depleted intracellular polyamines in the intestinal epithelial cells (IEC-6) derived from rat small intestinal crypt cells.	Eflornithine	15-44	ornithine decarboxylase 1	Rattus norvegicus	102-105
28976672-3	1998	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme for polyamine synthesis, for 4 days totally inhibited ODC activity and depleted intracellular polyamines in the intestinal epithelial cells (IEC-6) derived from rat small intestinal crypt cells.	Eflornithine	15-44	ornithine decarboxylase 1	Rattus norvegicus	187-190
28976672-3	1998	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme for polyamine synthesis, for 4 days totally inhibited ODC activity and depleted intracellular polyamines in the intestinal epithelial cells (IEC-6) derived from rat small intestinal crypt cells.	Eflornithine	46-50	ornithine decarboxylase 1	Rattus norvegicus	77-100
28976672-3	1998	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme for polyamine synthesis, for 4 days totally inhibited ODC activity and depleted intracellular polyamines in the intestinal epithelial cells (IEC-6) derived from rat small intestinal crypt cells.	Eflornithine	46-50	ornithine decarboxylase 1	Rattus norvegicus	102-105
28976672-3	1998	Treatment with alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme for polyamine synthesis, for 4 days totally inhibited ODC activity and depleted intracellular polyamines in the intestinal epithelial cells (IEC-6) derived from rat small intestinal crypt cells.	Eflornithine	46-50	ornithine decarboxylase 1	Rattus norvegicus	187-190
9796636-15	1998	Comparing the 6-month measurements with pretreatment, DFMO/PXM or DFMO significantly reduced TPA-induced ODC levels (Ps, 0.03 and 0.05).	Eflornithine	54-58	ornithine decarboxylase 1	Homo sapiens	105-108
9796636-15	1998	Comparing the 6-month measurements with pretreatment, DFMO/PXM or DFMO significantly reduced TPA-induced ODC levels (Ps, 0.03 and 0.05).	Eflornithine	66-70	ornithine decarboxylase 1	Homo sapiens	105-108
10225001-4	1999	The nitric oxide synthase (NOS) inhibitor NG-nitro l-arginine methyl ester stimulated DNA synthesis with a significant increase from control at 2.5 and 5 mM (p &lt; 0.05); in contrast, the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethyl ornithine (DFMO) inhibited DNA synthesis with a significant decrease from control at 19.65, 29.48, and 39.48 microM (p &lt; 0.05).	Eflornithine	229-259	nitric oxide synthase 2	Homo sapiens	4-25
10225001-4	1999	The nitric oxide synthase (NOS) inhibitor NG-nitro l-arginine methyl ester stimulated DNA synthesis with a significant increase from control at 2.5 and 5 mM (p &lt; 0.05); in contrast, the ornithine decarboxylase (ODC) inhibitor alpha-difluoromethyl ornithine (DFMO) inhibited DNA synthesis with a significant decrease from control at 19.65, 29.48, and 39.48 microM (p &lt; 0.05).	Eflornithine	261-265	nitric oxide synthase 2	Homo sapiens	4-25
10728786-0	1999	D,L-alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, induces differentiation in MEL cells.	Eflornithine	0-33	ornithine decarboxylase, structural 1	Mus musculus	64-87
10728786-1	1999	In the present study, the effect of D,L-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), on Friend"s murine erythroleukemia (MEL) cell differentiation is investigated.	Eflornithine	36-69	ornithine decarboxylase, structural 1	Mus musculus	107-130
10728786-1	1999	In the present study, the effect of D,L-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), on Friend"s murine erythroleukemia (MEL) cell differentiation is investigated.	Eflornithine	36-69	ornithine decarboxylase, structural 1	Mus musculus	132-135
10728786-1	1999	In the present study, the effect of D,L-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), on Friend"s murine erythroleukemia (MEL) cell differentiation is investigated.	Eflornithine	71-75	ornithine decarboxylase, structural 1	Mus musculus	107-130
10728786-1	1999	In the present study, the effect of D,L-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), on Friend"s murine erythroleukemia (MEL) cell differentiation is investigated.	Eflornithine	71-75	ornithine decarboxylase, structural 1	Mus musculus	132-135
9890191-7	1999	Pretreating with alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, which is a key enzyme in polyamine biosynthesis and therefore used to deplete cellular polyamine, prevented the protective effect of taurine.	Eflornithine	17-46	ornithine decarboxylase 1	Rattus norvegicus	77-100
9850069-3	1998	We studied whether the increased esophageal cell proliferation and susceptibility to NMBA-induced carcinogenesis induced by zinc deficiency can be inhibited by alpha-difluoromethylornithine (DFMO), an enzyme-activated, irreversible inhibitor of ornithine decarboxylase (the first enzyme in polyamine synthesis).	Eflornithine	160-189	ornithine decarboxylase 1	Rattus norvegicus	245-268
9850069-3	1998	We studied whether the increased esophageal cell proliferation and susceptibility to NMBA-induced carcinogenesis induced by zinc deficiency can be inhibited by alpha-difluoromethylornithine (DFMO), an enzyme-activated, irreversible inhibitor of ornithine decarboxylase (the first enzyme in polyamine synthesis).	Eflornithine	191-195	ornithine decarboxylase 1	Rattus norvegicus	245-268
9850069-11	1998	In addition, the expression of bax protein, an apoptosis accelerator, was markedly stronger in esophagi from Zn-/DFMO+ animals that showed increased apoptosis, whereas increased expression of bcl-2, an inhibitor of apoptosis, was only seen in the highly proliferative, zinc-deficient esophagus (Zn-/DFMO-).	Eflornithine	113-117	BCL2 associated X, apoptosis regulator	Rattus norvegicus	31-34
9850069-11	1998	In addition, the expression of bax protein, an apoptosis accelerator, was markedly stronger in esophagi from Zn-/DFMO+ animals that showed increased apoptosis, whereas increased expression of bcl-2, an inhibitor of apoptosis, was only seen in the highly proliferative, zinc-deficient esophagus (Zn-/DFMO-).	Eflornithine	299-303	BCL2 associated X, apoptosis regulator	Rattus norvegicus	31-34
9829706-1	1998	DFMO is an irreversible inhibitor of ornithine decarboxylase (ODC), the key enzyme in mammalian polyamine biosynthesis.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	37-60
9829706-1	1998	DFMO is an irreversible inhibitor of ornithine decarboxylase (ODC), the key enzyme in mammalian polyamine biosynthesis.	Eflornithine	0-4	ornithine decarboxylase 1	Homo sapiens	62-65
9829706-2	1998	The goal of this study was to determine the effects of DFMO 0.5 g/m2/day as a single oral dose on polyamine and ODC levels in rectal, rectosigmoidal, and cecal colonic mucosae of individuals at risk for colon cancer because of a personal history of adenomatous polyps of the colon or a family history of colon cancer in at least one first-degree relative.	Eflornithine	55-59	ornithine decarboxylase 1	Homo sapiens	112-115
9772292-5	1998	Clinical trials with 2-(difluoromethyl)ornithine, a selective inactivator of ornithine decarboxylase, a key enzyme of polyamine biosynthesis, are promising.	Eflornithine	21-48	ornithine decarboxylase 1	Homo sapiens	77-100
28976654-8	1998	Additionally, stimulation of epithelial growth by EGF was also blocked by depletion of cellular polyamines in DFMO-treated oesophageal explants.	Eflornithine	110-114	pro-epidermal growth factor	Oryctolagus cuniculus	50-53
9769382-1	1998	The mechanism by which DL-alpha-difluoromethylornithine (DFMO) inhibits angiogenesis is generally thought to involve the inhibition of the rate-limiting enzyme, ornithine decarboxylase (ODC), leading to polyamine depletion in cells and the ultimate cytostatic effect on proliferating endothelial cells.	Eflornithine	23-55	ornithine decarboxylase, structural 1	Mus musculus	161-184
9769382-1	1998	The mechanism by which DL-alpha-difluoromethylornithine (DFMO) inhibits angiogenesis is generally thought to involve the inhibition of the rate-limiting enzyme, ornithine decarboxylase (ODC), leading to polyamine depletion in cells and the ultimate cytostatic effect on proliferating endothelial cells.	Eflornithine	23-55	ornithine decarboxylase, structural 1	Mus musculus	186-189
9769382-1	1998	The mechanism by which DL-alpha-difluoromethylornithine (DFMO) inhibits angiogenesis is generally thought to involve the inhibition of the rate-limiting enzyme, ornithine decarboxylase (ODC), leading to polyamine depletion in cells and the ultimate cytostatic effect on proliferating endothelial cells.	Eflornithine	57-61	ornithine decarboxylase, structural 1	Mus musculus	161-184
9769382-1	1998	The mechanism by which DL-alpha-difluoromethylornithine (DFMO) inhibits angiogenesis is generally thought to involve the inhibition of the rate-limiting enzyme, ornithine decarboxylase (ODC), leading to polyamine depletion in cells and the ultimate cytostatic effect on proliferating endothelial cells.	Eflornithine	57-61	ornithine decarboxylase, structural 1	Mus musculus	186-189